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MINING THE MYCOBACTERIUM TUBERCULOSIS CELLULAR ENVELOPE FOR 
DIAGNOSTIC AND DRUG TARGETS 
 
The cellular envelope of Mycobacterium tuberculosis is a highly complex structure 
containing many lipids, carbohydrates and proteins. Together these components maintain cellular 
homeostasis and play an active role in the establishment and maintenance of intracellular 
infection. The World Health Organization estimates that upon exposure, 90% of infected persons 
will not succumb to active disease and likely remain a potential source of M. tuberculosis 
transmission upon the emergence of clinical symptoms. Throughout this complex disease course, 
physiological and structural changes occur within the cell envelope of the bacillus and facilitate 
its survival within an infected host. These physiological changes also influence the 
immunological interplay between bacteria and host cell, further contributing to the success of the 
pathogen. To understand these changes we must have a comprehensive knowledge of the cell 
wall proteins that contribute to the overall makeup of the mycobacterial envelope, understand the 
unique antigens that reside in or that are secreted from the bacillus and monitor these proteins 
under different physiological disease profiles. In the last decade many large-scale descriptive 
studies focusing on gene transcript profiles and proteomic composition of subcellular fractions 
have pioneered efforts in the understanding of M. tuberculosis physiology, immunology and 
pathogenesis at the level of systems biology. These studies have shown that M. tuberculsosis is 
capable of retaining essential gene products for respiration, nutrient uptake and energy 
metabolism both in vitro and in vivo and that the proteins within the cell wall are highly 
immunogenic for M.tuberculosis-specific T lymphocytes. Our first objective established a 
comprehensive description of the cell wall proteome of M. tuberculosis using traditional two-
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dimensional gel-based techniques and liquid-chromatogoraphy mass spectrometry (LC-MS). 
From this work, over 500 proteins were identified using a combination of differential detergent 
extraction and multi-dimensional-LC. A highly lipoprotein enriched fraction revealed that the 
majority of cell wall associated proteins were functionally annotated to mechanisms of 
intermediary metabolism (35%) and macromolecular synthesis and degradation (25%) building 
upon evidence that the M. tuberculosis cell wall is actively engaged in cellular homeostasis and 
remodeling events. Secondly, we investigated the role of the cell envelope proteins in the search 
for novel immunodiagnostic epitopes. It is well known that the cell wall of M. tuberculosis is 
highly immunogenic and contains both non-protein and protein antigens. Specifically, the 
proteins associated with the cell wall were shown to be uniquely responsible for the activation of 
human CD8 T cell clones generated from both actively and latently infected individuals. The 
immunological response to CD8 T cell antigens may be an effective means of distinguishing 
between latent TB infection (LTBI) and active disease. To broadly define the repertoire of CD8 
T cell antigens, 56 proteins from the cell wall proteome study were included in the design of a 
synthetic peptide library. Exhaustive screening of the peptide library for novel antigens and 
epitopes that elicit an immunological response in TB patients, resulted in the identification of 
eight cell wall antigens that are currently being investigated for their clinical utility. In addition, 
the cell wall proteome was also mined in the identification of an HLA-E restricted CD8 T cell 
epitope. HLA-E has low polymorphism in the human population and seems to be enriched in M. 
tuberculosis - containing phagosomes, therefore identification of this antigen could be used as a 
novel diagnostic or vaccine candidate. Using a MS-based proteomics approach, we discovered 
the HLA-E antigen to be the post-translationally modified glycoprotein Mpt32 (45kDa/Apa). 
Glycosylated proteins and lipids within the mycobacterial cell envelope are dominant and the 
role of this modification in the host immune response can now be elucidated. Lastly, the 
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composition and integrity of the M. tuberculosis cell envelope facilitates its adaptation and 
survival within various microenvironments. These physiological functions are influenced by the 
presence or absence of functionally linked genes and proteins whose relative abundance may 
change over time or within altered metabolic states. Our final efforts used nucleotide analog 
probes, to specifically bind and enrich proteins with an ATP-binding function and measure their 
relative abundance between altered states of growth (i.e. between active disease and hypoxia-
induced dormancy). With these efforts we classified 122 ATP-binding proteins in either 
metabolic state and demonstrated differential abundance patterns between actively growing and 
hypoxic cells within the functionally linked protein networks of energy metabolism, cell wall and 
lipid biosynthesis. These protein families represented in the M. tuberculosis ATPome are a 
subset of essential (60% of the Mtb-ATPome) gene products and may be relevant therapeutic 
targets for the future development of novel small molecule inhibitors against M. tuberculosis. 
The spectrum of studies undertaken to mine the cellular envelope for diagnostic and drug targets 
demonstrates a natural evolution of MS-based proteomics in the study of biologically relevant 
questions. From a purely descriptive characterization of the cell wall proteome, this data was 
utilized in a practical approach in the design of a high-throughput antigen/epitope-screening 
library and finally these studies culminate in a functionally relevant profile of the ATP-binding 
proteins of M. tuberculosis. Future work will continue to focus on developing hypothesis-driven 
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I. CHAPTER I: Tuberculosis, Physiology of the Bacillus and the Host Immune Response. 
 
1.1 Tuberculosis and Current World Problems 
Estimates from the World Health Organization (WHO) reported 8.5 to 9.2 million new 
cases of tuberculosis (TB) in 2010, with an overall global disease burden of over 2 billion people 
(1). Mycobacterium tuberculosis (M. tuberculosis) is transmitted into the lungs via close-contact 
aerosol and remains one of the leading causes of death worldwide (1.4 million deaths in 2010) 
despite extensive research, directly observed therapy short course (DOTS) initiatives and the 
widespread use of a vaccine (2). The majority of infected persons harbor the bacterium in a 
persistent state of metabolic dormancy, only 1 in 10 persons infected present with clinical 
symptoms. However, the frequency and scale of latent infections presents a major risk for the 
future re-emergence of active, transmittable disease. The burden of TB disease is monitored in 
over 204 countries and territories which encompasses ~ 99% of the world’s population (3). The 
STOP TB initiative organized by the WHO was initiated in the early 1990’s to control the 
resurgence of disease cases caused by Mtb infection. Their efforts included the rapid 
standardization and expansion of diagnostic methods and treatment regimens. The campaign 
objectives are currently stated as follows (www.stoptb.org): 
- Achieve universal access to quality diagnosis and patient-centered treatment 
- Reduce the human and socioeconomic burden associated with tuberculosis 
- Protect vulnerable populations from TB, TB-HIV co-infection and drug-resistant TB 
- Support development of new methods and enable their timely and effective use 
- Protect and promote human rights in TB prevention, care and control 
Because of these efforts, it is estimated that more than 36 million people were cured 
between 1995 and 2008, saving 6 million lives. However, worldwide the annual case rate of ~ 9 
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million people still remains and incidence of disease is falling at less than 1% peryear (2,3). 
Global initiatives for TB elimination have been set by the WHO and include a halt to the disease 
epidemic by 2015, with an overall goal of worldwide elimination of disease by 2050.  While 
progress has been made, the emergence of multi-drug resistant (MDR) and extensively-drug 
resistant (XDR) tuberculosis presents a severe problem, as does the continuing epidemic of HIV 
in high burden countries (4).  
TB is the leading cause of death among people living with HIV and is responsible for 
one-quarter of all HIV-related deaths, especially in sub-Saharan Africa where it estimated that 
80% of the TB cases from African nations are among people co-infected with the virus (1). In 
addition to HIV-TB co-infection, diabetes mellitus (DM) is now recognized as a major 
impedance to the successful treatment of TB infection. Persons with DM have a significantly 
increased risk (2-3X higher) of active TB. In countries such as China and India the prevalence of 
DM has increased dramatically in recent years and the implementation of dual DM-TB screening 
efforts among local clinics has helped to identify cases of dual burden (5-7).  
In order to fully realize the early and long-term goals set by the Stop TB global initiative the 
annual diagnoses of new TB cases must be dramatically improved from the estimated new case 
rate of 1.8 million per year. To achieve this goal there must be: (1) The development of rapid, 
accurate and inexpensive diagnostic tools to better identify cases of subclinical latent infection; 
(2) The design of new drugs and identification of new drug targets in order to circumvent 
problems of multi-drug resistance, and (3) Scientists and medical doctors need to understand the 
differences in virulence among clinically relevant strains and characterize the host factors that 
are responsible for determining the ultimate fate of disease outcome (i.e. progress into active or 
latent disease) (8).  
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1.1.2 Diagnosing Tuberculosis and the Need for Improved Diagnostic Tools 
TB is most universally diagnosed by direct microscopy of patient sputa or through the 
positive culturing of M. tuberculosis in clinical settings (9). In high burden countries direct smear 
examinations of non-concentrated sputum samples remains the “gold standard” necessary for the 
diagnosis of tuberculosis in most patients. Smear examination is subjected to acid-fast staining 
procedures such as the Ziehl-Neelsen stain or the auramine O fluorescence acid-fast stain (10). 
Staining in such a manner is dependent on the mycobacteria (and related actinomycetes) to retain 
the red staining dye after treatment with a mild acid-alcohol solution. The retention of the dye is 
due to the unique physiochemical properties of the mycobacterial cell envelope (i.e. the 
hydrophobic nature of the mycolic acid core wall). Despite extensive effort by the WHO to 
improve the technical capabilities of clinical diagnosticians in endemic regions, the sensitivity of 
identification of M. tuberculosis in sputa is low (11). Less than 50% of cases deemed positive by 
culture are also positive by smear microscopy and detection rates in patients co-infected with 
HIV is down to approximately 30% (10). However, culturing the bacteria from sputum smears is 
more costly and requires specialized biosafety infrastructure and takes 6-8 weeks for positive 
colony growth to occur (12).  Immunological-based diagnosis of TB begins with the tuberculin 
skin test (TST) and the measurement of delayed-type hypersensitivity reaction to soluble 
purified-protein derivative (PPD). More sophisticated is the measurement of T cell responses to 
select antigen panels of Mtb, using IFN-γ release assays (IGRA’s) (13). IGRA’s have an 
advantage over the TST, in that these assays can distinguish between those infected with Mtb 
from those vaccinated by M. bovis, BCG, however neither the TST or IGRA methods distinguish 
between active disease and latent TB infection.  
Biomarker discovery studies for M. tuberculosis are needed in order to develop second-
generation diagnostic assays in which the ability to distinguish between active and latent disease 
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is possible. Prognostically, M. tuberculosis biomarkers could help to determine if cases of latent 
infection would progress to active disease, and monitor the successes of trial drugs (12). In this 
context, efforts must be made at the systems level (i.e. transcriptome, proteome and metabolome) 
to understand these important distinctions among a variety of disease states and clinically 
relevant settings.  
1.1.3 Drug Resistant Tuberculosis and the Search for Novel Drug Targets. 
The emergence of drug-resistant tuberculosis was first observed shortly after the clinical 
use of streptomycin in the 1940’s and 1950’s (14,15). Ultimately the use of antibiotic 
monotherapy was replaced with a standard regimen of three to four drugs all working against 
distinct protein targets in the inhibition of cell wall biosynthesis (Isoniazid (INH), Ethambutol 
(EMB)) and protein translation (Rifampin (RIF), Pyrazinamide (PZA))(16). Currently the 
standard antibiotic regimen for active pulmonary TB is comprised of three drugs – INH, RIF and 
PZA. For susceptible M. tuberculosis strains, this regimen is prescribed for duration of 6 months. 
Multi-drug resistant TB (MDR-TB) accounts for approximately 4-6% of new TB cases 
worldwide (1). MDR-TB is defined as being resistant to both first-line drugs (i.e. INH/RIF). 
Treatment of resistant cases of infection requires the use of second line drugs for 18-24 months. 
This is a costly endeavor and is difficult to attain in resource-poor countries where MDR-TB 
may be commonplace (17). Drug resistant bacilli result from mutations of the genetic code.  
These changes result in the alteration of key amino acids within the primary sequences of target 
enzymes, negating the intracellular effectiveness of each drug. For INH resistance, mutations in 
two genes, inhA and katG, most dominantly define the drug-resistant phenotype (18-20). The 
primary target enzyme for isoniazid is the enoyl acyl reductase InhA (21). However INH in its 
pro-drug form must undergo activation by the catalase-peroxidase KatG prior to its binding 
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InhA.  Mutations in either of these genes prevent the drug from inhibiting the synthesis of 
mycolic acid, a key component in the cellular envelope.  For RIF, the cellular target is the RNA 
polymerase RpoB and mutations in the RpoB gene overwhelmingly represent RIF resistant 
clinical cases and are commonly associated with MDR-TB (22).  In addition to the increasing 
prevalence of MDR/XDR cases caused by inheritable genetic resistance mechanisms, drug-
tolerant bacilli confer resistance to drug treatment due to changes in their physiological and 
metabolic state (23) (Figure 1.1). The ability of M. tuberculosis to enter into a “phenotypically 
drug-resistant”, non-replicating dormant lifestyle is clinically defined as Latent TB infection 
(LTBI) (24). Treatment of such infections with standard drug regimens is problematic and 
requires a prolonged treatment duration (23,25). Identification of new drugs, with novel modes 
of action that are active against M. tuberculosis during varying physiological stages of infection 




Figure 1.1 – Physiological Metabolic States of Mycobacterium tuberculosis. 
In response to micro-environmental stressors, M. tuberculosis is capable of surviving in a 
multitude of physiological states. Survival throughout these stages depends on changes within 
the macromolecular architecture of the cellular envelope, which diminish our capacity to detect 
the pathogen and diagnose infection. Drug tolerance or resistance is characteristic of bacteria 
existing in a state of non-replicating persistence or dormancy and new drugs are needed to better 








1.2 History of Tuberculosis 
The etiologic agent of tuberculosis was first characterized in 1882 by Dr. Robert Koch 
however its history as a communicable disease of man and animal dates back thousands of years. 
The oldest proven case of mycobacterial disease was discovered in a 17,000-year-old bison in a 
North American cave (26) and biomarkers of M. tuberculosis-specific lipids remain detectable in 
this ancient specimen (27). In humans, evidence of tubercle lesions was first described in the 
9,000-year old skeletal remains of a woman and child within present day Israel (28). Evidence of 
Mtb infection has also been found in Egyptian and Peruvian mummies (29,30).  
Sociological and anthropological research has explored the impact Tuberculosis has had 
throughout history within social contexts. Analyses of ancient writings provide detailed 
descriptions of persons afflicted with pulmonary TB (31). The disease, believed to be caused by 
poverty, uncleanliness or immorality, had an overall negative social stigma. Evidence in ancient 
written records and death records seem to have downplayed the existence of TB disease (32). In 
the 17th, 18th and 19th centuries, new understandings and major social reforms, such as improved 
sanitation and housing and better nutrition were undertaken to reduce the prevalence of disease 
(33). Late in the 1800’s TB patients were isolated and treated in sanitariums in an active attempt 
to control disease outbreak (34). 
It wasn’t until the 1940’s that scientists discovered that streptomycin was an effective 
treatment for Mtb infection (15) however treatment with streptomycin alone led to antimicrobial 
resistant bacilli. Isoniazid was introduced in the mid-1950’s a miracle drug against Mtb and 
rifampin a few years later (35).  By the next decade, it was recognized that a combination of 
drugs was the most effective treatment for TB (14,36) and cases began to substantially decrease 
until the 1980’s and cases of multi-drug resistance began to emerge. Multi-drug resistant strains 
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are resistant to both rifampin and isoniazid and in 1993, the World Health Organization declared 
tuberculosis a global emergency (31).  
1.3 Physiology of M. tuberculosis - The Cellular Envelope 
M. tuberculosis is a rod shaped bacillus measuring 2 - 4 µm in length and has a doubling 
time of 18-24 hours. The cell envelope of M. tuberculosis is comprised of an inner plasma 
membrane, and a cell wall core built of peptidoglycan, arabinogalactan and mycolic acids.  
Surrounding this core is a capsule-like outer structure of non-covalently linked glycans, lipids 
and proteins (37) (Figure 1.2).  The chemical structure of the cell wall core and its constituents 
has been extensively studied and reviewed (38-44). Professor David Minnikin first proposed a 
seminal model of the structural composition of the mycobacterial cell envelope in 1982. He 
described a lipid bilayer - type architecture with an inner leaflet of mycolic acids attached to 
arabinogalactan and an outer leaflet of extractable phospholipids, glycolipids, peptidolipids and 
mycosides (45,46). Full elucidation of the mycobacterial structural core demonstrated more 
sophisticated model of interconnected networks between covalently attached and non-covalently 
linked macromolecules. In this depiction, the extractable lipids are intercalated into both leaflets, 
along with the extending carbon chains of the mycolic acids (47). The mycolic acids (MA) are 
long chain (C60-C90) α-branched, β-hydroxylated fatty acids (45,46) and comprise a core 
structure covalently attached to an inner complex of arabinogalactan and peptidoglycan (mAGP). 
This material accounts for ~ 60% of the dry weight of the bacillus. The highly cross-linked 
peptidoglycan (PG) is comprised of repeating units of N-acetyl glucosamine (GlcNAc) and N-





The penta-peptide side chains of PG are comprised of L-alanyl-D-isoglutaminylmeso-
diaminopimelyl-D-alanine (L-Ala-D-Glu-meso-DAP-D-Ala-D-Ala) (39). The degree of cross-
linking in mycobacterial PG is estimated to be 2.5 times greater than in that seen in E. coli (70-
80% versus 30-50-%, respectively) (38). Differential cross-linking patterns have been observed 
to occur between actively growing and dormant state bacteria potentially allowing the bacterium 
to survive through a variety of physiological and metabolic phenotypes (49). The L, D-
traspeptidases, LdtA and LdtB catalyze this differential cross-linking. The PG layer is covalently 
attached to the arabinogalactan (AG) polysaccharide via the C6 of some of the MurNAc or 
MurNGly residues (50). Structurally the AG is composed of elemental sugars of arabinose and 
galactose  (51,52). The linker unit is characterized as a two-sugar phosphate bridge of L-Rha(p) 
Figure 1.2 – Schematic Representation of the Major Components of the 
Mycobacterium tuberculosis cellular envelope. CM – Cellular (plasma) membrane; PG 
– Peptidoglycan; mAG – mycolyl-arabinogalactan. The outer capsule comprises non-
covalently attached glycans, lipids and proteins.  
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and D-GlcNAc (41). Like the structure of PG, the molecular features of AG are well defined 
(41). In addition to their utilization in the MA-core of the M. tuberculosis cell wall, additional 
mycolates are also key components of the virulence associated transport molecules trehalose 
monomycolate (TMM) and treholse dimycolate (TDM) (53,54). Additionally, several lipid and 
glycolipid components decorate the cell wall and contribute uniquely to the pathogenesis and 
virulence of the bacillus. These cell envelope associated virulence factors are summarized in 
Table 1.1.  
Table 1.1 Cell Envelope Associated Virulence Factors 





Outer leaflet of cell 
envelope 
Inhibits phagosome 
maturation, apoptosis and 
IFN-γ signaling (55) 
Lipomannan (LM) Immunomodulation 




Precursor to LAM (55) 




responses and cytokine 
secretion (57) 
Inhibits granuloma 





Blocks release of TNF-α, 




Neutral glycolipid  
Immunomodulation 
Induces cytokines, 
granuloma formation (60) 
Toxic  
 
1.4 The M. tuberculosis Cell Envelope in the Context of the Host 
The unique composition of the mycobacterial cell wall allows the bacterium to adapt to its 
intracellular environment and promote its survival and pathogenicity within an infected host cell 
(42). The dense hydrophobic outer lipid mycolate layer and the capsule control the permeability 
of the bacterial cell to small hydrophilic molecules.  The ability of such molecules to be shuttled 
both into and out of the cell remains poorly understood. Generally speaking however, pore-
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forming proteins, hydrophobic diffusion and lipo-peptide/protein mediated transport are the 
likely mechanisms contributing to cell wall permeability (61). Like those of gram-negative 
bacteria, pore-forming proteins allow the import and export of nutrients and other 
macromolecules. The pore-forming outer membrane protein OmpA is considered a virulence 
factor that mediates survival within host phagosomes (62). In Corynebacterium, two-component 
channels within the cell envelope have been described (63).  The lipoproteins of M.tuberculosis 
are highly enriched within the cell wall core (64), however their various cellular functions 
remain largely unknown. Several are strong immunogens (19kDa (lpqH) (65,66), 38kD (PstS1) 
(67) and are potent stimulators of IL-12 production in human macrophages. This induction is 
mediated by the pattern recognition receptor Toll-Like Receptor - 2 (TLR-2) (68). Specific 
functions for only a few proteins have been described. For example, the 38kDa lipoprotein is a 
phosphate-binding protein implicated in the active transport of nutrients (69), and LpqM has 
recently been described as a metalloproteinase necessary to mediate conjugal DNA transfer (70). 
Probably one of the most well characterized lipoproteins is LprG. In addition to its TLR2 agonist 
activity, LprG was shown to bind the triacylated glycolipids lipoarabinomannan (LAM), 
lipomannan (LM) and phosphatidylinositol mannoside (PIM).  The binding of glycolipids by a 
cell envelope associated lipoprotein may be indicative of their functional roles in glycolipid 
assembly and transport (71). In addition, LAM, LM and PIM, as described in Table 1.1 play key 
roles in other immunoregulatory processes. For example, LAM from virulent M. tuberculosis, 
but not from the avirulent M. smegmatis is capable of blocking phagosome maturation, apoptosis 
and the secretion of inflammatory cytokines such as IL-12 and IFN-γ (55). This phenomenon is 
attributed to differences in the modifications of the molecule’s terminal arabinose residues. LAM 
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isolated from M. smegmatis is pro-inflammatory due to the addition of a phospho-myo-inositol 
on the terminal arabinose sugar moiety (55). 
1.5  M. tuberculosis Infection 
M. tuberculosis is usually transmitted via close-contact aerosol (i.e. cough) originating 
from a person with active disease. Primary tuberculosis commonly occurs within twelve months 
of initial exposure, however the majority (90%) of infected persons effectively contain the 
bacteria without the onset of clinical symptoms (termed latent tuberculosis infection, LTBI). This 
immunological phenomenon is not well understood, however many factors are thought to 
contribute to the variance seen in the onset of clinical disease. Some of these factors are likely 
due to the virulence of the inhaled organism, the number of repeated exposures and the 
immunocompetence of the infected individual (72).  
Once transmitted, M. tuberculsosis takes up residence within alveolar macrophages and 
dendritic cells. Inhalation of as little as 10 bacilli is enough to initiate infection 
(http://www.cdc.gov/tb/topic/laboratory/BiosafetyGuidance_xdrtb.htm). Macrophages and 
dendritic cells resident in the airway first ingest the bacterium and initiate the production of pro-
inflammatory cytokines such as interleukin (IL)-12, IL-1β and TNF-α (73). IL-12 is critical for 
Th1 cell mediated immunity (74) and TNF activates macrophages to initiate killing and 
apoptosis and to secrete cytokines such as IFN-γ (72). Anti-inflammatory cytokines such as IL-
10 and TGF-β,  along with the immunosuppressant functions of Treg  cells can benefit the host by 
limiting inflammation and minimizing tissue damage in response to infection. However these 
functions also contribute to a less efficient bactericidal immune reaction (75). Infected host cells 
in the lungs and airway epithelium migrate to the thoracic lymph nodes to present antigen to 
CD4 and CD8 T cells (76). However, in the case of M. tuberculosis infected cells this priming 
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function is delayed for many days. Classic works by Wallgren and Poulsen clinically observed 
that the cellular immune response, as determined by TST skin test, could not be measured for at 
least 42 days in patients exposed and infected with M. tuberculosis (77,78). In mice, it has been 
shown that the migration of infected DCs and the appearance of antigen specific CD4 T cells 
does not occur before 11-14 days post-infection (79,80).  It is unclear why the migration of 
infected cells to the draining lymph nodes is delayed for such a significant period of time, 
however it may have something to do with inhibition of migratory receptors such as the CC-
chemokine receptor 7 as well as the apparent ability of M. tuberculosis to subvert apoptotic 
events initiated by neutrophils (81,82). Despite this delay in adaptive immune response, primed 
CD4 and CD8 T cells are able migrate back to the site of infection along with activated 
macrophages and B cells, initiating the formation of a granuloma (83). In addition, other cells 
such as monocytes, neutrophils and fibroblasts contribute to final architecture of the 
granulomatous lesion (84). Interesting studies using the zebrafish model of M. marinum, have 
demonstrated that early events in granuloma formation (i.e. the recruitment of uninfected cells) 
actually result in the subsequent infection of newly recruited cells (85). It is at this point the 
lifecycle of the bacterium and the immunological response to infection is thought to reach 
equilibrium (82). The actively replicating bacilli adopt alternative metabolic lifestyles (Figure 
1.1) (23) and gain the ability to survive within the protected microenvironment of the granuloma.  
1.5.1 Mycobacterial Antigens and the Host Immune Response   
M. tuberculosis is an intracellular pathogen. A host cell has many defensive strategies in 
which invading bacteria (or viruses) must subvert in order to successfully propagate infection. 
Mycobacteria spp. have co-evolved with surrogate hosts for millennia and have developed 
exquisite evasion mechanisms designed to ensure immune modulation and survival.  As with all 
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microbial species, the stimulation of the immune response is primarily initiated by the interaction 
between the cell envelope surface and host cell pattern recognition receptors. As mentioned in 
the previous section, the first demonstration of an antigen-induced immune response to 
mycobacterial species was the development of tuberculin by Robert Koch in 1890 (86). 
Tuberculin was a crude, non-specific preparation of mycobacterial products released into the 
culture medium upon heat inactivation of M. tuberculosis. Fatal reactions in “vaccinated” 
tuberculosis patients demonstrated the potent-immunoreactivity of the tuberculin preparation. 
Skin-reactivity, in the form of reddened induration was observed at the site of tuberculin 
injection in people previously known to have TB (87). The diagnostic potential of this 
preparation was further refined two decades later by Florence Seibert who determined the 
tuberculosis specific response (termed delayed-type hypersensitivity) could be assigned to a 
protein-enriched fraction of tuberculin (88). The proteomic composition of modern preparations 
of tuberculin (i.e. purified protein derivative, PPD) and relevant perspectives of immune-
diagnostics of TB has been recently published (89,90).  
Vaccination with BCG protects individuals throughout childhood and into adolescence. 
However, the WHO reports millions of newly infected persons each year. Childhood vaccination 
against M. tuberculosis is common practice among TB endemic regions worldwide. The vaccine 
is a live-attenuated strain of Mycobacterium bovis, BCG (1). It first came into use during the 
1920’s but didn’t become routine practice until after World War II (91). BCG vaccination in 
children is critical for the protection against infection with milliary tuberculosis and tuberculosis 
meningitis (92). However, immunity to M. tuberculosis wanes over time, and seems to be 
variable among geographical regions, resulting in an overall measured efficacy of 80% (93). 
Additionally, as this vaccine is a live-attenuated strain of M. bovis, the characteristic delayed-
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type hypersensitivity is induced when PPD is administered in diagnostic setting. This makes 
distinguishing BCG vaccination from latent infection difficult (94). Further, the immunological 
factors that distinguish active TB cases from those of “healthy” contacts (i.e. persons with close-
contact to TB patients showing no signs of disease), or persons with LTBI are not fully 
understood (95-98). However it is known that antigen-specific T cells with the ability to secrete 
IFN-γ (and other inflammatory cytokines) are necessary to invoke a productive cellular immune 
response (73,82).   
Characterization of both protein and non-protein agonists responsible for effective and 
long-lasting immune responses in human cases of M. tuberculosis infection will aid in the 
development of both novel diagnostic reagents and vaccine candidates. During the 1950’s and 
1960’s, the immunological properties of the extracted polysaccharide fraction of the bacillus 
were first elucidated. In these studies, crude envelope preparations comprised of arabinomannan, 
arabinogalactan and mannan (then termed Wax D) were shown to precipitate with antibody 
(precipitin positive reaction), interact with complement and stimulate hemagglutination with 
rabbit antiserum (99-102). Processing and presentation of mycobacterial antigens was also 
studied in the context of whole, heat-killed bacterium (103) or by live infection of murine 
macrophages (104). These studies and others demonstrated the immunostimulatory properties of 
the cell wall and that these antigens could be presented to the host cell surface to activate the 
cell-mediated immune response (105).   
Barnes and Hirschfield characterized the protein and peptide antigens of the cell envelope 
responsible for T cell stimulation and the induction of protective immunity (106,107). Cell wall 
associated antigens were tested in tuberculosis patients and healthy, tuberculin skin-test positive 
individuals. In the study of Barnes, et al., it was demonstrated that the protein-peptidoglycan 
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complex evoked similar immune responses to that induced by whole M. tuberculosis sonicate. 
Antigen-specific T cell lines were generated and identified several protein species ranging in size 
from 10 – 65 kDa, as having strong immunostimulatory activity. Three clones were also able to 
recognize protein antigens in the secreted culture filtrate isolated from in vitro grown M. 
tuberculosis (106). CD4 T cells respond to antigenic peptides presented on the cell surface of 
macrophages and dendritic cells in the context of major histocompatibility complex II (MHC II), 
while CD8 T cell antigens are presented on the host cell surface by MHC I molecules. The 
repertoire of CD4 and CD8 T cell antigens has been studied for some time and have associated 
the immune response to the antigenicity of many secreted proteins of the culture filtrate, 
including post-translationally modified proteins such as the 19kDA glyco-lipoprotein and the 
45kDa glycoprotein Mpt32 (106,108-112). Antigen discovery efforts have expanded with the 
utilization of genomics and proteomics based strategies in which families of antigenic gene 
products could be derived from sequencing of the genome. From this information, using genome 
fragment libraries identified a number of novel CD4 T cell antigens (112). Lists of cell envelope 
associated CD4 and CD8 T cell antigens are provided in Tables 1.2 and 1.3, respectively.  
Table 1.2 M. tuberculosis Antigens Recognized by Human CD4 T Cells 
Name 1 Gene Annotation Function 2 
DnaK/Hsp70 Rv0350 Chaperone 
GroEL2/Hsp65 Rv0440 Chaperone 
GroES/Hsp10 Rv3418c Chaperonin 





Ag85b Rv1886c Mycolyl-transferase/ 
fibronectin binding 
Ag85c Rv3803c Mycolyl- 
transferase/fibronectin 
binding 
Esat6 Rv3875 Virulence Factor 
Cfp10 Rv3874 Virulence Factor 
TB10.4/EsxH Rv0288 Virulence Factor 
TB10.3/EsxR Rv3019c Unknown 
TB12.9/EsxQ Rv3017c Unknown 
Mpt64 Rv1980c Unknown 
TB8.4 Rv1174c Unknown 
EsxN Rv1793 Unknown 
EsxV Rv3619c Unknown 
EsxL Rv1198 Unknown 
Esxl Rv1037c Unknown 
EsxO Rv2346c Unknown 
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PepA Rv0125 Serine protease 
PPE4 Rv0286 Unknown 
PPE18 Rv1196 Unknown 
PPE46 Rv3018c Unknown 
PPE47 Rv3021c Unknown 
PPE68 Rv3873 Unknown 
PE35 Rv3872 Unknown 
Hbha Rv0475 Adhesin 
LpqH Rv3763 Lipoprotein/Unknown 
PstS1 Rv0934 Phosphate Transport 
Mpt32/45kDa Rv1860 Glycoprotein/Unknown 
Rv1733c Rv1733c Transmembrane Protein 
Rv2029c Rv2029c Phosphofrucktokinase 
Rv2627c Rv2627c Unknown 
Rv2628 Rv2628 Unknown 
Rv2653 Rv2653 Prophage 
Rv2654 Rv2654 Prophage 
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Rv3407 Rv3407 Unknown 
 
1. Reference (113) 
2. Tuberculist (http://tuberculist.epfl.ch/) 
 
Table 1.3 M. tuberculosis Antigens Recognized by Human CD8 T Cells 
Name 1 Gene Annotation Restricting Allele2 
LpqH Rv3763 HLA-A2 
Ag85A Rv3804c HLA-A2 
Ag85B Rv1886c HLA-A2 
Ag85 Complex Rv3804c/Rv1886c/Rv3803c HLA-B35 
Ald Rv2780 HLA-A2 
CFP10 Rv3874 HLA-B3 
ESAT-6 Rv3875 HLA-A6802/B53/A2 
GlnS Rv2220 HLA-A2 
GroEL2/hsp65 Rv0440 HLA-A2 
HspX Rv2031c HLA-A2 
Mtb8.4 Rv1174c HLA-B3514/1501 
Mtb9.8 Rv0287 HLA-B0801/A0201 
Mtb39 Rv1196 HLA-B44 
Rv2093c Rv2093c HLA-B35 
Rv0341 Rv0341 HLA-A2 
SodA Rv3846 HLA-A2 
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1. Reference: (113) 
2. Reference: (114) 
1.5.2 The CD4 T cell Immune Response 
CD4 T cell immunity to mycobacterial infection is one of the essential defense 
mechanisms needed to minimize the progression of disease. Persons with acquired 
immunodeficiencies such as a positive HIV status, have an increased likelihood of developing 
TB disease from 5%-10% over a lifetime to 10% per year (115). Furthermore, persons with 
defects in genes that encode for the inflammatory response cytokines and/or their receptors (IFN-
γ, IL-12 and IL-23) are unusually susceptible to severe mycobacterial infection (116). Some 
patients that develop autoantibodies against IFN-γ, for example also are prone to uncontrolled, 
disseminated infections. In cases of advanced stages of disease or disseminated infection within 
previously immunocompetent individuals, it is commonly observed that patients have diminished 
CD4 T cell responses to characteristic antigenic repertoires (113). In the laboratory, depletion of 
CD4 T cells in mice results in severe impairment of the immune response to M. tuberculosis 
(117). Secretion of IFN-γ by both CD4 and CD8 T cells is key to macrophage activation and 
killing of infected cells (83). And it has recently been demonstrated that CD4 T cells must 
effectively secrete this cytokine in order to obtain optimal stimulation and co-secretion from 
other T cell subsets during M. tuberculosis infection in the mouse (118). This study and others 
suggests that future vaccine strategies that focus on CD4 T cell-specific immunity are needed not 
only to enhance the primary response to acute infection, but are also necessary to improve the 
efficiency of disease clearance mechanisms employed by other T cell subtypes such as CD8 
effector cells.  
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1.5.3  The CD8 T cell Immune Response 
Immunity to infection with M. tuberculosis requires both CD4 and CD8 T cells for 
successful control of infection. In humans, both cellular phenotypes have redundant functions 
such as cytolysis and the release of IFN-γ and TNF-α (119,120). The targeting of infected host 
cells for apoptosis has also been demonstrated for both cell types through the release of 
granulysin and induction of the perforin-granzyme pathway or through the Fas-Fas ligand 
pathways (121,122). However several studies have addressed the unique role CD8 T cells can 
play in the host defense against mycobacterial infection. In the mouse model of TB, a protective 
role for CD8 T cells in the host response was demonstrated in studies of adoptive transfer or in 
vivo depletion of CD8 T cells (117,123). In humans, unlike for CD4 T cells and their depletion in 
cases of HIV+ co-infection, the role of CD8 T cells in protection against M. tuberculosis is not as 
clear, however several hypothesis have been put forth. For example, using CD8 T cell clones 
from latently and actively infected individuals, CD8 T cells were shown to preferentially 
recognize and kill heavily infected dendritic cells and macrophages (124). This phenomenon was 
not observed for populations of CD4 T cells. From this work it was hypothesized that CD8 T 
cells may work to recognize cells in which the intracellular mycobacterial containment within 
the phagosome has been subverted, in which case cytolytic processes could then be initiated. 
Furthermore it has been demonstrated that antigen specific CD8 T cells are capable of 
recognizing M. tuberculosis residing in MHC class II negative cells (i.e cells incapable of 
presenting antigen to CD4 T cells) (125).  CD8 T cell antigens are presented in the context of 
MHC class I, a molecule that is present in all nucleated cells. This gives CD8 T lymphocytes an 
increased repertoire of cells in which to identify pathogen specific antigens. In individuals 
presenting with active TB disease, it is well established that M. tuberculosis resides within 
granulomatous lesions within the lungs, however much less is known about the nature of the 
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bacterial burden in humans during persistent infection (113). This increased capacity to detect a 
wider variety of infected cells potentially gives CD8 T lymphocytes an advantage over CD4 T 
lymphocytes during stages of clinical latency (124). The relative importance of CD8 T cell 
function during prolonged infection is further supported in small animal models, despite the 
inherent difficulty of modeling latency in vivo. Andersen, et al., demonstrated a pronounced 
affect over the control of latent infection and a higher incidence of reactivation in mice depleted 
of CD8 T cells compared to CD4-depleted mice (126). Also in the mouse model, mice incapable 
of presenting antigen via MHC class I (β2m-/-) had significantly increased bacterial burden 
within macrophages (127). Furthermore, M. tuberculosis specific CD8 T cells are more frequent 
in non-human primates exhibiting long-term infection (128) and just recently it has been 
published that in young children, the frequency and abundance of CD8 T cells are a robust 
indicator and diagnostic measure of primary M. tuberculosis infection (129). All of this 
information suggests that beyond their role in cytotoxicity and immune surveillance, CD8 T cells 
and elucidation of their cognate antigens may lead to improved diagnostics in both latently 
infected individuals and children, (9,130) as well as provide a target strategy for the development 
of novel vaccine candidates. 
1.5.4  Antigen Processing & Presentation by CD4 and CD8 T Cells 
Antigen processing pathways present in professional antigen presenting cells (APCs) 
(macrophages, monocytes and dendritic cells) transform protein antigens derived from the 
extracellular milieu or from the intracellular cytosol into peptides. Peptides are subsequently 
loaded onto MHC molecules (MHC class II for CD4 T cells and MHC I for CD8 T cells) for 
display on the cell surface to T lymphocytes. In general, antigen uptake occurs through 
endocytosis of soluble antigen or through the delivery of cytosolic proteins derived from 
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intracellular pathogens. Protein antigens are digested within acidic vesicular compartments of the 
APC generating MHC II – associated peptides or are processed through the proteosome into 
peptide fragments for MHC I association. The resulting peptides have structural characteristics 
required for binding within the peptide groove of either MHC class II molecules or I and act to 
stabilize the MHC-peptide complex for cell surface expression (131). In M. tuberculosis, the 
mechanisms involved in antigen processing and presentation on MHC II are more complex and 
are critical for the induction of an effective CD4 T cell immune response and subsequent control 
of infection (132).  In addition to the classical endocytosis model of antigen uptake, the 
phagocytosis of whole bacilli by the APC also results in the introduction of antigen in to the 
endocytic-processing pathway (133). Resident within the phagosome, M. tuberculosis specific 
ligands such as glycolipids, lipoproteins and other soluble antigens (Table 1.2) are readily 
accessible to the processing machinery. These ligands are recognized by Toll-like receptors 
(TLRs) and nucleotide-binding oligomerization domain (NOD) proteins (134,135), which 
initializes the pro-inflammatory immune response and activation of naïve T cells. Several studies 
have noted one mechanism by which M. tuberculosis-infected cells may go undetected by the 
CD4 cell mediated immune response. Noss and colleagues reported that MHC II antigen 
processing and presentation in murine bone marrow macrophages infected with M. tuberculosis 
is diminished and that this decrease is to due to low levels of MHC II expression (136).  Further 
studies, summarized in a review by Harding and Boom have demonstrated that the mechanism of 
immune evasion is mediated through the actions of TLR signaling initiated by the glycolipid and 
glycoprotein antigens. This results in an overall decreased expression of the MHC II processing 
and presentation pathway (132). 
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For CD8 T cells, activation occurs via the recognition of peptide epitopes associated with 
MHC I molecules. MHC I peptides are produced by the proteolytic digestion of cytosolic 
proteins derived from foreign antigens, viruses or as with tumor cells, an overabundance of 
mutated proteins, that may trigger processing and presentation by the MHC I pathway (131). 
Two pathways – the cytosolic and vacuolar models – represent the courses of antigen processing 
onto MHC I. In the cytosolic model, mycobacterial antigens internalized by phagosomes are able 
to escape the phagosomal compartments within the APC and gain access to the cytosolic 
processing machinery which consists of enzymes associated within the endoplasmic reticulum 
(ER) and the proteosome, a multiprotein enzyme complex responsible for degrading proteins into 
peptides(137). It has also been shown that several potent CD4 T cell antigens deriving from the 
secreted proteome of M. tuberculosis are able to escape the phagosome and be presented to CD8 
T cells at the cell surface (Table 1.3) (138,139). In depth studies following the processing of 
known CD8 T cell antigens characterized the M. tuberculosis containing phagosome as an 
organelle that contains MHC I processing molecules (transporter associated with antigen 
processing – TAP and the protein disulfide isomerase – PDI) typically localized to the 
endoplasmic reticulum (140,141). Song and Harding first described the second pathway, termed 
the vacuolar model. In this system, antigen processing and loading onto MHC I occurs within the 
endosome and is TAP and proteosome independent (142). Further, presentation of exogenous 
antigens occurs with the binding of post-processed MHC I molecules (i.e. MHC I previously 
stabilized and released from the ER-Golgi complex) (143). This model is dependent on 
endosomal proteases and also seems to be more active in microenvironments of lower pH, such 
as those experienced by bacilli residing in phagosomes (144). It should also be noted that for 
CD8 T cells, presentation by MHC I molecules are described as being either classically or non-
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classically restricted (145).  MHC I complexes are described as classical or non-classical via 
their human leukocyte antigen (HLA) allele. Classically restricted HLA molecules (HLA-1a) 
HLA – A, B and C are the most genetically diverse and have over 1,000 known alleles (146).  In 
contrast, non-polymorphic MHC class 1b molecules (HLA-EFG) present a limited array of 
peptides and represent a class of specialized receptors that can present leader sequences of 
endogenously synthesized class 1a molecules (147). In addition to peptide-presenting molecules, 
unconventional antigen presenting complexes have been described as being important for 
immunity against M. tuberculosis infection. For example, CD1 molecules are recognized by both 
CD8 and CD4 T cells and are designed to bind long acyl chains of lipid antigens. CD1 molecules 
are sub-typed as group I CD1 and include CD1a-c, or group II CD1, which is comprised of 
CD1d (148). Additionally, a new non-classical molecule termed MR1 has recently been 
characterized as an innate pathogen-reactive effector function (149) and may present alternative 
small-molecule metabolites derived from microbes (150).  
1.6 Conclusion 
Tuberculosis is an ancient disease. Its long history and co-evolution among a wide variety 
of animal species has made the successful eradication of this disease one of the most difficult 
challenges faced by modern society. Discovery of the tubercle bacilli and subsequent studies 
paved the way for detailed characterization of its physiology and biochemistry. The interaction 
of M. tuberculosis with the human host is almost too complex to properly summarize and new 
knowledge and advances in the study of host-pathogen interaction are evolving every year. The 
cellular envelope in particular is a key player to successful invasion and the establishment of 
successful intracellular growth. Among bacterial species, the chemical composition of its 
macromolecular structures has to be one of the most elegantly defined (Figure 1.2).  
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Immunologically, M. tuberculosis is a formidable foe. The organism is capable of not 
only surviving within the most harsh intracellular conditions of the phagosome, it is able to 
thrive within these environments. By inducing the formation of the granuloma, tubercle bacilli 
are able to persist within host tissues for decades in a constant battle between pathogen and host. 
This clinically quiescent state is vital to disease pathogenesis, as the bacterium can remain viable 
without overt damage to its host for many years before the onset of active disease and clinical 
symptoms. An active state of growth for the organism is in a way, its downfall. At this critical 
point, invading mycobacteria are most susceptible to the actions of first and second-line drugs 
and the damage to its host threatens its lifestyle. This is also when the bacteria are most virulent, 
most likely to increase its chances of transmission and propagation throughout the population. 
Tying the unique physiology of the bacillus, specifically the composition and integrity of its 
cellular envelope, to its disease pathogenesis is the bacterium’s ability to transition into and out 
of dormancy (or non-replicating persistence) within its hosts. Further knowledge of the structural 
features and resident proteins intercalated within the cell wall and envelope complex is key to 
answering relevant biological questions regarding the unique antigenic capacity of the bacillus 
and how these unique features contribute to the immunopathogenesis of both acute and latent 
infection. Further, if we can increase our understanding of these host-pathogen interactions at the 
systems level, new and exciting developments in both the diagnosis of disease bio-signatures and 
the identification of functionally relevant protein-protein interactions responsible for persistent 
survival of the bacillus will become clinically useful for the treatment of tuberculosis. 
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Proteomics is often defined as the large-scale study of proteins within a system (1). For 
several generations the techniques and technologies utilized in this multidisciplinary field have 
rapidly evolved. Fundamentally, however three central themes in proteomics have remained the 
same: (1) The large-scale identification of proteins, (2) the identification and characterization of 
post-translational modifications and (3) the analysis of protein-protein interactions (2,3). 
Developments in the next decade in the field of mass spectrometry-based proteomics will see 
new applications of proteome analysis (4), including the labeling and characterization of 
functional sub-proteomes (5), advances in the accuracy and sensitivity of quantitative 
measurements (6) and improvements in search algorithms and data analysis tools (7). With these 
advances proteomic studies are moving beyond descriptive analyses, answering hypothesis 
driven biological questions and further developing into unique assay platforms whereby 
hundreds of proteins can be quantitatively monitored in a given system (8). For tuberculosis 
research, proteomics and mass spectrometry have become powerful tools to answer biologically 
relevant questions. These studies have contributed useful insights into pathogen biology, 
including a more comprehensive understanding of strain diversity, cellular physiology, 
immunogenicity and interactions between the host and pathogen.  
2.2 The M. Tuberculosis Proteome 
The genome sequence of M. tuberculosis was published by Cole et al., in 1998 and which 
facilitated the rapid advances in the fields of genomics/transcriptomics and proteomics. 
Comprehensive studies of the M. tuberculosis proteome focused on the characterization of 
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subcellular fractions such as cytosol, cell wall and membrane, including the proteins secreted 
from the bacillus during in vitro growth. This information was often utilized to study changes is 
protein profles under various controlled conditions or to monitor the pathogen-specific proteome 
in the context of host cells. Proteomic studies were also frequently used to gather information on 
immunodominate proteins, and identify novel  B and T cell antigens for the development TB 
vaccines and diagnostic tools.   
2.2.1 Discovery & Descriptive Analyses 
Gel-based techniques for the study of M. tuberculosis proteins provided the first two 
dimensional gel electrophoresis (2DGE) reference maps of soluble protein fractions. Prior to the 
publication of the genome sequence of M. tuberculosis, H37Rv, Sonnenberg et al., successfully 
resolved the secreted immunodominant culture filtrate proteins of the bacillus, visualizing over 
200 protein spots. Using a combination of western blot analysis, N-terminal Edman sequencing 
and LC-MS of digested protein spots, approximately 40 proteins were characterized. This study 
also described the first observation of a then novel member of the Ag85 complex, Mpt51(9). 
Subsequent studies using 2DGE improved the resolving power of the gels by expanding the 
range in the first dimension separation, using immobilized pH gradients. The combination of the 
complete genome sequence (10) and the successful resolution of both secreted and cell 
associated protein fractions by 2DGE, facilitated the identification of hundreds of protein species 
by tandem mass spectrometry (LC-MS/MS). These included the first proteomic description of 
differences between the lab strain of H37Rv and vaccine strain M. bovis, BCG (11,12), and the 
development of the first online 2DGE database of M. tuberculosis proteins (http://www.mpiib-
berlin.mpg.de/2D-PAGE) (13). Despite the success of these initial studies, there were known 
limitations of 2DGE technology, especially in the identification of low-abundance proteins and 
proteins within highly insoluble fractions such as membrane and cell wall. Turning to liquid 
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chromatography-tandem mass spectrometry (LC-MS/MS), facilitated the identification of many 
more proteins using non-gel based approaches... Using LC-MS/MS in combination with 2DGE 
resulted in more comprehensive descriptions of the secreted proteins of the culture filtrate (14), 
cytosolic and cell wall proteins (15,16), whole cell lysate (17) and membrane fractions (18-21). 
Studies such as these represent a more than two decades of work in the field of proteomics. 
Computationally, each study pushed the limits of available bioinformatics tools that were built 
upon genomic sequence information and from this work, the reliability and accuracy of 
predictive algorithms (i.e. secretion signal prediction) could be verified (22). For other 
computational tools, such as transmembrane domain prediction, validating the presence or 
absence of membrane proteins was another challenge taken on in the study of the membrane 
proteome. The routine use of LC-MS/MS facilitated the identification and characterization of 
many predicted transmembrane proteins. Increased instrument sensitivity also allowed for the 
identification of other membrane-associated proteins with no physiological transmembrane 
features, thus new protein complexes were potentially defined  (23,24).   
2.2.2 Proteomic Analysis in vivo & Conditions Mimicking Host Environment 
Proteomic studies of M. tuberculosis grown in liquid culture are very valuable to the 
research community as baseline descriptions of the presence or absence of proteins within a 
fraction of interest. However, the ability of M. tuberculosis to invade the body and occupy 
unique niches within a host is a defining characteristic of the bacillus and recognizing proteins 
that are present during natural states of infection will aid the development of second-generation 
diagnostic reagents and identify relevant proteomic targets in the design of novel 
chemotherapeutics. Recently, the M. tuberculosis proteome was described during in vivo 
infection of guinea pigs. Proteomic profiles of M. tuberculosis isolated from granulomas were 
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characterized at day 30 post-aerosol challenge and compared to the proteomic profile of isolated 
bacilli at day 90. In this study, over 500 proteins were identified from M. tuberculosis isolated 
from the granulomas of infected guinea pigs (25). Proteins involved in nitrogen assimilation and 
cation transport were shown to be the least variable throughout the course of infection. When 
compared to representative in vitro models of gene transcription, the most correlative model was 
that of non-replicating persistence (NRP) in which the gene expression profile of the 
microaerophilic (NRP-1) was compared to the anaerobic, dormant state (NRP-2)(26,27). 
However, it was noted there was very little overlap between the in vivo-generated dataset and 
prior in vitro models simulating the host environment (26,28-31). Interestingly, the proteomic 
profile of bacilli isolated from the infected lung tissue of the guinea pig demonstrated the least 
correlation with models of nutrient depletion, leading to the hypothesis that the bacilli within an 
infected host are not as deprived of nutrients as once thought, as many proteins involved in lipid 
degradation were identified in this work (25). A second notable contrast between in vivo 
proteomic data and expression profiles generated during conditions mimicking the host 
environment was the absence of known secreted, immunodominant antigens such as HspX and 
other typically dominant proteins such as GroEl and DnaK (32). Kruh et al., hypothesized this 
was due to the rapid secretion of these proteins into the host milieu where their trafficking to the 
draining lymph node may occur or alternatively these proteins could be rapidly degraded.  To 
date, this has been the only proteome-based identification of proteins in the context of a 
mammalian host.  
As mycobacteria infect the cell, the bacilli are engulfed within phagosomal compartments 
in which they encounter several hostile host factors. Thus, several proteomic profiles unique to 
intraphagosomally grown M. tuberculosis have identified proteins unique to this phase of 
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virulence. Lee and colleagues first observed changes at the protein level when metabolically 
labeled proteins were monitored during intracellular growth in a human macrophage cell line. 
Labeled proteins were separated by 2DGE and unique changes in protein profiles were observed 
under conditions of heat-shock, low pH and in the presence of peroxides (33).  Following this 
work, Monahan and Betts et al., studied the intraphagosomal protein profile of the vaccine strain 
M. bovis, BCG. They determined six proteins to have increased abundance inside macrophages, 
most of which are involved in the stress response or transition into dormancy (34). These 
included chaperones GroEL1/2 and the heat shock protein HspX as well as the hypothetical 
protein Rv2623 – a protein known to be regulated by DosR. In 2006, Mattow and colleagues 
identified eleven proteins exclusive to phagasomal infection, including the malate dehydrogenase 
(Mdh) and the peptidyl-proline-cis-trans isomerase (PpiA) (35).  
Studies of the in vivo (or in situ) characterization of mycobacterial proteomes are 
relatively scarce. Most likely this is due to the lack of suitable methods for overcoming the 
extremely high abundance of host proteins in comparison to bacterial proteins and their accurate 
identification and quantification in high background. However, the methods employed within the 
in vivo proteome dataset demonstrate improvements in technical and computing resources that 
will facilitate similar, more targeted studies in the future.  
2.2.3 Comparison of Virulent & Avirulent Strains  
As mentioned above, the first proteomic analysis of both the virulent H37Rv and the 
avirulent M. bovis, BCG vaccine strain of mycobacteria was undertaken over a decade ago in an 
attempt to describe novel virulence determinants (11,13). The induction of protective immunity 
via BCG vaccination is attributed to the highly abundant secreted proteins which are presented to 
the immune system more efficiently with a live vaccine (36). Proteomic comparisons by 2DGE 
identified several proteins unique to each species. The M. tuberculosis specific proteins included 
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the 40kDa antigen Ald, the immunostimulatory antigen Mpt64, and members of the ESAT-6-like 
protein cluster, including Cfp10. ESAT-6 and Cfp10 are now used as M. tuberculosis-specific 
diagnostic reagents in the quantiferon-Gold immunoassay (37,38). Other antigens unique to M. 
tuberculosis include several hypothetical proteins (Rv0020c, Rv1684, Rv1893, Rv3046c, 
Rv3881c, Rv1198 and Rv1793), the chaperone GroES and elongation factor EF-Tu (39).  These 
proteins could potentially be used in the design of novel vaccines and/or diagnostic methods. 
Comparing the strains of M. tuberculosis H37Rv and M. tuberculosis H37Ra has also resulted in 
the identification of proteins unique to virulent strains. One study observed the upregulation of 
eleven proteins in H37Rv and the down regulation of three (40). Most recently, Målen and 
colleagues compared the proteomes of these two strains using label-free quantitative proteomics 
(described below) where more than 1700 proteins were identified from both strains. They 
identified 29 membrane-associated proteins. 19 proteins were higher in abundance for H37Rv, 
while 10 proteins were higher in H37Ra. Among the more abundant proteins identified in H37Rv 
were the ABC-transporters (Rv0933, Rv1273c and Rv1819c), as well as the protein-export 
membrane protein SecF (21). These studies and others demonstrate that the virulence factors at 
the proteome level are quite complex and differing pathological phenotypes cannot be attributed 
to the presence or absence of one factor or another.  
2.3 Proteomic Technologies  
The typical workflow in a proteomics experiment involves the enzymatic digestion of a 
protein sample, usually with site-specific enzymes such as trypsin.  Pre-fractionation of 
protein/peptide samples via liquid chromatography, one-dimensional or two-dimensional gel 
electrophoresis is employed to minimize the saturation levels of high abundance proteins and 
overall, yields higher proteome coverage (41). For several decades, two-dimensional gel 
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electrophoresis was the method of choice for gel-based pre-fractionation of protein samples, 
prior to enzymatic treatment. Gel-based fractionation techniques, were the technique of choice 
prior to the large-scale use of mass spectrometry (MS) for protein identification. Advances in 
throughput and MS technologies facilitated liquid-chromatography based fractionation 
techniques for the generation of peptide fractions. Once peptides are introduced into a mass 
spectrometer, fragment spectra (MS/MS spectra) are generated and recorded. Search algorithms 
such a SEQUEST (42) or MASCOT  (43) are able to align sequences in the database to the 
acquired data. Detection and identification of peptides unique to specific proteins confirm their 
presence within a given sample, where typically two unique peptides are enough to identify a 
protein (6). The following sections discuss the use of two-dimensional gel electrophoresis and 
multi-dimensional liquid chromatography techniques, with a brief review of MS technologies.  
2.3.1 Two Dimensional Gel Electrophoresis 
Early resolution of multi-protein sample sets utilized two-dimensional gel electrophoresis 
(2DGE) to generate protein maps present within cells or tissues. 2DGE technology separated 
proteins first via iso-electric point (iso-electric focusing), usually throughout relatively neutral 
pH ranges (pH 4-8) and then by molecular mass via sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) (44). Whole protein maps could be monitored over time, and 
changes to the protein profile observed (2,45). 2DGE immunoblots could be probed for reactivity 
against immune sera or protein antibodies to identify immunoreactive polypeptides and select 
protein targets (46). As a precursor to the identification of peptides via mass spectrometry, 
protein spots were excised out of the gel and processed for amino acid analysis via Edman 
degradation (47), or subjected to trypsin digestion for sequence analysis (48,49).  Fragment 
peptide sequences were searched against available databases, and proteins could be identified if 
sequences, molecular masses and predicted pI values could be cross-matched.  
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In addition to protein identification, post-translational modifications (PTM), such as 
phosphorylation and glycosylation can be visualized via 2DGE as these properties affect both the 
iso-electric point and molecular weight of proteins (50).   While a powerful technique, 
limitations to the broad applicability of 2DGE involve relatively low dynamic range, whereby 
the detection of low abundance proteins is often variable. Also, solubility issues especially with 
complex mixtures of hydrophobic proteins (i.e. membrane associated) are problematic (41) and 
increase the incidence of gel-to-gel variability. These factors, among others, limit the utility of 
traditional 2DGE to studies of relative abundance versus absolute quantification (50). New gel-
based technologies involving differential fluorescent labeling techniques such as those described 
for two-dimensional difference in gel electrophoresis (2D DIGE), expand the capabilities of 
traditional 2DGE and allow quantification of all protein spots relative to an internal standard 
(51).  However, despite these quantitative advances 2DGE is often complemented with non-gel 
based proteomic approaches.  
2.3.2 Liquid Chromatography 
The successful resolution of complex protein samples dominantly relies on at least two 
independent physiochemical properties such as those described for 2DGE. Similar to the 
separation of proteins by iso-electric point and molecular weight, complex protein samples may 
be resolved in the post-digestion process at the peptide level. Pioneering work in this field was 
accomplished over a decade ago in the Yates laboratory (52), and has since become the leading 
sample processing technique for peptide identification via liquid chromatography mass 
spectrometry (LC-MS) (53,54). Modern trends in peptide LC are focused on improving peak 
capacity through ultra-high performance liquid chromatography systems as well improving the 
capacity of multi-dimensional chromatographic techniques to streamline the processing of highly 
crude fractions prior to their introduction into a mass spectrometer (8).  
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2.3.4 Multi-Dimensional Liquid Chromatography  
In a 2DLC-based separation scheme, a protein mixture is digested by a protease (i.e. 
trypsin) and peptides are resolved in the first dimension over a strong-cation exchange (SCX) 
column, using increasing concentrations of salt in the mobile phase. These “salt-bumps” are then 
subsequently resolved over a C18 reverse phase (RP) column and directly introduced into the 
mass spectrometer for peptide identification (54). The two-dimensional approach can be tackled 
“offline” or “in-line” with the MS. In the offline method, the SCX and RP columns are setup on 
separate high-performance liquid chromatography (HPLC) systems. Fractions are collected 
manually and then undergo analysis in the MS. The LC-MS approach is advantageous because 
its peptide profiles are relatively unbiased, unlike gel-based systems in which membrane or other 
hydrophobic proteins are poorly represented. Also it is adaptable to multiple types of site-
specific (or non-specific) enzymes, increasing the probability that the majority of proteins can be 
represented in the mass spectrometer by at least one peptide (6).   
2.3.5 Affinity Chromatography 
Affinity chromatography separates proteins on the basis of a reversible interaction between a 
protein (or group of proteins) and a specific ligand coupled to a chromatography matrix. For LC-
MS based proteomics, affinity capture can be a powerful intermediate, purification tool prior to 
more precise methods such as RP-HPLC. Target proteins (or peptides) are selected out of 
complex mixtures using appropriate ligands and elution conditions. One example of affinity 
purification involves the purification of histidine-tagged recombinant proteins using immobilized 
metal affinity chromatography (55). Other examples are the use of streptavidin-conjugated resin 
to enrich for biotinylated molecules (56) or the enrichment of glycoproteins and polysaccharides 
with the hexose binding lectin, concavalin A (ConA) (57). Substances bound to either 
streptavidin or ConA resins are eluted off in the presence of competing ligand or by alterations in 
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pH. Eluted proteins are then subjected to protease digestion and peptides introduced into a mass 
spectrometer. They glycoproteome of M. tuberculosis was elucidated by first enriching 
mannosylated proteins through a ConA column purification prior to digestion with trypsin (58). 
As another example, the phosphoproteome of M. tuberculosis was characterized under a variety 
of environmental conditions and investigators were very successful at elucidating sites of 
phosphorylation for over 300 proteins. This study also employed the use of phospho-peptide 
affinity chromatography (59).  
2.4 Mass Spectrometry 
Mass spectrometry measures the mass-to-charge ratios (m/z) of ionized molecules and in 
MS-based proteomics, is used to determine the amino acid composition of peptides. A mass 
spectrometer is built from three compartments: an ion source, which converts sample molecules 
into ions, a mass analyzer that measures the m/z of the charged particles and a detector which 
measures the intensity of ions generated for each m/z value (3). The 2002 Nobel Prize in 
Chemistry was co-awarded for the development of two soft-ionization techniques -electrospray 
ionization (ESI) (60) and laser-desorption ionization (61), or matrix-assisted laser desorption 
ionization (MALDI).  ESI is capable of inducing ions from complex mixtures of molecules in 
solution and generates multiply charged species of parent ions. The ability to ionize particles in 
solution makes ESI instrumentation readily suitable for liquid-samples such as those generated 
from LC separation methods or enzymatic digests. MALDI techniques do not introduce multiple 
charge states of ions and are capable of analyzing peptide mixtures that have not undergone prior 
separation over an LC (3). For mass analysis, the ion trap, time-of-flight (TOF), quadropole and 
Fourier transform ion cyclotron (FTCIR-MS) mass analyzers are the most common in use for 
proteomics research. Ion traps, first invented in the 1950’s and 60’s can be considered the 
workhorse for routine protein identification platforms. Ions are captured in a column of 
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quadropoles and subjected to further fragmentation to generate MS/MS spectra. Traditional 
linear ion traps have relatively low mass accuracy, however are very versatile, robust and can be 
used in combination with other mass analyzers (62). FTICR-MS analyzers are also trapping 
instruments, with extremely high mass accuracy, resolvation power and dynamic range.  
However their routine operation in proteomics research is limited due to the high cost of 
instrumentation and the need for a large magnet (63). For TOF analyzers, the time it takes for 
ions with similar charge to reach a detector is measured, and this value is proportional to their 
m/z. Thus large ions will move more slowly than small ions. TOFs are usually coupled with 
MALDI ionization methods whose spectra of parent (single charged) ions are simpler to 
visualize and have been termed “peptide mass fingerprints” (64).  MS/MS fragmentation of 
MALDI-TOF spectra can be accomplished by separating two TOF sections with a collision cell 
(“TOF-TOF) (65) where amino acid sequences o peptides can be derived. TOF analyzers have 
high sensitivity, resolution and mass accuracy and can be coupled to an ESI ionization source 
(Q-TOF instruments). Using either ESI or MALDI-based instruments, raw spectra outputs are 
acquired and search algorithms interrogate comprehensive protein sequence databases, which are 
wholly dependent on the quality of available genome sequence information for a given organism. 
Whole-genome sequencing makes the provision of complete DNA/RNA sequence libraries 
possible and thus the quality of protein databases will only improve.  The two most widely used 
search algorithms in the proteomics field are SEQUEST™ (66) and MASCOT™ (43). New 
architectures of powerful MS instrumentation based on triple-quadropole (QQQ) and Orbitrap 
technologies have drastically improved sensitivity and data acquisition speed and have evolved 
the utility of MS-based proteomics from characterization of protein identifications to robust, 
quantitative assay platforms (8).  
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2.4.1 Quantitative Mass Spectrometry in the Study of the M. tuberculosis Proteome 
Techniques in quantitative mass spectrometry are either label-based or label-free. And 
facilitate the relative or absolute quantification of protein abundance changes among biological 
conditions. Several excellent reviews summarize the details of each labeling platform and their 
applicability in quantitative MS (6,8,67). Labeling techniques using radioactive isotopes were 
first used early in the days of 2DGE (45) and since then the use of stable isotopes to label cells is 
common practice (6), however for organisms with slow metabolic rates, such as M. tuberculosis 
these metabolic labeling approaches are not very efficient (68). Fortunately, chemical labeling 
techniques such as isotope-coded affinity tags (ICAT) and isobaric tags for relative and absolute 
quantitation (iTRAQ), as well as label-free spectral counting methods have proven to be very 
informative in comparing protein abundance differences between bacteria grown under various 
metabolic or environmental conditions, or characterizing protein factors that may be responsible 
for the hyper- or hypovirulent phenotypes observed for clinical isolates. 
2.4.2 Chemical Labeling Strategies 
 ICAT technology first described in 1999 is a chemical labeling technique used to study 
the relative abundance of peptides (i.e. proteins) under two different experimental conditions (6). 
It is not based on gel separation of proteins and thus is a much more versatile tool when 
comparing whole proteomes. The ICAT reagents (one heavy with 8 deuteriums, and one light) 
modify cysteine residues of peptides produced in each biological sample. A drawback to 
chemical labeling with ICAT reagents is the reliance on cysteine-containing peptides. The 
genome of M. tuberculosis does not encode for very many cysteine residues (10) and thus limits 
the utility of this chemical labeling approach. Technologies such as iTRAQ or Tandem Mass Tag 
(TMT) labels are specific for free amines generated after the digestion of protein samples (8) and 
are thus more universally applicable. These assays also enable the simultaneous study of multiple 
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experimental conditions – 8-plex systems for iTRAQ and 6-plex systems for TMT. As can be 
expected the data analysis and statistical validation that is required for the most complex of 
experimental designs is very intense, often requiring the use of mixed modeling approaches to 
find statistically significant protein abundance changes (69). 
One of the first uses of this labeling technology in the study of mycobacterial proteomics 
utilized isotope coded affinity tags (ICAT) to measure the differential abundance of large 
numbers (> 500) of M. tuberculosis proteins. Changes in the protein profile of bacteria in a state 
of NRP were observed using this approach. Characterization of proteins involved in small 
molecule metabolism, degradation and energy metabolism were observed to contribute to the 
unique protein profiles of M. tuberculosis in different metabolic states (27). The ICAT method 
relies on the labeling of cysteine residues of proteins. If the amino acid sequence of the gene 
product is devoid of cysteine residues, the labeling technique is not effective. Therefore, a less-
biased approach would be needed to make comparison between proteomes. Mehaffy et al., 
utilized iTRAQ to characterize the protein variability between closely related clinical isolates of 
M. tuberculosis. Using this approach, over 100 proteins in either the secreted culture filtrate or 
cytosolic protein fraction demonstrated quantitative differences in protein abundance among the 
three isolates tested. Basic metabolic proteins such as those involved in the TCA cycle, nutrient 
acquisition and proteins related to cell wall and cellular processes were found to be the most 
significantly different under the conditions tested (69).  
2.4.3 Label-free MS Quantitation 
Label-free methods, as the name implies, do not utilize the incorporation of stable 
isotopes into protein samples, nor do they rely on chemical modification of peptides. This 
method of measurement is especially useful when comparing large datasets. Proteins can be 
directly measured using intensity-based methods or indirectly measured using peptide spectral 
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counts (8). The spectral count technique has high dynamic range and is sufficiently reproducible 
if care is taken in the experimental setup (70).  
For M. tuberculosis, differences between hypo-virulent and hyper-virulent clinical 
isolates were quantified using a label-free spectral counting method. Similar to the iTRAQ study 
of Mehaffy, this study focused on identifying differences in virulence determinants between 
strains. Overall, 48 proteins were over-represented in the hypovirulent isolate, whereas 53 were 
over-represented in the hypervirulent. Functional classification of these proteins also identified 
proteins involved in cell wall organization and homeostasis and DNA transcription regulatory 
proteins. Also of note were the changes observed in the reduced repertoire of highly 
immunogenic proteins (Esx-like proteins and Mpt51) in the highly virulent strain (68). 
Advanced, but highly specific label-free techniques such as those used for absolute 
quantification of proteins within complex samples (single-reaction monitoring or multiple-
reaction monitoring) are becoming more widely utilized, especially in the identification of 
disease biomarkers. Applications of this technique afford the precise measurement of 100’s to 
theoretically 1000’s of specific proteins (71). This approach can also be used for comprehensive 
quantitative analysis measuring changes within primary metabolic pathways in cells grown or 
isolated from different metabolic states (72). Recently, a comprehensive set of proteins from the 
human pathogen Leptospirosa interrogans were monitored in 25 different disease states. This 
study demonstrated that in a single LC-MS/MS experiment around 5000 peptides, covering 1680 
L. interrogans proteins can be consistently detected and quantified during dynamic changes in 
the proteome (73). The utilization of MRM technology for M. tuberculosis can be modeled based 
on the studies described above. For example, differences among clinically relevant strains in 
regards to their immunogenic proteome can now be absolutely quantified. For example, a study 
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initiated in our laboratory has utilized targeted MRM strategies to characterize the differential 
abundance of the highly immunogenic Ag85 complex among six clinical isolates of M. 
tuberculosis that represent three different genomic clades (74). This is important to have 
characterized, as the major component for many second-generation subunit vaccines include 
proteins from this repertoire of antigens. As was observed previously, phenotypically hyper or 
hypo-virulent strains may alter their antigenic repertoire, making the immune response to 
infection (and by extension vaccination) less effective.     
2.5 Perspective on Chemical Proteomics & Drug Discovery for M. tuberculosis 
Beyond descriptive analyses, mass spectrometry (MS) and the field of chemical 
proteomics are being applied to answer more direct questions of protein function and regulation 
of enzyme activity. In addition, chemical proteomics in the drug-discovery pipeline enables the 
identification of direct or indirect profiling of drug-target interactions and lends itself to large-
scale selectivity profiling of hundreds of protein targets assayed against multiple drug 
chemotypes (75). Within the last decade, multiple chemoproteomic techniques and activity based 
protein probes have been developed  for profiling inhibitors of serine hydrolases (76), kinases 
(77) and histone de-acetylases (78) in the human proteome. By utilizing classical drug affinity 
chromatography techniques coupled to mass spectrometry and bioinformatic analysis (5), 
investigation of drug profiles in the physiologically relevant proteome of the mycobacterial cell 
can be accomplished. This is especially useful for the characterization of new drugs with novel 
modes of action, such as has been demonstrated in the high-throughput screening studies of M. 
tuberculosis-specific kinase inhibitors (79-83). For ATP-small molecule inhibitors specifically 
(i.e. kinase inhibitors), chemoproteomic platforms utilize active-site specific probes that are 
designed to bind target proteins in competetion with either broad range or specific inhibitors 
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(84). These probes then facilitate the enrichment of  ATP-binding proteins for profiling via MS . 
Inhibitor profiling has been successful in a wide number of disease applications (77,85,86), 
however none have investigated the utility of this approach for antimicrobial drug discovery. M. 
tuberculosis is one model organism for which these technologies can be adapted and where 
application of these techniques can have substantial impact on the identification of drug-target 
interactions and facilitate the development of novel small-molecule inhibitors for treatment of 
tuberculosis.   
2.6 Rationale and Objectives 
 
The advances described in the last several decades in the relatively new field of 
proteomics demonstrate the vast scope and potential this science has to offer, especially in the 
new era of systems biology-driven research (87,88). In contrast to genomic or transcriptomic 
studies, proteomics directly focuses on the characterization and quantification of specific gene 
products (6). For M. tuberculosis, the application of proteomic platforms to answer disease 
relevant questions related to the multi-stage infection profile of the bacillus is of great 
importance not only in the characterization of the physiology of the organism, but also in the 
detection of true M. tuberculosis infection in the absence of clinical symptoms (latent TB). 
Furthermore, this complicated disease lifecycle requires the identification and development of 
relevant progress-markers, measured during the course of antimicrobial therapy.  Within the next 
several years, advances in TB diagnostic research will see the development of LC-MS based 
methods capable of challenging the accuracy and throughput of traditional immunoassays in the 
unambiguous identification and quantification of relevant target proteins isolated from biofluids, 
such as saliva or urine (8,89).  Similarly, in the area of drug discovery, quantitative 
chemoproteomics platforms that isolate and characterize critical subproteomes can be utilized to 
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identify novel drug-target interactions of antimicrobial inhibitors in the treatment of tuberculosis. 
The work described in this dissertation applies a range of proteomic technologies and methods in 
the study of M. tuberculosis physiology and immunogenicity. We base these works in the 
hypothesis that the identification of new diagnostic reagents and drug targets can be gleaned 
from a global, whole proteome perspective of the mycobacterial cell envelope. The results of this 
study should contribute to the characterization of the mechanisms that are utilized to maintain 
bacterial survival within multiple disease states as well as the elucidation of novel epitopes 
unique to proteins of the cell wall.  
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III. CHAPTER III - Proteomic Definition of the Cell Wall of Mycobacterium 
tuberculosis 
Partially presented in Lisa M. Wolfe, Spencer B. Mehaffy, Nicole A. Kruh, and Karen M. 
Dobos. 2010. Proteomic Definition of the Cell Wall of Mycobacterium tuberculosis. Journal of 
Proteome Research. Nov 5;9(11):5816-26. Epub 2010 Sep 29. 
 
3.1 Introduction 
The cell wall of M. tuberculosis is a complex and diverse reservoir of proteins intermingled 
in a matrix of peptidoglycan, mycolic acids, lipids and carbohydrates. Collectively, the 
localization and secretion of these molecules into the extracellular milieu both stimulates (1-4) 
and represses (5-7) the host immune system, ultimately facilitating the survival of the bacillus 
throughout active infection and during stages of non-replicating persistance (8).   
Immunologically, resident and secreted proteins of the cell wall are known to mediate specific T 
cell responses, (9-12). The molecules and proteins of the cell wall also provide active means of 
antimicrobial resistance (13-15), and are generally associated with the critical processes of 
bacterial survival and immune modulation. The need for modern tools in the fight against 
tuberculosis necessitates the study and exploitation of the physiological interplay between the 
pathogen and host. In this study, we hypothesized that the cell wall proteome of M. tuberculosis 
was highly complex and that protein species associated with the highly insoluble subcellular 
fraction could lead to functional characterization of a subset of proteins that may play a role in 
host-pathogen interactions, facilitate T cell mediated immunity, and can be exploited in the 





3.1.1   M. tuberculosis Cell Wall  
For decades the macromolecular features of the mycobacterial cell wall, including the 
mycolic acid and arabinogalactan core, have been studied in detail (16). Structurally, the cell 
wall of M. tuberculosis is comprised of a distinct inner core of mycolic acid-arabinogalactan-
peptidoglycan (mAGP). In addition to the covalently attached lipids and carbohydrates, it is well 
known that the free lipids, lipoglycans and phosphotidyl inositols that reside in the outer core of 
the cell wall play key roles in modulation of the host immune response (5). Specifically, the 
molecules, lipoarabinomannan (LAM), lipomannan (LM) and phosphatidyl inositol mannoside 
(PIM) are known to aid the process of host immune evasion (17). In addition, virulence lipids 
such as trehalose dimycolate/monomycolate (TDM/TMM), phthiocerol dimycocerosate (PDIM) 
and sulfolipids (SL) and the protein machinery, such as MmpLs, required for their export are 
intercalated in the cell wall (18).  Numerous cell wall associated proteins, including many lipo 
and lipoglycoproteins, have also been described (19-21).  For example, the TLR2 agonists, lpqH 
(19kDa), phoS1 (38kDa) and lprG (Rv14llc) are all found in the cell wall (20-23) (24), where 
they function to regulate the action of macrophages and dendritic cells (25). PhoS1 also plays a 
role in bacterial escape from the host macrophage through apoptosis (26). Many other 
lipoproteins of unknown function are identified in the secreted proteome of M. tuberculosis 
culture filtrate (27-29).  
3.1.2 M. tuberculosis Proteomics 
The study of the secreted proteome of M. tuberculosis was driven by the search for novel 
immunodominant antigens, drug targets and biomarkers for disease (30-33). To build upon this 
work, a number of studies employed advances in proteomic technologies such as two-
dimensional gel electrophoresis (2DGE) and liquid chromatography mass spectrometry (LC-
MS/MS) to further mine additional subcellular compartments derived from the bacillus, such as 
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the intracellular cytosol, membrane and cell wall (34-39).  More recently, the proteomic 
definition of the bacillus in the context of the granuloma revealed the majority of the secreted 
proteome to be strikingly absent from the tubercle lesions (40). This finding could indicate either 
a rapid and efficient trafficking of the antigens in to the periphery or a rapid and efficient 
degradation of secreted protein in the host milieu. Bacterial proteins that were most dominant in 
vivo were those predicted to reside in the M. tuberculosis cellular envelope, indicating their 
overall importance in the establishment and maintenance of infection. Historically, the proteins 
within the cell wall have been difficult to resolve and identify by traditional 2DGE methods 
(32,41). Mawuenyega et al., employing two-dimensional liquid chromatography coupled with 
mass spectrometry (2DLC/MS) were the most successful at defining the cell wall proteome with 
the identification of 306 proteins (37). In this study, we set out to comprehensively describe the 
M. tuberculosis cell wall proteome in an effort to exploit additional proteins that may play a role 
in host-pathogen interactions and define new potential drug targets via discovery of unique 
biosynthetic or metabolic processes.  
3.2 Results 
3.2.1 Identification of Cell Wall Proteins 
To maximize the resolution and protein identification of cell wall proteins, the 
delipidated cell wall of M. tuberculosis was subjected to differential detergent extraction to 
maximize the solubility of a wide range of proteins. Guanidine hydrochloride (GuHCl) acts as a 
denaturant, sodium dodecyl sulfate (SDS) is a cationic detergent and Triton X-114 (TX-114) is a 
nonionic detergent. Proteins were resolved via two-dimensional gel electrophoresis (2DGE) 
using the experimental outline as depicted in Figure 3.1. 
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In comparison with the SDS and GuHCl extracts, the 2DGE separation was insufficient in 
resolving a significant number of proteins in the TX-114 detergent extract (Figure 3.2).  
This was most likely due to its increased hydrophobic content (42,43).  To better resolve 
the proteins in this fraction, a multi-dimensional chromatography approach was employed to 
enhance the resolution of any unique or uncharacterized protein families within the TX-114 
subset. From the 2DGE analysis, 290 proteins were identified with 122, 131 and 37 proteins 
identified in the GuHCl, SDS and TX-114 fractions respectively. For all fractions, over half were 
unique to each subset. Chromatographic separation via strong cation exchange (SCX),  combined 
with reverse phase chromatography of a trypsin digest of this CWP preparation, allowed the 
resolution of 364 proteins, including an additional 294 proteins not found in any of the 2DGE 
Figure 3.1 - Schematic Diagram of Cell Wall Proteome Workflow. The cell wall 
fraction was subjected to extraction with organic solvents to remove non-covalently 
bound lipids and lipoglycans and remaining proteins were either denatured in guanidine 
hydrochloride or solubilized with cationic (Sodium Dodecyl Sulfate, SDS) or nonionic 
(Triton X-114) surfactants. These extracts were resolved by 2DGE and spots analyzed by 
mass spectrometry for protein identification. 
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preparations (Figure 3.3).  Combining the data sets of both gel and non-gel based protein IDs led 
to the detection of 528 proteins, which are listed in Table form in Appendix I.  
 
 
One hundred and five of the 528 cell wall proteins identified were not reported in 
previous M. tuberculosis proteome publications at the time of manuscript submission 
(29,32,35,37,41), including two comprehensive proteomic databases 
http://www.ssi.dk/sw14644.asp (41) and http://web.mpiib-berlin.mpg.de/cgi-bin/pdbs/2d-
page/extern/index.cgi (44) (Table 3.1).   
Figure 3.2 - Identification of Cell Wall Proteins by Two-Dimensional Gel 
Electrophoresis and Two-Dimensional Liquid Chromatography. A. Detergent 
extraction and separation of cell wall protein subsets via 2DGE demonstrated the 
majority of proteins to be resolved using SDS and GuHCl. The lipoprotein –rich TX-114 
fraction was less amenable to gel separation. See text for details.  B. Cumulatively, 
separation of cell wall proteins by 2DGE resulted in the identification of 234 proteins. 
Separating the TX-114 protein subset by multidimensional chromatography (2DLC-
MS/MS) resolved an additional 294 proteins. 
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Table 3.1 – Cell Wall Proteins Unique to this Study 
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Tuberculist Class IDs : 
0  - Virulence, detoxification, adaptation 2 – Information pathways 
1 – Lipid metabolism    3 – Cell wall and processes 
4 – Stable RNAs    5 – Insertion sequences 
6 – PE/PPE    7 – Intermediary Metabolism 
8 – Unknown    9 – Regulatory Proteins 
10 – Conserved Hypotheticals                      16 – Hypothetical Protein, not in M, bovis BCG. (category 







3.2.2 Functional Annotation of Cell Wall Proteins 
 All identified proteins were grouped by functional category as defined by Institute 
Pasteur (45), demonstrating M. tuberculosis protein families present in each extract. Proteins in 
categories 3 (cell wall and cell wall processes) and 7 (intermediary metabolism) were 
consistently overrepresented among the CWP preparations (Figure 3.3). These were further 
classified into functional groups as defined by the Sanger Institute (Figure 3a-c). The majority of 
proteins were classified in either Category I – Small Molecule Metabolism (35%) or Category II 
– Macromolecule synthesis and degradation (25%) (Figure 3.4). Subclasses of category I showed 
roughly 5% of CW proteins sorting into small molecule degradation (I.A), 11% sorting into 
small molecule metabolism for energy (I.B), and the remaining ~19% classified as other (I.X), 
which included the classes: Central intermediary metabolism (I.C) and Amino acid biosynthesis 
(I.D). Proteins sorted into Category II, Macromolecule synthesis and degradation demonstrated  
Figure 3.3 - The Functional Category Distribution by Biological Sample. Proteins 
identified for each extraction method (GuHCl, SDS, TX114) were sorted by functional 
category as a percentage of total proteins per sample. Representation of all protein groups 
were identified with the exception of groups 4 and 8 (data not shown). Seventy percent of the 
proteins identified in the cell wall are associated with lipid metabolism (group 1), cell wall 
processes (group 3) and intermediary metabolism (group 7). In addition, 21% are conserved 
hypotheticals. Solid Black, SDS; White, GuHCl; Gray, TX114; hash, total.    
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an even distribution of proteins with subclasses pertaining to the synthesis, modification, and/or 
degradation of macromolecules (II.A, II.B – 12.5%) and cell envelope proteins (II.C – 12.1%).  
 
 
3.2.3 Putative Secreted Proteins within the Cell Wall  
The secreted proteins of M. tuberculosis have traditionally been characterized as 
important antigens and immune-modulators (4,11,12,46). Prior to being exported, many of these 
proteins are resident within the cell wall where their function remains largely unknown. To find 
the putative secreted proteins all identified proteins were subject to interrogation against Neural 
Network (NN) and Hidden Markov model (HMM) algorithms (SignalP -
http://www.cbs.dtu.dk/services/SignalP/) (47).  Which revealed 18%, 19%, 27% putative 
Figure 3.4 - The Functional Category Distribution of the Cell Wall Proteome. 
Assignments were made based on the Sanger Institute gene database. The distributions are 
among the major functional groups and the subgroups within functional groups I and II. 
The percentage for each subgroup indicates the percentage of the total number of identified 
proteins in its major functional group. I.X is defined by proteins involved in central 
intermediary metabolism, amino acid biosynthesis, polyamine synthesis, biosynthesis of 
cofactors, prosthetic groups, and carriers, lipid biosynthesis, polyketide and non-ribosomal 
peptide synthesis and broad regulatory functions.  
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secreted proteins in GuHCl, SDS, TX-114 CWP samples respectively, and 13% in the 2DLC 
resolved TX-114 CWP fraction. Cumulatively, of the 528 proteins identified in this study 87 
proteins were predicted to contain secretion signals and included the identification of 23 proteins 
uniquely found in this study (Table 3.2). The majority (60%) of the CWP associated with 
secretion are within the category of the cell wall and its processes (Figure 3.5). Further, many of 
these CWP are also membrane associated – either by description (35,37,38) or functional 
annotation. This finding is inline with the inclusion criteria for category 3 as defined by Cole and 
Camus (48). Of the 23 secreted CWP unique to this study, eleven have been described to be 
involved with small molecule and peptide binding. Additionally, 23 of the 87 secreted proteins 
are classified as hypothetical or unknown (Categories V and VI of Sanger Institute) illustrating 
that to a large extent, the functions of these exported proteins are poorly understood.  
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Figure 3.5 - Functional Classification for Putative Secreted Proteins and 
Lipoproteins. 
Eighty-seven cell wall proteins were predicted to contain secretion signals and 
putative lipoprotein motifs. Sixty percent of these proteins are classified within 
the cell wall and cell wall processes functional category.  
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3.2.4 Putative Lipoproteins 
Next, we interrogated the CWP to identify those with putative lipoprotein motifs. Here, a 
total of 16 proteins were predicted by LipoP (LipoP - http://www.cbs.dtu.dk/services/LipoP/) 
(49) to contain a signal peptidase II cleavage motif, and an additional 8 proteins were identified 
when compared to the 99 putative lipoproteins (2.5% of the genome) that reportedly exist within 
the M. tuberculosis proteome (20). The majority of the lipoproteins contain no additional 
functional classification, however 4 proteins (Rv0928, Rv0934, Rv2864c, Rv3666c) are involved 
with substrate binding and transport within the periplasm. One of two superoxide dismutases in 
M. tuberculosis, SodC (Rv0432), was also identified within the lipoprotein-enriched TX-114 
CWP fraction. This protein has recently been defined as a highly glycosylated protein and is a 
defined B-cell antigen (50,51).  Notably, no evidence of lipidation of this protein was 
characterized in this study suggesting that annotation of mycobacterial lipoproteins remains 
incomplete. Other putative lipoproteins identified in this study contain O-glycosylation motifs as 
predicted by NetOglyc and were found within the M. tuberculosis glycoproteome (Table 3.2) 
(52).  The function of these dual-modified lipo-glycoproteins, as well as the nature of their 
modification remain largely undefined – however recent characterization of lprG (Rv1411c) has 
revealed its function as a lipoglycan carrier of triacylated glycolipids (53).  
3.3 Discussion 
In this study, we focused on the gel-based two-dimensional separation of the cell wall 
and complemented that separation by liquid chromatography of digested TX-114 CWP. 
Identified protein families included known antigens – Fbp A, B, and C (Rv 3804c, Rv1886c, and 
Rv0129c), CFP10 (Rv3874) and Esat-6 like proteins EsxJ and EsxL (Rv1038c, Rv1198) along 
with antigens lpqH (Rv3763), lprG (Rv1411c) and lprA (Rv1270c). Others included members of 
the MmpL and Mce protein family of lipid export machinery. In concordance with previous 
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work (39,54), a number of ribosomal proteins are reported here, which may indicate a high level 
of protein synthesis occurring at the cytosol – cell wall interface, most likely to facilitate the 
entry of proteins into the cellular envelope. For over a decade, the advancement of techniques in 
2DGE, mass spectrometry and increased access to bioinformatic tools greatly enhanced 
proteomic studies of Mycobacterium tuberculosis. Largely descriptive, these studies were 
undertaken to identify novel virulence factors and drug targets (31,32,41). Subsequent studies set 
out to understand functional relationships between proteins and discover antigens responsible for 
adaptive T-cell responses (36,37,39,46,55).  
The quantitative techniques of mass spectrometric profiling - isotope coded affinity tag 
(iCAT) and isobaric tagging for relative and absolute quantification (iTRAQ) - have afforded the 
accurate monitoring of up and down regulation of proteins on a global scale (36,56). Previous 
work mining subcellular fractions of M. tuberculosis focused on the cytosol and culture filtrate 
fractions, resulted in thorough characterization and the creation of 2D gel databases 
(4,32,44,57,58). Efforts have been made more recently to resolve the insoluble cell wall fraction. 
As mentioned previously Mawuenyega et al was able to identify 300 proteins within the cell wall 
using 2DLC as a separation method. Their study demonstrated functional relationships among 
key protein families within the fatty-acid synthesis pathway. 
 Using these studies as experimental platforms, we were able to focus on the M. 
tuberculosis cell wall and were successful in reporting over 100 additional proteins that had not 
been identified previously. The elucidation of the cell wall proteome can facilitate subsequent 
studies of a more targeted nature where specific proteins can be monitored in response to various 
environmental, nutritional or drug pressures.  One of the most interesting yet poorly understood 
protein families residing within the cell wall of M. tuberculosis are the triacylated lipoproteins. 
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As stated above, Sutcliffe et al predicted 2.5% of the genome to encode for lipoproteins. 
Defining these proteins beyond their antigenic and immune modulatory potential remains quite 
elusive with only a few studies predicting functional roles for M. tuberculosis lipoproteins 
(15,26,59,60). In this study, the vast majority of proteins found were involved in small molecule 
and macromolecule metabolism. Specifically, many of the CWP were annotated as small 
molecule and nutrient binding. This builds upon the evidence that clearly defines two M. 
tuberculosis CW lipoproteins, LppX and LprG, as aiding and/or facilitating the transport of 
lipids and small molecules (15,61). The presence of these lipoproteins and perhaps other 
secreted, CW resident proteins provides a conduit between various nutrient transportation 
pathways that are required for cellular survival and growth while allowing the mycobacterial cell 
wall to maintain its rigid hydrophobic integrity.  
3.4  Materials and methods  
3.4.1 Preparation of the M. tuberculosis Cell Wall  
M. tuberculosis strain H37Rv was cultured in 2 L of glycerol alanine salts (GAS) medium 
(14) in roller bottles for 14 d at 37 °C with gentle agitation.  Cells were harvested (37), washed 
with phosphate-buffered saline (PBS) pH 7.4, and inactivated by gamma-irradiation. Cells were 
disrupted in a French press, free lipids removed and the cell wall was obtained as previously 
described (3). Briefly, 1 gram of lyophilized cell wall was subjected to two extractions of 2 h 
each followed by one 18 h extraction with chloroform:methanol (2:1 v/v) at a ratio of 30 mL per 
gram of cell wall. Extractions were performed at 22
o
C with agitation. Centrifugation at 27,000-x 
g for 30 min was performed to collect cell wall material. 2:1 extracted cell wall was dried under 
N2 and further extracted twice for 2 h and one 18 h extraction with chloroform:methanol:water 
(10:10:3 v/v/v) each at 22
o
C. The fully delipidated cell wall was dried under N2 and resuspended 
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in PBS pH 7.4. Cell wall protein was quantified by bicinchoninic acid (BCA) assay (Thermo 
Pierce).    
3.4.2 Detergent Extractions of Cell Wall Proteins.  
Cell wall protein (CWP) was solubilized by one of three methods using (i) Guanidine 
HCl (GuHCl), (ii) Sodium Dodecyl Sulfate (SDS) or (iii) TritionX-114 (TX-114). (i) 75mg of 
CWP was incubated at 22oC for 4 h with agitation. The sample was centrifuged at 27,000 x g for 
30 min. Solubilized proteins were exchanged into 0.01 M NH4HCO3, and the protein amount 
determined by BCA assay. (ii) SDS soluble proteins were generated by extraction of 100 mg of 
CWP with 2% SDS in PBS (w/v) as described previously (3). Briefly, the sample was bath 
sonicated for 3 h at 90oC and centrifuged at 27,000-x g at 22oC for 30 min, collected and 
centrifuged again. The fully cleared supernatant was then subjected to paired-ion extraction for 
removal of SDS (62). Proteins were concentrated by centrifugation as above and pellets washed 
with acetone at -20oC for 4 h. The final pellet was resuspended in 0.01 M NH4HCO3 and protein 
amount determined by BCA. (iii) A stock solution of 32% TX-114 in PBS was added to 300 mg 
of CWP to a final concentration of 4% detergent. Primary extraction occurred at 4oC for 16 h. 
The extract was allowed to bi-phase at 37oC for 30 min and was fully separated by centrifugation 
at 27,000-x g for 30 min. Each phase was back extracted two additional times for 2 h each. The 
TX-114 detergent phases were pooled, and proteins collected by cold acetone precipitation (63). 
Final TX-114 proteins were resuspended as above and protein amount determined by BCA 
assay.  
3.4.3 Two Dimensional Gel Electrophoresis (2DGE).  
Samples of 200 µg of each CWP preparation were solubilized for 9 to 14 h in rehydration 
buffer, 7M urea/2M thiourea, 1% Amidosulfobetaine-14 (ASB-14), 1% 3-[(3-Cholamidopropyl) 
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dimethylammonio]-1propanesulfonate (CHAPS), 1 mM Dithiothreitol (DTT), 0.25% NP-40, 
0.625% ZOOM™ carrier ampholytes 3-10, 1.9% ZOOM carrier ampholytes pH4-7 (Invitrogen). 
Solubilized CWP was applied on ZOOM pre-cast immobilized pH 4-7 linear gradient strips (7.0 
cm; Invitrogen) according to manufacturer instructions. Focusing was achieved using a stepwise 
voltage gradient of 200, 450, 700 and 1000 V, for 10 min each followed by focusing at 2000 V 
for 2 h.  SDSPAGE of the iso-electric focusing (IEF) strips was performed using ZOOM 4-12% 
Bis-Tris SDS-PAGE gradient gels (Invitrogen). The gels were stained by Coomassie blue R-250 
(Bio-Rad).  
3.4.4 Two-Dimensional Liquid Chromatography.   
5.0 mg of TX-114 CWP was digested with modified trypsin (Roche Diagnostics) at a 
ratio of 1:20 (E:S), in 0.1 M Urea, 20 mM methylamine. The digest was desalted using Sep-Pak 
Light C18 cartridge (Waters Inc.) and concentrated under vacuum. The resultant peptides were 
separated by strong cation-exchange (SCX) chromatography using a polysulfylethyl A column 
(460 um X 200 mm, 300 A; Poly LC Inc.) connected to a Waters Alliance analytical HPLC with 
a 2487 UV detector. The digest was applied in buffer A (5 mM K2PO4, 20% acetonitrile (ACN) 
pH 3.0) using a gradient of 0-80% Buffer B (A with 0.5 M KCl) over 75 min with a flow rate of 
1 mL/min. The elution of peptides was monitored at 214 nm, and fractions (3 mL each) were 
pooled based on UV absorbance. Each fraction (6 total) was concentrated under vacuum and 
resuspended into reverse phase Buffer A (0.1% TFA in H2O). Individual SCX pools were 
subjected to further separation by reversed-phase HPLC (RP-HPLC) using a monomeric C18 
column (4.6 mm x 150 mm, Vydac). Peptides were eluted using a gradient of 0-50% reverse-
phase buffer B (90% ACN in A) over 40 min at a flow rate of 1 mL/min. Peptides was manually 
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collected based on UV absorbance at 214 nm. A total of 139 RP-HPLC peptide fractions were 
collected and concentrated under vacuum. 
3.4.5 Mass Spectrometry 
Coomassie blue stained spots were excised from 2DGE gels and subjected to in-gel 
digestion (64,65) with modified trypsin (Roche Diagnostics). Digests and 2DLC peptide 
fractions were resolved by liquid chromatography-mass spectroscopy (LC-MS) using either an 
LCQ (2DGE) or LTQ (2DLC) as described previously (66). Tandem mass spectra were 
extracted, charge state deconvoluted and deisotoped by BioWorks version 3.2 (Thermo Finnigan, 
San Jose, CA). All MS/MS samples were analyzed using Sequest (Thermo Finnigan; version 27, 
rev. 12) Sequest was set up to search the TB genome database (version 2.0, Genbank accession 
#AL123456, 3912 entries) assuming the digestion enzyme trypsin, a fragment ion mass tolerance 
of 1.0 Da, a parent ion tolerance of 2.5 Da, and 3 allowable missed cleavages. Oxidation of 
methionine and acrylamide adduct of cysteine (2DGE spots) were specified in Sequest as 
variable modifications.   
3.4.6 Criteria for Peptide and Protein Identification  
Peptide identifications were accepted if they exceeded specific database search engine 
thresholds. Sequest identifications required at least deltaCn scores of greater than 0.3 and XCorr 
scores of greater than 1.5, 2.2, 2.5 and 2.5 for singly, doubly, triply and quadruply charged 
peptides (provided in Appendix II.  Scaffold (version Scaffold-01_05_21, Proteome Software 
Inc., Portland, OR) was used to validate MS/MS based peptide and protein identifications. 
Peptide identifications were accepted if they could be established at greater than 90% probability 
as specified by the Peptide Prophet algorithm (67). Protein identifications were accepted if they 
could be established at greater than 90% probability as assigned by the Protein Prophet algorithm 
 73 
(67) and contained at least two unique peptides. Protein identifications at the lower threshold of 
acceptance were manually inspected for spectra quality. The protein probability false discovery 
rate for the CWP identifications was 3.5% (68). Proteins that contained similar peptides and 
could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles 
of parsimony. 
3.4.7 SignalP and LipoP Interrogation  
FASTA sequence files for each annotated M. tuberculosis protein were collected and 
organized into small groups of 50. Each group was then submitted to the SignalP server 
(http://www.cbs.dtu.dk/services/SignalP/) (47,69,70) using the gram-positive option. The output 
was saved in HTML format and a Perl script written to combine the results from all HTML files 
into one file and then converted to tab delimited format. This generated a complete list of results 
that were sorted in a spreadsheet to create the subsets of Neural Network positive, Hidden 
Markov Model positive, and the union of the NN and HMM sets. These lists were input into a 
java application along with the list of proteins isolated from the cell wall fractions. This 
application simply compared the predicted list to those isolated and identified the proteins found 
in the cell wall that were also predicted in each subset as having a signal peptide. To predict 
lipoproteins, the M. tuberculosis peptide FASTA file from above was broken down into 1000 
sequences per file. These were run through the downloadable version of LipoP 
(http://www.cbs.dtu.dk/services/LipoP/). The output files were combined in a spreadsheet, and 
from the sorted data, a list was extracted with every signal peptidase II cleavage site generating a 
predicted lipoprotein list. This list was input into a Java application that would compare the cell 
wall proteins, identifying the predicted lipoproteins from each cell wall fraction. The positive 
results verified that both Signal P models had predicted a signal peptide.  
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3.5 Conclusion & Current Perspectives  
This work was undertaken in order to 1. Develop new techniques for solubilization and 
extraction of proteins from a highly insoluble matrix of cell wall lipids, carbohydrates and 
mycolic acids, 2. Optimize separation of these proteins via two-dimensional gel electrophoresis 
and multi-dimensional liquid chromatography and 3. Utilize techniques of shotgun proteomics 
and mass spectrometry to comprehensively describe a unique and highly sought after subcellular 
proteome of M. tuberculosis.  From these efforts we characterized 528 proteins, 87 proteins with 
known or predicted secretion signal motifs and 23 lipoproteins. While bacterial cell walls have 
historically been thought of as structural scaffolding with little active interplay between the 
extracellular milieu and inner cytosolic environment, this perception of a static bacterial structure 
is fading and we are beginning to understand the true complexity and dynamic nature of the 
biological processes being facilitated within the cell wall. For instance, these proteins may 
contribute to bacterial cell wall remodeling events in response to environmental stressors such as 
nutrient depletion, antibiotic pressures, the host immune response and tissue remodeling events 
throughout the course of infection.  Indeed several lipoproteins have been functionally associated 
with nutrient uptake and transport. For M. tuberculosis, the highly complex framework of the 
mAGP – outer lipid architecture can now be definitively complemented with a highly diverse 
protein population. This new perspective will provide further insight into cell wall remodeling 
processes during mycobacterial infection.  In the past the provision of experimental data 
generated from descriptive studies have been purely data driven, but “information poor”.  One of 
the primary objectives of this study was borne of the observation that proteins within the cell 
wall were highly immunogenic for non-classically restricted CD8 T cells. The inclusion of this 
proteomic dataset in the design of a synthetic peptide library for the elucidation of novel antigens 
(discussed in the following chapter) was the first step in the shift to data rich, information rich 
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proteomic studies in which functional associations, interacting protein-protein networks and 
novel biomarkers of disease can be extrapolated and quantified among differing 
microenvironments and altered disease states.  
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IV. CHAPTER IV: Mining the M. tuberculosis Proteome for CD8 T cell Antigens & 
Epitopes 
 
In the sections below, we describe a large-scale effort to identify both classically and 
non-classically restricted CD8 T cell antigens. The identification of immunodominant epitopes is 
achieved through a T cell based approach, utilizing cells derived from M. tuberculosis-infected 
patients. Our primary role in this contract was to develop methods for the identification of CD8 
specific antigens derived from the cell wall of M. tuberculosis. Specifically, our task was to 
identify the antigen presented in the context of the non-classically restricted molecule HLA-E.  
4.1 Introduction 
The cellular immune response to mycobacterial infection is essential to minimize 
dissemination and control the severity of disease. In the majority of immunocompetent patients 
lymphocytes and M. tuberculosis infected dendritic cells (DCs) and macrophages (MΦ) act to 
control the invading bacilli via a complex interplay of immune effectors (1). As summarized in 
Chapter 1, CD8 T cells are associated with a strong CD4 T cell response and influence the 
development of a Th1 phenotype. These events act to control primary infection and influence the 
development of latent disease when the bacteria take on a state of non-replicating persistence (2) 
(3). Unfortunately, the immune response alone is not able to completely eliminate the bacterial 
burden and reactivation of active disease can occur when the homeostatic balance between 
pathogen and host is perturbed. To better understand the dynamic lifecycle and physiological 
state of the bacilli during different disease states, we must work toward a comprehensive 
biochemical, molecular and immunological understanding of the antigens present during the 
cycles of M. tuberculosis infection (2,4). The immunodiagnostic tools (i.e. interferon-gamma 
release assays, IGRAs) that are currently available for tuberculosis are based only on the broadly 
defined repertoire of a set of known CD4 T cell antigens.  While their accuracy in diagnosing M. 
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tuberculosis infection is much improved, the assays are not designed to distinguish between 
LTBI or active disease and their accuracy in diagnosing tuberculosis within highly endemic 
regions is still under evaluation (5,6). To circumvent the shortcomings of current diagnostic 
methods, researchers must gain further insight into the antigenic repertoire of the M. tuberculosis 
proteome during multiple stages of infection. The cellular envelope is highly immunogenic and 
we hypothesize that the large reservoir of protein antigens that reside within or that are secreted 
from the bacillus can be exploited in the pursuit of novel T cell diagnostics. Because the cell 
envelope is key to maintaining homeostasis during multiple infection and disease states, antigens 
deriving from this structure during different stages of infection could be utilized in the design of 
improved immunodiagnostics that are capable of identifying persons at risk for disease 
progression or that reflect the bacterial burden within individual patients. Indeed the study of the 
CD8 T cell immune response has shown that CD8 T cells are uniquely capable of recognizing 
highly infected host cells (7) and that CD8 T cells are required to prevent reactivation of disease 
in a mouse model of latency (8). Continued efforts in the study of the antigenic repertoire 
restricted to CD8 T cells in tuberculosis patients have successfully characterized several novel 
antigens and epitopes relating to the cell envelope of the bacillus (4).   
In humans it is known that antigens presented at the host cell surface to CD8 T cells are 
presented in the context of either a classically MHC1a-restricted molecule (9-14) or non-
classically restricted molecule such as CD1 (15-17), HLA-E (10,18) and MR1 (19,20). Several 
studies have identified classically restricted HLA-A2 presented peptides, however the frequency 
of the HLA-A haplotypes among M. tuberculosis-infected individuals was found to be quite low 
(21), suggesting that subsequent large-scale antigen discovery efforts needed to focus on the 
processing and presentation of antigens associated with the HLA haplotypes observed most 
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frequently during M. tuberculosis infection. Towards the identification of the new CD8 T cell 
antigens, two approaches were undertaken in a highly collaborative effort between the OHSU 
and CSU. Lewinsohn et al. utilized an unbiased alternative epitope discovery platform to identify 
disease-relevant immunodominant CD8 T cell epitopes. This strategy implemented the 
generation of a synthetic peptide library, in which CD8 T cells could be tested directly ex vivo 
from tuberculosis patients presenting with different stages of clinical disease. Antigen discovery 
efforts also continued for the identification of the M. tuberculosis antigen presented in the 
context of HLA-E. Initial characterization schemes for HLA-E, based on high-throughput 
methods such as a genomic peptide library or through the screening of synthetic peptides, were 
not successful at identifying the cognate antigen. Therefore we utilized an alternative, 
biochemical approach based on the purification of native proteins and peptide fragments to 
isolate biological activity to a particular subcellular fraction. Mass spectrometry was then 
utilized to identify protein species resident within such a fraction, facilitating the identification of 
the cognate epitope.  
4.2 The High-Throughput CD8 T cell Antigen Discovery Project 
4.2.1 Synthetic Peptide Libraries for Epitope Screening 
Identification of the antigenic repertoire of human CD8 T cells in response to infection 
with M. tuberculosis can be accomplished in several complementary ways. As a high throughput 
strategy a synthetic peptide library was designed and developed by Dr. David Lewinsohn and his 
team at OHSU. Analysis of pathogen-derived T cell antigens were first described for the 
influenza A nucleoprotein. In these studies, it was observed that cytotoxic T-lymphocytes could 
not only respond to short peptide fragments within transfected cells, but that these CTLs were 
capable of recognizing short synthetic peptides on the cell surface of the antigen presenting cell 
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(22-24).. This work demonstrated that antigenic targets could be identified on the whole protein 
level and appropriate epitopes could be elucidated via synthetic means. Advancing this concept 
into a high throughput, microtiter based screening platform would require the integration of new 
technologies for the high throughput synthesis of peptides as well as computational interrogation 
of genomic and proteomic information to develop robust peptide libraries for ambitious 
screening efforts (25,26).  
4.2.2 Integration of Descriptive Analyses into the Design of an M. tuberculosis Genomic 
Peptide Library 
The development of the M. tuberculosis synthetic peptide library began with a 
comprehensive evaluation of available genomic and proteomic data that was both publically 
available (http://genolist.pasteur.fr/TubercuList/ and http://web.mpiib-berlin.mpg.de/cgi-
bin/pdbs/2d-page/extern/index.cgi)	   and provided through our description of the cell wall 
proteome (see Chapter III for details). Also, lists of secreted and cell associated proteins 
identified through proteomic analyses done at CSU (unpublished data), was provided via 
personal communication with Dr. Dobos. From this information roughly 10% of the M. 
tuberculosis genome (389 genes) were represented in the final repertoire of ~39,000 peptides 
(Figure 4.1). 
 After a comprehensive analysis and strategic weighting scheme were applied (see 4.2.3 







Figure 4.1  – Integration of Omics Data: Schematic diagram of the 
integration of genomic and proteomic data in the overall design of the 




Numerically, the cell wall proteome contributed 56 total protein sequences to the final 
peptide library (Figure 4.3) and 8 of those proteins were selected for clinical validation as part of 
the OHSU-led T cell antigen discovery effort. These included members of the proline-glutamate 
rich proteins (PPE51, PPE18), possible exported proteins with unknown function (Rv1184c), 
Figure 4.2  – Functional Distribution of the Genomic Peptide Library. Genomic and 
proteomic information was compiled and analyzed based on a number of factors which 
indicated the likelihood of a particular gene/protein of interest could be a CD8 T cell antigen. 
Genes meeting certain criteria – such as secretion status, known CD4 T cell antigens, 
functional category association, were assigned weights. Genes meeting a particular score 
chosen and a final list of 389 genes were selected to be included in the genomic peptide 
library.  The 389 genes were represented in a library of 39,000 overlapping synthetic 
peptides. Their functional distribution (as defined in Tuberculist) is illustrated.  
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ESAT-6 family proteins (EsxJ, EsxB). Others were the secreted antigens Mpt64 and Cfp21, as 
well as the iron-binding protein IdeR.  
 
 4.3 Discussion of the Genomic Peptide Library Screen 
The proteomic scale prediction of immunological characteristics is rapidly developing 
with the exponential increase in the availability of proteomic data (29). A challenge for any 
large-scale descriptive study – like the cell wall proteome, is the integration and interpretation of 
the data into productive experimental and clinical utility. However, this proteomic information 
has the potential to provide bioinformaticists (such as those designing peptide libraries) and 
Figure 4.3 – Venn Diagram Comparison. Proteome datasets from the Max 
Plank Bioinformatics Center (MP) and from the Cell Wall proteome work 
were integrated into the design of the genomic peptide library (PepLib). After 
rigorous scoring schemes were applied, a total of 56 Cell Wall proteins were 
included in the final list of 389 representative genes/proteins of the PepLib.   
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clinicians, relevant patient and population-scale information. This holds especially true for host 
and/or pathogen proteomes derived from true states of infection. Therefore the integration of 
proteomic data can contribute useful information in the immunomic characterization of a disease 
state. This is especially true when considering that binding to MHC I/II molecules is a 
competitive process in which selected peptides bind to their MHC in the context of very complex 
peptide mixtures derived from processing events within the cell.  Because of these dynamic 
interactions, Bremel and Homan present the idea that,  “predictive determination of preferential 
epitope binding can only be made when considered in the context of the whole proteome” (29). 
In support of this idea, integration of M. tuberculosis proteomic data in the design of the first 
iteration of the OHSU peptide library significantly contributed to the identification of potent 
CD8 T cell antigens. Design analysis of the library was performed in order to understand which 
component of the library was more likely to predict CD8 T cell antigens. The parameters 
included the testing of proteomic data, genomic data and whether or not the proteins were 
expressed in M. tuberculosis, BCG. Together these parameters made up the “composite-based 
evidence” score, which was one of the major factors in determining the final protein 
representation of the library. This analysis, performed by Drs. Byung Park and Tomi Mori at 
OHSU determined that it was the association with the proteomic data that increased the 
likelihood of predicting a “good” CD8 T cell antigen (defined by an antigen producing IFN-γ 
responses among the top 5% of donor screens) and that this increased likelihood had the most 
influence on the value of the overall composite based score (30). Several predictive algorithms 
are now being developed in which proteomic data sets can be screened and analyzed for the 
presence of T cell epitopes (31). This further development will expand the utility of such large-
scale descriptive proteomic platforms especially when looking at specific disease states and may 
 87 
shift the success rate of identifying disease-relevant epitopes away from classical, biochemical 
based approaches in which antigens are isolated from whole cells, digested into peptide 
fragments and tested for T cell reactivity.  
4.4 Biochemical Approaches to Define Non-Classically Restricted Epitopes  
As a second, complementary approach to antigen discovery we utilized a biochemical 
proteomics-based screen to identify CD8 T cell antigens for a subset of non-classically restricted 
T cell clones. These clones had failed to recognize antigens represented in the genomic peptide 
library. The rationale behind this alternative approach included the recognized limitations of the 
synthetic peptide approach. For example, the scope of the peptide library was limited to only 
10% of the annotated M. tuberculosis, H37Rv genome and the initial characterization of HLA-E 
restricted T cells demonstrated activity with hydrophobic fractions of M. tuberculosis cell wall 
(18). This lead to the hypothesis that the non-classical peptide antigens could be post-
translationally modified with motifs similar to other non-classically presented glycolipids 
(16,32).  Proteomics and mass spectrometry studies provide robust and reliable methods in the 
discovery of disease state biomarkers and identification of novel drug targets. A comprehensive, 
full proteome screen for non-classically restricted CD8 T cell antigens provides a means to 
qualify the antigenic potential of naturally occurring proteins in their native state. In the field of 
mass spectrometry, the “bottom up” approach to protein identification involves the initial 
separation of complex protein mixtures and their subsequent proteolytic digestion into peptides. 
Peptides are then introduced into a mass spectrometer and their fragment spectra are identified 
and mapped to their corresponding protein based on sequence matches of a protein database (33). 
When coupled to immunological assays (i.e. cell proliferation (34,35), serum reactivity (36,37) 
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and cytokine secretion (38)) large-scale antigen discovery platforms and proteomics can be 
applied to the study of biologically active native protein fractions (39).  
 4.5 Rationale for Identification of HLA-E Antigens of Mycobacterium tuberculosis 
The human CD8+ T cell response to M. tuberculosis infection has been shown to involve 
both the classical HLA-Ia restricted CD8+ T cells and those that are non-classically (neither 
HLA-Ia nor CD1) restricted (21). The HLA-Ib molecule HLA-E is the least polymorphic of the 
restricting antigen alleles, having only two human haplotypes – HLA-E0101 and HLA-E0103 
(40). Further, the HLA-E restricted phenotype appears to be relatively common in those infected 
with M. tuberculosis (21) and recent work has identified HLA-E to be enriched in the MHC I 
processing phagosome (41). Therefore the identification of pathogen-specific HLA-E antigens 
could be novel vaccine candidates or diagnostic targets. Two CD8 T cell clones generated from a 
latently infected individual (D160 1-23 and 1-29) are known to be HLA-E restricted (18). We set 
out to identify the cognate antigen associated with this restricting allele using a biochemical 
proteomics based approach. Non-classically restricted antigens could have broad utility in the 
design of peptide vaccines and could lead to the further characterization of other HLA-E binding 
peptides. In the following sections we describe our efforts to identify the antigen associated with 
the non-classical HLA-E restricted T cell clone 1-23 and present substantial evidence that the 
post-translationally modified glycoprotein Mpt32 (Rv1860, Apa) is the cognate antigen. 
Limitations on the “bottom up” mass spectrometry approach to elucidate the presented peptide 
sequence are discussed and alternative approaches to epitope discovery are proposed for future 
work. 
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 4.6 Results for HLA-E Antigen Discovery  
4.6.1  Delipidation and Pronase Digestion of the M. tuberculosis Cell Wall 
The HLA-E restricted T cell clone D160 1-23 was used to characterize the biological 
activity of subcellular fractions generated from mid-log phase grown M. tuberculosis, H37Rv by 
measuring antigen specific IFN-γ release by ELISPOT assay. Original work done in 
collaboration between OHSU and CSU had isolated activity to the cell wall of Mtb (18). To 
facilitate the identification of cell wall proteins by mass spectrometry the fraction was subjected 
to delipidation by treating with organic solvents (42). The delipidated cell wall (dCW) remained 
active in the ELISPOT assay and was used as a positive control in subsequent assays. Pronase 
digestion of the dCW (dCW_pro) enhanced secretion of IFN-γ from the HLA-E restricted T cell 
clone and was also included as a point of reference for potential antigens to be screened. Trypsin 
digestion of dCW was not biologically active.  
4.6.2 Characterization of X4-19 (HspX Knockout) Whole Cell Lysate 
M. tuberculosis X4-19 (ΔHspX), was obtained as a generous gift from Dr. Fred Quinn at 
the University of Georgia. This strain was used primarily to avoid the high abundance of HspX 
in active fractions, as the presence of this protein confounded our proteomic analysis (discussed 
further in the Discussion). The HspX knockout strain was grown to mid-log phase to collect 
culture filtrate. Whole cells were harvested to generate whole cell lysate (WCL).  An ELISPOT 
assay was performed on WCL with or without Pronase. From this analysis, it was determined 
that T cell reactivity was retained and enhanced in the absence of HspX, thus confirming that 
HspX was a confounding protein and not the cognate antigen. Pronase digests of ΔHspX_WCL 
were performed in triplicate and separated by RP-HPLC producing 30 peptide fractions per 
digest to produce a total of 90 fractions that could be assayed for T cell activity. Fractions I.9, 
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II.9, III.9 as well as fractions I/II/III.10 were reproducibly biologically active in these assays 
(Figure 4.4).  
 
Each of the 90 fractions was subjected to peptide and protein identification via liquid 
chromatography mass spectrometry (LC-MS). Several protein products were identified in each 
fraction, and results from this analysis were compared to the protein identifications found in 
previously positive samples (dCW and HspX-18). Results are summarized in Table 4.1.  
Figure 4.4 - IFN-γ  ELISPOT Screen on ΔHspX Pronase RP-HPLC Fractions. 
Triplicate digests of ΔHspX whole cell lysate (labeled I. II. III.), were separated by C18 
reverse phase chromatography to produce 30 fractions from each digest, for a total of 90 
fractions. Replicate III, fractions 1-30 are representative of each digest and active 
fractions 9 and 10 from replicates I and II are also depicted, in comparison to unseparated 
whole digest. Phytohemagluttanin (PHA) is used a positive control. 
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Table 4.1 - Summary table of Proteins Identified by LC-MS/MS in three positive, pronase 
digested fractions - delipidated cell wall (dCW), native HspX (nHspX) fraction 18 and 
ΔHspX fraction 9.  
 
4.6.3 Further Definition of ΔHspX Fraction 9 
Pronase digested ΔHspX generated a positive fraction when separated via RP-HPLC 
(fraction 9). To determine if the biological activity could be attributed to unique peptide 
interactions, secondary structure anomalies, or labile post-translational modifications, fraction 9 
was boiled in 4% SDS, 1mM DTT for 30 minutes.  Figure 4.5 demonstrates that reducing 
treatment of fraction 9 did not ablate IFN-γ secretion from D160 1-23 and that the individual 
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proteins identified via LC-MS (Table 4.1) were not responsible for activity. Fraction 9 was 
further resolved via RP-HPLC using an extended gradient of acetonitrile and subfractions 9A, 
9B, 9C were generated and reactivity was measured for subfraction 9A only (data not shown). 
Peptide fragments ranging from 700 Da to 2100 Da were visualized within the active fraction 
using matrix-asssted laser desorption ionization, time-of-flight (MALDI-TOF) mass 
spectrometry to generate a peptide fragment map.  
 Through the complementary analysis of subfraction 9A with LC-MS/MS peptide 
sequences could be assigned for several of the ion species seen by MALDI-TOF  (Figure 4.6), 
these included proteins of the Antigen 85 complex, as well as Mpt32 (Rv1860), a protein which 
had not been identified in other positive fractions.  
Figure 4.5  - IFN-γ  ELISPOT Against ΔHspX Fraction 9 and Select 
Proteins. Despite subjecting fraction 9 to boiling in 4% SDS, 1mM DTT, 
biological activity was retained. SFU counts for proteins listed in Table 
4.1 demonstrated no reactivity to the selected protein panel.  
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The T cell reactivity to the Ag85 complex had previously been ruled out, thus testing of both 
native and recombinant Mpt32 commenced (Figure 4.7).  
 4.6.4 Native Mpt32 Peptides are Presented in the Context of HLA-E  
Mpt32 is a 45kDa alanine and proline-rich secreted glycoprotein (43) and a known CD4 
T cell antigen (44). It is secreted into the culture filtrate of actively growing cells. To confirm the 
results observed from the testing of native whole protein, the ELISPOT assay was repeated with 
whole and pronase digested Mpt32, as well as whole and pronase digested CFP. Digested Mpt32 
gave an overwhelming response in the T cell ELISPOT assay, as did Pronase digested CFP from 
which Mpt32 is purified from (see Materials & Methods). Mpt32 digested with trypsin induced a 
response equivalent to undigested protein (Figure 4.8). This was not unexpected as the primary 















Figure 4.9 - Mpt32 is Presented in the Context of HLA-E. Culture Filtrate Proteins 
(CFP) from Mtb, H37Rv was tested as either a whole protein preparation or digested with 
pronase. Digestion of CFP with Pronase greatly enhances the T cell reactivity of this 
subcellular fraction. Along with CFP, native Mpt32 was digested with Pronase and 
trypsin. SFU for Mpt32+Pronase maxed out the readability of the assay and was 
determined to be too numerous to count. Mpt32+trypsin gave similar readings to 
undigested protein. Mpt32 is relatively resistant to trypsin, having less than 10 trypsin cut 
sites throughout its amino acid sequence.  
 
 95 
       Table 4.2  – Mpt32 Tryptic Peptides Assuming 0-2 Missed Cleavage Events 
 
The presentation of the Mpt32 epitope in the context of HLA-E was detectable in the 
ELISPOT assay down to 0.625µg/ml of sample (Figure 4.9). Overlapping synthetic peptides, the 
non-glycosylated recombinant Mpt32 from E. coli, nor the hyperglycosylated recombinant 
Mpt32 expressed in M. smegmatis resulted in a positive response. Therefore, characterization of 
the native protein and peptide products began with the isolation of a discrete peptide fraction 
from the Mpt32 Pronase digest (Fraction 8). Fraction 8 consistently induced IFN-γ secretion 
(Figure 4.10). Mpt32-Fraction 8 was digested with trypsin and biological activity was retained. 
MALDI-TOF spectra of this treated fraction detected the first 36 amino acids of the mature 
protein in its glycosylated form (showing a mass difference of -162 Da), correspseen by 
MALDI-TOF (Figure 4.6)  
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Figure 4.10 – Mpt32 Pronase Digest Presented by HLA-E. The HLA-E restricted T 
cell clone D160 1-23 was active in the presence of the Mpt32 Pronase antigen 
preparation, down to a concentration of 0.625 µg/ml.  
 
Figure 4.11 - Reverse Phase Fractions of Mpt32 Pronase Digest. Digested Mpt32 was 
separated over a C18 Reverse Phase column to elute discrete peptide fractions based on 




 4.6.5 Mass Spectrometry Analysis of Mpt32 Fractions 8 
LC-MS analysis of fractions 7, 8 and 9 identified a total of 34 unique peptides. Those 
unique to the biologically active fraction 8, belong to the amino terminus of the protein, which 
contains several O-mannosylated threonines.  Figure 4.11 highlights the protein coverage among 
the three reverse phase fractions, with Fraction 8 representing approximately 30% of the Mpt32 
protein sequence. Unfortunately the full characterization of the N-terminal glycopeptides present 
in these native fractions has not been successful. Evidence of the N-terminal glycopeptide was 
detected by MALDI-TOF analysis of a trypsin digested Fraction 8. The parent masses of 
3454.162, 3616.374 and 3778.577 ([M+H]+1) were visualized and putatively represent the 
mature N-terminal glycopeptide: 1-DPEPAPPVPTTAASPPSTAAAPPAPATPVAPPPPAA-36, 
however convincing MS/MS of the peptide has yet to be confirmed by LC-MS/MS.  
Figure 4.12 - Protein Sequence Coverage of Mpt32 Pronase Generated Peptides. 
Reverse phase fractions were collected and analyzed via LC-MS/MS to identify peptides 
present within each fraction. Fractions 7, 8 and 9 share many peptides, however the 
peptides identified in fraction 8 represent ~ 30% of the mature Mpt32 protein, compared 
with 22% (Fraction 7) and 13% (Fraction 9). Peptides unique to this fraction are located 
at the N-terminus where three glycosylated threonines reside (Thr10, Thr18 and Thr27).   
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4.6.6 Mannosylation State of Mpt32  
Overlapping synthetic peptides of those represented in Figure 4.11 were tested and found 
to be negative for the HLA-E restricted D160 1-23. This led to the hypothesis the mannosylation 
state of the N-terminal threonines contributed to the CD8 specific T cell response. Therefore, the 
glycopeptides present within the Mpt32 pronase digest were enriched over a Concavalin-A lectin 
column. This generated three fractions – flow through of non-glycosylated peptides, wash of 
excess non-specific binders and an eluate of mannosylated peptides (Figure 4.12). The response 
to the Con-A eluate was relatively modest in comparison to RP-HPLC purified fractions, 
however the reactivity to this fraction was consistent with our hypothesis that mycobacterial 
glycopeptides may be immunostimulatory for disease specific CD8 T cells. Further 
characterization of this phenomena and the defining epitope responsible for T cell stimulation 
remain to be elucidated.  
 
Figure 4.13 - Glycopeptide Enrichment of Mpt32 Pronase. Mpt32 Pronase 
digest was enriched for glycopeptides using ConA lectin chromatography.   
FT = flow through of unbound, non-glycosylated peptides, WA= wash of non-
specific binders, EL= glycopeptide enriched eluate. Normalized peptide 
concentration against dCW+Pronase.  
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4.7 Discussion  
The initial efforts to identify the HLA-E restricted antigen began with characterization of 
the antigenic activity of crude subcellular fractions  – cell wall, membrane, cytosol and culture 
filtrate, isolated from M. tuberculosis, H37Rv grown to mid-log phase. Included in these original 
assays was a preparation of the hydrophobic TX-114 extracted cell wall. The biological activity 
of a particular fraction was measured and quantified via IFN-γ ELISPOT. These original studies 
concluded that biological activity was exclusive to the cell wall (either crude preparation or TX-
114 soluble) and that activity was not affected if treated with nucleases such as DNase or RNase. 
Further, it was observed that cytokine secretion was greatly enhanced when the antigen source 
was pre-digested with the non-specific protease Pronase (18). Enzymatic treatment with 
additional proteases such as trypsin, chymotrypsion, endopeptidase Glu-C (V-8 protease), and 
proteinase K abolished T-cell reactivity. The ability of the different cleavage products to either 
induce INF-γ secretion or ablate it gave key evidence as to the biochemical properties of the 
HLA-E restricted antigen: 1. The antigen is a protein, 2. The antigen is resistant to specific 
proteolytic digestion and limited proteolysis with specific proteases such as trypsin, 
chymotrypsion and V-8 protease leaves large peptide fragments that may be insufficiently 
targeted to the proteosome for proper processing of the cognate epitope (Lewinsohn et al., 
unpublished observation) and 3. Biological activity observed in the cell wall (both untreated and 
TX-114 soluble) may be indicative of a modified protein product. Collaborative efforts between 
CSU and OHSU resulted in the identification of HspX (Acr, Rv2031c) as the HLA-E restricted 
antigen. However, synthetic overlapping peptides of this protein were generated and ELISPOT 
analysis showed no biological activity in response to this single protein library. Despite extensive 
effort to biochemically define the epitope associated with T cell reactivity, it was later concluded 
that HspX was not the HLA-E antigen.  
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Work continued on defining the antigenic protein in an HspX knockout strain of M, 
tuberculosis. Meticulous analysis of highly purified peptide fractions identified peptides 
belonging to the immunodominant, secreted glycoprotein Mpt32. Mpt32 is O-mannosylated at 
positions Threonine (Thr) 10, Thr18, Thr27 and Thr277. Thr10 and 18 are decorated with an α-
D-(1,2) linked mannobiose, Thr27 with a single mannose and Thr277 was shown to have either a 
single α-D-Man, mannobiose or triose (43). Evidence presented in the preceding sections 
suggests that the HLA-E T cell receptor is capable of recognizing a post-translationally 
mannosylated glycopeptide of Mpt32. Future work remains in the full definition of the cognate 
epitope presented by HLA-E. In the absence of synthetically modified peptide products, we must 
continue to pursue alternative means of proving that the N-terminus of the protein elicits a 
specific biological activity and that this activity is dependent on the state of mannosylation of a 
particular threonine.  
We are pursuing this line of work in several complementary ways: (1) Enzymatic 
treatment of the active fraction Mpt32 fraction 8, with α-mannosidase (2) Chemical alteration of 
the O-mannosylated N-terminus via acetylation or beta-elimination and (3) Genetic manipulation 
of the sites of glycosylation of Mpt32. Preliminary experiments for both enzymatic and chemical 
treatment (via acetylation) have been performed, however the precise characterization of the 
modifying treatments must be done to confirm proper alteration of the mannosyl moiety. We 
continue to pursue a genetic approach in which select mannosylation sites at the N and C-
terminus of the protein are mutated to amino acids that cannot accept a mannose modification. 
The O-mannosylation of serine or threonine amongst mycobacterial proteins has been 
characterized for T cell antigens such as the 19kDa lipoglycoprotein (45) and the B cell antigen 
SodC (46) however many more glycosylated proteins are known to exist in mycobacteria (47). 
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Unfortunately for the purposes of epitope screening, the synthetic production of O-mannoslyated 
Thr is cost-prohibitive and the chemistry involved is not typically performed in a commercial 
setting, therefore its success rate unknown (personal communication, Proteomics Manager New 
England Peptide). However, similar to the broad characterization of CD8 T cell antigens, 
understanding the immune response to mycobacterial glycoproteins and the processing and 
presentation of glycopeptides to T cells could aid in the development of T cell-based diagnostic 
tools as well as supplement the search for novel vaccine candidates. Including the development 
of unique subunit or peptide vaccines designed specifically to target infected cells and promote 
the secretion of pro-inflammatory cytokines (IFN-γ, TNF-α).  
Furthermore, knowledge of glycopeptide specific responses to mycobacterial infection 
would aid in the study of the unique CD8 T cell response in cases of active versus latent TB. 
Glycopeptide specific T cells could also be characterized by their ex vivo frequency as well as 
their cellular phenotype and function (45) within the infected host. Furthermore, we recognize 
the limitations of the bottom up approach to identify cognate epitopes within active fractions. 
One issue involved with this method is the generation of relatively complex peptide fractions that 
are only biologically active when digested with non-specific proteases such as pronase. This 
hinders the identification of peptides through automated search algorithms such as SEQUEST 
and Mascot and favors de novo or manual sequencing of the mass spectrometry data. Also 
related to this limitation is the reliance on often miss-annotated genomic information from which 
protein and peptide databases are created and searched. Bottom up approaches are also 
complicated with advancements in modern instrumentation in which the sensitivity has increased 
dramatically over time. Mass spectrometers are now able to detect and measure the presence of 
peptides over an expanded dynamic range. However this detection is not related to abundance of 
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the peptide in question. To overcome these limitations a more targeted approach would be most 
helpful in identifying cognate epitopes. With these methods the peptides being presented are 
eluted off of the antigen presenting molecule itself and directly analyzed via LC-MS (46-49).  
4.8 Materials and Methods 
4.8.1  Bacterial Growth and Isolation of Subcellular Fractions 
M. tuberculosis, H37Rv was cultured in glycerol-alanine-salts (GAS) media for 14 days at 
37oC, followed by harvest of supernatant and cells, lysis and subcellular fractionation as 
described previously(50). Briefly, culture filtrate proteins were separated from cells via filtration 
through a 0.22 µm membrane and concentrated using a stirred cell apparatus under N2, followed 
by dialysis into 0.01 M NH4HCO3. Whole cells were inactivated by γ-irradiation and 
resuspended in breaking buffer (PBS, 1mM EDTA) supplemented with protease inhibitors, 
DNase and RNase for serial passage through a French pressure cell (Thermo Scientific, MA). 
Whole cell lysate was dialyzed into 0.01 M NH4HCO3, and centrifuged at 27,000 x g at 4oC for 
1h to generate cell wall. The supernatant was subsequently centrifuged at 100,000 x g at 4oC for 
4 h to recover cell membrane. Cell wall, membrane and cytosol were all dialyzed and protein 
quantified via BCA (ThermoPierce, CA).  
4.8.2 Delipidation of the Cell Wall 
The cell wall fraction was subjected to organic extraction to remove non-covalently 
attached lipids and glycolipids (42). Lyophilized cell wall was subjected to two extractions of 2 h 
each followed by one 18 h extraction with chloroform/methanol (2:1, v/v) at a ratio of 30 mL/g 
of cell wall. Extractions were performed at 22 °C with agitation. Centrifugation at 27,000g for 30 
min was performed to collect cell wall material. The 2:1 extracted cell wall was dried under N2 
and further extracted twice for 2 h and one 18 h extraction with chloroform/methanol/water 
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(10:10:3, v/v/v) each at 22 °C. The fully delipidated cell wall was dried under N2 and 
resuspended in PBS, 0.1% ASB-14 pH 7.4 to maximize solubility. Cell wall protein was 
quantified by bicinchoninic acid (BCA) assay (Thermo Pierce). 
4.8.3 Purification of Native Proteins for Elispot Testing 
4.8.3.1 Ag85 complex and subunit purification   
Ammonium sulfate (NH4)2SO2 is added to the culture filtrate proteins (CFP) to a final 
concentration of 40% and proteins allowed to separate for 1 hour at 4oC. The CFP is then 
centrifuged at 16,000 x g for 30 minutes and supernatant removed for a second salt cut at 70%. 
The 40% pellet is resuspended in phenyl sepharose buffer A (10 mM KH2PO4 (pH 7.2), 1 mM 
EDTA, 1 mM DTT (1L) and a gradient is run through buffer B (10 mM Tris-Base (pH 8.9), 1 
mM EDTA, 1 mM DTT (1L), and then through C (10 mM Tris-Base (pH 8.9), 1 mM EDTA, 1 
mM DTT, 50% ethylene glycol (v/v)) to purify Ag85 complex. and Ag85A, B and C separately.  
4.8.3.2 Mpt32  
Unbound material from the phen-seph column (flow through) is run over concavalin-A 
lectin sepharose to purify Mpt32. Lyophilized starting material is resuspended in ConA binding 
buffer (50mM KH2PO4, 500mM NaCl, 1mM each of MgCl2, CaCl2, MnCl2 and 1mM DTT). 
Bound protein is eluted with excess 1M Methyl α-D-mannopyranoside). Mpt32 is polished over 
a C18 reverse phase column in 20mM ammonium bicarbonate, 1mM DTT and eluted off with an 
increasing gradient of 20mM ammonium bicarbonate, 70% acetonitrile. This step removes 
contaminating glycolipids from the Con-A lectin preparation.  
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4.8.3.3 38kDa and GroES  
The pellet generated from the centrifugation of the 70% ammonium sulfate cut of the 
CFP is also enriched over ConA to purify the 38kDa glycoprotein. Unbound ConA proteins are 
then used in the purification of GroES.  
 
4.8.3.4 19kDa     
  The 19kDa glycolipoprotein partitions into the detergent layer of the TX-114 soluble 
proteins of the cell wall subcellular fraction. It is purified using preparative SDS-PAGE and 
whole gel electro-elution. 
4.8.3.5 HspX  
HspX is purified by differential extraction of a 40,000 x g pellet of the WCL with 1% N-
octylthioglucoside in PBS. The detergent soluble fraction is dialyzed, lyophilized, and product 
resuspended in a buffer of 7.25 M urea, 0.4% 3-10 pharmalytes, 1.6% 4-7 pharmalytes, 1% N-
octylthioglucoside, 2mM DTT and incubated.  Soluble proteins are separated by preparative iso-
electric focusing, and fractions (of ~ 0.5 pH units) collected, screened, and those enriched in a-
crystallin are pooled. Polishing of the 16 kDa protein is achieved by size exclusion 
chromatography with a Sephadex-75 column and isocratic elution of the 16 kDa protein in a 
buffer of 3M Urea, 20mM Tris, 0.15M NaCl, 0.1% n-octylthioglucoside, 0.02% NaN3, pH 7.6. 
Purified a-crystallin is qualified and placed in inventory for distribution.  
4.8.4 Pronase Digestion 
Pronase (250 ku, EMD Millipore) was resuspended in digestion buffer - PBS, 0.1% ASB-
14 for subcellular fractions or 0.2M NH4HCO3 for purified proteins, at a concentration of 5.0 
mg/ml. Digestion was performed at 37oC, 16h at an enzyme to substrate ratio of 1:20 for all 
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samples. Enzymatic reactivity was quenched with rapid freeze thaw cycles at -80oC. Crude 
peptide lysates were kept frozen and shipped on dry ice to OHSU for T cell reactivity.  
4.8.5  γ-IFN ELISPOT  
All ELISPOT analysis was performed at OHSU as previously described (18). Briefly, 96-
well nitrocellulose backed plates were coated as recommended by the manufacturer with 
10µg/ml capture mouse anti-IFN-γ overnight at 4oC. Plates were then washed six times with 
PBS/0.05% Tween 20 (Sigma-Aldrich), blocked with RPMI 1640/10% HS for 1 h at room 
temperature. T cell clones (200) and APC (20,000) are added, and the plate incubated overnight 
at 37oC. Plates are extensively washed and anti-IFN-γ secondary antibody conjugated to HRP is 
added. AEC developer substrate is added and the reaction stopped by washing with distilled 
water.   
 4.8.6 Reverse Phase HPLC 
Whole protein digests (1mg to 5 mg) were separated on Waters Alliance 2695 HPLC 
(Waters Inc, Millford, MA) using a Grace Vydac Everest 300Å monomeric C18 column (4.6 x 
150mm, 238EV5115).  Fractions were collected every 2 minutes over a gradient of 0-50% B 
over 30 minutes, 0.5ml/min. Buffer A – 0.1% TFA in water, Buffer B – 0.1% TFA, 90% 
acetonitrile. For fraction 9A, the gradient was modified to begin at 15% B and increased to 30% 
B over 30 minutes. Fractions were collected every 3 minutes at a flow rate of 0.5 ml/min. For all 
peptide separations fractions were concentrated using vacuum centrifugation and resuspended at 
an approximate concentration of 0.1 ug/ul in Buffer A. Sample were kept frozen at -80oC and 
shipped on dry ice to OHSU for ELISPOT testing. 
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4.8.7 Concavalin-A Lectin Chromatography Of Peptides  
3 mg of purified Mpt32 was subjected to Pronase digestion as described above 
(concentration of 1 mg/ml). Peptides were incubated with rocking, in the presence of 2 ml of 
Con-A conjugated sepharose slurry (i.e. 1ml settled resin) (GE Life Sciences) at 4oC, for 16 h in 
a 15ml reaction tube. Resin-peptide mix was poured into an open column and allowed to settle. 
Flow through was collected. Resin was washed with 10 column volumes of binding buffer and 
collected. The peptides were eluted off with 10 CV of elution buffer. Collected fractions were 
exchanged back into 0.1% TFA after processing through solid-phase sep-pak columns (Waters) 
following manufacturer’s instructions.  
 4.8.8 Mass Spectrometry 
All mass spectrometry was performed in collaboration with the Proteomics and Metabolomics 
Facility located at Colorado State University. Liquid Chromatography Mass Spectrometry: 
Peptides were separated on a nanospray column (Zorbax C18, 5 mm, 75 mm ID 6 150 mm 
column). Samples were eluted into a LTQ linear ion trap mass spectrometer (Thermo) using a 
gradient of 0-100% B (A= 3% ACN, 0.1% formic acid; B =100% ACN, 0.1% formic acid) at a 
flow rate of 300 nL/min for 60 minutes. MALDI-TOF: 1 ml of peptide sample is mixed with 1 
ml of a mixed matrix solution (10mg/ml α-Cyano-4-hydroxycinnamic acid (CHCA) and 
10mg/ml 2,5-Dihydroxybenzoic acid (DHB) in 50% ACN, 0.1% TFA. The mixing of matrices 
enhanced intensity of ion peaks and allowed for the visualization of glycopeptides. The mixture 
is spotted on the MALDI target and allowed to air dry.  The sample is analyzed by an Ultraflex-
TOF/TOF mass spectrometer (Bruker Daltonics, Billerica, MA) in positive ion, reflector mode 
using a 25 kV accelerating voltage.   External calibration is done using a peptide calibration 
mixture (4 to 6 peptides) on a spot adjacent to the sample.  The raw data is processed in the 
FlexAnalysis software (version 3.3, Bruker Daltonics).  
 107 
 4.8.9 Peptide Identification 
LC-MS Database Searching: Tandem mass spectra were extracted, charge state 
deconvoluted and deisotoped by Xcalibur version 1.7 SP2. All MS/MS samples were analyzed 
using Sequest (Thermo Fisher Scientific, San Jose, CA, USA; version v.27, rev. 11). Sequest was 
set up to search the MtbV3_Reverse database (7992 entries) assuming non-specific cleavage. 
Parameters for both search engines were set to a fragment ion mass tolerance of 1.5 Da and a 
parent ion tolerance of 3.0 Da.  Oxidation of methionine was specified as variable modification. 
For glycopeptides, a modification of mannose (+162 da) and mannobiose (+324) were set as 
variable modification on threonine.  
MALDI-TOF spectra were collected and select ions were chosen for fragmentation. Peptide 
sequences were elucidated via de novo calculation of amino acid fragments. M+H single charged 
ion masses were matched if identified using LC-MS protein identification. 
 4.8.10 Criteria For Protein Identification 
Scaffold (version Scaffold_3.5.1, Proteome Software Inc., Portland, OR) was used to 
validate MS/MS based peptide and protein identifications. Peptide identifications were accepted 
if they exceeded specific database search engine thresholds. Sequest identifications required at 
least deltaCn scores of greater than 0.2 and XCorr scores of greater than 1.8, 2.0, 3.0 and 4.0 for 
singly, doubly, triply and quadruply charged peptides. Protein identifications assigned within 
each peptide fraction were accepted if they contained at least 2 identified peptides. All peptide 
spectra were manually inspected for sequence coverage and signal to noise.  
4.9 Summary and Conclusion 
Future work with Mpt32 will include specific manipulation of the glycosyl moieties 
located at the N-terminus of the protein through site-directed mutagenesis, and the 
overexpression of these mutants in an Mpt32 knockout strain of M. tuberculosis. Processing and 
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presentation of glycopeptides to T cells is known to occur and is of interest in the realms of 
autoimmunity (51), medical mycology (52) and cancer (53). Furthermore the glycosylation state 
of Mpt32 is known to affect its immunostimulatory properties for CD4 T cell activation (54,55). 
However the direct contribution of each glycopeptide in the generation of a cell-mediated 
immune response has never been elucidated. The genetic approach targeting the highly modified 
N-terminus of Mpt32, will unequivocally demonstrate the requirement of glycosylation for HLA-
E restricted T cell activation.   
The work described herein is the first description of a glycopeptide being presented in the 
context of HLA-E and the first mycobacterial protein to be presented in this manner. From this 
work, we also acknowledge the limitations of the “bottom up” proteomics approach to antigen 
discovery, especially when post-translational modifications and digestion with nonspecific 
proteases produce biologically active fractions. Mass spectrometry has been used quite 
successfully to characterize a number of both classically and non-classically restricted T cell 
epitopes (46,47). These approaches directly address peptides eluted off of the MHC molecule 
itself, and are aided with the use of synthetic peptide pools generated via analysis of predicted 
binders. Ultimately these studies identify epitopes with amino acid sequences similar to other, 
previously characterized epitopes (i.e. the MHC class 1a leader sequences in the case of HLA-E). 
However binding avidity of MHC Ia or b molecules is not necessarily an indicator of an 
immunostimulatory phenotype, therefore validation of defined epitopes must be performed. In 
our case, for this specific T cell clone, neither predictive algorithms nor the generation of 
synthetic peptides aided in the identification of the presented epitope. Ultimately, a proteomics 
based approach was successful in the identification of an HLA-E restricted M. tuberculosis 
antigen. However experimental approaches such as those described above are time consuming 
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and the characterization of one T cell clone, narrow in scope. A broader approach could involve 
the development of a library of T cell clones, irrespective of HLA haplotype, that are reactive 
against the glycoproteome of M. tuberculsosis grown under different physiological states. 
However, the continuing development and integration of proteome-scale prediction tools (29), 
which are trained to identify specific immune characteristics has the potential to increase the 
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5.1 Introduction 
M. tuberculosis is a highly adaptable organism, capable of surviving in multiple 
metabolic states. The cellular envelope of the bacillus provides integrity and protection from the 
insults encountered within the host environment and extracellular milieu. It is the dynamic nature 
of this structure that facilitates the survival of the bacterium throughout its diverse life cycle, 
regulating the physiological processes needed to acquire or expel the necessary molecules it 
needs to function in these altered capacities. Furthermore, M. tuberculosis infection remains a 
significant global health burden and the emergence of multi-drug resistant (MDR) and 
extensively drug resistant (XDR) cases continue to increase (1).  In a state of non-replicating 
persistence, the bacilli are able to maintain their integrity during the course of drug treatment. 
Novel chemotherapeutics for the treatment of disease are needed in order to target the bacteria 
during multiple metabolic states. By elucidating the functionally linked protein networks that 
mediate transitions into and out of particular disease and drug resistant states, the effective 
treatment time and complexity of antibiotic regimens used against M. tuberculosis can be 
reduced.  
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5.2 ATP Pathways and Chemoproteomics 
Beyond their function in cancer immune evasion and deregulated growth, ATP dependent 
catalytic pathways are being scrutinized for their roles in pathogen biology and their control over 
metabolic processes in multiple physiological stages. The recent description of ATP-competitive 
enzyme inhibitors as a novel class of antitubercular drugs(2-5) has bolstered interest in the 
identification of bacterial enzymes that utilize ATP - given that these enzymes may be feasible 
targets in the discovery and design of novel small molecule inhibitors of tuberculosis. 
Furthermore, elucidating ATP-dependent catalytic pathways present during different metabolic 
disease states is critical for understanding mechanisms of virulence and pathogenesis. 
Manipulation of these pathways via novel chemotherapeutic strategies could not only increase 
the effectiveness of drug treatment in MDR/XDR cases, but may possess potent in vivo efficacy 
against bacilli exhibiting multiple, often resistant phenotypes within the host (6). The study of 
kinases and other ATP-binding proteins (chaperones, ATPases, synthases and other metabolic 
enzymes) has become important in elucidating the roles of ATP-dependent pathways in the 
pathogenesis of cancer and other mechanisms of dysregulated growth. The large-scale profiling 
of such networks is facilitated with the use of active-site nucleotide probes (7). Traditionally 
studies have utilized this chemical proteomics approach to elucidate global kinase profiles of cell 
lines, as well as to map interaction networks using clinically approved kinase inhibitors 
(imatinib/dasatinib) (8,9), experimental inhibitor scaffolds (10) and/or broad spectrum kinase 
inhibitors such as staurosporine (7). Here we describe a chemical proteomics method that is 
designed to capture the full array of adenosine nucleotide-binding proteins, the ATPome, of M. 
tuberculosis, H37Rv. ATP-binding proteins are labeled with desthiobiotin-conjugated ATP 
(Figure 5.1) and subsequently digested with trypsin. Labeled peptides are captured via 
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streptavidin affinity chromatography subjected to LC-MS/MS for the identification of ATP-
labeled proteins.  
 
 
Figure 5.1 - Mechanism of Action of the Desthiobiotin Conjugated 
ATP Active Site Probe. This method utilizes a desthiobiotin-
conjugated ATP (A) as a molecular probe in which target enzymes are 
covalently modified within characteristic active sites – in this case the 
nucleotide binding domains of kinases and other ATP-binding proteins 
(B). As the nucleotide probe binds, the phosphodiester bond linking 
the desthiobiotin affinity tag to the ATP molecule undergoes a 
nucleophilic attack initiated by the free amine of conserved active-site 
lysine residues. The desthiobiotin-linked lysine can then be considered 
covalently modified and detectable via mass spectrometry.  
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5.3 Functionally Linked Protein Networks Associated with the Cellular Envelope of M. 
tuberculosis.  
The ATP-binding proteins of M. tuberculosis comprise a very unique and functional subset 
of the mycocaterial proteome. The proteins capable of nucleotide binding are targets for small-
molecule inhibitors because they are functionally distributed among a variety of enzyme classes 
and play essential, often non-redundant roles in basic cellular metabolism. The functional nature 
of this sub-proteome supports the general hypothesis that proteins of the mycobacterial ATPome 
provide necessary mechanisms of adaptation utilized in the maintenance of growth under a 
variety of microenvironmental conditions. The physiology and molecular architecture of the M. 
tuberculosis cellular envelope is a dynamic and highly biologically active scaffold. This structure 
and the signaling processes associated with maintaining it, also work to sustain viability of the 
pathogen during intracellular infection within host macrophages. This stage of infection is 
successful because the bacillus is capable of manipulating its environment in such a way as to 
evade the host immune response. Physiochemically, its molecular composition is responsible for 
the organism’s inherent tolerance to antimicrobial therapies, which prolongs effective treatment 
time. The molecular events that regulate the entrance into and exit out of different metabolic 
states remain poorly defined, although there are several hypotheses that remain testable (70,71). 
Approximately one-quarter of the M. tuberculosis genome remains functionally characterized as 
hypothetical (72). Recent re-annotation and prediction efforts concluded that the majority of 
hypothetical proteins could be redistributed among the categories of Small Molecule 
Metabolism, Cell Wall Processes, and Lipid Metabolism (54,55). As described in Chapter III, 
proteins extracted from the cell wall were significantly (70% of CWP) biased towards these 
categories. The utilization of ATP by these hypothetical proteins may provide further insight into 
their cellular roles and enzymatic functions and may lead to key insights in the study of 
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pathogen-specific mechanisms of persistence and reactivation. The idea of ATP binding and 
hydrolysis acting as a molecular switch controlling the transition into hypoxia has been observed 
in the study of mammalian models of low-oxygen conditions (56,57). For mycobacteria, one 
class of ATP-binding proteins, the Universal Stress Proteins (USPs), may be involved in the 
responses to changes in environmental and nutrient conditions leading to variations in virulence 
and adaptation. Several years ago, Drumm and Chan et al., investigated the nucleotide binding 
capabilities of Rv2623 and its role as a universal stress protein (USP)(58). Gene deletion mutants 
in M. tuberculosis, Erdmann demonstrated a hypervirulent phenotype that failed to enter into 
dormancy within susceptible Hartley guinea pigs. Disruption of the ATP-binding site of Rv2623 
resulted in similar attenuated phenotypes described for the deletion mutants. It was hypothesized 
that the binding of ATP by similar USPs could be a regulatory mechanism utilized in the 
transition from normal growth to an oxygen-poor state of dormancy.  
In this study we set out to (1) provide a comprehensive profile of ATP-binding proteins and 
catalytic pathways present within the native proteome of M. tuberculosis, H37Rv.      (2) Identify 
patterns of differential abundance of ATP-binding proteins present under normally growing and 
a hypoxia-induced, dormant state and (3) provide evidence of either competitive or transient 
ATP-binding states of nucleotide bound proteins for the identification of potential therapeutic 
targets of ATP-competitive kinase inhibitors. Through this work we identified essential gene 
products critical to survival, adaptation and the development of drug resistance. Many protein 
families were functionally linked with processes of cell wall integrity and metabolism. This work 
may lead to the identification of novel therapeutic targets and provide insight into the use of 





5.4.1 Comprehensive Proteomic Analysis of the M. tuberculosis ATPome 
A shotgun proteomics analysis was performed on the enriched subproteome of 
dethiobiotin-labeled ATP-binding proteins. We identified a total of 176 proteins, 122 were 
labeled via the nucleotide probe (Appendix III). Selective labeling was further validated by 
ranking the tagged proteins using a metric of ATP-labeling based on protein and peptide 
confidence levels greater than 90% as well as manual interpretation of spectral quality for each 
peptide sequence labeled with a desthiobiotin tag(11). This ranking accounted for the variation 
among identified peptides in signal to noise levels and sequence coverage. Proteins were listed 
by the quality of spectra demonstrating a desthiobiotin-labeled lysine (differential modification 
of lysine (K) of +196 Da). Low confidence peptide spectra exhibited no less than 90% peptide 
confidence with a minimum of one assigned peptide (number identified – 21). Medium 
confidence peptide spectra had a peptide score between 90 – 95% with two or more assigned 
peptides (number identified – 20).  Proteins determined to have labeling in the high confidence 
range, exhibited greater than 95% peptide confidence and had two or more unique peptides 
assigned for identification (number identified – 81). A no-probe, streptavidin-only control was 
performed to account for proteins that have inherent biotin-like domains and may non-
specifically interact with the streptavidin capture resin. Results from the control experiments 
revealed only a few proteins - chaperones GroEL2 (Rv0440), DnaK (Rv0350), HspX(Rv2031c),  
the acyl-carrier protein AcpM (Rv2244), the peptidyl-prolyl-cis-trans-isomerase PpiA (Rv0009) 
and the naturally biotinylated acetyl carboxylase AccA3 (Rv3285) - bound streptavidin non-
specifically in addition to being confidently labeled with the desthiobiotin probe. In the case of 
GroEL2, DnaK and HspX we believe the promiscuous binding to the affinity resin was due to 
the high abundance of each protein and their chaperoning function. PpiA, while not present in 
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high abundance aids in protein folding as well (12). AccA3 most likely bound the streptavidin 
capture resin by virtue of its biotin-binding domain (13). AcpM is functionally associated with 
AccA3 as both proteins are involved in long chain fatty acid synthesis. Their association in this 
pathway is visualized via the STRING database (v. 9.0 2012; (14)), with curated pathway 
interactions in the BioCyc v. 16.1 pathway collection (http://biocyc.org/ECOLI/NEW-
IMAGE?type=PATHWAY&object=PWY0-881). Overall, the utilization of the active site 
nucleotide probe to capture ATP-binding proteins resulted in a highly enriched proteome, with 















5.4.2 Functional Annotation of Labeled Proteins 
Functional annotation of the proteins using web-based services as well as in-house 
implementation of a variety of tools were carried out on various levels in the laboratory of Dr. 
Stephan Shürer, with final analysis provided by Dr. Susan Idicula-Thomas, at the University of 
Miami, Miller School of Medicine. This work was performed in collaboration with Dr. Schürer 
in order to identify the functional domains and domain families that were selectively labeled and 
enriched via our chemical proteomic techniques. To begin, the amino acid sequence of each 
identified protein and covalently labeled peptide sequence was provided to Dr. Idicula-Thomas 
and subjected to an InterPro (http://www.ebi.ac.uk/interpro/) pattern search to identify functional 
domains and associate these regions with domain families (Pfams) (17).  
 
It was determined that 13 ATP-associated Pfams were represented in the ATPome dataset 
across all ranges of labeling confidence (low to high, n=122) and none were represented in 
Figure 5.2  - Primary Sequence Analysis of ATP-Binding Peptides and Proteins.  
Each protein sequence was submitted for in silico analysis through InterPro 
(http://www.ebi.ac.uk/interpro/ ) and sorted via Gene Ontology (molecular function).  A - 
Approximately 80% of the ATP-binding (i.e. desthiobiotin labeled) proteins were found to 
be associated with ATP within an annotated functional domain. Binding confidence - 
high, medium, low - was empirically determined associated with the quality of labeled 
peptide specta (i.e confident sequence coverage and low signal to noise).  B – The 
functions of small molecule binding, transferase and oxidoreductase activity described the 
majority of ATPome enzymatic properties.  
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proteins identified, but not labeled with nucleotide probe (n = 54).Among the ATP-associated 
Pfams were proteins involved with ATP synthesis (PF00006) and peptidoglycan synthesis (Mur 
Ligase (PF01225)), as well as protein kinases (Pkinase PF00069).  Overall, approximately 80% 
of the ATPome had peptides that were labeled within a known or predicted ATP-associated Pfam 
domain (Figure 5.2A). Domain descriptions were then mapped to the GO term “ATP Binding” 
(GO ID:0005524) and associated with specific enzyme activities (Figure 5.2B). -  
 The majority of enzyme activities could be associated with small molecule binding 
(34%), transferase (17%) and oxidoreductase (16%) activity (Figure 5.2). The protein functional 
category Small Molecule Metabolism includes proteins involved in lipid metabolism, 
intermediary metabolism and regulatory proteins such as kinases. Categorization of the M. 
tuberculosis ATPome by broad protein function (i.e. Tuberculist Functional Categories - 
http://tuberculist.epfl.ch/) revealed that second and third to category 7 – Intermediary 
Metabolism, category 1 – Lipid Metabolism and category 10 – Conserved Hypotheticals, 
Figure 5.3 - Organization of the M. tuberculosis, H37Rv ATPome by 
Functional Category.  Representing nearly 50% of the ATPome were proteins 
within functional category 7 – Intermediary Metabolism and functional category 2 
– Lipid Metabolism. Conserved Hypotheticals (functional category 10) were the 
third most represented group.  
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respectively, represented a collective 33% of the enriched proteome (Figure 5.3). Proteins 
involved in fatty acid and mycolic acid biosynthesis (category 1) are of interest due to their key 
roles in maintenance of the cell envelope architecture and the essentiality of their encoding genes 
(16).  A complete list of labeled and unlabeled protein IDs and their corresponding functional 
categories is provided in Appendix III. 
5.4.3 Differential Abundance of Proteins in Normally Growing vs Hypoxic  Bacteria:  
We utilized the active site nucleotide probes to selectively capture and enrich for the M. 
tuberculosis ATPome under different growth conditions. Normally growing cells were compared 
to cells grown in limited oxygen conditions (see Materials and Methods). Overall, we identified 
61 differentially abundant proteins. Results were calculated for protein abundance changes that 
had a p-value less than 0.05 (11,18). The log of the fold change (FC) values was plotted against 
the calculated p-values in order to visualize the distribution of proteins between the two growth 
states (Figure 5.4).  Proteins were determined to be differentially abundant if they were only 
present within the hypoxic data set or had a calculated ration (log fold change, logFC) of spectral 
counts less than zero for proteins with higher abundance in hypoxic samples (Table 5.1). Proteins 


































conserved hypothetical protein Rv2623 32 kDa (0.0000) 1 14 -3.81
acyl-[acyl-carrier protein] desaturase desA1 Rv0824c 39 kDa (0.0000) 1 12 -3.58
hypothetical protein acg Rv2032 37 kDa (0.0003) 1 8 -3.00
phosphoribosylaminoimidazole-succinocarboxamide synthase purC Rv0780 33 kDa (0.0010) 1 7 -2.81
ketol-acid reductoisomerase ilvC Rv3001c 36 kDa (0.0010) 1 7 -2.81
acyl-[acyl-carrier protein] desaturase desA2 Rv1094 31 kDa (0.0000) 2 12 -2.58
isocitrate lyase icl Rv0467 47 kDa (0.0033) 1 6 -2.58
10 kda culture filtrate antigen esxB Rv3874 11 kDa (0.0100) 1 5 -2.32
40 kda secreted L-alanine dehydrogenase ald Rv2780 39 kDa (0.0000) 29 134 -2.21
citrate synthase I gltA2 Rv0896 48 kDa (0.0320) 1 4 -2.00
DNA gyrase subunit B gyrB Rv0005 78 kDa (0.0320) 1 4 -2.00
transcription termination factor rho Rv1297 65 kDa (0.0000) 4 15 -1.91
iron-regulated heparin binding hemagglutinin hbhA Rv0475 22 kDa (0.0004) 3 11 -1.87
ATP synthase alpha chain atpA Rv1308 59 kDa (0.0011) 4 11 -1.46
macrolide-transport ATP-binding protein ABC transporter Rv2477c 62 kDa (0.0005) 5 13 -1.38
6-phosphofructokinase pfkA Rv3010c 37 kDa (0.0140) 5 9 -0.85
fatty-acid oxidation protein fadB Rv0860 76 kDa (0.0010) 10 17 -0.77
heat shock protein hspX Rv2031c 16 kDa (0.0000) 133 223 -0.75
conserved hypothetical protein Rv1738 11 kDa (0.0019) 10 16 -0.68
bifunctional polyribonucleotide nucleotidyltransferase gpsI Rv2783c 80 kDa (0.0026) 13 18 -0.47
adenosylhomocysteinase sahH Rv3248c 54 kDa (0.0000) 45 53 -0.24
iron-regulated aconitate hydratase acn Rv1475c 102 kDa (0.0490) 10 11 -0.14
* A value of 1, indicates a normalized spectral abundance factor (NSAF) of 0 in hypoxic samples















polyphosphate kinase ppk Rv2984 83 kDa (0.0000) 66 1 6.04
phosphoglycerate kinase pgk Rv1437 43 kDa (0.0000) 57 2 4.83
acyl-CoA dehydrogenase fadE4 Rv0231 63 kDa (0.0002) 23 1 4.52
dehydrogenase Rv3389c 30 kDa (0.0010) 19 1 4.25
19 kda lipoprotein antigen precursor lpqH Rv3763 15 kDa (0.0021) 17 1 4.09
immunogenic protein mpt64 Rv1980c 25 kDa (0.0021) 17 1 4.09
hypothetical protein Rv2319c 32 kDa (0.0021) 17 1 4.09
aminomethyltransferase gcvT Rv2211c 40 kDa (0.0021) 17 1 4.09
superoxide dismutase sodA Rv3846 23 kDa (0.0031) 16 1 4.00
cysteinyl-tRNA synthetase 1 cysS1 Rv3580c 52 kDa (0.0031) 16 1 4.00
DNA polymerase I polA Rv1629 98 kDa (0.0031) 16 1 4.00
transmembrane serine/threonine-protein kinase E pknE Rv1743 61 kDa (0.0031) 16 1 4.00
iron-regulated short-chain dehydrogenase/reductase Rv3224 30 kDa (0.0006) 26 2 3.70
fatty-acid-CoA ligase fadD23 Rv3826 63 kDa (0.0099) 13 1 3.70
leucyl-tRNA synthetase leuS Rv0041 108 kDa (0.0150) 12 1 3.58
pyridoxamine 5-phosphate oxidase pdxH Rv2607 25 kDa (0.0150) 12 1 3.58
conserved hypothetical protein Rv2624c 29 kDa (0.0002) 34 3 3.50
aldehyde dehydrogenase Rv0458 55 kDa (0.0066) 19 2 3.25
acetyl-/propionyl-CoA carboxylase alpha subunit accA1 Rv2501c 71 kDa (0.0001) 45 5 3.17
fatty-acid-CoA ligase fadD7 Rv0119 55 kDa (0.0020) 27 3 3.17
electron transfer flavoprotein beta subunit fixA Rv3029c 28 kDa (0.0020) 27 3 3.17
fatty-acid-CoA ligase fadD36 Rv1193 50 kDa (0.0460) 9 1 3.17
transferase Rv1201c 33 kDa (0.0460) 9 1 3.17
phosphoribosylamine-glycine ligase purD Rv0772 44 kDa (0.0028) 26 3 3.12
pyruvate kinase pykA Rv1617 51 kDa (0.0021) 31 4 2.95
low molecular weight protein antigen cfp2 Rv2376c 17 kDa (0.0250) 15 2 2.91
glutamyl-tRNA Rv3009c 55 kDa (0.0000) 83 12 2.79
transmembrane serine/threonine-protein kinase H pknH Rv1266c 67 kDa (0.0036) 33 5 2.72
conserved alanine rich protein Rv2744c 29 kDa (0.0480) 13 2 2.70
transmembrane serine/threonine-protein kinase D pknD Rv0931c 70 kDa (0.0005) 51 8 2.67
conserved hypothetical protein Rv2159c 36 kDa (0.0320) 18 3 2.58
ATP-dependent protease ATP-binding subunit clpC1 Rv3596c 94 kDa (0.0000) 181 32 2.50
glutamine synthetase glnA2 Rv2222c 50 kDa (0.0280) 22 4 2.46
30S ribosomal protein S1 rpsA Rv1630 53 kDa (0.0360) 21 4 2.39
succinyl-CoA synthetase beta chain sucC Rv0951 41 kDa (0.0170) 40 9 2.15
endopeptidase ATP binding protein chain B clpB Rv0384c 93 kDa (0.0003) 131 33 1.99
glutamine synthetase glnA1 Rv2220 54 kDa (0.0200) 65 18 1.85
10 kda chaperonin groES Rv3418c 11 kDa (0.0049) 136 41 1.73
* A value of 1, indicates a normalized spectral abundance factor (NSAF) of 0. 
Table 1 - Proteins with Increased Abundance During Normal GrowthTable 5.2 – Proteins with Increased Abundance During Normal 
Growth 
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 During dormancy and hypoxic growth, M. tuberculosis undergoes changes in gene 
expression that typically involve the upregulation of enzymes involved in alternative metabolic 
pathways (i.e. Glyoxylate Bypass) and those observed to be under the control of the dormancy 
regulon DosR. The list of proteins in Table 5.2 includes the gene products HspX (Rv2031c), Acg 
(Rv2032c), TB31.7 (Rv2623), Rv2624c and Rv1738. These proteins are directly regulated or co-
expressed with the response regulator DosR (Rv3133c) (19). Beyond the level of individual 
genes we observe patterns of protein function that change between Normal and Hypoxic growth 
(Functional Categories 2, 3, 9 and 10) and those that remain relatively stable (Categories 0, 1, 
and 7) (Figure 5.5) 
Figure 5.4 - Comparison of Functional Categories 
Desthiobiotin-labeled proteins found to be differentially abundant between 
Normal and Hypoxic growth were sorted based on functional category 
(Tuberculist - http://tuberculist.epfl.ch/). Categories 4 (Stable RNAs), 5 
(Insertion Sequences & Phages) and 6 (PE/PPE) were not represented in 




Indeed, isocitrate lyase (icl, Rv0467) the enzyme that catalyzes the reversible cleavage of 
isocitrate to glyoxylate and succinate (20) and has a role in the growth, survival and persistence 
of M. tuberculosis in macrophages and mice (21) was found to be labeled with desthiobiotin-
ATP on Lys322 (PFAM: PF00463) and differentially abundant during hypoxic growth. The 
second enzyme involved in the glyoxylate cycle – malate synthase G (glcB, Rv1837c) was also 
labeled with our active site probe, however in this study its differencial abundance in hypoxic 
grown cultures was not significant (p-value > 0.60). We did, however confirm increased protein 
levels of GlcB via western blot (Figure 5.6). It is well known that the expression of alanine 
dehydrogenase (ald, Rv2780) is also upregulated during the growth of M. tuberculosis under low 
Figure V.5 – Densitometry Analysis. Several proteins found to be differentially 
abundant by NSAF were probed for immunoreactivity via western blot. The densitometry 
analysis of these blots corroborates the differences in protein levels between Normal and 
Hypoxic cells. The densitometry of each protein with its corresponding positive control 
(recombinant protein) is reported (top panel).  
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oxygen conditions (20).  It has recently been shown in M. tuberculosis and previously in M. 
smegmatis that alanine dehydrogenase is responsible for both glycine and alanine dehydrogenase 
activities (22,23). The main role of Ald is to generate L-alanine for peptidoglycan and protein 
synthesis (22). Both Icl and Ald are unique to bacteria with no human homologs, making them 
attractive drug targets. While no inhibitors for Ald have been reported, Icl inhibitors active 
against dormant and logarithmically grown mycobacteria are 3-nitro propionamides and              
5-nitro-2-furoic acid hydrazones (24).  Densitometry analysis of immunoblots of several proteins 
found to be in higher abundance during hypoxia via mass spectrometry, confirmed differences in 
protein levels (Figure 5.6).  
5.4.4 ATP-binding Properties of the M. tuberculosis ATPome 
In addition to describing the use of ATP by essential enzymes in the bacterial proteome 
(sections 5.2.1-2), and identifying those proteins that demonstrated differential abundance 
patterns between normal and hypoxic states of growth, the third and final goal of this work was 
to characterize proteins whose ATP-binding function may be utilized in the development of 
novel ATP-competitive antibiotics. The desthiobiotin labeling of active sites has been used in the 
Figure V.6 – NSAF Profiles of ATP-labeled Peptides in the Presence/Absence of 
Excess ATP-γ-S. Transient binding of ATP was observed in many proteins, including the 
DNA-binding transcriptional regulator DevR (left). In the presence of excess ATP-g-S, 
the normalized spectral count profile of the ATP-binding subunit of ClpC1 were 
significantly reduced in cultures grown under normal conditions (right).  
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study of many kinase inhibitor compounds that are clinically approved in the treatment of certain 
cancers.  In these studies the binding of the nucleotide probe is quantified in the presence or 
absence of the drug of choice. These experiments work under the assumption that for a specific 
compound – target interaction, the ATP-competitive inhibitor compound will compete out the 
binding of the nucleotide probe.  Our preliminary work into the chemical proteomics approach 
for identifying ATP-competitive inhibitors quantified the labeling of proteins in both normal and 
hypoxic states, in the presence of excess ATP (ATP-γ-S). Adenosine 5’-[γ-thio] triphosphate 
tetralithium (ATP-γ-S) is a non-hydrolysable analog of ATP. As the binding of ATP to various 
protein subunits and active sites can be very dynamic, it has been advantageous to utilize non-
hydrolysable ATP analogs to identify true ATP-binding states of proteins (25). With this set of 
experiments we asked these two questions (Figure 5.7): 1. Which proteins bind ATP transiently 
(i.e. are the binding of ATP-γ-S and the binding of desthiobiotin-ATP interchangeable)? 2. 
Which proteins have a significantly reduced capacity to bind nucleotide probe in the presence of 
excess ATP-γ-S?  Desthiobiotin-labeled peptides were quantified and those found to have a 
significant fold change differences between samples labeled in the presence of excess ATP-γ-S 



















Competitive Binders of Desthiobiotin-ATP Gene # Mol.Wt. P-Value AveNSAF_ATP-!-S* AveNSAF_ATP** Fold Change
  fatty-acid oxidation protein fadB Rv0860 76 kDa (0.0039) 1 6.33 6.33
  inosine-5-monophosphate dehydrogenase guaB3 Rv3410c 39 kDa (0.0056) 1 6.00 6.00
  transcription termination factor rho Rv1297 65 kDa (0.0079) 1 5.67 5.67
  macrolide-transport ATP-binding protein ABC transporter Rv2477c 62 kDa (0.0160) 1 5.00 5.00
  endopeptidase ATP binding protein chain B clpB Rv0384c 93 kDa (0.0031) 2.5 11.67 4.67
  iron-regulated heparin binding hemagglutinin hbhA Rv0475 22 kDa (0.0320) 1 4.33 4.33
  adenosylhomocysteinase sahH Rv3248c 54 kDa (0.0065) 5.5 18.33 3.33
  chaperone protein dnaK Rv0350 67 kDa (0.0001) 16 50.00 3.13
  adenylate kinase adk Rv0733 20 kDa (0.0400) 8 20.33 2.54
  acyl-[acyl-carrier protein] desaturase desA1 ! Rv0824c 39 kDa (0.2200) 2 4.67 2.33
  ATP synthase beta chain atpD ! Rv1310 53 kDa (0.1500) 5 11.33 2.27
  bifunctional acetyl-/propionyl-coenzyme A carboxylase alpha chain accA3! Rv3285 64 kDa (0.2600) 3 6.33 2.11
Transient Binders of Desthiobiotn-ATP
  50S ribosomal protein L7/L12 rplL Rv0652 13 kDa (0.3100) 4.5 8.67 1.93
  10 kda chaperonin groES Rv3418c 11 kDa (0.3600) 8 14.33 1.79
  ATP-dependent protease ATP-binding subunit clpC1 Rv3596c 94 kDa (0.5000) 7 11.33 1.62
  60 kda chaperonin 1 groEL1 Rv3417c 56 kDa (0.5100) 3.5 5.67 1.62
  conserved hypothetical protein Rv2623 32 kDa (0.5600) 3.5 5.33 1.52
  40 kda secreted L-alanine dehydrogenase ald Rv2780 39 kDa (0.0520) 36 45.33 1.26
  cold shock protein A cspA Rv3648c 7 kDa (0.4400) 4 5.00 1.25
  60 kda chaperonin 2 groEL2 Rv0440 57 kDa (0.0000) 135 168.67 1.25
  heat shock protein hspX Rv2031c 16 kDa (0.0002) 67.5 75.00 1.11
  transmembrane serine/threonine-protein kinase A pknA Rv0015c 46 kDa (0.3100) 4 4.33 1.08
  isocitrate lyase icl Rv0467 47 kDa (0.4300) 2.5 2.67 1.07
  integration host factor mihF Rv1388 21 kDa (0.0280) 19 20.00 1.05
  6-phosphofructokinase pfkA Rv3010c 37 kDa (0.3200) 3.5 3.67 1.05
  bifunctional polyribonucleotide nucleotidyltransferase gpsI Rv2783c 80 kDa (0.1600) 6.5 6.67 1.03
  iron-regulated elongation factor tu tuf Rv0685 44 kDa (0.0120) 20.5 20.33 0.99
  propionyl-CoA carboxylase beta chain 5 accD5 Rv3280 59 kDa (0.5000) 1.5 1.33 0.89
  conserved hypothetical protein Rv3269 10 kDa (0.1600) 4.5 4.00 0.89
  electron transfer flavoprotein beta subunit fixA Rv3029c 28 kDa (0.3300) 2 1.67 0.83
  conserved hypothetical protein Rv1738 11 kDa (0.0390) 7.5 6.00 0.80
  iron-regulated conserved hypothetical protein Rv1636 15 kDa (0.0093) 10 7.33 0.73
  transmembrane serine/threonine-protein kinase D pknD Rv0931c 70 kDa (0.0100) 6 3.33 0.56
  conserved hypothetical protein Rv3127 39 kDa (0.0640) 3 1.67 0.56
** Average spectral count of desthiobiotin-labeled peptides with no excess ATP-!-S
! P-value > 0.05
 * Average spectral count of desthiobiotin-labeled peptides in the presence of 500µM ATP-!-S. A value of 1 indicates 0 spectral counts in the 
presence of excess ATP analog. 
Table 3 - Competitive and Transient Binders of Desthiobiotin-ATP in Hypoxic Cultures
Table 5.3 – Competitive and Transient Binders of Desthiobiotin ATP in Hypoxic 
Cultures. 
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Competitive Binders of Desthiobiotin-ATP Gene # Mol. Wt. P-Value AveNSAF_ATP-!-S* AveNSAF_ATP** Fold Change
  acetyl-/propionyl-CoA carboxylase alpha subunit accA1 Rv2501c 71 kDa (0.0000) 1.00 15.67 15.67
  glutamyl-tRNA amidotransferase subunit B gatB Rv3009c 55 kDa (0.0000) 2.33 28.33 12.14
  inosine-5-monophosphate dehydrogenase guaB3 Rv3410c 39 kDa (0.0000) 1.00 11.67 11.67
  transmembrane serine/threonine-protein kinase H pknH Rv1266c 67 kDa (0.0000) 1.00 11.33 11.33
  fatty-acid-CoA ligase fadD7 Rv0119 55 kDa (0.0000) 1.00 9.67 9.67
  phosphoribosylamine-glycine ligase purD Rv0772 44 kDa (0.0000) 1.00 9.33 9.33
  tryptophanyl-tRNA synthetase trpS Rv3336c 36 kDa (0.0001) 1.00 7.00 7.00
  polyphosphate kinase ppk Rv2984 83 kDa (0.0000) 3.33 22.67 6.80
  phosphoglycerate kinase pgk Rv1437 43 kDa (0.0000) 3.00 19.67 6.56
  cysteinyl-tRNA synthetase 1 cysS1 Rv3580c 52 kDa (0.0005) 1.00 5.67 5.67
  fatty-acid-CoA ligase fadD23 Rv3826 63 kDa (0.0014) 1.00 5.00 5.00
  universal stress protein Rv2319c 32 kDa (0.0012) 1.33 6.33 4.75
  CTP synthase pyrG Rv1699 64 kDa (0.0024) 1.00 4.67 4.67
  phosphofructokinase pfkB Rv2029c 35 kDa (0.0073) 1.00 4.00 4.00
  ATP-dependent protease ATP-binding subunit clpC1 Rv3596c 94 kDa (0.0000) 15.33 61.00 3.98
  anchored-membrane serine/threonine-protein kinase pknF Rv1746 51 kDa (0.0130) 1.00 3.67 3.67
  chaperone protein htpG Rv2299c 73 kDa (0.0130) 1.00 3.67 3.67
  DNA polymerase I polA Rv1629 98 kDa (0.0078) 1.67 6.00 3.60
  acetate kinase ackA Rv0409 41 kDa (0.0220) 1.00 3.33 3.33
  UDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate-D-alanyl-
D-alanyl ligase murF Rv2157c 52 kDa (0.0220) 1.00 3.33 3.33
  conserved hypothetical protein Rv3282 23 kDa (0.0220) 1.00 3.33 3.33
  conserved hypothetical protein Rv2510c 57 kDa (0.0220) 1.00 3.33 3.33
  fatty-acid-CoA ligase fadD28 Rv2941 63 kDa (0.0077) 2.33 7.67 3.29
  nucleoside diphosphate kinase ndkA Rv2445c 15 kDa (0.0150) 2.00 6.33 3.17
  40 kda secreted L-alanine dehydrogenase ald Rv2780 39 kDa (0.0066) 3.00 9.33 3.11
  adenosylhomocysteinase sahH Rv3248c 54 kDa (0.0017) 5.00 15.00 3.00
  pyruvate kinase pykA Rv1617 51 kDa (0.0053) 3.67 11.00 3.00
  malate synthase G glcB Rv1837c 80 kDa (0.0420) 1.67 4.67 2.80
  aldehyde dehydrogenase Rv0458 55 kDa (0.0350) 2.67 7.00 2.63
  adenylate kinase adk Rv0733 20 kDa (0.0035) 17.33 36.67 2.12
  transmembrane serine/threonine-protein kinase D pknD Rv0931c 70 kDa (0.0400) 8.67 17.67 2.04
  ATP synthase beta chain atpD Rv1310 53 kDa (0.0250) 13.33 26.33 1.98
Transient Binders of Desthiobiotin-ATP
  endopeptidase ATP binding protein chain B clpB Rv0384c 93 kDa (0.0410) 25.33 44.33 1.75
 3-hydroxyacyl-thioester dehydrogenase htdY Rv3389c 30 kDa (0.4000) 4.67 7.00 1.50
  iron-regulated short-chain dehydrogenase/reductase Rv3224 30 kDa (0.4100) 6.33 9.33 1.47
  aminomethyltransferase gcvT Rv2211c 40 kDa (0.4300) 4.33 6.33 1.46
  phosphopantetheine adenylyltransferase kdtB Rv2965c 18 kDa (0.4700) 2.33 3.33 1.43
  chaperone protein dnaK Rv0350 67 kDa (0.3800) 40.00 57.00 1.43
  cold shock protein A cspA Rv3648c 7 kDa (0.5300) 5.67 7.67 1.35
  secreted fibronectin-binding protein antigen 85-B fbpB Rv1886c 35 kDa (0.5400) 2.00 2.67 1.33
  iron-regulated peptidyl-prolyl-cis-trans-isomerase A ppiA Rv0009 19 kDa (0.5400) 3.00 4.00 1.33
  glutamine synthetase glnA2 Rv2222c 50 kDa (0.5500) 6.00 8.00 1.33
  pyruvate dehydrogenase E2 component sucB Rv2215 57 kDa (0.5500) 7.33 9.67 1.32
  acyl-CoA dehydrogenase fadE5 Rv0244c 66 kDa (0.5700) 3.33 4.33 1.30
  pyruvate dehydrogenase E1 component aceE Rv2241 100 kDa (0.5700) 4.67 6.00 1.29
  60 kda chaperonin 2 groEL2 Rv0440 57 kDa (0.0180) 279.00 352.00 1.26
  iron-regulated conserved hypothetical protein Rv1636 15 kDa (0.3500) 17.00 21.00 1.24
  propionyl-CoA carboxylase beta chain 5 accD5 Rv3280 59 kDa (0.5800) 3.00 3.67 1.22
  low molecular weight protein antigen cfp2 Rv2376c 17 kDa (0.5000) 4.67 5.67 1.21
  glutamine synthetase glnA1 Rv2220 54 kDa (0.3000) 17.67 21.33 1.21
  heat shock protein hspX Rv2031c 16 kDa (0.1800) 36.00 43.33 1.20
  succinyl-CoA synthetase beta chain sucC Rv0951 41 kDa (0.3500) 11.67 14.00 1.20
  oligoribonuclease orn Rv2511 23 kDa (0.4800) 5.00 6.00 1.20
  protein transport protein secE2 Rv0379 8 kDa (0.5400) 3.33 4.00 1.20
  L-lactate dehydrogenase lldD2 Rv1872c 45 kDa (0.4500) 5.33 6.33 1.19
  conserved hypothetical protein Rv2159c 36 kDa (0.4300) 5.67 6.67 1.18
  bifunctional coenzyme A carboxylase alpha chain accA3 Rv3285 64 kDa (0.2800) 13.67 16.00 1.17
  50S ribosomal protein L7/L12 rplL Rv0652 13 kDa (0.2500) 16.00 18.67 1.17
  conserved hypothetical protein Rv3269 10 kDa (0.4800) 4.00 4.67 1.17
  ribosome recycling factor frr Rv2882c 21 kDa (0.5700) 2.33 2.67 1.14
  superoxide dismutase sodA Rv3846 23 kDa (0.3900) 5.33 6.00 1.13
  transmembrane serine/threonine-protein kinase E pknE Rv1743 61 kDa (0.3900) 5.33 6.00 1.13
  two component system transcriptional regulator devR Rv3133c 23 kDa (0.4600) 3.33 3.67 1.10
 tetrahydrodipicolinate N-succinyltransferase Rv1201c 33 kDa (0.4600) 3.33 3.67 1.10
  leucyl-tRNA synthetase leuS Rv0041 108 kDa (0.3800) 4.33 4.67 1.08
  iron-regulated elongation factor tu tuf Rv0685 44 kDa (0.0300) 40.33 43.33 1.07
  immunogenic protein mpt64 Rv1980c 25 kDa (0.3000) 6.00 6.33 1.06
  30S ribosomal protein S1 rpsA Rv1630 53 kDa (0.2500) 7.33 7.67 1.05
  transmembrane serine/threonine-protein kinase A pknA Rv0015c 46 kDa (0.2100) 8.67 9.00 1.04
  transcriptional regulator Rv0023 27 kDa (0.5600) 1.67 1.67 1.00
  hypothetical protein wag31 Rv2145c 28 kDa (0.4200) 2.67 2.67 1.00
  hypothetical protein Rv3818 58 kDa (0.5000) 2.00 2.00 1.00
  conserved alanine rich protein Rv2744c 29 kDa (0.2800) 5.00 5.00 1.00
  enoyl-CoA hydratase echA9 Rv1071c 36 kDa (0.3900) 3.00 3.00 1.00
  conserved hypothetical protein Rv2140c 19 kDa (0.5000) 2.00 2.00 1.00
Table 4 - Competitive and Transient Binders of Desthiobiotin-ATP in Normal Cultures
Table 5.4 – Competitive and Transient Binders of Desthiobiotin ATP in Normal Cultures 
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  thiosulfate sulfurtransferase cysA2 Rv0815c 31 kDa (0.5600) 1.67 1.67 1.00
  zinc-type alcohol dehydrogenase NAD dependent adhB Rv0761c 40 kDa (0.2300) 4.67 4.33 0.93
  transcriptional regulator moxR1 Rv1479 41 kDa (0.2800) 3.33 3.00 0.90
  60 kda chaperonin 1 groEL1 Rv3417c 56 kDa (0.0270) 16.33 14.67 0.90
  meromycolate extension acyl carrier protein acpM Rv2244 13 kDa (0.1400) 6.33 5.67 0.89
  haloalkane dehalogenase Rv2296 33 kDa (0.1500) 6.00 5.33 0.89
  succinyl-CoA synthetase alpha chain sucD Rv0952 31 kDa (0.1600) 5.67 5.00 0.88
  ATP synthase alpha chain atpA Rv1308 59 kDa (0.3300) 2.33 2.00 0.86
  integration host factor mihF Rv1388 21 kDa (0.0001) 41.33 34.67 0.84
  acyl-CoA dehydrogenase fadE25 Rv3274c 42 kDa (0.3500) 2.00 1.67 0.83
  DNA polymerase III beta chain dnaN Rv0002 42 kDa (0.3500) 2.00 1.67 0.83
  pyridoxamine 5-phosphate oxidase pdxH Rv2607 25 kDa (0.1100) 5.67 4.67 0.82
  10 kda chaperonin groES Rv3418c 11 kDa (0.0000) 50.33 40.67 0.81
  iron-regulated aconitate hydratase acn Rv1475c 102 kDa (0.1200) 5.00 4.00 0.80
  30S ribosomal protein S16 rpsP Rv2909c 17 kDa (0.3800) 1.67 1.33 0.80
  hypothetical protein cfp17 Rv1827 17 kDa (0.2000) 3.33 2.67 0.80
  fructose-bisphosphate aldolase fba Rv0363c 37 kDa (0.2000) 3.00 2.33 0.78
  short-chain type dehydrogenase/reductase Rv0148 30 kDa (0.2000) 3.00 2.33 0.78
  transcriptional regulator, tetR-family Rv0144 31 kDa (0.2000) 3.00 2.33 0.78
  19 kda lipoprotein antigen precursor lpqH Rv3763 15 kDa (0.0250) 8.67 6.33 0.73
  conserved hypothetical protein Rv2406c 15 kDa (0.2100) 2.33 1.67 0.71
  electron transfer flavoprotein beta subunit fixA Rv3029c 28 kDa (0.0039) 13.67 9.67 0.71
  enolase eno Rv1023 45 kDa (0.1300) 3.33 2.33 0.70
** Average spectral count of desthiobiotin-labeled peptides with no excess ATP-!-S
* Average spectral count of desthiobiotin-labeled peptides in the presence of 500µM ATP-!-S. A value of 
1 indicates 0 spectral counts in the presence of excess ATP analog. 
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5.4.5 ATP-binding proteins and Associated Biochemical Pathways 
In order to find clusters of protein families functionally linked in relevant biochemical 
pathways we utilized the list of 81 confidently labeled proteins and expanded our dataset to 
include non-labeled proteins that were confidently identified by mass spectrometry (i.e proteins 
with total spectral counts across biological replicates >5 with 90% Peptide Probability) 
irrespective of ATP-labeling (Appendix III). Functional association networks using the web 
based Search Tool for the Retrieval of Interacting Genes(14) (STRING v 9.0) were generated 
from the 81 ATP-binding proteins combined with the 54 unlabeled proteins. Emerging from this 
data set we visualized clusters of associated protein families (Figure 5.8) including members of 
the polyketide synthase family (Lipid Metabolism), ribosomal protein synthesis (Information 
Pathways), peptidoglycan and mycolic acid synthesis (Cell Wall and Processes).  Select 




Figure 5.7 - Protein-Protein Interaction networks of the M. tuberculosis ATPome. The list of 
protein IDs from our MS analysis was input into the STRING database (STRING v. 9.0; 
www.string-db.org) to identify known and predicted functional networks. 48% of the proteins in 
our shotgun analysis were shown to be functionally associated with at least one known 
interacting partner. Emerging protein clusters are functionally relevant in basic metabolism (i.e. 
respiratory chain, protein synthesis), cell wall biosynthesis (i.e. fatty acid, peptidoglycan 
synthesis), and virulence (i.e. lipid synthesis). Protein groups are numbered as follows: 1. 
Ribosomal Protein Synthesis, 2. Lipid Biosynthesis, 3. Cell Wall –Peptidoglycan, 4. Mycolic 









5.5.1 M. tuberculosis Kinases  
M. tuberculosis signal transduction is co-mediated by 3 main families of kinases and 2 
families of protein phosphatases. Of the kinases, the first family comprises eleven complete two 
component systems (TCS) each consisting of a membrane bound histidine kinase and a cytosolic 
response regulator, which directly interacts with DNA to affect gene transcription. The second 
family of kinases is comprised of 11 eukaryotic-like ser/thr kinases (STPKs) which 
phosphorylate various cellular targets (26-28). The third class of kinase is a newly discovered 
protein tyrosine kinase (PtkA) (28) . 
5.5.2 Ser/Thr Kinases 
Three of the eleven STPKs, PknA, PknB and PknG, are deemed necessary for successful 
intracellular infection and growth. PknB has been previously cited as a promising bacterial 
signaling target, as it is one of the most widely distributed STPKs among bacterial kinases (29) 
and contains a highly conserved active site (30).  We identified 6 STPK gene products, 
PknABDHEF.  PknA and PknB are essential transmembrane proteins responsible for cell growth 
and morphology(31,32). They are a part of an operon and are predominantly expressed during 
exponential growth in vitro. Protein level analysis of the M. tuberculosis proteome within 
granulomas of infected guinea pigs demonstrated protein levels of PknA decreasing during the 
course of 90-day infection, while levels of PknB begin to increase (33). While deemed non-
essential for growth in vitro, PknD, F and H have been implicated in a wide variety of important 
biological roles. For instance, phosphorylation of MmpL7 by PknD, affects the transport of a key 
virulence factor in M. tuberculosis pathogenesis, phthiocerol dimycocerosate (PDIM) (34). PknF 
has been shown to be critical for regulating cell growth, septum formation and glucose transport 
in vitro (35). In our ATPome, the Ser/Thr kinases were more abundant during active growth and 
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showed no trend towards increased abundance in hypoxic cultures. Monitoring these proteins 
using the active site labeling tools may need further optimization to provide more quantitative 
evidence of their differential presence during different states of growth.  
5.5.3 Two-Component Sensor Kinases and Response Regulators 
The sensor histidine kinase PrrB was the only two-component sensor kinase whose spectra 
exceeded the required protein and peptide probability thresholds set for confident identification 
in our ATPome.  The PrrA-PrrB TCS is required for early intracellular multiplication of M. 
tuberculosis in human macrophages (36). The prrAB genes are present in an operon and are co-
transcribed during logarithmic growth. During stationary phase and under conditions of hypoxia, 
transcript levels are decreased however protein levels remain relatively stable throughout growth 
phases. TCS’s are unique to bacteria and are absent in mammals and PrrAB is now known to be 
essential for mycobacterial survival and pathogenesis (37).  
5.5.4 Lipid Biosynthesis and Metabolism 
Polyketide synthases are large multi-domain proteins involved in lipid and mycolic acid 
biosynthesis. Pks5, Pks12 and Pks13 as well as the phthiocerol dimycocerate synthases 
PpsABCDE and mycocerosic acid synthase (Mas) work in coordination to synthesize the cell 
wall associated and virulence determinant phthiocerol dimycocerosate (PDIM)(38,39). Within 
this group of proteins PpsC was found to bind ATP. PpsC catalyzes the complete reduction of 
malonyl CoA in the synthesis of phthiocerol. The localization of the ATP nucleotide probe was 
not within any of the annotated domains of PpsC. Although PpsC is a non-essential enzyme, its 
associated protein partners identified in this study do play essential roles (pks12/13) (39).  
Overall, 10 proteins involved in the synthesis of fatty acids and mycolic acids are listed in our 
ATPome as nucleotide binding: AccA1, AccA3, AcpM, DesA1, DesA2, FadD21, FadD25, 
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FadD29, FadD32 and FadE23. The M. tuberculosis genome contains three biotin dependent 
essential acyl CoA carboxylases (AccA1 to 3) which are involved in the first step of fatty acid 
biosynthesis (i.e. the production of malonyl CoA and methyl malonyl CoA from acyl coenzyme 
A (CoA) (13). The biotin binding domain of these enzymes did allow for the non-specific 
attachment to the streptavidin capture affinity resin (as discussed in section 5.2.1) however their 
ATP-binding function is essential to their enzymatic activity, and labeling with nucleotide probe 
was located within an annotated nucleotide binding domain (K116) (40). 
The acyl carrier protein AcpM (Rv2244) is a versatile carrier of fatty acyl chains through 
the biosynthetic processes of FAS II (41). The essential acyl (ACP) membrane bound 
desaturases, DesA1 and DesA2 catalyze the introduction of the first double bond in saturated 
C16 and C18 fatty acids. DesA1 and desA2 are essential genes for mycobacterial survival and 
DesA1 is predicted to be a relevant drug target based on interactome and genome-scale structural 
analysis (42).  A third member of this family DesA3 is a putative target of the thiourea drug 
isoxyl (43).  
5.5.5 Information Pathways 
A known target for the antimycobacterial drug rifampin (RpoB) and other peripheral 
ribosomal proteins were keenly represented in our interaction data set (Figure 5.8). We identified 
16 gene products involved in the synthesis of proteins and 14 of them are essential. Protein 
synthesis is a highly conserved, cyclic process across all domains of life. A variety of soluble 
protein cofactors interact with the ribosome machinery. For example the essential and 
ubiquitously conserved GTP-binding proteins Tuf (EF-Tu, Rv0685) and FusA1 (EF-G, Rv0684) 
bind nucleotide as a mechanism of conformational change to facilitate translation (i.e. GTP 
hydrolysis by EF-Tu releases aminoacyl-tRNA). It should be noted that the phosphate-binding 
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loop of GTP-binding proteins resembles that of ATP-binding proteins (conserved P-loop NTPase 
family of proteins) with a conserved lysine essential for nucleotide binding (44). 
5.5.6 Cell Wall and Cell Wall Processes 
The processes involved in the formation of peptidoglycan (PG) are very well characterized 
in most bacteria. The mode of action for the beta-lactam class of antibiotics targets the formation 
of PG by irreversibly inhibiting the cellular activity of the penicillin binding proteins. The Mur 
ligases MurCDEF, located within the cytoplasm of mycobacteria assemble the peptide stem of 
PG. Specifically within our ATPome, we identified the D-glutamic acid ligase (MurD), the 
meso-diaminopimelic acid ligase (MurE) and the dipeptide D-Ala-D-Ala ligase (MurF). 
Dihyrodipicolinate reductase (DapB) belongs to the L-lysine biosynthetic pathway and in 
mycobacteria is also used in the synthesis of meso-diaminopimeleic acid. DapB catalyzes the 
reduction of dihydrodipicolinate to yield tetrahydrodipicolinate (45) and has been classified as a 
slow growth mutant (46).  
5.5.7 Intermediary metabolism and respiration            
Several conserved proteins involved in glycolysis (Pgk, PykA and PfkA), glyoxylate 
bypass (Icl, GlcB), TCA cycle (SucB,C and D), electron transport (FixA and B) and purine 
ribonucleotide biosynthesis (PurC and D) were identified in our study. pykA encoding pyruvate 
kinase, catalyzes the transphosphorylation of phosphoenol pyruvate (PEP) and ADP to pyruvate 
and ATP, and is essential for M. tuberculosis growth. The knockout of the pykA gene in M. 
tuberculosis resulted in the utilization of fatty acids for energy production (47,48) 
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5.6 Material and Methods 
5.6.1 Bacterial Growth:  
Mycobacterium tuberculosis H37Rv seed culture was grown to log phase (O.D600 1.2) in 
Middlebrook 7H9, ADC. Normally growing cultures: Three cultures (195 mL in 500 mL vented 
cap flasks) were inoculated with 2.5 ml of seed culture. A magnetic stir bar was added and 
cultures were incubated at 37oC with stirring (200 RPM). Final O.D600 1.2-1.6. Dormant cultures: 
Six cultures (paired-replicates of 390 mL in 500 mL sealed cap flasks) were inoculated with 5.0 
mL seed culture. Cultures were incubated at 37oC with stirring (100 RPM). Final O.D600 0.65-
0.70.  Cell pellets were harvested on days 7 (Normal) & 14 (Dormant). 
5.6.2 Sample Preparation:  
Cell pellets were resuspended at a concentration of 0.5 g/mL in IP/Lysis Buffer (25mM 
Tris-HCl pH 7.4, 150mM NaCl, 1mM EDTA, 1% NP-40 and 5% glycerol) containing HALTTM 
Protease/Phosphatase Inhibitor Cocktail (ThermoPierce). Resuspended cells were placed in 
Lysing Matrix B bead beater vials (pre-filled with 0.1 mm silica; MP Biomedicals). Lysis of 
cells occurred over 12 bead-beat cycles (30 sec lyse/45 sec rest on ice). Cell lysates were cleared 
of silica and cellular debris via centrifugation at 4,000 x g for 10 minutes. Supernatant was 
transferred to new microcentrifuge tube and centrifuged again for 10 minutes at 13,000 x g. 
Cleared lysate was then filtered through a 0.8mm/0.2mm syringe filter to sterilize lysate for 
working under BSL-2 conditions. The sterile lysate was desalted using 7K Thermo Scientific 
ZebaTM Spin Desalting columns and protein amount quantified by BCA (ThermoPierce). 500 µg 
aliquots of whole cell lysate were labeled with 5 mM Desthiobiotin-ATP for 10 minutes as per 
manufacturer’s instructions (ThermoPierce).  
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5.6.3 Active Site Peptide Capture:  
Desthiobiotin-ATP labeled proteins were reduced in 1mM DTT and alkylated in 1mM 
iodoacetamide before buffer exchange into digestion buffer (20 mM Tris pH 8.0, 2M urea). Each 
sample was digested with trypsin (1µg/µl) at an enzyme to substrate ratio of 1:50 for 2 hr at 
37oC. Peptide capture with streptavidin agarose resin and elution using 50% acetonitrile/0.1% 
TFA was followed as per manufacturer instructions.  
LC-MS: Peptides were separated on a nanospray column (Zorbax C18, 5 µm x 75 µm, 150 µm 
column). Samples were eluted into a LTQ linear ion trap mass spectrometer (Thermo) using a 
gradient of 0-100% B (A= 3% ACN, 0.1% formic acid; B =100% ACN, 0.1% formic acid) at a 
flow rate of 300 nL/min for 103 minutes. All samples were run in triplicate.  
5.6.4 Database Searching:  
Tandem mass spectra were extracted, charge state deconvoluted and deisotoped by 
Xcalibur version 2.2 SP1. All MS/MS samples were analyzed using Mascot (Matrix Science, 
London, UK; version 2.3.02) and Sequest (Thermo Fisher Scientific, San Jose, CA, USA; 
version v.27, rev. 11). Mascot and Sequest were set up to search the MtbReverse041712 database 
(7992 entries) assuming the digestion enzyme Trypsin. Parameters for both search engines were 
set to a fragment ion mass tolerance of 1.5 Da and a parent ion tolerance of 0.5 Da.  Oxidation of 
methionine, iodoacetamide derivative of cysteine and the desthiobiotin modification of lysine 
were specified in Mascot and Sequest as variable modifications.  
5.6.5 Criteria For Protein Identification:  
Scaffold (version Scaffold_3.6.1, Proteome Software Inc., Portland, OR) was used to 
validate MS/MS based peptide and protein identifications. Peptide identifications were accepted 
if they exceeded specific database search engine thresholds. Mascot identifications required at 
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least ion scores to be greater than both the associated identity scores and 50, 65, 65 and 65 for 
singly, doubly, triply and quadruply charged peptides. Sequest identifications required at least 
deltaCn scores of greater than 0.2 and XCorr scores of greater than 1.8, 2.0, 3.0 and 4.0 for 
singly, doubly, triply and quadruply charged peptides. Protein identifications were accepted if 
they contained at least 1 identified peptide. Peptide spectra meeting the most minimum 
requirement were manually inspected for quality. Proteins that contained similar peptides and 
could not be differentiated based on MS/MS analysis alone were grouped to satisfy the principles 
of parsimony. 
5.6.6 Statistical Analysis: 
The design for each experimental condition consisted of three biological replicates per 
sample group (Normal/Hypoxic-ATP, Normal/Hypoxic-ATP-γ-S and Normal/Hypoxic-
Streptavidin only). In the case of hypoxic cultures, 6 biological replicates were grown to set time 
points and cell material was pooled into 3-paired replicates and subsequently treated as triplicate 
replications. Each replicate was injected into the mass spectrometer 3 times for a total of 9 
injections per sample. Spectral count data, as visualized in Scaffold (Proteome Software, v. 
3.6.1) was normalized to Quantitative Values 
(http://www.proteomesoftware.com/pdf_files/Normalizing_Spectral_Counting-Scaffold.pdf) 
(49) and analysis was performed using Fisher’s Exact Test (FET) in the comparison of two 
groups (i.e Normal-ATP vs. Hypoxic-ATP or Normal-ATP vs Normal-ATP−γ-S). Fisher’s Exact 
Test is a valid method of identifying differences in protein abundance (i.e spectral counts) in 
shotgun proteomics data sets using experimental designs of at least 3 biological replicates and 
performs with similar power to more complex generalized linear modeling strategies (50).  
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5.6.7 Blast-Description:   
The most relevant description for each of the sequences was acquired based on the 
significant BLAST results.  The homologs for the sequences were retrieved using the blastp 
algorithm and the nonredundant database of NCBI. The Blast2GO suite (51) was used for this 
purpose, since it can annotate several sequences in one session. Pfam-domain based description:  
The domains present in the sequences, along with their Pfam and InterPro descriptions, were 
identified using the InterProscan Web service, which was accessed via the Pipeline Pilot 
(Accelrys) implementation in the sequence analysis collection. Mapping the domain and the 
labeled peptide sequences retained the information for the relevant domains. 
5.6.8 Gene Ontology Annotation:   
The Pfam domains were mapped to Gene Ontology (GO) terms using the lookup table 
provided by Pfam2go (http://www.geneontology.org/external2go/pfam2go).  GO terms are 
hierarchical and inter-related in nature.  All the GO terms originate from three distinct 
subsumption hierarchy trees, namely -cellular component, biological process and molecular 
function. Thus each domain can have multiple GO terms based on the level and type of 
annotation. An in-house script was written to retrieve GO annotations based on the root term as 
“molecular function” and their distance from the root term. 
5.6.9 Immunoblots:  
5 µg of normal and hypoxic lysate were separated on 4-12% Bis-Tris SDS-PAGE gel (Life 
Technologies (Invitrogen), Carlsbad, CA). Primary antibodies were either mouse monoclonal 
(HspX, Ald, Hbha, GlcB, KatG) or rabbit polyclonal (Rv0569, Rv1738, Rv2626c, Rv2032, 
Rv3133c) and diluted to suggested titers. All antibodies were provided through BEI Resources 
(www.beiresources.org). Control samples were recombinant proteins generated from E. coli or, if 
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unavailable, whole cell lysate from M. tuberculosis, H37Rv was used (Hbha, KatG, Ald). Protein 
bands were visualized via alkaline phosphatase conjugated IgG (Sigma). Densitometry analysis 
was performed via the ImageJ suite (http://rsbweb.nih.gov/ij/).  
5.7 Summary  
The results obtained in this study represent a first look into the ATP-binding proteome of 
the pathogenic organism, M. tuberculosis.  The majority of these proteins are essential gene 
products and may be relevant therapeutic targets. We quantitatively measured the differences in 
protein levels between normally growing and hypoxic state bacteria and provided preliminary 
data into the binding characteristics and utilization of ATP across multiple classes of functional 
enzymes. Using desthiobiotin-conjugate nucleotide probes in competition with ATP-analogs 
provides the framework necessary to pursue antimicrobial inhibitors whose mode of action relies 
on competition within the ATP-binding site of select protein targets (4,52). The utilization of 
ATP in lipid and cell wall biosynthesis pathways makes it tempting to speculate that a broad-
spectrum nucleotide competitive compound may affect these critical processes in such as way as 
to alter cell wall architecture and heterogeneity. Because the cell wall of M. tuberculosis is the 
primary defense mechanism against effective chemotherapies, breakdown of this structure using 
a novel class of antimicrobial could help circumvent the problems of multi-drug and extensively 
drug resistant bacteria (53). In our profile of ATP-binding proteins of normally growing and 
hypoxic state M. tuberculosis, we identified several proteins known to be under the control of the 
dormancy regulon dosR. The DevR-DevS TCS is implicated in virulence and mediates the 
expression of ~48 dormancy associated genes when M. tuberculosis adapts to hypoxia and is 
exposed to other stress factors like nitric oxide, carbon monoxide and ascorbic acid (59).  The 
~48 genes which comprise the devR dormancy regulon has some well known genes like hspX 
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(the alpha crystallin like chaperone), the nitrate reductase acg, and several uncharacterized 
hypothetical proteins such as Rv0569, Rv1738 and Rv2626c. A derivative of phenylcoumarin 
had reduced the survival of hypoxically adapted M. tuberculosis and also inhibited DevR binding 
to target DNA (60). We would expect to have identified the sensor kinase DevS, however it did 
not meet criteria for final inclusion, most likely due to its subcellular location with the plasma 
membrane. The response regulator DevR/DosR (Rv3133c) was shown to be confidently labeled 
with the ATP probe at the C-terminal DNA binding domain. In our competition experiments 
with 100-fold excess ATP-γS, the desthiobiotin nucleotide probe was still able to bind and label 
two lysines (K179 and K182) within the helix-turn-helix (HTH) DNA binding domain of DevR 
(UniProt ID >sp|P951931|167-186). The physiological implications of nucleotide binding to 
DevR remain to be elucidated. Furthermore, we identified several proteins belonging to the 
universal stress protein family (Rv2005c, Rv2028c, Rv2319c, Rv2623, Rv2624, and Rv2626c). 
This class of nucleotide binding proteins has been implicated in the events required for the 
activation of dormancy (4). 
5.8 Conclusion 
Genomic scale surveys of essential genes of M. tuberculosis and transcriptome-wide 
analyses of the bacterial response to environmental or metabolic conditions mimicking the host 
environment have been carried out (19,61,62). Additionally, large-scale proteomic profiling 
under simulatory in vitro conditions or in vivo have also been performed (33,63-65). Together 
these studies have shaped our understanding of possible roles of individual genes as well as 
functional protein groups in the context of various stages of pathogenesis. With the enormous 
amount of available data, various studies have attempted to gain insightful information using 
sophisticated models of computational analyses (66-68). However, understanding models of gene 
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regulation, protein-protein interactions and unique metabolic pathways at the systems level 
remains incomplete, especially for functional changes that mediate the switch into dormancy 
(69). Through the study of the M. tuberculosis ATPome, we have defined a functionally linked 
analysis among gene products of the mycobacterial proteome. Future work on the absolute 
quantification and monitoring of these proteins during transitions into and out of dormancy can 
further define, at the proteome level, a link between members of the DosR regulon and the 
central regulatory circuit that controls the transition into the states of non-replicating persistence 
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VI. CHAPTER VI: Concluding Remarks and Future Directions 
 
Robert Koch first identified M. tuberculosis as the causative agent of human tuberculosis 
in 1882 1. During that time it was estimated that TB was responsible for one-quarter of all deaths 
among developed nations and historical accounts estimate that “70-90% of the urban populations 
of Europe and North America were infected with the TB bacillus, and about 80% of those 
individuals who developed active tuberculosis died of it” 
(http://ocp.hul.harvard.edu/contagion/tuberculosis.html). One-hundred thirty years later the 
disease is mostly under control in first-world countries however vigilance towards the 
eradication of disease worldwide must be maintained if we are to see the reversal of incident 
cases in our children’s lifetime. Having evolved for thousands of years within animal species and 
man, M. tuberculosis has exquisite control over the immune mechanisms of its hosts. Despite 
great successes in the implementation of global control programs such as directly observed 
therapy, short course (DOTS) and epidemiological surveillance committees, attempts to lessen 
the control of the bacillus through the use of vaccine and multi-drug chemotherapies have not 
curtailed the successfulness of the pathogen. In the case of MDR-TB, human control over the 
disease is even lessened.  
Critical to the advancement of eradication and control programs will be the identification 
of disease-state biomarkers that will allow for the procurement of second-generation diagnostics. 
These simple, rapid and inexpensive methods will be designed to better detect true infection 
(versus exposure or past vaccination). Also, information must be provided about the drug-
susceptibility profile within the pathogen and the effectiveness of such treatments within the 
host. In addition, optimal targets for new anti-mycobacterial drugs must be identified in disease-
relevant states of infection. In this regard, drug, vaccine and molecular diagnostic targets can be 
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most efficiently identified using global biomarker-based discovery platforms 2. Gene expression 
profiles and elucidation of the transcriptome under various biological states continues to be a 
very informative tool when digging into the systems-level biology of an organism. Studies of the 
proteome focus on the characterization of functional gene products and take into account post-
translational events such as processing and cleavage, modification, secretion and subcellular 
localization. Advances in mass spectrometry-based proteomics have driven the successful 
application of these platforms in all areas of disease research.  
For Mycobacterium tuberculosis, thorough descriptions of both its gene expression and 
protein profiles have been utilized in the greater understanding of the patho-physiology of the 
organism. The cellular envelope of M. tuberculosis, recognized for decades as a key modulator 
of host-pathogen interactions is chemically well-defined 3 and is a major reservoir of both protein 
and non-protein based antigens 4. Key to its survival within the host is its ability to exist in a state 
of metabolic dormancy, induced to some extent, by the hypoxic environment encountered within 
a granuloma. Understanding this switch into and out of dormancy at the protein level will give us 
unique bio-signatures of functionally linked protein networks that can be further developed and 
studied quantitatively to assess their contribution to this state of metabolic growth. Further, 
proteins within these functional networks may be relevant drug targets for new drugs with novel 





6.1 Relevance of the Cell Wall Proteome 
Physiologically, the cell envelope of M. tuberculosis is highly hydrophobic and contains 
many proteins not amenable to traditional techniques of protein purification. Elucidation of the 
cell wall proteome was undertaken based from the observation that cell wall proteins were 
responsible for TB-specific immunoreactivity in non-classically restricted T cells (Chapter IV). 
Also a full characterization using both gel-based and non-gel based separation techniques had 
also not been previously published for M. tuberculosis. Our results demonstrated complimentary 
approaches to elucidating proteins non-covalently associated with the cell wall core. Extraction 
methods with SDS or guanidine hydrochloride for the most part, resolved soluble proteins and 
many antigens, known to be secreted into the extracellular milieu. The identification of these 
antigenic proteins with the cell wall lent support to the observation that cell wall proteins could 
be retained within the core to elicit an immune response. Extraction using Triton-X 100 
detergents generated a hydrophobic protein fraction enriched with many lipoproteins. The 
majority of these protein species could not be adequately resolved using gel-based methods, and 
a multi-dimensional liquid chromatography strategy was used to identify proteins within this 
fraction. From a biochemical standpoint the protein profiles generated in this study could be 
further refined to address multiple biologically relevant questions broadly pertaining to cell wall 
remodeling events. These include elucidation of lipid and glycolipid export systems and the 
changes in protein profiles in response to drug treatment – perhaps increased abundance of small 
molecule export systems or lipoproteins which may function to shuttle molecules across the 
hydrophobic barriers.  
Immunologically, the proteins of the cell wall could be more specifically defined as 
immune modulators of the host response to infection. Studies performed on in vivo grown bacilli 
demonstrated an almost complete absence of known secreted protein antigens. It was 
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hypothesized that these proteins were immediately detected and shuttled to the lymph node for 
presentation to antigen-specific T cells 5.  In the in vivo model, we can hypothesize that the 
remaining resident proteins of the cell wall must stay the course and mediate localized responses 
necessary to maintain infection as well as to maintain cell wall integrity.  
During the original collaboration in the identification of cell wall antigen-specific CD8 T 
cells, we began the process of elucidating whole protein fractions of cell wall proteins. In 
essence creating a cell wall protein library in which extracted proteins were purified using multi-
dimensional separation schemes. A diagram of this is depicted below (Figure 6.1).  The ultimate 
goal would then be to generate M. tuberculosis-specific T cell clones reactive to specific proteins 
within distinct cell wall fractions. From this information the minimal epitopes could be gleaned 
(if not post-translationally modified) and this information could be provided to repositories such 
as the Immune Epitope Database (www.iedb.org). Post-translationally modified (PTM) protein 
antigens would be of special interest as demonstration of PTM-specific T cell reactivity to 




6.2 Non-Classically Restricted T cell Antigens  
 
The primary objective in the proteomic approach to antigen discovery was the elucidation of 
the HLA-E restricted M. tuberculosis antigen. We identified the glycoprotein Mpt32 as being the 
cognate antigen and have evidence to suggest the glycosyl modifications at the N-terminus of the 
protein are responsible for T cell reactivity. Future work to definitively describe this glyco-
specific epitope will involve the generation of site-directed mutants unable to be glycosylated at 
known sites of modification. Furthermore, because the generation of synthetic modified peptides 
is cost-prohibitive, we plan to adapt an in vitro enzymatic assay in which enzymatically active 
Figure 6.1 – Generation of a Cell Wall Protein Library. In this schematic, M. tuberculosis 
proteins are separated via iso-electric point (Fractions I – V); gray scale indicates similar pH. 
Biologically active fractions are then further separated by size-exclusion chromatography, 
thereby creating a non-gel 2D separation scheme. From here, proteins can be further separated by 
additional HPLC chemistries (i.e. hydrophobic interaction chromatography). All protein fractions 
can be characterized via LC-MS/MS and MALDI-TOF mass spectrometry and fractions used in 
the generation of M. tuberculosis-specific CD8 T cell clones. 
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membrane preparations will glycosylate pools of overlapping synthetic peptides, spanning the N-
terminus of the protein. A brief description of this proposal is described below.  
6.2.1 Mpt32 Glycosylation Mutants and In vitro Glycosylation Assay 
 
Mpt32 (Apa, 45/47kDa) was the first glycoprotein to be characterized in mycobacteria 7 and 
alteration of its mannosylation state is known to down-regulate both delayed-type 
hypersensitivity (DTH) reactions in vivo, and T cell proliferation in vitro 8,9.  Since these original 
studies, important cellular functions of several mycobacterial glycoproteins and 
glycolipoproteins have been predicted or described 10-12. In the immunopathogenesis of cancer, 
glycosylation and specific glycosylation patterns affect biologic activity of antigen-specific T 
cells 13. Previous studies at CSU studied the role of glycosylation using Mpt32 specific murine T 
cell hybridomas and observed that glycosylation was required to retain T cell reactivity. 
However the results remained incomplete and the precise epitope responsible for reactivity was 
not fully confirmed.  
Our goal for Mpt32 in the CD8 T cell antigen study, will be to confidently identify sites of 
glycosylation that are required for the generation of a productive T cell response for the HLA-E 
restricted human T cell clone D160 1-23.  This would be the first description of an M. 
tuberculosis antigen presented in the context of HLA-E and would for the first time describe a 
glycosylation-dependent T cell response for CD8 T cells isolated from human patients. We have 
designed and generated glyco-mutant constructs with altered states of glycosylation, expressed 
and purified from an Mpt32 knockout strain of M. tuberculosis. Characterization of the sites of 
altered modification will be determined via mass spectrometry using a Thermo Scientific Orbi-
TRAP Velos, equipped with an ETD source. This instrument will provide the exquisite 
sensitivity and precise mass accuracy we will need to characterize glycopeptides present within 
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active fractions generated from native or recombinant protein preparations. We would expect to 
see an alteration of activity if our hypotheses that specific glycosyl moieties are required for T 
cell activation are correct. Briefly, recombinant constructs will be purified from cell lysate or 
culture filtrate and then be introduced to D160 1-23 to assess the differential ability of the glycan 
moieties to elicit biological activity, via γ-IFN ELISPOT. We expect that removal of specific 
threonine residues, and thus specific mannosylation patterns, will perturb the T cell response. 
These series of experiments will establish the role of adjacent glycosyl moieties in antigen 
recognition of an HLA-E restricted T cell antigen.  
Complementary to these genetic studies, overlapping synthetic peptides of the N-
terminus of Mpt32 have been designed and will carry a cleavable affinity FLAG tag (Sigma-
Aldrich) at each C-terminus. Tagged peptides will be used in a modified in vitro glycosylation 
assay in which membrane preparations from native bacilli will be used to generate O-
mannosylated glycopeptides 14. The affinity tags will be cleaved off and newly modified peptides 
tested for T cell reactivity. Modification will be confirmed by MALDI-TOF MS and peptides 
will be assayed for activity by ELISPOT. As control, Mpt32 specific peptides will also be 
generated from preparations of M. smegmatis membrane. The protein mannosylation function in 
M. smegmatis results in a hyper-glycosylated phenotype in comparison to M. tuberculosis – 
derived proteins. Recombinant Mpt32 purified from M. smegmatis does not activate HLA-E 
specific T cells. Future work may then further address questions of antigen processing and 
presentation of glycoprotein antigens something that has not been assessed for bacterial 
glycoproteins 15. It is well documented that processing of eukaryotic glycoproteins through the 
endocytic MHC II pathway does not alter or remove the carbohydrate moieties from the 
surrogate peptide and that the retention of the covalently linked glycan activates glycopeptide 
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specific T cell populations 16,17. For eubacterial glycoproteins, the processing pathways are less 
defined and it is unknown if the glycans are essential for TCR recognition, or initial processing 
and binding to MHC. Further it is unknown whether the addition of a glycan to a peptide will 
ablate a productive T cell response. Given the promiscuity of glycosylation in M. tuberculosis, 
both questions need to be addressed in order to understand the cell mediated immune response 
during disease.  The antigen processing mechanisms required for presentation within the context 
of HLA-E have been characterized 18,19. Using these studies as framework, we can look at 
processing of native Mpt32 and presentation of its glycosylated peptides. Perhaps these modified 
synthetic peptide products, which are specifically presented in the context of the non-
polymorphic HLA-E can be used to test for their capacity to detect TB disease in real-world 
clinical settings.  
6.3 Assessing ATP-inhibitors against cellular targets in M. tuberculosis 
 
In this section I propose a research plan for the identification of cellular targets of ATP-
inhibitor antimicrobial compounds, using quantitative chemical proteomics and the techniques 
utilized in the definition of the Mycobacterial ATPome (Chapter V).  
As was discussed in Chapter V, we identified broad classes of ATP-binding proteins in   M. 
tuberculosis, and measured their differential abundance in both normal, active growth and during 
hypoxia. In this work, we selectively enriched for and purified a unique subproteome using 
active site directed nucleotide probes in both actively growing and hypoxic state bacteria. The 
ATP-probes bind within conserved active sites and a desthiobiotin compound covalently attaches 
to adjacent lysines. This tagging facilitates purification and    identification of binding sites via 
LC-MS/MS. Using label-free quantitative proteomics we identified 122 ATP-binding proteins in 
either metabolic state, including several proteins under control of the dormancy regulon (DosR) 
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as well as five of ten, universal stress proteins. Primary sequence analysis of the ATP-binding 
proteins identified in this study revealed ATP-binding associated within a functional domain in 
80% of our proteome. Further, biosynthetic enzymes for the synthesis of the virulence lipid 
phthiocerol dimycoserate  (PDIM) and mycocerosic acid synthase (Pps-ACDE, Mas) were also 
enriched using the nucleotide affinity approach. Because we identified proteins that bind small 
molecule ligands (ATP), we expect several of these proteins to be relevant therapeutic targets for 
a novel class of ATP-inhibitor antibiotics in the treatment of tuberculosis.  
6.3.1 Universal Stress Proteins and Dormancy 
The M. tuberculosis dormancy regulon encodes 48 genes that are up regulated during 
hypoxia, during increased nitric oxide and carbon monoxide conditions. Encompassed in this 
regulon are 6 universal stress proteins, which are also over-expressed during multiple 
environmental stressors. Several of these proteins have ATP-binding domains and at least for one 
USP, Rv2623, disrupting the ATP-binding capacity of this protein prevented latency in 
experimentally infected guinea pigs. It has been proposed by Wayne and others that if M. 
tuberculosis is prevented from entering into its non-replicative dormant state, that it may be more 
susceptible to treatment with currently available antibiotics. I hypothesize that by inhibiting the 
ATP-binding function of Rv2623 and the other ATP-binding domain USPs using a competitive 
inhibitor, M. tuberculosis will remain in an actively growing state in vivo. The USPs are a 
conserved protein family observed in archaea, eubacteria, plants and fungi. They are absent in 
higher eukaryotes such as humans, thus making them a viable anti-bacterial target. There is 
ample evidence of the upregulation of the USP proteins by gene expression microarray analysis 
and molecular manipulation of a select number of USP proteins has demonstrated their 
redundant functions in vitro. No proteomic analysis has looked at this protein family under 
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varying in vitro or in vivo conditions.  Targeted mass spectrometry analysis of members of this 
protein family during normal growth and during hypoxia is needed in order to better characterize 
these proteins and their function in regulating the transition into and out of dormancy. 
6.3.2 M. tuberculosis kinases as drug targets 
Signal transduction in Mycobacterium tuberculosis is regulated by the activities of two main 
families of kinases. The first class comprises members of classical two-component systems 
(TCSs) and includes eleven membrane-bound sensor histidine kinases and their respective 
response regulators20. Phosphotransfer events mediated by the TCSs in bacteria are thought to be 
“short-term/transient” signals that are initiated in response to stimuli of the external environment. 
Each of these systems are known to play integral roles in mycobacterial physiology, virulence 
and growth. Tyagi, Av-Gay and others have done extensive review of TCSs and their effects on 
cellular physiology21-24. Two-component systems as novel drug targets have had limited success, 
which may be attributable their unconventional ATP-binding active site 25,26, however several 
compounds have been characterized 27. The second major class of kinases encoded within the 
mycobacterial genome, are the eukaryotic-like Ser/Thr kinases (STPKs). There are 11 members 
of this group and three are deemed essential for growth in vitro 28. Not surprisingly, studies of 
the STPKs in terms of bacterial physiology have revealed their vital roles in regulation of cell 
division and cell wall formation 24. Additionally, roles for STPKs in the context of successful 
intracellular infections have also been established 29. This makes the identification and validation 
of these and other ATP-binding proteins as novel drug targets a valuable priority 25,30.  
6.3.3 ATP-competitive Inhibitors 
Kinase inhibitor compounds have been utilized for many years primarily in the treatment of 
cancer 31. The majority of these compounds work in competition with ATP-binding. Bacterial 
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kinases and other ATP-binding proteins have the potential to be relevant therapeutic targets due 
to their roles in survival and pathogenesis. Thus, the evaluation of inhibitors for bacterial 
enzymes that utilize ATP is worthwhile 27.  Several groups have turned their focus on targeting 
signaling networks of M. tuberculosis - either through direct inhibition of specific kinases such 
as the STPK PknB or through phenotypic screening of chemically relevant (kinase/ATP-
inhibitor) libraries in which specific protein targets are unknown 32-35. Nearly a decade ago, 
Fernandez et al used Mycobacterium smegmatis to over express M. tuberculosis PknB to 
demonstrate that an increase in PknB levels was able to increase resistance to their K252a 
compound, however they were only able to see a modest 2-fold increase in resistance compared 
to controls 36. More recently, Lougheed et al used a target-based approach in which a small 
library of compounds was chosen for optimization against PknB. They used biochemical assays 
as a measure of drug effectiveness. However they were unable to correlate in vitro potencies with 
activity against whole cells. They were also unable to identify the in vivo target(s) of their 
inhibitors as PknB over expression in M. tuberculosis leads to undesirable phenotypic affects 
(i.e. slow growth, altered morphology) 37 which makes assessment of compound specificity 
difficult to interpret by traditional drug discovery efforts.  
Chemical proteomics techniques for the large-scale, unbiased identification of target proteins 
can identify cellular targets that are either directly or indirectly associated with sets of anti-
mycobacterial compounds. These proteins and signaling cascades are currently not targeted by 
available drug regimens in the treatment of tuberculosis. 
Current chemotherapeutic regimens for the treatment of pulmonary tuberculosis involve multiple 
antibiotics. Isoniazid and Rifampin are the standard-of-care first line drugs. These two are then 
coupled with Ethambutol and Pyrazinamide. The recommended treatment duration for patients 
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afflicted with active disease is no shorter than 6 months 38. The increase in prevalence of 
multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB is multifactorial, however 
TB drug discovery efforts need to identify compounds that can circumvent current mechanisms 
of drug resistance. As mentioned above, kinase inhibitors have had substantial success in the 
fields of cancer and inflammation. Kinase inhibitors to treat bacterial diseases are of interest 
despite the reduced repertoire of kinases encoded by bacterial genomes. Our methodologies for 
target deconvolution have the potential to bridge the transition between pre-clinical research of 
novel anti-TB active compounds and pre-clinical development (toxicology, formulation, binding 
profiles, pharmacokinetics) of such drugs using innovative, non-biased chemical proteomic 
techniques.  
The use of mass spectrometry and chemical proteomics in the drug discovery pipeline is 
in its infancy, but in the last decade has shown repeated success and proof-of-relevance concepts 
for many drug formulations. To date these techniques have not been applied in the study of 
inhibitors for infectious disease 27,39,40.  Several high-throughput compound screenings based on 
ATP-inhibitor scaffolds have identified compounds with acceptable activity against M. 
tuberculosis. 32,41-43. The cellular targets of these compounds remain unknown (with the 
exception of the D-ala-D-ala ligase). Proteomics-based strategies for inhibitors of mycobacterial 
kinases and other ATP-binding proteins can provide comprehensive characterization of several 
promising anti-TB compounds. Through these methods we can identify specific protein-drug 
interactions as well as characterize, protein profile changes in response to drug treatment. For a 
bacterium such as M. tuberculosis, where the development of novel antimicrobials is urgently 
needed, a focused and innovative approach in drug discovery efforts will have a great impact on 
how anti-TB drugs can be assessed beyond the pre-clinical stage. 
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Rv2476c  Rv2476c 176885 99.70% 2 2 2 0.01% 1.72% FSVAAMNADVLEIPTISRR 95.00% 1.99 0.173 0 0 1 0 2 2,091.48 316 334
GuHCl
hypo protein 
Rv2476c  Rv2476c 176885 99.70% 2 2 2 0.01% 1.72% YEIFVYSPR 95.00% 1.14 0.0725 1 0 0 0 2 1,174.39 788 796
GuHCl
hypo protein 
Rv1777  Rv1777 47169 99.40% 2 2 2 0.01% 9.45%
LWVDGMQDGCIEWMGAM
ANRLPMMVVAEL 95.00% 1.83 0.255 0 0 1 0 2 3,300.84 158 186
GuHCl
hypo protein 
Rv1777  Rv1777 47169 99.40% 2 2 2 0.01% 9.45%
VMEQFTVQAADRLWVDGM
QDGCIEWMGAMANR 89.00% 2.15 0.209 0 0 1 0 2 3,764.08 146 177
GuHCl
hypo protein 
Rv3592  Rv3592 11166 99.70% 2 2 3 0.01% 16.20% INAIEVPAGAGPELEK 95.00% 2.09 0.423 0 2 0 0 2 1,608.87 6 21
GuHCl
hypo protein 
Rv3592  Rv3592 11166 99.70% 2 2 3 0.01% 16.20% INAIEVPAGAGPELEKR 95.00% 3.35 0.446 0 1 0 0 2 1,765.07 6 22
GuHCl PE_PGRS   Rv1450c 107389 100.00% 3 3 3 0.01% 6.55%
GGAGGNGGAGGNGGQGV
VSDGAGGAGGAGGDGGA
PGDGANGGNGQGAGAFAG 83.40% 1.22 0.215 0 0 1 0 2 4,299.06 939 995
GuHCl PE_PGRS   Rv1450c 107389 100.00% 3 3 3 0.01% 6.55%
GGDGAFGGMSANATNPGE
NGPNGN 95.00% 1.73 0.322 0 1 0 0 2 2,164.18 859 882
GuHCl PE_PGRS   Rv1450c 107389 100.00% 3 3 3 0.01% 6.55% GGGEFV 95.00% 0.952 0.352 1 0 0 0 2 565.5384 1324 1329
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20%
AAVEEGIVAGGGVTLLQAA
PTLDELK 95.00% 5.37 0.574 0 19 0 0 2 2,523.85 403 428
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% AGAATEVELK 95.00% 1.69 0.433 2 1 0 0 2 989.0784 379 388
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% ASVPGGGDMGGMDF 84.20% 1.06 0.108 1 0 0 0 2 1,330.42 527 540
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% DETTIVEGAGDTDAIAGR 95.00% 5.57 0.373 1 8 0 0 2 1,791.88 326 343
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% DLLPLLEK 95.00% 2.2 0.423 24 0 0 0 2 941.3384 230 237
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% EIELEDPYEK 95.00% 3.28 0.399 7 0 0 0 2 1,265.44 58 67
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20%
EQIAATAAISAGDQSIGDLI
AEAMDK 95.00% 5.78 0.718 0 117 0 0 2 2,607.04 141 166
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% FDKGYISGYFVTDPER 95.00% 3.89 0.611 0 1 0 0 2 1,895.19 193 208
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% GLNALADAVK 95.00% 1.98 0.434 13 0 0 0 2 972.1784 18 27
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% GYISGYFVTDPER 95.00% 4.09 0.561 0 1 0 0 2 1,504.69 196 208
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20%
GYISGYFVTDPERQEAVLED
PYILLVSSK 95.00% 4.52 0.686 0 3 2 0 2 3,290.79 196 224
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% IGAELVK 95.00% 1.76 0.133 2 0 0 0 2 729.9184 68 74
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20%
KTDDVAGDGTTTATVLAQA
LVR 95.00% 6.11 0.65 0 87 0 0 2 2,204.35 79 100
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% KVVVTK 95.00% 2.03 0.271 1 0 0 0 2 673.7284 320 325
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20%
KVVVTKDETTIVEGAGDTD
AIAGR 95.00% 6.33 0.671 0 71 4 0 2 2,446.59 320 343
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% KWGAPTITNDGVSIAK 95.00% 4.78 0.58 0 2 0 0 2 1,658.95 42 57
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% LAGGVAVIK 95.00% 2.03 0.0469 1 0 0 0 2 828.0184 370 378
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% LEGDEATGANIVK 95.00% 1.87 0.29 1 0 0 0 2 1,317.45 429 441
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% NVAAGANPLGLK 95.00% 3.66 0.458 13 2 0 0 2 1,125.35 105 116
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% NVVLEK 95.00% 2.28 0.215 1 0 0 0 2 701.7584 36 41
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% QEAVLEDPYILLVSSK 95.00% 3.99 0.573 0 6 0 0 2 1,805.12 209 224
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% QIAFNSGLEPGVVAEK 95.00% 4.43 0.607 6 16 0 0 2 1,659.82 450 465
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20%
TDDVAGDGTTTATVLAQAL
VR 95.00% 5.16 0.517 0 21 0 0 2 2,076.15 80 100
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% VALEAPLK 95.00% 2.2 0.431 9 0 0 0 2 841.0684 442 449
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% VTETLLK 95.00% 1.25 0.262 3 0 0 0 2 803.9884 126 132
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% VTLGPK 95.00% 1.57 0.17 1 0 0 0 2 614.7584 28 33
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20%
VVVTKDETTIVEGAGDTDAI
AGR 95.00% 5.26 0.672 0 13 0 0 2 2,318.39 321 343
GuHCl
groEL2 
(groEL2)  Rv0440 56709 100.00% 28 35 466 1.39% 52.20% WGAPTITNDGVSIAK 95.00% 4.09 0.553 1 5 0 0 2 1,530.75 43 57






























































Rv2296  Rv2296 33340 100.00% 9 12 20 0.06% 35.00% AGYDAPFPDK 95.00% 1.88 0.256 1 0 0 0 2 1,081.27 194 203
GuHCl
hypo protein 
Rv2296  Rv2296 33340 100.00% 9 12 20 0.06% 35.00% AGYDAPFPDKTYQAGAR 95.00% 2.91 0.559 0 1 0 0 2 1,829.08 194 210
GuHCl
hypo protein 
Rv2296  Rv2296 33340 100.00% 9 12 20 0.06% 35.00% ASHFIQEDSGTELAER 95.00% 3.79 0.559 0 3 0 0 2 1,790.89 277 292
GuHCl
hypo protein 
Rv2296  Rv2296 33340 100.00% 9 12 20 0.06% 35.00% DPILGQADGPLIK 95.00% 3.61 0.43 1 1 0 0 2 1,337.74 250 262
GuHCl
hypo protein 
Rv2296  Rv2296 33340 100.00% 9 12 20 0.06% 35.00%
FEHLVGYPFAPHYVDVTAG
DTQPLR 95.00% 4.72 0.718 0 2 2 0 2 2,831.05 11 35
GuHCl
hypo protein 
Rv2296  Rv2296 33340 100.00% 9 12 20 0.06% 35.00% IEDYTYLR 95.00% 1.59 0.25 1 0 0 0 2 1,073.32 93 100
GuHCl
hypo protein 
Rv2296  Rv2296 33340 100.00% 9 12 20 0.06% 35.00% SAAGHRVLAPDLIGFGR 95.00% 2.05 0.268 0 0 1 0 2 1,738.08 70 86
GuHCl
hypo protein 
Rv2296  Rv2296 33340 100.00% 9 12 20 0.06% 35.00% VLAPDLIGFGR 95.00% 2.43 0.432 3 3 0 0 2 1,158.49 76 86
GuHCl
hypo protein 
Rv2296  Rv2296 33340 100.00% 9 12 20 0.06% 35.00% YSPVLPAGR 95.00% 1.6 0.208 1 0 0 0 2 960.1384 170 178
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% AELPGVDPDKDVDIMVR 95.00% 3.43 0.605 12 95 1 0 2 1,870.10 55 71
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% DFDGR 95.00% 1.17 0.0982 1 0 0 0 2 609.6684 86 90
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% DGQLTIK 95.00% 1.39 0.417 8 0 0 0 2 774.9684 72 78
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% FAAFPSFAGLRPTFDTR 95.00% 2.17 0.389 0 6 0 0 2 1,902.33 22 38
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40%
FPEFSELFAAFPSFAGLRPTF
DTR 95.00% 3.6 0.472 0 0 1 0 2 2,752.33 15 38
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% GILTVSVAVSEGKPTEK 95.00% 4.03 0.687 50 183 0 0 2 1,715.89 120 136
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% HIQIR 95.00% 1.62 0.141 4 0 0 0 2 666.8184 137 141
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% PGVDPDKDVDIMVR 95.00% 2.72 0.497 0 2 0 0 2 1,572.72 58 71
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% PVGADEDDIK 95.00% 2.36 0.3 14 0 0 0 2 1,059.14 105 114
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% SEFAYGSFVR 95.00% 3.2 0.561 18 8 0 0 2 1,163.28 91 100
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% SLFPEFSEL 95.00% 1.64 0.0877 3 0 0 0 2 1,069.30 13 21
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% SLFPEFSELFAAFPSFAGLR 95.00% 5.1 0.628 0 16 0 0 2 2,234.79 13 32
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40%
SLFPEFSELFAAFPSFAGLRP
TFDTR 95.00% 3.36 0.582 0 0 44 0 2 2,952.61 13 38
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% TVSLPVGADEDDIK 95.00% 3.35 0.531 18 25 0 0 2 1,459.59 101 114
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% TVSLPVGADEDDIKATYDK 95.00% 4.62 0.607 0 13 0 0 2 2,038.27 101 119
GuHCl hspX (hspX)  Rv2031c 16210 100.00% 16 21 524 1.56% 76.40% YEVR 95.00% 1.1 0.123 2 0 0 0 2 566.5884 51 54
GuHCl pra (pra)  Rv1078 25058 99.70% 2 2 2 0.01% 14.20% VLAAFIDWAPYVVL 95.00% 1.97 0.265 0 0 1 0 2 1,577.89 95 108
GuHCl pra (pra)  Rv1078 25058 99.70% 2 2 2 0.01% 14.20%
WDAKRQTLADKIMTTVCVP
I 95.00% 1.68 0.269 0 1 0 0 2 2,290.74 221 240
GuHCl ppsA (ppsA)  Rv2931 198816 99.70% 2 2 2 0.01% 4.10%
DEPIAVVGMGCRFPGGISC
PEALWDFLCER 95.00% 1.71 0.305 0 0 1 0 2 3,285.76 101 130
GuHCl ppsA (ppsA)  Rv2931 198816 99.70% 2 2 2 0.01% 4.10%
QVMWPKIGGSQVLHDAFP
PGSVDFFYLTASAAGIFGIP
GQGSYAAAN 95.00% 1.35 0.308 0 0 1 0 2 4,843.54 1611 1657
GuHCl kdpA (kdpA)  Rv1029 60146 99.70% 2 2 2 0.01% 8.23%
MVHDRRQGWAVLAIMGII
WIGMSVAAMSFEAK 95.00% 2.53 0.304 0 0 1 0 2 3,609.34 278 309
GuHCl kdpA (kdpA)  Rv1029 60146 99.70% 2 2 2 0.01% 8.23% TPEYLGKKIQATEMK 95.00% 1.31 0.334 0 1 0 0 2 1,754.17 413 427
GuHCl drrC (drrC)  Rv2938 29576 99.90% 3 3 4 0.01% 14.50% GFAMGGPVLSPMIGML 89.20% 1.74 0.202 0 0 1 0 2 1,595.09 237 252
GuHCl drrC (drrC)  Rv2938 29576 99.90% 3 3 4 0.01% 14.50%
GFAMGGPVLSPMIGMLVWT
AGICVVCAVPLAIGYR 95.00% 1.79 0.431 0 0 2 0 2 3,639.41 237 271
GuHCl drrC (drrC)  Rv2938 29576 99.90% 3 3 4 0.01% 14.50%
VWTAGICVVCAVPLAIGYR
RASTH 85.80% 1.43 0.245 0 0 1 0 2 2,615.90 253 276
GuHCl clpC (clpC)  Rv3596c 93537 99.70% 2 2 2 0.01% 5.19%
SQVEEIIGQGQQAPSGHIP
FTPR 95.00% 3.39 0.602 0 1 0 0 2 2,477.64 61 83
GuHCl clpC (clpC)  Rv3596c 93537 99.70% 2 2 2 0.01% 5.19%
TAVVEGLAQAIVHGEVPETL
K 95.00% 1.97 0.194 0 1 0 0 2 2,162.26 223 243
GuHCl
hypo protein 
Rv2280  Rv2280 48035 99.20% 2 2 8 0.02% 11.50%
AAAADGAAVGCGHAGDGN
VHMAIACKDPEK 85.70% 1.49 0.214 0 0 1 0 2 2,896.03 363 392
GuHCl
hypo protein 
Rv2280  Rv2280 48035 99.20% 2 2 8 0.02% 11.50%
GSGCGLSGAARPVEGGLLI
SFDR 95.00% 2.41 0.331 0 7 0 0 2 2,291.69 70 92
GuHCl pta (pta)  Rv0408 72912 97.00% 2 2 2 0.01% 7.54%
AAELGVDLDGATVIEPCASE
L 87.30% 1.27 0.277 0 1 0 0 2 2,145.36 419 439
GuHCl pta (pta)  Rv0408 72912 97.00% 2 2 2 0.01% 7.54%
TVPGISTVSSIFLMCLPDRV
LAYGDCAIIPN 79.50% 1.89 0.156 0 0 1 0 2 3,410.14 505 535
GuHCl accD6 Rv2247 50117 99.70% 2 2 2 0.01% 4.86% SKAEAGDTDIH 95.00% 1.34 0.0492 1 0 0 0 2 1,144.21 221 231
GuHCl accD6 Rv2247 50117 99.70% 2 2 2 0.01% 4.86% TYGGAYIAMNSR 95.00% 1.57 0.208 1 0 0 0 2 1,304.56 363 374
GuHCl kasA (kasA)  Rv2245 43266 99.70% 2 2 2 0.01% 9.62%
AWRQIVMGDADVAVCGGV
EGPIEALPIAAFSMMRAMST
R 95.00% 1.44 0.249 0 0 1 0 2 4,125.76 181 219
GuHCl kasA (kasA)  Rv2245 43266 99.70% 2 2 2 0.01% 9.62%
QIVMGDADVAVCGGVEGPI
EALPIAAFSMMRAMSTRN 95.00% 1.92 0.242 0 0 1 0 2 3,897.46 184 220
GuHCl tsf (tsf)  Rv2889c 28737 100.00% 3 3 5 0.01% 16.60% GDDAAAAHAVALQIAALR 95.00% 4.91 0.458 0 3 0 0 2 1,734.98 167 184
GuHCl tsf (tsf)  Rv2889c 28737 100.00% 3 3 5 0.01% 16.60% NAEFQTLADQVVAAAAAAK 95.00% 2.21 0.259 0 1 0 0 2 1,890.00 82 100
GuHCl tsf (tsf)  Rv2889c 28737 100.00% 3 3 5 0.01% 16.60%
NAEFQTLADQVVAAAAAAK
PADVDALK 95.00% 1.34 0.416 0 1 0 0 2 2,699.95 82 108
GuHCl
hypo protein 
Rv2488c  Rv2488c 120802 100.00% 3 3 6 0.02% 6.77%
AEVLAWQAYVGFAGEGDP
GATRAAGEEAR 87.90% 1.28 0.285 0 1 0 0 2 2,951.07 740 768
GuHCl
hypo protein 
Rv2488c  Rv2488c 120802 100.00% 3 3 6 0.02% 6.77%
AGSMLASMSKIHPGVDVVP
VDWSADGVSELVPTGTVTL 84.10% 1.24 0.28 0 0 1 0 2 3,841.11 22 59
GuHCl
hypo protein 
Rv2488c  Rv2488c 120802 100.00% 3 3 6 0.02% 6.77% LALVTEICHR 95.00% 1.23 -0.0399 4 0 0 0 2 1,155.37 414 423
GuHCl
hypo protein 
Rv1627c  Rv1627c 42368 99.70% 2 2 3 0.01% 8.96%
LLDICATSDGAAALIVASKS
FTEK 94.90% 1.4 0.291 0 1 0 0 2 2,425.98 208 231
GuHCl
hypo protein 
Rv1627c  Rv1627c 42368 99.70% 2 2 3 0.01% 8.96% YGATVEDFAQVK 95.00% 1.79 0.107 2 0 0 0 2 1,328.37 161 172
GuHCl rpsA (rpsA)  Rv1630 53184 100.00% 6 6 13 0.04% 18.70%
HDVDPNEVVSVGDEVEALV
LTK 95.00% 4.66 0.627 0 2 0 0 2 2,365.27 72 93
GuHCl rpsA (rpsA)  Rv1630 53184 100.00% 6 6 13 0.04% 18.70% HVEVPDQVVAVGDDAMVK 95.00% 4.24 0.615 0 4 0 0 2 1,924.77 330 347
GuHCl rpsA (rpsA)  Rv1630 53184 100.00% 6 6 13 0.04% 18.70% ISLSLK 95.00% 0.884 0.224 1 0 0 0 2 660.9784 358 363
GuHCl rpsA (rpsA)  Rv1630 53184 100.00% 6 6 13 0.04% 18.70% TAGGSLASDAQLAALR 95.00% 3.61 0.518 0 2 0 0 2 1,502.78 459 474
GuHCl rpsA (rpsA)  Rv1630 53184 100.00% 6 6 13 0.04% 18.70% THAIGQIVPGK 95.00% 1.68 0.474 0 1 0 0 2 1,121.29 290 300




Rv0926c  Rv0926c 37734 99.70% 2 2 2 0.01% 19.30%
CMEIVDYATYDSAVVMFDV
MGFGKPMDQIPML 94.60% 1.81 0.243 0 0 1 0 2 3,635.28 164 195
GuHCl
hypo protein 
Rv0926c  Rv0926c 37734 99.70% 2 2 2 0.01% 19.30%
RADLCPEWPQPAQPGGSY
RIEISGEPCYAMDICLSSR 95.00% 1.79 0.286 0 0 1 0 2 4,169.81 274 310
GuHCl
hypo protein 
Rv2880c  Rv2880c 29581 100.00% 3 3 3 0.01% 21.50%
AAAVRFRDFGPRGDGVDG
GSGPCYPQPCRR 95.00% 2.24 0.155 0 0 1 0 2 3,308.61 196 225
GuHCl
hypo protein 
Rv2880c  Rv2880c 29581 100.00% 3 3 3 0.01% 21.50%
NTVCISSQAGCGMACPFCA
TGQGGL 95.00% 1.84 0.293 0 0 1 0 2 2,606.79 116 140
GuHCl
hypo protein 
Rv2880c  Rv2880c 29581 100.00% 3 3 3 0.01% 21.50%
RNTVCISSQAGCGMACPFC
ATGQGGLTRN 95.00% 2.01 0.222 0 0 1 0 2 2,992.24 115 143
GuHCl
hypo protein 
Rv3894c  Rv3894c 153685 99.80% 2 2 2 0.01% 3.30% DVKLMVVTRN 95.00% 1.52 0.138 1 0 0 0 2 1,191.33 248 257
GuHCl
hypo protein 
Rv3894c  Rv3894c 153685 99.80% 2 2 2 0.01% 3.30%
TTTLMALMCSAATMYTPER
VTFFCIGGATMAQIGSL 90.50% 1.74 0.257 0 0 1 0 2 3,823.62 892 927
GuHCl
whiB3 
(whiB3)  Rv3416 11594 98.40% 2 2 2 0.01% 25.50%
GMDSSMFFHPDGERGRAR
TQR 87.70% 1.44 0.235 0 1 0 0 2 2,439.73 25 45
GuHCl whiB3 Rv3416 11594 98.40% 2 2 2 0.01% 25.50% QGLCR 89.00% 0.855 0.102 1 0 0 0 2 576.6684 20 24
GuHCl
hypo protein 
Rv2576c  Rv2576c 15742 99.70% 2 2 3 0.01% 42.90%
QVTYTVTTTSDLMANIRYM
SADPPSMAAFNADSSK 95.00% 2.28 0.218 0 0 2 0 2 3,819.30 51 85
GuHCl
hypo protein 
Rv2576c  Rv2576c 15742 99.70% 2 2 3 0.01% 42.90%
TPIAGGQPLVYTATLANPSQ
WAIVTASGGLR 95.00% 1.97 0.317 0 0 1 0 2 3,112.58 92 122
GuHCl
hypo protein 
Rv0386  Rv0386 116775 99.90% 2 2 2 0.01% 5.81%
RLAVFVGCFFVDDAQAVAC
SGDVQRYQVL 93.90% 1.59 0.257 0 0 1 0 2 3,249.42 447 475
GuHCl
hypo protein 
Rv0386  Rv0386 116775 99.90% 2 2 2 0.01% 5.81%
WCLGYAQLMRGELAAAAA
QFGEVVDEAEASQEVL 95.00% 2.34 0.199 0 0 1 0 2 3,698.98 741 774
GuHCl pks2 (pks2)  Rv3825c 225737 100.00% 4 4 4 0.01% 6.82%
FEAMLLLDDQTPVSTVATVT
SPGVVDFAVEALQEGVGH 80.00% 0.906 0.312 0 0 1 0 2 3,945.08 983 1020
GuHCl pks2 (pks2)  Rv3825c 225737 100.00% 4 4 4 0.01% 6.82%
MRETIEAIAAMGSEVVVEC
GDIAQPGTAERLVATAVATG
LPVR 95.00% 1.94 0.248 0 0 1 0 2 4,416.80 1811 1853
GuHCl pks2 (pks2)  Rv3825c 225737 100.00% 4 4 4 0.01% 6.82%
TPGDMQTIELAAFHRVPPG
PGQIEVAVRASSVN 95.00% 1.29 0.302 0 0 1 0 2 3,446.71 1434 1466
GuHCl pks2 (pks2)  Rv3825c 225737 100.00% 4 4 4 0.01% 6.82%
VYTGYAPVIGAPWLVAFAER
SRFFEVFSSSN 91.50% 1.74 0.217 0 0 1 0 2 3,469.88 1993 2023
GuHCl
wag31 
(wag31)  Rv2145c 28260 100.00% 9 13 26 0.08% 37.70% ADALQADAER 95.00% 1.61 0.218 1 0 0 0 2 1,060.14 180 189
GuHCl
wag31 
(wag31)  Rv2145c 28260 100.00% 9 13 26 0.08% 37.70% ANAEQILGEAR 95.00% 3.75 0.54 2 3 0 0 2 1,172.31 134 144
GuHCl
wag31 
(wag31)  Rv2145c 28260 100.00% 9 13 26 0.08% 37.70%
GSAAPVDSNADAGGFDQF
NR 95.00% 5.1 0.647 0 6 0 0 2 1,997.04 238 257
GuHCl
wag31 
(wag31)  Rv2145c 28260 100.00% 9 13 26 0.08% 37.70% HSEIMGTINQQR 95.00% 1.81 0.336 0 1 0 0 2 1,430.55 191 202
GuHCl
wag31 
(wag31)  Rv2145c 28260 100.00% 9 13 26 0.08% 37.70% HTADATVAEAR 95.00% 2.11 0.488 1 1 0 0 2 1,142.11 145 155
GuHCl
wag31 
(wag31)  Rv2145c 28260 100.00% 9 13 26 0.08% 37.70% KHSEIMGTINQQR 95.00% 1.79 0.416 0 1 0 0 2 1,558.75 190 202
GuHCl
wag31 
(wag31)  Rv2145c 28260 100.00% 9 13 26 0.08% 37.70% LIEENSDLR 95.00% 2.09 0.213 0 1 0 0 2 1,089.30 42 50
GuHCl
wag31 
(wag31)  Rv2145c 28260 100.00% 9 13 26 0.08% 37.70% TYLESQLEELGQR 95.00% 4.68 0.598 2 5 0 0 2 1,566.75 225 237
GuHCl
wag31 
(wag31)  Rv2145c 28260 100.00% 9 13 26 0.08% 37.70% VLSLAQDTADR 95.00% 2.83 0.418 1 1 0 0 2 1,189.33 106 116
GuHCl alaS (alaS)  Rv2555c 97307 100.00% 3 3 3 0.01% 9.62%
DTYGFPIELTLEMAAETGLQ
VDEIGFR 95.00% 1.84 0.247 0 0 1 0 2 3,033.52 401 427
GuHCl alaS (alaS)  Rv2555c 97307 100.00% 3 3 3 0.01% 9.62%
PAERIQRRGMADNYWSMG
IPGPCGPSSEIYYDR 95.00% 1.99 0.251 0 0 1 0 2 3,862.48 146 178
GuHCl alaS (alaS)  Rv2555c 97307 100.00% 3 3 3 0.01% 9.62%
TFTEQLDKAKAMGAIALFG
ESYPDEVR 95.00% 2.2 0.251 0 0 1 0 2 2,989.51 648 674
GuHCl
hypo protein 
Rv0858c  Rv0858c 42191 100.00% 3 3 4 0.01% 15.90% LRPYATTVFAEMSAL 95.00% 1.79 0.264 2 0 0 0 2 1,671.03 6 20
GuHCl
hypo protein 
Rv0858c  Rv0858c 42191 100.00% 3 3 4 0.01% 15.90% TITISSAAKMFN 95.00% 1.46 0.219 1 0 0 0 2 1,284.64 224 235
GuHCl
hypo protein 
Rv0858c  Rv0858c 42191 100.00% 3 3 4 0.01% 15.90%
VGVAAIPMSAFCDPAAGQA
SQQADVWNHLVRFTFCK 82.00% 1.82 0.166 0 0 1 0 2 3,909.24 341 376
GuHCl
hypo protein 
Rv2326c  Rv2326c 72818 99.70% 2 2 4 0.01% 6.17% QRLALAAALAR 95.00% 1.11 0.172 1 0 0 0 2 1,154.52 380 390
GuHCl
hypo protein 
Rv2326c  Rv2326c 72818 99.70% 2 2 4 0.01% 6.17%
RGRGTPTVVVSSLIGGFVF
GAAMVGMLAAMVR 95.00% 1.79 0.332 0 0 3 0 2 3,241.74 121 152
GuHCl rmlA (rmlA)  Rv0334 31475 99.70% 2 2 2 0.01% 17.00% DIQLITTPHDAPGFHR 95.00% 4.21 0.515 0 1 0 0 2 1,819.09 48 63
GuHCl rmlA (rmlA)  Rv0334 31475 99.70% 2 2 2 0.01% 17.00%
RFQSISGGAIFAYWVANPS
AYGVVEFGAEGMAL 95.00% 1.85 0.242 0 0 1 0 2 3,483.92 122 154
GuHCl
hypo protein 
Rv0798c  Rv0798c 28813 99.70% 2 2 3 0.01% 16.60%
TIFEGYSAASIEGIRSASSN
PALTL 95.00% 1.97 0.237 0 0 1 0 2 2,557.06 118 142
GuHCl
hypo protein 
Rv0798c  Rv0798c 28813 99.70% 2 2 3 0.01% 16.60% VVDVSDPGGPVTAAVSTGR 95.00% 2.54 0.596 0 2 0 0 2 1,784.68 36 54
GuHCl bioF (bioF)  Rv1569 40009 100.00% 3 3 8 0.02% 15.50%
HPAVIDGGVQALRIWGAGA
TGSR 95.00% 2.46 0.225 0 6 0 0 2 2,290.53 56 78
GuHCl bioF (bioF)  Rv1569 40009 100.00% 3 3 8 0.02% 15.50% IWGAGATGSRL 95.00% 1.33 0 1 0 0 0 2 1,089.31 69 79
GuHCl bioF (bioF)  Rv1569 40009 100.00% 3 3 8 0.02% 15.50%
MCGVAAVPDSAMVSVILGE
PESAVAAAAACLDAGVK 80.30% 1.8 0.161 0 0 1 0 2 3,478.75 306 341
GuHCl pabB (pabB)  Rv1005c 47862 100.00% 3 3 3 0.01% 14.40% CENPQFCQAR 94.60% 1.31 0.0753 1 0 0 0 2 1,196.22 20 29
GuHCl pabB (pabB)  Rv1005c 47862 100.00% 3 3 3 0.01% 14.40%
GIYCGTVGLASPVAGCELN
VAIRTVEFDTAGN 84.30% 1.09 0.303 0 0 1 0 2 3,270.55 379 410
GuHCl pabB (pabB)  Rv1005c 47862 100.00% 3 3 3 0.01% 14.40%
TVEFDTAGNAVLGVGGGIT
ADSDPDAEWAECLH 95.00% 1.43 0.301 0 0 1 0 2 3,319.38 402 434
GuHCl plsB1 (plsB1)  Rv1551 69176 99.80% 2 2 2 0.01% 6.44% RPEDLRFLVR 94.80% 1.06 0.0837 1 0 0 0 2 1,301.61 262 271
166
GuHCl plsB1 (plsB1)  Rv1551 69176 99.80% 2 2 2 0.01% 6.44%
WTLHQMVASGVVSVYDAG
TEAVWGIGEDQH 87.70% 1.62 0.235 0 0 1 0 2 3,244.17 382 411
GuHCl
hypo protein 
Rv0614  Rv0614 34626 99.90% 2 2 2 0.01% 28.20%
DTGVRLVDVKQDGGTSPPP
PFAPWDTPDGTPPPGTGLS
PTL 89.80% 2.02 0.238 0 0 1 0 2 4,142.57 174 214
GuHCl
hypo protein 
Rv0614  Rv0614 34626 99.90% 2 2 2 0.01% 28.20%
THCSTNDWIDRTAQFASGA
IVFSIGVLTAETGAGVVAAA
AGGVGAATAGVSL 95.00% 1.63 0.245 0 0 1 0 2 4,993.30 271 322
GuHCl dnaE1 Rv1547 129310 100.00% 3 3 3 0.01% 3.55% AGAFDSLGH 87.10% 0.951 -0.0264 1 0 0 0 2 874.9584 911 919
GuHCl dnaE1 Rv1547 129310 100.00% 3 3 3 0.01% 3.55% IALIAN 95.00% 0.952 0.197 1 0 0 0 2 614.8784 1091 1096
GuHCl
dnaE1 
(dnaE1)  Rv1547 129310 100.00% 3 3 3 0.01% 3.55%
TYSSYGADIVDDAVVLVNA
KVAVRDDR 92.90% 2.32 0.137 0 0 1 0 2 2,913.07 1064 1090
GuHCl
echA18 
(echA18)  Rv3373 22645 99.90% 2 2 2 0.01% 12.20%
AMTKMDEASNPCGGDIEA
EMCQL 95.00% 2.13 0.204 0 1 0 0 2 2,548.84 5 27
GuHCl
echA18 
(echA18)  Rv3373 22645 99.90% 2 2 2 0.01% 12.20%
RAMTKMDEASNPCGGDIE
AEMCQLMR 95.00% 1.25 0.269 0 0 1 0 2 2,937.36 4 29
GuHCl fixB (fixB)  Rv3028c 31672 100.00% 10 10 18 0.05% 59.10%
AAVDSGYYPGQFQVGQTG
K 95.00% 4.17 0.624 0 1 0 0 2 1,974.02 233 251
GuHCl fixB (fixB)  Rv3028c 31672 100.00% 10 10 18 0.05% 59.10%
AGAVEAEPAAGAGEQVSVE
VPAAAENAAR 95.00% 1.72 0.545 0 2 0 0 2 2,693.55 152 180
GuHCl fixB (fixB)  Rv3028c 31672 100.00% 10 10 18 0.05% 59.10%
AGMQTSKTIVAVNKDEEAP
IFEIADYGVVGDLFK 95.00% 2.31 0.319 0 0 1 0 2 3,658.17 271 304
GuHCl fixB (fixB)  Rv3028c 31672 100.00% 10 10 18 0.05% 59.10%
ALGEPAAVVVGVPGTAAPLV
DGLK 95.00% 4.22 0.534 0 4 0 0 2 2,202.43 28 51
GuHCl fixB (fixB)  Rv3028c 31672 100.00% 10 10 18 0.05% 59.10%
EPAVAGDRPELTEATIVVAG
GR 95.00% 2.1 0.485 0 3 0 0 2 2,209.34 185 206
GuHCl fixB (fixB)  Rv3028c 31672 100.00% 10 10 18 0.05% 59.10%
GVGSAENFSVVEALADSLG
AAVGASR 95.00% 6.4 0.633 0 3 0 0 2 2,435.50 207 232
GuHCl fixB (fixB)  Rv3028c 31672 100.00% 10 10 18 0.05% 59.10% IGSGLLVDVVDVR 95.00% 1.88 0.265 1 0 0 0 2 1,342.48 109 121
GuHCl fixB (fixB)  Rv3028c 31672 100.00% 10 10 18 0.05% 59.10% IYVAESDLVDK 95.00% 1.85 0.226 1 0 0 0 2 1,252.42 58 68
GuHCl fixB (fixB)  Rv3028c 31672 100.00% 10 10 18 0.05% 59.10%
TIVAVNKDEEAPIFEIADYG
VVGDLFK 95.00% 2.68 0.477 0 1 0 0 2 2,954.36 278 304
GuHCl fixB (fixB)  Rv3028c 31672 100.00% 10 10 18 0.05% 59.10% VAPQLTEAIK 95.00% 1.65 0.283 1 0 0 0 2 1,070.27 305 314
GuHCl ctpV (ctpV)  Rv0969 80083 99.70% 2 2 3 0.01% 5.84% AQVNGGPVVVGR 95.00% 1.18 0.102 2 0 0 0 2 1,153.05 532 543
GuHCl ctpV (ctpV)  Rv0969 80083 99.70% 2 2 3 0.01% 5.84%
TAVFVGQDGQVVGVLAVAD
TVKDDAADVVGRLH 95.00% 1.6 0.283 0 0 1 0 2 3,323.25 571 603
GuHCl sucD (sucD)  Rv0952 31212 99.70% 2 2 2 0.01% 10.90% LPVFGSVAEAMEK 95.00% 2.8 0.514 0 1 0 0 2 1,394.57 63 75
GuHCl sucD (sucD)  Rv0952 31212 99.70% 2 2 2 0.01% 10.90%
TNVSKPVVGYVAGFTAPEG
K 95.00% 4.87 0.524 0 1 0 0 2 2,022.13 236 255
GuHCl
hypo protein 
Rv0944  Rv0944 16445 99.00% 2 2 2 0.01% 24.10%
PCPVCGDTVREVSFADKSF
QYCPTCQTGGKALADR 95.00% 2.22 0.31 0 0 1 0 2 3,823.12 117 151
GuHCl
hypo protein 
Rv0944  Rv0944 16445 99.00% 2 2 2 0.01% 24.10%
TGLPCPVCGDTVREVSFAD
KSFQYCPTCQTGGKAL 82.60% 1.23 0.288 0 0 1 0 2 3,823.16 114 148
GuHCl
hypo protein 
Rv1984c  Rv1984c 21764 99.70% 2 2 2 0.01% 22.10%
IVLGGYSQGATVIDLSTSA
MPPAVADH 95.00% 2.1 0.249 0 0 1 0 2 2,687.98 112 138
GuHCl
hypo protein 
Rv1984c  Rv1984c 21764 99.70% 2 2 2 0.01% 22.10%
TINLCAPDDPICTGGGNIM
AH 95.00% 3.05 0.216 0 1 0 0 2 2,185.55 173 193
GuHCl mbtB (mbtB)  Rv2383c 151584 99.90% 2 2 2 0.01% 4.38%
AYVLFTSGSTGEPKGVEVA
HDAAMNTVETFIR 95.00% 2.42 0.296 0 0 1 0 2 3,415.65 693 724
GuHCl mbtB (mbtB)  Rv2383c 151584 99.90% 2 2 2 0.01% 4.38%
NACRVVADSGDDCPDWVA
GELWVSGRGIAR 94.50% 1.73 0.189 0 0 1 0 2 3,247.38 873 902
GuHCl
echA6 
(echA6)  Rv0905 26012 98.90% 2 2 2 0.01% 20.60%
AGDGSARAIVLTGQGTAFC
AGADLSGDAFAADYPDR 80.10% 1.12 0.252 0 0 1 0 2 3,560.97 39 74
GuHCl echA6 Rv0905 26012 98.90% 2 2 2 0.01% 20.60% VVAPDAFFQFPTSK 95.00% 3.14 0.479 0 1 0 0 2 1,554.74 112 125
GuHCl
fadD13 
(fadD13)  Rv3089 54442 99.10% 2 2 2 0.01% 12.50%
LRSAAADEPAVECGGDDNL
FIMYTSGTTGH 91.20% 2.16 0.204 0 0 1 0 2 3,116.39 141 170
GuHCl
fadD13 
(fadD13)  Rv3089 54442 99.10% 2 2 2 0.01% 12.50%
WGEIAAAIVVADQNEVSEQ
QIVEYCGTRLARYK 91.30% 1.78 0.159 0 0 1 0 2 3,783.06 437 469
GuHCl fadH (fadH)  Rv1175c 72884 99.90% 3 3 3 0.01% 7.86%
RARSVAVVGAGPAGLATAA
N 79.90% 1.8 0.283 0 1 0 0 2 1,809.94 375 394
GuHCl fadH (fadH)  Rv1175c 72884 99.90% 3 3 3 0.01% 7.86% SVAVVGAGPAGLATAAN 95.00% 1.08 0.179 1 0 0 0 2 1,426.46 378 394
GuHCl fadH (fadH)  Rv1175c 72884 99.90% 3 3 3 0.01% 7.86%
VPTIVTSVPGGAFVDISSAV
AEHVTIPVVASNR 95.00% 1.9 0.298 0 0 1 0 2 3,291.38 259 291
GuHCl ftsK (ftsK)  Rv2748c 94390 99.10% 2 2 2 0.01% 8.15%
CSDDGPPAWPSAEVPQDD
TATIPEASAGRGSGRRGRR 95.00% 1.64 0.26 0 0 1 0 2 3,825.06 344 380
GuHCl ftsK (ftsK)  Rv2748c 94390 99.10% 2 2 2 0.01% 8.15%
PWQRGEQIAVTSVADGVD
GVIATRLAVMSSKTVAR 84.00% 1.32 0.262 0 0 1 0 2 3,670.95 26 60
GuHCl lppC (lppC)  Rv1911c 19780 99.70% 2 2 3 0.01% 19.40%
ATTVDATTPAPAAEPLTIASP
MFADGAPIPVQFSCK 95.00% 2.29 0.306 0 0 2 0 2 3,605.13 41 76
GuHCl lppC (lppC)  Rv1911c 19780 99.70% 2 2 3 0.01% 19.40%
ATTVDATTPAPAAEPLTIASP
MFADGAPIPVQFSCKGAN 95.00% 1.72 0.313 0 0 1 0 2 3,902.44 41 79
GuHCl
hypo protein 
Rv0480c  Rv0480c 35145 99.90% 2 2 4 0.01% 15.90%
ARALDSMSYVAAAGQADP
GDARTGVGASSAAPTGVG
GSLVASPL 95.00% 2.08 0.161 0 0 1 0 2 4,032.37 248 291
GuHCl
hypo protein 
Rv0480c  Rv0480c 35145 99.90% 2 2 4 0.01% 15.90% VVFPEATMCR 95.00% 1.21 0.18 3 0 0 0 2 1,153.26 96 105
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60%
ATEYNNAAEAFAAQLVTAE
QSVEDLK 95.00% 5.02 0.643 0 7 0 0 2 2,784.90 95 120
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60%
GEALPAGGTTATPRPATETS
GGAIAEQPYGQ 95.00% 2.26 0.378 0 3 0 0 2 2,958.16 240 270
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60% LLSQLEQAK 95.00% 1.82 0.0279 3 0 0 0 2 1,030.28 154 162
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60% MLEVEQAGIQMAGHSR 95.00% 3.87 0.485 0 4 0 0 2 1,789.93 215 230
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60% QALTLADQATAAGDAAK 95.00% 3.97 0.601 0 5 0 0 2 1,616.83 78 94
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60% RYANAIGSAELAESSVQGR 95.00% 2.06 0.446 0 2 0 0 2 1,980.15 196 214
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60% SMSELAAPGNTPSLDEVR 95.00% 3.57 0.556 0 7 0 0 2 1,891.08 173 190
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60% THQALTQQAAQVIGNQR 95.00% 5.62 0.673 0 8 0 0 2 1,864.88 40 56
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60% TLHDQALSAAAQAK 95.00% 4.52 0.641 0 3 0 0 2 1,425.60 121 134
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60% VQIQQAIEEAQR 95.00% 4.54 0.531 0 4 0 0 2 1,413.45 28 39
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60% YANAIGSAELAESSVQGR 95.00% 4.32 0.547 0 10 0 0 2 1,823.95 197 214
GuHCl
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 12 12 57 0.17% 69.60% YLMALFSSK 86.40% 1.3 0 1 0 0 0 2 1,076.46 11 19
167
GuHCl ppiA (ppiA)  Rv0009 19222 100.00% 4 4 10 0.03% 35.20%
DYSTQNASGGPSGPFYDG
AVFHR 95.00% 2.64 0.504 0 3 0 0 2 2,431.53 51 73
GuHCl ppiA (ppiA)  Rv0009 19222 100.00% 4 4 10 0.03% 35.20% HTIFGEVIDAESQR 95.00% 4.11 0.595 0 3 0 0 2 1,602.70 141 154
GuHCl ppiA (ppiA)  Rv0009 19222 100.00% 4 4 10 0.03% 35.20% IALFGNHAPK 95.00% 2.02 0.336 0 1 0 0 2 1,068.35 28 37
GuHCl ppiA (ppiA)  Rv0009 19222 100.00% 4 4 10 0.03% 35.20% VIQGFMIQGGDPTGTGR 95.00% 3.25 0.565 0 3 0 0 2 1,750.96 74 90
GuHCl sigA (sigA)  Rv2703 57752 99.20% 2 2 2 0.01% 10.80%
EDDVAPDADDDLDSGDDE
DHEDLEAEAAVAPGQTADD
DEEIAEPTEK 95.00% 1.5 0.309 0 0 1 0 2 4,986.84 149 195
GuHCl sigA (sigA)  Rv2703 57752 99.20% 2 2 2 0.01% 10.80% EMDITPEKVL 86.80% 0.973 0 1 0 0 0 2 1,191.41 402 411
GuHCl
hypo protein 
Rv2005c  Rv2005c 30965 100.00% 3 3 4 0.01% 16.30% GLLGSVSSSLVR 95.00% 2.22 0.503 0 1 0 0 2 1,175.38 127 138
GuHCl
hypo protein 
Rv2005c  Rv2005c 30965 100.00% 3 3 4 0.01% 16.30%
SELVFSTPVPTMVEISNEAE
MVVLGSSGR 95.00% 3.08 0.591 0 2 0 0 2 3,099.29 93 121
GuHCl
hypo protein 
Rv2005c  Rv2005c 30965 100.00% 3 3 4 0.01% 16.30% VPVIVAR 95.00% 1.3 0.238 1 0 0 0 2 753.8284 287 293
GuHCl
hypo protein 
Rv1245c  Rv1245c 29197 100.00% 3 3 5 0.01% 21.00%
NATAAEGLDQAELAETFDK
R 95.00% 3.08 0.389 0 2 0 0 2 2,151.37 197 216
GuHCl
hypo protein 
Rv1245c  Rv1245c 29197 100.00% 3 3 5 0.01% 21.00% VAISDVDTDGLADTEHR 95.00% 2.06 0.363 0 2 0 0 2 1,814.85 33 49
GuHCl
hypo protein 
Rv1245c  Rv1245c 29197 100.00% 3 3 5 0.01% 21.00%
VAVVTGAGSGIGQALAIELA
R 95.00% 3.41 0.455 0 1 0 0 2 1,954.21 8 28
GuHCl ilvX (ilvX)  Rv3509c 52022 100.00% 3 3 3 0.01% 17.70% KYDAPL 87.50% 0.967 0 1 0 0 0 2 706.9184 106 111
GuHCl ilvX (ilvX)  Rv3509c 52022 100.00% 3 3 3 0.01% 17.70%
PADVCWSDGAHAAAGVPA
QAAAAPVDVGPVAGVLRSG
EPAMMLIGGDATR 95.00% 1.37 0.279 0 0 1 0 2 4,843.17 158 207
GuHCl ilvX (ilvX)  Rv3509c 52022 100.00% 3 3 3 0.01% 17.70%
SPVSFFAYPGMPSDLVPAG
CEVHVLAEPGGAADAL 94.60% 1.59 0.247 0 0 1 0 2 3,473.82 270 304
GuHCl mas (mas)  Rv2940c 224360 99.70% 2 2 3 0.01% 2.84%
AIVEEAPAEASAPESSPGDA
EVGPRLFMLSSTSSDALR 95.00% 1.21 0.362 0 0 1 0 2 3,847.26 424 461
GuHCl mas (mas)  Rv2940c 224360 99.70% 2 2 3 0.01% 2.84%
WRRAQGLPVSAIAWGAWG
EVGR 95.00% 2.01 0.219 0 0 2 0 2 2,424.68 1925 1946
GuHCl
hypo protein 
Rv2314c  Rv2314c 48694 99.90% 2 2 2 0.01% 15.50%
ADTGEPDDWDAPVPGTGA
GVFTGIAGSLSRGFR 95.00% 1.69 0.261 0 0 1 0 2 3,278.55 106 138
GuHCl
hypo protein 
Rv2314c  Rv2314c 48694 99.90% 2 2 2 0.01% 15.50%
TVELPAGRYQTIMPPSTVAD
MMIYLGWSMAGRGAQEGR 95.00% 1.89 0.287 0 0 1 0 2 4,175.85 215 252
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% AIFEVK 86.30% 1.33 0.0881 1 0 0 0 2 706.8684 46 51
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% ASLGIIAAAR 95.00% 1.4 0.149 1 0 0 0 2 943.2684 288 297
GuHCl
moxR 
(moxR)  Rv1479 40744 100.00% 21 23 35 0.10% 59.70%
AVPQQGHSVPPVMQAAAA
ASGR 95.00% 1.47 0.33 0 1 0 0 2 2,147.13 356 377
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% DYVIPQDVIEVIPDVLR 95.00% 4.01 0.534 0 1 0 0 2 1,984.24 306 322
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% EIIYR 95.00% 1.3 0.0766 1 0 0 0 2 693.9184 217 221
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% FLFK 79.80% 1.03 0 1 0 0 0 2 554.8184 201 204
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% GHVLLEGVPGVAK 95.00% 3.72 0.488 3 2 0 0 2 1,276.38 72 84
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% GRDYVIPQDVIEVIPDVLR 95.00% 5.41 0.654 0 2 0 0 2 2,197.49 304 322
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% IIVGQDQLVER 95.00% 1.77 0.138 1 0 0 0 2 1,270.41 53 63
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% INVGYPSPEEEREIIYR 95.00% 2.44 0.381 0 1 0 0 2 2,065.36 205 221
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% IQFTPDLVPTDIIGTR 95.00% 3.32 0.482 0 3 0 0 2 1,787.18 102 117
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% LVLTYDALADEISPEIVINR 95.00% 2.4 0.392 0 1 0 0 2 2,245.72 325 344
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% MLVGLLSK 95.00% 1.54 0.327 1 0 0 0 2 877.2178 64 71
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% QILSTGDLLR 95.00% 1.85 0.237 0 1 0 0 2 1,116.45 231 240
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% RIIVGQDQLVER 95.00% 2.67 0.474 0 2 0 0 2 1,426.61 52 63
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% SLALVR 95.00% 1.64 0.117 1 0 0 0 2 658.8484 298 303
GuHCl
moxR 
(moxR)  Rv1479 40744 100.00% 21 23 35 0.10% 59.70%
TFPMPSPFLVMATQNPIEHE
GVYPLPEAQR 95.00% 2.36 0.417 0 1 1 0 2 3,430.87 169 198
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% TLAVETFAR 95.00% 1.6 0.308 2 0 0 0 2 1,008.15 85 93
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% VLQTVALPQVNAVPQQGH 95.00% 2.49 0.389 0 1 0 0 2 1,899.85 345 362
GuHCl
moxR 
(moxR)  Rv1479 40744 100.00% 21 23 35 0.10% 59.70%
VLQTVALPQVNAVPQQGHS
VPPVMQAAAAASGR 95.00% 3.76 0.609 0 0 4 0 2 3,310.34 345 377
GuHCl moxR Rv1479 40744 100.00% 21 23 35 0.10% 59.70% VQSALLEVMQER 95.00% 3.78 0.432 0 2 0 0 2 1,419.52 150 161
GuHCl
hypo protein 
Rv1424c  Rv1424c 27410 99.70% 2 2 2 0.01% 26.10%
MTVVPGAPSRPASAVSRPS
YRQCVQASAQTSAR 95.00% 1.42 0.349 0 0 1 0 2 3,434.59 1 33
GuHCl
hypo protein 
Rv1424c  Rv1424c 27410 99.70% 2 2 2 0.01% 26.10%
VGYCYPAVTTPGKPPSVLLY
APSACDESLPSPR 95.00% 2.51 0.458 0 0 1 0 2 3,437.93 157 189
GuHCl bisC (bisC)  Rv1442 83373 100.00% 4 4 4 0.01% 12.80%
EWLEHMYDKWSAELDFPV
PSFAEFWR 92.90% 1.75 0.194 0 0 1 0 2 3,317.75 526 551
GuHCl bisC (bisC)  Rv1442 83373 100.00% 4 4 4 0.01% 12.80% MLGGYTASR 95.00% 1.43 0.161 1 0 0 0 2 972.1778 130 138
GuHCl bisC (bisC)  Rv1442 83373 100.00% 4 4 4 0.01% 12.80%
MQVYTSATHWGVFTARVH
GGDIAAVAALASDTN 83.40% 1.83 0.159 0 0 1 0 2 3,435.57 1 33
GuHCl bisC (bisC)  Rv1442 83373 100.00% 4 4 4 0.01% 12.80%
VDTIVVHEQYWTAMAKHA
DIVVPTTTSFER 95.00% 1.63 0.4 0 0 1 0 2 3,446.61 444 473
GuHCl
hypo protein 
Rv3282  Rv3282 22992 99.70% 2 2 4 0.01% 20.70%
AAAKAAQVATTLTGTQRIVA
ADCVVVACDSMLYIEGR 95.00% 1.96 0.297 0 0 3 0 2 3,911.32 54 90
GuHCl
hypo protein 
Rv3282  Rv3282 22992 99.70% 2 2 4 0.01% 20.70% PLLRSLVQR 95.00% 1.56 0.248 1 0 0 0 2 1,082.39 193 201
GuHCl
hypo protein 
Rv3224  Rv3224 29797 99.80% 2 2 2 0.01% 11.70%
KPEVYADAAYVIVNKPATEY
TGK 95.00% 3.36 0.515 0 1 0 0 2 2,528.84 216 238
GuHCl
hypo protein 
Rv3224  Rv3224 29797 99.80% 2 2 2 0.01% 11.70% LPGTVFTAAK 90.00% 1.09 0.00827 1 0 0 0 2 1,005.22 45 54
GuHCl
fbpC2 
(fbpC2)  Rv0129c 36754 100.00% 4 4 5 0.01% 18.80%
ADIQHVLNGATPPAAPAAPA
A 95.00% 3.45 0.622 0 2 0 0 2 1,954.16 320 340
GuHCl fbpC2 Rv0129c 36754 100.00% 4 4 5 0.01% 18.80% FLEGLTLR 95.00% 1.17 0.124 1 0 0 0 2 949.2684 272 279
GuHCl fbpC2 Rv0129c 36754 100.00% 4 4 5 0.01% 18.80% PGLPVEYLQVPSASMGR 95.00% 3.13 0.572 0 1 0 0 2 1,818.06 50 66
GuHCl fbpC2 Rv0129c 36754 100.00% 4 4 5 0.01% 18.80% VQFQGGGPHAVYLLDGLR 95.00% 2.64 0.405 0 1 0 0 2 1,928.16 70 87
GuHCl
hypo protein 
Rv2376c  Rv2376c 16617 99.00% 2 2 4 0.01% 28.60%
MKMVKSIAAGLTAAAAIGA
AAAGVTSIMAGGPVVYQM
QPVVFGAPL 82.50% 1.37 0.189 0 0 2 0 2 4,406.22 1 46
GuHCl
hypo protein 
Rv2376c  Rv2376c 16617 99.00% 2 2 4 0.01% 28.60%
MVKSIAAGLTAAAAIGAAAA
GVTSIMAGGPVVYQMQPV
VFGAPLPL 95.00% 1.81 0.372 0 0 2 0 2 4,357.14 3 48
GuHCl PPE (PPE)  Rv1361c 39965 99.00% 2 2 2 0.01% 10.60%
GFAPAAAQAVETAAQNGVQ
AMSSL 86.10% 1.72 0.288 0 1 0 0 2 2,291.38 268 291




Rv0830  Rv0830 33399 99.70% 2 2 2 0.01% 19.90%
AWPVGSIVYEVDMPEVIEF
KTATLSDLGAEPATER 95.00% 1.12 0.347 0 0 1 0 2 3,823.24 116 150
GuHCl
hypo protein 
Rv0830  Rv0830 33399 99.70% 2 2 2 0.01% 19.90%
WDLATSVGATATMVAAQRA
LAADPR 95.00% 1.86 0.274 0 1 0 0 2 2,560.85 9 33
GuHCl glf (glf)  Rv3809c 45797 98.50% 2 2 2 0.01% 5.26% TEADRALLATYR 88.20% 1.94 0.133 0 1 0 0 2 1,380.66 332 343
GuHCl glf (glf)  Rv3809c 45797 98.50% 2 2 2 0.01% 5.26% TVIMREYSR 88.80% 1.22 -0.0265 1 0 0 0 2 1,155.37 310 318
GuHCl
hypo protein 
Rv2623  Rv2623 31633 100.00% 8 10 36 0.11% 32.00%
AGPPTVHSEIVPAAAVPTLV
DMSK 95.00% 5.61 0.672 0 11 1 0 2 2,404.61 86 109
GuHCl
hypo protein 
Rv2623  Rv2623 31633 100.00% 8 10 36 0.11% 32.00%
GGYAGMLVGSVGETVAQLA
R 95.00% 4.56 0.654 0 10 0 0 2 1,953.10 267 286
GuHCl
hypo protein 
Rv2623  Rv2623 31633 100.00% 8 10 36 0.11% 32.00% HLIDDALK 95.00% 2.08 0.282 3 0 0 0 2 925.1984 70 77
GuHCl
hypo protein 
Rv2623  Rv2623 31633 100.00% 8 10 36 0.11% 32.00% LLGSVSSGLLR 95.00% 3.21 0.458 0 2 0 0 2 1,102.43 128 138
GuHCl
hypo protein 
Rv2623  Rv2623 31633 100.00% 8 10 36 0.11% 32.00% QLVQR 92.20% 1.19 0.189 1 0 0 0 2 643.6884 248 252
GuHCl
hypo protein 
Rv2623  Rv2623 31633 100.00% 8 10 36 0.11% 32.00% SEEAQLVVVGSR 95.00% 3.46 0.541 4 1 0 0 2 1,274.22 253 264
GuHCl
hypo protein 
Rv2623  Rv2623 31633 100.00% 8 10 36 0.11% 32.00% TPVIVAR 95.00% 1.68 0.218 1 0 0 0 2 755.8584 287 293
GuHCl
hypo protein 
Rv2623  Rv2623 31633 100.00% 8 10 36 0.11% 32.00% YPNVAITR 95.00% 2.38 0.274 0 2 0 0 2 934.0884 231 238
GuHCl
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 5 6 24 0.07% 48.00% DANNYEQQEQASQQILSS 95.00% 2.79 0.613 0 11 0 0 2 2,054.02 81 98
GuHCl
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 5 6 24 0.07% 48.00% DGLVR 95.00% 1.1 0.0548 1 0 0 0 2 559.6384 76 80
GuHCl
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 5 6 24 0.07% 48.00% FEVHAQTVEDEAR 95.00% 4.9 0.615 1 7 0 0 2 1,531.42 19 31
GuHCl
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 5 6 24 0.07% 48.00% FEVHAQTVEDEARR 95.00% 1.72 0.325 0 1 0 0 2 1,687.62 19 32
GuHCl
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 5 6 24 0.07% 48.00% NIVNMLHGVR 95.00% 2.5 0.358 0 3 0 0 2 1,169.31 66 75
GuHCl
hypo protein 
Rv0148  Rv0148 29760 100.00% 10 10 13 0.04% 59.40% AVANYDSVATEDGAANIIK 95.00% 3.06 0.524 0 1 0 0 2 1,923.09 66 84
GuHCl
hypo protein 
Rv0148  Rv0148 29760 100.00% 10 10 13 0.04% 59.40% DGTGAGSAMADEVVAEIR 95.00% 3.86 0.46 0 1 0 0 2 1,765.81 43 60
GuHCl
hypo protein 
Rv0148  Rv0148 29760 100.00% 10 10 13 0.04% 59.40%
EYALTLAGEGASVVVNDLG
GAR 95.00% 2.72 0.424 0 1 0 0 2 2,163.33 21 42
GuHCl
hypo protein 
Rv0148  Rv0148 29760 100.00% 10 10 13 0.04% 59.40% IAGFKL 95.00% 1.65 0.0764 1 0 0 0 2 648.9484 281 286
GuHCl
hypo protein 
Rv0148  Rv0148 29760 100.00% 10 10 13 0.04% 59.40% MTQDILPPEVLEK 95.00% 2.95 0.357 0 2 0 0 2 1,529.83 200 212
GuHCl
hypo protein 
Rv0148  Rv0148 29760 100.00% 10 10 13 0.04% 59.40%
TALDEFGAVHGVVSNAGIL
R 95.00% 4.94 0.524 0 1 0 0 2 2,027.20 85 104
GuHCl
hypo protein 
Rv0148  Rv0148 29760 100.00% 10 10 13 0.04% 59.40%
VALFGNDGANFDKPPSVQD
VAAR 95.00% 4.38 0.594 0 2 0 0 2 2,389.57 247 269
GuHCl
hypo protein 
Rv0148  Rv0148 29760 100.00% 10 10 13 0.04% 59.40%
VVVATSTSGLFGNFGQTNY
GAAK 95.00% 2.77 0.398 0 1 0 0 2 2,290.43 146 168
GuHCl
hypo protein 
Rv0148  Rv0148 29760 100.00% 10 10 13 0.04% 59.40% WAEITDLSGAK 95.00% 1.86 0.207 1 0 0 0 2 1,191.41 270 280
GuHCl
hypo protein 
Rv0148  Rv0148 29760 100.00% 10 10 13 0.04% 59.40% YNIHANALAPIAATR 95.00% 2.84 0.303 0 2 0 0 2 1,596.94 185 199
GuHCl
hypo protein 
Rv0142  Rv0142 33004 99.80% 3 3 3 0.01% 22.10%
CVAWGSGAEEFVDMAPAM
LGAADDASDFVPL 88.70% 2.1 0.173 0 0 1 0 2 3,247.52 69 99
GuHCl
hypo protein 
Rv0142  Rv0142 33004 99.80% 3 3 3 0.01% 22.10%
CVAWGSGAEEFVDMAPAM
LGAADDASDFVPLHPAVAA
AH 88.60% 1.11 0.268 0 0 1 0 2 3,899.15 69 107
GuHCl
hypo protein 
Rv0142  Rv0142 33004 99.80% 3 3 3 0.01% 22.10%
GQQDPCFRVPGDGTIWRT
SLLPTGPVTAR 87.80% 1.59 0.219 0 0 1 0 2 3,198.58 30 58
GuHCl
pks13 
(pks13)  Rv3800c 186428 99.20% 2 2 2 0.01% 3.69%
AVAAGKQAPNVFSVDGPVT
TGPVWVLAGFGAQHR 85.90% 1.13 0.275 0 0 1 0 2 3,406.51 691 724
GuHCl
pks13 
(pks13)  Rv3800c 186428 99.20% 2 2 2 0.01% 3.69%
FDEFGNIITDSAVAEEPEPE
LPGVTEEALR 95.00% 1.63 0.3 0 0 1 0 2 3,276.54 577 606
GuHCl
hypo protein 
Rv0139  Rv0139 36958 99.70% 2 2 2 0.01% 17.40%
TRFHGDVFDTATVAEAMAG
CDDVYYCVVDTR 95.00% 0.957 0.465 0 0 1 0 2 3,445.49 52 82
GuHCl
hypo protein 
Rv0139  Rv0139 36958 99.70% 2 2 2 0.01% 17.40%
VLQYAHDAGLPAVAMCVST
TYGGGDWGR 83.30% 1.28 0.26 0 0 1 0 2 2,913.10 156 183
GuHCl pepA (pepA)  Rv0125 34907 99.70% 2 2 2 0.01% 20.60%
GQVVGMNTAASDNFQLSQ
GGQGFAIPIGQAMAIAGQI
R 95.00% 1.16 0.397 0 0 1 0 2 3,838.27 217 254
GuHCl pepA (pepA)  Rv0125 34907 99.70% 2 2 2 0.01% 20.60%
TQDVAVLQLRGAGGLPSAA
IGGGVAVGEPVVAMGN 95.00% 1.33 0.336 0 0 1 0 2 3,249.44 124 158
GuHCl
hypo protein 
Rv0111  Rv0111 74323 99.30% 2 2 2 0.01% 6.42%
FAARCAATVVLAGASWWLI
EQPIRR 92.90% 1.36 0.272 0 0 1 0 2 2,787.29 374 398
GuHCl
hypo protein 
Rv0111  Rv0111 74323 99.30% 2 2 2 0.01% 6.42% IVVAGAAVIVVASVAMEQR 91.10% 1.85 0.242 0 1 0 0 2 1,899.97 310 328
GuHCl
hypo protein 
Rv1666c  Rv1666c 47816 99.00% 2 2 2 0.01% 3.72% LYSPGVISARR 94.40% 1.34 0.0537 1 0 0 0 2 1,219.50 294 304
GuHCl
hypo protein 
Rv1666c  Rv1666c 47816 99.00% 2 2 2 0.01% 3.72% SAPAQ 84.60% 0.517 0.39 1 0 0 0 2 473.4784 426 430
GuHCl pdhB (pdhB)  Rv2496c 38046 99.60% 2 2 2 0.01% 17.00%
PARPDETLAVAVSDITQSLT
MVQAINR 93.60% 1.63 0.285 0 1 0 0 2 2,914.25 8 34
GuHCl pdhB (pdhB)  Rv2496c 38046 99.60% 2 2 2 0.01% 17.00%
SGTDVTVVTYGNLVSTALS
SADTAEQQHDWSL 95.00% 2.18 0.429 0 0 1 0 2 3,354.34 222 253
GuHCl
hypo protein 
Rv3874  Rv3874 10776 100.00% 5 6 15 0.04% 61.00% ADEEQQQALSSQMGF 95.00% 2.51 0.266 0 1 0 0 2 1,685.69 86 100
GuHCl
hypo protein 
Rv3874  Rv3874 10776 100.00% 5 6 15 0.04% 61.00% QELDEISTNIR 95.00% 1.66 0.271 1 0 0 0 2 1,318.50 67 77
GuHCl
hypo protein 
Rv3874  Rv3874 10776 100.00% 5 6 15 0.04% 61.00% QKQELDEISTNIR 95.00% 3.74 0.576 0 3 0 0 2 1,574.80 65 77
GuHCl
hypo protein 
Rv3874  Rv3874 10776 100.00% 5 6 15 0.04% 61.00% TDAATLAQEAGNFER 95.00% 5.22 0.586 3 6 0 0 2 1,594.69 6 20
GuHCl
hypo protein 




Rv0831c  Rv0831c 30171 100.00% 4 4 6 0.02% 33.20%
DALVSTFQDLYGPAQVVFQ
EMITSR 95.00% 1.66 0.271 0 1 0 0 2 2,833.12 239 263
GuHCl
hypo protein 
Rv0831c  Rv0831c 30171 100.00% 4 4 6 0.02% 33.20% FTPGGLVLTEWQGAAVYR 95.00% 2.75 0.531 0 1 0 0 2 1,966.19 163 180
GuHCl
hypo protein 
Rv0831c  Rv0831c 30171 100.00% 4 4 6 0.02% 33.20%
LINDLPIERQAQDVSWGMT
APGGAPTPVADR 89.40% 1.35 0.241 0 0 1 0 2 3,277.69 43 73
GuHCl
hypo protein 
Rv0831c  Rv0831c 30171 100.00% 4 4 6 0.02% 33.20% YGPGMGQALDPNYHLR 95.00% 3.72 0.452 0 3 0 0 2 1,806.09 192 207
GuHCl
mmpL1 
(mmpL1)  Rv0402c 104792 99.60% 2 2 2 0.01% 3.34% GPHDAPSLIAMK 81.70% 1.27 0.164 1 0 0 0 2 1,237.55 54 65
GuHCl
mmpL1 
(mmpL1)  Rv0402c 104792 99.60% 2 2 2 0.01% 3.34%
TFDAANNDDSFYLPPEAFQ
N 95.00% 1.52 0.287 0 1 0 0 2 2,277.48 667 686
GuHCl
hypo protein 
Rv3835  Rv3835 47026 99.90% 3 3 3 0.01% 14.70% FEVAESIDMR 90.50% 0.998 0 1 0 0 0 2 1,197.35 122 131
GuHCl
hypo protein 
Rv3835  Rv3835 47026 99.90% 3 3 3 0.01% 14.70%
RFEVAESIDMRTFPGMEYG
QNAAPPSPAR 90.00% 2.17 0.222 0 0 1 0 2 3,242.65 121 149
GuHCl
hypo protein 
Rv3835  Rv3835 47026 99.90% 3 3 3 0.01% 14.70%
VWPAGTCLGIDATTNQPID
VPVDCAAPHAMEVSGTVN 89.20% 1.79 0.166 0 0 1 0 2 3,910.03 224 260
GuHCl
hypo protein 
Rv1179c  Rv1179c 100624 97.70% 2 2 2 0.01% 3.62% ESRAFAGNWR 83.30% 1.14 0.049 1 0 0 0 2 1,194.31 8 17
GuHCl
hypo protein 
Rv1179c  Rv1179c 100624 97.70% 2 2 2 0.01% 3.62%
LVTGQTFACPAAIEDDLIAF
CAER 87.70% 1.61 0.261 0 1 0 0 2 2,627.04 470 493
GuHCl atpG (atpG)  Rv1309 33874 100.00% 3 3 4 0.01% 17.70% IAPMVVEYVEEDIGPR 95.00% 2.81 0.498 0 1 0 0 2 1,834.00 202 217
GuHCl atpG (atpG)  Rv1309 33874 100.00% 3 3 4 0.01% 17.70%
QAQITQEISEIVGGANALAE
AR 95.00% 2.5 0.437 0 1 0 0 2 2,270.47 284 305
GuHCl atpG (atpG)  Rv1309 33874 100.00% 3 3 4 0.01% 17.70% VYAALLESAASELASR 95.00% 3.81 0.473 0 2 0 0 2 1,651.93 242 257
GuHCl atpA (atpA)  Rv1308 59271 100.00% 3 3 3 0.01% 8.38% ASEEEILTEIR 95.00% 1.24 0.262 1 0 0 0 2 1,290.48 477 487
GuHCl atpA (atpA)  Rv1308 59271 100.00% 3 3 3 0.01% 8.38% LSDDLGGGSLTGLPIIETK 95.00% 4.89 0.59 0 1 0 0 2 1,887.40 315 333
GuHCl atpA (atpA)  Rv1308 59271 100.00% 3 3 3 0.01% 8.38% TGEVLSVPVGDGFLGR 95.00% 2.37 0.463 0 1 0 0 2 1,603.73 94 109
GuHCl
fadE23 
(fadE23)  Rv3140 43327 99.70% 2 2 2 0.01% 8.98% ILDIFEGTQQIQQLVVAR 95.00% 4.47 0.525 0 1 0 0 2 2,072.39 373 390
GuHCl
fadE23 
(fadE23)  Rv3140 43327 99.70% 2 2 2 0.01% 8.98% TVELAGTTGYSEQSLLEK 95.00% 1.27 0.333 0 1 0 0 2 1,927.13 349 366
GuHCl cysA2 Rv0815c,Rv3117 30997 99.70% 2 2 2 0.01% 8.30% AFRDEVLAAINVK 95.00% 3.63 0.36 0 1 0 0 2 1,446.70 146 158
GuHCl cysA2 Rv0815c,Rv3117 30997 99.70% 2 2 2 0.01% 8.30% DFVDAQQFSK 95.00% 1.67 0.283 1 0 0 0 2 1,185.25 58 67
GuHCl ilvB (ilvB)  Rv3003c 66072 99.90% 2 2 2 0.01% 6.80% HHHIPGTIEMADWWAYL 95.00% 2.39 0.201 0 1 0 0 2 2,094.35 369 385
GuHCl ilvB (ilvB)  Rv3003c 66072 99.90% 2 2 2 0.01% 6.80%
SWLNSGGLGTMGFAIPAA
MGAKIAL 95.00% 1.73 0.301 0 1 0 0 2 2,452.15 445 469
GuHCl
hypo protein 
Rv1969  Rv1969 44371 99.70% 2 2 2 0.01% 18.20%
AIQLTPPYAGGPTMADGTVI
PQERTVVPVEWDDLRAQL 95.00% 1.62 0.21 0 0 1 0 2 4,123.57 103 140
GuHCl
hypo protein 
Rv1969  Rv1969 44371 99.70% 2 2 2 0.01% 18.20%
PNEVTYSEDWLRPDYVAPV
ADTPPDPAAAVTVDPATGL
R 94.40% 1.56 0.225 0 0 1 0 2 4,168.42 375 413
GuHCl
hypo protein 
Rv1941  Rv1941 25799 97.70% 2 2 2 0.01% 21.90%
CADIDGDAADAAATKIGCG
AAACR 86.70% 1.88 0.18 0 0 1 0 2 2,424.72 37 60
GuHCl
hypo protein 
Rv1941  Rv1941 25799 97.70% 2 2 2 0.01% 21.90%
LPAFVDTPMQQTAMAMFD
GALGAGGARSMIAR 85.10% 2.16 0.161 0 0 1 0 2 3,300.97 183 214
GuHCl
hypo protein 
Rv2721c  Rv2721c 72322 99.70% 2 2 2 0.01% 7.58%
GAKKGGQYPIGGDGIAQDF
VGGK 95.00% 1.22 0.323 0 0 1 0 2 2,221.57 241 263
GuHCl
hypo protein 
Rv2721c  Rv2721c 72322 99.70% 2 2 2 0.01% 7.58%
VVPETFVPQAFVPEAVAPEA
VPPDVHAADL 95.00% 2.09 0.249 0 0 1 0 2 3,113.11 576 605
GuHCl
hypo protein 
Rv1937  Rv1937 93412 99.90% 3 3 3 0.01% 7.27%
ECQSGICGTCVATCTAGRY
QMGRTEGLSDVER 84.10% 1.31 0.232 0 0 1 0 2 3,596.76 40 71
GuHCl
hypo protein 
Rv1937  Rv1937 93412 99.90% 3 3 3 0.01% 7.27%
TMPVRCDQTVLDAAEEHGV
AIVNECQSGICGTCVATCTA
GR 90.50% 0.892 0.369 0 0 1 0 2 4,440.50 17 57
GuHCl
hypo protein 
Rv1937  Rv1937 93412 99.90% 3 3 3 0.01% 7.27% YGAGHR 95.00% 1.24 0.232 1 0 0 0 2 660.6984 710 715
GuHCl glcB (glcB)  Rv1837c 80386 100.00% 5 5 32 0.10% 16.50%
FLDDSVPLSSGSFGDATGF
TVQDGQLVVALPDK 95.00% 3.19 0.523 0 2 0 0 2 3,384.72 175 207
GuHCl glcB (glcB)  Rv1837c 80386 100.00% 5 5 32 0.10% 16.50% GMWTMTELMADMVETK 95.00% 3.1 0.394 0 2 0 0 2 1,875.22 514 529
GuHCl glcB (glcB)  Rv1837c 80386 100.00% 5 5 32 0.10% 16.50%
NVGHLMTNDAIVDTDGSE
VFEGIMDAL 95.00% 3.08 0.482 0 2 0 0 2 2,865.12 340 366
GuHCl glcB (glcB)  Rv1837c 80386 100.00% 5 5 32 0.10% 16.50%
SQPWILAYEDHNVDAGLAA
GFSGR 95.00% 3.53 0.591 0 24 0 0 2 2,575.84 485 508
GuHCl glcB (glcB)  Rv1837c 80386 100.00% 5 5 32 0.10% 16.50%
WGSLYDALYGTDVIPETDG
AEK 95.00% 3.49 0.474 0 2 0 0 2 2,401.70 135 156
GuHCl thrA (thrA)  Rv1294 45502 100.00% 3 3 3 0.01% 12.50% GVPIELLTDDIEEL 95.00% 2.16 0.282 0 1 0 0 2 1,556.86 56 69
GuHCl thrA (thrA)  Rv1294 45502 100.00% 3 3 3 0.01% 12.50%
LMFYGQGAGGAPTASAVTG
DLVMAAR 95.00% 3.2 0.582 0 1 0 0 2 2,545.89 301 326
GuHCl thrA (thrA)  Rv1294 45502 100.00% 3 3 3 0.01% 12.50% YAQLPVAPMGFIETR 89.10% 1.59 0.223 0 1 0 0 2 1,710.04 340 354
GuHCl
hypo protein 
Rv0338c  Rv0338c 95436 99.70% 2 2 2 0.01% 3.51% FWVGCAGAYDDKAKK 95.00% 1.26 0.198 1 0 0 0 2 1,731.01 479 493
GuHCl
hypo protein 
Rv0338c  Rv0338c 95436 99.70% 2 2 2 0.01% 3.51% ILGMSMTAVVGVFALR 95.00% 1.52 0.0706 1 0 0 0 2 1,682.07 10 25
GuHCl deaD (deaD)  Rv1253 61436 99.60% 2 2 2 0.01% 5.68% HNGGKPR 95.00% 0.831 0.281 1 0 0 0 2 765.8384 552 558
GuHCl deaD (deaD)  Rv1253 61436 99.60% 2 2 2 0.01% 5.68%
VDFLVLDEADEMLTMGFAD
DVERIL 92.90% 1.31 0.326 0 0 1 0 2 2,874.34 157 181
GuHCl
hypo protein 
Rv1593c  Rv1593c 25890 99.40% 2 2 2 0.01% 16.10% MAHGSTAHEVL 95.00% 1.09 0 1 0 0 0 2 1,153.18 1 11
GuHCl
hypo protein 
Rv1593c  Rv1593c 25890 99.40% 2 2 2 0.01% 16.10%
PGIRMIASTYLGVVPSPATP
ELPADTR 89.40% 1.88 0.25 0 0 1 0 2 2,827.36 93 119
GuHCl
hypo protein 
Rv3243c  Rv3243c 30671 99.50% 2 3 3 0.01% 10.00% MSPRVPRLRWDDPFR 91.00% 1.34 0.288 0 1 0 0 2 1,945.33 1 15
GuHCl
hypo protein 
Rv3243c  Rv3243c 30671 99.50% 2 3 3 0.01% 10.00% TLFTTLQQLLIGK 95.00% 1.5 0.0286 1 1 0 0 2 1,476.97 46 58
GuHCl
fadE21 
(fadE21)  Rv2789c 44726 99.70% 2 2 2 0.01% 10.50%
LYSSEAATDVAMEAVQLFG




(fadE21)  Rv2789c 44726 99.70% 2 2 2 0.01% 10.50% NIGQFQLIQLK 94.30% 0.878 0.185 1 0 0 0 2 1,302.67 298 308
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% ADAVDDEELLELVEMEVR 95.00% 5.99 0.651 0 29 0 0 2 2,092.19 140 157
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% AFDQIDNAPEER 95.00% 2.9 0.518 1 2 0 0 2 1,405.50 48 59
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% EHVLLAR 95.00% 1.43 0.308 5 0 0 0 2 837.9684 120 126
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% ELLAAQEFDEDAPVVR 95.00% 4.2 0.601 5 28 0 0 2 1,802.92 158 173
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% ETDKPFLMPVEDVFTITGR 95.00% 3.79 0.489 0 26 1 0 2 2,212.55 207 225
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% FAIR 94.80% 1.22 0 1 0 0 0 2 506.6984 377 380
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% GITINIAHVEYQTDK 95.00% 2.74 0.515 0 4 0 0 2 1,702.92 62 76
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% GITINIAHVEYQTDKR 95.00% 4.51 0.66 0 13 0 0 2 1,859.12 62 77
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70%
GQVVTKPGTTTPHTEFEGQ
VYIL 79.80% 1.35 0.289 0 1 0 0 2 2,503.62 292 314
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70%
GQVVTKPGTTTPHTEFEGQ
VYILSK 95.00% 4.12 0.57 0 2 2 0 2 2,718.90 292 316
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70%
GQVVTKPGTTTPHTEFEGQ
VYILSKDEGGR 95.00% 2.07 0.393 0 0 1 0 2 3,233.40 292 321
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% GVINVNEEVEIVGIRPSTTK 95.00% 4.13 0.54 0 24 0 0 2 2,155.30 236 255
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% HTPFFNNYR 95.00% 1.56 0.212 1 0 0 0 2 1,196.34 322 330
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% HYAHVDAPGHADYIK 95.00% 3.48 0.561 1 6 0 0 2 1,694.80 78 92
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% IAHVEYQTDKR 95.00% 2.67 0.523 0 2 0 0 2 1,360.47 67 77
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% KADAVDDEELLELVEMEVR 95.00% 2.94 0.507 0 2 0 0 2 2,220.39 139 157
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% LIQPVAMDEGLR 95.00% 3.11 0.461 0 5 0 0 2 1,358.64 365 376
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70%
NMITGAAQMDGAILVVAAT
DGPMPQTR 95.00% 5.18 0.643 0 53 6 0 2 2,779.15 93 119
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% PQFYFR 95.00% 1.99 0.418 3 4 0 0 2 858.0384 331 336
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70%
TTDVTGVVTLPEGTEMVMP
GDNTNISVK 95.00% 2.7 0.505 0 14 0 0 2 2,939.04 337 364
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% TTLTAAITK 95.00% 1.3 0.378 1 0 0 0 2 920.1784 26 34
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70% TTVTGVEMFR 95.00% 2.52 0.432 0 1 0 0 2 1,157.21 256 265
GuHCl tuf (tuf)  Rv0685 43543 100.00% 23 30 266 0.79% 70.70%
WVASVEELMNAVDESIPDP
VR 95.00% 5.2 0.662 0 22 0 0 2 2,373.46 186 206
GuHCl fadE6 Rv0271c 78460 99.90% 2 2 2 0.01% 6.43% AASPVEQIIIAQEFTAGR 95.00% 1.21 -0.00674 1 0 0 0 2 1,902.16 412 429
GuHCl
fadE6 
(fadE6)  Rv0271c 78460 99.90% 2 2 2 0.01% 6.43%
ALDDAGESSSDVEFAAAVA
ATLAPATAQR 95.00% 1.88 0.252 0 1 0 0 2 2,806.97 277 305
GuHCl nadC (nadC)  Rv1596 29933 99.70% 2 2 4 0.01% 13.70% VPPGEALMTLEAQTR 95.00% 3.02 0.577 0 2 0 0 2 1,629.84 84 98
GuHCl nadC (nadC)  Rv1596 29933 99.70% 2 2 4 0.01% 13.70%
YGPDVTTLATVPASATTTAS
LVTR 95.00% 4.33 0.57 0 2 0 0 2 2,394.60 25 48
GuHCl
mmpL4 
(mmpL4)  Rv0450c 105188 99.90% 2 2 6 0.02% 5.48%
DAPSFEAMGRIGMVFKEGD
SDSFAMVIIEGN 95.00% 2.2 0.371 0 0 1 0 2 3,338.86 64 94
GuHCl
mmpL4 
(mmpL4)  Rv0450c 105188 99.90% 2 2 6 0.02% 5.48%
EMDRLMPQMVAQIPPQIEA
MEN 95.00% 2.21 0.274 0 0 5 0 2 2,573.01 621 642
GuHCl
hypo protein 
Rv2477c  Rv2477c 61876 99.70% 2 2 2 0.01% 9.50% GRAYPYEGNYSTYLEK 95.00% 1.01 0.171 1 0 0 0 2 1,912.20 232 247
GuHCl
hypo protein 
Rv2477c  Rv2477c 61876 99.70% 2 2 2 0.01% 9.50%
SYVDQARAGIDPRKTVWEV
VSDGLDYIQVGQTEVPSR 95.00% 2.02 0.275 0 0 1 0 2 4,136.33 387 423
GuHCl
hypo protein 
Rv2712c  Rv2712c 36939 99.00% 2 2 3 0.01% 16.20%
CVDGCGCSGVIDDPSASPL
AMAAVLDGRQLYPR 82.50% 2.7 0.113 0 0 1 0 2 3,567.98 127 159
GuHCl
hypo protein 
Rv2712c  Rv2712c 36939 99.00% 2 2 3 0.01% 16.20%
PAAAIAVIVDANGAQCPRC
NEEYR 95.00% 2.12 0.285 0 0 2 0 2 2,603.81 70 93
GuHCl recC (recC)  Rv0631c 119486 99.60% 2 2 2 0.01% 3.83%
GAKPFTFDPAALAAAQAAA
GKRCPPTAFISGR 92.30% 2.15 0.182 0 0 1 0 2 3,161.83 757 788
GuHCl recC (recC)  Rv0631c 119486 99.60% 2 2 2 0.01% 3.83% RRYGLDTVVH 95.00% 1.45 0.216 1 0 0 0 2 1,216.31 483 492
GuHCl ponA' Rv3682 84619 99.50% 2 2 3 0.01% 6.05% FQAKGLGSGGAK 95.00% 1.36 0.161 2 0 0 0 2 1,121.36 425 436
GuHCl
ponA' 
(ponA')  Rv3682 84619 99.50% 2 2 3 0.01% 6.05%
PEDGGPPPPVGSQVVEIPG
LPPITIPLLAPPPPAPPP 91.80% 1.9 0.171 0 0 1 0 2 3,609.29 774 810
GuHCl
mmpL11 
(mmpL11)  Rv0202c 103485 98.80% 2 2 3 0.01% 5.59%
SMHTTMSVFVTSTVSMFGI
ALAVDYSLFILMR 90.70% 1.6 0.192 0 0 1 0 2 3,606.31 225 256
GuHCl
mmpL11 
(mmpL11)  Rv0202c 103485 98.80% 2 2 3 0.01% 5.59%
TQLPRVAGAAQVDVGGPTA
LIK 89.20% 1.84 0.236 0 2 0 0 2 2,163.44 497 518
GuHCl ephE (ephE)  Rv3670 36316 99.20% 2 2 2 0.01% 8.87% LVRAIALISSPHPAAL 94.50% 1.58 0.221 0 0 1 0 2 1,630.11 143 158
GuHCl ephE (ephE)  Rv3670 36316 99.20% 2 2 2 0.01% 8.87% QAIQIPAAAHCAL 86.80% 1.3 0.0524 1 0 0 0 2 1,307.54 224 236
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% AALGGSDISAIK 95.00% 1.34 0.126 1 0 0 0 2 1,103.42 553 564
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30%
DAEAYLGEDITDAVITTPAY
FNDAQR 95.00% 2.93 0.518 0 2 0 0 2 2,861.16 102 127
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% DAGQIAGLNVLR 95.00% 2.95 0.482 0 3 0 0 2 1,227.45 132 143
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30%
EAEGGSKVPEDTLNKVDAA
VAEAK 95.00% 4.55 0.513 0 6 1 0 2 2,429.53 529 552
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% GTSGIDLTK 95.00% 1.05 0.25 1 0 0 0 2 892.0984 218 226
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30%
GVNPDEVVAVGAALQAGVL
K 95.00% 4.66 0.636 0 2 0 0 2 1,907.96 338 357
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% IQEGSGLSKEDIDR 95.00% 3.67 0.44 0 1 0 0 2 1,547.78 475 488
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% IVNEPTAAALAYGLDK 95.00% 4.36 0.559 1 3 0 0 2 1,646.98 144 159
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% IVNEPTAAALAYGLDKGEK 95.00% 4.08 0.622 0 4 0 0 2 1,961.33 144 162
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% KYTAPEISAR 95.00% 2.48 0.365 0 1 0 0 2 1,136.38 85 94
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% LLGSFELTGIPPAPR 95.00% 2.96 0.521 0 2 0 0 2 1,569.04 427 441
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% MPAVTDLVK 95.00% 2.46 0.429 2 1 0 0 2 990.1578 319 327
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% NGEVLVGQPAK 95.00% 2.72 0.43 1 0 0 0 2 1,112.16 45 55
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% NQAETLVYQTEK 95.00% 3.67 0.587 0 1 0 0 2 1,424.47 511 522
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30%
RDAEAYLGEDITDAVITTPA
YFNDAQRQATK 90.60% 2.16 0.152 0 0 1 0 2 3,445.84 101 131
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30%
SETFTTADDNQPSVQIQVY
QGER 95.00% 4.18 0.55 0 4 0 0 2 2,614.57 397 419
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30%
SVVSVLEGGDPVVVANSEG
SR 95.00% 3.8 0.588 0 1 0 0 2 2,057.91 14 34
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% TTPSIVAFAR 95.00% 1.37 0.27 2 0 0 0 2 1,063.25 35 44
GuHCl dnaK (dnaK)  Rv0350 66813 100.00% 19 22 43 0.13% 40.30% VPEDTLNKVDAAVAEAK 95.00% 3.69 0.53 0 2 0 0 2 1,770.87 536 552
GuHCl PPE (PPE)  Rv1801 41460 99.10% 2 2 2 0.01% 16.30%
AGLVGKLSVPQGWTVAAPE
IPSPAAALQATR 84.30% 2.2 0.153 0 0 1 0 2 3,058.48 324 354
GuHCl PPE (PPE)  Rv1801 41460 99.10% 2 2 2 0.01% 16.30%
TGAWSGPSSTSMASAAAP
YVAWMSATAVHAELAGAQ
AR 95.00% 2.44 0.266 0 0 1 0 2 3,754.99 53 90
GuHCl linB (linB)  Rv2579 33710 99.70% 2 2 3 0.01% 12.00% NLPIDGEPAEVVALVNEYR 95.00% 4.16 0.674 0 1 0 0 2 2,099.28 211 229
GuHCl linB (linB)  Rv2579 33710 99.70% 2 2 3 0.01% 12.00% SPQGEPMALEHNIFVER 95.00% 3.14 0.554 0 2 0 0 2 1,971.14 157 173
GuHCl pks4 (pks4)  Rv1181 168064 99.80% 2 2 3 0.01% 3.29% ELAELPGEPPRL 89.30% 1.27 0.0956 2 0 0 0 2 1,321.61 786 797
GuHCl pks4 (pks4)  Rv1181 168064 99.80% 2 2 3 0.01% 3.29%
GPVWVFSGQGSQWPGMG
TELLVAEPVFAATVAAMEPV
IAR 95.00% 1.42 0.328 0 0 1 0 2 4,190.51 33 72
GuHCl narH (narH)  Rv1162 62020 100.00% 3 3 3 0.01% 13.80%
PRICEHCLNPSCVASCPSG
AMYK 95.00% 1.84 0.203 0 0 1 0 2 2,538.88 182 204
171
GuHCl narH (narH)  Rv1162 62020 100.00% 3 3 3 0.01% 13.80%
TEDGIVLVDQDRCRGWRM
CVSGCPYK 95.00% 1.35 0.321 0 0 1 0 2 3,130.43 206 231
GuHCl narH (narH)  Rv1162 62020 100.00% 3 3 3 0.01% 13.80%
YEERYVIPTSYAGELPAAAM
TDDMGCSL 87.60% 2.2 0.177 0 0 1 0 2 3,087.51 456 483
GuHCl
hypo protein 
Rv3237c  Rv3237c 17216 99.70% 2 2 4 0.01% 25.60%
AGDVLIVIGTEDGIAGVEQI
VEKG 95.00% 1.91 0.21 0 1 0 0 2 2,383.61 137 160
GuHCl
hypo protein 
Rv3237c  Rv3237c 17216 99.70% 2 2 4 0.01% 25.60% LTDEEAEAVAQILGAPR 95.00% 4.03 0.532 0 3 0 0 2 1,783.98 54 70
GuHCl glnE (glnE)  Rv2221c 109089 99.90% 2 2 2 0.01% 5.84%
GYGSDADVMFVCEPATGV
DDARAVKWSTSIAERVR 95.00% 1.84 0.247 0 0 1 0 2 3,832.06 726 760
GuHCl glnE (glnE)  Rv2221c 109089 99.90% 2 2 2 0.01% 5.84%
PDDDRAPAAIAVIGMGRLG
GAELGYGSDADVMFVCEPA
TGVDDAR 95.00% 1.26 0.27 0 0 1 0 2 4,627.11 703 747
GuHCl
hypo protein 
Rv1130  Rv1130 57732 98.80% 2 2 2 0.01% 7.98%
DSYTKQHSAEYQSQAPIDL
ACR 95.00% 1.6 0.311 0 1 0 0 2 2,583.80 303 324
GuHCl
hypo protein 
Rv1130  Rv1130 57732 98.80% 2 2 2 0.01% 7.98%
VPDQDTKVRFFRVFCWCPV
L 79.80% 1.37 0.232 0 0 1 0 2 2,527.82 1 20
GuHCl groES Rv3418c 10754 100.00% 4 4 9 0.03% 47.00% DVLAVVSK 95.00% 1.75 0.436 2 0 0 0 2 830.8884 93 100
GuHCl
groES 
(groES)  Rv3418c 10754 100.00% 4 4 9 0.03% 47.00%
ILVQANEAETTTASGLVIPDT
AK 95.00% 1.9 0.536 0 1 0 0 2 2,343.63 13 35
GuHCl groES Rv3418c 10754 100.00% 4 4 9 0.03% 47.00% IPLDVAEGDTVIYSK 95.00% 4.24 0.49 0 4 0 0 2 1,620.89 59 73
GuHCl groES Rv3418c 10754 100.00% 4 4 9 0.03% 47.00% RIPLDVAEGDTVIYSK 95.00% 3.33 0.566 0 2 0 0 2 1,777.09 58 73
GuHCl
groEL1 
(groEL1)  Rv3417c 55859 100.00% 9 9 18 0.05% 33.40% AADAVSEALLASATPVSGK 95.00% 2.17 0.385 0 1 0 0 2 1,758.95 122 140
GuHCl
groEL1 
(groEL1)  Rv3417c 55859 100.00% 9 9 18 0.05% 33.40%
AAVEEGIVPGGGASLIHQA
R 95.00% 2.5 0.392 0 4 0 0 2 1,933.08 403 422
GuHCl
groEL1 
(groEL1)  Rv3417c 55859 100.00% 9 9 18 0.05% 33.40% AFGGPTVTNDGVTVAR 94.60% 1.5 0.267 0 1 0 0 2 1,562.56 42 57
GuHCl
groEL1 
(groEL1)  Rv3417c 55859 100.00% 9 9 18 0.05% 33.40%
AFLEDLAVVTGGQVVNPDA
GMVLR 82.10% 1.73 0.222 0 1 0 0 2 2,488.68 285 308
GuHCl
groEL1 
(groEL1)  Rv3417c 55859 100.00% 9 9 18 0.05% 33.40% DEQIGDLVGEAMSK 85.70% 1.61 0.256 0 1 0 0 2 1,508.65 153 166
GuHCl
groEL1 
(groEL1)  Rv3417c 55859 100.00% 9 9 18 0.05% 33.40% EIELEDPFEDLGAQLVK 95.00% 2.55 0.315 0 2 0 0 2 1,946.24 58 74
GuHCl
groEL1 
(groEL1)  Rv3417c 55859 100.00% 9 9 18 0.05% 33.40% LAGGVAVIK 95.00% 2.03 0.0469 1 0 0 0 2 828.0184 370 378
GuHCl
groEL1 
(groEL1)  Rv3417c 55859 100.00% 9 9 18 0.05% 33.40% LVAAGVNPIALGVGIGK 95.00% 3.2 0.51 0 1 0 0 2 1,549.89 105 121
GuHCl
groEL1 
(groEL1)  Rv3417c 55859 100.00% 9 9 18 0.05% 33.40%
RVVVSKDDTVIVDGGGTAE
AVAN 95.00% 2.44 0.274 0 5 0 0 2 2,273.21 320 342
GuHCl
groEL1 
(groEL1)  Rv3417c 55859 100.00% 9 9 18 0.05% 33.40%
TNDVAGDGTTTATILAQALI
K 95.00% 2.43 0.375 0 2 0 0 2 2,075.41 80 100
GuHCl
hypo protein 
Rv1151c  Rv1151c 25643 99.50% 2 2 2 0.01% 18.60%
CARCGVPYTDALPEMPEPAI
EVEPPVCDCGGLIRPDIVW
FGEPL 95.00% 1.39 0.256 0 0 1 0 2 4,899.55 112 155
GuHCl
hypo protein 
Rv1151c  Rv1151c 25643 99.50% 2 2 2 0.01% 18.60%
CGVPYTDALPEMPEPAIEVE
PPVCDCGGLIR 91.50% 2.06 0.199 0 0 1 0 2 3,414.81 115 145
GuHCl nirA (nirA)  Rv2391 62981 99.70% 2 2 2 0.01% 4.44% FTPYQKLVIL 95.00% 1.35 0.196 1 0 0 0 2 1,222.61 383 392
GuHCl nirA (nirA)  Rv2391 62981 99.70% 2 2 2 0.01% 4.44% WRRNLMACSGIEFCK 95.00% 2.07 0.216 0 1 0 0 2 1,886.31 418 432
GuHCl
hypo protein 
Rv2455c  Rv2455c 69134 99.10% 2 2 2 0.01% 7.81%
FNVVTFQAEDEIGGICAALG
AAYGGALGVTSTSGPGISL
K 84.90% 1.89 0.135 0 0 1 0 2 3,844.37 298 337
GuHCl
hypo protein 
Rv2455c  Rv2455c 69134 99.10% 2 2 2 0.01% 7.81% VVAPELNLGQL 94.70% 1.13 0.211 1 0 0 0 2 1,153.31 579 589
GuHCl
mmpL9 
(mmpL9)  Rv2339 104598 97.90% 2 2 2 0.01% 5.61% MADMLTMSDEMLVAIN 89.50% 1.61 0.167 1 0 0 0 2 1,818.23 513 528
GuHCl
mmpL9 
(mmpL9)  Rv2339 104598 97.90% 2 2 2 0.01% 5.61%
TMRTMMLTMRSTISGVQD
QMADMQDHATAMGQAFDT
AK 82.10% 1.72 0.219 0 0 1 0 2 4,242.85 641 678
GuHCl fbpB (fbpB)  Rv1886c 34564 99.70% 2 2 6 0.02% 12.00%
AVKPTGSAAIGLSMAGSSA
MIL 95.00% 4.15 0.5 0 1 0 0 2 2,066.58 154 175
GuHCl fbpB (fbpB)  Rv1886c 34564 99.70% 2 2 6 0.02% 12.00% PGLPVEYLQVPSPSMGR 95.00% 4.02 0.575 0 5 0 0 2 1,844.10 44 60
GuHCl
hypo protein 
Rv3786c  Rv3786c 44927 99.30% 2 2 2 0.01% 14.30% ELLYR 95.00% 1.3 0.0766 1 0 0 0 2 693.9184 75 79
GuHCl
hypo protein 
Rv3786c  Rv3786c 44927 99.30% 2 2 2 0.01% 14.30%
MADFCRPDWVMMVDADW
LVETDIDLR 87.20% 2.35 0.173 0 0 1 0 2 3,247.69 80 105
GuHCl
hypo protein 
Rv3786c  Rv3786c 44927 99.30% 2 2 2 0.01% 14.30%
MCPMVSRWDDPEYPDLIPV
MGTAEALR 95.00% 1.35 0.295 0 0 1 0 2 3,213.70 119 145
SDS
hypo protein 
Rv3107c  Rv3107c 56503 100.00% 3 3 3 0.01% 9.30% GVIAETFETACTWDGFDTL 95.00% 1.9 0.319 0 1 0 0 2 2,148.33 392 410
SDS
hypo protein 
Rv3107c  Rv3107c 56503 100.00% 3 3 3 0.01% 9.30%
GVIAETFETACTWDGFDTL
HAAVTDAARTAIWKVCGTG
VVTCR 95.00% 1.82 0.228 0 0 1 0 2 4,687.98 392 434
SDS
hypo protein 
Rv3107c  Rv3107c 56503 100.00% 3 3 3 0.01% 9.30% YPANCR 95.00% 1.24 0.149 1 0 0 0 2 794.8963 299 304
SDS PE_PGRS   Rv1450c 107389 97.60% 2 2 2 0.01% 4.29%
GGDGAFGGMSANATNPGE
NGPNGN 87.80% 2.29 0.169 0 1 0 0 2 2,164.18 859 882
SDS PE_PGRS   Rv1450c 107389 97.60% 2 2 2 0.01% 4.29%
GGDGGNAGNAGAGGPGG
TGSTAGKAGPAGSILH 83.70% 1.82 0.168 0 0 1 0 2 2,649.80 996 1028
SDS aspB (aspB)  Rv3565 41031 99.50% 2 2 2 0.01% 12.40%
GCEVVEIPCGPQTRFQPTA
QMLAEIDPPLR 92.20% 2.35 0.175 0 0 1 0 2 3,368.80 136 165
SDS aspB (aspB)  Rv3565 41031 99.50% 2 2 2 0.01% 12.40%
VAMASPGYPCYRNILSALG
CEVVEIPCGPQTR 95.00% 2.58 0.247 0 0 1 0 2 3,412.86 118 149
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30%
AASIAGLFLTTEAVVADKPE
K 95.00% 3.58 0.58 0 1 0 0 2 2,132.51 504 524
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% AQTGVYEDLLAAGVADPVK 95.00% 2.89 0.415 0 1 0 0 2 1,918.07 477 495
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% ASVPGGGDMGGMDF 95.00% 1.27 0.219 1 0 0 0 2 1,314.42 527 540
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% DETTIVEGAGDTDAIAGR 95.00% 3.74 0.364 0 5 0 0 2 1,791.88 326 343
SDS
groEL2 




(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% EIELEDPYEK 95.00% 2.83 0.331 6 0 0 0 2 1,265.44 58 67
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30%
EQIAATAAISAGDQSIGDLI
AEAMDK 95.00% 4.67 0.672 0 17 0 0 2 2,591.04 141 166
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% FLTTEAVVADKPEK 95.00% 2.82 0.444 0 1 0 0 2 1,548.74 511 524
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% GLNALADAVK 95.00% 2.07 0.49 5 0 0 0 2 972.1784 18 27
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30%
GLNAQTGVYEDLLAAGVAD
PVK 95.00% 3.91 0.537 0 3 0 0 2 2,202.42 474 495
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% GYISGYFVTDPER 95.00% 3.72 0.441 0 1 0 0 2 1,504.69 196 208
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30%
GYISGYFVTDPERQEAVLED
PYILLVSSK 95.00% 3.26 0.487 0 2 1 0 2 3,290.79 196 224
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% IGAELVK 95.00% 1.5 0.1 1 0 0 0 2 729.9184 68 74
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30%
KTDDVAGDGTTTATVLAQA
LVR 95.00% 6.1 0.616 0 44 1 0 2 2,204.35 79 100
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30%
KVVVTKDETTIVEGAGDTD
AIAGR 95.00% 5.8 0.665 0 17 0 0 2 2,446.59 320 343
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% KWGAPTITNDGVSIAK 95.00% 4.38 0.448 0 2 0 0 2 1,658.95 42 57
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% LEGDEATGANIVK 95.00% 1.59 0.266 1 0 0 0 2 1,317.45 429 441
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% LQAAPTLDELK 95.00% 1.3 0.26 1 0 0 0 2 1,199.50 418 428
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30%
NAQTGVYEDLLAAGVADPV
K 95.00% 2.5 0.25 0 1 0 0 2 2,032.17 476 495
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% NVAAGANPLGLK 95.00% 2.69 0.433 5 1 0 0 2 1,125.35 105 116
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% NVVLEK 95.00% 2.05 0.209 2 0 0 0 2 701.7584 36 41
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% QEAVLEDPYILLVSSK 95.00% 3.93 0.547 0 7 0 0 2 1,805.12 209 224
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% QIAFNSGLEPGVVAEK 95.00% 3.96 0.643 1 9 0 0 2 1,659.82 450 465
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30%
TDDVAGDGTTTATVLAQAL
VR 95.00% 5.02 0.513 0 10 0 0 2 2,076.15 80 100
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% VALEAPLK 95.00% 1.44 0.453 4 0 0 0 2 841.0684 442 449
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% VTETLLK 95.00% 1.17 0.0794 1 0 0 0 2 803.9884 126 132
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% VTLGPK 95.00% 1.5 0.192 1 0 0 0 2 614.7584 28 33
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30%
VVVTKDETTIVEGAGDTDAI
AGR 95.00% 4.33 0.59 0 2 0 0 2 2,318.39 321 343
SDS
groEL2 
(groEL2)  Rv0440 56709 100.00% 29 33 177 0.70% 53.30% WGAPTITNDGVSIAK 95.00% 3.89 0.584 0 2 0 0 2 1,530.75 43 57
SDS desA2 Rv1094 31342 99.70% 2 2 3 0.01% 12.00% LQNVADAGIFGKPQLR 95.00% 3.35 0.561 0 2 0 0 2 1,728.07 236 251
SDS desA2 Rv1094 31342 99.70% 2 2 3 0.01% 12.00% NLAAQIEEPILAGLIDR 95.00% 3.82 0.476 0 1 0 0 2 1,837.33 168 184
SDS clpP2 (clpP2)  Rv2460c 23491 99.00% 2 2 2 0.01% 26.60% ILTAEEAKDYGIIDTVLEYR 95.00% 2.69 0.48 0 1 0 0 2 2,313.80 188 207
SDS clpP2 (clpP2)  Rv2460c 23491 99.00% 2 2 2 0.01% 26.60%
MAIYDTMQYVRADIQTVCL
GQAASAAAVLLAAGTPGK 82.90% 1.05 0.345 0 0 1 0 2 3,771.40 87 123
SDS
hypo protein 
Rv1201c  Rv1201c 32591 99.60% 2 2 2 0.01% 11.00% LAVSDVPVELAALIGR 93.00% 1.94 0.177 0 1 0 0 2 1,623.92 42 57
SDS
hypo protein 
Rv1201c  Rv1201c 32591 99.60% 2 2 2 0.01% 11.00% TVIGSLDDVAADPYDAYLR 95.00% 2.23 0.385 0 1 0 0 2 2,055.35 70 88
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% AELPGVDPDK 95.00% 1.22 0.172 1 0 0 0 2 1,041.16 55 64
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% AELPGVDPDKDVDIMVR 95.00% 4.35 0.654 9 57 3 0 2 1,870.10 55 71
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10%
AELPGVDPDKDVDIMVRD
GQLTIK 95.00% 2.7 0.494 0 2 0 0 2 2,626.05 55 78
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% DGQLTIK 95.00% 1.32 0.228 5 0 0 0 2 774.9684 72 78
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% FAAFPSFAGLRPTFDTR 95.00% 2.03 0.285 0 1 0 0 2 1,902.33 22 38
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% GILTVSVAVSEGKPTEK 95.00% 4.34 0.615 35 200 0 0 2 1,715.89 120 136
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% HIQIR 95.00% 1.47 0.121 5 0 0 0 2 666.8184 137 141
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% LEDEMK 95.00% 1.08 0.188 3 0 0 0 2 780.9178 42 47
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% PGVDPDKDVDIMVR 95.00% 3.2 0.542 0 3 0 0 2 1,572.72 58 71
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% PVGADEDDIK 95.00% 2.04 0.379 8 0 0 0 2 1,059.14 105 114
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% SEFAYGSFVR 95.00% 2.71 0.565 9 4 0 0 2 1,163.28 91 100
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% SLFPEFSEL 95.00% 1.6 0.245 1 0 0 0 2 1,069.30 13 21
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% SLFPEFSELFAAFPSFAGLR 95.00% 3.83 0.572 0 4 0 0 2 2,234.79 13 32
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10%
SLFPEFSELFAAFPSFAGLRP
TFDTR 95.00% 2.87 0.58 0 0 24 0 2 2,952.61 13 38
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% TVSLPVGADEDDIK 95.00% 3.28 0.523 7 14 0 0 2 1,459.59 101 114
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% TVSLPVGADEDDIKATYDK 95.00% 4.98 0.539 0 6 0 0 2 2,038.27 101 119
SDS hspX (hspX)  Rv2031c 16210 100.00% 17 22 402 1.58% 77.10% YEVR 94.70% 1.04 0.164 1 0 0 0 2 566.5884 51 54
SDS
hypo protein 
Rv2030c  Rv2030c 74880 99.70% 2 2 3 0.01% 7.93%
ARYACFDHACADDGQAYGF
AAAFGAGPSCER 95.00% 2.01 0.22 0 0 1 0 2 3,413.67 403 433
SDS
hypo protein 
Rv2030c  Rv2030c 74880 99.70% 2 2 3 0.01% 7.93%
VAIDAPGGVPTHEVLAELVG
DAR 95.00% 2.54 0.312 0 2 0 0 2 2,287.41 246 268
SDS drrC (drrC)  Rv2938 29576 99.70% 2 2 2 0.01% 17.00%
GFAMGGPVLSPMIGMLVWT
AGICVVCAVPLAIGYRR 95.00% 1.22 0.302 0 0 1 0 2 3,811.61 237 272
SDS drrC (drrC)  Rv2938 29576 99.70% 2 2 2 0.01% 17.00%
QPVSYAIAAMRGFAMGGPV
LSPMIGMLVWTAGICVVCA
VPLAIGYR 95.00% 1.94 0.258 0 0 1 0 2 4,930.89 226 271
SDS
hypo protein 
Rv1006  Rv1006 61280 100.00% 3 3 4 0.02% 8.29%
GPLNAMGSPAIPSTAQEIPN
PLR 95.00% 3.43 0.54 0 2 0 0 2 2,348.82 35 57
SDS
hypo protein 
Rv1006  Rv1006 61280 100.00% 3 3 4 0.02% 8.29% TLPAAVDLK 95.00% 1.33 0.106 1 0 0 0 2 928.1684 468 476
SDS
hypo protein 
Rv1006  Rv1006 61280 100.00% 3 3 4 0.02% 8.29% YSVEAQPGSQALAGK 91.90% 1.72 0.25 0 1 0 0 2 1,506.61 418 432
SDS
hypo protein 
Rv3778c  Rv3778c 41833 100.00% 4 4 4 0.02% 16.60%
DAAREAVADLVNADPGGVV
LGADR 95.00% 2.07 0.305 0 0 1 0 2 2,352.45 64 87
SDS
hypo protein 
Rv3778c  Rv3778c 41833 100.00% 4 4 4 0.02% 16.60%
DPSVMNSFGSVSTNPYATG




Rv3778c  Rv3778c 41833 100.00% 4 4 4 0.02% 16.60%
EAVADLVNADPGGVVLGAD
R 95.00% 3.66 0.459 0 1 0 0 2 1,938.99 68 87
SDS
hypo protein 
Rv3778c  Rv3778c 41833 100.00% 4 4 4 0.02% 16.60%
LVHDVGALVVVDHSAAAPY
R 95.00% 5.8 0.439 0 1 0 0 2 2,090.14 182 201
SDS pknH (pknH)  Rv1266c 66735 98.80% 2 2 2 0.01% 14.20%
GSPPTITVIDTQEGAEGWE
CQRAMSVANNVVVDVNAC
GYR 80.20% 0.907 0.264 0 0 1 0 2 4,310.34 568 607
SDS pknH (pknH)  Rv1266c 66735 98.80% 2 2 2 0.01% 14.20%
PGPTGQPSWAPNSGPMPA
SGPTPTPQYYQGGGWGAP
PSGGPSPWAQTPR 95.00% 2.08 0.19 0 0 1 0 2 4,888.22 349 397
SDS kasB (kasB)  Rv2246 46371 100.00% 3 3 5 0.02% 10.50% AVSPLTVQK 95.00% 1.44 0.369 1 0 0 0 2 943.0384 156 164
SDS kasB (kasB)  Rv2246 46371 100.00% 3 3 5 0.02% 10.50%
IMGASITSDGFHMVAPDPN
GER 95.00% 2.79 0.345 0 1 0 0 2 2,319.60 286 307
SDS kasB (kasB)  Rv2246 46371 100.00% 3 3 5 0.02% 10.50% TLDDPFVEEFDLPVR 95.00% 3.87 0.524 0 3 0 0 2 1,793.00 65 79
SDS kasA (kasA)  Rv2245 43266 99.10% 2 2 3 0.01% 10.10%
QIVMGDADVAVCGGVEGPI
EALPIAAFSMMRAMSTRN 95.00% 2.48 0.331 0 0 2 0 2 3,842.38 184 220
SDS kasA (kasA)  Rv2245 43266 99.10% 2 2 3 0.01% 10.10%
QIVMGDADVAVCGGVEGPI
EALPIAAFSMMRAMSTRND
EPER 85.90% 1.4 0.266 0 0 1 0 2 4,453.00 184 225
SDS tkt (tkt)  Rv1449c 75539 99.70% 2 2 2 0.01% 3.43% AHGAAL 95.00% 0.887 0.188 1 0 0 0 2 539.6084 282 287
SDS tkt (tkt)  Rv1449c 75539 99.70% 2 2 2 0.01% 3.43% NGSGPVGLILTRQGVPVL 95.00% 2.06 0.24 0 0 1 0 2 1,778.05 541 558
SDS sucB (sucB)  Rv2215 57070 99.70% 2 2 4 0.02% 9.40% EGVNLTFLPFFAK 95.00% 2.24 0.272 0 1 0 0 2 1,483.84 368 380
SDS sucB (sucB)  Rv2215 57070 99.70% 2 2 4 0.02% 9.40%
PAPEPPPVQPTSGAPAGGD
AKPVLMPELGESVTEGTVIR 95.00% 3.09 0.539 0 0 3 0 2 3,867.21 102 140
SDS tsf (tsf)  Rv2889c 28737 100.00% 6 7 13 0.05% 32.50% NAEFQTLADQVVAAAAAAK 95.00% 4.16 0.587 0 1 0 0 2 1,890.00 82 100
SDS tsf (tsf)  Rv2889c 28737 100.00% 6 7 13 0.05% 32.50%
NAEFQTLADQVVAAAAAAK
PADVDALK 95.00% 3.13 0.582 0 3 3 0 2 2,699.95 82 108
SDS tsf (tsf)  Rv2889c 28737 100.00% 6 7 13 0.05% 32.50% NALAETDGDFDKAVEALR 95.00% 3.66 0.494 0 1 0 0 2 1,936.16 25 42
SDS tsf (tsf)  Rv2889c 28737 100.00% 6 7 13 0.05% 32.50% SADLPPAVGVLVEYR 95.00% 2.93 0.541 0 2 0 0 2 1,586.76 152 166
SDS tsf (tsf)  Rv2889c 28737 100.00% 6 7 13 0.05% 32.50% TVEQAIAELSAK 95.00% 1.65 0.212 1 0 0 0 2 1,260.41 116 127
SDS tsf (tsf)  Rv2889c 28737 100.00% 6 7 13 0.05% 32.50% YLSRDDVPEDIVASER 95.00% 2.47 0.378 0 2 0 0 2 1,865.02 187 202
SDS tyrS (tyrS)  Rv1689 46313 98.50% 2 2 2 0.01% 9.67%
AGGATGMIGDPRDVGERSL
NEADTVAEWTER 92.70% 1.54 0.249 0 0 1 0 2 3,278.43 71 101
SDS tyrS (tyrS)  Rv1689 46313 98.50% 2 2 2 0.01% 9.67% HFSVNVMLAR 83.30% 1.15 0 1 0 0 0 2 1,190.32 143 152
SDS
accD4 
(accD4)  Rv3799c 56151 99.70% 2 2 2 0.01% 7.54%
INGRPVGVFSHDQTVFGGT
VGEMFGRK 95.00% 1.99 0.345 0 0 1 0 2 2,894.10 86 112
SDS accD4 Rv3799c 56151 99.70% 2 2 2 0.01% 7.54% SYGGAYAVMGSK 95.00% 0.994 0.302 1 0 0 0 2 1,191.36 407 418
SDS
hypo protein 
Rv1230c  Rv1230c 41368 99.40% 2 2 2 0.01% 20.40%
ICIGSHGPPVGAPPFPPTAP
PPPFLPAAPPPPDPLAGPPG
DAGLAPPAPAPAG 90.30% 2.04 0.162 0 0 1 0 2 4,883.86 359 411
SDS
hypo protein 
Rv1230c  Rv1230c 41368 99.40% 2 2 2 0.01% 20.40%
PGTWARYATDGDDDGVAD
PQNLFDSTLAAAR 95.00% 1 0.458 0 1 0 0 2 3,268.54 205 235
SDS
fbpC2 
(fbpC2)  Rv0129c 36754 100.00% 3 3 8 0.03% 16.50%
ADIQHVLNGATPPAAPAAPA
A 95.00% 3.68 0.576 0 4 0 0 2 1,954.16 320 340
SDS fbpC2 Rv0129c 36754 100.00% 3 3 8 0.03% 16.50% PGLPVEYLQVPSASMGR 95.00% 3.1 0.532 0 1 0 0 2 1,818.06 50 66
SDS fbpC2 Rv0129c 36754 100.00% 3 3 8 0.03% 16.50% VQFQGGGPHAVYLLDGLR 95.00% 5.06 0.565 0 3 0 0 2 1,928.16 70 87
SDS hisH (hisH)  Rv1602 21368 99.00% 2 2 2 0.01% 18.90%
QRVGAEVEVTADTDAAMTA
DGLVVPGVGAFAACMAGLR
K 95.00% 1.46 0.262 0 0 1 0 2 3,882.13 24 62
SDS hisH (hisH)  Rv1602 21368 99.00% 2 2 2 0.01% 18.90%
VGAEVEVTADTDAAMTADG
LVVPGVGAFAACMAGLR 83.30% 1.03 0.313 0 0 1 0 2 3,469.63 26 61
SDS
hypo protein 
Rv3038c  Rv3038c 36031 98.60% 2 2 2 0.01% 10.40%
IAHNAGAVEVQTATEEFTAA
ML 94.40% 2.17 0.239 0 1 0 0 2 2,291.39 247 268
SDS
hypo protein 
Rv3038c  Rv3038c 36031 98.60% 2 2 2 0.01% 10.40% VVTNATKLPGLR 80.00% 1.09 0.219 1 0 0 0 2 1,269.51 201 212
SDS
hypo protein 
Rv3894c  Rv3894c 153685 99.90% 3 3 3 0.01% 4.08%
GKTTTLMALMCSAATMYTP
ERVTFFCIGGATMAQIGSL 79.80% 1.05 0.304 0 0 1 0 2 4,095.94 890 927
SDS
hypo protein 
Rv3894c  Rv3894c 153685 99.90% 3 3 3 0.01% 4.08%
MCSAATMYTPERVTFFCIG
GATMAQIGSLPHVTDIVSP
K 86.20% 1.76 0.235 0 0 1 0 2 4,220.88 899 937
SDS
hypo protein 
Rv3894c  Rv3894c 153685 99.90% 3 3 3 0.01% 4.08%
VTFFCIGGATMAQIGSLPHV
TDIVSPKDAEGIERIL 95.00% 2.23 0.367 0 0 1 0 2 3,875.55 911 946
SDS
hypo protein 
Rv2205c  Rv2205c 48556 99.70% 2 2 2 0.01% 13.10%
GGSACTDGGKGMIAELGG
LDAARR 95.00% 1.95 0.254 0 0 1 0 2 2,335.75 257 280
SDS
hypo protein 
Rv2205c  Rv2205c 48556 99.70% 2 2 2 0.01% 13.10%
VRPGPSWCGDGIGCAWA
WAGPWGRWFATRAMCPTR
TCVR 95.00% 1.46 0.389 0 0 1 0 2 4,466.97 1 39
SDS
fusA2 
(fusA2)  Rv0120c 75612 99.90% 2 2 2 0.01% 7.98%
AQMDKGVHAGYPVVDIRV
TL 93.50% 2.68 0.124 0 1 0 0 2 2,170.38 569 588
SDS
fusA2 
(fusA2)  Rv0120c 75612 99.90% 2 2 2 0.01% 7.98%
PGSVTEGTTVCDFDEAEIR
QQRSVGLAVASLAYDGIK 94.90% 1.13 0.312 0 0 1 0 2 3,956.26 53 89
SDS
wag31 
(wag31)  Rv2145c 28260 100.00% 4 4 11 0.04% 21.20% ANAEQILGEAR 90.30% 1.16 0.127 1 0 0 0 2 1,172.31 134 144
SDS
wag31 
(wag31)  Rv2145c 28260 100.00% 4 4 11 0.04% 21.20%
GSAAPVDSNADAGGFDQF
NR 95.00% 4.33 0.58 0 7 0 0 2 1,997.04 238 257
SDS
wag31 
(wag31)  Rv2145c 28260 100.00% 4 4 11 0.04% 21.20% TYLESQLEELGQR 95.00% 5.03 0.556 0 2 0 0 2 1,566.75 225 237
SDS
wag31 
(wag31)  Rv2145c 28260 100.00% 4 4 11 0.04% 21.20% VLSLAQDTADR 95.00% 2.65 0.354 0 1 0 0 2 1,189.33 106 116
SDS
hypo protein 
Rv0248c  Rv0248c 70663 99.70% 2 2 3 0.01% 7.12%
ALSSRPAVSAEAIDAAAQQ
ALSPFEGPK 95.00% 1.85 0.438 0 1 0 0 2 2,784.16 449 476
SDS
hypo protein 
Rv0248c  Rv0248c 70663 99.70% 2 2 3 0.01% 7.12% FIVFEAPAVVLATGGIGK 95.00% 2.77 0.546 0 2 0 0 2 1,790.14 197 214
SDS hsdM (hsdM)  Rv2756c 60067 99.20% 2 2 2 0.01% 14.30%
AAEGMEESQIEDLIDDPEQ
YQGYGVFVVPVSARWK 86.80% 1.28 0.264 0 0 1 0 2 3,974.19 67 101
SDS hsdM (hsdM)  Rv2756c 60067 99.20% 2 2 2 0.01% 14.30%
VYDPCCGSGGMFVQTEKFI
YEHDGDPKDVSIYGQESIE
ETWR 95.00% 1.68 0.32 0 0 1 0 2 4,818.16 224 265
SDS dnaK (dnaK)  Rv0350 66813 100.00% 6 6 10 0.04% 17.90%
AVGIDLGTTNSVVSVLEGG
DPVVVANSEGSR 95.00% 4.62 0.576 0 1 0 0 2 2,999.96 4 34
174
SDS dnaK (dnaK)  Rv0350 66813 100.00% 6 6 10 0.04% 17.90%
DAEAYLGEDITDAVITTPAY
FNDAQR 95.00% 2.04 0.323 0 1 0 0 2 2,861.16 102 127
SDS dnaK (dnaK)  Rv0350 66813 100.00% 6 6 10 0.04% 17.90%
GVNPDEVVAVGAALQAGVL
K 95.00% 4.08 0.633 0 3 0 0 2 1,907.96 338 357
SDS dnaK (dnaK)  Rv0350 66813 100.00% 6 6 10 0.04% 17.90% IVNEPTAAALAYGLDKGEK 95.00% 2.6 0.447 0 2 0 0 2 1,961.33 144 162
SDS dnaK (dnaK)  Rv0350 66813 100.00% 6 6 10 0.04% 17.90%
KGVNPDEVVAVGAALQAG
VLK 95.00% 4.7 0.507 0 1 0 0 2 2,036.16 337 357
SDS dnaK (dnaK)  Rv0350 66813 100.00% 6 6 10 0.04% 17.90% LLGSFELTGIPPAPR 95.00% 3.15 0.485 0 2 0 0 2 1,569.04 427 441
SDS
hypo protein 
Rv2191  Rv2191 69130 99.70% 2 2 4 0.02% 6.05%
IVGVSNDAAGLASPVRSAG
PWAAWAATAR 95.00% 1.79 0.438 0 0 3 0 2 2,824.08 562 590
SDS
hypo protein 
Rv2191  Rv2191 69130 99.70% 2 2 4 0.02% 6.05% RKRMTEMVML 95.00% 1.01 0.141 1 0 0 0 2 1,311.69 285 294
SDS
hypo protein 
Rv2326c  Rv2326c 72818 100.00% 3 3 6 0.02% 6.17%
GRGTPTVVVSSLIGGFVFG
AAMVGML 94.10% 2.02 0.241 0 0 1 0 2 2,556.91 122 147
SDS
hypo protein 
Rv2326c  Rv2326c 72818 100.00% 3 3 6 0.02% 6.17% QRLALAAALAR 92.20% 1.37 0.09 1 0 0 0 2 1,154.52 380 390
SDS
hypo protein 
Rv2326c  Rv2326c 72818 100.00% 3 3 6 0.02% 6.17%
RGRGTPTVVVSSLIGGFVF
GAAMVGMLAAMVR 95.00% 1.96 0.316 0 0 4 0 2 3,241.74 121 152
SDS
hypo protein 
Rv1075c  Rv1075c 32829 99.70% 2 2 2 0.01% 14.60%
GVCGQVDAMFVVGPPPDA
AVIMIGANDITALN 95.00% 1.3 0.32 0 0 1 0 2 3,157.53 124 155
SDS
hypo protein 
Rv1075c  Rv1075c 32829 99.70% 2 2 2 0.01% 14.60%
IRLSTKAIVGATSKGVCGQ
VDAMFVVGPPPDAAVIMIG
AN 95.00% 2.09 0.216 0 0 1 0 2 3,988.59 110 149
SDS
hypo protein 
Rv1256c  Rv1256c 44562 99.70% 2 2 3 0.01% 18.30%
GVPEEDWTQFDGWTQAIV
AANAVDGATTGALDAVGS
MMAYFTGLIER 95.00% 1.55 0.445 0 0 2 0 2 4,935.34 157 203
SDS
hypo protein 
Rv1256c  Rv1256c 44562 99.70% 2 2 3 0.01% 18.30%
MTSVMSHEFQLATAETWPN
PWPMYRAL 95.00% 1.72 0.264 0 0 1 0 2 3,244.65 1 27
SDS
hypo protein 
Rv3099c  Rv3099c 30458 100.00% 4 5 9 0.04% 30.70%
AAVQRPSSDDELGGPASPL
VLDEIAATMGFVVGK 95.00% 5.91 0.658 0 1 3 0 2 3,415.80 161 194
SDS
hypo protein 
Rv3099c  Rv3099c 30458 100.00% 4 5 9 0.04% 30.70% HLGTESGVGLLER 95.00% 2.87 0.529 0 1 0 0 2 1,368.52 96 108
SDS
hypo protein 
Rv3099c  Rv3099c 30458 100.00% 4 5 9 0.04% 30.70%
VLASLSDDEWNAPTTTPSG
PDSYGR 95.00% 2.52 0.479 0 1 0 0 2 2,637.83 119 143
SDS
hypo protein 
Rv3099c  Rv3099c 30458 100.00% 4 5 9 0.04% 30.70% VVDDFGGPAPTATIR 95.00% 3.63 0.461 0 3 0 0 2 1,516.66 226 240
SDS nadC (nadC)  Rv1596 29933 99.70% 2 2 7 0.03% 13.70% VPPGEALMTLEAQTR 95.00% 3.04 0.544 0 3 0 0 2 1,629.84 84 98
SDS nadC (nadC)  Rv1596 29933 99.70% 2 2 7 0.03% 13.70%
YGPDVTTLATVPASATTTAS
LVTR 95.00% 3.34 0.507 0 4 0 0 2 2,394.60 25 48
SDS nadA (nadA)  Rv1594 37390 99.70% 2 2 2 0.01% 14.30% MITPAALLRCL 95.00% 1.55 0.215 1 0 0 0 2 1,218.70 305 315
SDS nadA (nadA)  Rv1594 37390 99.70% 2 2 2 0.01% 14.30%
PGAVVVSYVNTTAAVKALT
DICCTSSNAVDVVASIDPD
R 95.00% 2.26 0.276 0 0 1 0 2 3,924.07 133 171
SDS helZ (helZ)  Rv2101 111615 100.00% 3 3 3 0.01% 6.02% RTACPSGLELDADGAYR 95.00% 2.41 0.164 0 0 1 0 2 1,796.06 349 365
SDS helZ (helZ)  Rv2101 111615 100.00% 3 3 3 0.01% 6.02% SGGMRLWAEDSDLLVK 94.30% 1.14 0.359 0 1 0 0 2 1,794.13 11 26
SDS helZ (helZ)  Rv2101 111615 100.00% 3 3 3 0.01% 6.02%
TTEQASLYQAVVADMMEKI
ENTEGIERR 95.00% 1.7 0.242 0 0 1 0 2 3,246.53 774 801
SDS
hypo protein 
Rv2100  Rv2100 58918 99.60% 2 2 2 0.01% 3.82% PSNLKCACRK 93.60% 1.02 0 1 0 0 0 2 1,191.48 438 447
SDS
hypo protein 
Rv2100  Rv2100 58918 99.60% 2 2 2 0.01% 3.82% VDARGLMMPRR 95.00% 1.42 0.00739 1 0 0 0 2 1,302.64 508 518
SDS
fadD19 
(fadD19)  Rv3515c 59691 99.50% 2 2 2 0.01% 6.20%
AEHAIDAVPDRVAVICGDE
QLTYAQLEDK 95.00% 1.82 0.343 0 0 1 0 2 3,242.48 11 39
SDS
fadD19 
(fadD19)  Rv3515c 59691 99.50% 2 2 2 0.01% 6.20% VTSGG 91.40% 0.764 0.22 1 0 0 0 2 420.3684 544 548
SDS bioF (bioF)  Rv1569 40009 99.70% 2 2 4 0.02% 14.00%
HPAVIDGGVQALRIWGAGA
TGSR 95.00% 2.17 0.244 0 3 0 0 2 2,290.53 56 78
SDS bioF (bioF)  Rv1569 40009 99.70% 2 2 4 0.02% 14.00%
MCGVAAVPDSAMVSVILGE
PESAVAAAAACL 95.00% 1.41 0.296 0 0 1 0 2 3,079.32 306 336
SDS
hypo protein 
Rv0036c  Rv0036c 27528 100.00% 5 5 5 0.02% 24.90% AESDDLDALVAHLPADR 95.00% 3.65 0.42 0 1 0 0 2 1,809.01 13 29
SDS
hypo protein 
Rv0036c  Rv0036c 27528 100.00% 5 5 5 0.02% 24.90% ALSTLDVNAVGEDAQR 95.00% 2.93 0.495 0 1 0 0 2 1,659.73 226 241
SDS
hypo protein 
Rv0036c  Rv0036c 27528 100.00% 5 5 5 0.02% 24.90% LHEELLAVPDGR 95.00% 3.46 0.532 0 1 0 0 2 1,349.54 106 117
SDS
hypo protein 
Rv0036c  Rv0036c 27528 100.00% 5 5 5 0.02% 24.90% SIAHL 95.00% 0.906 0.164 1 0 0 0 2 540.6784 162 166
SDS
hypo protein 
Rv0036c  Rv0036c 27528 100.00% 5 5 5 0.02% 24.90% WLTIAQAFAGPPGR 95.00% 3.91 0.487 0 1 0 0 2 1,485.80 242 255
SDS
hypo protein 
Rv3371  Rv3371 48830 99.90% 2 2 4 0.02% 4.93% MIHALAR 95.00% 1.35 0.0382 3 0 0 0 2 828.0778 318 324
SDS
hypo protein 
Rv3371  Rv3371 48830 99.90% 2 2 4 0.02% 4.93% PSAARRGRPSVPTAR 94.80% 1.12 0.312 0 0 1 0 2 1,579.80 429 443
SDS
hypo protein 
Rv2625c  Rv2625c 41463 99.70% 2 2 4 0.02% 6.36%
DAIPLGRIAGFVVNVHWSV
L 95.00% 2.58 0.213 0 3 0 0 2 2,164.46 3 22
SDS
hypo protein 
Rv2625c  Rv2625c 41463 99.70% 2 2 4 0.02% 6.36% FSDAG 95.00% 1.15 0.0767 1 0 0 0 2 496.5284 389 393
SDS sucD (sucD)  Rv0952 31212 99.70% 2 2 3 0.01% 10.90% LPVFGSVAEAMEK 95.00% 2.38 0.5 0 1 0 0 2 1,394.57 63 75
SDS sucD (sucD)  Rv0952 31212 99.70% 2 2 3 0.01% 10.90%
TNVSKPVVGYVAGFTAPEG
K 95.00% 4.94 0.513 0 2 0 0 2 2,022.13 236 255
SDS
hypo protein 
Rv1128c  Rv1128c 49258 99.70% 2 2 2 0.01% 8.20% AAPGMCNPEQK 95.00% 1.22 0.306 1 0 0 0 2 1,162.27 229 239
SDS
hypo protein 
Rv1128c  Rv1128c 49258 99.70% 2 2 2 0.01% 8.20%
IMLYAKDSGCSAPGCDVPG
YYCEVHH 95.00% 2.4 0.299 0 0 1 0 2 2,888.15 354 379
SDS phoS1 Rv0934 38194 100.00% 4 4 12 0.05% 23.80% ASFLDQVHFQPLPPAVVK 95.00% 3.18 0.535 0 2 0 0 2 1,994.23 346 363
175
SDS phoS1 Rv0934 38194 100.00% 4 4 12 0.05% 23.80% SDGSGDTFLFTQYLSK 95.00% 3.11 0.544 0 2 0 0 2 1,767.06 186 201
SDS
phoS1 
(phoS1)  Rv0934 38194 100.00% 4 4 12 0.05% 23.80%
TPANQAISMIDGPAPDGYPI
INYEYAIVNNR 95.00% 4.18 0.678 0 5 0 0 2 3,395.97 292 322
SDS
phoS1 
(phoS1)  Rv0934 38194 100.00% 4 4 12 0.05% 23.80%
TWDDPQIAALNPGVNLPGT
AVVPL 95.00% 2.01 0.313 0 3 0 0 2 2,459.75 160 183
SDS
hypo protein 
Rv0284  Rv0284 145124 99.70% 2 2 3 0.01% 1.50% DYGGGQLR 95.00% 1.39 0.137 2 0 0 0 2 865.9684 861 868
SDS
hypo protein 
Rv0284  Rv0284 145124 99.70% 2 2 3 0.01% 1.50% FASQTLDVGKIK 95.00% 1.59 0.0315 1 0 0 0 2 1,307.60 630 641
SDS lprG (lprG)  Rv1411c 24530 100.00% 3 3 6 0.02% 14.40% IPGLSLK 95.00% 2.08 0.374 2 0 0 0 2 728.0684 68 74
SDS lprG (lprG)  Rv1411c 24530 100.00% 3 3 6 0.02% 14.40% TLSGDLTTNPTAATGNVK 95.00% 2.8 0.583 0 3 0 0 2 1,761.95 75 92
SDS lprG (lprG)  Rv1411c 24530 100.00% 3 3 6 0.02% 14.40% VLANFADAK 91.50% 1.08 0.119 1 0 0 0 2 949.1284 145 153
SDS
hypo protein 
Rv2713  Rv2713 50736 99.80% 2 2 2 0.01% 8.55%
AGLEVQGRGRIFVDDRFQT
K 95.00% 1.93 0.258 0 0 1 0 2 2,293.59 282 301
SDS
hypo protein 
Rv2713  Rv2713 50736 99.80% 2 2 2 0.01% 8.55% IVGHGRFIDPHTILVEDQAR 88.60% 1.84 0.206 0 1 0 0 2 2,274.56 111 130
SDS
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 9 9 21 0.08% 62.60%
ATEYNNAAEAFAAQLVTAE
QSVEDLK 95.00% 4.29 0.564 0 4 0 0 2 2,784.90 95 120
SDS
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 9 9 21 0.08% 62.60%
GEALPAGGTTATPRPATETS
GGAIAEQPYGQ 95.00% 1.46 0.462 0 1 0 0 2 2,958.16 240 270
SDS
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 9 9 21 0.08% 62.60% MLEVEQAGIQMAGHSR 95.00% 2.92 0.504 0 2 0 0 2 1,757.93 215 230
SDS
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 9 9 21 0.08% 62.60% QALTLADQATAAGDAAK 95.00% 3.03 0.444 0 1 0 0 2 1,616.83 78 94
SDS
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 9 9 21 0.08% 62.60% SMSELAAPGNTPSLDEVR 95.00% 2.4 0.363 0 3 0 0 2 1,891.08 173 190
SDS
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 9 9 21 0.08% 62.60% THQALTQQAAQVIGNQR 95.00% 5.53 0.684 0 3 0 0 2 1,864.88 40 56
SDS
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 9 9 21 0.08% 62.60% TLHDQALSAAAQAK 95.00% 2.61 0.542 0 2 0 0 2 1,425.60 121 134
SDS
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 9 9 21 0.08% 62.60% VQIQQAIEEAQR 95.00% 4.72 0.503 0 2 0 0 2 1,413.45 28 39
SDS
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 9 9 21 0.08% 62.60% YANAIGSAELAESSVQGR 95.00% 3.89 0.496 0 3 0 0 2 1,823.95 197 214
SDS sucA (sucA)  Rv1248c 133954 99.70% 2 2 3 0.01% 3.38%
SVPRLMPGQGAIIGVGAME
YPAEFQGASEER 95.00% 2.31 0.232 0 0 2 0 2 3,249.65 251 281
SDS sucA (sucA)  Rv1248c 133954 99.70% 2 2 3 0.01% 3.38%
TNPGTIGTVHSVPRLMPGQ
GAIIGVGAMEYPAEFQGAS
EER 95.00% 1.69 0.221 0 0 1 0 2 4,243.64 241 281
SDS tpx (tpx)  Rv1932 16878 98.80% 2 2 6 0.02% 35.20%
TFDERAAASGATVLCVSKD
LPFAQK 80.40% 2.02 0.161 0 0 1 0 2 2,626.99 66 90
SDS tpx (tpx)  Rv1932 16878 98.80% 2 2 6 0.02% 35.20%
TVGELPAVGSPAPAFTLTGG
DLGVISSDQFRGK 95.00% 1.99 0.255 0 0 5 0 2 3,246.67 13 45
SDS
hypo protein 
Rv2258c  Rv2258c 37496 99.70% 2 2 3 0.01% 11.60% ALRPGGVLLMVDIK 94.80% 1.98 0.252 0 2 0 0 2 1,498.96 264 277
SDS
hypo protein 
Rv2258c  Rv2258c 37496 99.70% 2 2 3 0.01% 11.60%
SGADVADFGCGSGRAVKL
MAQAFGASR 95.00% 1.84 0.261 0 0 1 0 2 2,702.01 171 197
SDS
hypo protein 
Rv2005c  Rv2005c 30965 100.00% 3 3 4 0.02% 25.40% GLLGSVSSSLVR 95.00% 2.18 0.464 0 1 0 0 2 1,175.38 127 138
SDS
hypo protein 
Rv2005c  Rv2005c 30965 100.00% 3 3 4 0.02% 25.40%
IPLTVVHVVNADVATWPPM
PYPETWGVWQEDEGR 95.00% 1.6 0.281 0 0 1 0 2 3,907.00 36 69
SDS
hypo protein 
Rv2005c  Rv2005c 30965 100.00% 3 3 4 0.02% 25.40%
SELVFSTPVPTMVEISNEAE
MVVLGSSGR 95.00% 3.58 0.628 0 2 0 0 2 3,099.29 93 121
SDS
hypo protein 
Rv2223c  Rv2223c 55060 100.00% 3 3 3 0.01% 19.20%
AQDCVDRMGFSFLANIGTA
SVARDMDMVR 82.00% 1.68 0.227 0 0 1 0 2 3,281.69 190 218
SDS
hypo protein 
Rv2223c  Rv2223c 55060 100.00% 3 3 3 0.01% 19.20%
DADGHYSNDQDAFNAVRC
VDAPTPADPAAWVAADQR 94.70% 1.86 0.192 0 0 1 0 2 3,831.84 374 409
SDS
hypo protein 
Rv2223c  Rv2223c 55060 100.00% 3 3 3 0.01% 19.20%
SCREFIADTSEIRTARCATV
SVPVDYDQPGGTQAK 95.00% 1.39 0.381 0 0 1 0 2 3,845.11 57 91
SDS mutA (mutA)  Rv1492 64695 99.70% 2 3 3 0.01% 7.15% RDRPAPPIEEVVAVASR 95.00% 1.51 0.259 0 0 1 0 2 1,863.01 192 208
SDS mutA (mutA)  Rv1492 64695 99.70% 2 3 3 0.01% 7.15%
YRDEVADIVQAARAAGVSR
VYLAGPEK 95.00% 2.39 0.355 0 1 1 0 2 2,906.18 557 583
SDS
moxR 
(moxR)  Rv1479 40744 100.00% 17 20 44 0.17% 57.80%
AVPQQGHSVPPVMQAAAA
ASGR 81.90% 1.66 0.188 0 1 0 0 2 2,147.13 356 377
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% DYVIPQDVIEVIPDVLR 95.00% 3.92 0.466 0 4 0 0 2 1,984.24 306 322
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% GHVLLEGVPGVAK 95.00% 3.73 0.512 2 3 0 0 2 1,276.38 72 84
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% GRDYVIPQDVIEVIPDVLR 95.00% 4.48 0.637 0 3 0 0 2 2,197.49 304 322
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% IIVGQDQLVER 95.00% 2.04 0.174 2 2 0 0 2 1,270.41 53 63
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% IQFTPDLVPTDIIGTR 95.00% 3.13 0.508 0 3 0 0 2 1,787.18 102 117
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% LVLTYDALADEISPEIVINR 95.00% 4.54 0.539 0 2 0 0 2 2,245.72 325 344
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% MLVGLLSK 95.00% 1.17 0.241 3 0 0 0 2 877.2178 64 71
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% QGREEFDTELGPVVAN 95.00% 2.55 0.41 0 1 0 0 2 1,761.76 121 136
SDS
moxR 
(moxR)  Rv1479 40744 100.00% 17 20 44 0.17% 57.80%
SASPAHEAPPGGAEGLAAE
VHTLER 95.00% 2.4 0.436 0 0 1 0 2 2,455.54 21 45
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% SLALVR 95.00% 1.32 0 2 0 0 0 2 658.8484 298 303
SDS
moxR 
(moxR)  Rv1479 40744 100.00% 17 20 44 0.17% 57.80%
TFPMPSPFLVMATQNPIEHE
GVYPLPEAQR 95.00% 2.67 0.475 0 3 2 0 2 3,430.87 169 198
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% TLAVETFAR 95.00% 1.6 0.297 2 0 0 0 2 1,008.15 85 93
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% VLQTVALPQVN 95.00% 1.89 0.188 3 0 0 0 2 1,182.23 345 355
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% VLQTVALPQVNAVPQQGH 95.00% 2.24 0.381 0 2 0 0 2 1,899.85 345 362
SDS
moxR 
(moxR)  Rv1479 40744 100.00% 17 20 44 0.17% 57.80%
VLQTVALPQVNAVPQQGHS
VPPVMQAAAAASGR 95.00% 2.7 0.385 0 0 2 0 2 3,310.34 345 377
SDS moxR Rv1479 40744 100.00% 17 20 44 0.17% 57.80% VQSALLEVMQER 95.00% 3.75 0.445 0 1 0 0 2 1,419.52 150 161
SDS ctaB (ctaB)  Rv1451 33489 100.00% 4 4 6 0.02% 25.00%
QDYQVAGVPMLPAVATERQ
VTKQILIYTWL 95.00% 2.18 0.34 0 0 1 0 2 3,433.93 203 232
SDS ctaB (ctaB)  Rv1451 33489 100.00% 4 4 6 0.02% 25.00% QVTK 88.40% 1.01 0.0243 3 0 0 0 2 475.4884 221 224
SDS ctaB (ctaB)  Rv1451 33489 100.00% 4 4 6 0.02% 25.00%
RRTSQNVVWGGAAGCMPV
MIGWSAITGTIAWPAL 91.00% 1.59 0.273 0 0 1 0 2 3,560.08 147 180
SDS ctaB (ctaB)  Rv1451 33489 100.00% 4 4 6 0.02% 25.00%
TSQNVVWGGAAGCMPVMI
GWSAITGTIAWPALAMFAII
FFWTPPH 95.00% 1.13 0.32 0 0 1 0 2 4,910.76 149 193
SDS accD5 Rv3280 59337 97.10% 2 2 2 0.01% 8.21% DMGCDVNL 86.00% 1.04 0 1 0 0 0 2 866.9384 443 450
SDS
accD5 
(accD5)  Rv3280 59337 97.10% 2 2 2 0.01% 8.21%
GDGVVTGYGTIDGRDVCIF




Rv2864c  Rv2864c 62996 99.70% 2 2 2 0.01% 4.98%
TIPNYGGFDLGVVPMSRAF
ASSCN 95.00% 2.25 0.251 0 0 1 0 2 2,520.85 396 419
SDS
hypo protein 
Rv2864c  Rv2864c 62996 99.70% 2 2 2 0.01% 4.98%
TIPNYGGFDLGVVPMSRAF
ASSCNTTFAEL 95.00% 2.46 0.349 0 0 1 0 2 3,254.71 396 425
SDS
hypo protein 
Rv0892  Rv0892 55021 100.00% 3 3 3 0.01% 9.29%
CPTVAVVGAGMSGMCVAIT
LLSAGITDVCIYEK 95.00% 1.8 0.389 0 0 1 0 2 3,361.85 5 37
SDS
hypo protein 
Rv0892  Rv0892 55021 100.00% 3 3 3 0.01% 9.29%
MTGRCPTVAVVGAGMSGM
CVAITLLSAGITDVCIYEK 92.60% 1.82 0.237 0 0 1 0 2 3,823.40 1 37
SDS
hypo protein 
Rv0892  Rv0892 55021 100.00% 3 3 3 0.01% 9.29%
MTGRCPTVAVVGAGMSGM
CVAITLLSAGITDVCIYEKA
DDVGGTWR 95.00% 1.8 0.419 0 0 1 0 2 4,820.42 1 46
SDS fmu (fmu)  Rv1407 48476 99.60% 2 2 2 0.01% 6.56%
DERSWVGELAPDAQNDPI
GH 93.90% 1.59 0.246 0 0 1 0 2 2,207.27 140 159
SDS fmu (fmu)  Rv1407 48476 99.60% 2 2 2 0.01% 6.56% PVELLRVDGR 95.00% 1.5 0.213 1 0 0 0 2 1,154.33 318 327
SDS fadA (fadA)  Rv0859 42397 99.60% 2 2 3 0.01% 10.40% AAVLASGMPVTSGGVQLNR 94.20% 1.93 0.248 0 1 0 0 2 1,829.00 72 90
SDS fadA (fadA)  Rv0859 42397 99.60% 2 2 3 0.01% 10.40%
IVATATSGADPVIMLTGPTP
ATR 95.00% 4.91 0.423 0 2 0 0 2 2,257.62 286 308
SDS atpG (atpG)  Rv1309 33874 99.30% 2 2 4 0.02% 9.51% LESARPYAFEITR 89.20% 1.45 0.276 0 1 0 0 2 1,553.88 40 52
SDS atpG (atpG)  Rv1309 33874 99.30% 2 2 4 0.02% 9.51% VYAALLESAASELASR 95.00% 3.28 0.351 0 3 0 0 2 1,651.93 242 257
SDS
hypo protein 
Rv3389c  Rv3389c 30278 100.00% 3 3 7 0.03% 15.20% LHAPLPAAGK 95.00% 1.47 0.266 2 0 0 0 2 975.2484 87 96
SDS
hypo protein 
Rv3389c  Rv3389c 30278 100.00% 3 3 7 0.03% 15.20% LSVVTEVADIQDKGEGK 95.00% 3.91 0.488 0 3 0 0 2 1,788.89 97 113
SDS
hypo protein 
Rv3389c  Rv3389c 30278 100.00% 3 3 7 0.03% 15.20% VGTFNPAALLHGSQGIR 95.00% 2.64 0.479 0 2 0 0 2 1,739.00 70 86
SDS
hypo protein 
Rv0194  Rv0194 129234 99.40% 2 2 2 0.01% 1.59% EVPALAGINLR 89.80% 1.12 -0.0759 1 0 0 0 2 1,153.42 955 965
SDS
hypo protein 
Rv0194  Rv0194 129234 99.40% 2 2 2 0.01% 1.59% PPGPDPLR 95.00% 0.793 0.324 1 0 0 0 2 849.0484 610 617
SDS
hypo protein 
Rv2631  Rv2631 27844 98.80% 2 2 2 0.01% 30.60%
PGIVRASYAMPDVHWGYG
FPIGGVAATDVDNDGVVSP
GGVGFDISCGVR 79.70% 0.924 0.348 0 0 1 0 2 4,937.22 18 66
SDS
hypo protein 
Rv2631  Rv2631 27844 98.80% 2 2 2 0.01% 30.60%
QMEQAMGRYGIAVPDRQL
ACVPVHSPDGQAYL 95.00% 1.47 0.446 0 0 1 0 2 3,573.92 218 249
SDS katG (katG)  Rv1908c 80556 100.00% 3 3 4 0.02% 9.59%
DIEEVMTTSQPWWPADYG
HYGPLFIRMAWH 95.00% 1.74 0.266 0 0 1 0 2 3,636.09 79 108
SDS katG (katG)  Rv1908c 80556 100.00% 3 3 4 0.02% 9.59%
SSYGTGTGKDAITSGIEVV
WTN 82.70% 1.35 0.327 0 1 0 0 2 2,244.38 302 323
SDS katG (katG)  Rv1908c 80556 100.00% 3 3 4 0.02% 9.59% TDASQEQTDVESFAVLEPK 95.00% 3.9 0.49 0 2 0 0 2 2,095.10 572 590
SDS
hypo protein 
Rv2623  Rv2623 31633 100.00% 7 7 37 0.15% 30.00%
AGPPTVHSEIVPAAAVPTLV
DMSK 95.00% 5.07 0.651 0 10 0 0 2 2,404.61 86 109
SDS
hypo protein 
Rv2623  Rv2623 31633 100.00% 7 7 37 0.15% 30.00%
AGPPTVHSEIVPAAAVPTLV
DMSKDAVLMVVGCL 95.00% 2.37 0.223 0 0 1 0 2 3,476.83 86 119
SDS
hypo protein 
Rv2623  Rv2623 31633 100.00% 7 7 37 0.15% 30.00%
GGYAGMLVGSVGETVAQLA
R 95.00% 4.07 0.634 0 16 0 0 2 1,953.10 267 286
SDS
hypo protein 
Rv2623  Rv2623 31633 100.00% 7 7 37 0.15% 30.00% HLIDDALK 95.00% 1.52 0.107 4 0 0 0 2 925.1984 70 77
SDS
hypo protein 
Rv2623  Rv2623 31633 100.00% 7 7 37 0.15% 30.00% SEEAQLVVVGSR 95.00% 1.91 0.347 2 0 0 0 2 1,274.22 253 264
SDS
hypo protein 
Rv2623  Rv2623 31633 100.00% 7 7 37 0.15% 30.00% TPVIVAR 95.00% 1.92 0.341 3 0 0 0 2 755.8584 287 293
SDS
hypo protein 
Rv2623  Rv2623 31633 100.00% 7 7 37 0.15% 30.00% YPNVAITR 95.00% 1.42 0.132 1 0 0 0 2 934.0884 231 238
SDS
hypo protein 
Rv2622  Rv2622 29524 99.00% 2 2 2 0.01% 14.70%
VTDAADTGLSDASADVVIG
EAMLTMQGN 95.00% 1.98 0.232 0 0 1 0 2 2,769.94 105 132
SDS
hypo protein 
Rv2622  Rv2622 29524 99.00% 2 2 2 0.01% 14.70% VVTASMALLQPR 83.70% 1.36 0.316 0 1 0 0 2 1,286.52 206 217
SDS
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 3 5 13 0.05% 41.80% DANNYEQQEQASQQILSS 95.00% 3.46 0.497 0 3 0 0 2 2,054.02 81 98
SDS
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 3 5 13 0.05% 41.80% FEVHAQTVEDEAR 95.00% 4.24 0.48 1 5 0 0 2 1,531.42 19 31
SDS
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 3 5 13 0.05% 41.80% NIVNMLHGVR 95.00% 2.45 0.361 2 2 0 0 2 1,153.31 66 75
SDS fbpA (fbpA)  Rv3804c 35668 98.90% 2 2 3 0.01% 9.76% FLEGFVR 81.70% 1.48 0.197 1 0 0 0 2 868.0384 271 277
SDS fbpA (fbpA)  Rv3804c 35668 98.90% 2 2 3 0.01% 9.76% NDPLLNVGK 95.00% 1.62 0.18 2 0 0 0 2 970.1584 234 242
SDS fbpA (fbpA)  Rv3804c 35668 98.90% 2 2 3 0.01% 9.76% PGLPVEYLQVPSPSMGR 95.00% 4.58 0.556 0 12 0 0 2 1,828.10 47 63
SDS
hypo protein 
Rv1907c  Rv1907c 24017 97.30% 2 2 2 0.01% 23.70%
GAEMCWMCDHPEATAEEY
LDEVYGIML 85.30% 1.23 0.255 0 0 1 0 2 3,266.60 56 82
SDS
hypo protein 
Rv1907c  Rv1907c 24017 97.30% 2 2 2 0.01% 23.70%
LAGCWCLPGAICQTPRAW
WSQARR 84.40% 1.87 0.17 0 0 1 0 2 2,732.16 21 44
SDS
hypo protein 
Rv2307c  Rv2307c 29653 99.50% 2 2 2 0.01% 16.40%
ALPVVAIVALVASGVIMFIW
SQQR 95.00% 2.04 0.266 0 0 1 0 2 2,570.02 8 31
SDS
hypo protein 
Rv2307c  Rv2307c 29653 99.50% 2 2 2 0.01% 16.40%
RLIYFPSAGPVPSASSVLPA
GR 92.40% 2.18 0.172 0 0 1 0 2 2,243.70 32 53
SDS
hypo protein 
Rv0148  Rv0148 29760 100.00% 4 4 5 0.02% 28.70% AVANYDSVATEDGAANIIK 95.00% 3.94 0.514 0 2 0 0 2 1,923.09 66 84
SDS
hypo protein 
Rv0148  Rv0148 29760 100.00% 4 4 5 0.02% 28.70% DGTGAGSAMADEVVAEIR 95.00% 1.72 0.349 0 1 0 0 2 1,765.81 43 60
SDS
hypo protein 
Rv0148  Rv0148 29760 100.00% 4 4 5 0.02% 28.70%
EYALTLAGEGASVVVNDLG
GAR 95.00% 2.48 0.362 0 1 0 0 2 2,163.33 21 42
SDS
hypo protein 
Rv0148  Rv0148 29760 100.00% 4 4 5 0.02% 28.70%
VALFGNDGANFDKPPSVQD
VAAR 95.00% 4.59 0.542 0 1 0 0 2 2,389.57 247 269
SDS
hypo protein 
Rv0142  Rv0142 33004 99.70% 2 2 2 0.01% 12.70%
CVAWGSGAEEFVDMAPAM
LGAADDASDFVPL 95.00% 1.4 0.312 0 0 1 0 2 3,247.52 69 99
SDS
hypo protein 
Rv0142  Rv0142 33004 99.70% 2 2 2 0.01% 12.70%
CVAWGSGAEEFVDMAPAM
LGAADDASDFVPLHPAVAA
AH 95.00% 1.64 0.304 0 0 1 0 2 3,915.15 69 107
SDS
hypo protein 
Rv0111  Rv0111 74323 99.80% 2 2 2 0.01% 6.42%
FAARCAATVVLAGASWWLI




Rv0111  Rv0111 74323 99.80% 2 2 2 0.01% 6.42% IVVAGAAVIVVASVAMEQR 91.70% 1.81 0.281 0 1 0 0 2 1,899.97 310 328
SDS
hypo protein 
Rv3874  Rv3874 10776 99.90% 2 2 2 0.01% 28.00% QKQELDEISTNIR 95.00% 3.22 0.503 0 1 0 0 2 1,574.80 65 77
SDS
hypo protein 
Rv3874  Rv3874 10776 99.90% 2 2 2 0.01% 28.00% TDAATLAQEAGNFER 95.00% 4.39 0.564 0 1 0 0 2 1,594.69 6 20
SDS
hypo protein 
Rv3877  Rv3877 53964 99.30% 2 2 2 0.01% 9.39%
VSPVVKRTLELIDGAMIAAI
IPML 91.60% 1.73 0.251 0 1 0 0 2 2,568.34 473 496
SDS
hypo protein 
Rv3877  Rv3877 53964 99.30% 2 2 2 0.01% 9.39%
YAERWCAWALLAATVAIPT
GLTAK 82.00% 1.19 0.226 0 0 1 0 2 2,578.12 414 437
SDS pdhC (pdhC)  Rv2495c 41042 98.80% 2 2 2 0.01% 12.00% LLVIALK 95.00% 1.67 0 1 0 0 0 2 770.1684 225 231
SDS pdhC (pdhC)  Rv2495c 41042 98.80% 2 2 2 0.01% 12.00%
SFPVPDLGEGLQEVTVTCW
SVAVGDDVEINQTLCSVET
AK 80.40% 1.41 0.227 0 0 1 0 2 4,309.38 9 48
SDS nrp (nrp)  Rv0101 269359 100.00% 4 4 4 0.02% 3.90%
AVLTAPAPTPVSIPQMLAAQ
VARIPEAEAVCCGDASMTY
R 93.80% 0.974 0.308 0 0 1 0 2 4,117.63 1482 1521
SDS nrp (nrp)  Rv0101 269359 100.00% 4 4 4 0.02% 3.90% DRGYVKAVR 89.10% 1.62 0.0782 1 0 0 0 2 1,064.19 303 311
SDS nrp (nrp)  Rv0101 269359 100.00% 4 4 4 0.02% 3.90% PIDPANPPPR 95.00% 1.9 0.203 1 0 0 0 2 1,074.30 1571 1580
SDS nrp (nrp)  Rv0101 269359 100.00% 4 4 4 0.02% 3.90%
VMLNAYGPTETTICAAISAP
LRPGSGMPPIGVPVSGAAL 95.00% 1.31 0.445 0 0 1 0 2 3,853.60 1764 1802
SDS
hypo protein 
Rv0831c  Rv0831c 30171 99.70% 2 2 5 0.02% 12.50% FTPGGLVLTEWQGAAVYR 95.00% 3.95 0.594 0 2 0 0 2 1,966.19 163 180
SDS
hypo protein 
Rv0831c  Rv0831c 30171 99.70% 2 2 5 0.02% 12.50% YGPGMGQALDPNYHLR 95.00% 2.78 0.442 0 3 0 0 2 1,790.09 192 207
SDS
hypo protein 
Rv2063c  Rv2063c 12394 98.60% 2 2 2 0.01% 29.50%
DTGTTTTSSSSIPVSSSSTE
TTTAGRCLPGSPAR 81.20% 2.02 0.152 0 0 1 0 2 3,302.48 7 40
SDS
hypo protein 
Rv2063c  Rv2063c 12394 98.60% 2 2 2 0.01% 29.50%
ELDTGTTTTSSSSIPVSSSS
TETTTAGRCL 93.60% 1.62 0.318 0 1 0 0 2 2,979.13 5 34
SDS
hypo protein 
Rv1179c  Rv1179c 100624 99.70% 2 2 3 0.01% 4.90% CGTER 95.00% 0.687 0.32 1 0 0 0 2 565.5684 94 98
SDS
hypo protein 
Rv1179c  Rv1179c 100624 99.70% 2 2 3 0.01% 4.90%
GAVAAVSVVGASTATAVAS
ANLGMLAGAGTAGAIVAAG
VGL 95.00% 2.74 0.305 0 0 2 0 2 3,442.67 718 758
SDS atpD (atpD)  Rv1310 53077 100.00% 11 14 31 0.12% 40.10% DEQGQDVLLFIDNIFR 95.00% 3.21 0.537 0 4 0 0 2 1,923.24 254 269
SDS atpD (atpD)  Rv1310 53077 100.00% 11 14 31 0.12% 40.10% DTALVFGQMDEPPGTR 95.00% 2.02 0.377 0 1 0 0 2 1,750.91 223 238
SDS atpD (atpD)  Rv1310 53077 100.00% 11 14 31 0.12% 40.10%
GDFDHVPEQAFFLIGGLDD
LAK 95.00% 3.63 0.589 0 5 0 0 2 2,405.82 456 477
SDS atpD (atpD)  Rv1310 53077 100.00% 11 14 31 0.12% 40.10%
GIFPAVDPLASSSTILDPSV
VGDEHYR 95.00% 3.67 0.534 0 4 3 0 2 2,844.17 352 378
SDS atpD (atpD)  Rv1310 53077 100.00% 11 14 31 0.12% 40.10% IALFGGAGVGK 95.00% 1.96 0.209 1 0 0 0 2 990.2484 167 177
SDS atpD (atpD)  Rv1310 53077 100.00% 11 14 31 0.12% 40.10% KPPAFEELEPR 95.00% 2.9 0.385 1 1 0 0 2 1,313.56 134 144
SDS atpD (atpD)  Rv1310 53077 100.00% 11 14 31 0.12% 40.10%
MPSAVGYQPTLADEMGELQ
ER 95.00% 3.96 0.529 0 4 0 0 2 2,339.57 284 304
SDS atpD (atpD)  Rv1310 53077 100.00% 11 14 31 0.12% 40.10% NFGGTSVFAGVGER 95.00% 3.32 0.523 0 2 0 0 2 1,398.42 191 204
SDS atpD (atpD)  Rv1310 53077 100.00% 11 14 31 0.12% 40.10%
SITSMQAVYVPADDYTDPA
PATTFAHLDATTELSR 95.00% 4.28 0.544 0 0 1 0 2 3,774.14 312 346
SDS atpD (atpD)  Rv1310 53077 100.00% 11 14 31 0.12% 40.10% VTGPVVDVEFPR 95.00% 3.07 0.522 2 1 0 0 2 1,315.29 26 37
SDS atpD (atpD)  Rv1310 53077 100.00% 11 14 31 0.12% 40.10% VVDLLTPYVR 95.00% 1.37 0.206 1 0 0 0 2 1,175.35 154 163
SDS nuoG (nuoG)  Rv3151 85374 99.70% 2 2 2 0.01% 5.71% HPLDCPMCDK 95.00% 0.819 0.25 1 0 0 0 2 1,246.44 111 120
SDS nuoG (nuoG)  Rv3151 85374 99.70% 2 2 2 0.01% 5.71%
QQVGIYADEPFESYFSGNT
VQICPVGALTGTAYRFR 80.70% 1.97 0.145 0 0 1 0 2 3,987.37 192 227
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% ALELQAPSVVHR 95.00% 2.96 0.395 2 3 0 0 2 1,320.42 131 142
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% AMKEVAGSL 95.00% 1.1 0 2 0 0 0 2 922.0778 385 393
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% ASEEEILTEIR 95.00% 1.62 0.0601 2 1 0 0 2 1,290.48 477 487
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% EAYPGDVFYLHSR 95.00% 3.49 0.56 0 3 0 0 2 1,554.72 295 307
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% ELEAFAAFASDLDAASK 95.00% 1.87 0.281 0 1 0 0 2 1,757.06 402 418
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30%
GFAATGGGSVVPDEHVEAL
DEDKLAK 95.00% 4.36 0.582 0 3 0 0 2 2,613.75 510 535
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% LSDDLGGGSLTGLPIIETK 95.00% 4.01 0.497 0 3 0 0 2 1,887.40 315 333
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% LTEEAADKLTEVIK 95.00% 4.66 0.399 0 3 0 0 2 1,560.85 492 505
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% LVELLK 95.00% 1.9 0.157 3 0 0 0 2 714.9884 427 432
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% QGVKEPLQTGIK 95.00% 1.59 0.287 0 1 0 0 2 1,298.51 143 154
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30%
QPQSQPMPVEEQVVSIFLG
TGGHLDSVPVEDVR 95.00% 3.71 0.572 0 0 3 0 2 3,592.61 433 465
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% RALELQAPSVVHR 95.00% 2.7 0.373 0 1 0 0 2 1,476.62 130 142
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% RTGEVLSVPVGDGFLGR 95.00% 3.89 0.391 0 2 0 0 2 1,759.93 93 109
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% TGEVLSVPVGDGFLGR 95.00% 2.58 0.429 0 2 0 0 2 1,603.73 94 109
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30%
TLEEGGAMDYTTIVAAAAS
ESAGFK 95.00% 4.3 0.644 0 3 0 0 2 2,507.78 222 246
SDS atpA (atpA)  Rv1308 59271 100.00% 16 19 41 0.16% 41.30% VVNPLGQPIDGR 95.00% 3.16 0.406 2 1 0 0 2 1,265.40 110 121
SDS atpF (atpF)  Rv1306 18307 99.70% 2 2 5 0.02% 10.50% AEQQVASTLQTAHEQLK 95.00% 4.07 0.543 0 3 0 0 2 1,882.91 118 134
SDS atpF (atpF)  Rv1306 18307 99.70% 2 2 5 0.02% 10.50% AEQQVASTLQTAHEQLKR 95.00% 2.3 0.497 0 2 0 0 2 2,039.11 118 135
SDS
fadE23 
(fadE23)  Rv3140 43327 100.00% 5 5 7 0.03% 24.40%
GFAGVMETFDNTRPIVAAM
AVGIGRAALEEIR 91.90% 1.9 0.161 0 0 1 0 2 3,364.93 243 274
SDS
fadE23 
(fadE23)  Rv3140 43327 100.00% 5 5 7 0.03% 24.40% ILDIFEGTQQIQQLVVAR 95.00% 2.46 0.235 0 1 0 0 2 2,072.39 373 390
SDS
fadE23 
(fadE23)  Rv3140 43327 100.00% 5 5 7 0.03% 24.40% LLGLSSSELK 89.90% 1.11 0.121 1 0 0 0 2 1,047.41 392 401
SDS
fadE23 
(fadE23)  Rv3140 43327 100.00% 5 5 7 0.03% 24.40%
QAIIVKTHQGAAEMMRPIA
R 95.00% 1.64 0.282 0 0 1 0 2 2,238.68 12 31
SDS
fadE23 
(fadE23)  Rv3140 43327 100.00% 5 5 7 0.03% 24.40% TVELAGTTGYSEQSLLEK 95.00% 3.24 0.517 0 3 0 0 2 1,927.13 349 366
SDS cysA2 Rv0815c,Rv3117 30997 100.00% 7 7 9 0.04% 36.50% AANEDGTFKSDEELAK 95.00% 2.17 0.2 0 1 0 0 2 1,725.89 201 216
SDS cysA2 Rv0815c,Rv3117 30997 100.00% 7 7 9 0.04% 36.50% DFVDAQQFSK 95.00% 2.3 0.399 3 0 0 0 2 1,185.25 58 67
SDS cysA2 Rv0815c,Rv3117 30997 100.00% 7 7 9 0.04% 36.50% ILAPAHLPQEQSQR 95.00% 2.35 0.333 0 1 0 0 2 1,588.80 173 186
SDS cysA2 Rv0815c,Rv3117 30997 100.00% 7 7 9 0.04% 36.50% LYADAGLDNSK 95.00% 1.15 0.27 1 0 0 0 2 1,167.41 217 227
SDS cysA2 Rv0815c,Rv3117 30997 100.00% 7 7 9 0.04% 36.50% NLIDVR 87.30% 1.53 0.105 1 0 0 0 2 729.8884 159 164
SDS
cysA2 
(cysA2)  Rv0815c,Rv3117 30997 100.00% 7 7 9 0.04% 36.50%
NYDGSWTEYGSLVGAPIEL
GS 95.00% 1.87 0.404 0 1 0 0 2 2,216.43 257 277
SDS
cysA2 
(cysA2)  Rv0815c,Rv3117 30997 100.00% 7 7 9 0.04% 36.50%
VVFVEVDEDTSAYDRDHIA
GAIK 88.70% 1.3 0.239 0 0 1 0 2 2,550.67 22 44
SDS
hypo protein 
Rv0712  Rv0712 32693 99.50% 2 2 3 0.01% 16.10%
CPGAMVFCPTAGPVDLRD
WR 92.50% 2.46 0.151 0 2 0 0 2 2,279.56 78 97
SDS
hypo protein 
Rv0712  Rv0712 32693 99.50% 2 2 3 0.01% 16.10%
VDLPGGSFRMGSTRFYPEE
APIHTVTVR 95.00% 1.73 0.248 0 0 1 0 2 3,137.48 6 33
SDS ctpA (ctpA)  Rv0092 78832 100.00% 3 3 3 0.01% 6.70% DRGHVVAMVGDGIN 95.00% 1.26 0.156 1 0 0 0 2 1,440.46 627 640
178
SDS ctpA (ctpA)  Rv0092 78832 100.00% 3 3 3 0.01% 6.70%
HAESLGETAVFVEVDGEPC
GVIAVADAVK 88.10% 1.85 0.242 0 0 1 0 2 2,913.89 541 569
SDS ctpA (ctpA)  Rv0092 78832 100.00% 3 3 3 0.01% 6.70% VEQAQAQK 95.00% 0.932 0.267 1 0 0 0 2 901.8484 341 348
SDS
hypo protein 
Rv0064  Rv0064 107352 100.00% 3 3 3 0.01% 12.30%
GGDAASAPPPGAGGPAPPQ
AVPPPRTTQPPAAPPRGPDV
PPATVAEL 95.00% 1.71 0.317 0 0 1 0 2 4,354.73 907 953
SDS
hypo protein 
Rv0064  Rv0064 107352 100.00% 3 3 3 0.01% 12.30%
VGYAPTLAESLDQVFGPGT
GRVATARGGDAASAPPPGA
GGPAPPQAVPPPR 95.00% 1.3 0.383 0 0 1 0 2 4,806.23 881 931
SDS
hypo protein 
Rv0064  Rv0064 107352 100.00% 3 3 3 0.01% 12.30%
VYYGEVIAQADPDYAIVGG
APGSAPREYDTDTSKYTYT
GAGGVSIGN 79.60% 1.27 0.247 0 0 1 0 2 4,819.18 493 539
SDS
hypo protein 
Rv2488c  Rv2488c 120802 100.00% 2 2 6 0.02% 3.25%
FFGASAAAIINDPTSSAQIS
CARGDLN 95.00% 1.95 0.241 0 0 1 0 2 2,770.22 888 914
SDS
hypo protein 
Rv2488c  Rv2488c 120802 100.00% 2 2 6 0.02% 3.25% LALVTEICHR 95.00% 1.53 0.0362 5 0 0 0 2 1,155.37 414 423
SDS pckA (pckA)  Rv0211 67236 99.90% 2 2 3 0.01% 4.62%
TYICSAKEIDAGPTNNWMD
PGEMRSIMK 95.00% 1.97 0.258 0 0 2 0 2 3,247.86 86 113
SDS pckA (pckA)  Rv0211 67236 99.90% 2 2 3 0.01% 4.62% WMDPGEMR 94.10% 1.09 0.0000118 1 0 0 0 2 1,038.19 102 109
SDS
hypo protein 
Rv1937  Rv1937 93412 99.70% 2 2 2 0.01% 4.89%
GVAIVNECQSGICGTCVAT
CTAGR 95.00% 1.49 0.345 0 0 1 0 2 2,385.43 34 57
SDS
hypo protein 
Rv1937  Rv1937 93412 99.70% 2 2 2 0.01% 4.89%
TMPVRCDQTVLDAAEEHGV
AIVNECQSGICGTCVATCTA
GR 95.00% 1.77 0.254 0 0 1 0 2 4,353.42 17 57
SDS glcB (glcB)  Rv1837c 80386 100.00% 2 2 2 0.01% 2.83% GDLAAAVDKDGTAFLR 95.00% 2.06 0.456 0 1 0 0 2 1,620.91 297 312
SDS glcB (glcB)  Rv1837c 80386 100.00% 2 2 2 0.01% 2.83% NVGHL 95.00% 0.962 0.227 1 0 0 0 2 539.5384 340 344
SDS
hypo protein 
Rv3725  Rv3725 32707 99.50% 2 2 3 0.01% 5.83% MLSTNMAGAQN 95.00% 1.32 0.219 1 0 0 0 2 1,154.31 94 104
SDS
hypo protein 
Rv3725  Rv3725 32707 99.50% 2 2 3 0.01% 5.83% MQNATMR 92.40% 1.57 0.0627 2 0 0 0 2 867.9978 1 7
SDS
hypo protein 
Rv0282  Rv0282 68089 100.00% 3 3 4 0.02% 13.50%
ATGPDDFHLAYAAALASTG
GPEEFAK 95.00% 4.92 0.59 0 2 0 0 2 2,608.95 134 159
SDS
hypo protein 
Rv0282  Rv0282 68089 100.00% 3 3 4 0.02% 13.50%
LGMFAPALSYLEEPDGPVAV
AAVDGALAK 95.00% 1.8 0.364 0 1 0 0 2 2,890.38 226 254
SDS
hypo protein 
Rv0282  Rv0282 68089 100.00% 3 3 4 0.02% 13.50%
MAGVGEGDSGGVERDDIG
MVAASPVASRVN 86.50% 1.45 0.208 0 0 1 0 2 2,920.95 1 30
SDS
hypo protein 
Rv1279  Rv1279 57313 99.70% 2 2 2 0.01% 2.65% GHTH 85.40% 0.668 0.35 1 0 0 0 2 451.3684 509 512
SDS
hypo protein 
Rv1279  Rv1279 57313 99.70% 2 2 2 0.01% 2.65% TLYHPMGTCR 93.10% 0.907 0.0127 1 0 0 0 2 1,195.39 465 474
SDS
hypo protein 
Rv1278  Rv1278 93301 100.00% 3 3 4 0.02% 9.14% EDAVPVLIDDAL 95.00% 0.95 0.216 2 0 0 0 2 1,270.44 815 826
SDS
hypo protein 
Rv1278  Rv1278 93301 100.00% 3 3 4 0.02% 9.14%
GFTDPERLAKMGEVFDTIG
ADGQVIVLTCSPTR 95.00% 1.98 0.257 0 0 1 0 2 3,542.01 827 859
SDS
hypo protein 
Rv1278  Rv1278 93301 100.00% 3 3 4 0.02% 9.14%
PTGEWSAAVSRLAAAEAAV
ADCAAAVAEVDDGVRR 95.00% 1.86 0.249 0 0 1 0 2 3,528.59 191 225
SDS adhD (adhD)  Rv3086 38323 99.70% 2 2 4 0.02% 10.30%
CDMGATILEGCMPDGSFRF
HSQGTDFGAMCMLGTFAE
R 95.00% 1.98 0.196 0 0 3 0 2 4,266.89 105 142
SDS adhD (adhD)  Rv3086 38323 99.70% 2 2 4 0.02% 10.30%
EGCMPDGSFRFHSQGTDF
GAMCMLGTFAER 95.00% 1.66 0.326 0 0 1 0 2 3,303.71 113 142
SDS
hypo protein 
Rv3071  Rv3071 40448 99.70% 2 2 2 0.01% 10.00% EGLPIHR 95.00% 1.03 0.113 1 0 0 0 2 821.9884 260 266
SDS
hypo protein 
Rv3071  Rv3071 40448 99.70% 2 2 2 0.01% 10.00%
SEDPPVTVAAVDIESKIRSL
VDDVTAMTDR 95.00% 1.7 0.289 0 0 1 0 2 3,247.49 66 95
SDS aroG (aroG)  Rv2178c 50623 99.70% 2 2 2 0.01% 7.79%
VEITGENVTECLGGAQDIS
ETDLAGR 95.00% 2.1 0.188 0 1 0 0 2 2,749.88 410 435
SDS aroG (aroG)  Rv2178c 50623 99.70% 2 2 2 0.01% 7.79% VSRMGNHKVR 95.00% 1.17 0.191 1 0 0 0 2 1,200.29 335 344
SDS lpqB (lpqB)  Rv3244c 61133 98.60% 2 2 2 0.01% 7.38%
VTPVPGAFGRMPEQTAAAV
SRSGRQVASVVTL 91.50% 1.71 0.219 0 0 1 0 2 3,241.39 333 364
SDS lpqB (lpqB)  Rv3244c 61133 98.60% 2 2 2 0.01% 7.38% VVFVETRSAEK 86.60% 1.23 0.0248 1 0 0 0 2 1,265.29 93 103
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% ADAVDDEELLELVEMEVR 95.00% 5.15 0.699 0 22 0 0 2 2,076.19 140 157
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% AFDQIDNAPEER 95.00% 3.57 0.406 3 2 0 0 2 1,405.50 48 59
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% EHVLLAR 95.00% 1.55 0.295 5 0 0 0 2 837.9684 120 126
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% ELLAAQEFDEDAPVVR 95.00% 3.57 0.571 3 19 0 0 2 1,802.92 158 173
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% ETDKPFLMPVEDVFTITGR 95.00% 3.44 0.556 0 22 0 0 2 2,212.55 207 225
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% FAIR 95.00% 1.27 0 3 0 0 0 2 506.6984 377 380
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% FPDLNETK 95.00% 1.65 0.151 2 0 0 0 2 964.1384 40 47
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% GITINIAHVEYQTDKR 95.00% 3.58 0.583 0 9 0 0 2 1,859.12 62 77
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70%
GQVVTKPGTTTPHTEFEGQ
VYILSK 95.00% 3.53 0.57 0 2 1 0 2 2,718.90 292 316
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% GVINVNEEVEIVGIRPSTTK 95.00% 4.31 0.672 0 14 0 0 2 2,155.30 236 255
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% HTPFFNNYR 95.00% 1.16 0.112 2 0 0 0 2 1,196.34 322 330
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% HYAHVDAPGHADYIK 95.00% 4.43 0.57 1 5 0 0 2 1,694.80 78 92
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% IAHVEYQTDKR 95.00% 3.22 0.493 0 5 0 0 2 1,360.47 67 77
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% IGTIGHVDHGK 95.00% 1.68 0.22 1 0 0 0 2 1,134.24 15 25
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% LIQPVAMDEGLR 95.00% 3.01 0.49 4 9 0 0 2 1,342.64 365 376
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70%
NMITGAAQMDGAILVVAAT
DGPMPQTR 95.00% 2.02 0.522 0 8 0 0 2 2,763.15 93 119
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% PQFYFR 95.00% 1.87 0.348 3 1 0 0 2 858.0384 331 336
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70%
TTDVTGVVTLPEGTEMVMP
GDNTN 95.00% 1.86 0.272 0 1 0 0 2 2,479.49 337 360
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70%
TTDVTGVVTLPEGTEMVMP
GDNTNISVK 95.00% 3.07 0.478 0 15 0 0 2 2,907.04 337 364
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70% TTVTGVEMFR 95.00% 1.52 0.234 1 0 0 0 2 1,141.21 256 265
SDS tuf (tuf)  Rv0685 43543 100.00% 21 27 179 0.70% 71.70%
WVASVEELMNAVDESIPDP
VR 95.00% 5.04 0.563 0 16 0 0 2 2,373.46 186 206
SDS fusA (fusA)  Rv0684 77153 100.00% 9 10 18 0.07% 24.00%
DTTTGDTLSDPNQQIVLES
MTFPDPVIEVAIEPK 95.00% 3.06 0.426 0 0 2 0 2 3,719.10 387 420
SDS fusA (fusA)  Rv0684 77153 100.00% 9 10 18 0.07% 24.00%
EYIPSVDAGAQDAMQYGVL
AGYPLVNLK 95.00% 3.47 0.638 0 3 0 0 2 3,000.42 544 571
SDS fusA (fusA)  Rv0684 77153 100.00% 9 10 18 0.07% 24.00% ILYYTGINYK 95.00% 1.59 0.264 2 0 0 0 2 1,248.67 33 42
SDS fusA (fusA)  Rv0684 77153 100.00% 9 10 18 0.07% 24.00% LAEEDPTFK 95.00% 1.63 0.12 1 0 0 0 2 1,050.22 435 443
SDS fusA (fusA)  Rv0684 77153 100.00% 9 10 18 0.07% 24.00%
LGETYDTVEIPADLAEQAEE
YR 95.00% 3.39 0.556 0 2 0 0 2 2,513.70 195 216
SDS fusA (fusA)  Rv0684 77153 100.00% 9 10 18 0.07% 24.00% VIINLEPFTGEEGATYEFESK 95.00% 4.47 0.637 0 2 0 0 2 2,374.67 515 535
SDS fusA (fusA)  Rv0684 77153 100.00% 9 10 18 0.07% 24.00% VLDGAVAVFDGK 95.00% 2.28 0.249 2 0 0 0 2 1,191.29 101 112
SDS fusA (fusA)  Rv0684 77153 100.00% 9 10 18 0.07% 24.00% VTLLDGAYHEVDSSEMAFK 95.00% 3.58 0.516 0 2 0 0 2 2,129.33 572 590




(echA4)  Rv0673 33523 99.50% 2 2 2 0.01% 13.10%
LFTGDCITGAQAAEWGLAV
EAPEPADLDER 92.30% 1.9 0.198 0 0 1 0 2 3,218.54 198 227
SDS echA4 Rv0673 33523 99.50% 2 2 2 0.01% 13.10% MVSTVFDGAAR 95.00% 0.867 0.0533 1 0 0 0 2 1,154.25 264 274
SDS pks5 (pks5)  Rv1527c 223837 99.50% 2 2 2 0.01% 0.66% DLLRDMGIEH 92.50% 1.14 0.192 1 0 0 0 2 1,215.47 1597 1606
SDS pks5 (pks5)  Rv1527c 223837 99.50% 2 2 2 0.01% 0.66% MCDK 95.00% 1.02 0.165 1 0 0 0 2 496.6184 2094 2097
SDS
hypo protein 
Rv0622  Rv0622 36094 99.20% 2 2 2 0.01% 9.38%
CTGSDDAAMSFCVYCGAEL
ADPTR 86.00% 1.12 0.306 0 0 1 0 2 2,555.77 19 42
SDS
hypo protein 
Rv0622  Rv0622 36094 99.20% 2 2 2 0.01% 9.38%
CTGSDDAAMSFCVYCGAEL
ADPTRCGACGAYK 95.00% 2.23 0.274 0 0 1 0 2 3,467.78 19 50
SDS
mmpL12 
(mmpL12)  Rv1522c 122384 99.40% 2 2 2 0.01% 5.24%
DADKPSMAGFNIPPQIFSR
DEFKK 92.60% 2.2 0.206 0 0 1 0 2 2,756.35 728 751
SDS
mmpL12 
(mmpL12)  Rv1522c 122384 99.40% 2 2 2 0.01% 5.24%
DESPHGIRIGVIRTVGSTG
GVITSAGLIFAASMFGL 93.00% 1.8 0.255 0 0 1 0 2 3,589.26 908 943
SDS adi (adi)  Rv2531c 106013 99.40% 2 2 2 0.01% 4.54% RYATPFFDALR 95.00% 1.34 0.121 1 0 0 0 2 1,357.70 287 297
SDS adi (adi)  Rv2531c 106013 99.40% 2 2 2 0.01% 4.54%
TLVSTTFVVPYPPGFPVLVP
GQLVSKEIIYFL 89.40% 1.09 0.314 0 0 1 0 2 3,523.20 845 876
SDS
hypo protein 
Rv1866  Rv1866 83165 99.60% 2 2 2 0.01% 5.91% ERVMFGPAVTA 93.70% 1.3 0.0494 1 0 0 0 2 1,178.29 768 778
SDS
hypo protein 
Rv1866  Rv1866 83165 99.60% 2 2 2 0.01% 5.91%
SELVAAVSAWTSTRTPVQA
AGALQAAGVAAGPMNR 95.00% 2.12 0.266 0 0 1 0 2 3,411.63 658 692
SDS rpsA (rpsA)  Rv1630 53184 100.00% 5 5 10 0.04% 16.40%
HDVDPNEVVSVGDEVEALV
LTK 95.00% 3.36 0.525 0 4 0 0 2 2,365.27 72 93
SDS rpsA (rpsA)  Rv1630 53184 100.00% 5 5 10 0.04% 16.40% HVEVPDQVVAVGDDAMVK 95.00% 4.56 0.602 0 2 0 0 2 1,924.77 330 347
SDS rpsA (rpsA)  Rv1630 53184 100.00% 5 5 10 0.04% 16.40% SEFLNNLQK 95.00% 1.26 0.192 1 0 0 0 2 1,093.30 200 208
SDS rpsA (rpsA)  Rv1630 53184 100.00% 5 5 10 0.04% 16.40% TAGGSLASDAQLAALR 95.00% 3.48 0.406 0 2 0 0 2 1,502.78 459 474
SDS rpsA (rpsA)  Rv1630 53184 100.00% 5 5 10 0.04% 16.40% YFNDGDIVEGTIVK 95.00% 2.6 0.485 0 1 0 0 2 1,570.76 32 45
SDS pks12 Rv2048c 431553 100.00% 4 4 4 0.02% 2.96% DIMITLGMFTH 95.00% 1.01 0.204 1 0 0 0 2 1,295.67 1401 1411
SDS
pks12 
(pks12)  Rv2048c 431553 100.00% 4 4 4 0.02% 2.96%
LLLPMPADWSYAEAAAISA
VFTTAYYAFIHL 92.50% 2.13 0.181 0 0 1 0 2 3,419.23 1457 1487
SDS
pks12 
(pks12)  Rv2048c 431553 100.00% 4 4 4 0.02% 2.96%
SSEPIAIVGMSCRFPGGVD
SPEGLWQMVADARDVMSE
FPTDR 95.00% 1.22 0.296 0 0 1 0 2 4,646.10 33 74
SDS
pks12 
(pks12)  Rv2048c 431553 100.00% 4 4 4 0.02% 2.96%
TPAVRTTSEDPIAIVGMACR
YPGGVNSPDDMWDMLIQG
R 95.00% 1.69 0.319 0 0 1 0 2 4,238.81 2048 2086
SDS
mmpL11 
(mmpL11)  Rv0202c 103485 99.70% 2 2 4 0.02% 2.90% MMRLSR 95.00% 1.62 0.0863 1 0 0 0 2 810.0978 1 6
SDS
mmpL11 
(mmpL11)  Rv0202c 103485 99.70% 2 2 4 0.02% 2.90%
TQLPRVAGAAQVDVGGPTA
LIK 95.00% 1.87 0.276 0 3 0 0 2 2,163.44 497 518
SDS
hypo protein 
Rv1815  Rv1815 22768 99.00% 2 2 3 0.01% 26.70%
FGVSTGETCGTVESVNNG
WFTMSHGVLSEK 95.00% 2.3 0.415 0 0 2 0 2 3,249.25 140 169
SDS
hypo protein 
Rv1815  Rv1815 22768 99.00% 2 2 3 0.01% 26.70%
SVWGGFPAAVSWRSTSEQ
VHADLGVTPLA 83.70% 1.79 0.221 0 0 1 0 2 3,027.13 193 221
SDS linB (linB)  Rv2579 33710 100.00% 3 3 6 0.02% 14.70% NLPIDGEPAEVVALVNEYR 95.00% 4.22 0.631 0 4 0 0 2 2,099.28 211 229
SDS linB (linB)  Rv2579 33710 100.00% 3 3 6 0.02% 14.70% SPQGEPMALEHNIFVER 95.00% 2.43 0.369 0 1 0 0 2 1,971.14 157 173
SDS linB (linB)  Rv2579 33710 100.00% 3 3 6 0.02% 14.70% VLPGAILR 95.00% 1.07 0.1 1 0 0 0 2 839.1384 174 181
SDS
hypo protein 
Rv3903c  Rv3903c 88316 99.40% 2 2 2 0.01% 6.86%
LRAAAVAWRSAGTQFALTEI
QSTAGPMGVIR 89.30% 2 0.203 0 0 1 0 2 3,247.75 151 181
SDS
hypo protein 
Rv3903c  Rv3903c 88316 99.40% 2 2 2 0.01% 6.86%
SNPVGVVIDGTGQQLKGFG
EEAFGMAK 95.00% 1.7 0.269 0 0 1 0 2 2,737.99 312 338
SDS
hypo protein 
Rv1165  Rv1165 67530 99.30% 2 2 2 0.01% 2.71% AGKVGGHKLTAR 95.00% 1.12 0.0659 1 0 0 0 2 1,195.40 339 350
SDS
hypo protein 
Rv1165  Rv1165 67530 99.30% 2 2 2 0.01% 2.71% GITIL 89.10% 0.864 0.117 1 0 0 0 2 516.7684 51 55
SDS narG (narG)  Rv1161 136906 99.90% 3 3 4 0.02% 3.25%
AVNGDRSAELVTLPSFDTID
GH 90.20% 1.91 0.263 0 1 0 0 2 2,315.50 429 450
SDS narG (narG)  Rv1161 136906 99.90% 3 3 4 0.02% 3.25% IMSIDFR 84.60% 0.895 0.123 1 0 0 0 2 898.1978 765 771
SDS narG (narG)  Rv1161 136906 99.90% 3 3 4 0.02% 3.25% TPDAHWMAEAR 95.00% 1.67 0.172 2 0 0 0 2 1,301.38 272 282
SDS
hypo protein 
Rv0327c  Rv0327c 49994 99.70% 2 2 3 0.01% 9.13%
APEIQSQVVWAAVGGDDG
FLEAVLKEGMRR 95.00% 2.06 0.286 0 0 2 0 2 3,246.52 281 310
SDS
hypo protein 
Rv0327c  Rv0327c 49994 99.70% 2 2 3 0.01% 9.13% NITTVPKHGAH 95.00% 1.28 0.0985 1 0 0 0 2 1,175.24 421 431
SDS groES Rv3418c 10754 100.00% 6 6 9 0.04% 71.00% DVLAVVSK 95.00% 1.34 0.282 1 0 0 0 2 830.8884 93 100
SDS groES Rv3418c 10754 100.00% 6 6 9 0.04% 71.00% EKPQEGTVVAVGPGR 95.00% 2.89 0.443 0 1 0 0 2 1,524.50 36 50
SDS
groES 
(groES)  Rv3418c 10754 100.00% 6 6 9 0.04% 71.00%
ILVQANEAETTTASGLVIPDT
AK 95.00% 3.2 0.485 0 4 0 0 2 2,343.63 13 35
SDS groES Rv3418c 10754 100.00% 6 6 9 0.04% 71.00% IPLDVAEGDTVIYSK 95.00% 4.46 0.515 0 1 0 0 2 1,620.89 59 73
SDS groES Rv3418c 10754 100.00% 6 6 9 0.04% 71.00% RIPLDVAEGDTVIYSK 95.00% 3.96 0.591 0 1 0 0 2 1,777.09 58 73
SDS groES Rv3418c 10754 100.00% 6 6 9 0.04% 71.00% VNIKPLEDK 94.30% 1.51 0.0813 1 0 0 0 2 1,056.31 4 12
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60% AADAVSEALLASATPVSGK 95.00% 3.16 0.447 1 2 0 0 2 1,758.95 122 140
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60%
AAVEEGIVPGGGASLIHQA
R 95.00% 3.88 0.578 0 5 0 0 2 1,933.08 403 422
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60% AEIDKSDSDWDREK 95.00% 2.73 0.381 0 1 0 0 2 1,694.86 349 362
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60% AFGGPTVTNDGVTVAR 95.00% 2.64 0.462 0 4 0 0 2 1,562.56 42 57
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60%
AFLEDLAVVTGGQVVNPDA
GMVLR 95.00% 4.99 0.605 0 7 0 0 2 2,472.68 285 308
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60% DEQIGDLVGEAMSK 95.00% 3.22 0.498 0 3 0 0 2 1,508.65 153 166
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60% EIELEDPFEDLGAQLVK 95.00% 3.55 0.476 0 7 0 0 2 1,946.24 58 74
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60% EVGLEVLGSAR 95.00% 1.74 0.276 2 0 0 0 2 1,130.22 309 319
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60% LVAAGVNPIALGVGIGK 95.00% 4.69 0.624 1 3 0 0 2 1,549.89 105 121
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60% PDLLPLLEK 95.00% 1.59 0.285 1 0 0 0 2 1,038.46 229 237
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60%
RVVVSKDDTVIVDGGGTAE
AVAN 95.00% 2.1 0.277 0 2 0 0 2 2,273.21 320 342
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60% TGIAQVATVSSR 95.00% 3.03 0.601 0 1 0 0 2 1,190.23 141 152
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60%
TGIAQVATVSSRDEQIGDL
VGEAMSK 95.00% 3.89 0.561 0 2 0 0 2 2,663.86 141 166
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60% TLSYGDLAADGVIDPVK 95.00% 3.18 0.579 0 2 0 0 2 1,735.02 482 498
SDS
groEL1 
(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60%
TNDVAGDGTTTATILAQALI




(groEL1)  Rv3417c 55859 100.00% 16 18 57 0.22% 43.60%
VVVSKDDTVIVDGGGTAEA
VANR 95.00% 3.3 0.46 0 2 0 0 2 2,273.21 321 343
SDS
hypo protein 
Rv0540  Rv0540 22922 99.30% 2 2 2 0.01% 18.20% DCCAPGSR 90.60% 1.19 0.0403 1 0 0 0 2 808.8484 203 210
SDS
hypo protein 
Rv0540  Rv0540 22922 99.30% 2 2 2 0.01% 18.20%
DTLDAVAAAPVTARAVALTG
DLDSAADSAEIR 93.80% 1.2 0.281 0 0 1 0 2 3,128.46 43 74
SDS
hypo protein 
Rv1330c  Rv1330c 54284 99.80% 2 2 2 0.01% 3.73% LVEVDGVPVQK 87.20% 1.48 0.153 1 0 0 0 2 1,183.17 403 413
SDS
hypo protein 
Rv1330c  Rv1330c 54284 99.80% 2 2 2 0.01% 3.73% MVSAAGGR 94.60% 0.989 0.236 1 0 0 0 2 764.8278 217 224
SDS
mmpL2 
(mmpL2)  Rv0507 106188 99.50% 2 2 2 0.01% 5.06% GTPLQGAAIYLGGTAATFK 95.00% 1.42 0.417 0 1 0 0 2 1,838.26 737 755
SDS
mmpL2 
(mmpL2)  Rv0507 106188 99.50% 2 2 2 0.01% 5.06%
PLGTTIKHTSIPFIISMQGV
NSSEQMEFMK 92.10% 1.23 0.265 0 0 1 0 2 3,386.05 476 505
SDS fas (fas)  Rv2524c 326201 99.90% 2 2 2 0.01% 1.27% LLATYSELRSR 95.00% 1.53 0.267 1 0 0 0 2 1,309.66 584 594
SDS fas (fas)  Rv2524c 326201 99.90% 2 2 2 0.01% 1.27%
RDEIIAAMAKTAKPYFGDVA
DMTYLQWL 95.00% 1.15 0.331 0 0 1 0 2 3,235.96 713 740
SDS fbpB (fbpB)  Rv1886c 34564 100.00% 3 3 16 0.06% 15.10% AADMWGPSSDPAWER 95.00% 3.12 0.371 0 2 0 0 2 1,676.81 216 230
SDS fbpB (fbpB)  Rv1886c 34564 100.00% 3 3 16 0.06% 15.10% PGLPVEYLQVPSPSMGR 95.00% 4.58 0.556 0 12 0 0 2 1,828.10 44 60
SDS fbpB (fbpB)  Rv1886c 34564 100.00% 3 3 16 0.06% 15.10% WETFLTSELPQWLSANR 95.00% 2.42 0.497 0 2 0 0 2 2,079.38 137 153
SDS
hypo protein 
Rv1273c  Rv1273c 62098 100.00% 3 3 8 0.03% 16.30%
FSGTVADNLRYGGGPDQV
VTEQEMWEALR 95.00% 2.05 0.35 0 0 6 0 2 3,243.39 422 450
SDS
hypo protein 
Rv1273c  Rv1273c 62098 100.00% 3 3 8 0.03% 16.30%
IDSGQMQVGSLIAFLSYFA
QILMAVLMATMTL 95.00% 1.82 0.196 0 0 1 0 2 3,466.42 264 295
SDS
hypo protein 
Rv1273c  Rv1273c 62098 100.00% 3 3 8 0.03% 16.30%
QILFLVQMTATVLVTAPIMC
VGGIIMAIHQEAAL 95.00% 1.15 0.318 0 0 1 0 2 3,614.42 124 157
SDS
hypo protein 
Rv1794  Rv1794 32381 99.70% 2 2 6 0.02% 10.30% LLYGVIDDENQPPGSR 95.00% 3.32 0.398 0 3 0 0 2 1,774.01 94 109
SDS
hypo protein 
Rv1794  Rv1794 32381 99.70% 2 2 6 0.02% 10.30% VLAAPDLEVVALLSR 95.00% 2.64 0.429 0 3 0 0 2 1,566.87 77 91
SDS
hypo protein 
Rv3786c  Rv3786c 44927 99.50% 2 2 3 0.01% 7.13%
MADFCRPDWVMMVDADW
LVETDIDLR 91.90% 2.11 0.204 0 0 2 0 2 3,247.69 80 105
SDS
hypo protein 
Rv3786c  Rv3786c 44927 99.50% 2 2 3 0.01% 7.13%
MADFCRPDWVMMVDADW
LVETDIDLRAVL 95.00% 1.67 0.338 0 0 1 0 2 3,427.96 80 108
TX114 lprA (lprA)  Rv1270c 24856 99.70% 2 4 8 0.09% 11.50% ITGNSSADDIATLAGSR 95.00% 3.96 0.556 1 4 0 0 2 1,649.90 175 191
TX114 lprA (lprA)  Rv1270c 24856 99.70% 2 4 8 0.09% 11.50% LAVTGDVPNLR 95.00% 2.36 0.316 2 1 0 0 2 1,155.31 67 77
TX114
hypo protein 
Rv3534c  Rv3534c 36425 99.70% 2 2 2 0.02% 9.54% EARDNGGSICRIATH 95.00% 1.42 0.234 0 1 0 0 2 1,600.76 99 113
TX114
hypo protein 
Rv3534c  Rv3534c 36425 99.70% 2 2 2 0.02% 9.54% KLIGGQEDQLIDIALEIK 95.00% 1.55 0.301 0 1 0 0 2 1,997.60 318 335
TX114
hypo protein 
Rv3786c  Rv3786c 44927 99.60% 2 2 3 0.04% 13.00%
MADFCRPDWVMMVDADW
LVETDIDLR 95.00% 1.42 0.29 0 0 2 0 2 3,247.69 80 105
TX114
hypo protein 
Rv3786c  Rv3786c 44927 99.60% 2 2 3 0.04% 13.00%
MCPMVSRWDDPEYPDLIPV
MGTAEALR 93.30% 1.24 0.222 0 0 1 0 2 3,213.70 119 145
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20%
AAVEEGIVAGGGVTLLQAA
PTLDELK 95.00% 3.21 0.448 0 2 0 0 2 2,523.85 403 428
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% ASVPGGGDMGGMDF 95.00% 1.52 0.305 1 0 0 0 2 1,298.42 527 540
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% AVEKVTETLLK 95.00% 1.45 0.254 1 0 0 0 2 1,231.44 122 132
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% DETTIVEGAGDTDAIAGR 95.00% 2.76 0.321 0 1 0 0 2 1,791.88 326 343
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% DLLPLLEK 95.00% 1.89 0.349 2 0 0 0 2 941.3384 230 237
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% EIELEDPYEK 95.00% 2.65 0.353 1 0 0 0 2 1,265.44 58 67
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20%
EQIAATAAISAGDQSIGDLI
AEAMDK 95.00% 3.09 0.591 0 1 0 0 2 2,607.04 141 166
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% GLNALADAVK 95.00% 1.31 0.352 3 0 0 0 2 972.1784 18 27
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20%
KTDDVAGDGTTTATVLAQA
LVR 95.00% 5.59 0.62 0 4 0 0 2 2,204.35 79 100
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20%
KVVVTKDETTIVEGAGDTD
AIAGR 95.00% 6.6 0.69 0 4 0 0 2 2,446.59 320 343
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% KWGAPTITNDGVSIAK 95.00% 2.39 0.318 0 1 0 0 2 1,658.95 42 57
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% LAGGVAVIK 95.00% 1.44 0.197 1 0 0 0 2 828.0184 370 378
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% NVAAGANPLGLK 95.00% 2.21 0.302 1 0 0 0 2 1,125.35 105 116
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% QEAVLEDPYILLVSSK 95.00% 3.71 0.507 0 1 0 0 2 1,805.12 209 224
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% QIAFNSGLEPGVVAEK 95.00% 3.72 0.611 0 3 0 0 2 1,659.82 450 465
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20%
TDDVAGDGTTTATVLAQAL
VR 95.00% 4.17 0.507 0 2 0 0 2 2,076.15 80 100
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% VALEAPLK 95.00% 1.74 0.237 1 0 0 0 2 841.0684 442 449
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20%
VVVTKDETTIVEGAGDTDAI
AGR 95.00% 4.86 0.639 0 1 0 0 2 2,318.39 321 343
TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 19 19 33 0.39% 42.20% WGAPTITNDGVSIAK 95.00% 3.38 0.613 0 2 0 0 2 1,530.75 43 57
TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 6 8 15 0.18% 29.10% AAEGYLEAATSR 95.00% 2.31 0.467 0 1 0 0 2 1,239.37 83 94
TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 6 8 15 0.18% 29.10%
AEGYVDQAVELTQEALGTV
ASQTR 95.00% 6.5 0.559 0 4 1 0 2 2,537.53 122 145
TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 6 8 15 0.18% 29.10% KAAEGYLEAATSR 95.00% 2.65 0.566 0 1 0 0 2 1,367.57 82 94
TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 6 8 15 0.18% 29.10% LQEDLPEQLTELR 95.00% 4.34 0.601 1 4 0 0 2 1,584.84 60 72
TX114
hypo protein 




Rv0475  Rv0475 21517 100.00% 6 8 15 0.18% 29.10% PEQLTELR 95.00% 1.38 0.167 1 0 0 0 2 986.1384 65 72
TX114 hspX (hspX)  Rv2031c 16210 99.90% 2 2 7 0.08% 18.80% AELPGVDPDKDVDIMVR 95.00% 2.74 0.471 0 4 0 0 2 1,886.10 55 71
TX114 hspX (hspX)  Rv2031c 16210 99.90% 2 2 7 0.08% 18.80% SEFAYGSFVR 95.00% 1.41 0.271 3 0 0 0 2 1,163.28 91 100
TX114
hypo protein 
Rv1393c  Rv1393c 55234 100.00% 3 3 3 0.04% 15.20% IPGGKAVHR 95.00% 0.832 0.253 1 0 0 0 2 935.0884 224 232
TX114
hypo protein 
Rv1393c  Rv1393c 55234 100.00% 3 3 3 0.04% 15.20%
TGKRVGIIGTGASAVQVIPE
MAPIVSHLTVFQR 95.00% 1.88 0.273 0 0 1 0 2 3,434.91 169 201
TX114
hypo protein 
Rv1393c  Rv1393c 55234 100.00% 3 3 3 0.04% 15.20%
VTEPIDKITPTAVATTDGAS
HEIDVLVLATGFK 95.00% 1.75 0.202 0 0 1 0 2 3,411.84 309 341
TX114 sodC (sodC)  Rv0432 23826 100.00% 4 4 13 0.15% 27.50%
GDGSAMLVTTTDAFTMDDL
LSGAK 95.00% 4.13 0.603 0 7 0 0 2 2,434.84 166 189
TX114 sodC (sodC)  Rv0432 23826 100.00% 4 4 13 0.15% 27.50% TAIIIHAGADNFANIPPER 95.00% 4.51 0.687 0 4 0 0 2 2,021.43 190 208
TX114 sodC (sodC)  Rv0432 23826 100.00% 4 4 13 0.15% 27.50%
YVQVNGTPGPDETTLTTGD
AGK 95.00% 5.63 0.631 0 1 0 0 2 2,222.28 209 230
TX114 sodC (sodC)  Rv0432 23826 100.00% 4 4 13 0.15% 27.50%
YVQVNGTPGPDETTLTTGD
AGKR 95.00% 2.53 0.368 0 1 0 0 2 2,378.48 209 231
TX114 lppX (lppX)  Rv2945c 24122 100.00% 4 4 5 0.06% 29.60% ASIDLGSGSIQLTQSK 95.00% 3.66 0.625 0 1 0 0 2 1,605.92 210 225
TX114 lppX (lppX)  Rv2945c 24122 100.00% 4 4 5 0.06% 29.60% LFDDWSNLGSISELSTSR 95.00% 3.39 0.474 0 2 0 0 2 2,028.37 122 139
TX114 lppX (lppX)  Rv2945c 24122 100.00% 4 4 5 0.06% 29.60% PATVWIAQDGSHHLVR 95.00% 4.85 0.512 0 1 0 0 2 1,787.87 194 209
TX114 lppX (lppX)  Rv2945c 24122 100.00% 4 4 5 0.06% 29.60% TTGKVDSLLGITSADVDVR 95.00% 2.6 0.292 0 1 0 0 2 1,948.17 73 91
TX114 cdsA (cdsA)  Rv2881c 31985 99.50% 2 2 2 0.02% 21.90%
HPMVPTISPKKSWEGFAGS
LVCGITATIITATFL 90.70% 1.08 0.258 0 0 1 0 2 3,647.43 203 236
TX114 cdsA (cdsA)  Rv2881c 31985 99.50% 2 2 2 0.02% 21.90%
IGGQAAVWLTWPFGAVGAL
AGFGGMVVVCMIWR 95.00% 1.9 0.137 0 0 1 0 2 3,438.94 92 124
TX114
hypo protein 
Rv3894c  Rv3894c 153685 99.70% 2 2 3 0.04% 3.08% DVKLMVVTRN 95.00% 1.23 0.0884 1 0 0 0 2 1,191.33 248 257
TX114
hypo protein 
Rv3894c  Rv3894c 153685 99.70% 2 2 3 0.04% 3.08%
GKRGAWTPPTVASPTAMGS
ALETGQVGVDLGPH 95.00% 1.82 0.24 0 0 2 0 2 3,247.49 304 336
TX114 pks2 (pks2)  Rv3825c 225737 99.70% 2 2 2 0.02% 2.40%
NSRTQPTQKMRETIEAIAA
MGSEVVVECGDIAQPGTAE
R 95.00% 2.52 0.349 0 0 1 0 2 4,192.48 1802 1840
TX114 pks2 (pks2)  Rv3825c 225737 99.70% 2 2 2 0.02% 2.40% SPGGSTVAVHPL 95.00% 1.27 0.313 1 0 0 0 2 1,122.14 905 916
TX114
mmpL8 
(mmpL8)  Rv3823c 115984 100.00% 3 3 3 0.04% 8.26%
DTATTPAMAGFYIPPELLSYA
TGESVKAETMPSEYR 90.70% 1.31 0.258 0 0 1 0 2 3,929.51 750 785
TX114
mmpL8 
(mmpL8)  Rv3823c 115984 100.00% 3 3 3 0.04% 8.26%
GDTIDADASFVANNTEWAS
PVLGALDSSPMCTADPACA
SAR 91.90% 1.3 0.21 0 0 1 0 2 4,187.52 596 636
TX114
mmpL8 
(mmpL8)  Rv3823c 115984 100.00% 3 3 3 0.04% 8.26% MGFGLGEASAFLL 83.30% 1.57 0.033 1 0 0 0 2 1,329.71 734 746
TX114 bioB (bioB)  Rv1589 37500 99.70% 2 2 2 0.02% 9.46%
MRWCGPEVEVEGIISLKTG
GCPEDCHFCSQSGL 95.00% 2.49 0.24 0 0 1 0 2 3,783.12 65 97
TX114 bioB (bioB)  Rv1589 37500 99.70% 2 2 2 0.02% 9.46% TGGCPEDCH 95.00% 1.05 0.193 1 0 0 0 2 1,060.99 82 90
TX114
hypo protein 
Rv1520  Rv1520 39528 99.80% 2 2 4 0.05% 11.30%
HVRHAVGGEIAMLPETMAV
YR 81.60% 1.32 0.244 0 1 0 0 2 2,370.59 181 201
TX114
hypo protein 
Rv1520  Rv1520 39528 99.80% 2 2 4 0.05% 11.30% QPSYDDIPANVMPIDWYLH 95.00% 2.04 0.21 0 3 0 0 2 2,275.61 163 181
TX114 fixB (fixB)  Rv3028c 31672 99.70% 2 2 2 0.02% 16.70%
AGAVEAEPAAGAGEQVSVE
VPAAAENAAR 95.00% 3.4 0.549 0 1 0 0 2 2,693.55 152 180
TX114 fixB (fixB)  Rv3028c 31672 99.70% 2 2 2 0.02% 16.70%
ALGEPAAVVVGVPGTAAPLV
DGLK 95.00% 3.66 0.585 0 1 0 0 2 2,202.43 28 51
TX114 phoS1 Rv0934 38194 100.00% 5 7 17 0.20% 26.50% ASFLDQVHFQPLPPAVVK 95.00% 4.11 0.616 0 6 0 0 2 1,994.23 346 363
TX114 phoS1 Rv0934 38194 100.00% 5 7 17 0.20% 26.50% SDGSGDTFLFTQYLSK 95.00% 3.54 0.521 1 5 0 0 2 1,767.06 186 201
TX114
phoS1 
(phoS1)  Rv0934 38194 100.00% 5 7 17 0.20% 26.50%
SSGNFLLPDAQSIQAAAAG
FASK 95.00% 3.17 0.433 0 1 0 0 2 2,252.64 269 291
TX114
phoS1 
(phoS1)  Rv0934 38194 100.00% 5 7 17 0.20% 26.50%
TPANQAISMIDGPAPDGYPI
INYEYAIVNNR 95.00% 5.02 0.637 0 2 1 0 2 3,395.97 292 322
TX114 phoS1 Rv0934 38194 100.00% 5 7 17 0.20% 26.50% VLAAMYQGTIK 88.90% 1.31 0 1 0 0 0 2 1,195.50 149 159
TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 10 10 61 0.72% 61.10%
ATEYNNAAEAFAAQLVTAE
QSVEDLK 95.00% 4.2 0.567 0 4 0 0 2 2,784.90 95 120
TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 10 10 61 0.72% 61.10%
GEALPAGGTTATPRPATETS
GGAIAEQPYGQ 95.00% 2.55 0.545 0 7 0 0 2 2,958.16 240 270
TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 10 10 61 0.72% 61.10% MLEVEQAGIQMAGHSR 95.00% 4 0.421 0 5 0 0 2 1,757.93 215 230
TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 10 10 61 0.72% 61.10% QALTLADQATAAGDAAK 95.00% 4.06 0.656 0 5 0 0 2 1,616.83 78 94
TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 10 10 61 0.72% 61.10% RYANAIGSAELAESSVQGR 95.00% 3.65 0.473 0 4 0 0 2 1,980.15 196 214
TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 10 10 61 0.72% 61.10% SMSELAAPGNTPSLDEVR 95.00% 2.9 0.453 0 16 0 0 2 1,891.08 173 190
TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 10 10 61 0.72% 61.10% THQALTQQAAQVIGNQR 95.00% 5.11 0.697 0 6 0 0 2 1,864.88 40 56
TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 10 10 61 0.72% 61.10% VQIQQAIEEAQR 95.00% 3.55 0.499 0 2 0 0 2 1,413.45 28 39
TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 10 10 61 0.72% 61.10% YANAIGSAELAESSVQGR 95.00% 4.28 0.599 0 11 0 0 2 1,823.95 197 214
TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 10 10 61 0.72% 61.10% YLMALFSSK 95.00% 1.26 0.298 1 0 0 0 2 1,060.46 11 19
TX114 ppiA (ppiA)  Rv0009 19222 100.00% 5 6 15 0.18% 48.40%
DYSTQNASGGPSGPFYDG
AVFHR 95.00% 3.46 0.541 0 3 0 0 2 2,431.53 51 73
TX114 ppiA (ppiA)  Rv0009 19222 100.00% 5 6 15 0.18% 48.40% HTIFGEVIDAESQR 95.00% 5.08 0.667 0 3 0 0 2 1,602.70 141 154
TX114 ppiA (ppiA)  Rv0009 19222 100.00% 5 6 15 0.18% 48.40%
TATDGNDRPTDPVVIESITI
S 95.00% 2.28 0.315 0 3 0 0 2 2,202.39 162 182
TX114 ppiA (ppiA)  Rv0009 19222 100.00% 5 6 15 0.18% 48.40% TVANFVGLAQGTK 95.00% 1.45 0.248 1 1 0 0 2 1,306.42 38 50
TX114 ppiA (ppiA)  Rv0009 19222 100.00% 5 6 15 0.18% 48.40% VIQGFMIQGGDPTGTGR 95.00% 2.26 0.396 0 4 0 0 2 1,750.96 74 90
TX114 sucA (sucA)  Rv1248c 133954 100.00% 3 3 3 0.04% 7.00%
LTTEDFAGVTISLTNPGTIGT
VH 91.70% 1.05 0.252 0 0 1 0 2 2,345.59 228 250
TX114 sucA (sucA)  Rv1248c 133954 100.00% 3 3 3 0.04% 7.00%
SVPRLMPGQGAIIGVGAME
YPAEFQGASEER 95.00% 2.09 0.233 0 0 1 0 2 3,249.65 251 281
TX114 sucA (sucA)  Rv1248c 133954 100.00% 3 3 3 0.04% 7.00%
YVGQKRFSLEGAESVIPMM
DAAIDQCAEHGL 95.00% 1.56 0.255 0 0 1 0 2 3,367.81 485 515
TX114 pckA (pckA)  Rv0211 67236 99.70% 2 2 3 0.04% 9.41%
GAEDPKLGVEITDSEYVVV
SMRTMTRMGK 95.00% 2.21 0.182 0 0 1 0 2 3,249.61 136 164
TX114 pckA (pckA)  Rv0211 67236 99.70% 2 2 3 0.04% 9.41%
TYICSAKEIDAGPTNNWMD
PGEMRSIMK 95.00% 1.29 0.229 0 0 2 0 2 3,247.86 86 113
TX114
hypo protein 
Rv3421c  Rv3421c 21553 98.50% 2 2 2 0.02% 24.60%
AGMASAAAYGHALGIPVYG
VCSLDAIGGQTIGDTLVVT




Rv3421c  Rv3421c 21553 98.50% 2 2 2 0.02% 24.60% AHAERLTPNVL 83.90% 1.42 0.0493 1 0 0 0 2 1,221.37 42 52
TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 4 4 9 0.11% 21.50%
AGPPTVHSEIVPAAAVPTLV
DMSK 95.00% 3.6 0.624 0 2 0 0 2 2,388.61 86 109
TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 4 4 9 0.11% 21.50%
GGYAGMLVGSVGETVAQLA
R 95.00% 3.7 0.568 0 3 0 0 2 1,953.10 267 286
TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 4 4 9 0.11% 21.50% HLIDDALK 95.00% 1.52 0.413 2 0 0 0 2 925.1984 70 77
TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 4 4 9 0.11% 21.50% SEEAQLVVVGSR 95.00% 1.35 0.295 2 0 0 0 2 1,274.22 253 264
TX114 lprF (lprF)  Rv1368 26833 100.00% 3 3 3 0.04% 18.40% GLGAVVGQVQNPTIQGR 95.00% 4.7 0.607 0 1 0 0 2 1,694.73 161 177
TX114 lprF (lprF)  Rv1368 26833 100.00% 3 3 3 0.04% 18.40% IYDPGIILDKDR 95.00% 1.49 0.386 0 1 0 0 2 1,418.89 149 160
TX114 lprF (lprF)  Rv1368 26833 100.00% 3 3 3 0.04% 18.40% VSGTIDAAVIDPIVPQLGK 95.00% 2.36 0.355 0 1 0 0 2 1,894.21 188 206
TX114 atpF (atpF)  Rv1306 18307 100.00% 7 7 20 0.24% 29.80% AEQQVASTLQTAHEQLK 95.00% 4.79 0.61 0 3 0 0 2 1,882.91 118 134
TX114 atpF (atpF)  Rv1306 18307 100.00% 7 7 20 0.24% 29.80% AEQQVASTLQTAHEQLKR 95.00% 3.15 0.453 0 3 0 0 2 2,039.11 118 135
TX114 atpF (atpF)  Rv1306 18307 100.00% 7 7 20 0.24% 29.80% ERDAVELDLR 95.00% 1.9 0.16 2 0 0 0 2 1,216.37 136 145
TX114 atpF (atpF)  Rv1306 18307 100.00% 7 7 20 0.24% 29.80%
KSDEQFAAAQADYDEAMTE
AR 95.00% 3.87 0.61 0 4 0 0 2 2,364.48 73 93
TX114 atpF (atpF)  Rv1306 18307 100.00% 7 7 20 0.24% 29.80% QTAHEQLKRER 95.00% 1.07 0.0504 1 0 0 0 2 1,396.50 127 137
TX114 atpF (atpF)  Rv1306 18307 100.00% 7 7 20 0.24% 29.80%
SDEQFAAAQADYDEAMTEA
R 95.00% 4.95 0.584 0 4 0 0 2 2,220.28 74 93
TX114 atpF (atpF)  Rv1306 18307 100.00% 7 7 20 0.24% 29.80% VRAEQQVASTLQTAHEQLK 95.00% 4.77 0.604 0 3 0 0 2 2,138.18 116 134
TX114
fadE18 
(fadE18)  Rv1933c 38459 97.70% 2 2 2 0.02% 10.50%
ACADMMIEIDATRATVMFA
AMSAANGDELQTVAPLAK 82.90% 1.19 0.266 0 0 1 0 2 3,878.51 265 301
TX114
fadE18 
(fadE18)  Rv1933c 38459 97.70% 2 2 2 0.02% 10.50%
HACADMMIEIDATRATVMF
AAMSAANGDEL 87.20% 2.2 0.124 0 0 1 0 2 3,277.73 264 293
TX114
hypo protein 
Rv3792  Rv3792 69499 99.70% 2 2 3 0.04% 5.44%
AAVDPLCRLAVVGAIAAAIG
STTWL 95.00% 1.53 0.361 0 1 0 0 2 2,511.97 301 325
TX114
hypo protein 
Rv3792  Rv3792 69499 99.70% 2 2 3 0.04% 5.44% YYPAIDAAIR 95.00% 1.29 0.18 2 0 0 0 2 1,153.48 497 506
TX114 lpqH (lpqH)  Rv3763 15096 100.00% 3 3 17 0.20% 34.00%
IAIGGAATGIAAVLTDGNPP
EVK 95.00% 3.68 0.539 0 3 0 0 2 2,136.50 76 98
TX114 lpqH (lpqH)  Rv3763 15096 100.00% 3 3 17 0.20% 34.00% ITGTATGVDMANPMSPVNK 95.00% 3.37 0.499 0 12 0 0 2 1,937.14 132 150
TX114 lpqH (lpqH)  Rv3763 15096 100.00% 3 3 17 0.20% 34.00% SVGLGNVNGVTL 95.00% 1.27 0.231 2 0 0 0 2 1,130.16 99 110
TX114
hypo protein 
Rv3496c  Rv3496c 47183 99.50% 2 2 2 0.02% 12.40%
SETPVPELTWVPAGGGAPV
GNPADLQSL 95.00% 1.02 0.346 0 0 1 0 2 2,760.93 398 425
TX114
hypo protein 
Rv3496c  Rv3496c 47183 99.50% 2 2 2 0.02% 12.40%
SSDVKITMSVSKDVKVPVD
VQAVIMSPN 89.90% 1.74 0.174 0 0 1 0 2 2,991.23 75 102
TX114
hypo protein 
Rv3083  Rv3083 55466 99.70% 2 2 2 0.02% 4.44% CAVPNGDLFK 95.00% 1.04 0.251 1 0 0 0 2 1,135.32 298 307
TX114
hypo protein 
Rv3083  Rv3083 55466 99.70% 2 2 2 0.02% 4.44% IAIQRKLYQACR 95.00% 1.24 0.332 0 0 1 0 2 1,534.96 248 259
TX114 tuf (tuf)  Rv0685 43543 100.00% 6 6 8 0.09% 23.70% EHVLLAR 95.00% 1.56 0.182 1 0 0 0 2 837.9684 120 126
TX114 tuf (tuf)  Rv0685 43543 100.00% 6 6 8 0.09% 23.70% ELLAAQEFDEDAPVVR 95.00% 4.1 0.584 0 1 0 0 2 1,802.92 158 173
TX114 tuf (tuf)  Rv0685 43543 100.00% 6 6 8 0.09% 23.70% ETDKPFLMPVEDVFTITGR 95.00% 3.41 0.491 0 2 0 0 2 2,212.55 207 225
TX114 tuf (tuf)  Rv0685 43543 100.00% 6 6 8 0.09% 23.70% HYAHVDAPGHADYIK 95.00% 2.96 0.593 0 1 0 0 2 1,694.80 78 92
TX114 tuf (tuf)  Rv0685 43543 100.00% 6 6 8 0.09% 23.70%
TTDVTGVVTLPEGTEMVMP
GDNTNISVK 95.00% 2.55 0.311 0 2 0 0 2 2,923.04 337 364
TX114 tuf (tuf)  Rv0685 43543 100.00% 6 6 8 0.09% 23.70% TTLTAAITK 91.20% 0.991 0 1 0 0 0 2 920.1784 26 34
TX114
hypo protein 
Rv2471  Rv2471 60426 99.10% 2 2 2 0.02% 8.24%
IPPFGFSTCPDTWLPMPPE
WAALTAEKQR 95.00% 2.02 0.292 0 0 1 0 2 3,288.91 433 461
TX114
hypo protein 
Rv2471  Rv2471 60426 99.10% 2 2 2 0.02% 8.24% YFFRDGRGPDGSLPPN 82.30% 1.16 0.22 0 0 1 0 2 1,796.11 153 168
TX114
pks12 
(pks12)  Rv2048c 431553 99.50% 2 2 2 0.02% 1.54%
SYARTGGFVDGVADFDPAF
FGISPSEALAMDPQHRML 95.00% 1.82 0.319 0 0 1 0 2 3,991.56 92 128
TX114
pks12 
(pks12)  Rv2048c 431553 99.50% 2 2 2 0.02% 1.54%
VDSDAPLDDSALAAVVTTG
EPQVLWRR 90.00% 1.3 0.263 0 0 1 0 2 2,883.07 3335 3361
TX114
mmpL11 
(mmpL11)  Rv0202c 103485 99.70% 2 2 3 0.04% 2.90% MMRLSR 95.00% 1.41 0.139 1 0 0 0 2 810.0978 1 6
TX114
mmpL11 
(mmpL11)  Rv0202c 103485 99.70% 2 2 3 0.04% 2.90%
TQLPRVAGAAQVDVGGPTA
LIK 95.00% 2.26 0.141 0 2 0 0 2 2,163.44 497 518
TX114 lpqG (lpqG)  Rv3623 24818 99.70% 2 2 3 0.04% 17.90%
VISISEASGAAPTHEAPAPP
R 95.00% 4.14 0.621 0 1 0 0 2 2,059.26 195 215
TX114 lpqG (lpqG)  Rv3623 24818 99.70% 2 2 3 0.04% 17.90%
VTVAPQYSNPEPAGTATITG
YR 95.00% 4.11 0.655 0 2 0 0 2 2,294.44 99 120
TX114 narG (narG)  Rv1161 136906 99.70% 2 2 2 0.02% 1.87% AGKHLVCTVFDL 95.00% 1.67 0.0876 1 0 0 0 2 1,303.49 463 474
TX114 narG (narG)  Rv1161 136906 99.70% 2 2 2 0.02% 1.87% TPDAHWMAEAR 95.00% 1.7 0.138 1 0 0 0 2 1,301.38 272 282
TX114 dppA (dppA)  Rv3666c 58365 99.50% 2 2 2 0.02% 4.07% FGGEEGRLRR 90.90% 1.1 0.175 1 0 0 0 2 1,177.37 307 316
TX114 dppA (dppA)  Rv3666c 58365 99.50% 2 2 2 0.02% 4.07% SRTTMSGLRVVN 95.00% 1.46 0.195 1 0 0 0 2 1,321.47 150 161
TX114
hemB 
(hemB)  Rv0512 34853 99.10% 2 2 2 0.02% 13.70% AGADIVLTYWAVDAAGWLT 95.00% 2 0.217 0 0 1 0 2 1,994.26 311 329
TX114
hemB 
(hemB)  Rv0512 34853 99.10% 2 2 2 0.02% 13.70%
AVAQAESGAHVVGPSGMM
DGQVAAIR 83.60% 1.47 0.183 0 0 1 0 2 2,542.56 158 183
TX114 fas (fas)  Rv2524c 326201 98.90% 2 2 2 0.02% 1.50%
IRWEDDPQPGWYDTESGE
MVDESELVQRYHDAVVQR 95.00% 1.87 0.255 0 0 1 0 2 4,353.38 2482 2517
TX114 fas (fas)  Rv2524c 326201 98.90% 2 2 2 0.02% 1.50% SLVHLDHAAR 79.50% 1.14 0.0204 1 0 0 0 2 1,119.23 1116 1125
2DLC TX114
hypo protein 
Rv1771  Rv1771 48027 100.00% 4 4 6 0.03% 15.40% ALGPQLAQR 95.00% 2.54 0.339 0 2 0 0 2 954.1484 90 98
2DLC TX114
hypo protein 
Rv1771  Rv1771 48027 100.00% 4 4 6 0.03% 15.40%
LGLENQGDVDPQSITGATA
TATHGTGVR 95.00% 4.39 0.528 0 0 1 0 2 2,767.85 100 127
2DLC TX114
hypo protein 
Rv1771  Rv1771 48027 100.00% 4 4 6 0.03% 15.40% SLPIMFPIEVR 95.00% 2.8 0.46 0 2 0 0 2 1,302.71 323 333
2DLC TX114
hypo protein 
Rv1771  Rv1771 48027 100.00% 4 4 6 0.03% 15.40% VLDVDQPTGLVTVEGGAK 95.00% 3.51 0.287 0 0 1 0 2 1,798.85 70 87
2DLC TX114lprA (lprA)  Rv1270c 24856 100.00% 3 5 13 0.08% 11.50% ITGNSSADDIATLAGSR 95.00% 3.88 0.656 0 4 4 0 2 1,649.90 175 191
2DLC TX114lprA (lprA)  Rv1270c 24856 100.00% 3 5 13 0.08% 11.50% LAVTGDVPNLR 95.00% 1.58 0.308 2 1 0 0 2 1,155.31 67 77
2DLC TX114lprA (lprA)  Rv1270c 24856 100.00% 3 5 13 0.08% 11.50% SSADDIATLAGSR 95.00% 2.36 0.426 0 2 0 0 2 1,264.45 179 191
2DLC TX114
hypo protein 
Rv3718c  Rv3718c 15643 99.80% 2 3 3 0.02% 16.30% ILSPHYSEYQVLEGGK 95.00% 3.39 0.499 0 0 1 0 2 1,821.07 33 48
2DLC TX114
hypo protein 
Rv3718c  Rv3718c 15643 99.80% 2 3 3 0.02% 16.30% TFAPLGLK 95.00% 1.29 0.437 1 1 0 0 2 847.1684 122 129
2DLC TX114prfB (prfB)  Rv3105c 42107 99.90% 2 2 2 0.01% 6.61% SGAGGVDAADWAEMLMR 95.00% 4.2 0.597 0 1 0 0 2 1,737.94 142 158
2DLC TX114prfB (prfB)  Rv3105c 42107 99.90% 2 2 2 0.01% 6.61% VLDVEGLR 95.00% 2.37 0.338 0 1 0 0 2 901.0084 29 36
2DLC TX114
hypo protein 




Rv1748  Rv1748 27050 100.00% 4 4 11 0.06% 14.40% TELDGLIVLPDR 95.00% 3.89 0.444 0 4 0 0 2 1,341.66 217 228
2DLC TX114
hypo protein 
Rv1748  Rv1748 27050 100.00% 4 4 11 0.06% 14.40% TELDGLIVLPDRTR 95.00% 2.14 0.271 0 0 2 0 2 1,598.96 217 230
2DLC TX114
hypo protein 
Rv1748  Rv1748 27050 100.00% 4 4 11 0.06% 14.40% WLEYELDAAK 95.00% 3.26 0.454 0 2 0 0 2 1,238.48 99 108
2DLC TX114
hypo protein 
Rv1747  Rv1747 92104 99.40% 2 2 2 0.01% 4.39%
GVTWTIDGDKTLLDGISLT
AR 87.10% 2.09 0.149 0 0 1 0 2 2,233.70 323 343
2DLC TX114
hypo protein 
Rv1747  Rv1747 92104 99.40% 2 2 2 0.01% 4.39% VHIGNPDGPALDFEVGR 95.00% 2.99 0.533 0 0 1 0 2 1,793.93 89 105
2DLC TX114
hypo protein 
Rv2466c  Rv2466c 23017 99.80% 2 2 4 0.02% 8.70% EVAKVR 95.00% 1.17 0.197 1 0 0 0 2 701.7384 31 36
2DLC TX114
hypo protein 
Rv2466c  Rv2466c 23017 99.80% 2 2 4 0.02% 8.70% VLDPLYTAMGNR 95.00% 3.52 0.564 0 3 0 0 2 1,350.64 86 97
2DLC TX114lpqE (lpqE)  Rv3584 18769 99.80% 2 3 12 0.07% 18.10% AGQGSVMVPISAGLATPHE 95.00% 3.95 0.606 0 4 0 0 2 1,822.95 164 182
2DLC TX114lpqE (lpqE)  Rv3584 18769 99.80% 2 3 12 0.07% 18.10% IQAVQTSDFIQPGK 95.00% 3.44 0.445 0 6 2 0 2 1,532.72 62 75
2DLC TX114clpB (clpB)  Rv0384c 92520 100.00% 6 7 15 0.09% 9.91% ALADFLFDDER 95.00% 2.99 0.543 0 3 0 0 2 1,312.58 619 629
2DLC TX114clpB (clpB)  Rv0384c 92520 100.00% 6 7 15 0.09% 9.91% FLPDKAIDLVDEAASR 95.00% 4.04 0.584 0 3 1 0 2 1,761.13 386 401
2DLC TX114clpB (clpB)  Rv0384c 92520 100.00% 6 7 15 0.09% 9.91% KLDAALPQAQAR 89.30% 1.84 0.188 0 0 1 0 2 1,282.56 513 524
2DLC TX114clpB (clpB)  Rv0384c 92520 100.00% 6 7 15 0.09% 9.91% LVGATTLDEYR 95.00% 3.14 0.517 0 4 0 0 2 1,238.42 311 321
2DLC TX114clpB (clpB)  Rv0384c 92520 100.00% 6 7 15 0.09% 9.91% LVQQAIGDQLAK 95.00% 3.05 0.557 0 2 0 0 2 1,284.50 810 821
2DLC TX114clpB (clpB)  Rv0384c 92520 100.00% 6 7 15 0.09% 9.91% NNPVLIGEPGVGK 95.00% 2.5 0.502 0 4 0 0 2 1,294.45 200 212
2DLC TX114clpB (clpB)  Rv0384c 92520 100.00% 6 7 15 0.09% 9.91% NPVLIGEPGVGK 95.00% 2.59 0.556 0 2 0 0 2 1,180.35 201 212
2DLC TX114clpB (clpB)  Rv0384c 92520 100.00% 6 7 15 0.09% 9.91% TKNNPVLIGEPGVGK 95.00% 3.18 0.287 0 0 2 0 2 1,523.75 198 212
2DLC TX114clpB (clpB)  Rv0384c 92520 100.00% 6 7 15 0.09% 9.91% VVQVLSR 95.00% 1.99 0.318 0 1 0 0 2 800.8084 190 196
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% AGAATEVELK 95.00% 3.15 0.448 2 17 0 0 2 989.0784 379 388
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% AGAATEVELKER 95.00% 3.14 0.521 0 3 7 0 2 1,274.38 379 390
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% AGGVAVIK 95.00% 1.59 0.304 2 1 0 0 2 714.8184 371 378
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% ALADAVK 95.00% 1.62 0.187 2 0 0 0 2 687.8284 21 27
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% APGFGDR 95.00% 2.04 0.604 0 13 0 0 2 719.8184 276 282
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40%
AQTGVYEDLLAAGVADPVK
VTR 95.00% 2.24 0.346 0 1 0 0 2 2,274.44 477 498
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% ASVPGGGDMGGMDF 95.00% 1.75 0.491 6 4 0 0 2 1,314.42 527 540
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% AVEKVTETLLK 95.00% 2.69 0.517 6 18 19 0 2 1,231.44 122 132
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% DLLPLLEK 95.00% 1.83 0.399 8 1 0 0 2 941.3384 230 237
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% EIELEDPYEK 95.00% 1.33 0.0984 1 0 0 0 2 1,265.44 58 67
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% EIELEDPYEKIGAELVK 95.00% 4.57 0.488 0 4 3 0 2 1,976.34 58 74
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40%
EIELEDPYEKIGAELVKEVA
K 95.00% 2.8 0.319 0 0 1 0 2 2,403.79 58 78
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% GLNALADAVK 95.00% 2.13 0.394 13 17 0 0 2 972.1784 18 27
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% IEDAVR 95.00% 1.44 0.245 2 3 0 0 2 702.7684 394 399
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% IGAELVK 95.00% 1.53 0.0906 4 8 0 0 2 729.9184 68 74
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% IGAELVKEVAK 95.00% 3.93 0.471 0 4 3 0 2 1,157.37 68 78
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% KTDDVAGDGTTTATVL 94.60% 1.77 0.261 0 1 0 0 2 1,565.62 79 94
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40%
KTDDVAGDGTTTATVLAQA
L 95.00% 4.48 0.625 0 3 0 0 2 1,949.08 79 98
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40%
KTDDVAGDGTTTATVLAQA
LVR 95.00% 5.96 0.684 0 11 11 0 2 2,204.35 79 100
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40%
KVVVTKDETTIVEGAGDTD
AIAGR 95.00% 5.16 0.607 0 2 13 0 2 2,446.59 320 343
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% KWGAPTITNDGVSIAK 95.00% 3.95 0.521 0 2 2 0 2 1,658.95 42 57
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% LAGGVAVIK 95.00% 1.86 0.247 5 15 0 0 2 828.0184 370 378
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% LPLLEK 95.00% 1.77 0.368 3 1 0 0 2 713.0384 232 237
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% NALADAVK 95.00% 1.88 0.381 3 0 0 0 2 801.9284 20 27
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40%
NAQTGVYEDLLAAGVADPV
KVTR 95.00% 1.91 0.246 0 0 1 0 2 2,388.54 476 498
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% NVAAGANPL 95.00% 1.78 0.273 4 2 0 0 2 826.8984 105 113
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% NVAAGANPLGL 95.00% 2.27 0.438 2 0 0 0 2 997.1484 105 115
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% NVAAGANPLGLK 95.00% 2.97 0.522 6 21 1 0 2 1,125.35 105 116
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% NVVLEK 95.00% 1.68 0.227 4 4 0 0 2 701.7584 36 41
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% NVVLEKK 95.00% 2.29 0.387 0 1 0 0 2 829.9584 36 42
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% QIAFNSGLEPGVVAEK 95.00% 3.55 0.622 0 8 7 0 2 1,659.82 450 465
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% SGLEPGVVAEK 95.00% 2.12 0.438 0 1 0 0 2 1,086.14 455 465
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% TIAYDEEAR 95.00% 1.84 0.457 0 1 0 0 2 1,068.18 4 12
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% TIAYDEEARR 95.00% 1.92 0.301 0 1 0 0 2 1,224.38 4 13
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% VAAGANPLGLK 95.00% 3.1 0.611 0 4 0 0 2 1,011.25 106 116
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% VALEAPLK 95.00% 1.8 0.372 2 16 0 0 2 841.0684 442 449
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% VAQIRQEIEN 95.00% 1.9 0.285 0 1 0 0 2 1,200.27 344 353
2DLC TX114
groEL2 




(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% VTETLLK 95.00% 1.11 0.227 2 11 0 0 2 803.9884 126 132
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% VTLGPK 95.00% 1.19 0.209 3 0 0 0 2 614.7584 28 33
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40% WGAPTITNDGVSIAK 95.00% 4.2 0.636 0 11 0 0 2 1,530.75 43 57
2DLC TX114
groEL2 
(groEL2)  Rv0440 56709 100.00% 42 66 364 2.10% 47.40%
WGAPTITNDGVSIAKEIELE
DPYEK 95.00% 4.26 0.613 0 0 4 0 2 2,777.17 43 67
2DLC TX114
hypo protein 
Rv3547  Rv3547 17354 99.80% 2 2 7 0.04% 12.60% IPVALLTTTGR 95.00% 2.82 0.274 0 1 0 0 2 1,142.44 44 54
2DLC TX114
hypo protein 
Rv3547  Rv3547 17354 99.80% 2 2 7 0.04% 12.60% VNPLYFLR 95.00% 2.24 0.428 0 6 0 0 2 1,022.31 61 68
2DLC TX114tig (tig)  Rv2462c 50566 100.00% 8 8 20 0.12% 22.50% AAFDAEAR 95.00% 2.91 0.454 0 2 0 0 2 850.9384 337 344
2DLC TX114tig (tig)  Rv2462c 50566 100.00% 8 8 20 0.12% 22.50% ASLSDQVR 95.00% 2.38 0.257 0 1 0 0 2 875.9284 264 271
2DLC TX114tig (tig)  Rv2462c 50566 100.00% 8 8 20 0.12% 22.50% FNELLVEQGSSR 95.00% 2.78 0.509 0 4 0 0 2 1,379.50 325 336
2DLC TX114tig (tig)  Rv2462c 50566 100.00% 8 8 20 0.12% 22.50% NQLPTMFADVR 95.00% 2.68 0.416 0 5 0 0 2 1,292.49 399 409
2DLC TX114tig (tig)  Rv2462c 50566 100.00% 8 8 20 0.12% 22.50% QYGIEPQQLFGYLQER 95.00% 3.98 0.7 0 3 0 0 2 1,970.24 383 398
2DLC TX114tig (tig)  Rv2462c 50566 100.00% 8 8 20 0.12% 22.50% STVEQLSPTR 95.00% 2.77 0.497 0 2 0 0 2 1,118.17 3 12
2DLC TX114tig (tig)  Rv2462c 50566 100.00% 8 8 20 0.12% 22.50% VSAGEAEEAEPADEGAAR 88.20% 1.86 0.204 0 0 1 0 2 1,759.67 441 458
2DLC TX114tig (tig)  Rv2462c 50566 100.00% 8 8 20 0.12% 22.50%
YGQAVAESDVQPLGRPNIE
VTK 95.00% 3.38 0.585 0 0 2 0 2 2,372.51 76 97
2DLC TX114rpsB (rpsB)  Rv2890c 31072 99.80% 2 2 6 0.03% 6.97% SAALLTR 95.00% 2.05 0.373 0 4 0 0 2 731.9584 209 215
2DLC TX114rpsB (rpsB)  Rv2890c 31072 99.80% 2 2 6 0.03% 6.97% VIASAVAEGLQAR 95.00% 3 0.428 0 2 0 0 2 1,285.41 216 228
2DLC TX114
hypo protein 
Rv2296  Rv2296 33340 100.00% 6 6 9 0.05% 24.30% AAWEALGR 95.00% 2.44 0.206 0 1 0 0 2 874.0084 230 237
2DLC TX114
hypo protein 
Rv2296  Rv2296 33340 100.00% 6 6 9 0.05% 24.30% AGYDAPFPDKTYQAGAR 95.00% 3.9 0.65 0 0 2 0 2 1,829.08 194 210
2DLC TX114
hypo protein 
Rv2296  Rv2296 33340 100.00% 6 6 9 0.05% 24.30% ASHFIQEDSGTELAER 95.00% 3.05 0.379 0 0 1 0 2 1,790.89 277 292
2DLC TX114
hypo protein 
Rv2296  Rv2296 33340 100.00% 6 6 9 0.05% 24.30% LVPTSPDDPAVPANR 95.00% 2.03 0.236 0 0 1 0 2 1,549.68 215 229
2DLC TX114
hypo protein 
Rv2296  Rv2296 33340 100.00% 6 6 9 0.05% 24.30% SAAGHRVLAPDLIGFGR 94.80% 1.95 0.206 0 0 1 0 2 1,738.08 70 86
2DLC TX114
hypo protein 
Rv2296  Rv2296 33340 100.00% 6 6 9 0.05% 24.30% VLAPDLIGFGR 95.00% 2.88 0.502 0 3 0 0 2 1,158.49 76 86
2DLC TX114
hypo protein 
Rv1096  Rv1096 31059 99.80% 2 2 5 0.03% 8.25% LVTVSELLGPR 95.00% 3.18 0.441 0 4 0 0 2 1,184.41 223 233
2DLC TX114
hypo protein 
Rv1096  Rv1096 31059 99.80% 2 2 5 0.03% 8.25% YRPAGGLSNDAVR 95.00% 2.08 0.25 0 0 1 0 2 1,376.55 141 153
2DLC TX114desA2 Rv1094 31342 99.80% 2 2 3 0.02% 8.73% DWDPSQSTLPR 95.00% 2.61 0.254 0 1 0 0 2 1,302.42 53 63
2DLC TX114desA2 Rv1094 31342 99.80% 2 2 3 0.02% 8.73% ITAWGLAGEPSLK 95.00% 3.44 0.537 0 2 0 0 2 1,343.68 258 270
2DLC TX114glyA (glyA)  Rv1093 45012 100.00% 3 3 4 0.02% 6.10% IAATPEFADR 95.00% 1.88 0.291 0 1 0 0 2 1,091.28 273 282
2DLC TX114glyA (glyA)  Rv1093 45012 100.00% 3 3 4 0.02% 6.10% LMAPDVAK 95.00% 1.94 0.244 0 1 0 0 2 845.0684 297 304
2DLC TX114glyA (glyA)  Rv1093 45012 100.00% 3 3 4 0.02% 6.10% VLDFAAFR 95.00% 2.56 0.484 0 2 0 0 2 939.1484 178 185
2DLC TX114
hypo protein 
Rv3046c  Rv3046c 13333 100.00% 3 3 9 0.05% 29.80% STPLTEEQIGEVVR 95.00% 2.06 0.265 0 2 0 0 2 1,558.61 40 53
2DLC TX114
hypo protein 
Rv3046c  Rv3046c 13333 100.00% 3 3 9 0.05% 29.80% VALLSLLR 95.00% 2.51 0.338 0 4 0 0 2 885.2484 32 39
2DLC TX114
hypo protein 
Rv3046c  Rv3046c 13333 100.00% 3 3 9 0.05% 29.80% WLQVGYPEGVPGPDR 95.00% 3.03 0.459 0 3 0 0 2 1,670.77 17 31
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% AELPGVDPDK 95.00% 1.95 0.415 0 1 0 0 2 1,041.16 55 64
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% AELPGVDPDKDVDIMVR 95.00% 4.62 0.686 1 22 36 0 2 1,870.10 55 71
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% DFDGRSEFAYGSFVR 95.00% 2.97 0.349 0 0 1 0 2 1,753.93 86 100
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% DGQLTIK 95.00% 2.43 0.478 12 26 0 0 2 774.9684 72 78
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% DGQLTIKAER 95.00% 2.18 0.375 0 1 2 0 2 1,131.35 72 81
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% GILTVSVAVSEGK 95.00% 2.39 0.402 0 0 9 0 2 1,260.37 120 132
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% GILTVSVAVSEGKPTEK 95.00% 3.23 0.587 0 2 3 0 2 1,715.89 120 136
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% HIQIR 95.00% 1.38 0.206 4 0 0 0 2 666.8184 137 141
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% LEDEMKEGR 95.00% 2.01 0.249 0 2 0 0 2 1,107.27 42 50
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% LEDEMKEGRYEVR 95.00% 2.55 0.227 0 0 2 0 2 1,654.84 42 54
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% LMRLEDEMK 95.00% 3.48 0.422 1 10 13 0 2 1,165.52 39 47
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% LMRLEDEMKEGR 95.00% 2.63 0.377 0 0 1 0 2 1,523.87 39 50
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% MRLEDEMK 95.00% 1.76 0.258 0 1 0 0 2 1,052.32 40 47
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% PGVDPDKDVDIMVR 95.00% 4 0.493 0 2 2 0 2 1,556.72 58 71
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% SEFAYGSFVR 95.00% 3.45 0.583 10 41 0 0 2 1,163.28 91 100
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% TEQKDFDGR 95.00% 2.18 0.256 0 1 0 0 2 1,096.17 82 90
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% TVSLPVGADEDDIK 95.00% 3.62 0.53 0 2 3 0 2 1,459.59 101 114
2DLC TX114hspX (hspX)  Rv2031c 16210 100.00% 18 28 214 1.23% 71.50% TVSLPVGADEDDIKATYDK 95.00% 5.44 0.678 0 3 0 0 2 2,038.27 101 119
2DLC TX114cysM2 Rv1077 48617 100.00% 3 3 5 0.03% 8.62% LADAVSAHMSPPLR 95.00% 3.01 0.512 0 0 1 0 2 1,465.73 402 415
2DLC TX114cysM2 Rv1077 48617 100.00% 3 3 5 0.03% 8.62% MIGAGELVSAAGK 95.00% 2.99 0.526 0 3 0 0 2 1,204.46 416 428
2DLC TX114cysM2 Rv1077 48617 100.00% 3 3 5 0.03% 8.62% YDLLGFLSEGAGR 95.00% 2.66 0.331 0 1 0 0 2 1,398.73 451 463
2DLC TX114ephD (ephD)  Rv2214c 64011 99.50% 2 3 13 0.08% 3.04% ETALAFAR 90.90% 1.59 0.237 0 1 0 0 2 879.0584 339 346
2DLC TX114ephD (ephD)  Rv2214c 64011 99.50% 2 3 13 0.08% 3.04% VADAIVSAVK 95.00% 1.92 0.086 3 9 0 0 2 973.0484 548 557
2DLC TX114eno (eno)  Rv1023 44912 100.00% 6 9 16 0.09% 16.80% AAADSAELPLFR 95.00% 3 0.449 0 2 1 0 2 1,261.54 120 131
2DLC TX114eno (eno)  Rv1023 44912 100.00% 6 9 16 0.09% 16.80% DLISR 95.00% 1.59 0.152 2 0 0 0 2 603.7984 219 223
2DLC TX114eno (eno)  Rv1023 44912 100.00% 6 9 16 0.09% 16.80% GVANALLVK 95.00% 2.76 0.359 0 3 0 0 2 885.0684 327 335
2DLC TX114eno (eno)  Rv1023 44912 100.00% 6 9 16 0.09% 16.80% IEEALGDAAR 95.00% 3.21 0.427 0 3 0 0 2 1,045.21 405 414
2DLC TX114eno (eno)  Rv1023 44912 100.00% 6 9 16 0.09% 16.80% LVDQALVDLDGTPDKSR 95.00% 4.07 0.574 0 1 2 0 2 1,843.09 88 104
2DLC TX114eno (eno)  Rv1023 44912 100.00% 6 9 16 0.09% 16.80% WGAEVYHALK 95.00% 3.32 0.498 0 2 1 0 2 1,174.30 180 189
2DLC TX114eno (eno)  Rv1023 44912 100.00% 6 9 16 0.09% 16.80% YAGDLAFPR 95.00% 3.06 0.564 0 1 0 0 2 1,010.25 415 423
2DLC TX114
hypo protein 
Rv0283  Rv0283 55924 100.00% 4 5 11 0.06% 9.11% ADALLAHDTLVPDSR 95.00% 3.57 0.51 0 3 0 0 2 1,594.83 512 526
2DLC TX114
hypo protein 
Rv0283  Rv0283 55924 100.00% 4 5 11 0.06% 9.11% GNLIGIPGAPER 95.00% 2.83 0.527 0 1 0 0 2 1,194.49 156 167
2DLC TX114
hypo protein 
Rv0283  Rv0283 55924 100.00% 4 5 11 0.06% 9.11% LGADEVAKLPVSR 95.00% 3.44 0.434 0 1 2 0 2 1,355.57 351 363
2DLC TX114
hypo protein 
Rv0283  Rv0283 55924 100.00% 4 5 11 0.06% 9.11% STELDQFPR 95.00% 2.71 0.439 0 4 0 0 2 1,093.22 147 155
2DLC TX114gcvT (gcvT)  Rv2211c 39579 99.80% 2 3 4 0.02% 8.18% GPGAAQFVNSALTNDLGR 95.00% 4.42 0.599 0 2 0 0 2 1,788.98 76 93
2DLC TX114gcvT (gcvT)  Rv2211c 39579 99.80% 2 3 4 0.02% 8.18% TAVGLFDVSHLGK 95.00% 3.91 0.546 0 1 1 0 2 1,344.52 59 71
2DLC TX114
fadD15 
(fadD15)  Rv2187 63985 99.80% 2 2 4 0.02% 3.67% IADDGELLVR 95.00% 3.16 0.238 0 2 0 0 2 1,101.32 408 417
2DLC TX114
fadD15 
(fadD15)  Rv2187 63985 99.80% 2 2 4 0.02% 3.67% NVAPAVLEDQLR 95.00% 1.83 0.466 0 2 0 0 2 1,325.44 472 483
2DLC TX114
hypo protein 
Rv2971  Rv2971 30314 100.00% 3 4 7 0.04% 12.40% LIDTAYAYGNEAAVGR 95.00% 4.03 0.491 0 2 2 0 2 1,684.91 50 65
2DLC TX114
hypo protein 
Rv2971  Rv2971 30314 100.00% 3 4 7 0.04% 12.40% TPAQVLLR 95.00% 2.93 0.196 0 2 0 0 2 898.0884 218 225
2DLC TX114
hypo protein 




Rv2159c  Rv2159c 36358 100.00% 8 9 20 0.12% 27.30% AGGLVFAR 95.00% 2.32 0.366 0 2 0 0 2 790.9484 180 187
2DLC TX114
hypo protein 
Rv2159c  Rv2159c 36358 100.00% 8 9 20 0.12% 27.30% ETLLVGQVPR 95.00% 2.57 0.347 0 4 0 0 2 1,112.23 56 65
2DLC TX114
hypo protein 
Rv2159c  Rv2159c 36358 100.00% 8 9 20 0.12% 27.30% FVNHIEPVAPR 95.00% 3.09 0.592 0 2 4 0 2 1,279.38 3 13
2DLC TX114
hypo protein 
Rv2159c  Rv2159c 36358 100.00% 8 9 20 0.12% 27.30% IGTWIGAAAEGQVSR 95.00% 4.16 0.545 0 1 0 0 2 1,516.66 325 339
2DLC TX114
hypo protein 
Rv2159c  Rv2159c 36358 100.00% 8 9 20 0.12% 27.30% MRRAGGLVFARK 89.90% 2.32 0.17 0 1 0 0 2 1,378.75 177 188
2DLC TX114
hypo protein 
Rv2159c  Rv2159c 36358 100.00% 8 9 20 0.12% 27.30% RAGGAVAEVYAEAR 95.00% 3.29 0.438 0 0 4 0 2 1,420.46 14 27
2DLC TX114
hypo protein 
Rv2159c  Rv2159c 36358 100.00% 8 9 20 0.12% 27.30% TGLAPHQVTDDDVAAAR 95.00% 3.56 0.487 0 0 1 0 2 1,737.75 285 301
2DLC TX114
hypo protein 
Rv2159c  Rv2159c 36358 100.00% 8 9 20 0.12% 27.30% VVGSWHGEPMPMSSR 94.50% 2.49 0.145 0 0 1 0 2 1,657.74 248 262
2DLC TX114
hypo protein 
Rv2953  Rv2953 45088 99.80% 2 2 2 0.01% 4.07% IALAGR 95.00% 1.08 0.0072 1 0 0 0 2 600.8284 36 41
2DLC TX114
hypo protein 
Rv2953  Rv2953 45088 99.80% 2 2 2 0.01% 4.07% SNALQEWAYGR 95.00% 1.74 0.337 0 1 0 0 2 1,295.41 261 271
2DLC TX114secD (secD)  Rv2587c 60218 100.00% 3 5 12 0.07% 5.58% EALAQAQQIISAR 95.00% 2.77 0.375 2 3 2 0 2 1,399.62 65 77
2DLC TX114secD (secD)  Rv2587c 60218 100.00% 3 5 12 0.07% 5.58% LGIDLQGGTR 95.00% 2.63 0.389 0 2 0 0 2 1,030.27 40 49
2DLC TX114secD (secD)  Rv2587c 60218 100.00% 3 5 12 0.07% 5.58% TPDGSAPSR 95.00% 2.37 0.335 0 3 0 0 2 887.9484 56 64
2DLC TX114
hypo protein 
Rv0497  Rv0497 33073 100.00% 3 3 5 0.03% 14.50% QISVAELLAR 95.00% 2.51 0.42 0 3 0 0 2 1,100.33 15 24
2DLC TX114
hypo protein 
Rv0497  Rv0497 33073 100.00% 3 3 5 0.03% 14.50% TVYWSQPEPR 95.00% 2.41 0.508 0 1 0 0 2 1,263.31 105 114
2DLC TX114
hypo protein 
Rv0497  Rv0497 33073 100.00% 3 3 5 0.03% 14.50%
VQVGEAAPQSPAEPVAEQV
AEEPTR 95.00% 3.25 0.472 0 0 1 0 2 2,590.41 80 104
2DLC TX114sigH (sigH)  Rv3223c 24208 99.70% 2 2 2 0.01% 8.80% GLLADVAR 94.70% 2.11 0.19 0 1 0 0 2 814.9984 193 200
2DLC TX114sigH (sigH)  Rv3223c 24208 99.70% 2 2 2 0.01% 8.80% ILTNTYINSYR 95.00% 3.24 0.468 0 1 0 0 2 1,358.70 85 95
2DLC TX114drrA (drrA)  Rv2936 35801 99.80% 2 2 3 0.02% 5.74% IELADIALR 95.00% 3.62 0.295 0 2 0 0 2 1,014.38 295 303
2DLC TX114drrA (drrA)  Rv2936 35801 99.80% 2 2 3 0.02% 5.74% IVALDDVSFK 95.00% 2.32 0.506 0 1 0 0 2 1,107.32 22 31
2DLC TX114ppsE (ppsE)  Rv2935 158695 100.00% 4 4 6 0.03% 3.16% DAGVSDKTLADPAYVR 95.00% 3.29 0.29 0 0 2 0 2 1,678.85 47 62
2DLC TX114ppsE (ppsE)  Rv2935 158695 100.00% 4 4 6 0.03% 3.16% LSDVAYTLAR 95.00% 2.62 0.424 0 1 0 0 2 1,109.33 487 496
2DLC TX114ppsE (ppsE)  Rv2935 158695 100.00% 4 4 6 0.03% 3.16% LTEAGIPVR 95.00% 2.23 0.346 0 2 0 0 2 956.1384 723 731
2DLC TX114ppsE (ppsE)  Rv2935 158695 100.00% 4 4 6 0.03% 3.16% RIPAATAEALER 95.00% 2.09 0.359 0 0 1 0 2 1,298.56 1433 1444
2DLC TX114
hypo protein 
Rv1006  Rv1006 61280 99.80% 2 2 3 0.02% 7.41%
DGRDDSGFYPVATLDIPRD
AQTAVNAS 95.00% 2.48 0.442 0 0 1 0 2 2,853.08 541 567
2DLC TX114
hypo protein 
Rv1006  Rv1006 61280 99.80% 2 2 3 0.02% 7.41% SSDQPTPASVAETVR 95.00% 2.48 0.427 0 2 0 0 2 1,545.50 487 501
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% AAEGYLEAATSR 95.00% 1.72 0.245 2 4 1 0 2 1,239.37 83 94
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% AAKLVGIELPK 95.00% 3.45 0.365 0 3 0 0 2 1,139.52 151 161
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% ATVNELITNLR 95.00% 3.17 0.468 0 3 0 0 2 1,244.47 26 36
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% FTAEELR 95.00% 1.42 0.241 1 11 0 0 2 865.9984 75 81
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% FTAEELRK 95.00% 1.96 0.468 0 0 2 0 2 994.1984 75 82
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% KAAAKK 95.00% 1.09 0.0867 1 0 0 0 2 616.8584 180 185
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% KAAEGYLEAATSR 95.00% 4 0.65 0 5 2 0 2 1,367.57 82 94
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% LQEDLPEQLTELR 95.00% 3.94 0.57 1 8 1 0 2 1,584.84 60 72
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% LRSQQSFEEVSAR 95.00% 3.78 0.442 0 0 1 0 2 1,537.61 109 121
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% LVGIELPK 95.00% 1.89 0.265 4 6 0 0 2 869.1584 154 161
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% SQQSFEEVSAR 95.00% 2.86 0.512 0 6 0 0 2 1,268.21 111 121
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% VGIELPK 95.00% 1.85 0.166 2 0 0 0 2 755.9584 155 161
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% YNELVER 95.00% 2.5 0.499 0 8 0 0 2 922.9884 95 101
2DLC TX114
hypo protein 
Rv0475  Rv0475 21517 100.00% 14 22 92 0.53% 44.20% YNELVERGEAALER 95.00% 3.87 0.547 0 6 14 0 2 1,649.80 95 108
2DLC TX114
hypo protein 
Rv0474  Rv0474 15346 100.00% 3 3 8 0.05% 25.00% ASDVASDIGSFIR 95.00% 3.48 0.61 0 1 0 0 2 1,338.54 15 27
2DLC TX114
hypo protein 
Rv0474  Rv0474 15346 100.00% 3 3 8 0.05% 25.00% SGVSNPYLSQVER 95.00% 3.9 0.553 0 4 0 0 2 1,436.47 44 56
2DLC TX114
hypo protein 
Rv0474  Rv0474 15346 100.00% 3 3 8 0.05% 25.00% VSAEVLYVR 95.00% 3.12 0.447 0 3 0 0 2 1,036.09 75 83
2DLC TX114fadB2 Rv0468 30678 99.80% 2 2 3 0.02% 5.59% GFYTY 95.00% 0.783 0.0972 1 0 0 0 2 650.7684 282 286
2DLC TX114fadB2 Rv0468 30678 99.80% 2 2 3 0.02% 5.59% LSDLVGLDTLK 95.00% 3.51 0.539 0 2 0 0 2 1,174.52 235 245
2DLC TX114lsr2 (lsr2)  Rv3597c 12081 100.00% 3 4 12 0.07% 24.10% GAIDREQSAAIR 95.00% 2.86 0.393 0 0 2 0 2 1,287.49 73 84
2DLC TX114lsr2 (lsr2)  Rv3597c 12081 100.00% 3 4 12 0.07% 24.10% GRIPADVIDAYHAAT 95.00% 2.18 0.347 0 4 2 0 2 1,570.78 98 112
2DLC TX114lsr2 (lsr2)  Rv3597c 12081 100.00% 3 4 12 0.07% 24.10% IPADVIDAYHAAT 95.00% 3 0.482 0 4 0 0 2 1,357.53 100 112
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% AIDLIDEAGAR 95.00% 3.92 0.327 0 1 0 0 2 1,144.41 399 409
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% AIDLIDEAGARMRIR 89.60% 2.39 0.176 0 0 1 0 2 1,717.21 399 413
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% FLPDKAIDLIDEAGAR 95.00% 3.8 0.518 0 2 0 0 2 1,745.23 394 409
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% GELQTIGATTLDEYR 95.00% 2.72 0.576 0 2 0 0 2 1,667.90 315 329
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% GGESGSPSTSLVLDQFGR 95.00% 3.89 0.641 0 3 0 0 2 1,794.93 159 176
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% NLTAAAMEGK 92.90% 1.63 0.246 0 2 0 0 2 1,006.21 177 186
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% NLTAAAMEGKLDPVIGR 85.70% 2.16 0.175 0 0 1 0 2 1,773.15 177 193
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% NNPVLIGEPGVGK 95.00% 2.5 0.502 0 4 0 0 2 1,294.45 210 222
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% NPVLIGEPGVGK 95.00% 2.59 0.556 0 2 0 0 2 1,180.35 211 222
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% SLESLGISLEGVR 95.00% 4.15 0.448 0 2 0 0 2 1,360.63 48 60
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% TKNNPVLIGEPGVGK 95.00% 3.18 0.287 0 0 2 0 2 1,523.75 208 222
2DLC TX114clpC (clpC)  Rv3596c 93537 100.00% 12 12 23 0.13% 12.40% VMQVLSR 95.00% 2.11 0.375 0 1 0 0 2 832.9384 200 206
2DLC TX114
hypo protein 




Rv2280  Rv2280 48035 100.00% 3 3 3 0.02% 10.00% IKQSFDPAGILNPGVVFGDT 95.00% 2.71 0.417 0 1 0 0 2 2,076.41 440 459
2DLC TX114
hypo protein 
Rv2280  Rv2280 48035 100.00% 3 3 3 0.02% 10.00% TGYFLELEDPVK 95.00% 4.09 0.41 0 1 0 0 2 1,411.66 422 433
2DLC TX114
hypo protein 
Rv1269c  Rv1269c 12532 100.00% 3 5 12 0.07% 23.40% AAAEATAVK 95.00% 2.22 0.374 0 2 0 0 2 831.8884 60 68
2DLC TX114
hypo protein 
Rv1269c  Rv1269c 12532 100.00% 3 5 12 0.07% 23.40% AYQGGVGPTLAAAMK 95.00% 3.01 0.628 0 4 2 0 2 1,435.68 93 107
2DLC TX114
hypo protein 
Rv1269c  Rv1269c 12532 100.00% 3 5 12 0.07% 23.40%
AYQGGVGPTLAAAMKDALT
K 95.00% 3.63 0.61 0 2 2 0 2 1,964.36 93 112
2DLC TX114sodC (sodC)  Rv0432 23826 99.80% 2 2 4 0.02% 9.58%
YVQVNGTPGPDETTLTTGD
AGK 95.00% 4.01 0.637 0 2 0 0 2 2,222.28 209 230
2DLC TX114sodC (sodC)  Rv0432 23826 99.80% 2 2 4 0.02% 9.58%
YVQVNGTPGPDETTLTTGD
AGKR 95.00% 2.14 0.431 0 0 2 0 2 2,378.48 209 231
2DLC TX114
hypo protein 
Rv0431  Rv0431 16887 99.80% 2 4 10 0.06% 13.40% TLGAAVELR 95.00% 1.34 0.262 1 3 0 0 2 930.0984 139 147
2DLC TX114
hypo protein 
Rv0431  Rv0431 16887 99.80% 2 4 10 0.06% 13.40% VYNISGTEGAAAR 95.00% 3.08 0.479 0 5 1 0 2 1,309.41 81 93
2DLC TX114lppS (lppS)  Rv2518c 43347 99.80% 2 2 5 0.03% 6.62% WSTTEQLGYNR 95.00% 2.68 0.562 0 2 0 0 2 1,355.45 112 122
2DLC TX114lppS (lppS)  Rv2518c 43347 99.80% 2 2 5 0.03% 6.62% YTLNATALGLGGAATR 95.00% 5 0.631 0 3 0 0 2 1,550.89 124 139
2DLC TX114
hypo protein 
Rv2260  Rv2260 22119 99.70% 2 2 2 0.01% 13.70% GTALDAPVLMHPGDAVLWR 93.70% 2.28 0.201 0 1 0 0 2 2,020.34 76 94
2DLC TX114
hypo protein 
Rv2260  Rv2260 22119 99.70% 2 2 2 0.01% 13.70% SYSDFPTILR 95.00% 2.13 0.316 0 1 0 0 2 1,199.50 162 171
2DLC TX114embR Rv1267c 41916 99.30% 2 2 2 0.01% 6.19% ASAVIAELEAL 85.10% 2.49 0.137 0 1 0 0 2 1,087.29 187 197
2DLC TX114embR Rv1267c 41916 99.30% 2 2 2 0.01% 6.19% TTAAGTVTVLDQR 95.00% 2.87 0.35 0 1 0 0 2 1,333.37 268 280
2DLC TX114lppX (lppX)  Rv2945c 24122 100.00% 6 7 14 0.08% 33.90% ANPLAAK 95.00% 1.16 0.271 1 0 0 0 2 684.8784 92 98
2DLC TX114lppX (lppX)  Rv2945c 24122 100.00% 6 7 14 0.08% 33.90% ASIDLGSGSIQLTQSK 95.00% 4.77 0.695 0 3 0 0 2 1,605.92 210 225
2DLC TX114lppX (lppX)  Rv2945c 24122 100.00% 6 7 14 0.08% 33.90% ITGTIPASSVK 95.00% 1.88 0.428 0 1 0 0 2 1,074.30 173 183
2DLC TX114lppX (lppX)  Rv2945c 24122 100.00% 6 7 14 0.08% 33.90% LFDDWSNLGSISELSTSR 95.00% 6.1 0.6 0 5 0 0 2 2,028.37 122 139
2DLC TX114lppX (lppX)  Rv2945c 24122 100.00% 6 7 14 0.08% 33.90% TSVHVAVR 95.00% 2.33 0.33 0 1 0 0 2 868.7884 65 72
2DLC TX114lppX (lppX)  Rv2945c 24122 100.00% 6 7 14 0.08% 33.90% TTGKVDSLLGITSADVDVR 95.00% 5.41 0.519 0 2 1 0 2 1,948.17 73 91
2DLC TX114
hypo protein 
Rv0407  Rv0407 36940 100.00% 3 3 4 0.02% 7.44% FLELFQSDLAPR 95.00% 3.99 0.548 0 2 0 0 2 1,436.80 320 331
2DLC TX114
hypo protein 
Rv0407  Rv0407 36940 100.00% 3 3 4 0.02% 7.44% FWAPLSLTAEQK 95.00% 2.3 0.214 0 1 0 0 2 1,391.68 248 259
2DLC TX114
hypo protein 
Rv0407  Rv0407 36940 100.00% 3 3 4 0.02% 7.44% RFLELFQSDLAPR 91.00% 1.77 0.179 0 0 1 0 2 1,593.00 319 331
2DLC TX114pknH (pknH)  Rv1266c 66735 100.00% 3 3 4 0.02% 7.51% FGPLTPPR 95.00% 1.76 0.294 0 1 0 0 2 885.1284 108 115
2DLC TX114pknH (pknH)  Rv1266c 66735 100.00% 3 3 4 0.02% 7.51% LMTAEFSKDPVFR 95.00% 2.31 0.345 0 0 1 0 2 1,541.87 46 58
2DLC TX114pknH (pknH)  Rv1266c 66735 100.00% 3 3 4 0.02% 7.51%
SQESTLPAPPKPVPPPTMPA
TAMAPR 95.00% 3.84 0.473 0 0 2 0 2 2,671.15 291 316
2DLC TX114accD6 Rv2247 50117 100.00% 4 4 9 0.05% 10.40% ALHAVGQVFEAMIR 95.00% 3.35 0.443 0 0 1 0 2 1,542.75 107 120
2DLC TX114accD6 Rv2247 50117 100.00% 4 4 9 0.05% 10.40% SGVLAAAGTVNGVR 95.00% 2.86 0.521 0 2 0 0 2 1,272.30 40 53
2DLC TX114accD6 Rv2247 50117 100.00% 4 4 9 0.05% 10.40% TVGVLANNPLR 95.00% 3.25 0.502 0 2 0 0 2 1,154.31 280 290
2DLC TX114accD6 Rv2247 50117 100.00% 4 4 9 0.05% 10.40% VFVTGPDVVR 95.00% 3.01 0.333 0 4 0 0 2 1,089.07 157 166
2DLC TX114kasB (kasB)  Rv2246 46371 100.00% 5 5 8 0.05% 14.20% IEAVPIAGFAQMR 95.00% 2.73 0.612 0 2 0 0 2 1,403.70 222 234
2DLC TX114kasB (kasB)  Rv2246 46371 100.00% 5 5 8 0.05% 14.20%
IMGASITSDGFHMVAPDPN
GER 95.00% 2.7 0.377 0 0 2 0 2 2,303.60 286 307
2DLC TX114kasB (kasB)  Rv2246 46371 100.00% 5 5 8 0.05% 14.20% MGYLQR 86.90% 1.64 0.213 0 1 0 0 2 767.9684 100 105
2DLC TX114kasB (kasB)  Rv2246 46371 100.00% 5 5 8 0.05% 14.20% MSTVLSR 95.00% 2.08 0.288 0 2 0 0 2 793.9484 106 112
2DLC TX114kasB (kasB)  Rv2246 46371 100.00% 5 5 8 0.05% 14.20% YMPNGAAAAVGLER 95.00% 3.11 0.533 0 1 0 0 2 1,420.63 165 178
2DLC TX114kasA (kasA)  Rv2245 43266 100.00% 3 6 17 0.10% 13.20% GLLAGESGIHALEDEFVTK 95.00% 3.98 0.647 0 1 1 0 2 1,987.28 35 53
2DLC TX114kasA (kasA)  Rv2245 43266 100.00% 3 6 17 0.10% 13.20% IVESYDLMNAGGPR 95.00% 3.18 0.481 0 2 2 0 2 1,522.77 122 135
2DLC TX114kasA (kasA)  Rv2245 43266 100.00% 3 6 17 0.10% 13.20%
LLGAGITSDAFHMVAPAAD
GVR 95.00% 6.75 0.688 0 4 7 0 2 2,170.51 265 286
2DLC TX114acpM (acpM)  Rv2244 12474 100.00% 7 13 42 0.24% 47.80% AKIESENPDAVANVQAR 95.00% 4.73 0.583 0 4 8 0 2 1,812.88 93 109
2DLC TX114acpM (acpM)  Rv2244 12474 100.00% 7 13 42 0.24% 47.80% IESENPDAVANVQAR 95.00% 4.77 0.399 0 2 3 0 2 1,613.60 95 109
2DLC TX114acpM (acpM)  Rv2244 12474 100.00% 7 13 42 0.24% 47.80% IPDEDLAGLR 95.00% 1.56 0.349 2 4 0 0 2 1,099.37 59 68
2DLC TX114acpM (acpM)  Rv2244 12474 100.00% 7 13 42 0.24% 47.80% LEEENPEAAQALR 95.00% 3.96 0.382 0 1 1 0 2 1,470.58 80 92
2DLC TX114acpM (acpM)  Rv2244 12474 100.00% 7 13 42 0.24% 47.80% TVGDVVAYIQK 95.00% 4.31 0.511 2 5 0 0 2 1,193.26 69 79
2DLC TX114acpM (acpM)  Rv2244 12474 100.00% 7 13 42 0.24% 47.80%
TVGDVVAYIQKLEEENPEAA
QALR 95.00% 5.8 0.643 0 7 2 0 2 2,644.82 69 92
2DLC TX114acpM (acpM)  Rv2244 12474 100.00% 7 13 42 0.24% 47.80% YGVKIPDEDLAGLR 95.00% 4.5 0.341 0 0 1 0 2 1,546.89 55 68
2DLC TX114aceE (aceE)  Rv2241 100168 100.00% 4 4 6 0.03% 4.44% ALGGFVPER 95.00% 2.27 0.32 0 1 0 0 2 946.0884 462 470
2DLC TX114aceE (aceE)  Rv2241 100168 100.00% 4 4 6 0.03% 4.44% GFVLGATAGR 95.00% 2.85 0.429 0 1 0 0 2 949.0984 626 635
2DLC TX114aceE (aceE)  Rv2241 100168 100.00% 4 4 6 0.03% 4.44% GPVIAVSDWMR 95.00% 3.03 0.515 0 3 0 0 2 1,231.39 804 814
2DLC TX114aceE (aceE)  Rv2241 100168 100.00% 4 4 6 0.03% 4.44% IIQELESFFR 95.00% 3.41 0.486 0 1 0 0 2 1,282.60 275 284
2DLC TX114hsp (hsp)  Rv0251c 17768 100.00% 5 5 8 0.05% 32.70% APAETQAQR 95.00% 2.84 0.554 0 3 0 0 2 971.9784 146 154
2DLC TX114hsp (hsp)  Rv0251c 17768 100.00% 5 5 8 0.05% 32.70%
LPAHVTSEAIAASYDAGVLT
VR 95.00% 2.83 0.489 0 0 1 0 2 2,242.46 118 139
2DLC TX114hsp (hsp)  Rv0251c 17768 100.00% 5 5 8 0.05% 32.70% PVWDVEPWDR 95.00% 2.71 0.474 0 2 0 0 2 1,299.30 10 19
2DLC TX114hsp (hsp)  Rv0251c 17768 100.00% 5 5 8 0.05% 32.70% VAGAYKAPAETQAQR 95.00% 3.13 0.504 0 0 1 0 2 1,561.66 140 154
2DLC TX114hsp (hsp)  Rv0251c 17768 100.00% 5 5 8 0.05% 32.70% YGSFR 83.60% 1.22 0.337 0 1 0 0 2 629.7484 109 113
2DLC TX114
hypo protein 
Rv2095c  Rv2095c 33747 99.80% 2 2 2 0.01% 6.33% LLLGFGSDVR 95.00% 2.8 0.4 0 1 0 0 2 1,077.37 279 288
2DLC TX114
hypo protein 
Rv2095c  Rv2095c 33747 99.80% 2 2 2 0.01% 6.33% VLAPESLAQR 95.00% 2.25 0.294 0 1 0 0 2 1,084.25 289 298
2DLC TX114greA (greA)  Rv1080c 17837 99.60% 2 2 3 0.02% 13.40% QLQDLLSNAK 95.00% 1.79 0.379 0 1 0 0 2 1,130.38 66 75
2DLC TX114greA (greA)  Rv1080c 17837 99.60% 2 2 3 0.02% 13.40% QSGVALPGSVVK 91.20% 2.02 0.223 0 2 0 0 2 1,142.19 82 93
2DLC TX114glnA1 Rv2220 53522 99.80% 2 2 3 0.02% 6.49% LVPGYEAPINLVYSQR 95.00% 3.38 0.492 0 0 1 0 2 1,820.11 330 345
2DLC TX114glnA1 Rv2220 53522 99.80% 2 2 3 0.02% 6.49% SVFDDGLAFDGSSIR 95.00% 3.62 0.578 0 2 0 0 2 1,586.81 45 59
2DLC TX114
hypo protein 
Rv2216  Rv2216 31654 100.00% 3 3 4 0.02% 12.30% AAFGEFADEGLLIGQR 95.00% 2.44 0.259 0 1 0 0 2 1,695.01 256 271
2DLC TX114
hypo protein 
Rv2216  Rv2216 31654 100.00% 3 3 4 0.02% 12.30% AVNRPTPL 95.00% 1.81 0.251 0 2 0 0 2 868.0084 240 247
2DLC TX114
hypo protein 
Rv2216  Rv2216 31654 100.00% 3 3 4 0.02% 12.30% TGVVLSPAGGMLR 95.00% 2.31 0.418 0 1 0 0 2 1,258.49 162 174
2DLC TX114sucB (sucB)  Rv2215 57070 100.00% 6 8 15 0.09% 18.40%
AEPAPSPPAAQPAGAAEGA
PYVTPLVR 95.00% 3.69 0.532 0 0 2 0 2 2,586.82 223 249
2DLC TX114sucB (sucB)  Rv2215 57070 100.00% 6 8 15 0.09% 18.40% AIADIAAR 95.00% 1.96 0.165 2 3 0 0 2 801.0384 440 447
2DLC TX114sucB (sucB)  Rv2215 57070 100.00% 6 8 15 0.09% 18.40% AKAPAPAAQAAAAPAPK 95.00% 3.73 0.485 0 0 1 0 2 1,502.80 286 302
2DLC TX114sucB (sucB)  Rv2215 57070 100.00% 6 8 15 0.09% 18.40% APPAPAPALAHLR 95.00% 1.94 0.472 0 2 2 0 2 1,282.60 303 315
2DLC TX114sucB (sucB)  Rv2215 57070 100.00% 6 8 15 0.09% 18.40%
IGVAADIGAAPAPKPAPKPV
PEPAPTPK 95.00% 3.02 0.484 0 0 2 0 2 2,659.20 195 222
2DLC TX114sucB (sucB)  Rv2215 57070 100.00% 6 8 15 0.09% 18.40% LIDGADAGR 95.00% 2.12 0.309 0 1 0 0 2 888.0784 525 533
2DLC TX114pepB (pepB)  Rv2213 53431 100.00% 4 4 6 0.03% 10.30% AGYGGVIGVGQGSSRPPR 95.00% 3.82 0.579 0 0 1 0 2 1,715.84 236 253
2DLC TX114pepB (pepB)  Rv2213 53431 100.00% 4 4 6 0.03% 10.30% IPGVMGSDEFRDR 95.00% 2.29 0.189 0 0 1 0 2 1,479.69 401 413
187
2DLC TX114pepB (pepB)  Rv2213 53431 100.00% 4 4 6 0.03% 10.30% LILADAIVR 95.00% 3.07 0.488 0 3 0 0 2 984.3484 366 374
2DLC TX114pepB (pepB)  Rv2213 53431 100.00% 4 4 6 0.03% 10.30% STVADLANVSGQR 95.00% 2.68 0.388 0 1 0 0 2 1,318.33 440 452
2DLC TX114
hypo protein 
Rv2629  Rv2629 40822 100.00% 3 4 12 0.07% 9.89% DAKQELIDSLEEAVR 95.00% 4.18 0.425 0 6 2 0 2 1,716.93 49 63
2DLC TX114
hypo protein 
Rv2629  Rv2629 40822 100.00% 3 4 12 0.07% 9.89% IAPLDGVGALLR 95.00% 2.23 0.572 0 3 0 0 2 1,195.57 351 362
2DLC TX114
hypo protein 
Rv2629  Rv2629 40822 100.00% 3 4 12 0.07% 9.89% TDLLSTLPQR 95.00% 2.81 0.261 0 1 0 0 2 1,144.42 206 215
2DLC TX114tsf (tsf)  Rv2889c 28737 99.80% 2 2 4 0.02% 10.30% ALLDVAGVTVTR 95.00% 4.41 0.54 0 2 0 0 2 1,215.34 251 262
2DLC TX114tsf (tsf)  Rv2889c 28737 99.80% 2 2 4 0.02% 10.30% YLSRDDVPEDIVASER 95.00% 3.18 0.489 0 0 2 0 2 1,865.02 187 202
2DLC TX114prsA (prsA)  Rv1017c 35442 99.80% 2 2 2 0.01% 6.75% LIADLLK 95.00% 2 0.28 0 1 0 0 2 786.1984 119 125
2DLC TX114prsA (prsA)  Rv1017c 35442 99.80% 2 2 2 0.01% 6.75% WADALGGVPLAFIHK 95.00% 2.83 0.258 0 0 1 0 2 1,595.95 188 202
2DLC TX114
hypo protein 
Rv1261c  Rv1261c 16738 99.80% 2 2 4 0.02% 8.05% PIPVVVLTR 95.00% 2.06 0.628 0 2 0 0 2 994.1684 140 148
2DLC TX114
hypo protein 
Rv1261c  Rv1261c 16738 99.80% 2 2 4 0.02% 8.05% TSRPIPVVVLTR 95.00% 3.22 0.291 0 0 2 0 2 1,338.55 137 148
2DLC TX114amiC (amiC)  Rv2888c 50898 100.00% 3 3 4 0.02% 4.86% PLAIMR 92.30% 1.06 0.159 1 0 0 0 2 701.0184 355 360
2DLC TX114amiC (amiC)  Rv2888c 50898 100.00% 3 3 4 0.02% 4.86% QLTLK 95.00% 1.49 0.188 1 0 0 0 2 602.8184 276 280
2DLC TX114amiC (amiC)  Rv2888c 50898 100.00% 3 3 4 0.02% 4.86% VVLGTGLVSLGK 95.00% 2.71 0.413 0 2 0 0 2 1,143.36 113 124
2DLC TX114
hypo protein 
Rv2091c  Rv2091c 26001 100.00% 3 3 4 0.02% 7.38% GTYEVGRPQ 95.00% 2.6 0.541 0 2 0 0 2 1,007.01 236 244
2DLC TX114
hypo protein 
Rv2091c  Rv2091c 26001 100.00% 3 3 4 0.02% 7.38% VTVTFQDNK 95.00% 2.75 0.602 0 1 0 0 2 1,052.06 227 235
2DLC TX114
hypo protein 
Rv2091c  Rv2091c 26001 100.00% 3 3 4 0.02% 7.38% VTVTFQDNKGTYEVGRPQ 95.00% 2.67 0.196 0 0 1 0 2 2,040.05 227 244
2DLC TX114lpqT (lpqT)  Rv1016c 24045 99.80% 2 2 4 0.02% 10.60% GESYPTAMLMVFK 95.00% 2.63 0.588 0 1 0 0 2 1,474.82 110 122
2DLC TX114lpqT (lpqT)  Rv1016c 24045 99.80% 2 2 4 0.02% 10.60% IVFPTGAPPAK 95.00% 2.51 0.412 0 3 0 0 2 1,098.36 181 191
2DLC TX114ask (ask)  Rv3709c 44411 99.80% 2 2 4 0.02% 5.70% VSLIGAGMR 95.00% 2.69 0.455 0 2 0 0 2 904.1484 347 355
2DLC TX114ask (ask)  Rv3709c 44411 99.80% 2 2 4 0.02% 5.70% VTIVGLPDIPGYAAK 95.00% 1.96 0.352 0 2 0 0 2 1,514.86 267 281
2DLC TX114secA (secA)  Rv3240c 105974 100.00% 5 5 12 0.07% 7.38% FNGAALETLLTR 95.00% 3.3 0.328 0 1 0 0 2 1,306.63 594 605
2DLC TX114secA (secA)  Rv3240c 105974 100.00% 5 5 12 0.07% 7.38% NVLLNVIDR 95.00% 3.17 0.342 0 4 0 0 2 1,056.26 769 777
2DLC TX114secA (secA)  Rv3240c 105974 100.00% 5 5 12 0.07% 7.38% SAQTQVEQQNFEVR 95.00% 3.57 0.447 0 0 2 0 2 1,664.52 625 638
2DLC TX114secA (secA)  Rv3240c 105974 100.00% 5 5 12 0.07% 7.38% TLYPVGITADSLTR 95.00% 3.22 0.509 0 4 0 0 2 1,507.82 707 720
2DLC TX114secA (secA)  Rv3240c 105974 100.00% 5 5 12 0.07% 7.38%
VADYVGTLSDDVEKLTDAE
LR 95.00% 4.35 0.634 0 0 1 0 2 2,310.52 20 40
2DLC TX114lldD2 (lldD2)  Rv1872c 45325 100.00% 6 7 15 0.09% 13.30% AIEILQTGVIR 95.00% 4.44 0.524 0 4 0 0 2 1,213.52 373 383
2DLC TX114lldD2 (lldD2)  Rv1872c 45325 100.00% 6 7 15 0.09% 13.30% DIEFHPTILR 95.00% 2.75 0.312 0 2 0 0 2 1,241.54 75 84
2DLC TX114lldD2 (lldD2)  Rv1872c 45325 100.00% 6 7 15 0.09% 13.30% GVDGIVLSNHGGR 95.00% 2.91 0.429 0 0 2 0 2 1,281.34 292 304
2DLC TX114lldD2 (lldD2)  Rv1872c 45325 100.00% 6 7 15 0.09% 13.30% LGPIGAPT 95.00% 1.13 0.465 1 1 0 0 2 725.9384 407 414
2DLC TX114lldD2 (lldD2)  Rv1872c 45325 100.00% 6 7 15 0.09% 13.30% RLGAALTIQDLR 95.00% 1.95 0.198 0 0 1 0 2 1,327.73 30 41
2DLC TX114lldD2 (lldD2)  Rv1872c 45325 100.00% 6 7 15 0.09% 13.30% RLGPIGAPT 95.00% 1.73 0.399 0 4 0 0 2 882.1384 406 414
2DLC TX114asd (asd)  Rv3708c 36212 99.80% 2 3 5 0.03% 7.54% GLALFVSGDNLR 95.00% 3.39 0.529 0 2 0 0 2 1,262.55 316 327
2DLC TX114asd (asd)  Rv3708c 36212 99.80% 2 3 5 0.03% 7.54% TLLDERDFPASAVR 95.00% 3.59 0.424 0 1 2 0 2 1,590.85 20 33
2DLC TX114
hypo protein 
Rv1871c  Rv1871c 14645 100.00% 4 4 6 0.03% 34.90% AMGTDLLTIR 95.00% 2.91 0.367 0 1 0 0 2 1,091.45 116 125
2DLC TX114
hypo protein 
Rv1871c  Rv1871c 14645 100.00% 4 4 6 0.03% 34.90% FVVNPIGR 94.40% 1.98 0.202 0 1 0 0 2 902.0284 18 25
2DLC TX114
hypo protein 
Rv1871c  Rv1871c 14645 100.00% 4 4 6 0.03% 34.90% QLPMTMLETIGR 95.00% 2.04 0.448 0 2 0 0 2 1,422.79 26 37
2DLC TX114
hypo protein 
Rv1871c  Rv1871c 14645 100.00% 4 4 6 0.03% 34.90% SGTAYLLPDDDPRQR 95.00% 1.82 0.403 0 0 2 0 2 1,704.97 88 102
2DLC TX114argB (argB)  Rv1654 30918 99.80% 2 2 3 0.02% 7.14% AVIGGVPSAHIIDGR 95.00% 2.61 0.57 0 2 0 0 2 1,462.67 258 272
2DLC TX114argB (argB)  Rv1654 30918 99.80% 2 2 3 0.02% 7.14%
VEACLRAVIGGVPSAHIIDG
R 95.00% 1.84 0.263 0 0 1 0 2 2,192.45 252 272
2DLC TX114otsA (otsA)  Rv3490 55845 99.80% 2 2 5 0.03% 5.80% SPGGLVTALEPVLR 95.00% 4.21 0.612 0 4 0 0 2 1,409.66 46 59
2DLC TX114otsA (otsA)  Rv3490 55845 99.80% 2 2 5 0.03% 5.80% WAQSFLDALAGAHPR 95.00% 3.32 0.427 0 0 1 0 2 1,640.89 483 497
2DLC TX114
hypo protein 
Rv2028c  Rv2028c 29422 99.10% 2 2 2 0.01% 12.50% LLYAIEPDDPGYAAHGAAAR 95.00% 2.64 0.442 0 0 1 0 2 2,072.44 40 59
2DLC TX114
hypo protein 
Rv2028c  Rv2028c 29422 99.10% 2 2 2 0.01% 12.50% QEAGCTLLVVGQQYL 81.40% 1.88 0.197 0 0 1 0 2 1,679.79 265 279
2DLC TX114
hypo protein 
Rv0559c  Rv0559c 12099 99.50% 2 2 4 0.02% 19.60% FGIYGPQDYNAWLAK 95.00% 3.36 0.633 0 3 0 0 2 1,744.10 39 53
2DLC TX114
hypo protein 
Rv0559c  Rv0559c 12099 99.50% 2 2 4 0.02% 19.60% SATFLQR 89.60% 1.62 0.287 0 1 0 0 2 822.9784 70 76
2DLC TX114
hypo protein 
Rv1636  Rv1636 15294 100.00% 4 6 13 0.08% 34.20% LIIASAYLPQHEDAR 95.00% 4.56 0.62 0 4 1 0 2 1,698.06 34 48
2DLC TX114
hypo protein 
Rv1636  Rv1636 15294 100.00% 4 6 13 0.08% 34.20% LLGSVPANVSR 95.00% 2.82 0.216 0 3 0 0 2 1,113.27 124 134
2DLC TX114
hypo protein 
Rv1636  Rv1636 15294 100.00% 4 6 13 0.08% 34.20% VDVLIVHTT 95.00% 2.89 0.608 0 2 0 0 2 997.0284 138 146
2DLC TX114
hypo protein 
Rv1636  Rv1636 15294 100.00% 4 6 13 0.08% 34.20% VTGTAPIYEILHDAK 95.00% 2.79 0.461 0 2 1 0 2 1,628.92 60 74
2DLC TX114polA (polA)  Rv1629 98425 100.00% 4 4 9 0.05% 4.31% ALNEAQLASR 95.00% 2.62 0.341 0 2 0 0 2 1,073.24 841 850
2DLC TX114polA (polA)  Rv1629 98425 100.00% 4 4 9 0.05% 4.31% FTPEAVVEK 94.90% 1.47 0.306 0 1 0 0 2 1,020.06 174 182
2DLC TX114polA (polA)  Rv1629 98425 100.00% 4 4 9 0.05% 4.31% SFTLDDLSLR 95.00% 3.01 0.515 0 4 0 0 2 1,167.48 433 442
2DLC TX114polA (polA)  Rv1629 98425 100.00% 4 4 9 0.05% 4.31% SLVDNVDAVR 95.00% 2.81 0.422 0 2 0 0 2 1,088.09 227 236
2DLC TX114
hypo protein 
Rv1626  Rv1626 22652 99.80% 2 3 5 0.03% 12.20% RDGIDAASEIASK 95.00% 2.61 0.451 0 1 2 0 2 1,333.57 71 83
2DLC TX114
hypo protein 
Rv1626  Rv1626 22652 99.80% 2 3 5 0.03% 12.20% RVLIAEDEALIR 95.00% 3.9 0.374 0 2 0 0 2 1,398.75 15 26
2DLC TX114
hypo protein 
Rv2030c  Rv2030c 74880 100.00% 8 8 18 0.10% 12.60% AIGVVYLPATER 95.00% 2.37 0.463 0 2 0 0 2 1,289.49 623 634
2DLC TX114
hypo protein 
Rv2030c  Rv2030c 74880 100.00% 8 8 18 0.10% 12.60% ALEPLEVTSR 95.00% 2.51 0.51 0 4 0 0 2 1,115.27 658 667
2DLC TX114
hypo protein 




Rv2030c  Rv2030c 74880 100.00% 8 8 18 0.10% 12.60% DFVEWLR 95.00% 2.12 0.237 0 2 0 0 2 965.0884 349 355
2DLC TX114
hypo protein 
Rv2030c  Rv2030c 74880 100.00% 8 8 18 0.10% 12.60% LLATPTAGPSLR 95.00% 2.88 0.435 0 3 0 0 2 1,197.55 221 232
2DLC TX114
hypo protein 
Rv2030c  Rv2030c 74880 100.00% 8 8 18 0.10% 12.60% LSRDAEAPLDVVR 95.00% 3.38 0.334 0 0 2 0 2 1,441.62 607 619
2DLC TX114
hypo protein 
Rv2030c  Rv2030c 74880 100.00% 8 8 18 0.10% 12.60%
VAIDAPGGVPTHEVLAELVG
DAR 95.00% 3.96 0.548 0 0 2 0 2 2,287.41 246 268
2DLC TX114
hypo protein 
Rv2030c  Rv2030c 74880 100.00% 8 8 18 0.10% 12.60% VVVNDDVVR 95.00% 2 0.274 0 1 0 0 2 1,014.87 92 100
2DLC TX114
fbpC2 
(fbpC2)  Rv0129c 36754 99.50% 2 2 2 0.01% 8.53%
ADIQHVLNGATPPAAPAAPA
A 90.00% 1.79 0.253 0 0 1 0 2 1,954.16 320 340
2DLC TX114fbpC2 Rv0129c 36754 99.50% 2 2 2 0.01% 8.53% FLEGLTLR 95.00% 2.3 0.183 0 1 0 0 2 949.2684 272 279
2DLC TX114frr (frr)  Rv2882c 20810 100.00% 3 4 8 0.05% 16.80% ANPGMFSR 95.00% 1.74 0.417 0 2 0 0 2 880.0484 32 39
2DLC TX114frr (frr)  Rv2882c 20810 100.00% 3 4 8 0.05% 16.80% LVVIKPYEANQLR 95.00% 2.05 0.336 0 2 1 0 2 1,543.86 64 76
2DLC TX114frr (frr)  Rv2882c 20810 100.00% 3 4 8 0.05% 16.80% VAVPQLTEER 95.00% 2.47 0.5 0 3 0 0 2 1,142.16 100 109
2DLC TX114appC (appC)  Rv1623c 53809 99.80% 2 2 3 0.02% 4.12% MFQQQPMK 95.00% 2.18 0.28 0 1 0 0 2 1,054.24 251 258
2DLC TX114appC (appC)  Rv1623c 53809 99.80% 2 2 3 0.02% 4.12% PTGDQLVRLTVK 95.00% 1.25 0.334 0 0 2 0 2 1,327.53 408 419
2DLC TX114trpC (trpC)  Rv1611 28005 100.00% 3 3 4 0.02% 11.00% ASVSIPVLR 95.00% 2 0.223 0 2 0 0 2 942.1184 110 118
2DLC TX114trpC (trpC)  Rv1611 28005 100.00% 3 3 4 0.02% 11.00% FQGSLDDLDAVR 95.00% 2.86 0.451 0 1 0 0 2 1,336.50 98 109
2DLC TX114trpC (trpC)  Rv1611 28005 100.00% 3 3 4 0.02% 11.00% IVSVVTEQR 95.00% 2.78 0.39 0 1 0 0 2 1,031.01 88 96
2DLC TX114
hypo protein 
Rv3448  Rv3448 46713 98.60% 2 2 2 0.01% 4.28%
LSGALAASCITAGGGLMLV
R 79.60% 1.86 0.2 0 0 1 0 2 1,878.37 120 139
2DLC TX114
hypo protein 
Rv3448  Rv3448 46713 98.60% 2 2 2 0.01% 4.28% SGALAASCITAGGGLMLVR 93.30% 1.85 0.263 0 0 1 0 2 1,806.22 121 139
2DLC TX114
hypo protein 
Rv0569  Rv0569 9504 100.00% 3 5 13 0.08% 35.20% FGAVQSAILHAR 95.00% 3.5 0.436 0 2 3 0 2 1,270.46 75 86
2DLC TX114
hypo protein 
Rv0569  Rv0569 9504 100.00% 3 5 13 0.08% 35.20% SSDGSPPYVVR 95.00% 2.53 0.426 0 2 0 0 2 1,164.19 30 40
2DLC TX114
hypo protein 
Rv0569  Rv0569 9504 100.00% 3 5 13 0.08% 35.20% VGDWLVIK 95.00% 1.87 0.272 2 4 0 0 2 930.1084 5 12
2DLC TX114sahH (sahH)  Rv3248c 54306 100.00% 6 6 13 0.08% 13.90% GVTEETTTGVLR 95.00% 2.33 0.275 0 2 0 0 2 1,263.26 214 225
2DLC TX114sahH (sahH)  Rv3248c 54306 100.00% 6 6 13 0.08% 13.90% IADLSLADFGR 95.00% 3.62 0.502 0 2 0 0 2 1,178.51 23 33
2DLC TX114sahH (sahH)  Rv3248c 54306 100.00% 6 6 13 0.08% 13.90% IAEHEMPGLMSLR 95.00% 2.77 0.373 0 0 2 0 2 1,484.85 38 50
2DLC TX114sahH (sahH)  Rv3248c 54306 100.00% 6 6 13 0.08% 13.90% SIIVLSEGR 95.00% 2.77 0.378 0 2 0 0 2 974.1984 398 406
2DLC TX114sahH (sahH)  Rv3248c 54306 100.00% 6 6 13 0.08% 13.90% VFLNLLR 95.00% 2.07 0.374 0 4 0 0 2 875.1884 189 195
2DLC TX114sahH (sahH)  Rv3248c 54306 100.00% 6 6 13 0.08% 13.90% VNVKPQVDLWTFGDTGR 95.00% 2.82 0.359 0 0 1 0 2 1,933.05 381 397
2DLC TX114infA (infA)  Rv3462c 8471 100.00% 4 5 9 0.05% 53.40% IELENGHKVL 83.60% 2.06 0.114 0 0 1 0 2 1,152.34 25 34
2DLC TX114infA (infA)  Rv3462c 8471 100.00% 4 5 9 0.05% 53.40% ILPEDRVVVELSPYDLSR 95.00% 2.34 0.27 0 0 1 0 2 2,101.43 48 65
2DLC TX114infA (infA)  Rv3462c 8471 100.00% 4 5 9 0.05% 53.40% VVEPLPNAMFR 95.00% 3.31 0.459 0 4 1 0 2 1,273.48 14 24
2DLC TX114infA (infA)  Rv3462c 8471 100.00% 4 5 9 0.05% 53.40% VVVELSPYDLSR 95.00% 2.3 0.535 0 2 0 0 2 1,377.51 54 65
2DLC TX114topA (topA)  Rv3646c 102303 100.00% 5 5 6 0.03% 6.75% ALEELGIGRPSTYSSIIK 95.00% 2.47 0.288 0 0 1 0 2 1,935.46 525 542
2DLC TX114topA (topA)  Rv3646c 102303 100.00% 5 5 6 0.03% 6.75% KPRIPVK 90.60% 1.75 0.235 0 1 0 0 2 838.1284 128 134
2DLC TX114topA (topA)  Rv3646c 102303 100.00% 5 5 6 0.03% 6.75% LVGINLEGIDAR 95.00% 3.69 0.437 0 2 0 0 2 1,270.57 628 639
2DLC TX114topA (topA)  Rv3646c 102303 100.00% 5 5 6 0.03% 6.75% MVFHEITEPAIR 95.00% 2.65 0.219 0 0 1 0 2 1,443.69 136 147
2DLC TX114topA (topA)  Rv3646c 102303 100.00% 5 5 6 0.03% 6.75% SMDLQTVTLEDALR 95.00% 2.31 0.377 0 1 0 0 2 1,592.85 769 782
2DLC TX114rpsM (rpsM)  Rv3460c 14333 97.80% 2 2 2 0.01% 15.30% DLTEEQLIHLR 80.30% 1.69 0.255 0 1 0 0 2 1,367.62 47 57
2DLC TX114rpsM (rpsM)  Rv3460c 14333 97.80% 2 2 2 0.01% 15.30% LVGVDLPR 88.70% 2.67 0.0992 0 1 0 0 2 869.0284 4 11
2DLC TX114metE (metE)  Rv1133c 81532 100.00% 7 9 15 0.09% 9.62% AGEIDEAEYVRR 95.00% 2.17 0.399 0 0 3 0 2 1,408.50 455 466
2DLC TX114metE (metE)  Rv1133c 81532 100.00% 7 9 15 0.09% 9.62% EVVVLAR 95.00% 2.02 0.186 0 1 0 0 2 785.8084 359 365
2DLC TX114metE (metE)  Rv1133c 81532 100.00% 7 9 15 0.09% 9.62% LHLPPLPTTTIGSYPQTSAIR 95.00% 3.29 0.533 0 0 2 0 2 2,264.79 427 447
2DLC TX114metE (metE)  Rv1133c 81532 100.00% 7 9 15 0.09% 9.62% SELEAVAATLR 95.00% 1.28 0.231 2 1 0 0 2 1,160.31 41 51
2DLC TX114metE (metE)  Rv1133c 81532 100.00% 7 9 15 0.09% 9.62% TSRSELEAVAATLR 95.00% 2.98 0.44 0 1 3 0 2 1,504.69 38 51
2DLC TX114metE (metE)  Rv1133c 81532 100.00% 7 9 15 0.09% 9.62% VPSAEEMADSLR 95.00% 3.11 0.577 0 1 0 0 2 1,305.43 704 715
2DLC TX114metE (metE)  Rv1133c 81532 100.00% 7 9 15 0.09% 9.62% WAVGAFR 95.00% 1.97 0.33 0 1 0 0 2 806.8984 626 632
2DLC TX114icd2 (icd2)  Rv0066c 82534 100.00% 3 3 7 0.04% 6.04% IEASDISVAAR 95.00% 3.34 0.502 0 2 0 0 2 1,132.29 39 49
2DLC TX114icd2 (icd2)  Rv0066c 82534 100.00% 3 3 7 0.04% 6.04% TFNAALEAVQG 95.00% 2.4 0.447 0 3 0 0 2 1,121.18 735 745
2DLC TX114icd2 (icd2)  Rv0066c 82534 100.00% 3 3 7 0.04% 6.04%
TIVLKPEVPLDDGDVIDSMF
MSK 95.00% 3.51 0.61 0 0 2 0 2 2,551.08 209 231
2DLC TX114pks2 (pks2)  Rv3825c 225737 99.90% 2 2 3 0.02% 1.36% ELSDLPGAVPR 95.00% 2.68 0.464 0 2 0 0 2 1,154.34 1317 1327
2DLC TX114pks2 (pks2)  Rv3825c 225737 99.90% 2 2 3 0.02% 1.36% LGLFPFR 95.00% 1.87 0.319 0 2 0 0 2 850.1884 1674 1680
2DLC TX114pks2 (pks2)  Rv3825c 225737 99.90% 2 2 3 0.02% 1.36% NMGIEHVYDSR 95.00% 1.54 0.267 0 0 1 0 2 1,321.42 1608 1618
2DLC TX114
hypo protein 
Rv0386  Rv0386 116775 99.40% 2 2 2 0.01% 1.84% ADENAR 93.50% 1.1 -0.0216 1 0 0 0 2 675.6784 603 608
2DLC TX114
hypo protein 
Rv0386  Rv0386 116775 99.40% 2 2 2 0.01% 1.84% SEAGEVDAVFARHR 90.30% 1.86 0.182 0 0 1 0 2 1,544.53 513 526
2DLC TX114sec (sec)  Rv0379 7948 100.00% 3 3 4 0.02% 29.60% IKLEVSFK 95.00% 2.24 0.313 0 0 1 0 2 964.2684 57 64
2DLC TX114sec (sec)  Rv0379 7948 100.00% 3 3 4 0.02% 29.60% LEVSFK 95.00% 1.48 0.353 0 1 0 0 2 722.8684 59 64
2DLC TX114sec (sec)  Rv0379 7948 100.00% 3 3 4 0.02% 29.60% VIEQDMAVDSAGK 95.00% 2.91 0.568 0 2 0 0 2 1,363.45 40 52
2DLC TX114
wag31 
(wag31)  Rv2145c 28260 100.00% 8 11 31 0.18% 39.60% ADAMLADAQSR 95.00% 3.33 0.356 0 2 0 0 2 1,149.32 158 168
2DLC TX114
wag31 
(wag31)  Rv2145c 28260 100.00% 8 11 31 0.18% 39.60% ANAEQILGEAR 95.00% 4.16 0.451 1 7 0 0 2 1,172.31 134 144
2DLC TX114
wag31 
(wag31)  Rv2145c 28260 100.00% 8 11 31 0.18% 39.60%
GSAAPVDSNADAGGFDQF
NR 95.00% 4.71 0.551 0 3 6 0 2 1,997.04 238 257
2DLC TX114
wag31 
(wag31)  Rv2145c 28260 100.00% 8 11 31 0.18% 39.60% HSEIMGTINQQR 95.00% 2.39 0.401 0 0 1 0 2 1,414.55 191 202
2DLC TX114
wag31 
(wag31)  Rv2145c 28260 100.00% 8 11 31 0.18% 39.60% HTADATVAEAR 95.00% 2.3 0.558 0 1 0 0 2 1,142.11 145 155
2DLC TX114
wag31 
(wag31)  Rv2145c 28260 100.00% 8 11 31 0.18% 39.60% LEQLR 95.00% 1.49 0.0791 3 0 0 0 2 658.8184 209 213
2DLC TX114
wag31 
(wag31)  Rv2145c 28260 100.00% 8 11 31 0.18% 39.60% LIEENSDLR 95.00% 2.74 0.34 0 2 0 0 2 1,089.30 42 50
2DLC TX114
wag31 
(wag31)  Rv2145c 28260 100.00% 8 11 31 0.18% 39.60% TYLESQLEELGQR 95.00% 4.36 0.48 0 2 3 0 2 1,566.75 225 237
2DLC TX114
wag31 
(wag31)  Rv2145c 28260 100.00% 8 11 31 0.18% 39.60% VLSLAQDTADR 95.00% 2.92 0.527 0 3 0 0 2 1,189.33 106 116
2DLC TX114
hypo protein 
Rv0361  Rv0361 29964 99.80% 2 3 6 0.03% 3.64% FTAPGFDAK 95.00% 1.68 0.515 0 4 0 0 2 954.1484 68 76
2DLC TX114
hypo protein 
Rv0361  Rv0361 29964 99.80% 2 3 6 0.03% 3.64% RFTAPGFDAK 95.00% 2.18 0.292 0 1 1 0 2 1,110.35 67 76
2DLC TX114
hypo protein 
Rv1926c  Rv1926c 16496 99.80% 2 3 8 0.05% 13.20% GSVTPAVSQFNAR 95.00% 2.52 0.479 0 3 3 0 2 1,334.35 87 99
2DLC TX114
hypo protein 




Rv0247c  Rv0247c 28607 99.80% 2 2 2 0.01% 9.68% IAELEMHPLDTR 95.00% 2.89 0.392 0 0 1 0 2 1,425.72 176 187
2DLC TX114
hypo protein 
Rv0247c  Rv0247c 28607 99.80% 2 2 2 0.01% 9.68% LQQTQTPDLAVR 95.00% 2.76 0.507 0 1 0 0 2 1,370.49 39 50
2DLC TX114dnaJ (dnaJ)  Rv0352 41327 100.00% 4 4 10 0.06% 12.20% DLHPDANPGNPAAGER 95.00% 2.81 0.343 0 0 1 0 2 1,631.72 36 51
2DLC TX114dnaJ (dnaJ)  Rv0352 41327 100.00% 4 4 10 0.06% 12.20% LAGQGEAGLR 95.00% 2.93 0.435 0 1 0 0 2 972.1284 261 270
2DLC TX114dnaJ (dnaJ)  Rv0352 41327 100.00% 4 4 10 0.06% 12.20% LFAGGGFGGR 95.00% 2.88 0.436 0 6 0 0 2 939.1484 77 86
2DLC TX114dnaJ (dnaJ)  Rv0352 41327 100.00% 4 4 10 0.06% 12.20% SGGSGDLLVTVK 95.00% 2.9 0.503 0 2 0 0 2 1,133.27 347 358
2DLC TX114qcrA (qcrA)  Rv2195 46906 99.80% 2 2 4 0.02% 3.96% NPVMLIR 95.00% 2.31 0.345 0 2 0 0 2 843.1084 317 323
2DLC TX114qcrA (qcrA)  Rv2195 46906 99.80% 2 2 4 0.02% 3.96% YQGETIYLAR 95.00% 2.63 0.373 0 2 0 0 2 1,214.45 254 263
2DLC TX114lppM (lppM)  Rv2171 23796 99.80% 2 2 3 0.02% 10.60% LKPGVVSTMSAQAR 95.00% 3.1 0.414 0 0 1 0 2 1,445.65 164 177
2DLC TX114lppM (lppM)  Rv2171 23796 99.80% 2 2 3 0.02% 10.60% NGNIVILEGR 95.00% 3.16 0.303 0 2 0 0 2 1,085.29 115 124
2DLC TX114
hypo protein 
Rv3651  Rv3651 37950 99.70% 2 2 2 0.01% 6.38% APAVPVDDLAQR 95.00% 2.01 0.209 0 0 1 0 2 1,252.34 212 223
2DLC TX114
hypo protein 
Rv3651  Rv3651 37950 99.70% 2 2 2 0.01% 6.38% KLVPITTFLR 94.90% 1.86 0.206 0 1 0 0 2 1,188.61 26 35
2DLC TX114
fadA3 
(fadA3)  Rv1074c 42638 100.00% 3 3 6 0.03% 13.80%
AGMAITDIDLVEINEAFAVQ
VLGSAREL 95.00% 2.39 0.176 0 0 1 0 2 2,963.41 315 342
2DLC TX114fadA3 Rv1074c 42638 100.00% 3 3 6 0.03% 13.80% AKELGLTPLAR 95.00% 2.97 0.461 0 4 0 0 2 1,169.55 276 286
2DLC TX114fadA3 Rv1074c 42638 100.00% 3 3 6 0.03% 13.80% GSLVGMRPDDLAVQMVR 95.00% 3.59 0.531 0 0 1 0 2 1,845.11 20 36
2DLC TX114fabG4 Rv0242c 46781 100.00% 8 12 26 0.15% 23.60% ADILVNNAGITR 95.00% 2.53 0.282 0 2 0 0 2 1,257.50 289 300
2DLC TX114fabG4 Rv0242c 46781 100.00% 8 12 26 0.15% 23.60% AGEPPLTGSLLIGGAGR 95.00% 3.06 0.371 0 2 2 0 2 1,566.95 39 55
2DLC TX114fabG4 Rv0242c 46781 100.00% 8 12 26 0.15% 23.60% ALEGFTR 95.00% 1.92 0.378 0 2 0 0 2 793.9484 140 146
2DLC TX114
fabG4 
(fabG4)  Rv0242c 46781 100.00% 8 12 26 0.15% 23.60%
GATTALVYLSPDAKPAATGL
ESTMR 95.00% 3.21 0.547 0 0 3 0 2 2,522.99 155 179
2DLC TX114fabG4 Rv0242c 46781 100.00% 8 12 26 0.15% 23.60% GIGATIAEVFAR 95.00% 3.23 0.45 1 4 2 0 2 1,205.43 224 235
2DLC TX114fabG4 Rv0242c 46781 100.00% 8 12 26 0.15% 23.60% GLHEFFTPVLR 95.00% 2.64 0.484 0 3 1 0 2 1,316.56 101 111
2DLC TX114fabG4 Rv0242c 46781 100.00% 8 12 26 0.15% 23.60% VAIVTGAAR 95.00% 2.39 0.354 0 1 0 0 2 857.9484 215 223
2DLC TX114fabG4 Rv0242c 46781 100.00% 8 12 26 0.15% 23.60% VIGLSSIAGIAGNR 95.00% 3.29 0.584 0 3 0 0 2 1,328.66 342 355
2DLC TX114
hypo protein 
Rv0309  Rv0309 22510 99.80% 2 2 3 0.02% 16.50% TGITTHIGSAGMAPEAK 95.00% 3.54 0.378 0 0 1 0 2 1,642.91 71 87
2DLC TX114
hypo protein 
Rv0309  Rv0309 22510 99.80% 2 2 3 0.02% 16.50%
WWSGDDNSPTFNSMQVC
QK 95.00% 1.93 0.369 0 2 0 0 2 2,289.33 124 142
2DLC TX114echA8 Rv1070c 27256 100.00% 3 3 5 0.03% 12.80% AFESSLSEGLLYER 95.00% 3.07 0.484 0 1 0 0 2 1,601.89 214 227
2DLC TX114echA8 Rv1070c 27256 100.00% 3 3 5 0.03% 12.80% FGQPEIK 95.00% 2.16 0.319 0 2 0 0 2 818.9884 127 133
2DLC TX114echA8 Rv1070c 27256 100.00% 3 3 5 0.03% 12.80% LGVLPGMGGSQR 95.00% 2.1 0.416 0 2 0 0 2 1,172.39 134 145
2DLC TX114
hypo protein 
Rv3099c  Rv3099c 30458 100.00% 3 3 9 0.05% 12.00% LDGLQFTR 95.00% 2.8 0.334 0 3 0 0 2 950.1684 241 248
2DLC TX114
hypo protein 
Rv3099c  Rv3099c 30458 100.00% 3 3 9 0.05% 12.00% VLLELTGPLSR 95.00% 2.87 0.507 0 4 0 0 2 1,198.54 204 214
2DLC TX114
hypo protein 
Rv3099c  Rv3099c 30458 100.00% 3 3 9 0.05% 12.00% VVDDFGGPAPTATIR 95.00% 2.52 0.521 0 2 0 0 2 1,516.66 226 240
2DLC TX114hisD (hisD)  Rv1599 45326 99.70% 2 2 2 0.01% 7.31% GAELTAAELR 95.00% 2.37 0.315 0 1 0 0 2 1,031.21 9 18
2DLC TX114hisD (hisD)  Rv1599 45326 99.70% 2 2 2 0.01% 7.31%
TPVDMITGPGNIYVTAAKRL
CR 93.70% 1.65 0.279 0 0 1 0 2 2,377.86 211 232
2DLC TX114
hypo protein 
Rv1558  Rv1558 16329 100.00% 3 4 7 0.04% 29.10% AIWWQR 87.50% 1.39 0.262 0 1 0 0 2 859.9984 112 117
2DLC TX114
hypo protein 
Rv1558  Rv1558 16329 100.00% 3 4 7 0.04% 29.10% AVAVWPDYASYQTK 95.00% 3.23 0.435 0 2 1 0 2 1,599.70 118 131
2DLC TX114
hypo protein 
Rv1558  Rv1558 16329 100.00% 3 4 7 0.04% 29.10%
SGGTEGTQLQGKPVILLTTV
GAK 95.00% 3.98 0.648 0 0 3 0 2 2,256.59 25 47
2DLC TX114
hypo protein 
Rv1544  Rv1544 28182 100.00% 3 3 4 0.02% 9.74% GFPLMLVAR 95.00% 2.53 0.38 0 1 0 0 2 1,004.34 33 41
2DLC TX114
hypo protein 
Rv1544  Rv1544 28182 100.00% 3 3 4 0.02% 9.74% SLLLPAIR 94.20% 1.56 0.268 0 1 0 0 2 883.2984 249 256
2DLC TX114
hypo protein 
Rv1544  Rv1544 28182 100.00% 3 3 4 0.02% 9.74% TVVPGIVPK 95.00% 1.56 0.4 0 2 0 0 2 910.0184 229 237
2DLC TX114
hypo protein 
Rv1543  Rv1543 36803 99.80% 2 2 5 0.03% 5.57% FTTVHMALVR 95.00% 1.63 0.371 0 0 2 0 2 1,175.34 232 241
2DLC TX114
hypo protein 
Rv1543  Rv1543 36803 99.80% 2 2 5 0.03% 5.57% NLLDAVQGR 95.00% 2.52 0.445 0 3 0 0 2 986.1184 37 45
2DLC TX114rne (rne)  Rv2444c 103341 100.00% 3 4 6 0.03% 4.09% EVVPSDAGVIIR 95.00% 2.52 0.379 0 2 0 0 2 1,255.36 490 501
2DLC TX114rne (rne)  Rv2444c 103341 100.00% 3 4 6 0.03% 4.09% FLVYVPGASSTGISR 95.00% 2.84 0.451 0 2 1 0 2 1,554.80 460 474
2DLC TX114rne (rne)  Rv2444c 103341 100.00% 3 4 6 0.03% 4.09% RVLDALTALDGR 95.00% 2.81 0.483 0 1 0 0 2 1,300.60 38 49
2DLC TX114fba (fba)  Rv0363c 36527 99.30% 2 2 3 0.02% 9.01% LRPDILAQGQQVAAAK 95.00% 3.57 0.518 0 0 2 0 2 1,679.98 222 237
2DLC TX114fba (fba)  Rv0363c 36527 99.30% 2 2 3 0.02% 9.01% PIAGHMFTNYDGVLK 85.30% 1.67 0.237 0 0 1 0 2 1,679.99 286 300
2DLC TX114
fadE25 
(fadE25)  Rv3274c 41706 99.80% 2 3 9 0.05% 5.66% ITQIYEGTNQIQR 95.00% 4.1 0.485 0 2 2 0 2 1,564.77 368 380
2DLC TX114
fadE25 
(fadE25)  Rv3274c 41706 99.80% 2 3 9 0.05% 5.66% LGTMGLILR 95.00% 2.44 0.28 0 5 0 0 2 974.4184 102 110
2DLC TX114oxcA (oxcA)  Rv0118c 61154 99.70% 2 2 2 0.01% 6.87%
AAYRIGQVQDIGRGVARAI
R 84.80% 1.63 0.288 0 0 1 0 2 2,171.53 138 157
2DLC TX114oxcA (oxcA)  Rv0118c 61154 99.70% 2 2 2 0.01% 6.87%
SASPCTVLTDGCHLVVDAL
K 95.00% 2.25 0.218 0 1 0 0 2 2,030.22 5 24
2DLC TX114fixA (fixA)  Rv3029c 28063 100.00% 3 4 7 0.04% 16.20% AVEEALQIR 95.00% 1.84 0.406 2 2 0 0 2 1,029.15 43 51
2DLC TX114fixA (fixA)  Rv3029c 28063 100.00% 3 4 7 0.04% 16.20% LTDGDFTLDR 89.60% 2.88 0.0738 0 1 0 0 2 1,153.37 20 29
2DLC TX114fixA (fixA)  Rv3029c 28063 100.00% 3 4 7 0.04% 16.20%
TAGEKVTDEGEGGNQIVQY
LVAQK 95.00% 4.55 0.6 0 0 2 0 2 2,535.59 241 264
2DLC TX114rpoA (rpoA)  Rv3457c 37689 100.00% 6 9 26 0.15% 20.50% EGVHTVGELVAR 95.00% 1.88 0.474 0 2 0 0 2 1,267.21 267 278
2DLC TX114rpoA (rpoA)  Rv3457c 37689 100.00% 6 9 26 0.15% 20.50% GYVPAVQNR 95.00% 1.74 0.452 0 2 0 0 2 1,004.01 145 153
2DLC TX114rpoA (rpoA)  Rv3457c 37689 100.00% 6 9 26 0.15% 20.50% IPVDSIYSPVLK 95.00% 3.62 0.447 0 3 1 0 2 1,331.66 162 173
2DLC TX114rpoA (rpoA)  Rv3457c 37689 100.00% 6 9 26 0.15% 20.50% TDFDKLILDVETK 95.00% 3.84 0.41 0 1 3 0 2 1,537.89 187 199
2DLC TX114rpoA (rpoA)  Rv3457c 37689 100.00% 6 9 26 0.15% 20.50% TLLSSIPGAAVTSIR 95.00% 3.37 0.553 0 6 0 0 2 1,486.86 41 55
2DLC TX114rpoA (rpoA)  Rv3457c 37689 100.00% 6 9 26 0.15% 20.50% TLVELFGLAR 95.00% 1.48 0.155 2 6 0 0 2 1,119.42 214 223
2DLC TX114fixB (fixB)  Rv3028c 31672 100.00% 4 7 19 0.11% 16.40%
AAVDSGYYPGQFQVGQTG
K 95.00% 4.77 0.646 0 1 1 0 2 1,974.02 233 251
2DLC TX114fixB (fixB)  Rv3028c 31672 100.00% 4 7 19 0.11% 16.40% IGSGLLVDVVDVR 95.00% 3.51 0.458 1 10 0 0 2 1,342.48 109 121
2DLC TX114fixB (fixB)  Rv3028c 31672 100.00% 4 7 19 0.11% 16.40% VAPQLTEAIK 95.00% 1.76 0.449 2 2 0 0 2 1,070.27 305 314
2DLC TX114fixB (fixB)  Rv3028c 31672 100.00% 4 7 19 0.11% 16.40% VSAELITAAR 95.00% 2.56 0.437 0 2 0 0 2 1,031.21 18 27
2DLC TX114
hypo protein 
Rv2626c  Rv2626c 15500 99.80% 2 3 6 0.03% 21.00% GLAAGLDPNTATAGELAR 95.00% 3.78 0.598 0 3 1 0 2 1,698.99 58 75
2DLC TX114
hypo protein 
Rv2626c  Rv2626c 15500 99.80% 2 3 6 0.03% 21.00% LVGIVTEADIAR 95.00% 2.87 0.544 0 2 0 0 2 1,257.47 110 121
2DLC TX114
hypo protein 




Rv0981  Rv0981 25844 99.80% 2 2 3 0.02% 10.90% GTGDDLPILVLTAR 95.00% 1.94 0.278 0 1 0 0 2 1,441.79 70 83
2DLC TX114rpmA (rpmA)  Rv2441c 8950 99.80% 2 2 4 0.02% 16.30% AGEILVR 95.00% 2.59 0.213 0 1 0 0 2 757.9184 33 39
2DLC TX114rpmA (rpmA)  Rv2441c 8950 99.80% 2 2 4 0.02% 16.30% GASSSRN 95.00% 0.952 0.129 3 0 0 0 2 678.6884 6 12
2DLC TX114ctpV (ctpV)  Rv0969 80083 100.00% 3 4 5 0.03% 3.51% AQVNGGPVVVGR 84.20% 1.02 0.102 2 0 0 0 2 1,153.05 532 543
2DLC TX114ctpV (ctpV)  Rv0969 80083 100.00% 3 4 5 0.03% 3.51% VLAEVLPQDK 95.00% 2.32 0.33 0 1 0 0 2 1,112.26 632 641
2DLC TX114ctpV (ctpV)  Rv0969 80083 100.00% 3 4 5 0.03% 3.51% VLAEVLPQDKVAEVR 95.00% 3.23 0.482 0 1 1 0 2 1,666.78 632 646
2DLC TX114
hypo protein 
Rv0968  Rv0968 10245 99.80% 2 3 16 0.09% 32.70%
AGEEVPPLAVAGSDDGHD
H 95.00% 1.99 0.266 0 0 1 0 2 1,873.77 80 98
2DLC TX114
hypo protein 
Rv0968  Rv0968 10245 99.80% 2 3 16 0.09% 32.70% LMFADVLAEASER 95.00% 5.15 0.582 0 11 4 0 2 1,468.71 67 79
2DLC TX114
hypo protein 
Rv0902c  Rv0902c 47812 99.20% 2 2 2 0.01% 3.59% IEATLSALER 95.00% 3.44 0.337 0 1 0 0 2 1,103.36 280 289
2DLC TX114
hypo protein 
Rv0902c  Rv0902c 47812 99.20% 2 2 2 0.01% 3.59% IWNEQN 84.90% 0.948 -0.013 1 0 0 0 2 803.8184 217 222
2DLC TX114
hypo protein 
Rv0954  Rv0954 30185 99.80% 2 2 5 0.03% 3.63% FDPYGQYGR 95.00% 1.51 0.336 0 4 0 0 2 1,103.24 168 176
2DLC TX114
hypo protein 
Rv0954  Rv0954 30185 99.80% 2 2 5 0.03% 3.63% PKFDPYGQYGR 95.00% 2.25 0.338 0 0 1 0 2 1,328.56 166 176
2DLC TX114sucD (sucD)  Rv0952 31212 100.00% 7 7 12 0.07% 27.70% AADFIK 95.00% 1.19 0.384 0 1 0 0 2 664.8784 230 235
2DLC TX114sucD (sucD)  Rv0952 31212 100.00% 7 7 12 0.07% 27.70% AGTQIVGGVNAR 95.00% 3.07 0.308 0 2 0 0 2 1,143.17 34 45
2DLC TX114sucD (sucD)  Rv0952 31212 100.00% 7 7 12 0.07% 27.70% EILLSL 95.00% 1.54 0.001 2 0 0 0 2 687.9984 298 303
2DLC TX114sucD (sucD)  Rv0952 31212 100.00% 7 7 12 0.07% 27.70% LPVFGSVAEAMEK 95.00% 2.92 0.569 0 1 0 0 2 1,378.57 63 75
2DLC TX114sucD (sucD)  Rv0952 31212 100.00% 7 7 12 0.07% 27.70%
TNVSKPVVGYVAGFTAPEG
K 95.00% 2.59 0.398 0 0 2 0 2 2,022.13 236 255
2DLC TX114sucD (sucD)  Rv0952 31212 100.00% 7 7 12 0.07% 27.70% TPSATAALAR 95.00% 2.29 0.455 0 2 0 0 2 959.1384 288 297
2DLC TX114sucD (sucD)  Rv0952 31212 100.00% 7 7 12 0.07% 27.70% VIVQGITGSEATVHTAR 95.00% 2.51 0.408 0 0 2 0 2 1,739.77 14 30
2DLC TX114sucC (sucC)  Rv0951 40908 100.00% 7 10 16 0.09% 19.10% AIATEIGRPVMVK 95.00% 3.43 0.36 0 1 0 0 2 1,385.69 33 45
2DLC TX114sucC (sucC)  Rv0951 40908 100.00% 7 10 16 0.09% 19.10% GVDLDFAR 95.00% 1.55 0.234 2 2 0 0 2 893.0184 146 153
2DLC TX114sucC (sucC)  Rv0951 40908 100.00% 7 10 16 0.09% 19.10% ILALDAK 95.00% 1.89 0.25 0 1 0 0 2 744.0784 201 207
2DLC TX114sucC (sucC)  Rv0951 40908 100.00% 7 10 16 0.09% 19.10% MDLFEYQAK 95.00% 2.75 0.408 0 1 0 0 2 1,145.40 1 9
2DLC TX114sucC (sucC)  Rv0951 40908 100.00% 7 10 16 0.09% 19.10% NILGLDIK 95.00% 2.38 0.414 1 1 0 0 2 886.2684 74 81
2DLC TX114sucC (sucC)  Rv0951 40908 100.00% 7 10 16 0.09% 19.10%
SIAEQGHLPAEVLDTAAVTI
AK 95.00% 3.94 0.606 0 2 4 0 2 2,235.51 154 175
2DLC TX114sucC (sucC)  Rv0951 40908 100.00% 7 10 16 0.09% 19.10% VPVNAVK 95.00% 2.03 0.302 0 1 0 0 2 726.7284 139 145
2DLC TX114ald (ald)  Rv2780 38695 99.90% 2 3 7 0.04% 7.01% GLSTHEGALLSER 95.00% 2.54 0.348 0 0 3 0 2 1,370.56 342 354
2DLC TX114ald (ald)  Rv2780 38695 99.90% 2 3 7 0.04% 7.01% VAITPAGVAELTR 95.00% 2.65 0.508 0 3 1 0 2 1,298.47 16 28
2DLC TX114
hypo protein 
Rv3880c  Rv3880c 12150 100.00% 4 6 12 0.07% 20.90% ALTLAAR 95.00% 0.981 0.195 2 0 0 0 2 715.9584 13 19
2DLC TX114
hypo protein 
Rv3880c  Rv3880c 12150 100.00% 4 6 12 0.07% 20.90% IEDGLLK 95.00% 1.71 0.312 2 2 0 0 2 788.0684 60 66
2DLC TX114
hypo protein 
Rv3880c  Rv3880c 12150 100.00% 4 6 12 0.07% 20.90% KLGAEAVAQR 95.00% 3.03 0.397 0 1 0 0 2 1,043.18 67 76
2DLC TX114
hypo protein 
Rv3880c  Rv3880c 12150 100.00% 4 6 12 0.07% 20.90% LGAEAVAQR 95.00% 3.71 0.502 2 3 0 0 2 914.9784 68 76
2DLC TX114phoS1 Rv0934 38194 100.00% 6 10 70 0.40% 21.10% ASFLDQVHFQPLPPAVVK 95.00% 5.47 0.664 0 19 27 0 2 1,994.23 346 363
2DLC TX114phoS1 Rv0934 38194 100.00% 6 10 70 0.40% 21.10% LSDALIATISS 95.00% 1.43 0.535 4 0 0 0 2 1,091.42 364 374
2DLC TX114phoS1 Rv0934 38194 100.00% 6 10 70 0.40% 21.10% PGVNLPGTAVVPLHR 95.00% 4.81 0.403 0 0 2 0 2 1,527.67 171 185
2DLC TX114phoS1 Rv0934 38194 100.00% 6 10 70 0.40% 21.10% SDGSGDTFLFTQYLSK 95.00% 4.54 0.622 0 3 3 0 2 1,767.06 186 201
2DLC TX114
phoS1 
(phoS1)  Rv0934 38194 100.00% 6 10 70 0.40% 21.10%
SDGSGDTFLFTQYLSKQDP
EGWGK 95.00% 3.79 0.587 0 0 2 0 2 2,664.98 186 209
2DLC TX114phoS1 Rv0934 38194 100.00% 6 10 70 0.40% 21.10% VLAAMYQGTIK 95.00% 3.17 0.41 2 7 1 0 2 1,211.50 149 159
2DLC TX114
phoS2 
(phoS2)  Rv0928 37917 99.40% 2 2 2 0.01% 10.30%
AFLQSTIGAGQSGLGDNGY
IPIPDEFKSR 95.00% 2.01 0.289 0 0 1 0 2 3,040.61 333 361
2DLC TX114phoS2 Rv0928 37917 99.40% 2 2 2 0.01% 10.30% LSTAVNAIA 88.60% 1.51 0.258 0 1 0 0 2 860.0084 362 370
2DLC TX114moeZ Rv3206c 42124 99.80% 2 2 3 0.02% 5.36% IDGAQLIPK 95.00% 1.52 -0.056 1 0 0 0 2 955.2684 320 328
2DLC TX114moeZ Rv3206c 42124 99.80% 2 2 3 0.02% 5.36% LITGIGETLLGR 95.00% 3.45 0.531 0 2 0 0 2 1,243.67 227 238
2DLC TX114serA (serA)  Rv2996c 54504 100.00% 9 12 18 0.10% 22.00% AGTDVAESVR 95.00% 2.61 0.453 0 1 0 0 2 1,004.95 291 300
2DLC TX114serA (serA)  Rv2996c 54504 100.00% 9 12 18 0.10% 22.00% AGVGLDNVDVDAATAR 95.00% 4.57 0.601 0 5 1 0 2 1,544.55 72 87
2DLC TX114serA (serA)  Rv2996c 54504 100.00% 9 12 18 0.10% 22.00% GELAAEEVEVLR 95.00% 2.69 0.28 0 1 0 0 2 1,315.37 354 365
2DLC TX114serA (serA)  Rv2996c 54504 100.00% 9 12 18 0.10% 22.00% GGLVDEAALADAITGGHVR 95.00% 4.32 0.607 0 1 1 0 2 1,822.98 233 251
2DLC TX114serA (serA)  Rv2996c 54504 100.00% 9 12 18 0.10% 22.00% IGQLVAQR 95.00% 2.71 0.375 0 3 0 0 2 885.0184 152 159
2DLC TX114serA (serA)  Rv2996c 54504 100.00% 9 12 18 0.10% 22.00% SATTVDAEVLAAAPK 95.00% 3.31 0.385 0 1 1 0 2 1,444.56 51 65
2DLC TX114serA (serA)  Rv2996c 54504 100.00% 9 12 18 0.10% 22.00% TKPGVIIVNAAR 95.00% 3.25 0.243 0 0 1 0 2 1,239.49 221 232
2DLC TX114serA (serA)  Rv2996c 54504 100.00% 9 12 18 0.10% 22.00% TPETAGLIDKEALAK 95.00% 2.92 0.412 0 0 1 0 2 1,557.93 206 220
2DLC TX114serA (serA)  Rv2996c 54504 100.00% 9 12 18 0.10% 22.00% TVGVVGLGR 95.00% 2.06 0.289 0 1 0 0 2 857.8784 143 151
2DLC TX114
hypo protein 
Rv3205c  Rv3205c 31334 99.80% 2 2 2 0.01% 9.59% STAEAFPGLAHTAALVR 95.00% 2.32 0.245 0 0 1 0 2 1,712.94 273 289
2DLC TX114
hypo protein 
Rv3205c  Rv3205c 31334 99.80% 2 2 2 0.01% 9.59% VRETLFVDGVR 95.00% 2.86 0.341 0 0 1 0 2 1,291.38 62 72
2DLC TX114echA6 Rv0905 26012 99.70% 2 2 3 0.02% 7.82% AMLLSAEK 94.90% 1.65 0.294 0 1 0 0 2 863.1584 149 156
2DLC TX114echA6 Rv0905 26012 99.70% 2 2 3 0.02% 7.82% YGLALDNWSIR 95.00% 3.67 0.479 0 2 0 0 2 1,308.63 126 136
2DLC TX114
hypo protein 
Rv0901  Rv0901 18891 100.00% 3 4 14 0.08% 34.90% AGADGSGPQGWLVK 95.00% 2.83 0.485 0 4 0 0 2 1,343.45 116 129
2DLC TX114
hypo protein 
Rv0901  Rv0901 18891 100.00% 3 4 14 0.08% 34.90% IPVVPYAPYGPGSAR 95.00% 3.24 0.467 0 4 4 0 2 1,544.78 101 115
2DLC TX114
hypo protein 
Rv0901  Rv0901 18891 100.00% 3 4 14 0.08% 34.90%
TKVATESAAEQIPVAGEPAA
EPIPVAGEPAAR 95.00% 5.09 0.636 0 0 2 0 2 3,129.33 69 100
2DLC TX114
mpt64 
(mpt64)  Rv1980c 24805 99.80% 2 2 4 0.02% 7.02% GTQAVVLK 95.00% 2.14 0.224 0 2 0 0 2 815.8884 108 115
2DLC TX114
mpt64 
(mpt64)  Rv1980c 24805 99.80% 2 2 4 0.02% 7.02% SAIDSMLA 95.00% 1.39 0.23 2 0 0 0 2 808.0384 221 228
2DLC TX114
hypo protein 
Rv3816c  Rv3816c 28404 99.70% 2 2 2 0.01% 7.34% DRPKKL 94.10% 1.03 0.0752 1 0 0 0 2 757.0384 160 165
2DLC TX114
hypo protein 
Rv3816c  Rv3816c 28404 99.70% 2 2 2 0.01% 7.34% LGGGAPSLAEAAR 95.00% 2.8 0.521 0 1 0 0 2 1,170.39 222 234
2DLC TX114guaA (guaA)  Rv3396c 56009 100.00% 4 5 7 0.04% 6.67% ELGLPEEIVAR 95.00% 1.9 0.424 0 2 0 0 2 1,226.44 389 399
2DLC TX114guaA (guaA)  Rv3396c 56009 100.00% 4 5 7 0.04% 6.67% FTLVEPLR 95.00% 2.39 0.291 0 1 0 0 2 975.2084 369 376
2DLC TX114guaA (guaA)  Rv3396c 56009 100.00% 4 5 7 0.04% 6.67% LLFKDEVR 95.00% 2.27 0.316 0 1 1 0 2 1,020.29 377 384
2DLC TX114guaA (guaA)  Rv3396c 56009 100.00% 4 5 7 0.04% 6.67% VPYEVLER 95.00% 2.57 0.343 0 2 0 0 2 1,005.08 488 495
2DLC TX114
hypo protein 




Rv0292  Rv0292 35915 99.50% 2 3 8 0.05% 8.46% RRRIAEPATCTRTTVL 89.00% 1.79 0.274 0 0 1 0 2 1,903.20 71 86
2DLC TX114
hypo protein 
Rv0291  Rv0291 46108 100.00% 3 3 4 0.02% 7.59% MVDQAALGAAIR 95.00% 3.13 0.397 0 1 0 0 2 1,216.46 211 222
2DLC TX114
hypo protein 
Rv0291  Rv0291 46108 100.00% 3 3 4 0.02% 7.59% NVAFAGAAAL 95.00% 1.47 0.344 1 0 0 0 2 905.0384 430 439
2DLC TX114
hypo protein 
Rv0291  Rv0291 46108 100.00% 3 3 4 0.02% 7.59% SRYPGLNATEVVR 95.00% 3.51 0.201 0 0 2 0 2 1,462.59 357 369
2DLC TX114
hypo protein 
Rv0290  Rv0290 47927 100.00% 3 3 10 0.06% 5.93% EILPAVQR 95.00% 1.4 0.371 0 1 0 0 2 926.0884 32 39
2DLC TX114
hypo protein 
Rv0290  Rv0290 47927 100.00% 3 3 10 0.06% 5.93% LLEDLPR 95.00% 2.28 0.246 0 4 0 0 2 856.1384 312 318
2DLC TX114
hypo protein 
Rv0290  Rv0290 47927 100.00% 3 3 10 0.06% 5.93% LTEMALPAELPLR 95.00% 3.14 0.593 0 5 0 0 2 1,454.92 19 31
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% ALQDLAHVGSVASALEPER 95.00% 4.08 0.62 0 1 4 0 2 1,964.11 869 887
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% AVVVQSVPEPK 95.00% 3.27 0.433 0 2 0 0 2 1,153.10 713 723
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% DPLVFDAR 95.00% 2.63 0.398 0 1 0 0 2 933.0884 812 819
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% FADTLR 95.00% 1.7 0.369 0 2 0 0 2 722.8984 544 549
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% GASFTTLLGIEDASR 95.00% 4.18 0.61 0 2 0 0 2 1,538.84 416 430
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% GVGFLVPAPGATPIR 89.60% 1.92 0.204 0 1 0 0 2 1,452.73 681 695
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% HTVPLATTLR 90.50% 1.3 0.322 0 1 0 0 2 1,109.29 163 172
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% KLIATIGEQLAR 95.00% 4.87 0.462 0 4 5 0 2 1,313.73 752 763
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% LDVPALWAPR 95.00% 2.65 0.401 0 4 0 0 2 1,138.39 431 440
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% LIATIGEQLAR 95.00% 3.3 0.336 0 1 0 0 2 1,185.53 753 763
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% LIFEAR 95.00% 1.27 0.123 2 0 0 0 2 748.9984 4 9
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% NPLLAR 95.00% 1.94 0.243 0 2 0 0 2 683.9184 947 952
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% SIGDVPTGIDLTK 95.00% 1.9 0.278 0 1 0 0 2 1,316.59 199 211
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50%
SIGDVPTGIDLTKVSPITVL
GER 95.00% 2.6 0.346 0 0 3 0 2 2,368.78 199 221
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% STYVDGIYEPPQTAK 95.00% 3.21 0.456 0 3 2 0 2 1,669.84 698 712
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% VSPITVLGER 95.00% 2.37 0.434 0 2 0 0 2 1,071.21 212 221
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% WLPHVDIPGR 95.00% 2.46 0.495 0 2 0 0 2 1,190.38 263 272
2DLC TX114
hypo protein 
Rv0284  Rv0284 145124 100.00% 18 22 53 0.31% 13.50% WPLGEIDRPFEMR 95.00% 3.11 0.514 0 2 6 0 2 1,647.01 798 810
2DLC TX114
hypo protein 
Rv0282  Rv0282 68089 100.00% 7 7 15 0.09% 11.30% ADLIGQHIGETEAK 95.00% 2.65 0.393 0 0 2 0 2 1,482.68 419 432
2DLC TX114
hypo protein 
Rv0282  Rv0282 68089 100.00% 7 7 15 0.09% 11.30% ALGIAVYQR 95.00% 3.31 0.516 0 4 0 0 2 991.1984 47 55
2DLC TX114
hypo protein 
Rv0282  Rv0282 68089 100.00% 7 7 15 0.09% 11.30% GLGLSVR 89.30% 1.88 0.147 0 4 0 0 2 701.8684 624 630
2DLC TX114
hypo protein 
Rv0282  Rv0282 68089 100.00% 7 7 15 0.09% 11.30% LAAESTPDTNGISR 95.00% 2.78 0.578 0 1 0 0 2 1,432.61 550 563
2DLC TX114
hypo protein 
Rv0282  Rv0282 68089 100.00% 7 7 15 0.09% 11.30% SGFAALTR 95.00% 2.83 0.469 0 1 0 0 2 823.0084 66 73
2DLC TX114
hypo protein 
Rv0282  Rv0282 68089 100.00% 7 7 15 0.09% 11.30% SLDIAGNGR 95.00% 2 0.327 0 1 0 0 2 903.0784 565 573
2DLC TX114
hypo protein 
Rv0282  Rv0282 68089 100.00% 7 7 15 0.09% 11.30% TATTAGVLQR 95.00% 2.13 0.383 0 2 0 0 2 1,018.10 102 111
2DLC TX114lexA (lexA)  Rv2720 23045 99.80% 2 2 4 0.02% 10.60% ELVGEGTLFLLK 95.00% 3.3 0.54 0 3 0 0 2 1,319.69 125 136
2DLC TX114lexA (lexA)  Rv2720 23045 99.80% 2 2 4 0.02% 10.60% VLSADSALTER 95.00% 2.91 0.553 0 1 0 0 2 1,162.31 1 11
2DLC TX114lprG (lprG)  Rv1411c 24530 100.00% 5 7 22 0.13% 23.70% DTINGQNTIR 95.00% 2.88 0.347 0 3 0 0 2 1,132.27 158 167
2DLC TX114lprG (lprG)  Rv1411c 24530 100.00% 5 7 22 0.13% 23.70% GSGNSVQMTLSK 95.00% 3.39 0.594 0 7 0 0 2 1,209.33 212 223
2DLC TX114lprG (lprG)  Rv1411c 24530 100.00% 5 7 22 0.13% 23.70% IPGLSLK 95.00% 1.95 0.374 2 2 0 0 2 728.0684 68 74
2DLC TX114lprG (lprG)  Rv1411c 24530 100.00% 5 7 22 0.13% 23.70% TLSGDLTTNPTAATGNVK 95.00% 2.52 0.507 0 2 4 0 2 1,761.95 75 92
2DLC TX114lprG (lprG)  Rv1411c 24530 100.00% 5 7 22 0.13% 23.70% VQVTKPPVS 95.00% 2.16 0.379 0 2 0 0 2 954.9484 228 236
2DLC TX114fadD2 Rv0270 59876 100.00% 6 6 9 0.05% 12.10% AGDGVAILAR 95.00% 2.64 0.356 0 2 0 0 2 943.1284 110 119
2DLC TX114fadD2 Rv0270 59876 100.00% 6 6 9 0.05% 12.10% AVSLAQPPLGK 95.00% 3.15 0.405 0 1 0 0 2 1,081.32 171 181
2DLC TX114fadD2 Rv0270 59876 100.00% 6 6 9 0.05% 12.10% IFVGNAFPFEGYTGGGGK 95.00% 2.91 0.453 0 2 0 0 2 1,819.09 417 434
2DLC TX114fadD2 Rv0270 59876 100.00% 6 6 9 0.05% 12.10% SIGQYVAR 86.00% 1.5 0.272 0 1 0 0 2 893.9984 18 25
2DLC TX114fadD2 Rv0270 59876 100.00% 6 6 9 0.05% 12.10% VIIYDDEYTK 95.00% 1.75 0.428 0 2 0 0 2 1,259.49 161 170
2DLC TX114fadD2 Rv0270 59876 100.00% 6 6 9 0.05% 12.10% WFVIANYGAAR 95.00% 2.45 0.36 0 1 0 0 2 1,268.48 123 133
2DLC TX114lysX (lysX)  Rv1640c 128192 99.80% 2 2 2 0.01% 2.99% ETLYRSNMK 95.00% 2.24 0.21 0 1 0 0 2 1,142.40 587 595
2DLC TX114lysX (lysX)  Rv1640c 128192 99.80% 2 2 2 0.01% 2.99%
HRDIAEDEMAQTITRADSW
RDTETER 95.00% 2.16 0.271 0 0 1 0 2 3,150.34 444 469
2DLC TX114ideR (ideR)  Rv2711 25214 100.00% 4 6 11 0.06% 21.70% ALAIAVMR 95.00% 1.92 0.301 0 1 0 0 2 861.1278 70 77
2DLC TX114ideR (ideR)  Rv2711 25214 100.00% 4 6 11 0.06% 21.70% LTELPAGSPVAVVVR 95.00% 3.72 0.636 0 2 2 0 2 1,508.63 154 168
2DLC TX114ideR (ideR)  Rv2711 25214 100.00% 4 6 11 0.06% 21.70% MNELVDTTEMYLR 95.00% 4.19 0.449 0 2 0 0 2 1,615.89 1 13
2DLC TX114ideR (ideR)  Rv2711 25214 100.00% 4 6 11 0.06% 21.70% TIYDLEEEGVTPLR 95.00% 2.78 0.451 0 2 2 0 2 1,635.86 14 27
2DLC TX114
hypo protein 
Rv1919c  Rv1919c 16785 99.80% 2 2 5 0.03% 12.30% FFAGQLVK 95.00% 2.25 0.331 0 3 0 0 2 910.1184 138 145
2DLC TX114
hypo protein 
Rv1919c  Rv1919c 16785 99.80% 2 2 5 0.03% 12.30% TSSAPAATLFR 95.00% 2.14 0.521 0 2 0 0 2 1,122.34 13 23
2DLC TX114
hypo protein 
Rv3720  Rv3720 46835 99.80% 2 2 2 0.01% 5.95% SIGVEHILPIAPPPQEAR 95.00% 2.54 0.275 0 0 1 0 2 1,925.26 101 118
2DLC TX114
hypo protein 
Rv3720  Rv3720 46835 99.80% 2 2 2 0.01% 5.95% VLANVVR 95.00% 1.93 0.226 0 1 0 0 2 770.8084 94 100
2DLC TX114nirB (nirB)  Rv0252 90335 99.80% 2 3 7 0.04% 2.58% IKLGVSGCAR 95.00% 1.44 0.244 5 1 0 0 2 1,004.25 687 696
2DLC TX114nirB (nirB)  Rv0252 90335 99.80% 2 3 7 0.04% 2.58% LYVAGNGGMTPK 95.00% 0.951 0.259 1 0 0 0 2 1,224.44 717 728
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% AIGSAELAESSVQGR 95.00% 3.21 0.496 0 1 1 0 2 1,475.57 200 214
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% GEALPAGGTTATPR 95.00% 2.55 0.546 0 2 0 0 2 1,299.45 240 253
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50%
GEALPAGGTTATPRPATETS




(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% LEQIR 95.00% 1.49 0.0791 3 0 0 0 2 658.8184 231 235
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% LLSQLEQAK 95.00% 2.68 0.447 0 12 0 0 2 1,030.28 154 162
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% LQVNVR 95.00% 1.65 0.231 2 0 0 0 2 728.7584 72 77
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% MLEVEQAGIQMAGHSR 95.00% 4.2 0.54 0 7 19 0 2 1,757.93 215 230
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% MQEQVSASLR 95.00% 3.41 0.435 0 4 0 0 2 1,149.23 163 172
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% NAMVLQQK 95.00% 2.89 0.442 0 5 0 0 2 948.0678 140 147
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% PATETSGGAIAEQPYGQ 95.00% 4.14 0.446 0 0 1 0 2 1,677.73 254 270
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% QALTLADQATAAGDAAK 95.00% 3.02 0.56 0 1 1 0 2 1,616.83 78 94
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% RYANAIGSAELAESSVQGR 95.00% 3.32 0.523 0 2 2 0 2 1,980.15 196 214
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% SMSELAAPGNTPSLDEVR 95.00% 3.05 0.442 0 6 0 0 2 1,875.08 173 190
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50%
SMSELAAPGNTPSLDEVRD
K 95.00% 2.6 0.525 0 3 5 0 2 2,134.38 173 192
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% THQALTQQAAQVIGNQR 95.00% 6.02 0.561 0 4 1 0 2 1,864.88 40 56
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% TLHDQALSAAAQAK 95.00% 3.32 0.508 0 2 4 0 2 1,425.60 121 134
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% VQIQQAIEEAQR 95.00% 3.16 0.567 0 5 0 0 2 1,413.45 28 39
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% YANAIGSAELAESSVQGR 95.00% 4.77 0.591 0 6 4 0 2 1,823.95 197 214
2DLC TX114
35kd_ag 
(35kd_ag)  Rv2744c 29240 100.00% 19 28 112 0.65% 71.50% YLMALFSSK 95.00% 2.72 0.638 2 5 0 0 2 1,076.46 11 19
2DLC TX114lpqI (lpqI)  Rv0237 39500 100.00% 3 3 3 0.02% 7.73% AAVNLLR 95.00% 2.35 0.174 0 1 0 0 2 756.9484 288 294
2DLC TX114lpqI (lpqI)  Rv0237 39500 100.00% 3 3 3 0.02% 7.73% EVPAVLDRLEQALR 95.00% 1.55 0.317 0 0 1 0 2 1,609.84 347 360
2DLC TX114lpqI (lpqI)  Rv0237 39500 100.00% 3 3 3 0.02% 7.73% FGVSEAVLR 95.00% 3.57 0.397 0 1 0 0 2 978.0684 323 331
2DLC TX114
hypo protein 
Rv2074  Rv2074 14974 100.00% 4 5 8 0.05% 36.50% AAVNSDIDAVRDAELR 95.00% 2.57 0.464 0 0 2 0 2 1,715.86 88 103
2DLC TX114
hypo protein 
Rv2074  Rv2074 14974 100.00% 4 5 8 0.05% 36.50% HLAMLTTLR 95.00% 2.38 0.417 0 1 0 0 2 1,056.40 22 30
2DLC TX114
hypo protein 
Rv2074  Rv2074 14974 100.00% 4 5 8 0.05% 36.50% LSDDALAFLSER 95.00% 3.86 0.531 0 3 1 0 2 1,337.64 10 21
2DLC TX114
hypo protein 
Rv2074  Rv2074 14974 100.00% 4 5 8 0.05% 36.50% SGLAVLSQVDGAR 95.00% 2.88 0.48 0 1 0 0 2 1,273.38 68 80
2DLC TX114
hypo protein 
Rv2050  Rv2050 12954 100.00% 3 3 9 0.05% 25.20% NGMEGTLIEGDLPEPK 95.00% 3.66 0.552 0 2 0 0 2 1,701.01 58 73
2DLC TX114
hypo protein 
Rv2050  Rv2050 12954 100.00% 3 3 9 0.05% 25.20% SIEELEELLK 95.00% 3.47 0.342 0 3 0 0 2 1,203.50 90 99
2DLC TX114
hypo protein 
Rv2050  Rv2050 12954 100.00% 3 3 9 0.05% 25.20% SIEELEELLKER 95.00% 3.6 0.41 0 4 0 0 2 1,488.80 90 101
2DLC TX114
hypo protein 
Rv2005c  Rv2005c 30965 100.00% 3 4 13 0.08% 11.50% GLLGSVSSSLVR 95.00% 3.14 0.528 3 8 0 0 2 1,175.38 127 138
2DLC TX114
hypo protein 
Rv2005c  Rv2005c 30965 100.00% 3 4 13 0.08% 11.50% LAGWQER 91.30% 1.83 0.172 0 1 0 0 2 859.9484 224 230
2DLC TX114
hypo protein 
Rv2005c  Rv2005c 30965 100.00% 3 4 13 0.08% 11.50% LAGWQERYPDVPVSR 95.00% 3.45 0.33 0 0 1 0 2 1,773.91 224 238
2DLC TX114
hypo protein 
Rv2005c  Rv2005c 30965 100.00% 3 4 13 0.08% 11.50% VPVIVAR 95.00% 2.14 0.295 0 1 0 0 2 753.8284 287 293
2DLC TX114
hypo protein 
Rv2096c  Rv2096c 35282 100.00% 3 3 7 0.04% 11.40% DLGIPLEVGR 95.00% 2.06 0.507 0 4 0 0 2 1,069.31 57 66
2DLC TX114
hypo protein 
Rv2096c  Rv2096c 35282 100.00% 3 3 7 0.04% 11.40% SSVAGYSDSPSVEAFSR 95.00% 3.54 0.654 0 2 0 0 2 1,746.77 30 46
2DLC TX114
hypo protein 
Rv2096c  Rv2096c 35282 100.00% 3 3 7 0.04% 11.40% VSALEPTEGYR 95.00% 1.71 0.258 0 1 0 0 2 1,222.32 67 77
2DLC TX114
hypo protein 
Rv2032  Rv2032 36542 100.00% 4 4 6 0.03% 16.00% ADAILLR 95.00% 2.43 0.194 0 1 0 0 2 772.0784 114 120
2DLC TX114
hypo protein 
Rv2032  Rv2032 36542 100.00% 4 4 6 0.03% 16.00% IDVIADDMRPELAAASK 95.00% 1.98 0.317 0 0 1 0 2 1,816.21 151 167
2DLC TX114
hypo protein 
Rv2032  Rv2032 36542 100.00% 4 4 6 0.03% 16.00% LRADAILLR 95.00% 2.72 0.186 0 2 0 0 2 1,041.48 112 120
2DLC TX114
hypo protein 
Rv2032  Rv2032 36542 100.00% 4 4 6 0.03% 16.00% VGLAPEMEEPPPATPR 95.00% 2.77 0.273 0 0 1 0 2 1,691.90 301 316
2DLC TX114
hypo protein 
Rv2032  Rv2032 36542 100.00% 4 4 6 0.03% 16.00% VLVLSTYDNER 95.00% 2.19 0.258 0 2 0 0 2 1,309.44 235 245
2DLC TX114ilvX (ilvX)  Rv3509c 52022 99.80% 2 3 3 0.02% 6.02% ALDLLDISRPTMDFVK 95.00% 3.98 0.535 0 1 1 0 2 1,835.37 457 472
2DLC TX114ilvX (ilvX)  Rv3509c 52022 99.80% 2 3 3 0.02% 6.02% SGEPAMMLIGGDATR 95.00% 2.95 0.444 0 1 0 0 2 1,506.83 193 207
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% AGAALDYSALYPAGR 95.00% 3.97 0.493 0 3 0 0 2 1,496.82 848 862
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% AGLELLAFGGR 95.00% 3.89 0.527 0 1 0 0 2 1,104.43 1642 1652
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% ANLEQAGLR 95.00% 2.29 0.338 0 1 0 0 2 972.1284 1337 1345
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% ELAEFEGELPR 95.00% 3.16 0.442 0 2 0 0 2 1,290.47 1307 1317
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% GLLTELHR 95.00% 2.63 0.248 0 1 0 0 2 939.1684 840 847
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% GRDGVVIVYGPR 95.00% 2.1 0.229 0 0 1 0 2 1,288.40 1271 1282
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% ITRELAEFEGELPR 95.00% 3.83 0.462 0 0 2 0 2 1,660.97 1304 1317
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% LFMLSSTSSDALR 95.00% 4.07 0.58 0 4 0 0 2 1,428.82 449 461
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% LGLFPFR 95.00% 1.87 0.319 0 2 0 0 2 850.1884 1667 1673
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% LLTLGWQQR 95.00% 2.29 0.388 0 1 0 0 2 1,115.37 1190 1198
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% LVDAPLPAWTHAR 95.00% 1.93 0.318 0 0 2 0 2 1,447.67 863 875
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% LVLDVPR 95.00% 1.89 0.295 0 1 0 0 2 811.9784 1739 1745
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% SVAVTPEQAPLYR 95.00% 3.16 0.377 0 1 0 0 2 1,431.54 1750 1762
2DLC TX114mas (mas)  Rv2940c 224360 100.00% 14 14 24 0.14% 6.82% VGDPDEHSLLAGR 95.00% 2.08 0.366 0 0 2 0 2 1,366.47 1283 1295
2DLC TX114ftsY (ftsY)  Rv2921c 43981 100.00% 3 4 7 0.04% 13.70% IDTSGLPAVGDDATVPR 95.00% 2.85 0.39 0 2 2 0 2 1,684.84 70 86
2DLC TX114ftsY (ftsY)  Rv2921c 43981 100.00% 3 4 7 0.04% 13.70%
TIADVHLPEFEPEPQAPEVP
EADAIAPPEGR 95.00% 4.59 0.59 0 0 2 0 2 3,323.55 92 122
2DLC TX114ftsY (ftsY)  Rv2921c 43981 100.00% 3 4 7 0.04% 13.70% VVLGAADTFR 95.00% 2.46 0.516 0 1 0 0 2 1,049.17 254 263
2DLC TX114
hypo protein 
Rv1488  Rv1488 41232 100.00% 9 11 21 0.12% 27.30%
AGRPTPEMLAYQYLQTLPE




Rv1488  Rv1488 41232 100.00% 9 11 21 0.12% 27.30% AMILTAEGTR 95.00% 3.02 0.502 0 4 0 0 2 1,079.33 190 199
2DLC TX114
hypo protein 
Rv1488  Rv1488 41232 100.00% 9 11 21 0.12% 27.30% AVATAEAIAR 95.00% 2.89 0.444 0 4 0 0 2 973.0884 357 366
2DLC TX114
hypo protein 
Rv1488  Rv1488 41232 100.00% 9 11 21 0.12% 27.30% DQINAQLR 95.00% 2.22 0.435 0 2 0 0 2 958.0984 139 146
2DLC TX114
hypo protein 
Rv1488  Rv1488 41232 100.00% 9 11 21 0.12% 27.30% LLGKPGEDGVFR 95.00% 1.85 0.33 0 1 0 0 2 1,288.56 310 321
2DLC TX114
hypo protein 
Rv1488  Rv1488 41232 100.00% 9 11 21 0.12% 27.30% QAAILAAEADR 95.00% 2.4 0.315 0 1 0 0 2 1,129.32 222 232
2DLC TX114
hypo protein 
Rv1488  Rv1488 41232 100.00% 9 11 21 0.12% 27.30% QAQILAAEGAK 95.00% 1.9 0.389 0 2 0 0 2 1,100.29 211 221
2DLC TX114
hypo protein 
Rv1488  Rv1488 41232 100.00% 9 11 21 0.12% 27.30% SIDPPPSIQASMEK 95.00% 2 0.253 0 1 1 0 2 1,500.80 167 180
2DLC TX114
hypo protein 
Rv1488  Rv1488 41232 100.00% 9 11 21 0.12% 27.30% TFAAIK 95.00% 1.39 0.288 2 2 0 0 2 650.8784 260 265
2DLC TX114inhA (inhA)  Rv1484 28511 99.80% 2 2 2 0.01% 6.32% ALLPIMN 95.00% 0.988 0.142 1 0 0 0 2 788.1178 133 139
2DLC TX114inhA (inhA)  Rv1484 28511 99.80% 2 2 2 0.01% 6.32% SNLVAAGPIR 95.00% 2.96 0.494 0 1 0 0 2 998.1984 186 195
2DLC TX114gcpE (gcpE)  Rv2868c 40431 99.90% 2 2 3 0.02% 5.43% AAGAAGIPIR 95.00% 2.7 0.457 0 2 0 0 2 897.1584 134 143
2DLC TX114gcpE (gcpE)  Rv2868c 40431 99.90% 2 2 3 0.02% 5.43% SAVAFGALLSR 95.00% 3.36 0.458 0 1 0 0 2 1,092.34 230 240
2DLC TX114moxR Rv1479 40744 100.00% 8 10 19 0.11% 21.50% ASLGIIAAAR 95.00% 3.2 0.524 0 2 0 0 2 943.2684 288 297
2DLC TX114moxR Rv1479 40744 100.00% 8 10 19 0.11% 21.50% GHVLLEGVPGVAK 95.00% 4.01 0.594 0 2 0 0 2 1,276.38 72 84
2DLC TX114moxR Rv1479 40744 100.00% 8 10 19 0.11% 21.50% IIVGQDQLVER 95.00% 3.15 0.436 0 2 1 0 2 1,270.41 53 63
2DLC TX114moxR Rv1479 40744 100.00% 8 10 19 0.11% 21.50% MLVGLLSK 95.00% 1.84 0.411 3 2 0 0 2 861.2184 64 71
2DLC TX114moxR Rv1479 40744 100.00% 8 10 19 0.11% 21.50% QILSTGDLLR 95.00% 2.16 0.343 0 1 0 0 2 1,116.45 231 240
2DLC TX114moxR Rv1479 40744 100.00% 8 10 19 0.11% 21.50% TLAVETFAR 95.00% 2.42 0.444 0 4 0 0 2 1,008.15 85 93
2DLC TX114moxR Rv1479 40744 100.00% 8 10 19 0.11% 21.50% VQSALLEVMQER 95.00% 3.65 0.553 0 1 0 0 2 1,403.52 150 161
2DLC TX114moxR Rv1479 40744 100.00% 8 10 19 0.11% 21.50% VVGGTFSR 82.60% 1.69 0.195 0 1 0 0 2 822.8384 94 101
2DLC TX114
hypo protein 
Rv1473  Rv1473 58375 99.80% 2 2 2 0.01% 4.43% AGEIGYLPQDPKVGDL 95.00% 1.65 0.208 0 0 1 0 2 1,672.96 63 78
2DLC TX114
hypo protein 
Rv1473  Rv1473 58375 99.80% 2 2 2 0.01% 4.43% RTLSGGQR 95.00% 1.45 0.11 1 0 0 0 2 874.9984 160 167
2DLC TX114trxC (trxC)  Rv3914 12526 99.80% 2 2 4 0.02% 19.80% ELSDVVPNLN 95.00% 1.56 0.223 2 0 0 0 2 1,100.16 107 116
2DLC TX114trxC (trxC)  Rv3914 12526 99.80% 2 2 4 0.02% 19.80% MVAPVLEEIATER 95.00% 2.43 0.48 0 2 0 0 2 1,474.64 42 54
2DLC TX114
hypo protein 
Rv1466  Rv1466 12366 99.80% 2 2 9 0.05% 16.50% ALGFTV 95.00% 1.31 0.483 5 0 0 0 2 607.7184 110 115
2DLC TX114
hypo protein 
Rv1466  Rv1466 12366 99.80% 2 2 9 0.05% 16.50% SALVGSGLVDDIR 95.00% 4.01 0.57 0 4 0 0 2 1,302.50 74 86
2DLC TX114bisC (bisC)  Rv1442 83373 99.70% 2 2 3 0.02% 3.13% DPDSMCVHGN 94.30% 1.31 0.365 0 1 0 0 2 1,132.09 712 721
2DLC TX114bisC (bisC)  Rv1442 83373 99.70% 2 2 3 0.02% 3.13% IAMPAMVPPYANAR 95.00% 2.58 0.205 0 0 2 0 2 1,518.87 486 499
2DLC TX114accA3 Rv3285 63732 100.00% 5 5 8 0.05% 12.20% DLGDKVTAR 95.00% 2.26 0.338 0 2 0 0 2 975.1184 122 130
2DLC TX114
accA3 
(accA3)  Rv3285 63732 100.00% 5 5 8 0.05% 12.20%
GAHTGAAASGDAVTAPMQ
GTVVK 82.20% 2.29 0.193 0 0 1 0 2 2,098.11 522 544
2DLC TX114accA3 Rv3285 63732 100.00% 5 5 8 0.05% 12.20% IANGEKLDITEDPTPR 95.00% 3.75 0.359 0 0 2 0 2 1,770.09 325 340
2DLC TX114accA3 Rv3285 63732 100.00% 5 5 8 0.05% 12.20% NFLPAPGPVTK 95.00% 1.9 0.308 0 2 0 0 2 1,141.38 356 366
2DLC TX114accA3 Rv3285 63732 100.00% 5 5 8 0.05% 12.20% TIDEIPELYESAVR 95.00% 4.16 0.483 0 1 0 0 2 1,635.87 183 196
2DLC TX114
hypo protein 
Rv3281  Rv3281 18995 100.00% 3 4 13 0.08% 15.30% ITLQEMTHMR 95.00% 2.87 0.308 0 1 1 0 2 1,260.52 167 176
2DLC TX114
hypo protein 
Rv3281  Rv3281 18995 100.00% 3 4 13 0.08% 15.30% WGLPVDQLR 95.00% 2.56 0.491 0 6 0 0 2 1,084.26 150 158
2DLC TX114
hypo protein 
Rv3281  Rv3281 18995 100.00% 3 4 13 0.08% 15.30% YPVFSWQR 95.00% 2.64 0.352 0 5 0 0 2 1,083.19 159 166
2DLC TX114accD5 Rv3280 59337 99.80% 2 2 4 0.02% 2.55% GYIGTALR 95.00% 2.03 0.421 0 2 0 0 2 851.0984 522 529
2DLC TX114accD5 Rv3280 59337 99.80% 2 2 4 0.02% 2.55% ITVITR 95.00% 1.91 0 2 0 0 0 2 702.8884 424 429
2DLC TX114gap (gap)  Rv1436 35907 100.00% 8 12 43 0.25% 31.60% AAALNIVPTSTGAAK 95.00% 2.28 0.461 0 2 0 0 2 1,385.64 206 220
2DLC TX114gap (gap)  Rv1436 35907 100.00% 8 12 43 0.25% 31.60% AIGLVMPQLK 95.00% 3.33 0.498 0 3 0 0 2 1,070.44 221 230
2DLC TX114gap (gap)  Rv1436 35907 100.00% 8 12 43 0.25% 31.60% ASVDEINAAFK 95.00% 2.69 0.57 1 9 0 0 2 1,165.31 258 268
2DLC TX114gap (gap)  Rv1436 35907 100.00% 8 12 43 0.25% 31.60% EGPAALPWGDL 95.00% 2.01 0.306 0 1 0 0 2 1,126.32 85 95
2DLC TX114gap (gap)  Rv1436 35907 100.00% 8 12 43 0.25% 31.60% LVDLVTLVGK 95.00% 3.36 0.483 4 8 0 0 2 1,057.28 328 337
2DLC TX114gap (gap)  Rv1436 35907 100.00% 8 12 43 0.25% 31.60% VLDDEFGIVK 95.00% 1.49 0.363 2 2 0 0 2 1,135.31 169 178
2DLC TX114gap (gap)  Rv1436 35907 100.00% 8 12 43 0.25% 31.60% VVSWYDNEWGYSNR 95.00% 4.81 0.595 0 3 1 0 2 1,775.77 314 327
2DLC TX114gap (gap)  Rv1436 35907 100.00% 8 12 43 0.25% 31.60%
YYDAPIVSSDIVTDPHSSIF
DSGLTK 95.00% 4.58 0.655 0 0 7 0 2 2,829.23 281 306
2DLC TX114
hypo protein 
Rv0730  Rv0730 25962 99.80% 2 5 10 0.06% 5.37% EIADALLAALER 95.00% 3.24 0.414 1 4 1 0 2 1,285.64 26 37
2DLC TX114
hypo protein 
Rv0730  Rv0730 25962 99.80% 2 5 10 0.06% 5.37% REIADALLAALER 95.00% 3.75 0.529 0 3 1 0 2 1,441.84 25 37
2DLC TX114
hypo protein 
Rv1184c  Rv1184c 37801 100.00% 5 6 13 0.08% 20.60% GLDPLTAPGSIVEGAR 95.00% 2.42 0.485 0 1 0 0 2 1,553.82 334 349
2DLC TX114
hypo protein 
Rv1184c  Rv1184c 37801 100.00% 5 6 13 0.08% 20.60% GLLGSPAFGG 95.00% 1.28 0.484 4 2 0 0 2 876.0984 350 359
2DLC TX114
hypo protein 
Rv1184c  Rv1184c 37801 100.00% 5 6 13 0.08% 20.60%
LANDPTAPAPDKLQFTTFG
DPTGR 95.00% 4.08 0.684 0 0 2 0 2 2,531.94 154 177
2DLC TX114
hypo protein 
Rv1184c  Rv1184c 37801 100.00% 5 6 13 0.08% 20.60% NDNWFTRPVSVDPVR 95.00% 3.44 0.423 0 0 2 0 2 1,802.85 319 333
2DLC TX114
hypo protein 
Rv1184c  Rv1184c 37801 100.00% 5 6 13 0.08% 20.60% VVYALGGAR 95.00% 2.38 0.43 0 2 0 0 2 906.0184 52 60
2DLC TX114
hypo protein 
Rv3269  Rv3269 9732 99.80% 2 3 4 0.02% 11.80% LKVADVMAEAR 95.00% 3.24 0.516 0 1 2 0 2 1,203.40 63 73
2DLC TX114
hypo protein 
Rv3269  Rv3269 9732 99.80% 2 3 4 0.02% 11.80% VADVMAEAR 95.00% 3 0.461 0 1 0 0 2 961.9984 65 73
2DLC TX114
hypo protein 
Rv1423  Rv1423 34915 99.80% 2 2 3 0.02% 8.62% ALEILGDTVPEHLASAGK 95.00% 3.37 0.621 0 1 0 0 2 1,822.13 247 264
2DLC TX114
hypo protein 
Rv1423  Rv1423 34915 99.80% 2 2 3 0.02% 8.62% LANFDDANLR 95.00% 3.01 0.422 0 2 0 0 2 1,149.38 222 231
2DLC TX114
mmpS3 
(mmpS3)  Rv2198c 30936 99.80% 2 3 6 0.03% 12.40% APGDIISVTYVDAAGR 95.00% 3.66 0.608 0 2 0 0 2 1,605.80 223 238
2DLC TX114
mmpS3 
(mmpS3)  Rv2198c 30936 99.80% 2 3 6 0.03% 12.40%
AYSAPESEHVTGGPYVPAD
LR 95.00% 3.78 0.541 0 2 2 0 2 2,217.32 56 76
2DLC TX114rpsD (rpsD)  Rv3458c 23458 99.80% 2 2 2 0.01% 10.40% TDLVGGDQAFEK 95.00% 2.32 0.382 0 1 0 0 2 1,280.37 17 28
2DLC TX114rpsD (rpsD)  Rv3458c 23458 99.80% 2 2 2 0.01% 10.40% VLIHQLPER 95.00% 1.78 0.373 0 0 1 0 2 1,105.31 175 183
2DLC TX114
hypo protein 
Rv3520c  Rv3520c 37567 100.00% 4 4 7 0.04% 12.10% DLAALV 95.00% 1.13 0.256 2 0 0 0 2 601.7484 342 347
2DLC TX114
hypo protein 




Rv3520c  Rv3520c 37567 100.00% 4 4 7 0.04% 12.10% LPLTGEGTTGLGK 95.00% 2.65 0.478 0 2 0 0 2 1,244.54 146 158
2DLC TX114
hypo protein 
Rv3520c  Rv3520c 37567 100.00% 4 4 7 0.04% 12.10% MGYTQVVDEVTK 95.00% 3.87 0.569 0 2 0 0 2 1,370.38 273 284
2DLC TX114
hypo protein 
Rv0108c  Rv0108c 7554 99.80% 2 2 3 0.02% 24.60% VNHQLQVIEK 95.00% 2.58 0.162 0 0 1 0 2 1,208.26 44 53
2DLC TX114
hypo protein 
Rv0108c  Rv0108c 7554 99.80% 2 2 3 0.02% 24.60% YIVLESK 95.00% 2.03 0.341 0 2 0 0 2 852.0684 23 29
2DLC TX114
ompA 
(ompA)  Rv0899 33525 99.80% 2 2 4 0.02% 11.00%
GVAGDHIATVGLGSVNPIA
SNATPEGR 95.00% 4.24 0.645 0 0 3 0 2 2,561.70 289 315
2DLC TX114ompA Rv0899 33525 99.80% 2 2 4 0.02% 11.00% IVADYLVAR 95.00% 2.69 0.369 0 1 0 0 2 1,020.22 280 288
2DLC TX114PE (PE)  Rv2431c 10669 99.80% 2 2 3 0.02% 36.40% AATFLVEYAR 95.00% 2.46 0.202 0 2 0 0 2 1,141.33 51 60
2DLC TX114PE (PE)  Rv2431c 10669 99.80% 2 2 3 0.02% 36.40%
AIQSDAQVAPMTTAVRPPA
ADLVSEK 95.00% 3.48 0.604 0 0 1 0 2 2,667.93 25 50
2DLC TX114
fadE10 
(fadE10)  Rv0873 70728 100.00% 8 8 12 0.07% 14.20% AAQIPDEYVK 95.00% 1.6 0.344 0 1 0 0 2 1,134.27 79 88
2DLC TX114
fadE10 
(fadE10)  Rv0873 70728 100.00% 8 8 12 0.07% 14.20% EFGALATHLR 95.00% 2.15 0.398 0 1 0 0 2 1,115.33 488 497
2DLC TX114
fadE10 
(fadE10)  Rv0873 70728 100.00% 8 8 12 0.07% 14.20% FLTVSPSSEAKL 95.00% 2.38 0.421 0 2 0 0 2 1,279.53 639 650
2DLC TX114
fadE10 
(fadE10)  Rv0873 70728 100.00% 8 8 12 0.07% 14.20% FPLGLIHPFPKPSDAEEAR 95.00% 5.3 0.568 0 0 2 0 2 2,122.59 38 56
2DLC TX114
fadE10 
(fadE10)  Rv0873 70728 100.00% 8 8 12 0.07% 14.20% IFEGSSEIMR 95.00% 3.52 0.374 0 2 0 0 2 1,169.43 420 429
2DLC TX114
fadE10 
(fadE10)  Rv0873 70728 100.00% 8 8 12 0.07% 14.20% LANDVLEGR 95.00% 2.87 0.452 0 1 0 0 2 987.1184 595 603
2DLC TX114
fadE10 
(fadE10)  Rv0873 70728 100.00% 8 8 12 0.07% 14.20% LREFLDTVDGSVIER 95.00% 3.88 0.465 0 0 2 0 2 1,749.99 64 78
2DLC TX114
fadE10 
(fadE10)  Rv0873 70728 100.00% 8 8 12 0.07% 14.20% TEAFLVK 95.00% 1.71 0.276 0 1 0 0 2 807.9684 57 63
2DLC TX114
hypo protein 
Rv3224  Rv3224 29797 100.00% 4 4 8 0.05% 17.00% DGANIALIAK 95.00% 3.35 0.512 0 3 0 0 2 986.3084 28 37
2DLC TX114
hypo protein 
Rv3224  Rv3224 29797 100.00% 4 4 8 0.05% 17.00% FDLMNGIQVR 95.00% 2.92 0.536 0 3 0 0 2 1,193.44 113 122
2DLC TX114
hypo protein 
Rv3224  Rv3224 29797 100.00% 4 4 8 0.05% 17.00% TMFISGASR 95.00% 2.31 0.531 0 1 0 0 2 970.2084 7 15
2DLC TX114
hypo protein 
Rv3224  Rv3224 29797 100.00% 4 4 8 0.05% 17.00% WLRPTAYMMAKYGMTLCAL 95.00% 2.37 0.215 0 0 1 0 2 2,253.93 156 174
2DLC TX114fadB (fadB)  Rv0860 76088 100.00% 6 6 11 0.06% 9.44% FLPPESLLS 95.00% 1.07 0.356 2 0 0 0 2 1,003.32 712 720
2DLC TX114fadB (fadB)  Rv0860 76088 100.00% 6 6 11 0.06% 9.44% SDALLAR 95.00% 2.06 0.161 0 1 0 0 2 745.9584 386 392
2DLC TX114fadB (fadB)  Rv0860 76088 100.00% 6 6 11 0.06% 9.44% SGLWPGLR 82.30% 2.04 0.271 0 1 0 0 2 886.1184 613 620
2DLC TX114fadB (fadB)  Rv0860 76088 100.00% 6 6 11 0.06% 9.44%
TMIQARPEDAGDVFNTVET
IKR 95.00% 6.02 0.587 0 0 2 0 2 2,492.79 72 93
2DLC TX114fadB (fadB)  Rv0860 76088 100.00% 6 6 11 0.06% 9.44% VFDYTLAIGK 95.00% 3.17 0.599 0 3 0 0 2 1,127.42 489 498
2DLC TX114fadB (fadB)  Rv0860 76088 100.00% 6 6 11 0.06% 9.44% YFASLVTGQVAK 95.00% 3.05 0.654 0 2 0 0 2 1,284.45 286 297
2DLC TX114rhlE (rhlE)  Rv3211 56686 99.40% 2 2 2 0.01% 4.74% RRDTDCDGQKTAQH 87.80% 1.5 0.278 0 0 1 0 2 1,689.68 430 443
2DLC TX114rhlE (rhlE)  Rv3211 56686 99.40% 2 2 2 0.01% 4.74% TFAFGVPLLQR 95.00% 2.48 0.422 0 1 0 0 2 1,249.54 61 71
2DLC TX114fadA (fadA)  Rv0859 42397 100.00% 3 3 5 0.03% 7.20% AAEAWSGGYFAK 95.00% 3.98 0.556 0 2 0 0 2 1,258.42 178 189
2DLC TX114fadA (fadA)  Rv0859 42397 100.00% 3 3 5 0.03% 7.20% FQKDLNIPDEKL 95.00% 2.59 0.191 0 2 0 0 2 1,460.84 337 348
2DLC TX114fadA (fadA)  Rv0859 42397 100.00% 3 3 5 0.03% 7.20% RSQQKAAEAWSGGYFAK 85.00% 1.93 0.182 0 0 1 0 2 1,886.10 173 189
2DLC TX114
hypo protein 
Rv0854  Rv0854 16328 99.80% 2 3 4 0.02% 14.30% GTIDTATEALR 95.00% 0.932 0.302 1 1 0 0 2 1,148.33 127 137
2DLC TX114
hypo protein 
Rv0854  Rv0854 16328 99.80% 2 3 4 0.02% 14.30% WTLVSSTQQR 95.00% 2.67 0.43 0 2 0 0 2 1,206.25 78 87
2DLC TX114rplM (rplM)  Rv3443c 16287 99.80% 2 2 4 0.02% 12.20% AILGMLPK 95.00% 2.18 0.292 0 3 0 0 2 843.2684 104 111
2DLC TX114rplM (rplM)  Rv3443c 16287 99.80% 2 2 4 0.02% 12.20% LAVAAANLLR 95.00% 3.06 0.482 0 1 0 0 2 1,012.31 28 37
2DLC TX114trkA (trkA)  Rv2691 24222 99.90% 2 2 4 0.02% 8.37% FGTGVLPEPK 95.00% 1.9 0.403 0 2 0 0 2 1,045.23 179 188
2DLC TX114trkA (trkA)  Rv2691 24222 99.90% 2 2 4 0.02% 8.37% VYIAAISGR 95.00% 2.76 0.483 0 2 0 0 2 950.1784 197 205
2DLC TX114gatC (gatC)  Rv3012c 10698 99.40% 2 2 2 0.01% 27.30% DVNVTRPDETVPCL 88.40% 1.81 0.212 0 0 1 0 2 1,558.57 59 72
2DLC TX114gatC (gatC)  Rv3012c 10698 99.40% 2 2 2 0.01% 27.30% QVLDQAPDAVDGR 95.00% 2.19 0.49 0 1 0 0 2 1,384.39 76 88
2DLC TX114hupB (hupB)  Rv2986c 22169 100.00% 6 8 22 0.13% 21.50% AELIDVLTQK 95.00% 2.95 0.485 2 4 0 0 2 1,130.37 4 13
2DLC TX114hupB (hupB)  Rv2986c 22169 100.00% 6 8 22 0.13% 21.50% AVVSGAQR 95.00% 1.8 0.259 0 1 0 0 2 787.7484 87 94
2DLC TX114hupB (hupB)  Rv2986c 22169 100.00% 6 8 22 0.13% 21.50% LPAEGPAVK 95.00% 2.25 0.414 0 3 0 0 2 882.0384 95 103
2DLC TX114hupB (hupB)  Rv2986c 22169 100.00% 6 8 22 0.13% 21.50% MNKAELIDVLTQK 95.00% 4.61 0.521 0 2 5 0 2 1,503.87 1 13
2DLC TX114hupB (hupB)  Rv2986c 22169 100.00% 6 8 22 0.13% 21.50% QATAAVENVVDTIVR 95.00% 4.53 0.577 0 3 0 0 2 1,586.54 20 34
2DLC TX114hupB (hupB)  Rv2986c 22169 100.00% 6 8 22 0.13% 21.50% RQATAAVENVVDTIVR 95.00% 3.21 0.366 0 0 2 0 2 1,742.74 19 34
2DLC TX114
hypo protein 
Rv2129c  Rv2129c 31314 99.80% 2 2 4 0.02% 5.80% LTVVADVR 95.00% 1.69 0.319 0 1 0 0 2 872.9084 57 64
2DLC TX114
hypo protein 
Rv2129c  Rv2129c 31314 99.80% 2 2 4 0.02% 5.80% VVFITGAAR 95.00% 2.69 0.429 0 3 0 0 2 934.0684 8 16
2DLC TX114dnaJ2 Rv2373c 40438 99.80% 2 2 3 0.02% 5.76% ELHPDVNPDEAAQAK 95.00% 2.84 0.296 0 0 2 0 2 1,634.67 30 44
2DLC TX114dnaJ2 Rv2373c 40438 99.80% 2 2 3 0.02% 5.76% SLLGQML 95.00% 1.57 0.256 1 0 0 0 2 778.0478 177 183
2DLC TX114
hypo protein 
Rv0048c  Rv0048c 30768 99.80% 2 2 3 0.02% 5.54% AVTLGDLQR 95.00% 2.57 0.279 0 2 0 0 2 973.1184 55 63
2DLC TX114
hypo protein 
Rv0048c  Rv0048c 30768 99.80% 2 2 3 0.02% 5.54% TAVGIMR 95.00% 1.99 0.3 0 1 0 0 2 747.9184 221 227
2DLC TX114
hypo protein 
Rv2556c  Rv2556c 13874 100.00% 3 3 6 0.03% 12.40% IVDLTDAVR 95.00% 2.9 0.504 0 4 0 0 2 1,002.14 11 19
2DLC TX114
hypo protein 
Rv2556c  Rv2556c 13874 100.00% 3 3 6 0.03% 12.40% LSFVEG 95.00% 1.85 0.481 1 0 0 0 2 651.7184 124 129
2DLC TX114
hypo protein 
Rv2556c  Rv2556c 13874 100.00% 3 3 6 0.03% 12.40% RIVDLTDAVR 95.00% 2.39 0.297 0 1 0 0 2 1,158.34 10 19
2DLC TX114
hypo protein 
Rv0183  Rv0183 34889 99.80% 2 3 4 0.02% 7.12% LGAAGLVTYALDHR 95.00% 3.37 0.463 0 1 2 0 2 1,457.73 97 110
2DLC TX114
hypo protein 
Rv0183  Rv0183 34889 99.80% 2 3 4 0.02% 7.12% NFAGIGDVR 95.00% 2.91 0.351 0 1 0 0 2 949.0684 53 61
2DLC TX114katG (katG)  Rv1908c 80556 100.00% 6 6 10 0.06% 10.10% DGAGAGTIPDPFGGPGR 95.00% 1.99 0.457 0 1 0 0 2 1,542.74 357 373
2DLC TX114katG (katG)  Rv1908c 80556 100.00% 6 6 10 0.06% 10.10% FAPLNSWPDNASLDK 95.00% 2.19 0.37 0 1 0 0 2 1,675.98 129 143
2DLC TX114katG (katG)  Rv1908c 80556 100.00% 6 6 10 0.06% 10.10% FVQDFVAAWDK 95.00% 3.55 0.538 0 1 0 0 2 1,326.42 720 730
2DLC TX114katG (katG)  Rv1908c 80556 100.00% 6 6 10 0.06% 10.10% SPTMLATDLSLR 95.00% 2.7 0.439 0 2 0 0 2 1,305.68 374 385
2DLC TX114katG (katG)  Rv1908c 80556 100.00% 6 6 10 0.06% 10.10% VDLVFGSNSELR 95.00% 2.83 0.55 0 3 0 0 2 1,336.47 694 705




Rv2623  Rv2623 31633 100.00% 10 12 41 0.24% 30.00%
AGPPTVHSEIVPAAAVPTLV
DMSK 95.00% 2.68 0.422 0 0 1 0 2 2,388.61 86 109
2DLC TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 10 12 41 0.24% 30.00% HLIDDALK 95.00% 2.93 0.535 0 5 0 0 2 925.1984 70 77
2DLC TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 10 12 41 0.24% 30.00% LAGWQER 91.30% 1.83 0.172 0 1 0 0 2 859.9484 224 230
2DLC TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 10 12 41 0.24% 30.00% LAGWQERYPNVAITR 95.00% 4.51 0.362 0 0 2 0 2 1,775.02 224 238
2DLC TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 10 12 41 0.24% 30.00% LLGSVSSGLLR 95.00% 1.54 0.275 2 10 0 0 2 1,102.43 128 138
2DLC TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 10 12 41 0.24% 30.00% SEEAQLVVVGSR 95.00% 3.19 0.464 0 3 0 0 2 1,274.22 253 264
2DLC TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 10 12 41 0.24% 30.00% TPVIVAR 95.00% 1.55 0.347 2 6 0 0 2 755.8584 287 293
2DLC TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 10 12 41 0.24% 30.00% TPVIVARESLT 95.00% 2.86 0.511 0 2 0 0 2 1,186.34 287 297
2DLC TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 10 12 41 0.24% 30.00% VVEQASLR 95.00% 2.71 0.429 0 2 0 0 2 901.9184 78 85
2DLC TX114
hypo protein 
Rv2623  Rv2623 31633 100.00% 10 12 41 0.24% 30.00% YPNVAITR 95.00% 2.67 0.399 0 5 0 0 2 934.0884 231 238
2DLC TX114
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 5 8 21 0.12% 51.00% DANNYEQQEQASQQILSS 95.00% 3.42 0.587 0 3 1 0 2 2,054.02 81 98
2DLC TX114
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 5 8 21 0.12% 51.00% FEVHAQTVEDEAR 95.00% 1.89 0.204 0 0 1 0 2 1,531.42 19 31
2DLC TX114
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 5 8 21 0.12% 51.00% FMTDPHAMR 95.00% 2.07 0.541 0 2 1 0 2 1,106.32 5 13
2DLC TX114
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 5 8 21 0.12% 51.00% NIVNML 95.00% 1.36 0.213 1 0 0 0 2 719.8878 66 71
2DLC TX114
hypo protein 
Rv1038c  Rv1038c,Rv1197,Rv2347c,Rv3620c10959 100.00% 5 8 21 0.12% 51.00% NIVNMLHGVR 95.00% 1.57 0.212 2 10 0 0 2 1,153.31 66 75
2DLC TX114fbpA (fbpA)  Rv3804c 35668 100.00% 3 4 8 0.05% 9.17% ALGATPNTGPAPQGA 95.00% 1.79 0.442 0 2 0 0 2 1,323.45 324 338
2DLC TX114fbpA (fbpA)  Rv3804c 35668 100.00% 3 4 8 0.05% 9.17% FLEGFVR 95.00% 1.64 0.324 2 0 0 0 2 868.0384 271 277
2DLC TX114fbpA (fbpA)  Rv3804c 35668 100.00% 3 4 8 0.05% 9.17% NDPLLNVGK 95.00% 2.16 0.0152 2 2 0 0 2 970.1584 234 242
2DLC TX114
hypo protein 
Rv0174  Rv0174 53988 100.00% 3 3 4 0.02% 10.90%
DPYVPLGTNPWFGDPNQIL
TCPAPGAR 91.50% 1.91 0.22 0 0 1 0 2 2,898.32 384 410
2DLC TX114
hypo protein 
Rv0174  Rv0174 53988 100.00% 3 3 4 0.02% 10.90% GTVPSEIGPALDNSNR 95.00% 2.27 0.505 0 2 0 0 2 1,627.77 130 145
2DLC TX114
hypo protein 
Rv0174  Rv0174 53988 100.00% 3 3 4 0.02% 10.90% LVDSTQAIVGDFK 95.00% 3.56 0.608 0 1 0 0 2 1,393.57 176 188
2DLC TX114lprK (lprK)  Rv0173 42223 99.80% 2 3 5 0.03% 6.15% LLAYVGGR 95.00% 2.09 0.456 0 2 0 0 2 849.0684 219 226
2DLC TX114lprK (lprK)  Rv0173 42223 99.80% 2 3 5 0.03% 6.15% YTPNPNDAPGGPLVER 95.00% 2.94 0.328 0 1 2 0 2 1,697.85 370 385
2DLC TX114
hypo protein 
Rv0172  Rv0172 56481 100.00% 3 3 8 0.05% 6.04% GDFFAVVR 95.00% 2.12 0.423 0 2 0 0 2 910.9884 207 214
2DLC TX114
hypo protein 
Rv0172  Rv0172 56481 100.00% 3 3 8 0.05% 6.04% GGPVLADNAVIPVER 95.00% 2.18 0.505 0 1 0 0 2 1,507.63 124 138
2DLC TX114
hypo protein 
Rv0172  Rv0172 56481 100.00% 3 3 8 0.05% 6.04% NIQLEPPYR 95.00% 2.79 0.397 0 5 0 0 2 1,130.36 115 123
2DLC TX114
hypo protein 
Rv2047c  Rv2047c 91335 99.80% 2 2 2 0.01% 3.28% CGRDTAPAAGPELVSAR 90.90% 1.81 0.305 0 1 0 0 2 1,729.86 514 530
2DLC TX114
hypo protein 
Rv2047c  Rv2047c 91335 99.80% 2 2 2 0.01% 3.28% RGVGVCGGRVR 91.20% 1.72 0.249 0 1 0 0 2 1,116.13 737 747
2DLC TX114mce1 (mce1)  Rv0169 47770 100.00% 3 3 5 0.03% 9.69%
DTYSPELFCTIRNFYDADPL
AK 95.00% 2.16 0.262 0 0 2 0 2 2,638.15 289 310
2DLC TX114mce1 (mce1)  Rv0169 47770 100.00% 3 3 5 0.03% 9.69% FILDVDPR 95.00% 1.92 0.269 0 1 0 0 2 975.2084 90 97
2DLC TX114mce1 (mce1)  Rv0169 47770 100.00% 3 3 5 0.03% 9.69% YIHLIPANVNADIK 95.00% 3.94 0.411 0 0 2 0 2 1,581.97 98 111
2DLC TX114
hypo protein 
Rv1390  Rv1390 11793 99.80% 2 3 8 0.05% 20.00% EIHADLLEHTEGE 95.00% 1.85 0.566 0 2 2 0 2 1,493.55 98 110
2DLC TX114
hypo protein 
Rv1390  Rv1390 11793 99.80% 2 3 8 0.05% 20.00% YALVIYAAK 95.00% 2.89 0.612 0 4 0 0 2 1,012.33 51 59
2DLC TX114
hypo protein 
Rv0227c  Rv0227c 45510 99.80% 2 2 3 0.02% 6.18% FTQNVGYTPEGK 95.00% 2.99 0.479 0 1 0 0 2 1,341.41 197 208
2DLC TX114
hypo protein 
Rv0227c  Rv0227c 45510 99.80% 2 2 3 0.02% 6.18% GLNDENPPTAIPLR 95.00% 2.15 0.441 0 2 0 0 2 1,507.81 138 151
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% AAYLDGSLR 95.00% 1.93 0.451 0 2 0 0 2 966.2084 616 624
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% DILWSDFSAR 95.00% 2.64 0.423 0 4 0 0 2 1,210.46 61 70
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% DVLLVSAGTIPR 95.00% 2.39 0.516 0 2 0 0 2 1,241.49 592 603
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% FFEAFAPYGLK 95.00% 2.63 0.516 0 3 0 0 2 1,290.65 332 342
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% FLDFSTER 95.00% 2.61 0.232 0 1 0 0 2 1,015.20 48 55
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% FLDFSTERDGVAR 95.00% 2.17 0.504 0 0 2 0 2 1,513.70 48 60
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% GILNGSEPVSPASMR 95.00% 2.5 0.646 0 7 0 0 2 1,515.75 316 330
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% GVPRDDEPPLDLSNVK 95.00% 2.86 0.408 0 0 2 0 2 1,751.95 300 315
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% IKDLVIIDGR 95.00% 2.89 0.182 0 1 0 0 2 1,142.54 491 500
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% IRFPANTNLVR 95.00% 2.9 0.257 0 0 1 0 2 1,301.59 21 31
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% ISESRAEGAPDDALWVR 95.00% 3.92 0.393 0 0 2 0 2 1,873.06 457 473
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% KFFEAFAPYGLK 95.00% 4.15 0.425 0 2 2 0 2 1,418.85 331 342
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% LDHQPIVDDIR 95.00% 2.92 0.235 0 0 2 0 2 1,321.51 569 579
2DLC TX114
fadD32 
(fadD32)  Rv3801c 69214 100.00% 14 15 34 0.20% 23.40% SGVGSPTVFATSD 84.00% 0.901 0 1 0 0 0 2 1,225.20 625 637
2DLC TX114
hypo protein 




Rv0148  Rv0148 29760 100.00% 4 4 10 0.06% 18.50%
VALFGNDGANFDKPPSVQD
VAAR 95.00% 4.14 0.637 0 0 6 0 2 2,389.57 247 269
2DLC TX114
hypo protein 
Rv0148  Rv0148 29760 100.00% 4 4 10 0.06% 18.50% VIVVTGAGGGLGR 95.00% 2.97 0.0762 0 1 0 0 2 1,156.26 8 20
2DLC TX114
hypo protein 
Rv0148  Rv0148 29760 100.00% 4 4 10 0.06% 18.50% WAEITDLSGAK 95.00% 2.6 0.261 0 2 0 0 2 1,191.41 270 280
2DLC TX114
hypo protein 
Rv0147  Rv0147 55018 99.50% 2 2 2 0.01% 5.14% KQQLRALQK 89.60% 1.44 0.198 1 0 0 0 2 1,113.40 71 79
2DLC TX114
hypo protein 
Rv0147  Rv0147 55018 99.50% 2 2 2 0.01% 5.14% LPFGGVGASGMGAYHGR 95.00% 3.97 0.603 0 0 1 0 2 1,634.85 449 465
2DLC TX114hisI (hisI)  Rv2122c 10225 99.80% 2 2 2 0.01% 24.70% GLSLDDVYR 95.00% 2.46 0.464 0 1 0 0 2 1,038.22 83 91
2DLC TX114hisI (hisI)  Rv2122c 10225 99.80% 2 2 2 0.01% 24.70% LLEEAGEVWLAAEH 95.00% 2.12 0.228 0 1 0 0 2 1,567.68 45 58
2DLC TX114bfrB (bfrB)  Rv3841 20424 100.00% 5 5 9 0.05% 34.30% AGANLFELENFVAR 95.00% 3.33 0.5 0 3 0 0 2 1,551.78 149 162
2DLC TX114bfrB (bfrB)  Rv3841 20424 100.00% 5 5 9 0.05% 34.30% EALALALDQER 95.00% 2.87 0.438 0 2 0 0 2 1,229.46 90 100
2DLC TX114bfrB (bfrB)  Rv3841 20424 100.00% 5 5 9 0.05% 34.30% EVDVAPAASGAPHAAGGRL 95.00% 1.44 0.361 0 0 1 0 2 1,746.81 163 181
2DLC TX114bfrB (bfrB)  Rv3841 20424 100.00% 5 5 9 0.05% 34.30% TVTDQVGR 95.00% 2.21 0.385 0 2 0 0 2 875.8084 101 108
2DLC TX114bfrB (bfrB)  Rv3841 20424 100.00% 5 5 9 0.05% 34.30% VEIPGVDTVR 95.00% 1.93 0.295 0 1 0 0 2 1,085.10 73 82
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% AAAAHVLPDAQLTAAEQR 95.00% 3.86 0.45 0 0 4 0 2 1,833.97 1112 1129
2DLC TX114
pks13 
(pks13)  Rv3800c 186428 100.00% 15 16 33 0.19% 12.10%
AEGPITAEDVLTSSNIEALA
DKVR 95.00% 3.4 0.549 0 0 1 0 2 2,500.81 1421 1444
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% AGEEIPQTKEEIR 95.00% 2.66 0.333 0 0 1 0 2 1,500.67 1564 1576
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% ALGQIEADRTSEVGKQ 95.00% 3.01 0.521 0 0 3 0 2 1,702.83 1718 1733
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% DGNVDLAALVR 95.00% 3.73 0.433 0 5 0 0 2 1,143.27 1101 1111
2DLC TX114
pks13 
(pks13)  Rv3800c 186428 100.00% 15 16 33 0.19% 12.10%
DIKGFDSEFFAVAKTEADNI
DPQQRMAL 95.00% 1.78 0.309 0 0 1 0 2 3,174.66 182 209
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% FVGLIDAVR 95.00% 1.97 0.174 2 2 0 0 2 990.1884 1555 1563
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% MITTPTDWPR 95.00% 1.77 0.415 0 1 0 0 2 1,218.46 507 516
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% SEGGGMLVLK 95.00% 2.87 0.43 0 1 0 0 2 991.2184 352 361
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% SNGLIAPNQDAQADVLR 95.00% 1.87 0.282 0 1 0 0 2 1,782.98 388 404
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% SPGGIFNELPR 95.00% 3.95 0.459 0 1 0 0 2 1,187.44 1394 1404
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% SPGGIFNELPRLDDEAAAK 95.00% 3.07 0.427 0 0 3 0 2 2,001.38 1394 1412
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% TYLEAGQIDGFVR 95.00% 3.86 0.566 0 3 0 0 2 1,469.67 1445 1457
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% WSEFLEEPR 95.00% 2.59 0.313 0 2 0 0 2 1,193.32 157 165
2DLC TX114pks13 Rv3800c 186428 100.00% 15 16 33 0.19% 12.10% WSPDSGETIAER 95.00% 1.94 0.352 0 2 0 0 2 1,348.43 1226 1237
2DLC TX114
hypo protein 
Rv3134c  Rv3134c 27989 99.80% 2 2 2 0.01% 9.70% AATHAALWAVDEAVNR 95.00% 2.97 0.167 0 0 1 0 2 1,695.74 19 34
2DLC TX114
hypo protein 
Rv3134c  Rv3134c 27989 99.80% 2 2 2 0.01% 9.70% AVVVGIDGSR 95.00% 2.62 0.521 0 1 0 0 2 972.9884 9 18
2DLC TX114
hypo protein 
Rv3870  Rv3870 80897 99.80% 2 2 2 0.01% 3.21% AGVTVITLGNHR 95.00% 2.1 0.239 0 0 1 0 2 1,238.34 337 348
2DLC TX114
hypo protein 
Rv3870  Rv3870 80897 99.80% 2 2 2 0.01% 3.21% MGEVLTGELDRR 95.00% 1.86 0.332 0 0 1 0 2 1,376.59 544 555
2DLC TX114
hypo protein 
Rv3133c  Rv3133c 23245 100.00% 8 9 19 0.11% 27.20% AAAALMAK 95.00% 2.65 0.319 0 1 0 0 2 747.0184 129 136
2DLC TX114
hypo protein 
Rv3133c  Rv3133c 23245 100.00% 8 9 19 0.11% 27.20% DLLSR 95.00% 1.59 0.152 2 0 0 0 2 603.7984 68 72
2DLC TX114
hypo protein 
Rv3133c  Rv3133c 23245 100.00% 8 9 19 0.11% 27.20% MFLAEK 95.00% 2.03 0.27 0 2 0 0 2 738.9984 174 179
2DLC TX114
hypo protein 
Rv3133c  Rv3133c 23245 100.00% 8 9 19 0.11% 27.20% MFLAEKTVKN 95.00% 2.14 0.185 1 0 0 0 2 1,197.47 174 183
2DLC TX114
hypo protein 
Rv3133c  Rv3133c 23245 100.00% 8 9 19 0.11% 27.20% PDVAVLDVR 95.00% 3.42 0.389 0 3 0 0 2 984.0284 48 56
2DLC TX114
hypo protein 
Rv3133c  Rv3133c 23245 100.00% 8 9 19 0.11% 27.20% TQAAVFATELK 95.00% 3.39 0.522 0 2 0 0 2 1,179.33 198 208
2DLC TX114
hypo protein 
Rv3133c  Rv3133c 23245 100.00% 8 9 19 0.11% 27.20% VFLVDDHEVVR 95.00% 1.63 0.256 0 0 1 0 2 1,328.30 4 14
2DLC TX114
hypo protein 
Rv3133c  Rv3133c 23245 100.00% 8 9 19 0.11% 27.20% VPAARPDVAVLDVR 95.00% 3.07 0.497 0 2 5 0 2 1,478.58 43 56
2DLC TX114
hypo protein 
Rv3874  Rv3874 10776 100.00% 6 11 41 0.24% 80.00% ADEEQQQALSSQMGF 95.00% 3.71 0.499 0 5 5 0 2 1,685.69 86 100
2DLC TX114
hypo protein 
Rv3874  Rv3874 10776 100.00% 6 11 41 0.24% 80.00% GAAGTAAQAAVVR 95.00% 4.34 0.371 0 5 1 0 2 1,143.14 45 57
2DLC TX114
hypo protein 
Rv3874  Rv3874 10776 100.00% 6 11 41 0.24% 80.00% ISGDLK 95.00% 1.3 0.0999 1 0 0 0 2 632.8484 21 26
2DLC TX114
hypo protein 
Rv3874  Rv3874 10776 100.00% 6 11 41 0.24% 80.00% QKQELDEISTNIR 95.00% 3.08 0.443 0 2 6 0 2 1,574.80 65 77
2DLC TX114
hypo protein 
Rv3874  Rv3874 10776 100.00% 6 11 41 0.24% 80.00% TDAATLAQEAGNFER 95.00% 4.46 0.587 0 3 4 0 2 1,594.69 6 20
2DLC TX114
hypo protein 
Rv3874  Rv3874 10776 100.00% 6 11 41 0.24% 80.00% TQIDQVESTAGSLQGQWR 95.00% 4.64 0.528 0 5 4 0 2 2,005.03 27 44
2DLC TX114
hypo protein 
Rv3871  Rv3871 64543 99.80% 2 2 2 0.01% 3.89% EVVLDQLGTAESR 95.00% 3.27 0.539 0 1 0 0 2 1,417.47 12 24
2DLC TX114
hypo protein 
Rv3871  Rv3871 64543 99.80% 2 2 2 0.01% 3.89% FALGIMDEPR 95.00% 3.62 0.414 0 1 0 0 2 1,149.47 53 62
2DLC TX114
hypo protein 
Rv3132c  Rv3132c 62222 99.80% 2 3 5 0.03% 3.63% AIVHSATSLVDAR 95.00% 3 0.557 0 2 1 0 2 1,340.46 70 82
2DLC TX114
hypo protein 
Rv3132c  Rv3132c 62222 99.80% 2 3 5 0.03% 3.63% TFLGVPVR 95.00% 1.76 0.47 0 2 0 0 2 889.0284 154 161
2DLC TX114
hypo protein 
Rv3869  Rv3869 51075 100.00% 3 3 6 0.03% 8.12% FVALQSPDPR 95.00% 2.4 0.357 0 3 0 0 2 1,130.29 394 403
2DLC TX114
hypo protein 
Rv3869  Rv3869 51075 100.00% 3 3 6 0.03% 8.12% LVLGNPANPATVK 95.00% 2.26 0.212 0 1 0 0 2 1,294.51 103 115
2DLC TX114
hypo protein 
Rv3869  Rv3869 51075 100.00% 3 3 6 0.03% 8.12% SLGLSSPQNAPWEIVR 95.00% 2.64 0.513 0 2 0 0 2 1,755.00 428 443
2DLC TX114
hypo protein 
Rv3865  Rv3865 10600 100.00% 3 3 7 0.04% 35.90% ATDTVAGISGR 95.00% 2.96 0.329 0 1 0 0 2 1,048.13 29 39
2DLC TX114
hypo protein 
Rv3865  Rv3865 10600 100.00% 3 3 7 0.04% 35.90% FNDTLQEFETTR 95.00% 2.41 0.458 0 2 0 0 2 1,501.62 51 62
2DLC TX114
hypo protein 
Rv3865  Rv3865 10600 100.00% 3 3 7 0.04% 35.90% VLAGMHNEIVGDIK 95.00% 3.09 0.457 0 0 4 0 2 1,496.74 14 27
197
2DLC TX114hns (hns)  Rv3852 13806 100.00% 5 6 28 0.16% 35.10% IETNGQLAAAAK 95.00% 2.86 0.479 0 8 0 0 2 1,187.39 70 81
2DLC TX114hns (hns)  Rv3852 13806 100.00% 5 6 28 0.16% 35.10% IETNGQLAAAAKDAAAQAK 95.00% 4.64 0.585 0 2 0 0 2 1,843.11 70 88
2DLC TX114hns (hns)  Rv3852 13806 100.00% 5 6 28 0.16% 35.10% PAEAPVSLQQR 95.00% 3.06 0.469 0 2 0 0 2 1,196.27 59 69
2DLC TX114hns (hns)  Rv3852 13806 100.00% 5 6 28 0.16% 35.10% SAPPKPAEAPVSLQQR 95.00% 2.26 0.46 0 2 8 0 2 1,676.87 54 69
2DLC TX114hns (hns)  Rv3852 13806 100.00% 5 6 28 0.16% 35.10% STVEGANDALAR 95.00% 2.69 0.439 0 6 0 0 2 1,204.26 89 100
2DLC TX114
hypo protein 
Rv3849  Rv3849 14691 100.00% 4 4 12 0.07% 37.90% AEGITMSAPYLSQLR 95.00% 4.22 0.599 0 4 0 0 2 1,638.01 35 49
2DLC TX114
hypo protein 
Rv3849  Rv3849 14691 100.00% 4 4 12 0.07% 37.90% LFDTVYPPGR 95.00% 2.21 0.493 0 5 0 0 2 1,165.38 12 21
2DLC TX114
hypo protein 
Rv3849  Rv3849 14691 100.00% 4 4 12 0.07% 37.90% TNPSGATMAALANFFR 95.00% 4.31 0.632 0 1 0 0 2 1,685.99 54 69
2DLC TX114
hypo protein 
Rv3849  Rv3849 14691 100.00% 4 4 12 0.07% 37.90% VLDRIDELR 95.00% 1.86 0.273 0 0 2 0 2 1,129.39 117 125
2DLC TX114
hypo protein 
Rv0831c  Rv0831c 30171 99.80% 2 2 3 0.02% 8.49% AQVSSIVGLER 95.00% 2.89 0.223 0 1 0 0 2 1,159.25 118 128
2DLC TX114
hypo protein 
Rv0831c  Rv0831c 30171 99.80% 2 2 3 0.02% 8.49% NQAIVVETTAYR 95.00% 3.11 0.459 0 2 0 0 2 1,365.42 90 101
2DLC TX114metK (metK)  Rv1392 42997 99.80% 2 3 7 0.04% 7.44% AIGEVFDLRPGAIIR 95.00% 2.84 0.398 0 2 1 0 2 1,628.07 349 363
2DLC TX114metK (metK)  Rv1392 42997 99.80% 2 3 7 0.04% 7.44% FVLGGPMGDAGLTGR 95.00% 3.56 0.481 0 4 0 0 2 1,464.74 251 265
2DLC TX114mIHF (mIHF)  Rv1388 20800 100.00% 7 8 22 0.13% 25.30% GGTNLTQVLK 95.00% 2.21 0.416 0 2 0 0 2 1,031.19 120 129
2DLC TX114mIHF (mIHF)  Rv1388 20800 100.00% 7 8 22 0.13% 25.30% KALLEK 95.00% 1.85 0.31 0 1 0 0 2 701.9984 181 186
2DLC TX114mIHF (mIHF)  Rv1388 20800 100.00% 7 8 22 0.13% 25.30% KALLEKFGSA 95.00% 2.83 0.323 0 1 0 0 2 1,064.41 181 190
2DLC TX114mIHF (mIHF)  Rv1388 20800 100.00% 7 8 22 0.13% 25.30% LEALPK 95.00% 1.16 0.151 2 0 0 0 2 670.9184 146 151
2DLC TX114mIHF (mIHF)  Rv1388 20800 100.00% 7 8 22 0.13% 25.30% MKVSALLEALPK 95.00% 3.84 0.484 0 1 0 0 2 1,300.75 140 151
2DLC TX114mIHF (mIHF)  Rv1388 20800 100.00% 7 8 22 0.13% 25.30% VKAQEIMTELEIAPTR 95.00% 4.43 0.519 0 3 0 0 2 1,830.17 155 170
2DLC TX114mIHF (mIHF)  Rv1388 20800 100.00% 7 8 22 0.13% 25.30% VSALLEALPK 95.00% 3.72 0.389 4 8 0 0 2 1,041.35 142 151
2DLC TX114pyrR (pyrR)  Rv1379 20609 99.80% 2 2 2 0.01% 10.90% VPTSRSESVHVR 95.00% 1.28 0.341 0 0 1 0 2 1,354.29 168 179
2DLC TX114pyrR (pyrR)  Rv1379 20609 99.80% 2 2 2 0.01% 10.90% VVLLGIPTR 95.00% 1.96 0.4 0 1 0 0 2 968.2284 50 58
2DLC TX114
hypo protein 
Rv3688c  Rv3688c 16684 99.80% 2 2 3 0.02% 14.30% MLLAAIQTEEVSGK 95.00% 2.3 0.398 0 1 0 0 2 1,490.78 29 42
2DLC TX114
hypo protein 
Rv3688c  Rv3688c 16684 99.80% 2 2 3 0.02% 14.30% SDLTQAMK 95.00% 2.47 0.519 0 2 0 0 2 894.0784 10 17
2DLC TX114
hypo protein 
Rv3075c  Rv3075c 33083 99.80% 2 3 6 0.03% 7.82% LAFGIGDFR 95.00% 2.34 0.403 0 3 0 0 2 996.2984 156 164
2DLC TX114
hypo protein 
Rv3075c  Rv3075c 33083 99.80% 2 3 6 0.03% 7.82% RLPNVPIVALVETAR 95.00% 3.57 0.398 0 1 2 0 2 1,648.93 125 139
2DLC TX114lprF (lprF)  Rv1368 26833 100.00% 5 7 19 0.11% 26.10% DAIDGLATVK 95.00% 1.54 0.39 2 4 0 0 2 1,003.20 178 187
2DLC TX114lprF (lprF)  Rv1368 26833 100.00% 5 7 19 0.11% 26.10% GGDYVSVGPAEK 95.00% 3.34 0.55 0 2 0 0 2 1,179.19 137 148
2DLC TX114lprF (lprF)  Rv1368 26833 100.00% 5 7 19 0.11% 26.10% GLGAVVGQVQNPTIQGR 95.00% 4.3 0.63 0 2 0 0 2 1,694.73 161 177
2DLC TX114lprF (lprF)  Rv1368 26833 100.00% 5 7 19 0.11% 26.10% IYDPGIILDKDR 95.00% 2.63 0.54 0 2 4 0 2 1,418.89 149 160
2DLC TX114lprF (lprF)  Rv1368 26833 100.00% 5 7 19 0.11% 26.10% MKPNTPVVATEFLVTNK 95.00% 3.82 0.396 0 0 3 0 2 1,890.15 114 130
2DLC TX114
hypo protein 
Rv1324  Rv1324 32120 100.00% 5 6 11 0.06% 17.80% KSYQAILDANPGSVEAK 95.00% 4.31 0.449 0 0 1 0 2 1,792.06 190 206
2DLC TX114
hypo protein 
Rv1324  Rv1324 32120 100.00% 5 6 11 0.06% 17.80% LIALVR 95.00% 1.6 0.0444 2 1 0 0 2 684.9684 259 264
2DLC TX114
hypo protein 
Rv1324  Rv1324 32120 100.00% 5 6 11 0.06% 17.80% NLANALY 95.00% 1.46 0.459 2 0 0 0 2 778.9784 298 304
2DLC TX114
hypo protein 
Rv1324  Rv1324 32120 100.00% 5 6 11 0.06% 17.80% QQLEDGDFVAAR 95.00% 1.98 0.457 0 2 0 0 2 1,349.40 178 189
2DLC TX114
hypo protein 
Rv1324  Rv1324 32120 100.00% 5 6 11 0.06% 17.80% WVDSLLSATAGK 95.00% 3.22 0.559 0 3 0 0 2 1,248.46 145 156
2DLC TX114atpC (atpC)  Rv1311 13117 100.00% 3 4 11 0.06% 25.60% FLFTR 95.00% 1.24 0.112 3 0 0 0 2 683.9184 22 26
2DLC TX114atpC (atpC)  Rv1311 13117 100.00% 3 4 11 0.06% 25.60% HIPLVAQLVDDAMVR 95.00% 3.63 0.469 0 0 1 0 2 1,693.91 38 52
2DLC TX114atpC (atpC)  Rv1311 13117 100.00% 3 4 11 0.06% 25.60% TTVGEIGILPR 95.00% 1.38 0.199 2 5 0 0 2 1,156.41 27 37
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% FTQAGSEVSTLLGR 95.00% 3.08 0.512 0 7 0 0 2 1,466.63 270 283
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20%
GIFPAVDPLASSSTILDPSV
VGDEHYR 95.00% 3.01 0.543 0 1 5 0 2 2,844.17 352 378
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% GVEVIDTGR 95.00% 2.69 0.328 0 2 0 0 2 945.9584 87 95
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% IALFGGAGVGK 95.00% 2.07 0.403 1 2 0 0 2 990.2484 167 177
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% KAESLGAKL 95.00% 2.95 0.411 0 2 0 0 2 917.2084 478 486
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% KPPAFEELEPR 95.00% 3.23 0.134 0 0 1 0 2 1,313.56 134 144
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% NFGGTSVFAGVGER 95.00% 2.51 0.315 0 1 0 0 2 1,398.42 191 204
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% SISVPVGEGVK 95.00% 1.75 0.378 0 3 0 0 2 1,072.11 96 106
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% TEMLETGLK 95.00% 2.62 0.51 0 2 0 0 2 1,022.27 145 153
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% TISLQPTDGLVR 95.00% 2.33 0.455 0 9 0 0 2 1,300.54 75 86
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% TVLIQEMINR 95.00% 3.24 0.419 3 5 1 0 2 1,233.49 178 187
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% VAQEVIR 95.00% 1.87 0.241 0 1 0 0 2 814.8384 379 385
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% VTGPVVDVEFPR 95.00% 3.39 0.501 2 7 2 0 2 1,315.29 26 37
2DLC TX114atpD (atpD)  Rv1310 53077 100.00% 14 21 59 0.34% 34.20% VVDLLTPYVR 95.00% 2.12 0.454 1 1 0 0 2 1,175.35 154 163
2DLC TX114nuoI (nuoI)  Rv3153 23417 99.50% 2 2 3 0.02% 14.20% PEMAAPPHPR 90.00% 1.83 0.277 0 1 0 0 2 1,103.26 170 179
2DLC TX114nuoI (nuoI)  Rv3153 23417 99.50% 2 2 3 0.02% 14.20%
TPGATDKDYYLGNVTAEGL
R 95.00% 4.35 0.588 0 0 2 0 2 2,142.42 180 199
2DLC TX114atpG (atpG)  Rv1309 33874 100.00% 5 6 14 0.08% 18.70% ALTLMANR 95.00% 2.21 0.529 0 2 0 0 2 890.1784 274 281
2DLC TX114atpG (atpG)  Rv1309 33874 100.00% 5 6 14 0.08% 18.70% LESARPYAFEITR 95.00% 2.52 0.393 0 1 0 0 2 1,553.88 40 52
2DLC TX114atpG (atpG)  Rv1309 33874 100.00% 5 6 14 0.08% 18.70% SATDNADDLIK 95.00% 2 0.386 0 2 0 0 2 1,163.36 263 273
2DLC TX114atpG (atpG)  Rv1309 33874 100.00% 5 6 14 0.08% 18.70% SEELFSLLR 95.00% 3.06 0.321 0 2 0 0 2 1,094.38 100 108
2DLC TX114atpG (atpG)  Rv1309 33874 100.00% 5 6 14 0.08% 18.70% VYAALLESAASELASR 95.00% 3.83 0.44 0 6 1 0 2 1,651.93 242 257
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30% AIDAMTPIGR 95.00% 2.33 0.375 0 5 0 0 2 1,045.35 155 164
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30% AISLLLR 95.00% 1.55 0.159 2 2 0 0 2 786.1784 283 289
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30% ALELQAPSVVHR 95.00% 2.46 0.449 0 3 5 0 2 1,320.42 131 142
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30% DSQKLTEEAADKLTEVIK 95.00% 3.6 0.551 0 0 1 0 2 2,019.33 488 505
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30% EAYPGDVFYLHSR 95.00% 1.96 0.353 0 2 0 0 2 1,554.72 295 307
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30% LDLSQYR 95.00% 1.84 0.346 0 4 0 0 2 895.0984 395 401
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30% LTEEAADKLTEVIK 95.00% 3.28 0.368 0 2 0 0 2 1,560.85 492 505
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30% LVELLK 95.00% 1.75 0.147 1 2 0 0 2 714.9884 427 432
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30% TGEVLSVPVGDGFLGR 95.00% 3.64 0.571 0 3 1 0 2 1,603.73 94 109
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30% VGGAAQIK 91.10% 2.08 0.155 0 1 0 0 2 743.8484 377 384
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30% VVNPLGQPIDGR 95.00% 2.84 0.575 0 6 3 0 2 1,265.40 110 121
2DLC TX114atpA (atpA)  Rv1308 59271 100.00% 12 17 47 0.27% 21.30%
VVNPLGQPIDGRGDVDSDT
R 95.00% 1.81 0.486 0 0 4 0 2 2,111.20 110 129
2DLC TX114atpH (atpH)  Rv1307 48787 100.00% 6 7 12 0.07% 14.60% ILDVQPR 95.00% 2.05 0.302 0 2 0 0 2 841.0084 302 308
2DLC TX114atpH (atpH)  Rv1307 48787 100.00% 6 7 12 0.07% 14.60% LAAAEARLPD 95.00% 3.17 0.444 0 1 0 0 2 1,027.26 437 446
2DLC TX114atpH (atpH)  Rv1307 48787 100.00% 6 7 12 0.07% 14.60% LLDREAVVTR 95.00% 2.09 0.224 0 0 1 0 2 1,172.34 212 221
2DLC TX114atpH (atpH)  Rv1307 48787 100.00% 6 7 12 0.07% 14.60% VGAPTLEVLR 95.00% 3.08 0.435 0 2 0 0 2 1,055.21 245 254
2DLC TX114atpH (atpH)  Rv1307 48787 100.00% 6 7 12 0.07% 14.60% WSANSDLIDAIEHVSR 95.00% 3.43 0.457 0 2 2 0 2 1,813.99 261 276
2DLC TX114atpH (atpH)  Rv1307 48787 100.00% 6 7 12 0.07% 14.60% YLTVPAEDATPR 95.00% 1.91 0.475 0 2 0 0 2 1,333.49 222 233
198
2DLC TX114atpF (atpF)  Rv1306 18307 100.00% 7 10 28 0.16% 35.10% AEQQVASTLQTAHEQLK 95.00% 4.09 0.696 0 2 5 0 2 1,882.91 118 134
2DLC TX114atpF (atpF)  Rv1306 18307 100.00% 7 10 28 0.16% 35.10% AHVGTMSATL 95.00% 1.92 0.275 0 1 0 0 2 988.0784 146 155
2DLC TX114atpF (atpF)  Rv1306 18307 100.00% 7 10 28 0.16% 35.10% AHVGTMSATLASR 95.00% 2.63 0.377 0 0 4 0 2 1,302.44 146 158
2DLC TX114atpF (atpF)  Rv1306 18307 100.00% 7 10 28 0.16% 35.10% DAVELDLR 95.00% 1.66 0.184 2 0 0 0 2 931.0684 138 145
2DLC TX114atpF (atpF)  Rv1306 18307 100.00% 7 10 28 0.16% 35.10% ERDAVELDLR 95.00% 2.8 0.259 0 1 3 0 2 1,216.37 136 145
2DLC TX114atpF (atpF)  Rv1306 18307 100.00% 7 10 28 0.16% 35.10% ILGVDLTASAATR 95.00% 3.91 0.612 2 6 0 0 2 1,288.56 159 171
2DLC TX114atpF (atpF)  Rv1306 18307 100.00% 7 10 28 0.16% 35.10% VQASSLR 95.00% 1.47 0.241 2 0 0 0 2 760.8284 94 100
2DLC TX114
hypo protein 
Rv3143  Rv3143 14336 100.00% 3 3 5 0.03% 25.60% AEAAVPHPVDPIVLGR 95.00% 1.87 0.226 0 0 1 0 2 1,641.78 107 122
2DLC TX114
hypo protein 
Rv3143  Rv3143 14336 100.00% 3 3 5 0.03% 25.60% ILVYSDNVQTR 95.00% 2.45 0.564 0 2 0 0 2 1,308.44 10 20
2DLC TX114
hypo protein 
Rv3143  Rv3143 14336 100.00% 3 3 5 0.03% 25.60% TVLSLLR 95.00% 1.22 0.151 2 0 0 0 2 802.0684 123 129
2DLC TX114
fadE23 
(fadE23)  Rv3140 43327 100.00% 4 4 7 0.04% 8.23% AALEEIR 83.60% 1.89 0.172 0 1 0 0 2 801.9784 268 274
2DLC TX114
fadE23 
(fadE23)  Rv3140 43327 100.00% 4 4 7 0.04% 8.23% IFVTAGSR 95.00% 2.29 0.37 0 2 0 0 2 850.9984 163 170
2DLC TX114
fadE23 
(fadE23)  Rv3140 43327 100.00% 4 4 7 0.04% 8.23% KLQAIIVK 95.00% 2.7 0.421 0 2 0 0 2 913.2684 10 17
2DLC TX114
fadE23 
(fadE23)  Rv3140 43327 100.00% 4 4 7 0.04% 8.23% LLGLSSSELK 95.00% 2.54 0.429 0 2 0 0 2 1,047.41 392 401
2DLC TX114
fadE24 
(fadE24)  Rv3139 49629 99.80% 2 2 2 0.01% 6.62%
AAELGITAINIPEDFDGIAE
HR 95.00% 3.54 0.524 0 0 1 0 2 2,353.76 149 170
2DLC TX114
fadE24 
(fadE24)  Rv3139 49629 99.80% 2 2 2 0.01% 6.62% AEQGLPFAR 95.00% 2.58 0.376 0 1 0 0 2 989.1484 406 414
2DLC TX114PPE (PPE)  Rv3136 37962 100.00% 3 3 8 0.05% 8.16% IQLLAL 95.00% 1.36 0.0083 1 0 0 0 2 670.9984 115 120
2DLC TX114PPE (PPE)  Rv3136 37962 100.00% 3 3 8 0.05% 8.16% LTVMAHPPAAG 95.00% 2.3 0.491 0 5 0 0 2 1,065.22 370 380
2DLC TX114PPE (PPE)  Rv3136 37962 100.00% 3 3 8 0.05% 8.16% MDFALLPPEVNSAR 95.00% 1.67 0.317 0 2 0 0 2 1,560.87 1 14
2DLC TX114
hypo protein 
Rv2185c  Rv2185c 16276 99.90% 2 2 4 0.02% 13.20% LIDGALKDLK 95.00% 2.66 0.175 0 2 0 0 2 1,086.55 130 139
2DLC TX114
hypo protein 
Rv2185c  Rv2185c 16276 99.90% 2 2 4 0.02% 13.20% MLMDAAIFK 95.00% 2.54 0.498 0 2 0 0 2 1,040.48 54 62
2DLC TX114
hypo protein 
Rv0771  Rv0771 16056 99.80% 2 2 5 0.03% 11.10% ANVAEVLAK 95.00% 2.15 0.431 0 2 0 0 2 914.9984 130 138
2DLC TX114
hypo protein 
Rv0771  Rv0771 16056 99.80% 2 2 5 0.03% 11.10% LNSAIER 95.00% 1.73 0.278 0 3 0 0 2 802.9784 105 111
2DLC TX114cspB (cspB)  Rv0871 14971 100.00% 3 3 5 0.03% 23.00% LIEPPPSLSR 95.00% 1.6 0.429 0 2 0 0 2 1,109.44 64 73
2DLC TX114cspB (cspB)  Rv0871 14971 100.00% 3 3 5 0.03% 23.00% SSALPTGVEALK 95.00% 2.35 0.441 0 2 0 0 2 1,173.38 30 41
2DLC TX114cspB (cspB)  Rv0871 14971 100.00% 3 3 5 0.03% 23.00% VEFGIASGR 95.00% 2.18 0.504 0 1 0 0 2 936.0484 46 54
2DLC TX114
hypo protein 
Rv3127  Rv3127 38470 100.00% 6 6 14 0.08% 23.80% AQAILQR 95.00% 2.2 0.255 0 2 0 0 2 799.9784 109 115
2DLC TX114
hypo protein 
Rv3127  Rv3127 38470 100.00% 6 6 14 0.08% 23.80%
FPQPNQPDQLATVEFSPID
HVTAGQR 95.00% 6.89 0.715 0 0 2 0 2 2,894.03 81 106
2DLC TX114
hypo protein 
Rv3127  Rv3127 38470 100.00% 6 6 14 0.08% 23.80% LVVASQLSEVLR 95.00% 4.28 0.538 0 3 0 0 2 1,314.47 157 168
2DLC TX114
hypo protein 
Rv3127  Rv3127 38470 100.00% 6 6 14 0.08% 23.80% RPLDSVLQIR 95.00% 2.84 0.132 0 1 0 0 2 1,197.49 312 321
2DLC TX114
hypo protein 
Rv3127  Rv3127 38470 100.00% 6 6 14 0.08% 23.80% VGIAPPLAAVPAPTPR 95.00% 2.81 0.445 0 2 0 0 2 1,527.83 296 311
2DLC TX114
hypo protein 
Rv3127  Rv3127 38470 100.00% 6 6 14 0.08% 23.80% VLVLSTPSDTR 95.00% 2.44 0.474 0 4 0 0 2 1,188.34 230 240
2DLC TX114
hypo protein 
Rv1109c  Rv1109c 22940 100.00% 3 3 10 0.06% 21.70% APFQTLLANR 95.00% 2.81 0.435 0 4 0 0 2 1,131.40 196 205
2DLC TX114
hypo protein 
Rv1109c  Rv1109c 22940 100.00% 3 3 10 0.06% 21.70% FALYSVSDTPETTTASR 95.00% 3.64 0.571 0 4 0 0 2 1,847.01 113 129
2DLC TX114
hypo protein 
Rv1109c  Rv1109c 22940 100.00% 3 3 10 0.06% 21.70% TILMYPMTLASQAAHVVMR 95.00% 1.58 0.303 0 0 2 0 2 2,182.60 28 46
2DLC TX114
sseC2 
(sseC2)  Rv0814c,Rv3118 10147 100.00% 4 4 15 0.09% 71.00%
ALSAAGNGDAVVQPSGAGI
HEVDVK 95.00% 3.39 0.592 0 0 4 0 2 2,363.38 74 98
2DLC TX114sseC2 Rv0814c,Rv3118 10147 100.00% 4 4 15 0.09% 71.00% FFAAPGSWTLR 95.00% 2.77 0.62 0 4 0 0 2 1,253.53 63 73
2DLC TX114
sseC2 
(sseC2)  Rv0814c,Rv3118 10147 100.00% 4 4 15 0.09% 71.00% QGLTLPASVDLEKETVITGR 95.00% 2.48 0.504 0 0 2 0 2 2,128.44 7 26
2DLC TX114sseC2 Rv0814c,Rv3118 10147 100.00% 4 4 15 0.09% 71.00% VVDGDGQAVGGAFVR 95.00% 4.95 0.548 0 5 0 0 2 1,447.36 27 41
2DLC TX114cysA2 Rv0815c,Rv3117 30997 100.00% 4 7 12 0.07% 12.30% AFRDEVLAAINVK 95.00% 2.84 0.272 0 1 4 0 2 1,446.70 146 158
2DLC TX114cysA2 Rv0815c,Rv3117 30997 100.00% 4 7 12 0.07% 12.30% DFVDAQQFSK 95.00% 3.37 0.487 1 3 0 0 2 1,185.25 58 67
2DLC TX114cysA2 Rv0815c,Rv3117 30997 100.00% 4 7 12 0.07% 12.30% LLSER 95.00% 1.37 0.0014 1 0 0 0 2 617.7984 68 72
2DLC TX114cysA2 Rv0815c,Rv3117 30997 100.00% 4 7 12 0.07% 12.30% NLIDVR 95.00% 1.47 0.271 1 1 0 0 2 729.8884 159 164
2DLC TX114fprA (fprA)  Rv3106 49323 99.80% 2 2 2 0.01% 3.95% FLTSPIEIK 95.00% 1.77 0.274 0 1 0 0 2 1,048.42 271 279
2DLC TX114fprA (fprA)  Rv3106 49323 99.80% 2 2 2 0.01% 3.95% LASLAELLR 95.00% 2.45 0.231 0 1 0 0 2 986.3584 444 452
2DLC TX114
hypo protein 
Rv2978c  Rv2978c 51387 97.60% 2 2 2 0.01% 4.79% DATEMLRQK 86.50% 1.88 0.208 0 1 0 0 2 1,108.30 315 323
2DLC TX114
hypo protein 
Rv2978c  Rv2978c 51387 97.60% 2 2 2 0.01% 4.79% WQTSRAGKRAGKR 82.00% 1.88 0.176 0 0 1 0 2 1,502.76 113 125
2DLC TX114adk (adk)  Rv0733 20076 100.00% 4 4 11 0.06% 26.00% LGIPQISTGELFR 95.00% 2.47 0.312 0 3 0 0 2 1,431.82 24 36
2DLC TX114adk (adk)  Rv0733 20076 100.00% 4 4 11 0.06% 26.00% TVDAVGTMDEVFAR 95.00% 2.45 0.441 0 3 0 0 2 1,511.54 161 174
2DLC TX114adk (adk)  Rv0733 20076 100.00% 4 4 11 0.06% 26.00% VLLLGPPGAGK 95.00% 2.37 0.396 0 3 0 0 2 1,022.36 3 13
2DLC TX114adk (adk)  Rv0733 20076 100.00% 4 4 11 0.06% 26.00% VSEEVLLER 95.00% 2.52 0.292 0 2 0 0 2 1,074.14 115 123
2DLC TX114
hypo protein 
Rv3615c  Rv3615c 10777 100.00% 3 4 18 0.10% 17.50% AIDGLFT 95.00% 0.98 0.295 5 0 0 0 2 736.9484 97 103
2DLC TX114
hypo protein 
Rv3615c  Rv3615c 10777 100.00% 3 4 18 0.10% 17.50% IYSEADEAWR 95.00% 2.34 0.549 0 5 0 0 2 1,240.36 86 95
2DLC TX114
hypo protein 
Rv3615c  Rv3615c 10777 100.00% 3 4 18 0.10% 17.50% KAIDGLFT 95.00% 1.36 0.364 4 4 0 0 2 865.1484 96 103
2DLC TX114ilvN (ilvN)  Rv3002c 18169 100.00% 6 6 9 0.05% 23.80% EALLR 95.00% 1.42 0 1 0 0 0 2 601.7984 135 139
2DLC TX114ilvN (ilvN)  Rv3002c 18169 100.00% 6 6 9 0.05% 23.80% GKLEALLR 95.00% 2.18 0.289 0 1 0 0 2 900.2484 132 139
2DLC TX114ilvN (ilvN)  Rv3002c 18169 100.00% 6 6 9 0.05% 23.80% LINVIK 95.00% 2.06 0.202 0 1 0 0 2 699.9884 70 75
2DLC TX114ilvN (ilvN)  Rv3002c 18169 100.00% 6 6 9 0.05% 23.80% SQVIEAVNLFR 95.00% 4.38 0.551 0 3 0 0 2 1,276.42 102 112
2DLC TX114ilvN (ilvN)  Rv3002c 18169 100.00% 6 6 9 0.05% 23.80% VAALFSR 95.00% 1.96 0.264 0 2 0 0 2 763.9284 22 28
2DLC TX114ilvN (ilvN)  Rv3002c 18169 100.00% 6 6 9 0.05% 23.80% VLEPFGIR 85.30% 2 0.164 0 1 0 0 2 931.1584 140 147
2DLC TX114sppA (sppA)  Rv0724 65918 100.00% 5 5 11 0.06% 9.15% GLVDELGGLR 95.00% 3.19 0.355 0 4 0 0 2 1,029.24 533 542
2DLC TX114sppA (sppA)  Rv0724 65918 100.00% 5 5 11 0.06% 9.15% IVSYPGSSLWDMVRPR 85.10% 1.46 0.258 0 0 1 0 2 1,864.19 562 577
2DLC TX114sppA (sppA)  Rv0724 65918 100.00% 5 5 11 0.06% 9.15% LGVGSDAVR 95.00% 1.81 0.513 0 3 0 0 2 873.9184 459 467
2DLC TX114sppA (sppA)  Rv0724 65918 100.00% 5 5 11 0.06% 9.15% VLAGLDEDTEVR 95.00% 2.64 0.475 0 2 0 0 2 1,317.39 550 561
199
2DLC TX114sppA (sppA)  Rv0724 65918 100.00% 5 5 11 0.06% 9.15% VWTGADALDRGL 95.00% 1.43 0.292 1 0 0 0 2 1,274.45 523 534
2DLC TX114
hypo protein 
Rv3614c  Rv3614c 19784 100.00% 4 5 11 0.06% 31.50% AQSAQYAFILDR 95.00% 3.05 0.491 0 3 0 0 2 1,383.64 116 127
2DLC TX114
hypo protein 
Rv3614c  Rv3614c 19784 100.00% 4 5 11 0.06% 31.50% IDHVELSAR 95.00% 2.79 0.387 0 1 3 0 2 1,040.15 84 92
2DLC TX114
hypo protein 
Rv3614c  Rv3614c 19784 100.00% 4 5 11 0.06% 31.50%
KTVGETWGLPSPEEAAAAE
AEVFATR 95.00% 2.68 0.355 0 0 1 0 2 2,718.86 144 169
2DLC TX114
hypo protein 
Rv3614c  Rv3614c 19784 100.00% 4 5 11 0.06% 31.50% TVSVSTLMDGR 95.00% 2.44 0.535 0 3 0 0 2 1,182.27 73 83
2DLC TX114
hypo protein 
Rv3193c  Rv3193c 107455 100.00% 3 3 4 0.02% 4.44% LLDPTIVSPAFTQFQQGK 95.00% 5.06 0.68 0 0 1 0 2 1,991.34 370 387
2DLC TX114
hypo protein 
Rv3193c  Rv3193c 107455 100.00% 3 3 4 0.02% 4.44% VAALQEIQAAIGAAR 95.00% 3.09 0.482 0 1 0 0 2 1,482.72 949 963
2DLC TX114
hypo protein 
Rv3193c  Rv3193c 107455 100.00% 3 3 4 0.02% 4.44% WGNLLTLPVAR 95.00% 3.04 0.451 0 2 0 0 2 1,240.54 833 843
2DLC TX114rpsC (rpsC)  Rv0707 29970 100.00% 3 3 5 0.03% 9.85% AGIADVEIER 95.00% 3.14 0.344 0 1 0 0 2 1,073.20 49 58
2DLC TX114rpsC (rpsC)  Rv0707 29970 100.00% 3 3 5 0.03% 9.85% PGIVIGR 95.00% 2.5 0.263 0 3 0 0 2 711.9084 72 78
2DLC TX114rpsC (rpsC)  Rv0707 29970 100.00% 3 3 5 0.03% 9.85% QVQLNILEVK 95.00% 3.49 0.433 0 1 0 0 2 1,184.36 97 106
2DLC TX114rpsJ (rpsJ)  Rv0700 11381 99.80% 2 2 4 0.02% 24.80% LIDIIDPTPK 95.00% 2.34 0.467 0 2 0 0 2 1,125.56 73 82
2DLC TX114rpsJ (rpsJ)  Rv0700 11381 99.80% 2 2 4 0.02% 24.80% TGASVVGPVPLPTEK 95.00% 2.32 0.402 0 2 0 0 2 1,452.55 32 46
2DLC TX114
hypo protein 
Rv2536  Rv2536 24608 99.80% 2 3 3 0.02% 10.00% AADTDVFSAVR 95.00% 1.15 0.414 1 1 0 0 2 1,152.18 157 167
2DLC TX114
hypo protein 
Rv2536  Rv2536 24608 99.80% 2 3 3 0.02% 10.00% TTESDTPTEVIR 95.00% 2.63 0.401 0 1 0 0 2 1,349.39 202 213
2DLC TX114
hypo protein 
Rv0036c  Rv0036c 27528 99.80% 2 2 3 0.02% 10.10% LHEELLAVPDGR 95.00% 2.9 0.417 0 1 0 0 2 1,349.54 106 117
2DLC TX114
hypo protein 
Rv0036c  Rv0036c 27528 99.80% 2 2 3 0.02% 10.10% WLTIAQAFAGPPGR 95.00% 2.72 0.383 0 2 0 0 2 1,485.80 242 255
2DLC TX114
hypo protein 
Rv0079  Rv0079 29457 100.00% 4 4 8 0.05% 17.90% EHGLPFLFFTDQATGR 95.00% 3.87 0.549 0 0 2 0 2 1,837.12 231 246
2DLC TX114
hypo protein 
Rv0079  Rv0079 29457 100.00% 4 4 8 0.05% 17.90% GQLLYSR 95.00% 1.88 0.383 0 2 0 0 2 837.0484 247 253
2DLC TX114
hypo protein 
Rv0079  Rv0079 29457 100.00% 4 4 8 0.05% 17.90% LTTPAEALVTR 95.00% 1.57 0.376 0 3 0 0 2 1,172.37 127 137
2DLC TX114
hypo protein 
Rv0079  Rv0079 29457 100.00% 4 4 8 0.05% 17.90% SRPTPVLTEAAAVDR 95.00% 3.48 0.508 0 0 1 0 2 1,583.72 214 228
2DLC TX114
hypo protein 
Rv2115c  Rv2115c 67385 99.80% 2 2 2 0.01% 4.27% AIDTESNLGQYL 95.00% 2.33 0.389 0 1 0 0 2 1,324.53 598 609
2DLC TX114
hypo protein 
Rv2115c  Rv2115c 67385 99.80% 2 2 2 0.01% 4.27% ENAVGSHAPTRSAR 95.00% 1.53 0.398 0 1 0 0 2 1,453.46 41 54
2DLC TX114
hypo protein 
Rv1996  Rv1996 33860 99.80% 2 2 6 0.03% 6.94% GGFPGMHLGSVSR 95.00% 2.65 0.509 0 4 0 0 2 1,302.47 282 294
2DLC TX114
hypo protein 
Rv1996  Rv1996 33860 99.80% 2 2 6 0.03% 6.94% LNWAPIEWR 95.00% 2.89 0.455 0 2 0 0 2 1,185.42 217 225
2DLC TX114
hypo protein 
Rv2509  Rv2509 27996 100.00% 4 4 8 0.05% 17.50% AIVAPIVGAFYK 95.00% 2.67 0.557 0 2 0 0 2 1,249.57 252 263
2DLC TX114
hypo protein 
Rv2509  Rv2509 27996 100.00% 4 4 8 0.05% 17.50% REDVLTELAAR 95.00% 3.46 0.421 0 1 0 0 2 1,273.45 42 52
2DLC TX114
hypo protein 
Rv2509  Rv2509 27996 100.00% 4 4 8 0.05% 17.50% VSLNALER 95.00% 2.32 0.287 0 2 0 0 2 902.0484 221 228
2DLC TX114
hypo protein 
Rv2509  Rv2509 27996 100.00% 4 4 8 0.05% 17.50% VTVDVRPADLADPQER 95.00% 3.71 0.512 0 0 3 0 2 1,781.83 59 74
2DLC TX114rplI (rplI)  Rv0056 16152 100.00% 4 4 6 0.03% 28.90% AAIEALGPIALPVK 95.00% 3.71 0.476 0 3 0 0 2 1,363.80 70 83
2DLC TX114rplI (rplI)  Rv0056 16152 100.00% 4 4 6 0.03% 28.90% GLAIVASR 95.00% 1.74 0.139 1 0 0 0 2 786.9784 34 41
2DLC TX114rplI (rplI)  Rv0056 16152 100.00% 4 4 6 0.03% 28.90% LFGSVTAADVVAAIKK 95.00% 2.94 0.286 0 1 0 0 2 1,590.88 91 106
2DLC TX114rplI (rplI)  Rv0056 16152 100.00% 4 4 6 0.03% 28.90% NFLLPR 84.40% 1.49 0.235 0 1 0 0 2 760.0384 28 33
2DLC TX114rpsF (rpsF)  Rv0053 10917 99.80% 2 2 2 0.01% 26.00% AAPATVSELDR 95.00% 2.96 0.54 0 1 0 0 2 1,130.23 67 77
2DLC TX114rpsF (rpsF)  Rv0053 10917 99.80% 2 2 2 0.01% 26.00% TVAPSLETFLNVVR 95.00% 2.64 0.383 0 1 0 0 2 1,546.71 18 31
2DLC TX114
mmaA2 
(mmaA2)  Rv0644c 32707 100.00% 3 3 7 0.04% 9.41% TGFTLTR 95.00% 1.64 0.383 0 3 0 0 2 795.9684 218 224
2DLC TX114
mmaA2 
(mmaA2)  Rv0644c 32707 100.00% 3 3 7 0.04% 9.41% VGYIDVNQFTLAK 95.00% 3.3 0.577 0 2 0 0 2 1,468.69 275 287
2DLC TX114
mmaA2 
(mmaA2)  Rv0644c 32707 100.00% 3 3 7 0.04% 9.41% YLTGCAK 95.00% 0.874 0.264 2 0 0 0 2 755.9484 265 271
2DLC TX114
hypo protein 
Rv1957  Rv1957 20089 99.80% 2 2 3 0.02% 16.60%
EILSRPMPVSPGAQWPATR
GTP 95.00% 2.11 0.236 0 0 1 0 2 2,349.71 160 181
2DLC TX114
hypo protein 
Rv1957  Rv1957 20089 99.80% 2 2 3 0.02% 16.60% FALYPYIR 95.00% 2.22 0.343 0 2 0 0 2 1,043.42 135 142
2DLC TX114
hypo protein 
Rv3780  Rv3780 19466 100.00% 3 4 10 0.06% 11.20% AQLQQMR 95.00% 1.9 0.394 0 3 0 0 2 874.9984 150 156
2DLC TX114
hypo protein 
Rv3780  Rv3780 19466 100.00% 3 4 10 0.06% 11.20% IGTMIK 95.00% 1.19 0.153 2 1 0 0 2 662.9684 54 59
2DLC TX114
hypo protein 
Rv3780  Rv3780 19466 100.00% 3 4 10 0.06% 11.20% QLLEEVR 94.90% 1.81 0.206 0 4 0 0 2 886.9884 60 66
2DLC TX114
hypo protein 
Rv2721c  Rv2721c 72322 100.00% 10 12 24 0.14% 20.30% AAGGAAGPLGAK 95.00% 3.36 0.488 0 2 0 0 2 941.1384 232 243
2DLC TX114
hypo protein 
Rv2721c  Rv2721c 72322 100.00% 10 12 24 0.14% 20.30% AGGDTSTLGVR 95.00% 3.26 0.485 0 2 0 0 2 1,034.10 52 62
2DLC TX114
hypo protein 
Rv2721c  Rv2721c 72322 100.00% 10 12 24 0.14% 20.30% FTGGMISWNR 95.00% 3.13 0.469 0 2 0 0 2 1,169.40 370 379
2DLC TX114
hypo protein 
Rv2721c  Rv2721c 72322 100.00% 10 12 24 0.14% 20.30% GALNAAWDK 95.00% 2.7 0.421 0 2 0 0 2 946.1084 154 162
2DLC TX114
hypo protein 
Rv2721c  Rv2721c 72322 100.00% 10 12 24 0.14% 20.30% GAMVAAWDK 95.00% 2.3 0.421 0 1 0 0 2 949.0784 336 344
2DLC TX114
hypo protein 




Rv2721c  Rv2721c 72322 100.00% 10 12 24 0.14% 20.30%
KGGQYPIGGDGIAQDFVG
GK 95.00% 4.25 0.598 0 2 1 0 2 1,965.24 244 263
2DLC TX114
hypo protein 
Rv2721c  Rv2721c 72322 100.00% 10 12 24 0.14% 20.30% LGAPVGDQTVDGDVVSQK 95.00% 3.11 0.567 0 0 1 0 2 1,785.73 352 369
2DLC TX114
hypo protein 
Rv2721c  Rv2721c 72322 100.00% 10 12 24 0.14% 20.30% MFFTPATGAK 95.00% 1.76 0.401 0 3 0 0 2 1,071.35 82 91
2DLC TX114
hypo protein 
Rv2721c  Rv2721c 72322 100.00% 10 12 24 0.14% 20.30%
VSTFSAADNPVIFWTPEHG
AFVVR 95.00% 3.41 0.613 0 0 5 0 2 2,648.79 130 153
2DLC TX114ppiA (ppiA)  Rv0009 19222 100.00% 10 14 34 0.20% 53.80% ASGGPSGPFYDGAVFHR 95.00% 1.83 0.297 0 0 1 0 2 1,722.85 57 73
2DLC TX114ppiA (ppiA)  Rv0009 19222 100.00% 10 14 34 0.20% 53.80%
DYSTQNASGGPSGPFYDG
AVFHR 95.00% 3.62 0.536 0 0 1 0 2 2,431.53 51 73
2DLC TX114ppiA (ppiA)  Rv0009 19222 100.00% 10 14 34 0.20% 53.80% FGNHAPK 95.00% 2.3 0.227 0 2 0 0 2 770.8684 31 37
2DLC TX114ppiA (ppiA)  Rv0009 19222 100.00% 10 14 34 0.20% 53.80% HTIFGEVIDAESQR 95.00% 3.17 0.648 0 3 5 0 2 1,602.70 141 154
2DLC TX114ppiA (ppiA)  Rv0009 19222 100.00% 10 14 34 0.20% 53.80% IALFGN 91.50% 1.25 0.0147 1 0 0 0 2 634.8484 28 33
2DLC TX114ppiA (ppiA)  Rv0009 19222 100.00% 10 14 34 0.20% 53.80% IALFGNHAPK 95.00% 2.73 0.415 0 8 1 0 2 1,068.35 28 37
2DLC TX114ppiA (ppiA)  Rv0009 19222 100.00% 10 14 34 0.20% 53.80% SPLATATATLHTNR 95.00% 3.1 0.47 0 0 2 0 2 1,454.66 10 23
2DLC TX114ppiA (ppiA)  Rv0009 19222 100.00% 10 14 34 0.20% 53.80% TVANFVGLAQGTK 95.00% 3.57 0.531 0 1 0 0 2 1,306.42 38 50
2DLC TX114ppiA (ppiA)  Rv0009 19222 100.00% 10 14 34 0.20% 53.80% VIQGFMIQGGDPTGTGR 95.00% 4.43 0.495 0 2 3 0 2 1,750.96 74 90
2DLC TX114ppiA (ppiA)  Rv0009 19222 100.00% 10 14 34 0.20% 53.80% VVEAISK 95.00% 1.74 0.272 2 2 0 0 2 745.8184 155 161
2DLC TX114
hypo protein 
Rv0007  Rv0007 31024 99.80% 2 3 3 0.02% 9.54% FISGASAPVTGPAAAVR 95.00% 3.55 0.488 0 1 1 0 2 1,572.76 85 101
2DLC TX114
hypo protein 
Rv0007  Rv0007 31024 99.80% 2 3 3 0.02% 9.54% IPDAGDPPPWQR 95.00% 2.05 0.219 0 1 0 0 2 1,349.53 37 48
2DLC TX114gyrA (gyrA)  Rv0006 92259 99.80% 2 2 5 0.03% 2.15% LLSLNVVR 95.00% 2.13 0.356 0 2 0 0 2 914.1384 711 718
2DLC TX114gyrA (gyrA)  Rv0006 92259 99.80% 2 2 5 0.03% 2.15% LTPLAMEMLR 95.00% 1.91 0.438 0 3 0 0 2 1,175.62 134 143
2DLC TX114gyrB (gyrB)  Rv0005 78422 100.00% 3 3 6 0.03% 3.92% GLTINL 95.00% 1.26 0.105 2 0 0 0 2 630.8684 242 247
2DLC TX114gyrB (gyrB)  Rv0005 78422 100.00% 3 3 6 0.03% 3.92% SALTSVVNK 95.00% 2.25 0.376 0 2 0 0 2 918.9984 361 369
2DLC TX114gyrB (gyrB)  Rv0005 78422 100.00% 3 3 6 0.03% 3.92% TFHYPGGLVDFVK 95.00% 4.62 0.553 0 0 2 0 2 1,480.68 289 301
2DLC TX114desA1 Rv0824c 38752 100.00% 4 4 5 0.03% 12.70% DYLVVTR 95.00% 2 0.432 0 2 0 0 2 865.9584 116 122
2DLC TX114desA1 Rv0824c 38752 100.00% 4 4 5 0.03% 12.70% IFEREDFTGEGAK 95.00% 3.29 0.473 0 0 1 0 2 1,499.70 272 284
2DLC TX114desA1 Rv0824c 38752 100.00% 4 4 5 0.03% 12.70% IHLDEVVMPVLK 95.00% 3.92 0.559 0 1 0 0 2 1,393.65 257 268
2DLC TX114desA1 Rv0824c 38752 100.00% 4 4 5 0.03% 12.70% SVDPVELEKLR 95.00% 1.7 0.287 0 1 0 0 2 1,285.46 123 133
2DLC TX114dnaN (dnaN)  Rv0002 42096 100.00% 4 4 5 0.03% 8.71% AGIGGSDVR 95.00% 1.96 0.249 0 1 0 0 2 831.8984 217 225
2DLC TX114dnaN (dnaN)  Rv0002 42096 100.00% 4 4 5 0.03% 8.71% LVALVADR 95.00% 2.64 0.423 0 1 0 0 2 857.0184 286 293
2DLC TX114dnaN (dnaN)  Rv0002 42096 100.00% 4 4 5 0.03% 8.71% MEFADGSVR 95.00% 1.15 0.228 1 0 0 0 2 1,028.10 299 307
2DLC TX114dnaN (dnaN)  Rv0002 42096 100.00% 4 4 5 0.03% 8.71% VGLTDLTFR 95.00% 2.95 0.451 0 2 0 0 2 1,022.24 8 16
2DLC TX114
fadD31 
(fadD31)  Rv1925 66311 100.00% 9 11 17 0.10% 18.20% AFAPYGLPR 95.00% 2.52 0.335 0 1 0 0 2 992.2684 340 348
2DLC TX114
fadD31 
(fadD31)  Rv1925 66311 100.00% 9 11 17 0.10% 18.20% HGLSVADLSFLPAGAIPR 95.00% 6.49 0.719 0 3 1 0 2 1,822.23 580 597
2DLC TX114
fadD31 
(fadD31)  Rv1925 66311 100.00% 9 11 17 0.10% 18.20% IADLLTIDGR 95.00% 2.95 0.473 2 2 0 0 2 1,087.45 501 510
2DLC TX114
fadD31 
(fadD31)  Rv1925 66311 100.00% 9 11 17 0.10% 18.20%
LQSPLAEGSHADGSAIDDT
WLR 95.00% 2.49 0.508 0 0 2 0 2 2,340.62 462 483
2DLC TX114
fadD31 
(fadD31)  Rv1925 66311 100.00% 9 11 17 0.10% 18.20% LVIIAER 93.70% 1.82 0.192 0 1 0 0 2 814.0684 550 556
2DLC TX114
fadD31 
(fadD31)  Rv1925 66311 100.00% 9 11 17 0.10% 18.20% NAVEGFLNNVPR 95.00% 2.67 0.395 0 1 0 0 2 1,330.41 154 165
2DLC TX114
fadD31 
(fadD31)  Rv1925 66311 100.00% 9 11 17 0.10% 18.20% VVTAAPNFAYEWAAQR 95.00% 2.67 0.566 0 1 0 0 2 1,794.88 291 306
2DLC TX114
fadD31 
(fadD31)  Rv1925 66311 100.00% 9 11 17 0.10% 18.20% WIQALSEGSR 95.00% 2.56 0.48 0 2 0 0 2 1,147.31 278 287
2DLC TX114
fadD31 
(fadD31)  Rv1925 66311 100.00% 9 11 17 0.10% 18.20% YVGDLVAYR 95.00% 2.83 0.439 0 1 0 0 2 1,056.19 46 54
2DLC TX114lpqH (lpqH)  Rv3763 15096 100.00% 5 7 18 0.10% 25.80% ITGTATGVDMAN 95.00% 2.13 0.546 0 1 0 0 2 1,151.25 132 143
2DLC TX114lpqH (lpqH)  Rv3763 15096 100.00% 5 7 18 0.10% 25.80% ITGTATGVDMANPMSPVNK 95.00% 4.49 0.508 0 4 6 0 2 1,905.14 132 150
2DLC TX114lpqH (lpqH)  Rv3763 15096 100.00% 5 7 18 0.10% 25.80% PMSPVNK 85.60% 2 0.14 0 1 0 0 2 788.9078 144 150
2DLC TX114lpqH (lpqH)  Rv3763 15096 100.00% 5 7 18 0.10% 25.80% SVGLGNVNGVTL 95.00% 2.24 0.388 0 2 0 0 2 1,130.16 99 110
2DLC TX114lpqH (lpqH)  Rv3763 15096 100.00% 5 7 18 0.10% 25.80%
SVGLGNVNGVTLGYTSGTG
QGN 95.00% 5.41 0.652 0 3 1 0 2 2,053.04 99 120
2DLC TX114fadA2 Rv0243 46058 100.00% 5 5 8 0.05% 11.60% LDMVVGGAVLK 95.00% 3.5 0.468 0 2 0 0 2 1,118.31 59 69
2DLC TX114fadA2 Rv0243 46058 100.00% 5 5 8 0.05% 11.60% LGLDAALGSIDR 95.00% 4.32 0.44 0 2 0 0 2 1,201.56 365 376
2DLC TX114fadA2 Rv0243 46058 100.00% 5 5 8 0.05% 11.60% PVFGVK 95.00% 1.67 0.314 0 1 0 0 2 646.7284 251 256
2DLC TX114fadA2 Rv0243 46058 100.00% 5 5 8 0.05% 11.60% TGLSMGEHAAVTAK 89.90% 1.67 0.224 0 0 1 0 2 1,373.51 179 192
2DLC TX114fadA2 Rv0243 46058 100.00% 5 5 8 0.05% 11.60% VAVLGGNR 95.00% 1.99 0.295 0 2 0 0 2 785.8384 15 22
2DLC TX114glcB (glcB)  Rv1837c 80386 100.00% 3 3 5 0.03% 4.72% FALNAANAR 95.00% 2.68 0.378 0 1 0 0 2 948.1384 126 134
2DLC TX114glcB (glcB)  Rv1837c 80386 100.00% 3 3 5 0.03% 4.72% NYTAPGGGQFTLPGR 95.00% 2.85 0.593 0 1 0 0 2 1,536.74 319 333
2DLC TX114glcB (glcB)  Rv1837c 80386 100.00% 3 3 5 0.03% 4.72% VIEPIDMDAYR 95.00% 2.16 0.459 0 3 0 0 2 1,322.59 72 82
2DLC TX114
hypo protein 
Rv1836c  Rv1836c 69659 100.00% 3 3 4 0.02% 7.39% LSNVVAALENR 95.00% 3.73 0.564 0 1 0 0 2 1,186.30 507 517
2DLC TX114
hypo protein 
Rv1836c  Rv1836c 69659 100.00% 3 3 4 0.02% 7.39% PAALTAALGK 95.00% 2.67 0.564 0 2 0 0 2 913.2084 556 565
2DLC TX114
hypo protein 
Rv1836c  Rv1836c 69659 100.00% 3 3 4 0.02% 7.39%
VSDVKPPSSPVTSFPALPST
LSVGDDSMR 95.00% 4.4 0.591 0 0 1 0 2 2,975.29 445 473
2DLC TX114rho (rho)  Rv1297 65084 100.00% 5 5 8 0.05% 11.80% KNELIAAIEEIR 95.00% 4.42 0.549 0 1 0 0 2 1,399.78 62 73
2DLC TX114rho (rho)  Rv1297 65084 100.00% 5 5 8 0.05% 11.80% LVEQGKDVVVLLDSITR 95.00% 3.84 0.581 0 1 0 0 2 1,885.13 428 444
2DLC TX114rho (rho)  Rv1297 65084 100.00% 5 5 8 0.05% 11.80%
TSGYLPGPHDVYVSMNMV
R 95.00% 1.75 0.299 0 0 1 0 2 2,156.33 241 259
2DLC TX114rho (rho)  Rv1297 65084 100.00% 5 5 8 0.05% 11.80% VFPAVDVNPSGTR 95.00% 2.08 0.32 0 2 0 0 2 1,359.38 529 541
2DLC TX114rho (rho)  Rv1297 65084 100.00% 5 5 8 0.05% 11.80% VIDLIMPIGK 95.00% 3.23 0.446 0 3 0 0 2 1,099.56 336 345
2DLC TX114sigA (sigA)  Rv2703 57752 99.80% 2 2 4 0.02% 4.17% SQVLRDYLD 95.00% 2.47 0.456 0 2 0 0 2 1,109.27 520 528
2DLC TX114sigA (sigA)  Rv2703 57752 99.80% 2 2 4 0.02% 4.17% TLDEIGQVYGVTR 95.00% 2.42 0.393 0 2 0 0 2 1,451.56 488 500
2DLC TX114lpqN (lpqN)  Rv0583c 23665 100.00% 4 7 29 0.17% 11.40% LLPESSR 95.00% 1.53 0.3 2 0 0 0 2 801.9984 95 101
2DLC TX114lpqN (lpqN)  Rv0583c 23665 100.00% 4 7 29 0.17% 11.40% LTGDIDPAK 95.00% 1.71 0.428 1 2 0 0 2 930.1684 128 136
2DLC TX114lpqN (lpqN)  Rv0583c 23665 100.00% 4 7 29 0.17% 11.40% LTGDIDPAKVLQFAPGELK 95.00% 4.94 0.502 0 2 8 0 2 2,013.49 128 146
2DLC TX114lpqN (lpqN)  Rv0583c 23665 100.00% 4 7 29 0.17% 11.40% VLQFAPGELK 95.00% 2.81 0.502 2 12 0 0 2 1,102.34 137 146
2DLC TX114
hypo protein 
Rv1231c  Rv1231c 20396 99.40% 2 2 3 0.02% 10.60% LAIGEVPTR 95.00% 2.5 0.347 0 2 0 0 2 956.1384 131 139
2DLC TX114
hypo protein 
Rv1231c  Rv1231c 20396 99.40% 2 2 3 0.02% 10.60% YLLVQTLLVL 87.70% 1.59 0.117 1 0 0 0 2 1,175.56 44 53
2DLC TX114lprC (lprC)  Rv1275 18853 100.00% 4 4 11 0.06% 26.10% AIQGVDSIVMR 95.00% 3.01 0.516 0 3 0 0 2 1,189.37 123 133
2DLC TX114lprC (lprC)  Rv1275 18853 100.00% 4 4 11 0.06% 26.10% FWFEQGSLSNER 95.00% 4.48 0.567 0 3 0 0 2 1,500.63 98 109
2DLC TX114lprC (lprC)  Rv1275 18853 100.00% 4 4 11 0.06% 26.10% LMELTLATNA 95.00% 2.06 0.396 0 1 0 0 2 1,093.38 171 180
201
2DLC TX114lprC (lprC)  Rv1275 18853 100.00% 4 4 11 0.06% 26.10% WQAANPAGLIDITR 95.00% 4.21 0.647 0 4 0 0 2 1,526.83 84 97
2DLC TX114
hypo protein 
Rv1220c  Rv1220c 22090 99.80% 2 2 3 0.02% 6.98% AQEVLTR 95.00% 2.09 0.305 0 2 0 0 2 816.8684 120 126
2DLC TX114
hypo protein 
Rv1220c  Rv1220c 22090 99.80% 2 2 3 0.02% 6.98% DAEVIAVR 95.00% 2.35 0.144 0 1 0 0 2 872.9184 179 186
2DLC TX114
hypo protein 
Rv1265  Rv1265 25211 100.00% 4 4 12 0.07% 21.20% ILFTHIAVPVMTR 95.00% 2.11 0.363 0 0 3 0 2 1,514.86 152 164
2DLC TX114
hypo protein 
Rv1265  Rv1265 25211 100.00% 4 4 12 0.07% 21.20% LVGEHTEEWLAK 95.00% 2.79 0.484 0 1 0 0 2 1,412.52 195 206
2DLC TX114
hypo protein 
Rv1265  Rv1265 25211 100.00% 4 4 12 0.07% 21.20% QVLDTLVDAGVAR 95.00% 3.69 0.572 0 6 0 0 2 1,357.44 171 183
2DLC TX114
hypo protein 
Rv1265  Rv1265 25211 100.00% 4 4 12 0.07% 21.20% TAMSAVDDLR 95.00% 2.71 0.498 0 2 0 0 2 1,079.23 209 218
2DLC TX114
hypo protein 
Rv0580c  Rv0580c 18017 100.00% 5 8 23 0.13% 25.20% AVVSELFLR 95.00% 1.62 0.164 1 4 0 0 2 1,034.22 106 114
2DLC TX114
hypo protein 
Rv0580c  Rv0580c 18017 100.00% 5 8 23 0.13% 25.20% IPTLEEFAEAVDR 95.00% 3.58 0.66 0 5 1 0 2 1,490.67 137 149
2DLC TX114
hypo protein 
Rv0580c  Rv0580c 18017 100.00% 5 8 23 0.13% 25.20% MLGLSFR 95.00% 1.9 0.379 2 5 0 0 2 824.1484 127 133
2DLC TX114
hypo protein 
Rv0580c  Rv0580c 18017 100.00% 5 8 23 0.13% 25.20% RIPTLEEFAEAVDR 95.00% 3.33 0.497 0 4 0 0 2 1,646.87 136 149
2DLC TX114
hypo protein 
Rv0580c  Rv0580c 18017 100.00% 5 8 23 0.13% 25.20% TQLMVVSFTGR 95.00% 2.73 0.519 0 1 0 0 2 1,239.39 39 49
2DLC TX114lpqZ (lpqZ)  Rv1244 29552 100.00% 4 4 5 0.03% 26.20% AENIVPLYR 95.00% 2.55 0.337 0 1 0 0 2 1,075.29 226 234
2DLC TX114lpqZ (lpqZ)  Rv1244 29552 100.00% 4 4 5 0.03% 26.20%
AIVSALPEGIAAGDYTTAAE
DKPALVVTQSTAK 95.00% 2.4 0.573 0 0 2 0 2 3,260.67 108 140
2DLC TX114lpqZ (lpqZ)  Rv1244 29552 100.00% 4 4 5 0.03% 26.20% NDATMFAALR 95.00% 2.58 0.339 0 1 0 0 2 1,110.36 184 193
2DLC TX114lpqZ (lpqZ)  Rv1244 29552 100.00% 4 4 5 0.03% 26.20%
QVAAGADPAAVAAGWLAE
HPLGR 95.00% 1.79 0.299 0 0 1 0 2 2,229.39 264 286
2DLC TX114mdh (mdh)  Rv1240 34273 100.00% 5 6 8 0.05% 20.40% ALNAVAADDVR 95.00% 3.25 0.542 0 2 0 0 2 1,115.18 116 126
2DLC TX114mdh (mdh)  Rv1240 34273 100.00% 5 6 8 0.05% 20.40% ASGSLLGPDRPIELR 95.00% 2.63 0.475 0 1 1 0 2 1,582.00 26 40
2DLC TX114mdh (mdh)  Rv1240 34273 100.00% 5 6 8 0.05% 20.40% GAAIIDAR 95.00% 2.35 0.244 0 1 0 0 2 787.0084 228 235
2DLC TX114mdh (mdh)  Rv1240 34273 100.00% 5 6 8 0.05% 20.40% GASSAASAASATIDAAR 95.00% 2.56 0.391 0 1 0 0 2 1,478.63 236 252
2DLC TX114mdh (mdh)  Rv1240 34273 100.00% 5 6 8 0.05% 20.40% SDLLEANGAIFTAQGK 95.00% 4.34 0.65 0 2 0 0 2 1,635.94 100 115
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% GGILENDVIVK 95.00% 1.76 0.204 1 1 0 0 2 1,157.36 492 502
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% IVHPTLGISTR 95.00% 3.41 0.411 0 2 6 0 2 1,194.44 458 468
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% KTAEVVDAFTTSK 95.00% 3.07 0.483 0 2 0 0 2 1,397.50 222 234
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% LVANSLIK 95.00% 2.29 0.191 0 1 0 0 2 858.1484 447 454
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% PVFRPPVDPASR 95.00% 2.71 0.433 0 0 4 0 2 1,338.50 66 77
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% QLAIGQDAPIEVVR 95.00% 3.81 0.633 0 4 1 0 2 1,509.69 520 533
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% SLSDSASGLGFAIPVNEMK 95.00% 4.72 0.5 0 5 2 0 2 1,924.29 428 446
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% SVSNAIASGAQVANVK 95.00% 4.32 0.518 0 6 4 0 2 1,516.54 469 484
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% TAEVVDAFTTSK 95.00% 3.64 0.588 0 3 0 0 2 1,269.30 223 234
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% TDLAVLK 95.00% 1.96 0.348 0 3 0 0 2 759.9684 326 332
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% TTVVFNDGK 95.00% 1.66 0.256 0 2 0 0 2 981.0084 305 313
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% TTVVFNDGKEVPANLVGR 95.00% 2.49 0.268 0 0 1 0 2 1,917.00 305 322
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% VDNVDNLTVAR 95.00% 3.13 0.342 0 2 0 0 2 1,216.21 333 343
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% VGDEVLAVGAPLGLR 95.00% 3.37 0.581 0 4 2 0 2 1,466.66 352 366
2DLC TX114htrA (htrA)  Rv1223 56527 100.00% 15 22 60 0.35% 28.60% VRVGDEVLAVGAPLGLR 95.00% 4.78 0.596 0 2 2 0 2 1,721.93 350 366
2DLC TX114nusA (nusA)  Rv2841c 37623 99.80% 2 2 4 0.02% 5.76% GISVNELLETIK 95.00% 2.6 0.452 0 3 0 0 2 1,316.62 16 27
2DLC TX114nusA (nusA)  Rv2841c 37623 99.80% 2 2 4 0.02% 5.76% SALLTAYR 95.00% 1.89 0.212 0 1 0 0 2 895.1584 28 35
2DLC TX114
hypo protein 
Rv1209  Rv1209 13071 100.00% 4 4 8 0.05% 27.00% ATTATTLPAFGVTR 95.00% 1.91 0.408 0 1 0 0 2 1,407.60 38 51
2DLC TX114
hypo protein 
Rv1209  Rv1209 13071 100.00% 4 4 8 0.05% 27.00% ELEALR 95.00% 1.13 0.132 1 0 0 0 2 730.8984 81 86
2DLC TX114
hypo protein 
Rv1209  Rv1209 13071 100.00% 4 4 8 0.05% 27.00% GYKTSEVDWVLER 95.00% 2.89 0.408 0 0 2 0 2 1,582.69 65 77
2DLC TX114
hypo protein 
Rv1209  Rv1209 13071 100.00% 4 4 8 0.05% 27.00% TSEVDWVLER 95.00% 3.49 0.524 0 4 0 0 2 1,234.24 68 77
2DLC TX114
hypo protein 
Rv3671c  Rv3671c 40703 100.00% 3 3 4 0.02% 14.10% LSGPDIYGDPEPVTR 95.00% 2.5 0.458 0 1 0 0 2 1,616.83 315 329
2DLC TX114
hypo protein 
Rv3671c  Rv3671c 40703 100.00% 3 3 4 0.02% 14.10%
TPVIPVASPDPALVNNPVVA
ATEPSVVK 95.00% 4 0.574 0 0 1 0 2 2,782.91 179 206
2DLC TX114
hypo protein 
Rv3671c  Rv3671c 40703 100.00% 3 3 4 0.02% 14.10% VLEGTGFVISPDR 95.00% 1.99 0.365 0 2 0 0 2 1,390.56 217 229
2DLC TX114
hypo protein 
Rv0686  Rv0686 28526 99.80% 2 2 4 0.02% 6.04% INDQPLVK 95.00% 2.21 0.344 0 1 0 0 2 927.1084 92 99
2DLC TX114
hypo protein 
Rv0686  Rv0686 28526 99.80% 2 2 4 0.02% 6.04% LAELESLR 95.00% 2.27 0.368 0 3 0 0 2 931.1784 237 244
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% AFDQIDNAPEER 95.00% 2.29 0.396 0 1 1 0 2 1,405.50 48 59
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% EHVLLAR 95.00% 2.03 0.287 0 3 0 0 2 837.9684 120 126
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% ELLAAQEFDEDAPVVR 95.00% 2.42 0.444 0 2 0 0 2 1,802.92 158 173
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% ETDKPFLMPVEDVFTITGR 95.00% 2.32 0.342 0 2 0 0 2 2,196.55 207 225
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% GTVVTGR 95.00% 1.17 0.254 2 0 0 0 2 689.6584 226 232
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% GTVVTGRVER 95.00% 1.81 0.295 0 1 0 0 2 1,074.03 226 235
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% GVINVNEEVEIVGIRPSTTK 95.00% 1.97 0.269 0 0 2 0 2 2,155.30 236 255
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% KLLDQGQAGDNVGL 95.00% 3.73 0.53 0 3 0 0 2 1,428.62 266 279
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% LIQPVAMDEGLR 95.00% 4.38 0.547 3 15 1 0 2 1,358.64 365 376
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% PQFYFR 95.00% 1.58 0.254 2 10 0 0 2 858.0384 331 336
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% TTLTAAITK 92.70% 1.47 0.286 0 1 0 0 2 920.1784 26 34
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% TTVTGVEMFR 95.00% 3.06 0.468 2 8 0 0 2 1,141.21 256 265
2DLC TX114tuf (tuf)  Rv0685 43543 100.00% 13 19 61 0.35% 37.10% VSALKALEGDAK 95.00% 3.02 0.474 0 1 1 0 2 1,202.46 174 185
2DLC TX114fusA (fusA)  Rv0684 77153 100.00% 7 7 14 0.08% 13.10% AHVPLSEMFGYVGDLR 95.00% 5.25 0.65 0 3 0 0 2 1,792.04 652 667
2DLC TX114fusA (fusA)  Rv0684 77153 100.00% 7 7 14 0.08% 13.10% ATTDEPFAALAFK 95.00% 3.4 0.611 0 3 0 0 2 1,382.66 308 320
2DLC TX114fusA (fusA)  Rv0684 77153 100.00% 7 7 14 0.08% 13.10% IAGSQVLK 95.00% 2.07 0.338 0 2 0 0 2 815.9984 591 598
2DLC TX114fusA (fusA)  Rv0684 77153 100.00% 7 7 14 0.08% 13.10% IATHPFFGK 95.00% 1.85 0.293 0 0 3 0 2 1,018.27 321 329
2DLC TX114fusA (fusA)  Rv0684 77153 100.00% 7 7 14 0.08% 13.10%
LGETYDTVEIPADLAEQAEE
YRTK 95.00% 2.02 0.307 0 0 1 0 2 2,743.00 195 218
2DLC TX114fusA (fusA)  Rv0684 77153 100.00% 7 7 14 0.08% 13.10% LTYIR 90.80% 1.62 0.239 0 1 0 0 2 665.9184 330 334
2DLC TX114fusA (fusA)  Rv0684 77153 100.00% 7 7 14 0.08% 13.10% VYSGTVESGSQVINATK 95.00% 4.32 0.59 0 0 1 0 2 1,740.75 335 351
2DLC TX114rpsG (rpsG)  Rv0683 17583 99.90% 2 2 3 0.02% 12.20% ALDNVKPALEVR 95.00% 2.14 0.345 0 0 2 0 2 1,325.54 65 76
2DLC TX114rpsG (rpsG)  Rv0683 17583 99.90% 2 2 3 0.02% 12.20% WLVGYSR 95.00% 1.69 0.295 0 1 0 0 2 881.0184 103 109
2DLC TX114rpoC (rpoC)  Rv0668 146721 100.00% 4 4 6 0.03% 4.56% ELDRLEDIWSTFTK 95.00% 2.48 0.172 0 0 1 0 2 1,754.10 215 228
202
2DLC TX114rpoC (rpoC)  Rv0668 146721 100.00% 4 4 6 0.03% 4.56% IGLATAEDIR 95.00% 2.84 0.377 0 3 0 0 2 1,059.33 12 21
2DLC TX114rpoC (rpoC)  Rv0668 146721 100.00% 4 4 6 0.03% 4.56% LGIQAFEPMLVEGKAIQLH 95.00% 1.79 0.23 0 0 1 0 2 2,111.57 507 525
2DLC TX114rpoC (rpoC)  Rv0668 146721 100.00% 4 4 6 0.03% 4.56% TFHQGGVGEDITGGLPR 95.00% 4.18 0.33 0 0 1 0 2 1,741.86 1014 1030
2DLC TX114rpoB (rpoB)  Rv0667 129201 100.00% 8 8 16 0.09% 6.91% ALMGANMQR 95.00% 2.26 0.449 0 1 0 0 2 992.2284 599 607
2DLC TX114rpoB (rpoB)  Rv0667 129201 100.00% 8 8 16 0.09% 6.91% FGFSEIMR 95.00% 2.88 0.526 0 1 0 0 2 987.2484 246 253
2DLC TX114rpoB (rpoB)  Rv0667 129201 100.00% 8 8 16 0.09% 6.91% LSALGPGGLSR 95.00% 2.68 0.389 0 2 0 0 2 1,028.33 449 459
2DLC TX114rpoB (rpoB)  Rv0667 129201 100.00% 8 8 16 0.09% 6.91% RQPVTVLLK 95.00% 2.62 0.412 0 1 0 0 2 1,054.28 225 233
2DLC TX114rpoB (rpoB)  Rv0667 129201 100.00% 8 8 16 0.09% 6.91% SEAPLVGTGMELR 95.00% 2.31 0.539 0 2 0 0 2 1,360.57 615 627
2DLC TX114rpoB (rpoB)  Rv0667 129201 100.00% 8 8 16 0.09% 6.91% TVGELIQNQIR 95.00% 2.62 0.318 0 3 0 0 2 1,271.44 374 384
2DLC TX114rpoB (rpoB)  Rv0667 129201 100.00% 8 8 16 0.09% 6.91% VNPFGFIETPYR 95.00% 3.1 0.6 0 2 0 0 2 1,440.68 500 511
2DLC TX114rpoB (rpoB)  Rv0667 129201 100.00% 8 8 16 0.09% 6.91% VVVSQLVR 95.00% 2.75 0.387 0 4 0 0 2 899.8784 168 175
2DLC TX114
hypo protein 
Rv0093c  Rv0093c 29580 99.90% 2 2 2 0.01% 13.10%
DGERAPVPSARVDEHLGEC
SACR 95.00% 2.12 0.241 0 0 1 0 2 2,512.55 61 83
2DLC TX114
hypo protein 
Rv0093c  Rv0093c 29580 99.90% 2 2 2 0.01% 13.10% HCATIDGMDCEVAR 95.00% 1.78 0.29 0 0 1 0 2 1,578.65 40 53
2DLC TX114rplL (rplL)  Rv0652 13423 100.00% 10 15 52 0.30% 43.10% AKLEAAGATVTVK 95.00% 3.75 0.53 1 5 2 0 2 1,259.43 118 130
2DLC TX114rplL (rplL)  Rv0652 13423 100.00% 10 15 52 0.30% 43.10% DLVDGAPKPLL 95.00% 2.65 0.339 0 1 0 0 2 1,138.46 95 105
2DLC TX114rplL (rplL)  Rv0652 13423 100.00% 10 15 52 0.30% 43.10% DLVDGAPKPLLEK 95.00% 1.56 0.377 3 7 0 0 2 1,395.76 95 107
2DLC TX114rplL (rplL)  Rv0652 13423 100.00% 10 15 52 0.30% 43.10%
EAADEAKAKLEAAGATVTV
K 95.00% 3.23 0.466 0 0 1 0 2 1,974.17 111 130
2DLC TX114rplL (rplL)  Rv0652 13423 100.00% 10 15 52 0.30% 43.10% EIVSGL 95.00% 1.32 0.301 1 0 0 0 2 617.7184 83 88
2DLC TX114rplL (rplL)  Rv0652 13423 100.00% 10 15 52 0.30% 43.10% EIVSGLGLK 95.00% 1.86 0.38 7 4 0 0 2 916.1684 83 91
2DLC TX114rplL (rplL)  Rv0652 13423 100.00% 10 15 52 0.30% 43.10% EIVSGLGLKEAK 95.00% 3.26 0.473 0 6 0 0 2 1,244.55 83 94
2DLC TX114rplL (rplL)  Rv0652 13423 100.00% 10 15 52 0.30% 43.10% LEAAGATVTVK 95.00% 3.02 0.563 0 8 0 0 2 1,060.15 120 130
2DLC TX114rplL (rplL)  Rv0652 13423 100.00% 10 15 52 0.30% 43.10% LSTDELLDAFK 95.00% 3.32 0.598 2 2 0 0 2 1,252.58 4 14
2DLC TX114rplL (rplL)  Rv0652 13423 100.00% 10 15 52 0.30% 43.10% VDGAPKPLLEK 95.00% 2.14 0.448 0 2 0 0 2 1,167.46 97 107
2DLC TX114rplJ (rplJ)  Rv0651 18461 100.00% 3 3 8 0.05% 23.00% AAGLFNAPASQLAR 95.00% 2.9 0.385 0 1 0 0 2 1,387.67 147 160
2DLC TX114rplJ (rplJ)  Rv0651 18461 100.00% 3 3 8 0.05% 23.00% GGYMDGHPLTVAEVER 95.00% 4.04 0.393 0 0 2 0 2 1,731.81 107 122
2DLC TX114rplJ (rplJ)  Rv0651 18461 100.00% 3 3 8 0.05% 23.00% GLTVANLAELR 95.00% 2.87 0.411 0 5 0 0 2 1,157.40 30 40
2DLC TX114lppZ (lppZ)  Rv3006 38734 100.00% 4 6 12 0.07% 18.50% LAPSTGAVTGEPDVVR 95.00% 2.02 0.451 0 3 0 0 2 1,569.61 303 318
2DLC TX114lppZ (lppZ)  Rv3006 38734 100.00% 4 6 12 0.07% 18.50% LMYAYISTPTDNR 95.00% 2.35 0.467 0 1 0 0 2 1,545.90 138 150
2DLC TX114lppZ (lppZ)  Rv3006 38734 100.00% 4 6 12 0.07% 18.50%
TAGDAEKLDDVVFPLFPQG
GGFPR 95.00% 3.49 0.329 0 1 1 0 2 2,534.88 344 367
2DLC TX114lppZ (lppZ)  Rv3006 38734 100.00% 4 6 12 0.07% 18.50% VADGDIPKDILTGIPK 95.00% 3.22 0.469 0 2 4 0 2 1,653.11 154 169
2DLC TX114
hypo protein 
Rv2969c  Rv2969c 26811 100.00% 3 3 5 0.03% 17.30% IKEIVGDVPGIDSAAATATS 95.00% 2.69 0.531 0 3 0 0 2 1,916.16 236 255
2DLC TX114
hypo protein 
Rv2969c  Rv2969c 26811 100.00% 3 3 5 0.03% 17.30% LVTQPGTSNPK 95.00% 1.88 0.345 0 1 0 0 2 1,142.26 68 78
2DLC TX114
hypo protein 
Rv2969c  Rv2969c 26811 100.00% 3 3 5 0.03% 17.30% YIEKVDGLAAAVN 95.00% 1.81 0.391 0 1 0 0 2 1,363.55 198 210
2DLC TX114rplA (rplA)  Rv0641 24739 99.80% 2 2 3 0.02% 11.10% LLAENYGAAIDEVLR 95.00% 3.81 0.483 0 2 0 0 2 1,647.98 184 198
2DLC TX114rplA (rplA)  Rv0641 24739 99.80% 2 2 3 0.02% 11.10% TNLYTPLQAAK 95.00% 1.72 0.438 0 1 0 0 2 1,220.50 18 28
2DLC TX114nusG (nusG)  Rv0639 25396 100.00% 7 9 25 0.14% 29.00% ETPVELTFGQVSKI 95.00% 1.98 0.286 0 1 0 0 2 1,548.71 225 238
2DLC TX114nusG (nusG)  Rv0639 25396 100.00% 7 9 25 0.14% 29.00% KVLPGYILVR 95.00% 2.27 0.312 0 2 0 0 2 1,158.53 103 112
2DLC TX114nusG (nusG)  Rv0639 25396 100.00% 7 9 25 0.14% 29.00% MDLTDDSWAAVR 95.00% 2.43 0.482 0 2 0 0 2 1,380.53 113 124
2DLC TX114nusG (nusG)  Rv0639 25396 100.00% 7 9 25 0.14% 29.00% NTPGVTGFVGATSR 95.00% 2.23 0.524 0 2 0 0 2 1,364.39 125 138
2DLC TX114nusG (nusG)  Rv0639 25396 100.00% 7 9 25 0.14% 29.00%
NTPGVTGFVGATSRPSALA
LDDVVK 95.00% 2.1 0.522 0 1 2 0 2 2,473.69 125 149
2DLC TX114nusG (nusG)  Rv0639 25396 100.00% 7 9 25 0.14% 29.00% PSALALDDVVK 95.00% 4.09 0.449 0 2 0 0 2 1,128.32 139 149
2DLC TX114nusG (nusG)  Rv0639 25396 100.00% 7 9 25 0.14% 29.00% VLVSIFGR 95.00% 1.56 0.202 2 11 0 0 2 891.0884 217 224
2DLC TX114secE (secE)  Rv0638 16906 99.80% 2 3 3 0.02% 6.21% TALVTK 95.00% 1.11 0 1 0 0 0 2 632.7684 28 33
2DLC TX114secE (secE)  Rv0638 16906 99.80% 2 3 3 0.02% 6.21% TALVTKPVVR 95.00% 2.52 0.369 0 1 1 0 2 1,084.23 28 37
2DLC TX114
hypo protein 
Rv0636  Rv0636 14916 100.00% 3 3 4 0.02% 14.80% FTAVVPVPNDGK 95.00% 1.85 0.312 0 2 0 0 2 1,244.30 87 98
2DLC TX114
hypo protein 
Rv0636  Rv0636 14916 100.00% 3 3 4 0.02% 14.80%
FTAVVPVPNDGKGAELVFN
GR 95.00% 2.66 0.518 0 0 1 0 2 2,188.35 87 107
2DLC TX114
hypo protein 
Rv0636  Rv0636 14916 100.00% 3 3 4 0.02% 14.80% GAELVFNGR 95.00% 2.29 0.334 0 1 0 0 2 963.0684 99 107
2DLC TX114gpsI (gpsI)  Rv2783c 79718 100.00% 3 4 6 0.03% 4.52% DGLVHISK 95.00% 2.65 0.359 0 2 0 0 2 869.0184 690 697
2DLC TX114gpsI (gpsI)  Rv2783c 79718 100.00% 3 4 6 0.03% 4.52% IAKVEDVVNVGDK 95.00% 2.79 0.552 0 1 2 0 2 1,386.43 704 716
2DLC TX114gpsI (gpsI)  Rv2783c 79718 100.00% 3 4 6 0.03% 4.52% VPVDKIGEVIGPK 95.00% 1.73 0.382 0 0 1 0 2 1,351.57 602 614
2DLC TX114htpG (htpG)  Rv2299c 72945 100.00% 4 4 6 0.03% 5.87% ELISNASDALDK 95.00% 2.97 0.56 0 2 0 0 2 1,276.54 35 46
2DLC TX114htpG (htpG)  Rv2299c 72945 100.00% 4 4 6 0.03% 5.87% FAELLAER 95.00% 2.41 0.26 0 1 0 0 2 949.1784 635 642
2DLC TX114htpG (htpG)  Rv2299c 72945 100.00% 4 4 6 0.03% 5.87% SPHLEAFK 84.90% 2.12 0.138 0 0 1 0 2 929.0984 459 466
2DLC TX114htpG (htpG)  Rv2299c 72945 100.00% 4 4 6 0.03% 5.87% YSDFIAWPIR 95.00% 2.86 0.454 0 2 0 0 2 1,268.60 206 215
2DLC TX114ahpC (ahpC)  Rv2428 21549 100.00% 4 4 4 0.02% 19.50% KGDPTLDAGELLK 95.00% 3.38 0.452 0 1 0 0 2 1,357.72 180 192
2DLC TX114ahpC (ahpC)  Rv2428 21549 100.00% 4 4 4 0.02% 19.50% NVDEVLR 95.00% 2.03 0.268 0 1 0 0 2 844.8584 157 163
2DLC TX114ahpC (ahpC)  Rv2428 21549 100.00% 4 4 4 0.02% 19.50% TLPFPMLSDIK 95.00% 1.8 0.338 0 1 0 0 2 1,262.74 105 115
2DLC TX114ahpC (ahpC)  Rv2428 21549 100.00% 4 4 4 0.02% 19.50% VVFFWPK 95.00% 2.06 0.439 0 1 0 0 2 923.0784 49 55
2DLC TX114
hypo protein 
Rv1703c  Rv1703c 21520 100.00% 3 3 5 0.03% 23.00% AYLPDLQSILDR 95.00% 3.35 0.596 0 3 0 0 2 1,404.80 125 136
2DLC TX114
hypo protein 
Rv1703c  Rv1703c 21520 100.00% 3 3 5 0.03% 23.00% FAYEKSMLINVGDEKGTL 95.00% 2.42 0.259 0 0 1 0 2 2,016.45 8 25
2DLC TX114
hypo protein 
Rv1703c  Rv1703c 21520 100.00% 3 3 5 0.03% 23.00% VYSVELAEANASNAR 95.00% 4.31 0.436 0 0 1 0 2 1,594.64 61 75
2DLC TX114oppD (oppD)  Rv1281c 65275 99.90% 2 2 2 0.01% 3.27% RRAVELLDL 95.00% 2.35 0.29 1 0 0 0 2 1,085.37 130 138
2DLC TX114oppD (oppD)  Rv1281c 65275 99.90% 2 2 2 0.01% 3.27% VAELLDIVGLR 95.00% 3.52 0.425 0 1 0 0 2 1,198.49 479 489
2DLC TX114
mmpL3 
(mmpL3)  Rv0206c 100857 99.80% 2 2 4 0.02% 2.75% IGLGEIHLPDER 95.00% 2.9 0.465 0 0 2 0 2 1,349.64 744 755
2DLC TX114
mmpL3 
(mmpL3)  Rv0206c 100857 99.80% 2 2 4 0.02% 2.75% PARPPVTAGLVAAR 95.00% 3.85 0.369 0 0 2 0 2 1,376.59 764 777
2DLC TX114
hypo protein 
Rv1875  Rv1875 15961 100.00% 4 4 4 0.02% 31.30% AQLVGPDDPRPWLVDGER 95.00% 2.29 0.299 0 0 1 0 2 2,021.20 85 102
2DLC TX114
hypo protein 
Rv1875  Rv1875 15961 100.00% 4 4 4 0.02% 31.30% ARPQLAVTFR 95.00% 1.85 0.27 0 1 0 0 2 1,159.37 64 73
2DLC TX114
hypo protein 
Rv1875  Rv1875 15961 100.00% 4 4 4 0.02% 31.30% AVVLITPTR 95.00% 2.52 0.435 0 1 0 0 2 970.1584 134 142
2DLC TX114
hypo protein 
Rv1875  Rv1875 15961 100.00% 4 4 4 0.02% 31.30% GLAVVSTVR 95.00% 2.59 0.47 0 1 0 0 2 901.9384 16 24
2DLC TX114
hypo protein 
Rv0020c  Rv0020c 56862 100.00% 7 7 11 0.06% 18.20%
GGYPPETGGYPPQPGYPRP
R 95.00% 1.53 0.309 0 0 1 0 2 2,144.41 200 219
2DLC TX114
hypo protein 




Rv0020c  Rv0020c 56862 100.00% 7 7 11 0.06% 18.20%
HPDQGDYPEQIGYPDQGG
YPEQR 95.00% 4.25 0.55 0 0 1 0 2 2,647.70 220 242
2DLC TX114
hypo protein 
Rv0020c  Rv0020c 56862 100.00% 7 7 11 0.06% 18.20% KLEQTVGDAFAR 95.00% 2.57 0.372 0 0 1 0 2 1,335.50 14 25
2DLC TX114
hypo protein 
Rv0020c  Rv0020c 56862 100.00% 7 7 11 0.06% 18.20% LGHSEIIVR 95.00% 2.54 0.261 0 0 2 0 2 1,024.22 517 525
2DLC TX114
hypo protein 
Rv0020c  Rv0020c 56862 100.00% 7 7 11 0.06% 18.20% LPDTGVSR 95.00% 1.99 0.299 0 3 0 0 2 844.9384 467 474
2DLC TX114
hypo protein 
Rv0020c  Rv0020c 56862 100.00% 7 7 11 0.06% 18.20% VPGYAPQGGGYAEPAGR 95.00% 2.55 0.396 0 1 0 0 2 1,647.74 385 401
2DLC TX114
hypo protein 
Rv3699  Rv3699 24980 99.80% 2 2 3 0.02% 12.00% FPAYLLTAHK 95.00% 2.5 0.454 0 0 2 0 2 1,161.50 222 231
2DLC TX114
hypo protein 
Rv3699  Rv3699 24980 99.80% 2 2 3 0.02% 12.00% FSTVIDSTLFHSLPVDSR 95.00% 3.66 0.563 0 1 0 0 2 2,022.30 113 130
2DLC TX114
hypo protein 
Rv2477c  Rv2477c 61876 100.00% 3 3 6 0.03% 5.56% DLSFSLPR 95.00% 2.04 0.352 0 3 0 0 2 935.1984 339 346
2DLC TX114
hypo protein 
Rv2477c  Rv2477c 61876 100.00% 3 3 6 0.03% 5.56% LTEELAWVR 95.00% 3.14 0.167 0 1 0 0 2 1,117.27 266 274
2DLC TX114
hypo protein 
Rv2477c  Rv2477c 61876 100.00% 3 3 6 0.03% 5.56% TIVGLETPDSGSVK 95.00% 2.15 0.461 0 2 0 0 2 1,403.54 366 379
2DLC TX114rpsA (rpsA)  Rv1630 53184 100.00% 5 5 14 0.08% 11.60% AWLEQTQSEVR 95.00% 3.04 0.409 0 2 0 0 2 1,347.35 189 199
2DLC TX114rpsA (rpsA)  Rv1630 53184 100.00% 5 5 14 0.08% 11.60% FAAAEAAGR 95.00% 2.9 0.352 0 2 0 0 2 863.9684 435 443
2DLC TX114rpsA (rpsA)  Rv1630 53184 100.00% 5 5 14 0.08% 11.60% GFLPASLVEMR 95.00% 2.75 0.543 0 5 0 0 2 1,236.52 146 156
2DLC TX114rpsA (rpsA)  Rv1630 53184 100.00% 5 5 14 0.08% 11.60% SEFLNNLQK 95.00% 2.09 0.397 0 2 0 0 2 1,093.30 200 208
2DLC TX114rpsA (rpsA)  Rv1630 53184 100.00% 5 5 14 0.08% 11.60% TAGGSLASDAQLAALR 95.00% 3.58 0.456 0 3 0 0 2 1,502.78 459 474
2DLC TX114
hypo protein 
Rv3690  Rv3690 23702 99.80% 2 2 3 0.02% 14.70% ELEETGMLNPAAGR 95.00% 2.8 0.396 0 2 0 0 2 1,488.70 128 141
2DLC TX114
hypo protein 
Rv3690  Rv3690 23702 99.80% 2 2 3 0.02% 14.70% GGDYQLFDAGQLTAAQHR 95.00% 3.18 0.51 0 0 1 0 2 1,949.11 85 102
2DLC TX114
hypo protein 
Rv3676  Rv3676 24742 99.80% 2 2 2 0.01% 8.93% SVLISDSER 95.00% 1.84 0.34 0 1 0 0 2 1,006.13 210 218
2DLC TX114
hypo protein 
Rv3676  Rv3676 24742 99.80% 2 2 2 0.01% 8.93% TSSATTITEVR 95.00% 2.81 0.416 0 1 0 0 2 1,166.23 90 100
2DLC TX114
hypo protein 
Rv1829  Rv1829 18097 100.00% 4 5 13 0.08% 20.70% DLIAALGHSLK 95.00% 3.45 0.36 0 2 0 0 2 1,138.51 63 73
2DLC TX114
hypo protein 
Rv1829  Rv1829 18097 100.00% 4 5 13 0.08% 20.70% IAALGHSLK 95.00% 2.5 0.406 0 2 0 0 2 910.2084 65 73
2DLC TX114
hypo protein 
Rv1829  Rv1829 18097 100.00% 4 5 13 0.08% 20.70% PSDSVAIALR 95.00% 3.02 0.336 0 3 0 0 2 1,029.23 101 110
2DLC TX114
hypo protein 
Rv1829  Rv1829 18097 100.00% 4 5 13 0.08% 20.70% VEQPQNQPVLLLR 95.00% 3.2 0.43 0 4 2 0 2 1,534.70 11 23
2DLC TX114
hypo protein 
Rv1827  Rv1827 17201 100.00% 3 5 12 0.07% 19.10% FLLDQAITSAGR 95.00% 4.11 0.504 0 3 0 0 2 1,292.61 70 81
2DLC TX114
hypo protein 
Rv1827  Rv1827 17201 100.00% 3 5 12 0.07% 19.10% LVFLTGPK 95.00% 1.61 0.336 2 4 0 0 2 875.1584 144 151
2DLC TX114
hypo protein 
Rv1827  Rv1827 17201 100.00% 3 5 12 0.07% 19.10% LVFLTGPKQGEDDGSTGGP 95.00% 4.5 0.627 0 2 1 0 2 1,876.06 144 162
2DLC TX114secA2 Rv1821 88902 99.80% 2 3 6 0.03% 3.84% MLAGDVIEMATGEGK 95.00% 5.09 0.535 0 3 0 0 2 1,522.80 131 145
2DLC TX114secA2 Rv1821 88902 99.80% 2 3 6 0.03% 3.84% TLAGAIAAAGYALAGR 95.00% 3.04 0.476 0 2 1 0 2 1,447.83 146 161
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% AALGGSDISAIK 95.00% 3.02 0.591 2 10 0 0 2 1,103.42 553 564
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% DAGQIAGLNVLR 95.00% 3.78 0.425 4 5 2 0 2 1,227.45 132 143
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00%
EAEGGSKVPEDTLNKVDAA
VAEAK 95.00% 5.21 0.544 0 0 3 0 2 2,429.53 529 552
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% GTSGIDLTK 95.00% 2.03 0.362 0 1 0 0 2 892.0984 218 226
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% ITQDLLDR 95.00% 1.96 0.191 1 3 0 0 2 974.2184 281 288
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% IVNEPTAAALAYGLDKGEK 95.00% 1.6 0.31 0 0 1 0 2 1,961.33 144 162
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% LLGSFELTGIPPAPR 95.00% 2.46 0.417 0 2 0 0 2 1,569.04 427 441
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% MPAVTDLVK 95.00% 1.69 0.299 1 9 0 0 2 974.1584 319 327
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% NGEVLVGQPAK 95.00% 2.55 0.387 0 1 0 0 2 1,112.16 45 55
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% NQAETLVYQTEK 95.00% 3.3 0.497 0 3 3 0 2 1,424.47 511 522
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% NQAVTNVDR 95.00% 2.47 0.298 0 2 0 0 2 1,016.94 56 64
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% TTPSIVAFAR 95.00% 2.07 0.511 0 6 0 0 2 1,063.25 35 44
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00%
TTPSIVAFARNGEVLVGQPA
K 95.00% 1.98 0.495 0 0 1 0 2 2,156.39 35 55
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% VVDWLVDK 95.00% 2.32 0.46 0 4 0 0 2 974.0284 208 215
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% VVDWLVDKFK 95.00% 4.26 0.554 0 2 3 0 2 1,249.43 208 217
2DLC TX114dnaK (dnaK)  Rv0350 66813 100.00% 16 23 73 0.42% 27.00% YTAPEISAR 95.00% 2.1 0.45 0 4 0 0 2 1,008.18 86 94
2DLC TX114grpE (grpE)  Rv0351 24482 99.80% 2 2 3 0.02% 8.51% QGYQLGEQVLR 95.00% 2.11 0.364 0 1 0 0 2 1,291.39 170 180
2DLC TX114grpE (grpE)  Rv0351 24482 99.80% 2 2 3 0.02% 8.51% VQADFANYR 95.00% 2.21 0.488 0 2 0 0 2 1,084.15 65 73
2DLC TX114
hypo protein 
Rv1198  Rv1198 9910 99.80% 2 2 3 0.02% 31.90% AQAGLLEAEHQAIIR 95.00% 1.92 0.502 0 0 2 0 2 1,620.89 19 33
2DLC TX114
hypo protein 
Rv1198  Rv1198 9910 99.80% 2 2 3 0.02% 31.90% NFQVIYEQANAHGQK 95.00% 2.08 0.256 0 0 1 0 2 1,747.80 60 74
2DLC TX114PPE (PPE)  Rv1196 39140 100.00% 4 5 11 0.06% 15.30% AGGGLSGVLR 95.00% 3.02 0.252 0 5 0 0 2 887.0484 367 376
2DLC TX114PPE (PPE)  Rv1196 39140 100.00% 4 5 11 0.06% 15.30% ALPLTSLTSAAER 95.00% 2.83 0.613 0 2 0 0 2 1,330.64 337 349
2DLC TX114PPE (PPE)  Rv1196 39140 100.00% 4 5 11 0.06% 15.30%
GFAPAAAAQAVQTAAQNGV
R 95.00% 2.66 0.447 0 0 1 0 2 1,899.92 268 287
2DLC TX114PPE (PPE)  Rv1196 39140 100.00% 4 5 11 0.06% 15.30% GPGQMLGGLPVGQMGAR 95.00% 3.58 0.531 0 2 1 0 2 1,626.91 350 366
2DLC TX114pks7 (pks7)  Rv1661 221021 100.00% 3 3 3 0.02% 2.07% LDRAAL 91.10% 1.16 0.0246 1 0 0 0 2 658.8784 1922 1927
2DLC TX114pks7 (pks7)  Rv1661 221021 100.00% 3 3 3 0.02% 2.07%
MTQAGLAPLTTEQALGFLDT
AL 84.80% 2.33 0.153 0 1 0 0 2 2,279.76 1889 1910
2DLC TX114pks7 (pks7)  Rv1661 221021 100.00% 3 3 3 0.02% 2.07% SGEQADRAAEVAALLR 95.00% 2.28 0.23 0 0 1 0 2 1,657.82 1728 1743
2DLC TX114infB (infB)  Rv2839c 93992 100.00% 4 4 6 0.03% 5.44% GGGVGAAPGTGFR 95.00% 2.27 0.373 0 1 0 0 2 1,104.17 234 246
2DLC TX114infB (infB)  Rv2839c 93992 100.00% 4 4 6 0.03% 5.44% GPVATVLVQR 95.00% 3.3 0.5 0 1 0 0 2 1,040.08 591 600
2DLC TX114infB (infB)  Rv2839c 93992 100.00% 4 4 6 0.03% 5.44% LITFIDTPGHEAFTAMR 95.00% 1.62 0.292 0 0 1 0 2 1,937.35 450 466
2DLC TX114infB (infB)  Rv2839c 93992 100.00% 4 4 6 0.03% 5.44% LSEQGEFVK 95.00% 2.61 0.438 0 3 0 0 2 1,037.12 26 34
2DLC TX114pks4 (pks4)  Rv1181 168064 100.00% 6 6 9 0.05% 5.75% AGIELLAFGGR 95.00% 3.89 0.527 0 1 0 0 2 1,104.43 1119 1129
2DLC TX114pks4 (pks4)  Rv1181 168064 100.00% 6 6 9 0.05% 5.75% ANLEQAGLR 95.00% 2.29 0.338 0 1 0 0 2 972.1284 813 821
2DLC TX114pks4 (pks4)  Rv1181 168064 100.00% 6 6 9 0.05% 5.75% ATAAQPL 81.30% 0.809 0 1 0 0 0 2 671.7784 1362 1368
2DLC TX114pks4 (pks4)  Rv1181 168064 100.00% 6 6 9 0.05% 5.75% ELAELPGEPPR 95.00% 2.03 0.505 0 1 0 0 2 1,208.41 786 796
2DLC TX114pks4 (pks4)  Rv1181 168064 100.00% 6 6 9 0.05% 5.75% FLAELGSLPR 95.00% 3.27 0.374 0 2 0 0 2 1,103.45 1492 1501
2DLC TX114pks4 (pks4)  Rv1181 168064 100.00% 6 6 9 0.05% 5.75% FLAELGSLPREEWPR 95.00% 2.18 0.197 0 0 2 0 2 1,801.17 1492 1506
2DLC TX114pks4 (pks4)  Rv1181 168064 100.00% 6 6 9 0.05% 5.75%
IHNVAAFPGAAYCEMALAA
AR 95.00% 2.68 0.327 0 1 0 0 2 2,148.50 430 450
2DLC TX114pks4 (pks4)  Rv1181 168064 100.00% 6 6 9 0.05% 5.75% LGLFPFR 95.00% 1.87 0.319 0 2 0 0 2 850.1884 1144 1150
204
2DLC TX114pks4 (pks4)  Rv1181 168064 100.00% 6 6 9 0.05% 5.75% TTLGELSEVR 95.00% 2.73 0.479 0 2 0 0 2 1,105.22 451 460
2DLC TX114
hypo protein 
Rv1586c  Rv1586c 51693 99.50% 2 2 2 0.01% 6.40% QAYADILAGASL 95.00% 1.83 0.249 0 0 1 0 2 1,193.47 183 194
2DLC TX114
hypo protein 
Rv1586c  Rv1586c 51693 99.50% 2 2 2 0.01% 6.40% VDEATFWAAQAVLDAPGR 90.40% 1.64 0.227 0 0 1 0 2 1,918.03 257 274
2DLC TX114
hypo protein 
Rv3237c  Rv3237c 17216 99.80% 2 2 2 0.01% 10.00% EVLLPGVGLR 95.00% 2.32 0.448 0 1 0 0 2 1,053.28 5 14
2DLC TX114
hypo protein 
Rv3237c  Rv3237c 17216 99.80% 2 2 2 0.01% 10.00% FTELTR 95.00% 1.61 0.354 0 1 0 0 2 766.9184 75 80
2DLC TX114
hypo protein 
Rv1144  Rv1144 25770 99.80% 2 2 4 0.02% 7.20% DGVFPL 95.00% 1.46 0.0613 1 0 0 0 2 647.7584 95 100
2DLC TX114
hypo protein 
Rv1144  Rv1144 25770 99.80% 2 2 4 0.02% 7.20% GGVVGMTLPIAR 95.00% 3.47 0.539 0 3 0 0 2 1,171.41 161 172
2DLC TX114groES Rv3418c 10754 100.00% 7 9 37 0.21% 67.00% DVLAVVSK 95.00% 2.03 0.44 7 6 0 0 2 830.8884 93 100
2DLC TX114groES Rv3418c 10754 100.00% 7 9 37 0.21% 67.00% EKPQEGTVVAVGPGR 95.00% 2.29 0.273 0 0 2 0 2 1,524.50 36 50
2DLC TX114groES Rv3418c 10754 100.00% 7 9 37 0.21% 67.00% IPLDVAEGDTVIYSK 95.00% 3.84 0.568 0 6 0 0 2 1,620.89 59 73
2DLC TX114groES Rv3418c 10754 100.00% 7 9 37 0.21% 67.00% RIPLDVAEGDTVIYSK 95.00% 3.44 0.586 0 3 5 0 2 1,777.09 58 73
2DLC TX114groES Rv3418c 10754 100.00% 7 9 37 0.21% 67.00% VNIKPLEDK 95.00% 1.93 0.304 0 0 1 0 2 1,056.31 4 12
2DLC TX114groES Rv3418c 10754 100.00% 7 9 37 0.21% 67.00% YGGTEIK 95.00% 2.13 0.389 0 2 0 0 2 767.9184 74 80
2DLC TX114groES Rv3418c 10754 100.00% 7 9 37 0.21% 67.00% YNGEEYLILSAR 95.00% 4.07 0.573 0 5 0 0 2 1,428.73 81 92
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% AADAVSEALLASATPVSGK 95.00% 3.71 0.591 0 2 5 0 2 1,758.95 122 140
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30%
AAVEEGIVPGGGASLIHQA
R 95.00% 4.31 0.656 0 7 11 0 2 1,933.08 403 422
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% AFGGPTVTNDGVTVAR 95.00% 2.55 0.38 0 2 0 0 2 1,562.56 42 57
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% AGGVAVIK 95.00% 1.59 0.304 2 1 0 0 2 714.8184 371 378
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% AMEVGMDKLADTVR 95.00% 3.85 0.529 0 3 6 0 2 1,552.77 14 27
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% ESVEDAVAAAK 95.00% 1.96 0.571 0 3 0 0 2 1,090.06 392 402
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% EVGLEVLGSAR 95.00% 3.16 0.566 3 13 0 0 2 1,130.22 309 319
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% GPYFGDR 95.00% 1.99 0.439 0 7 0 0 2 811.9384 276 282
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% KALTELR 95.00% 2.03 0.243 0 4 0 0 2 831.0984 423 429
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% KESVEDAVAAAK 95.00% 4.23 0.442 0 1 3 0 2 1,218.26 391 402
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% LAGGVAVIK 95.00% 1.86 0.247 5 15 0 0 2 828.0184 370 378
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% LIEYDETAR 95.00% 2.51 0.429 0 1 0 0 2 1,110.30 4 12
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% LPLLEK 95.00% 1.77 0.368 3 1 0 0 2 713.0384 232 237
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% LVAAGVNPIAL 95.00% 2.04 0.32 2 0 0 0 2 1,038.27 105 115
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% LVAAGVNPIALGVGIGK 95.00% 4.79 0.619 0 3 4 0 2 1,549.89 105 121
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% MVLTTETVVVDKPAK 95.00% 1.99 0.392 0 0 1 0 2 1,647.80 513 527
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% PDAGMVLR 95.00% 2.64 0.449 0 2 0 0 2 859.0384 301 308
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% SAVLNASSVAR 95.00% 3.76 0.425 0 7 0 0 2 1,075.14 502 512
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% TGIAQVATVSSR 95.00% 3.06 0.553 0 1 0 0 2 1,190.23 141 152
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30%
TGIAQVATVSSRDEQIGDL
VGEAMSK 95.00% 5.29 0.73 0 0 6 0 2 2,663.86 141 166
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% VGAATETALK 95.00% 2.49 0.296 0 2 0 0 2 961.0784 379 388
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% VGAATETALKER 95.00% 2.68 0.492 0 1 3 0 2 1,246.38 379 390
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% VGEAMSK 95.00% 0.983 -0.0794 1 0 0 0 2 737.7978 160 166
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30% VSELPAGHGLNVN 95.00% 2.54 0.325 0 2 0 0 2 1,307.34 469 481
2DLC TX114
groEL1 
(groEL1)  Rv3417c 55859 100.00% 22 29 107 0.62% 47.30%
VVVSKDDTVIVDGGGTAEA
VANR 95.00% 1.79 0.26 0 0 1 0 2 2,273.21 321 343
2DLC TX114
hypo protein 
Rv1100  Rv1100 24545 100.00% 4 6 11 0.06% 22.30% LPQLPGGWTPNSGGR 95.00% 2.91 0.503 0 2 0 0 2 1,537.76 97 111
2DLC TX114
hypo protein 
Rv1100  Rv1100 24545 100.00% 4 6 11 0.06% 22.30% NAATSIVGFISPTGR 95.00% 3.22 0.347 0 4 1 0 2 1,491.73 128 142
2DLC TX114
hypo protein 
Rv1100  Rv1100 24545 100.00% 4 6 11 0.06% 22.30% TLASATQSQPPLPAR 95.00% 3.24 0.446 0 1 2 0 2 1,538.78 219 233
2DLC TX114
hypo protein 
Rv1100  Rv1100 24545 100.00% 4 6 11 0.06% 22.30% TLGFPIR 88.70% 1.93 0.213 0 1 0 0 2 804.0884 90 96
2DLC TX114
hypo protein 
Rv0504c  Rv0504c 18342 99.80% 2 2 4 0.02% 10.80% APDHFLVGR 95.00% 2.66 0.41 0 0 1 0 2 1,012.14 17 25
2DLC TX114
hypo protein 
Rv0504c  Rv0504c 18342 99.80% 2 2 4 0.02% 10.80% FNIPINIAR 95.00% 2.79 0.264 0 3 0 0 2 1,058.42 78 86
2DLC TX114nrdZ (nrdZ)  Rv0570 74472 100.00% 5 5 6 0.03% 10.40% AAFPTAAEIAPQWHLR 81.10% 1.55 0.204 0 0 1 0 2 1,780.06 594 609
2DLC TX114nrdZ (nrdZ)  Rv0570 74472 100.00% 5 5 6 0.03% 10.40%
FLDDVIDVSRYPFPELGEAA
R 95.00% 5 0.595 0 0 1 0 2 2,410.79 419 439
2DLC TX114nrdZ (nrdZ)  Rv0570 74472 100.00% 5 5 6 0.03% 10.40% GAFPAFTDSR 95.00% 2.24 0.357 0 2 0 0 2 1,069.23 494 503
2DLC TX114nrdZ (nrdZ)  Rv0570 74472 100.00% 5 5 6 0.03% 10.40% LGEAGLDDVAR 95.00% 3.03 0.407 0 1 0 0 2 1,116.25 72 82
2DLC TX114nrdZ (nrdZ)  Rv0570 74472 100.00% 5 5 6 0.03% 10.40% LYDSAAGVVSMGGR 95.00% 1.47 0.341 0 1 0 0 2 1,383.53 252 265
2DLC TX114fum (fum)  Rv1098c 50124 100.00% 4 4 7 0.04% 5.70% AVENFPISGR 95.00% 3.25 0.408 0 2 0 0 2 1,090.22 35 44
2DLC TX114fum (fum)  Rv1098c 50124 100.00% 4 4 7 0.04% 5.70% DRRLDVLAMAK 95.00% 1.47 0.329 0 0 1 0 2 1,288.65 455 465
2DLC TX114fum (fum)  Rv1098c 50124 100.00% 4 4 7 0.04% 5.70% LDVLAMAK 95.00% 2.34 0.455 0 1 0 0 2 861.1484 458 465
2DLC TX114fum (fum)  Rv1098c 50124 100.00% 4 4 7 0.04% 5.70% LSIEDLDR 95.00% 2.17 0.213 0 3 0 0 2 961.1984 449 456
2DLC TX114grcC1 Rv0562 35510 100.00% 4 4 6 0.03% 14.60% AKDVLAQYAAQAR 95.00% 3.05 0.441 0 0 1 0 2 1,405.59 296 308
2DLC TX114grcC1 Rv0562 35510 100.00% 4 4 6 0.03% 14.60% ALAALVDYTVSR 95.00% 4.01 0.435 0 1 0 0 2 1,279.48 322 333
2DLC TX114grcC1 Rv0562 35510 100.00% 4 4 6 0.03% 14.60% GTSENVDSIEQYLK 95.00% 3.53 0.474 0 2 0 0 2 1,583.70 164 177
2DLC TX114grcC1 Rv0562 35510 100.00% 4 4 6 0.03% 14.60% TGSLIGAAGR 95.00% 2.89 0.476 0 2 0 0 2 903.1084 183 192
2DLC TX114pknD (pknD)  Rv0931c 69494 100.00% 5 7 22 0.13% 9.19% LISPQYSDNAVFR 95.00% 3.86 0.556 0 5 2 0 2 1,510.75 45 57
205
2DLC TX114pknD (pknD)  Rv0931c 69494 100.00% 5 7 22 0.13% 9.19% MIDGTSLR 95.00% 1.89 0.265 0 1 0 0 2 893.1484 94 101
2DLC TX114pknD (pknD)  Rv0931c 69494 100.00% 5 7 22 0.13% 9.19% TPLAVAVDSDR 95.00% 2.49 0.452 0 2 0 0 2 1,144.22 637 647
2DLC TX114pknD (pknD)  Rv0931c 69494 100.00% 5 7 22 0.13% 9.19% VPPALDQVIAK 95.00% 2.46 0.548 0 3 0 0 2 1,151.36 242 252
2DLC TX114pknD (pknD)  Rv0931c 69494 100.00% 5 7 22 0.13% 9.19% WSPGDSATVAGPLAADSR 95.00% 4.13 0.453 0 6 3 0 2 1,758.89 327 344
2DLC TX114
hypo protein 
Rv1097c  Rv1097c 29855 100.00% 3 4 7 0.04% 9.56% TSSITVDGVR 95.00% 2.76 0.493 0 3 0 0 2 1,035.07 222 231
2DLC TX114
hypo protein 
Rv1097c  Rv1097c 29855 100.00% 3 4 7 0.04% 9.56% VDADITIADSSR 95.00% 3.61 0.547 0 1 0 0 2 1,263.41 235 246
2DLC TX114
hypo protein 
Rv1097c  Rv1097c 29855 100.00% 3 4 7 0.04% 9.56% VIEALK 95.00% 1.63 0.198 2 1 0 0 2 672.8684 284 289
2DLC TX114
hypo protein 
Rv2161c  Rv2161c 30750 97.40% 2 2 2 0.01% 9.72% AFEVIAR 84.80% 2.06 0.104 0 1 0 0 2 805.9484 185 191
2DLC TX114
hypo protein 
Rv2161c  Rv2161c 30750 97.40% 2 2 2 0.01% 9.72%
MQFVTDLTPPPQLVAVWAE
ER 82.90% 2.41 0.13 0 0 1 0 2 2,428.65 6 26
2DLC TX114guaB2 Rv3411c 54848 99.80% 2 2 4 0.02% 5.67% FEVDQSKQVAEVMTK 95.00% 3.51 0.537 0 0 2 0 2 1,739.79 177 191
2DLC TX114guaB2 Rv3411c 54848 99.80% 2 2 4 0.02% 5.67% SAAAALVDAGADAVK 95.00% 2.75 0.496 0 2 0 0 2 1,330.45 318 332
2DLC TX114dapB (dapB)  Rv2773c 25715 99.80% 2 2 3 0.02% 10.20% GADVDGIPVHAVR 95.00% 2.37 0.343 0 0 1 0 2 1,306.31 174 186
2DLC TX114dapB (dapB)  Rv2773c 25715 99.80% 2 2 3 0.02% 10.20% TSFVPGVLLAVR 95.00% 2.61 0.554 0 2 0 0 2 1,259.46 215 226
2DLC TX114mrr (mrr)  Rv2528c 33631 99.80% 2 2 4 0.02% 5.23% LLEAMGYGR 95.00% 3.13 0.389 0 2 0 0 2 1,010.30 175 183
2DLC TX114mrr (mrr)  Rv2528c 33631 99.80% 2 2 4 0.02% 5.23% VDMAVLR 95.00% 2.08 0.377 0 2 0 0 2 803.9384 97 103
2DLC TX114ppp (ppp)  Rv0018c 53763 99.80% 2 2 4 0.02% 2.33% KEIVK 95.00% 1.4 0.0609 3 0 0 0 2 616.7884 278 282
2DLC TX114ppp (ppp)  Rv0018c 53763 99.80% 2 2 4 0.02% 2.33% LIELALR 95.00% 2.54 0.0909 0 1 0 0 2 828.1984 218 224
2DLC TX114
hypo protein 
Rv2955c  Rv2955c 35901 99.80% 2 2 3 0.02% 8.41% AVIAGAAELLR 95.00% 3.61 0.527 0 2 0 0 2 1,084.36 247 257
2DLC TX114
hypo protein 
Rv2955c  Rv2955c 35901 99.80% 2 2 3 0.02% 8.41% LAPVVALEPAPGTHSR 95.00% 2.04 0.383 0 0 1 0 2 1,615.79 148 163
2DLC TX114
hypo protein 
Rv2345  Rv2345 70012 99.80% 2 2 2 0.01% 3.94% ALLDAVDSAATDIR 95.00% 4.79 0.652 0 1 0 0 2 1,431.69 412 425
2DLC TX114
hypo protein 
Rv2345  Rv2345 70012 99.80% 2 2 2 0.01% 3.94% SLEQALFTAESR 95.00% 3.02 0.577 0 1 0 0 2 1,352.54 517 528
2DLC TX114argH (argH)  Rv1659 49725 99.80% 2 3 5 0.03% 5.96% FAGGPSDALAALSK 95.00% 4.57 0.561 0 2 1 0 2 1,305.62 13 26
2DLC TX114argH (argH)  Rv1659 49725 99.80% 2 3 5 0.03% 5.96% VAEQLNAIGEAAER 95.00% 3.34 0.496 0 2 0 0 2 1,471.56 450 463
2DLC TX114sigK (sigK)  Rv0445c 21017 99.80% 2 2 4 0.02% 10.20% LAANLSTIK 95.00% 2.58 0.323 0 1 0 0 2 931.2584 162 170
2DLC TX114sigK (sigK)  Rv0445c 21017 99.80% 2 2 4 0.02% 10.20% LSSDLDALLR 95.00% 2.67 0.403 0 3 0 0 2 1,103.46 7 16
2DLC TX114
hypo protein 
Rv2298  Rv2298 34969 100.00% 3 3 4 0.02% 8.67% FLTDMVR 95.00% 2.11 0.188 0 2 0 0 2 882.0884 311 317
2DLC TX114
hypo protein 
Rv2298  Rv2298 34969 100.00% 3 3 4 0.02% 8.67% IEPLLATLR 83.00% 1.69 0.286 0 1 0 0 2 1,026.42 233 241
2DLC TX114
hypo protein 
Rv2298  Rv2298 34969 100.00% 3 3 4 0.02% 8.67% YLDVDGIGQVSR 95.00% 2.65 0.521 0 1 0 0 2 1,322.44 3 14
2DLC TX114
hypo protein 
Rv0444c  Rv0444c 23865 100.00% 5 7 14 0.08% 35.30% ETMAVVSAATTAEPPAHLR 95.00% 1.5 0.249 0 0 1 0 2 1,969.08 53 71
2DLC TX114
hypo protein 
Rv0444c  Rv0444c 23865 100.00% 5 7 14 0.08% 35.30% GAGTATVVFSR 95.00% 2.59 0.403 0 1 0 0 2 1,066.10 138 148
2DLC TX114
hypo protein 
Rv0444c  Rv0444c 23865 100.00% 5 7 14 0.08% 35.30%
GVLTRPSPPPTVAEQVLTAP
DVR 95.00% 2.96 0.511 0 0 3 0 2 2,401.59 109 131
2DLC TX114
hypo protein 
Rv0444c  Rv0444c 23865 100.00% 5 7 14 0.08% 35.30% TAILDATKPEVR 95.00% 2.9 0.359 0 2 2 0 2 1,314.57 72 83
2DLC TX114
hypo protein 
Rv0444c  Rv0444c 23865 100.00% 5 7 14 0.08% 35.30% VAAAPSPVAAAFNDEVR 95.00% 4.7 0.632 0 2 3 0 2 1,685.73 33 49
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% ADAILIR 95.00% 2.43 0.194 0 1 0 0 2 772.0784 316 322
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% AVVITGTPEQLSR 95.00% 1.95 0.25 0 1 0 0 2 1,371.49 235 247
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% ELADAILIR 95.00% 2.04 0.232 0 1 0 0 2 1,014.38 314 322
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% FVEIGVK 94.10% 2.27 0.115 0 1 0 0 2 791.9084 1684 1690
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% GLGIGIVPAATR 95.00% 3.34 0.365 0 2 0 0 2 1,125.42 360 371
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% LASAIAGGAPMYQRPGDR 95.00% 1.81 0.308 0 0 1 0 2 1,832.21 3021 3038
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% LFTLDRDFIQEIR 95.00% 2.82 0.434 0 0 2 0 2 1,667.12 1606 1618
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% LLDGGATVIATTSKLDEER 95.00% 1.94 0.344 0 0 1 0 2 1,990.33 2137 2155
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% MLVDTQGTDQWISAGK 95.00% 3.59 0.405 0 2 0 0 2 1,750.95 654 669
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% NLFTVGATPEVAR 95.00% 2.43 0.415 0 2 0 0 2 1,375.49 376 388
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94%
PVAACATAAVSVEEGVDKI
R 95.00% 1.67 0.301 0 0 1 0 2 1,987.05 2716 2735
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% SFILVPGIDVPFHSR 95.00% 2.05 0.413 0 0 1 0 2 1,685.01 1554 1568
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% SLVHLDHAAR 89.30% 1.79 0.256 0 1 0 0 2 1,119.23 1116 1125
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% TYKPYGPVLSDAINDQLR 95.00% 4.62 0.535 0 0 3 0 2 2,051.44 1848 1865
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% VGIDQGAEIVDVAAR 95.00% 3.84 0.499 0 1 0 0 2 1,513.57 1300 1314
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% VGVAEFR 95.00% 1.67 0.233 0 1 0 0 2 777.7884 1572 1578
2DLC TX114fas (fas)  Rv2524c 326201 100.00% 17 17 23 0.13% 6.94% VLLWAVQR 95.00% 2.37 0.224 0 1 0 0 2 985.1384 2242 2249
2DLC TX114pknB (pknB)  Rv0014c 66491 99.80% 2 2 2 0.01% 4.15% ADLARDPSFYLR 95.00% 2.58 0.223 0 0 1 0 2 1,424.78 44 55
2DLC TX114pknB (pknB)  Rv0014c 66491 99.80% 2 2 2 0.01% 4.15% GQSSADAIATLQNR 95.00% 2.98 0.41 0 1 0 0 2 1,432.57 367 380
2DLC TX114
hypo protein 
Rv1794  Rv1794 32381 99.80% 2 2 5 0.03% 6.00% GPSASVLSLK 95.00% 2.8 0.485 0 3 0 0 2 959.1784 236 245
2DLC TX114
hypo protein 
Rv1794  Rv1794 32381 99.80% 2 2 5 0.03% 6.00% IALYQQAR 95.00% 2.48 0.485 0 2 0 0 2 963.1784 252 259
2DLC TX114
hypo protein 
Rv2302  Rv2302 8572 99.80% 2 2 4 0.02% 23.70% SADGSPPYVVR 95.00% 2.15 0.391 0 2 0 0 2 1,148.19 30 40
2DLC TX114
hypo protein 
Rv2302  Rv2302 8572 99.80% 2 2 4 0.02% 23.70% VGDYLVVK 95.00% 2.98 0.247 0 2 0 0 2 892.9784 5 12
2DLC TX114
hypo protein 
Rv1784  Rv1784 101451 100.00% 3 3 4 0.02% 3.00% FGVEQVR 95.00% 2.44 0.339 0 2 0 0 2 834.8084 671 677
2DLC TX114
hypo protein 
Rv1784  Rv1784 101451 100.00% 3 3 4 0.02% 3.00% FLDALWGEIAR 95.00% 2.91 0.369 0 1 0 0 2 1,291.63 105 115
2DLC TX114
hypo protein 
Rv1784  Rv1784 101451 100.00% 3 3 4 0.02% 3.00% VGTVIIDQLR 95.00% 2.89 0.369 0 1 0 0 2 1,114.31 333 342
2DLC TX114
hypo protein 
Rv1782  Rv1782 53671 99.80% 2 2 2 0.01% 7.71%
ADALVEHDTLPMDMTPAEL
VVPK 95.00% 3.2 0.227 0 0 1 0 2 2,493.83 484 506
2DLC TX114
hypo protein 













 Rv0002  dnaN  DNA POLYMERASE III (BETA CHAIN) DNAN (DNA NUCLEOTIDYLTRANSFERASE) 2  II.A.5 D 16
 Rv0005  gyrB  DNA GYRASE (SUBUNIT B) GYRB (DNA TOPOISOMERASE (ATP-HYDROLYSING)) 2  II.A.5 D 22, 24
 Rv0006  gyrA  DNA GYRASE (SUBUNIT A) GYRA (DNA TOPOISOMERASE (ATP-HYDROLYSING)) 2  II.A.5 D 22
 Rv0007  Rv0007  POSSIBLE CONSERVED MEMBRANE PROTEIN 3  V D
 Rv0009  ppiA  PROBABLE IRON-REGULATED PEPTIDYL-PROLYL CIS-TRANS ISOMERASE A PPIA (PPIase A) 2  II.A.6 A, C, D 42, 22, 16, 24
 Rv0014c  pknB  TRANSMEMBRANE SERINE/THREONINE-PROTEIN KINASE B PKNB (PROTEIN KINASE B) (STPK B) 9  I.J.3 D
 Rv0018c  pstP  POSSIBLE SERINE/THREONINE PHOSPHATASE PSTP 9  I.J.3 D
 Rv0020c  TB39.8  CONSERVED HYPOTHETICAL PROTEIN TB39.8 10  V D 42, 24
 Rv0036c  Rv0036c  CONSERVED HYPOTHETICAL PROTEIN 10  V B, D 42, 22
 Rv0048c  Rv0048c  POSSIBLE MEMBRANE PROTEIN 3  VI D 22, 24
 Rv0053  rpsF  PROBABLE 30S RIBOSOMAL PROTEIN S6 RPSF 2  II.A.1 D 42, 22
 Rv0056  rplI  PROBABLE 50S RIBOSOMAL PROTEIN L9 RPLI 2  II.A.1 D 42, 22, 24
 Rv0064  Rv0064  PROBABLE CONSERVED TRANSMEMBRANE PROTEIN 3  II.C.5 B 16, 24
 Rv0066c  icd2  PROBABLE ISOCITRATE DEHYDROGENASE [NADP] ICD2 (OxALOSUCCINATE DECARBOxYLASE) 7  I.B.3 D 22, 24
 Rv0079  Rv0079  HYPOTHETICAL PROTEIN 16  VI D 22, 24
 Rv0092  ctpA  PROBABLE CATION TRANSPORTER P-TYPE ATPASE A CTPA 3  III.A.2 B
 Rv0093c  Rv0093c  PROBABLE CONSERVED MEMBRANE PROTEIN 3  VI D 24
 Rv0101  nrp  PROBABLE PEPTIDE SYNTHETASE NRP (PEPTIDE SYNTHASE) 1  I.I B 24
 Rv0108c  Rv0108c  HYPOTHETICAL PROTEIN 16  VI D 42
 Rv0111  Rv0111  POSSIBLE TRANSMEMBRANE ACYLTRANSFERASE 7  IV.H A, B 24
 Rv0118c  o37cA  PROBABLE OxALYL-CoA DECARBOxYLASE OxCA 7  I.A.1 D 24
 Rv0120c  fusA2  PROBABLE ELONGATION FACTOR G FUSA2 (EF-G) 2  II.A.6 B 42, 22, 24
 Rv0125  pepA  PROBABLE SERINE PROTEASE PEPA (SERINE PROTEINASE) (MTB32A) 7  II.B.3 A 42, 16
 Rv0129c  fbpC  SECRETED ANTIGEN 85-C FBPC (85C) (AG58C) (MYCOLYL TRANSFERASE 85C) 1  I.H.3 A, B, D 42, 16
 Rv0139  Rv0139  POSSIBLE OxIDOREDUCTASE 7  I.B.7 A 24
 Rv0142  Rv0142  CONSERVED HYPOTHETICAL PROTEIN 10  VI A, B
 Rv0147  Rv0147  PROBABLE ALDEHYDE DEHYDROGENASE (NAD+) DEPENDENT 7  I.B.7 D 22, 24
 Rv0148  Rv0148  PROBABLE SHORT-CHAIN TYPE DEHYDROGENASE/REDUCTASE 7  I.B.7 A, B, D 42, 22
 Rv0169  mce1A  MCE-FAMILY PROTEIN MCE1A 0  IV.A D 24
 Rv0172  mce1D  MCE-FAMILY PROTEIN MCE1D 0 IV.A D 16
 Rv0173  lprK  POSSIBLE MCE-FAMILY LIPOPROTEIN LPRK (MCE-FAMILY LIPOPROTEIN MCE1E) 3  II.C.1 D 16
 Rv0174  mce1F  MCE-FAMILY PROTEIN MCE1F 0  IV.A D 16, 24
 Rv0183  Rv0183  POSSIBLE LYSOPHOSPHOLIPASE 7  I.B.7 D 42, 22, 24
 Rv0194  Rv0194  PROBABLE DRUGS-TRANSPORT TRANSMEMBRANE ATP-BINDING PROTEIN ABC TRANSPORTER 3  II.C.5 C 24
 Rv0202c  mmpL11  PROBABLE CONSERVED TRANSMEMBRANE TRANSPORT PROTEIN MMPL11 3  II.C.4 A, B, C 24
 Rv0206c  mmpL3  POSSIBLE CONSERVED TRANSMEMBRANE TRANSPORT PROTEIN MMPL3 3  II.C.4 D 24
 Rv0211  pckA  PROBABLE IRON-REGULATED PHOSPHOENOLPYRUVATE CARBOxYKINASE [GTP] 7  I.C.2 B, C 42, 22, 16, 24
 Rv0227c  Rv0227c  PROBABLE CONSERVED MEMBRANE PROTEIN 3  II.C.5 D 22, 24
 Rv0237  lpqI  PROBABLE CONSERVED LIPOPROTEIN LPQI 3  II.C.1 D 16, 24
 Rv0242c  fabG4  PROBABLE 3-OxOACYL-[ACYL-CARRIER PROTEIN] REDUCTASE FABG4 1  I.H.1 D 42, 22, 16, 24
 Rv0243  fadA2  PROBABLE ACETYL-CoA ACYLTRANSFERASE FADA2 (3-KETOACYL-CoA THIOLASE) 1  I.A.3 D 42, 22, 24
 Rv0247c  Rv0247c  PROBABLE SUCCINATE DEHYDROGENASE [IRON-SULFUR SUBUNIT] (SUCCINIC DEHYDROGENASE) 7  I.B.7 D 22
 Rv0248c  Rv0248c  PROBABLE SUCCINATE DEHYDROGENASE [IRON-SULFUR SUBUNIT] (SUCCINIC DEHYDROGENASE) 7  I.B.7 B 22, 24
 Rv0251c  hsp  HEAT SHOCK PROTEIN HSP (HEAT-STRESS-INDUCED RIBOSOME-BINDING PROTEIN A) 0  III.B D 22, 24
 Rv0252  nirB  PROBABLE NITRITE REDUCTASE [NAD(P)H] LARGE SUBUNIT [FAD FLAVOPROTEIN] NIRB 7  I.B.6.b D 24
 Rv0270  fadD2  PROBABLE FATTY-ACID-CoA LIGASE FADD2 (FATTY-ACID-CoA SYNTHETASE) 1  I.A.3 D 42, 22, 24
 Rv0271c  fadE6  PROBABLE ACYL-CoA DEHYDROGENASE FADE6 1  I.A.3 A 22, 24
 Rv0282  Rv0282  CONSERVED HYPOTHETICAL PROTEIN 10  V B, D 22, 24
 Rv0283  Rv0283  POSSIBLE CONSERVED MEMBRANE PROTEIN 3  V D 22, 16, 24
 Rv0284  Rv0284  POSSIBLE CONSERVED MEMBRANE PROTEIN 3  V B, D 22, 24
 Rv0290  Rv0290  PROBABLE CONSERVED TRANSMEMBRANE PROTEIN 3  II.C.5 D 22, 24
 Rv0291  mycP3  PROBABLE MEMBRANE-ANCHORED MYCOSIN MYCP3 (SERINE PROTEASE) 7  II.C.5 D 42, 22, 16
 Rv0292  Rv0292  PROBABLE CONSERVED TRANSMEMBRANE PROTEIN 3  II.C.5 D 22
 Rv0309  Rv0309  POSSIBLE CONSERVED ExPORTED PROTEIN 3  VI D 16
 Rv0327c  cyp135A1  POSSIBLE CYTOCHROME P450 135A1 CYP135A1 7  IV.F B
 Rv0334  rmlA  ALPHA-D-GLUCOSE-1-PHOSPHATE THYMIDYLYLTRANSFERASE RMLA (DTDP-GLUCOSE SYNTHASE) 7  I.C.3 A 22
 Rv0338c  Rv0338c  PROBABLE IRON-SULFUR-BINDING REDUCTASE 7  V A 22, 24
 Rv0350  dnaK  PROBABLE CHAPERONE PROTEIN DNAK (HEAT SHOCK PROTEIN 70) 0  III.B A, B, D 42, 22, 16, 24
 Rv0351  grpE  PROBABLE GRPE PROTEIN (HSP-70 COFACTOR) 0  III.B D 42
 Rv0352  dnaJ1  PROBABLE CHAPERONE PROTEIN DNAJ1 0  III.B D 24
 Rv0361  Rv0361  PROBABLE CONSERVED MEMBRANE PROTEIN 3  II.C.5 D
 Rv0363c  fba  PROBABLE FRUCTOSE-BISPHOSPHATE ALDOLASE FBA 7  I.B.1 D 42, 22, 16
 Rv0379  secE2  POSSIBLE PROTEIN TRANSPORT PROTEIN SECE2 3  III.D D 42, 22
 Rv0384c  clpB  PROBABLE ENDOPEPTIDASE ATP BINDING PROTEIN (CHAIN B)  (HEAT SHOCK PROTEIN F84.1) 0  III.B D 42, 22, 24
 Rv0386  Rv0386  PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN (PROBABLY LUxR/UHPA-FAMILY) 9  I.J.1 A, D 24
 Rv0402c  mmpL1  PROBABLE CONSERVED TRANSMEMBRANE TRANSPORT PROTEIN MMPL1 3  II.C.4 A 16, 24
 Rv0407  fgd1  PROBABLE F420-DEPENDENT GLUCOSE-6-PHOSPHATE DEHYDROGENASE FGD1 7  IV.G D 22
 Rv0431  Rv0431  PUTATIVE TUBERCULIN RELATED PEPTIDE 3  II.C.2 D
 Rv0432  sodC  PROBABLE PERIPLASMIC SUPEROxIDE DISMUTASE [CU-ZN] SODC 0  III.F C, D 22, 24
 Rv0440  groEL2  60 KDA CHAPERONIN 2 GROEL2 (PROTEIN CPN60-2) (GROEL PROTEIN 2) (65 KDA ANTIGEN) 0  III.B A,B,C, D 42, 22, 24
 Rv0444c  Rv0444c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 22
 Rv0445c  sigK  PROBABLE ALTERNATIVE RNA POLYMERASE SIGMA FACTOR SIGK 2  II.A.7 D 22, 24
 Rv0450c  mmpL4  PROBABLE CONSERVED TRANSMEMBRANE TRANSPORT PROTEIN MMPL4 3  II.C.4 A 24
 Rv0468  fadB2  PROBABLE 3-HYDROxYBUTYRYL-CoA DEHYDROGENASE FADB2 1  I.A.3 D 42, 22, 24
 Rv0474  Rv0474  PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN 9  I.J.1 D 24
 Rv0480c  Rv0480c  POSSIBLE AMIDOHYDROLASE 7  V A 24
 Rv0497  Rv0497  PROBABLE CONSERVED TRANSMEMBRANE PROTEIN 3  II.C.5 D
 Rv0504c  Rv0504c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 22
 Rv0507  mmpL2  PROBABLE CONSERVED TRANSMEMBRANE TRANSPORT PROTEIN MMPL2 3  II.C.4 B 24
 Rv0512  hemB  PROBABLE DELTA-AMINOLEVULINIC ACID DEHYDRATASE HEMB (PORPHOBILINOGEN SYNTHASE) 7  I.G.12 C
 Rv0540  Rv0540  CONSERVED HYPOTHETICAL PROTEIN 10  V B 22
 Rv0559c  Rv0559c  POSSIBLE CONSERVED SECRETED PROTEIN 3  II.C.5 D 42, 16
 Rv0562  grcC1  PROBABLE POLYPRENYL-DIPHOSPHATE SYNTHASE GRCC1 7  I.G.11 D 22
 Rv0569  Rv0569  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42, 24
 Rv0570  nrdZ  PROBABLE RIBONUCLEOSIDE-DIPHOSPHATE REDUCTASE (LARGE SUBUNIT) 2  I.F.3 D 22, 24
 Rv0580c  Rv0580c  CONSERVED HYPOTHETICAL PROTEIN 10  VI D 42, 24
 Rv0583c  lpqN  PROBABLE CONSERVED LIPOPROTEIN LPQN 3  II.C.1 D 22, 16
 Rv0614  Rv0614  CONSERVED HYPOTHETICAL PROTEIN 10  V A
 Rv0622  Rv0622  POSSIBLE MEMBRANE PROTEIN 3  II.C.5 B
 Rv0631c  recC  PROBABLE ExONUCLEASE V (GAMMA CHAIN) RECC (ExODEOxYRIBONUCLEASE V GAMMA CHAIN) 2  II.A.5 A 16, 24
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 Rv0636  Rv0636  CONSERVED HYPOTHETICAL PROTEIN 10  VI D 42, 24
 Rv0638  secE1  PROBABLE PREPROTEIN TRANSLOCASE SECE1 3  III.D D
 Rv0639  nusG  PROBABLE TRANSCRIPTION ANTITERMINATION PROTEIN NUSG 2  II.A.7 D 42, 22
 Rv0641  rplA  PROBABLE 50S RIBOSOMAL PROTEIN L1 RPLA 2  II.A.1 D 42, 22, 24
 Rv0644c  mmaA2  METHOxY MYCOLIC ACID SYNTHASE 2 MMAA2 (METHYL MYCOLIC ACID SYNTHASE 2) 1  I.H.2 D 22
 Rv0651  rplJ  PROBABLE 50S RIBOSOMAL PROTEIN L10 RPLJ 2  II.A.1 D 42, 22, 24
 Rv0652  rplL  PROBABLE 50S RIBOSOMAL PROTEIN L7/L12 RPLL (SA1) 2  II.A.1 D 42, 22, 24
 Rv0667  rpoB  DNA-DIRECTED RNA POLYMERASE (BETA CHAIN) RPOB (TRANSCRIPTASE BETA CHAIN) 2  II.A.7 D 22, 24
 Rv0668  rpoC  DNA-DIRECTED RNA POLYMERASE (BETA' CHAIN) RPOC (TRANSCRIPTASE BETA' CHAIN) 2  II.A.7 D 22, 24
 Rv0673  echA4  POSSIBLE ENOYL-CoA HYDRATASE ECHA4 (ENOYL HYDRASE) 1  I.A.3 B 24
 Rv0683  rpsG  PROBABLE 30S RIBOSOMAL PROTEIN S7 RPSG 2  II.A.1 D 22, 24
 Rv0684  fusA1  PROBABLE ELONGATION FACTOR G FUSA1 (EF-G) 2  II.A.6 B, D 42
 Rv0685  tuf  PROBABLE IRON-REGULATED ELONGATION FACTOR TU TUF (EF-TU) 2  II.A.6 A, B, C, D 42, 22, 24
 Rv0686  Rv0686  PROBABLE MEMBRANE PROTEIN 3  II.C.5 D 22
 Rv0700  rpsJ  30S RIBOSOMAL PROTEIN S10 RPSJ (TRANSCRIPTION ANTITERMINATION FACTOR NUSE) 2  II.A.1 D 42, 22, 24
 Rv0707  rpsC  PROBABLE 30S RIBOSOMAL PROTEIN S3 RPSC 2  II.A.1 D 22, 24
 Rv0712  Rv0712  CONSERVED HYPOTHETICAL PROTEIN 10  V B
 Rv0724  sppA  POSSIBLE PROTEASE IV SPPA (ENDOPEPTIDASE IV) (SIGNAL PEPTIDE PEPTIDASE) 3  II.B.3 D 42, 22, 24
 Rv0730  Rv0730  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42, 22
 Rv0733  adk  PROBABLE ADENYLATE KINASE ADK (ATP-AMP TRANSPHOSPHORYLASE) 7  I.F.5 D 42, 22
 Rv0771  Rv0771  POSSIBLE 4-CARBOxYMUCONOLACTONE DECARBOxYLASE (CMD) 7  II.B.6 D
 Rv0798c  cfp29  29 KDa ANTIGEN CFP29 0  IV.E A 22, 24
 Rv0814c  sseC2  CONSERVED HYPOTHETICAL PROTEIN SSEC2 7  I.C.5 D 42, 22
 Rv0815c  cysA2  PROBABLE THIOSULFATE SULFURTRANSFERASE CYSA2 (RHODANESE-LIKE PROTEIN) 7  I.D.3 A, B, D 42, 22, 24
 Rv0824c  desA1  PROBABLE ACYL-[ACYL-CARRIER PROTEIN] DESATURASE DESA1 (ACYL-[ACP] DESATURASE) 1  I.H.2 D 42, 22, 24
 Rv0830  Rv0830  CONSERVED HYPOTHETICAL PROTEIN 10  V A 22
 Rv0831c  Rv0831c  CONSERVED HYPOTHETICAL PROTEIN 10  V A, B, D 22, 24
 Rv0854  Rv0854  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42
 Rv0858c  Rv0858c  PROBABLE AMINOTRANSFERASE 7  IV.H A
 Rv0859  fadA  POSSIBLE ACYL-CoA THIOLASE FADA 1  I.A.3 B, D 42, 22
 Rv0860  fadB  PROBABLE FATTY OxIDATION PROTEIN FADB 1  I.A.3 D 42, 22, 24
 Rv0871  cspB  PROBABLE COLD SHOCK-LIKE PROTEIN B CSPB 0  III.E D 42, 22
 Rv0873  fadE10  PROBABLE ACYL-CoA DEHYDROGENASE FADE10 1  I.A.3 D 22, 24
 Rv0892  Rv0892  PROBABLE MONOOxYGENASE 7  I.B.7 B
 Rv0899  ompA  OUTER MEMBRANE PROTEIN A OMPA 3  II.C.2 D
 Rv0901  Rv0901  POSSIBLE CONSERVED ExPORTED OR MEMBRANE PROTEIN 3  V D 22
 Rv0902c  prrB  TWO COMPONENT SENSOR HISTIDINE KINASE PRRB 9  I.J.2 D
 Rv0905  echA6  POSSIBLE ENOYL-CoA HYDRATASE ECHA6 (ENOYL HYDRASE) 1  I.A.3 A, D 42, 22, 24
 Rv0926c  Rv0926c  CONSERVED HYPOTHETICAL PROTEIN 10  V A
 Rv0928  pstS3  PERIPLASMIC PHOSPHATE-BINDING LIPOPROTEIN PSTS3 (PBP-3) (PSTS3) (PHOS1) 3  III.A.4 D 16
 Rv0931c  pknD  TRANSMEMBRANE SERINE/THREONINE-PROTEIN KINASE D PKND 9  I.J.3 D 22, 24
 Rv0934  pstS1  PERIPLASMIC PHOSPHATE-BINDING LIPOPROTEIN PSTS1 (PBP-1) (PSTS1) 3  III.A.4 B, C, D 42, 22, 16, 24
 Rv0944  Rv0944  POSSIBLE FORMAMIDOPYRIMIDINE-DNA GLYCOSYLASE (FAPY-DNA GLYCOSYLASE) 2  II.A.5 A 24
 Rv0951  sucC  PROBABLE SUCCINYL-CoA SYNTHETASE (BETA CHAIN) SUCC (SCS-BETA) 7  I.B.3 D 24
 Rv0952  sucD  PROBABLE SUCCINYL-CoA SYNTHETASE (ALPHA CHAIN) SUCD (SCS-ALPHA) 7  I.B.3 A, B, D 42, 22, 24
 Rv0954  Rv0954  PROBABLE CONSERVED TRANSMEMBRANE PROTEIN 3  II.C.2 D
 Rv0968  Rv0968  CONSERVED HYPOTHETICAL PROTEIN 10  V D 22
 Rv0969  ctpV  PROBABLE METAL CATION TRANSPORTER P-TYPE ATPASE CTPV 3  III.A.2 A, D 22
 Rv0981  mprA  MYCOBACTERIAL PERSISTENCE REGULATOR MRPA 9  I.J.2 D 22
 Rv1005c  pabB  Probable para-aminobenzoate synthase component I PABD 7  I.G.2 A 24
 Rv1006  Rv1006  HYPOTHETICAL PROTEIN 16  VI B, D 22, 24
 Rv1016c  lpqT  PROBABLE CONSERVED LIPOPROTEIN LPQT 3  II.C.1 D
 Rv1017c  prsA  PROBABLE RIBOSE-PHOSPHATE PYROPHOSPHOKINASE PRSA 7  I.F.1 D 42, 22, 24
 Rv1023  eno  PROBABLE ENOLASE ENO 7  I.B.1 D 22, 24
 Rv1029  kdpA  Probable Potassium-transporting ATPase A chain KDPA 3  III.A.2 A
 Rv1038c  es37J  ESAT-6 LIKE PROTEIN ESxJ (ESAT-6 LIKE PROTEIN 2) 3  V A, B, D 42, 22, 16, 24
 Rv1070c  echA8  PROBABLE ENOYL-CoA HYDRATASE ECHA8 (ENOYL HYDRASE) 1  I.A.3 D 22
 Rv1074c  fadA3  PROBABLE BETA-KETOACYL CoA THIOLASE FADA3 1  I.A.3 D 42, 22, 16
 Rv1075c  Rv1075c  CONSERVED ExPORTED PROTEIN 3  V B 16, 24
 Rv1077  cbs  Probable cystathionine beta-synthase CBS (Serine sulfhydrase) (Beta-thionase) 7  I.D.3 D 22, 16
 Rv1078  pra  Probable Proline-rich antigen homolog pra 10  V A 22
 Rv1080c  greA  PROBABLE TRANSCRIPTION ELONGATION FACTOR GREA 2  II.A.6 D 42, 22,  24
 Rv1093  glyA1  Probable Serine hydroxymethyltransferase 1 glyA1 7  I.D.3 D 42, 22, 24
 Rv1094  desA2  POSSIBLE ACYL-[ACYL-CARRIER PROTEIN] DESATURASE DESA2 1  I.H.2 B, D 22, 24
 Rv1096  Rv1096  POSSIBLE GLYCOSYL HYDROLASE 7  I.A.1 D
 Rv1097c  Rv1097c  PROBABLE MEMBRANE GLYCINE AND PROLINE RICH PROTEIN 3  II.C.5 D 24
 Rv1098c  fum  PROBABLE FUMARASE FUM (Fumarate hydratase) 7  I.B.3 D 42, 22, 16, 24
 Rv1100  Rv1100  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv1109c  Rv1109c  CONSERVED HYPOTHETICAL PROTEIN 10  VI D 42, 22, 24
 Rv1128c  Rv1128c  CONSERVED HYPOTHETICAL PROTEIN 5  IV.B.2 B
 Rv1130  Rv1130  CONSERVED HYPOTHETICAL PROTEIN 10  V A 24
 Rv1133c  metE  HOMOCYSTEINE METHYLTRANSFERASE METE 7  I.D.2 D 22, 24
 Rv1144  Rv1144  PROBABLE SHORT-CHAIN TYPE DEHYDROGENASE/REDUCTASE 7  I.B.7 D 22
 Rv1151c  Rv1151c  PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN 9  I.J.1 A
 Rv1161  narG  PROBABLE RESPIRATORY NITRATE REDUCTASE (ALPHA CHAIN) NARG 7  I.B.6.b B, C 16, 24
 Rv1162  narH  PROBABLE RESPIRATORY NITRATE REDUCTASE (BETA CHAIN) NARH 7  I.B.6.b A 24
 Rv1165  typA  POSSIBLE GTP-BINDING TRANSLATION ELONGATION FACTOR 2  V B 24
 Rv1175c  fadH  PROBABLE NADPH DEPENDENT 2,4-DIENOYL-COA REDUCTASE FADH 1  I.A.3 A 24
 Rv1179c  Rv1179c  HYPOTHETICAL PROTEIN 16  VI B 22, 24
 Rv1181  pks4  PROBABLE POLYKETIDE BETA-KETOACYL SYNTHASE PKS4 1  I.I A, D 22, 24
 Rv1184c  Rv1184c  POSSIBLE ExPORTED PROTEIN 3  V D
 Rv1196  PPE18  PPE FAMILY PROTEIN 6  IV.C.2 D
 Rv1198  es37L  PUTATIVE ESAT-6 LIKE PROTEIN ESxL (ESAT-6 LIKE PROTEIN 4) 3  V D 42, 22, 16, 24
 Rv1201c  Rv1201c  PROBABLE TRANSFERASE 7  V B 42
 Rv1209  Rv1209  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv1220c  Rv1220c  PROBABLE METHYLTRANSFERASE 7  IV.H D 22
 Rv1223  htrA  PROBABLE SERINE PROTEASE HTRA (DEGP PROTEIN) 7  II.B.3 D 24
 Rv1230c  Rv1230c  POSSIBLE MEMBRANE PROTEIN 3  II.C.5 B
 Rv1231c  Rv1231c  PROBABLE MEMBRANE PROTEIN 3  VI D 24
 Rv1240  mdh  PROBABLE MALATE DEHYDROGENASE MDH 7  I.B.3 D 42, 22, 24
 Rv1244  lpqZ  PROBABLE LIPOPROTEIN LPQZ 3  II.C.1 D 24
 Rv1245c  Rv1245c  PROBABLE SHORT-CHAIN TYPE DEHYDROGENASE/REDUCTASE 7  I.B.7 A 42, 22, 24
 Rv1248c  sucA  PROBABLE 2-OxOGLUTARATE DEHYDROGENASE SUCA (Alpha-ketoglutarate dehydrogenase) 7  I.B.3 B, C 24
 Rv1253  deaD  PROBABLE COLD-SHOCK DEAD-BOx PROTEIN A HOMOLOG DEAD 2  II.A.7 A 24
 Rv1256c  cyp130  PROBA BLE CYTOCHROME P450 130 CYP130 7  IV.F B
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 Rv1261c  Rv1261c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 22
 Rv1265  Rv1265  HYPOTHETICAL PROTEIN 16  VI D 22
 Rv1266c  pknH  PROBABLE TRANSMEMBRANE SERINE/THREONINE-PROTEIN KINASE H PKNH (STPK H) 9  I.J.3 B, D
 Rv1267c  embR  PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN EMBR 9  I.J.1 D 24
 Rv1269c  Rv1269c  CONSERVED PROBABLE SECRETED PROTEIN 3  V D 42, 16
 Rv1270c  lprA  POSSIBLE LIPOPROTEIN LPRA 3  II.C.1 C, D 22, 16, 24
 Rv1273c  Rv1273c  PROBABLE DRUGS-TRANSPORT TRANSMEMBRANE ATP-BINDING PROTEIN ABC TRANSPORTER 3  II.C.5 B
 Rv1275  lprC  POSSIBLE LIPOPROTEIN LPRC 3  II.C.1 D 22, 24
 Rv1278  Rv1278  HYPOTHETICAL PROTEIN 16  VI B 24
 Rv1279  Rv1279  PROBABLE DEHYDROGENASE FAD flavoprotein GMC oxidoreductase 7  I.B.7 B 22, 24
 Rv1281c  oppD  PROBABLE OLIGOPEPTIDE-TRANSPORT ATP-BINDING PROTEIN ABC TRANSPORTER OPPD 3  III.A.1 D 24
 Rv1294  thrA  PROBABLE HOMOSERINE DEHYDROGENASE THRA 7  I.D.2 A 22
 Rv1297  rho  PROBABLE TRANSCRIPTION TERMINATION FACTOR RHO HOMOLOG 2  II.A.7 D 42, 22, 24
Rv1306  atpF  PROBABLE ATP SYNTHASE B CHAIN ATPF 7  I.B.8 B, C, D 22
 Rv1307  atpH  PROBABLE ATP SYNTHASE DELTA CHAIN ATPH 7  I.B.8 D 22, 24
 Rv1308  atpA  PROBABLE ATP SYNTHASE ALPHA CHAIN ATPA 7  I.B.8 A, B, D 42, 22, 24
 Rv1309  atpG  PROBABLE ATP SYNTHASE GAMMA CHAIN ATPG 7  I.B.8 A, B, D 22, 24
 Rv1310  atpD  PROBABLE ATP SYNTHASE BETA CHAIN ATPD 7  I.B.8 B, D 22, 16, 24
 Rv1311  atpC  PROBABLE ATP SYNTHASE EPSILON CHAIN ATPC 7  I.B.8 D 22, 24
 Rv1324  Rv1324  POSSIBLE THIOREDOxIN 7  VI D 42, 22, 24
 Rv1330c  Rv1330c  CONSERVED HYPOTHETICAL PROTEIN 10  V B
 Rv1361c  PPE19  PPE FAMILY PROTEIN 6  IV.C.2 A
 Rv1368  lprF  PROBABLE CONSERVED LIPOPROTEIN LPRF 3  II.C.1 C, D 22, 24
 Rv1379  pyrR  PROBABLE PYRIMIDINE OPERON REGULATORY PROTEIN PYRR 9  I.J.1 D
 Rv1388  mihF  PUTATIVE INTEGRATION HOST FACTOR MIHF 2  II.A.4 D 22, 24
 Rv1390  rpoZ  PROBABLE DNA-DIRECTED RNA POLYMERASE (OMEGA CHAIN) RPOZ 2  VI D 42
 Rv1392  metK  PROBABLE S-ADENOSYLMETHIONINE SYNTHETASE METK (MAT) (AdoMet synthetase) 7  I.D.2 D 42, 22, 24
 Rv1393c  Rv1393c  PROBABLE MONOxYGENASE 7  I.B.7 C
 Rv1407  fmu  PROBABLE FMU PROTEIN (SUN PROTEIN) 2  II.A.4 B 24
 Rv1411c  lprG  PROBABLE CONSERVED LIPOPROTEIN LPRG 3  II.C.1 B, D 22, 24
 Rv1423  whiA  PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN WHIA 9  I.J.1 D 22, 24
 Rv1424c  Rv1424c  POSSIBLE MEMBRANE PROTEIN 3  II.C.5 A 24
 Rv1436  gap  PROBABLE GLYCERALDEHYDE 3-PHOSPHATE DEHYDROGENASE GAP (GAPDH) 7  I.B.1 D 42, 22, 16, 24
 Rv1442  bisC  PROBABLE BIOTIN SULFOxIDE REDUCTASE BISC (BDS reductase) (BSO reductase) 7  I.G.1 A, D
 Rv1449c  tkt  PROBABLE TRANSKETOLASE TKT (TK) 7  I.B.5 B 22, 16, 24
 Rv1450c  PE_PGRS27  PE-PGRS FAMILY PROTEIN 6  IV.C.1.b A
 Rv1451  ctaB  PROBABLE CYTOCHROME C OxIDASE ASSEMBLY FACTOR CTAB 7  I.B.6.a B
 Rv1466  Rv1466  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv1473  Rv1473  PROBABLE MACROLIDE-TRANSPORT ATP-BINDING PROTEIN ABC TRANSPORTER 3  II.C.5 D 24
 Rv1479  mo37R1  PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN MOxR1 9  I.J.1 A, B, D 42, 22, 24
 Rv1484  inhA  NADH-DEPENDENT ENOYL-[ACYL-CARRIER-PROTEIN] REDUCTASE INHA 1  I.H.1 D 42, 22
 Rv1488  Rv1488  POSSIBLE ExPORTED CONSERVED PROTEIN 3  V D 22, 16, 24
 Rv1492  mutA  PROBABLE METHYLMALONYL-CoA MUTASE SMALL SUBUNIT MUTA (MCM) 1  I.A.3 B 24
 Rv1520  Rv1520  probable sugar transferase 7  IV.H C 24
 Rv1522c  mmpL12  PROBABLE CONSERVED TRANSMEMBRANE TRANSPORT PROTEIN MMPL12 3  II.C.4 B 24
 Rv1527c  pks5  Probable polyketide synthase pks5 1  I.I B 24
 Rv1543  Rv1543  POSSIBLE FATTY ACYL-CoA REDUCTASE 1  I.H.3 D 42, 22, 24
 Rv1544  Rv1544  Possible ketoacyl reductase 1  I.I D 42, 22
 Rv1547  dnaE1  PROBABLE DNA POLYMERASE III (ALPHA CHAIN) DNAE1 (DNA NUCLEOTIDYLTRANSFERASE) 2  II.A.5 A 22
 Rv1551  plsB1  Possible acyltransferase plsB1 1  I.H.3 A 24
 Rv1558  Rv1558  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42, 22
 Rv1569  bioF1  PROBABLE 8-AMINO-7-OxONONANOATE SYNTHASE BIOF1 (AONS) 7  I.G.1 A, B 24
 Rv1586c  Rv1586c  Probable phiRv1 integrase 5  IV.B.3 D
 Rv1589  bioB  PROBABLE BIOTIN SYNTHETASE BIOB 7  I.G.1 C 24
 Rv1593c  Rv1593c  CONSERVED HYPOTHETICAL PROTEIN 10  V A 22
 Rv1594  nadA  Probable quinolinate synthetase nadA 7  I.G.7 B
 Rv1596  nadC  Probable nicotinate-nucleotide pyrophosphatase nadC 7  I.G.7 A, B 42, 22
 Rv1599  hisD  Probable histidinol dehydrogenase HisD (HDH) 7  I.D.5 D
 Rv1602  hisH  Probable amidotransferase hisH 7  I.D.5 B
 Rv1611  trpC  Probable indole-3-glycerol phosphate synthase trpC 7  I.D.4 D 24
 Rv1623c  cydA  Probable integral membrane cytochrome D ubiquinol oxidase (subunit I) cydA 7  I.B.6.c D
 Rv1626  Rv1626  Probable two-component system transcriptional regulator 9  I.J.2 D 42, 22, 24
 Rv1627c  Rv1627c  Probable nonspecific lipid-transfer protein 1  I.H.3 A 22
 Rv1629  polA  PROBABLE DNA POLYMERASE I POLA 2  II.A.5 D 22, 24
 Rv1630  rpsA  PROBABLE RIBOSOMAL PROTEIN S1 RPSA 2  II.A.1 A, B, D 22, 24
 Rv1636  TB15.3  IRON-REGULATED CONSERVED HYPOTHETICAL PROTEIN TB15.3 10  V D 42, 22
 Rv1640c  lys37  Possible lysyl-tRNA synthetase 2 lysx 2  II.A.3 D 24
 Rv1654  argB  Probable Acetylglutamate kinase argB 7  I.D.1 D 22
 Rv1659  argH  Probable Argininosuccinate lyase argH 7  I.D.1 D
 Rv1661  pks7  Probable polyketide synthase pks7 1  I.I D 24
 Rv1666c  cyp139  Probable cytochrome P450 139 CYP139 7  IV.F A
 Rv1689  tyrS  Probable Tyrosyl-tRNA synthase tyrS (TYRRS) 2  II.A.3 B 24
 Rv1703c  Rv1703c  Probable catechol-o-methyltransferase 7  IV.H D 42, 22, 24
 Rv1747  Rv1747  PROBABLE CONSERVED TRANSMEMBRANE ATP-BINDING PROTEIN ABC TRANSPORTER 3  II.C.5 D 24
 Rv1748  Rv1748  HYPOTHETICAL PROTEIN 16  VI D
 Rv1771  Rv1771  PROBABLE OxIDOREDUCTASE 7  I.B.7 D 22, 24
 Rv1777  cyp144  Probable cytochrome p450 144 CYP144 7  IV.F A
 Rv1782  Rv1782  PROBABLE CONSERVED MEMBRANE PROTEIN 3  V D 22
 Rv1784  Rv1784  CONSERVED HYPOTHETICAL PROTEIN 10  V D 16, 24
 Rv1794  Rv1794  CONSERVED HYPOTHETICAL PROTEIN 10  V B, D 42, 22
 Rv1801  PPE29  PPE FAMILY PROTEIN 6  IV.C.2 A
 Rv1815  Rv1815  CONSERVED HYPOTHETICAL PROTEIN 10  V B 16
 Rv1821  secA2  POSSIBLE PREPROTEIN TRANSLOCASE ATPase SECA2 3  III.D D 22, 24
 Rv1827  cfp17  CONSERVED HYPOTHETICAL PROTEIN CFP17 10  V D 42, 22, 16
 Rv1829  Rv1829  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42, 22
 Rv1836c  Rv1836c  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv1837c  glcB  PROBABLE MALATE SYNTHASE G GLCB 7  I.B.4 A, B, D 42, 22, 16, 24
 Rv1866  Rv1866  CONSERVED HYPOTHETICAL PROTEIN 1  V B 24
 Rv1871c  Rv1871c  CONSERVED HYPOTHETICAL PROTEIN 10  VI D 22
 Rv1872c  lldD2  POSSIBLE L-LACTATE DEHYDROGENASE (CYTOCHROME) LLDD2 7  I.B.6.a D 22, 24
 Rv1875  Rv1875  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42, 24
 Rv1886c  fbpB  SECRETED ANTIGEN 85-B FBPB (85B) (ANTIGEN 85 COMPLEx B) (MYCOLYL TRANSFERASE 85B) 1  I.H.3 A, B 42, 22, 16
 Rv1908c  katG  CATALASE-PEROxIDASE-PEROxYNITRITASE T KATG 0  III.F B, D 16, 24
 Rv1911c  lppC  PROBABLE LIPOPROTEIN LPPC 3  II.C.1 A 16
 Rv1919c  Rv1919c  CONSERVED HYPOTHETICAL PROTEIN 10  II.C.2 D 22
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 Rv1925  fadD31  PROBABLE ACYL-CoA LIGASE FADD31 (ACYL-COA SYNTHETASE) (ACYL-CoA SYNTHASE) 1  I.A.3 D 24
 Rv1926c  mpt63  IMMUNOGENIC PROTEIN MPT63 (ANTIGEN MPT63/MPB63) 3  VI D 42, 16
 Rv1932  tp37  PROBABLE THIOL PEROxIDASE TPx 0  III.F B 42, 16
 Rv1937  Rv1937  POSSIBLE OxYGENASE 7  I.B.7 A, B 24
 Rv1957  Rv1957  HYPOTHETICAL PROTEIN 16  VI D
 Rv1969  mce3D  MCE-FAMILY PROTEIN MCE3D 0  IV.A A
 Rv1980c  mpt64  IMMUNOGENIC PROTEIN MPT64 (ANTIGEN MPT64/MPB64) 3  II.C.2 D 42, 16
 Rv1984c  cfp21  PROBABLE CUTINASE PRECURSOR CFP21 3  II.C.2 A 16
 Rv1996  Rv1996  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42, 22, 24
 Rv2005c  Rv2005c  CONSERVED HYPOTHETICAL PROTEIN 10  V A, B, D 42, 22, 24
 Rv2028c  Rv2028c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 22
 Rv2030c  Rv2030c  CONSERVED HYPOTHETICAL PROTEIN 10  V B, D 22, 24
 Rv2031c  hspX  HEAT SHOCK PROTEIN HSPx (ALPHA-CRSTALLIN HOMOLOG) (14 kDa ANTIGEN) (HSP16.3) 0  III.B A, B, C, D 42, 22, 24
 Rv2032  acg  Conserved hypothetical protein Acg 10  V D 22, 24
 Rv2047c  Rv2047c  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv2048c  pks12  Probable polyketide synthase pks12 1  I.I B, C 24
 Rv2050  Rv2050  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42
 Rv2063c Rv2063c  hypothetical protein 0  VI B
 Rv2074  Rv2074  CONSERVED HYPOTHETICAL PROTEIN 10  VI D 42, 16
 Rv2091c  Rv2091c  Probable membrane protein 3  II.C.5 D 24
 Rv2095c  Rv2095c  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv2096c  Rv2096c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 24
 Rv2100  Rv2100  CONSERVED HYPOTHETICAL PROTEIN 5  V B 24
 Rv2101  helZ  PROBABLE HELICASE HELZ 2  II.A.5 B 24
 Rv2115c  Rv2115c  Probable ATPase 3  III.C D 42, 22, 24
 Rv2122c  hisE  Probable phosphoribosyl-AMP pyrophosphatase HisE 7  I.D.5 D
 Rv2129c  Rv2129c  Probable oxidoreductase 7  I.B.7 D 24
 Rv2145c  wag31  CONSERVED HYPOTHETICAL PROTEIN WAG31 3  II.C.2 A, B, D 42, 22, 24
 Rv2159c  Rv2159c  CONSERVED HYPOTHETICAL PROTEIN 10  VI D 22, 24
 Rv2171  lppM  Probable conserved lipoprotein lppM 3  II.C.1 D
 Rv2178c  aroG  Probable 3-deoxy-D-arabino-heptulosonate 7-phosphate synthase AroG 7  I.D.4 B 42, 22, 24
 Rv2185c  TB16.3  CONSERVED HYPOTHETICAL PROTEIN TB16.3 10  V D 42, 22
 Rv2187  fadD15  Probable long-chain-fatty-acid-CoA ligase fadD15 (FATTY-ACID-CoA SYNTHETASE) 1  I.A.3 D 22
 Rv2191  Rv2191  CONSERVED HYPOTHETICAL PROTEIN 2  II.A.5 B 24
 Rv2195  qcrA  Probable Rieske iron-sulfur protein QcrA 7  I.B.6.a D 22, 24
 Rv2198c  mmpS3  PROBABLE CONSERVED MEMBRANE PROTEIN MMPS3 3  II.C.4 D
 Rv2205c  Rv2205c  CONSERVED HYPOTHETICAL PROTEIN 10  V B
 Rv2211c  gcvT  Probable aminomethyltransferase GcvT (Glycine cleavage system T protein) 7  I.C.1 D
 Rv2213  pepB  Probable aminopeptidase PepB 7  II.B.3 D 22
 Rv2214c  ephD  Possible short-chain dehydrogenase EphD 0  III.F D 22, 24
 Rv2215  sucB  Probable pyruvate dehydrogenase (E2 component) SucB 7  I.B.3 B, D 42, 22, 24
 Rv2216  Rv2216  CONSERVED HYPOTHETICAL PROTEIN 10  V D 22
 Rv2220  glnA1  GLUTAMINE SYNTHETASE GLNA1 (GLUTAMINE SYNTHASE) (GS-I) 7  I.D.1 D 42, 22, 16, 24
 Rv2221c  glnE  GLUTAMATE-AMMONIA-LIGASE ADENYLYLTRANSFERASE 7  I.D.1 A 22
 Rv2223c  Rv2223c  Probable exported protease 3  II.C.2 B
 Rv2241  aceE  Probable pyruvate dehydrogenase E1 component aceE (PYRUVATE DECARBOxYLASE) 7  I.B.2 D 22, 16, 24
 Rv2244  acpM  MEROMYCOLATE ExTENSION ACYL CARRIER PROTEIN ACPM 1  I.H.1 D 22, 24
 Rv2245  kasA  3-OxOACYL-[ACYL-CARRIER PROTEIN] SYNTHASE 1 KASA (BETA-KETOACYL-ACP SYNTHASE) (KAS I) 1  I.H.1 A, B, D 42, 22, 24
 Rv2246  kasB  3-OxOACYL-[ACYL-CARRIER PROTEIN] SYNTHASE 2 KASB (BETA-KETOACYL-ACP SYNTHASE) (KAS I) 1  I.H.1 B, D 42, 22, 24
 Rv2247  accD6  ACETYL/PROPIONYL-CoA CARBOxYLASE (BETA SUBUNIT) ACCD6 1  I.H.1 A, D
 Rv2258c  Rv2258c  Possible transcriptional regulatory protein 9  I.J.1 B 22
 Rv2260  Rv2260  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv2280  Rv2280  Probable dehydrogenase 7  I.B.7 A, D 22
 Rv2296  Rv2296  Probable haloalkane dehalogenase 7  IV.I A, D 42, 22, 24
 Rv2298  Rv2298  CONSERVED HYPOTHETICAL PROTEIN 10  V D 22, 24
 Rv2299c  htpG  PROBABLE CHAPERONE PROTEIN HTPG (HEAT SHOCK PROTEIN) (HSP90 FAMILY PROTEIN) 0  III.B D 22, 24
 Rv2302  Rv2302  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42
 Rv2307c  Rv2307c  CONSERVED HYPOTHETICAL PROTEIN 10  V B
 Rv2314c  Rv2314c  CONSERVED HYPOTHETICAL PROTEIN 10  V A 16
 Rv2326c  Rv2326c  POSSIBLE TRANSMEMBRANE ATP-BINDING PROTEIN ABC TRANSORTER 3  II.C.5 A, B 22
 Rv2345  Rv2345  POSSIBLE CONSERVED TRANSMEMBRANE PROTEIN 3  II.C.2 D 22, 24
 Rv2373c  dnaJ2  PROBABLE CHAPERONE PROTEIN DNAJ2 0  III.B D 19
 Rv2376c  cfp2  LOW MOLECULAR WEIGHT ANTIGEN CFP2 (LOW MOLECULAR WEIGHT PROTEIN ANTIGEN 2) 3  V A 16
 Rv2383c  mbtB  PHENYLOxAZOLINE SYNTHASE MBTB (PHENYLOxAZOLINE SYNTHETASE) 1  I.I A 24
 Rv2391  nirA  PROBABLE FERREDOxIN-DEPENDENT NITRITE REDUCTASE NIRA 7  I.B.6.b A 19
 Rv2428  ahpC  ALKYL HYDROPEROxIDE REDUCTASE C PROTEIN AHPC (ALKYL HYDROPEROxIDASE C) 0  III.F D 42, 22
 Rv2431c  PE25  PE FAMILY PROTEIN 6  IV.C.1.a D 16
 Rv2441c  rpmA  PROBABLE 50S RIBOSOMAL PROTEIN L27 RPMA 2  II.A.1 D 24
 Rv2444c  rne  POSSIBLE RIBONUCLEASE E RNE 2  II.B.1 D 22, 24
 Rv2455c  Rv2455c  PROBABLE OxIDOREDUCTASE (ALPHA SUBUNIT) 7  I.B.7 A 22
 Rv2460c  clpP2  PROBABLE ATP-DEPENDENT CLP PROTEASE PROTEOLYTIC SUBUNIT 2 CLPP2 7  II.B.3 B 22, 24
 Rv2462c  tig  PROBABLE TRIGGER FACTOR (TF) PROTEIN TIG 3  III.D D 42, 22, 24
 Rv2466c  Rv2466c  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv2471  aglA  PROBABLE ALPHA-GLUCOSIDASE AGLA (MALTASE) (GLUCOINVERTASE) 7  II.A.8 C 24
 Rv2476c  gdh  PROBABLE NAD-DEPENDENT GLUTAMATE DEHYDROGENASE GDH (NAD-GDH) 7  VI A 22, 24
 Rv2477c  Rv2477c  PROBABLE MACROLIDE-TRANSPORT ATP-BINDING PROTEIN ABC TRANSPORTER 3  II.C.5 A, D 22, 24
 Rv2488c  Rv2488c  PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN (LUxR-FAMILY) 9  I.J.1 A, B 24
 Rv2495c  pdhC  PROBABLE DIHYDROLIPOAMIDE S-ACETYLTRANSFERASE E2 COMPONENT 7  I.B.2 B 24
 Rv2496c  pdhB  PROBABLE PYRUVATE DEHYDROGENASE E1 COMPONENT (BETA SUBUNIT) 7  I.B.2 A 22, 24
 Rv2509  Rv2509  PROBABLE SHORT-CHAIN TYPE DEHYDROGENASE/REDUCTASE 7  I.B.7 D 22, 24
 Rv2518c  lppS  PROBABLE CONSERVED LIPOPROTEIN LPPS 3  II.C.1 D
 Rv2524c  fas  PROBABLE FATTY ACID SYNTHASE FAS (FATTY ACID SYNTHETASE) 1  I.H.1 B, C, D 22, 24
 Rv2528c  mrr  PROBABLE RESTRICTION SYSTEM PROTEIN MRR 2  II.A.5 D 22
 Rv2531c  Rv2531c  PROBABLE AMINO ACID DECARBOxYLASE 7  I.A.2 B 24
 Rv2536  Rv2536  PROBABLE CONSERVED TRANSMEMBRANE PROTEIN 3  II.C.5 D 24
 Rv2555c  alaS  PROBABLE ALANYL-TRNA SYNTHETASE ALAS (ALANINE--TRNA LIGASE) 2  II.A.3 A 22, 24
 Rv2556c  Rv2556c  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv2576c  Rv2576c  POSSIBLE CONSERVED MEMBRANE PROTEIN 3  VI A 16
 Rv2579  dhaA  POSSIBLE HALOALKANE DEHALOGENASE DHAA (1-CHLOROHExANE HALIDOHYDROLASE) 7  IV.I A, B 42, 22
 Rv2587c  secD  PROBABLE PROTEIN-ExPORT MEMBRANE PROTEIN SECD 3  III.D D 24
 Rv2622  Rv2622  POSSIBLE METHYLTRANSFERASE (METHYLASE) 7  IV.H B 24
 Rv2623  TB31.7  CONSERVED HYPOTHETICAL PROTEIN TB31.7 10  V A, B, C, D 22, 24
 Rv2625c  Rv2625c  PROBABLE CONSERVED TRANSMEMBRANE ALANINE AND LEUCINE RICH PROTEIN 3  V B 22
 Rv2626c  Rv2626c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42, 22, 24
 Rv2629  Rv2629  CONSERVED HYPOTHETICAL PROTEIN 10  VI D 24
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 Rv2631  Rv2631  CONSERVED HYPOTHETICAL PROTEIN 10  V B 16
 Rv2691  ceoB  TRK SYSTEM POTASSIUM UPTAKE PROTEIN CEOB 3  III.A.2 D 22
 Rv2703  sigA  RNA POLYMERASE SIGMA FACTOR SIGA (SIGMA-A) 2  II.A.7 A, D 22, 24
 Rv2711  ideR  IRON-DEPENDENT REPRESSOR AND ACTIVATOR IDER 9  I.J.1 D 42, 22
 Rv2712c  Rv2712c  HYPOTHETICAL PROTEIN 16  VI A
 Rv2713  sthA  PROBABLE SOLUBLE PYRIDINE NUCLEOTIDE TRANSHYDROGENASE STHA 7  I.B.7 B 24
 Rv2720  le37A  REPRESSOR LExA 9  I.J.1 D
 Rv2721c  Rv2721c  POSSIBLE CONSERVED TRANSMEMBRANE ALANINE AND GLYCINE RICH PROTEIN 3  V A, D 16
 Rv2744c  35kd_ag  CONSERVED 35 KDA ALANINE RICH PROTEIN 10  V A, B, C, D 42, 22, 24
 Rv2748c  ftsK  POSSIBLE CELL DIVISION TRANSMEMBRANE PROTEIN FTSK 3  III.C A 24
 Rv2756c  hsdM  POSSIBLE TYPE I RESTRICTION/MODIFICATION SYSTEM DNA METHYLASE 2  II.A.5 B 24
 Rv2773c  dapB  DIHYDRODIPICOLINATE REDUCTASE DAPB (DHPR) 7  I.D.2 D 42, 22
 Rv2780  ald  SECRETED L-ALANINE DEHYDROGENASE ALD (40 KDA ANTIGEN) (TB43) 7  I.A.2 D 42, 22, 24
 Rv2783c  gpsI  BIFUNCTIONAL PROTEIN POLYRIBONUCLEOTIDE NUCLEOTIDYLTRANSFERASE 2  II.A.7 D 22, 24
 Rv2789c  fadE21  PROBABLE ACYL-CoA DEHYDROGENASE FADE21 1  I.A.3 A
 Rv2839c  infB  PROBABLE TRANSLATION INITIATION FACTOR IF-2 INFB 2  II.A.6 D 22, 24
 Rv2841c  nusA  PROBABLE N UTILIZATION SUBSTANCE PROTEIN A NUSA 2  II.A.7 D 22
 Rv2864c  Rv2864c  POSSIBLE PENICILLIN-BINDING LIPOPROTEIN 3  II.C.3 B
 Rv2868c  gcpE  PROBABLE GCPE PROTEIN 10  V D 22
 Rv2880c  Rv2880c  CONSERVED HYPOTHETICAL PROTEIN 10  V A
 Rv2881c  cdsA  PROBABLE INTEGRAL MEMBRANE PHOSPHATIDATE CYTIDYLYLTRANSFERASE 1  I.H.3 C
 Rv2882c  frr  RIBOSOME RECYCLING FACTOR FRR (RIBOSOME RELEASING FACTOR) (RRF) 2  II.A.6 D 42, 22
 Rv2888c  amiC  PROBABLE AMIDASE AMIC (AMINOHYDROLASE) 7  IV.I D 22
 Rv2889c  tsf  PROBABLE ELONGATION FACTOR TSF (EF-TS) 2  II.A.6 A, B, D 42, 22, 24
 Rv2890c  rpsB  PROBABLE 30S RIBOSOMAL PROTEIN S2 RPSB 2  II.A.1 D 22, 24
 Rv2921c  ftsY  PROBABLE CELL DIVISION PROTEIN FTSY (SIGNAL RECOGNITION PARTICLE RECEPTOR) 3  III.C D 22
 Rv2931  ppsA  PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSA 1  I.I A
 Rv2935  ppsE  PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE SYNTHASE PPSE 1  I.I D 24
 Rv2936  drrA  PROBABLE DAUNORUBICIN-DIM-TRANSPORT ATP-BINDING PROTEIN ABC TRANSPORTER DRRA 3  III.A.6 D
 Rv2938  drrC  PROBABLE DAUNORUBICIN-DIM-TRANSPORT ABC TRANSPORTER DRRC 3  III.A.6 A, B
 Rv2940c  mas  PROBABLE MULTIFUNCTIONAL MYCOCEROSIC ACID SYNTHASE MEMBRANE-ASSOCIATED MAS 1  I.I A, D 22, 24
 Rv2945c  lppX  PROBABLE CONSERVED LIPOPROTEIN LPPX 3  II.C.1 C, D 22, 16, 24
 Rv2953  Rv2953  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42, 22, 24
 Rv2955c  Rv2955c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 24
 Rv2969c  Rv2969c  POSSIBLE CONSERVED MEMBRANE OR SECRETED PROTEIN 3  II.C.5 D 22, 24
 Rv2971  Rv2971  PROBABLE OxIDOREDUCTASE 7  I.B.7 D 42, 22
 Rv2986c  hupB  PROBABLE DNA-BINDING PROTEIN HU HOMOLOG HUPB (HISTONE-LIKE PROTEIN) (HLP) 2  II.A.4 D 22, 24
 Rv2996c  serA1  PROBABLE D-3-PHOSPHOGLYCERATE DEHYDROGENASE SERA1 (PGDH) 7  I.D.3 D 22, 24
 Rv3002c  ilvN  PROBABLE ACETOLACTATE SYNTHASE (SMALL SUBUNIT) ILVN 7  I.D.7 D 22
 Rv3003c  ilvB1  PROBABLE ACETOLACTATE SYNTHASE (LARGE SUBUNIT)(ACETOHYDROxY-ACID SYNTHASE) 7  I.D.7 A 19
 Rv3006  lppZ  PROBABLE CONSERVED LIPOPROTEIN LPPZ 3  II.C.1 D 22, 16
 Rv3012c  gatC  PROBABLE GLUTAMYL-TRNA(GLN) AMIDOTRANSFERASE (SUBUNIT C)(Glu-ADT SUBUNIT C) 2  II.A.3 D
 Rv3028c  fi37B  PROBABLE ELECTRON TRANSFER FLAVOPROTEIN (ALPHA-SUBUNIT) 7  I.B.6.c A, C, D 42, 22, 24
 Rv3029c  fi37A  PROBABLE ELECTRON TRANSFER FLAVOPROTEIN (BETA-SUBUNIT) 7  I.B.6.c D 42, 22, 24
 Rv3038c  Rv3038c  CONSERVED HYPOTHETICAL PROTEIN 10  VI B 22
 Rv3046c  Rv3046c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42
 Rv3071  Rv3071  CONSERVED HYPOTHETICAL PROTEIN 10  VI B 24
 Rv3075c  Rv3075c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42, 22
 Rv3083  Rv3083  PROBABLE MONOOxYGENASE (HYDROxYLASE) 7  I.B.7 C
 Rv3086  adhD  PROBABLE ZINC-TYPE ALCOHOL DEHYDROGENASE ADHD (ALDEHYDE REDUCTASE) 7  I.B.7 B
 Rv3089  fadD13  PROBABLE CHAIN -FATTY-ACID-CoA LIGASE FADD13 (FATTY-ACYL-CoA SYNTHETASE) 1  I.A.3 A 24
 Rv3099c  Rv3099c  CONSERVED HYPOTHETICAL PROTEIN 10  VI B, D 22, 24
 Rv3105c  prfB  PROBABLE PEPTIDE CHAIN RELEASE FACTOR 2 PRFB (RF-2) 2  II.A.6 D 42
 Rv3106  fprA  NADPH:ADRENODOxIN OxIDOREDUCTASE FPRA (NADPH-FERREDOxIN REDUCTASE) 7  I.B.6.c D 16
 Rv3107c  agpS  POSSIBLE ALKYLDIHYDROxYACETONEPHOSPHATE SYNTHASE AGPS (ALKYL-DHAP SYNTHASE) 1  I.B.7 B
 Rv3127  Rv3127  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42, 22, 24
 Rv3132c  devS  TWO COMPONENT SENSOR HISTIDINE KINASE DEVS 9  I.J.2 D 22
 Rv3133c  devR  TWO COMPONENT TRANSCRIPTIONAL REGULATORY PROTEIN DEVR 9  I.J.2 D 42, 22, 24
 Rv3134c  Rv3134c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 22, 24
 Rv3136  PPE51  PPE FAMILY PROTEIN 6  IV.C.2 D
 Rv3139  fadE24  PROBABLE ACYL-CoA DEHYDROGENASE FADE24 1  I.A.3 D 22, 24
 Rv3140  fadE23  PROBABLE ACYL-CoA DEHYDROGENASE FADE23 1  I.A.3 A, B, D 22
 Rv3143  Rv3143  PROBABLE RESPONSE REGULATOR 9  I.J.2 D 42
 Rv3151  nuoG  PROBABLE NADH DEHYDROGENASE I (CHAIN G) (NADH-UBIQUINONE OxIDOREDUCTASE CHAIN G) 7  I.B.6.a B 22, 24
 Rv3153  nuoI  PROBABLE NADH DEHYDROGENASE I (CHAIN I)(NADH-UBIQUINONE OxIDOREDUCTASE CHAIN I) 7  I.B.6.a D 24
 Rv3193c  Rv3193c  PROBABLE CONSERVED TRANSMEMBRANE PROTEIN 3  II.C.5 D 22, 16
 Rv3205c  Rv3205c  CONSERVED HYPOTHETICAL PROTEIN 10  VI D 22
 Rv3206c  moeB1  PROBABLE MOLYBDENUM COFACTOR BIOSYNTHESIS PROTEIN(MPT-SYNTHASE SULFURYLASE) 7  I.G.4 D
 Rv3211  rhlE  PROBABLE ATP-DEPENDENT RNA HELICASE RHLE 2  II.A.7 D
 Rv3223c  sigH  ALTERNATIVE RNA POLYMERASE SIGMA-E FACTOR (SIGMA-24) SIGH (RPOE) 2  II.A.7 D 19
 Rv3224  Rv3224  POSSIBLE IRON-REGULATED SHORT-CHAIN DEHYDROGENASE/REDUCTASE 7  I.B.7 A, D 42, 22, 24
 Rv3237c  Rv3237c  CONSERVED HYPOTHETICAL PROTEIN 10  III.A.2 A, D 22
 Rv3240c  secA1  PROBABLE PREPROTEIN TRANSLOCASE SECA1 1 SUBUNIT 3  III.D D 22, 16, 24
 Rv3243c  Rv3243c  HYPOTHETICAL PROTEIN 16  VI A
 Rv3244c  lpqB  PROBABLE CONSERVED LIPOPROTEIN LPQB 3  II.C.1 B 16, 24
 Rv3248c  sahH  PROBABLE ADENOSYLHOMOCYSTEINASE SAHH (S-ADENOSYL-L-HOMOCYSTEINE HYDROLASE) 7  I.C.5 D 22, 16, 24
 Rv3269  Rv3269  CONSERVED HYPOTHETICAL PROTEIN 0  III.B D 42, 22
 Rv3274c  fadE25  PROBABLE ACYL-CoA DEHYDROGENASE FADE25 1  I.A.3 D 42, 22, 24
 Rv3280  accD5  PROBABLE PROPIONYL-CoA CARBOxYLASE BETA CHAIN 5 ACCD5 (PCCASE) 1  I.H.1 D 42, 22
 Rv3281  Rv3281  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv3282  Rv3282  CONSERVED HYPOTHETICAL PROTEIN 10  V A
 Rv3285  accA3  PROBABLE BIFUNCTIONAL PROTEIN ACETYL-/PROPIONYL-COENZYME A CARBOxYLASE  1  I.H.1 D 22, 24
 Rv3371  Rv3371  CONSERVED HYPOTHETICAL PROTEIN 10  V B 24
 Rv3373  echA18  PROBABLE ENOYL-CoA HYDRATASE(ENOYL HYDRASE) (UNSATURATED ACYL-CoA HYDRATASE) 1  I.A.3 A
 Rv3389c  Rv3389c  POSSIBLE DEHYDROGENASE 7  I.B.7 B 42, 22, 24
 Rv3396c  guaA  PROBABLE GMP SYNTHASE [GLUTAMINE-HYDROLYZING] GLUTAMINE AMIDOTRANSFERASE) 7  I.F.1 D 42
 Rv3411c  guaB2  PROBABLE INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE GUAB2 (IMP DEHYDROGENASE) 7  I.F.1 D 42, 24
 Rv3416  whiB3  TRANSCRIPTIONAL REGULATORY PROTEIN WHIB-LIKE WHIB3 9  I.J.1 A
 Rv3417c  groEL1  60 KDA CHAPERONIN 1 GROEL1 (PROTEIN CPN60-1) (GROEL PROTEIN 1) 0  III.B A, B, D 22, 24
 Rv3418c  groES  10 KDA CHAPERONIN GROES (PROTEIN CPN10) (PROTEIN GROES) 0  III.B A, B, D 42, 22, 16, 24
 Rv3421c  Rv3421c  CONSERVED HYPOTHETICAL PROTEIN 10  V C
 Rv3443c  rplM  PROBABLE 50S RIBOSOMAL PROTEIN L13 RPLM 2  II.A.1 D 22, 24
 Rv3448  Rv3448  PROBABLE CONSERVED INTEGRAL MEMBRANE PROTEIN 3  II.C.5 D
 Rv3457c  rpoA  PROBABLE DNA-DIRECTED RNA POLYMERASE (ALPHA CHAIN) 2  II.A.7 D 42, 22, 24
 Rv3458c  rpsD  PROBABLE 30S RIBOSOMAL PROTEIN S4 RPSD 2  II.A.1 D 22, 24
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 Rv3462c  infA  PROBABLE TRANSLATION INITIATION FACTOR IF-1 INFA 2  II.A.6 D 42, 24
 Rv3490  otsA  PROBABLE ALPHA, ALPHA-TREHALOSE-PHOSPHATE SYNTHASE [UDP-FORMING] 0  III.E D 22, 24
 Rv3496c  mce4D  MCE-FAMILY PROTEIN MCE4D 0  IV.A C
 Rv3509c  ilv37  PROBABLE ACETOHYDROxYACID SYNTHASE ILVx (ACETOLACTATE SYNTHASE) 7  I.D.7 A, D 42, 22, 16
 Rv3515c  fadD19  PROBABLE FATTY-ACID-CoA LIGASE FADD19 (FATTY-ACID-CoA SYNTHETASE) 1  I.A.3 B
 Rv3520c  Rv3520c  POSSIBLE COENZYME F420-DEPENDENT OxIDOREDUCTASE 7  IV.G D 22
 Rv3534c  Rv3534c  PROBABLE 4-HYDROxY-2-OxOVALERATE ALDOLASE (HOA) 7  II.B.6 C
 Rv3547  Rv3547  CONSERVED HYPOTHETICAL PROTEIN 10  V D 22, 24
 Rv3565  aspB  POSSIBLE ASPARTATE AMINOTRANSFERASE ASPB (TRANSAMINASE A) (ASPAT) 7  I.D.2 B
 Rv3584  lpqE  POSSIBLE CONSERVED LIPOPROTEIN LPQE 3  II.C.1 D 22, 16
 Rv3592  TB11.2  CONSERVED HYPOTHETICAL PROTEIN TB11.2 10  V A 42, 22
 Rv3596c  clpC1  PROBABLE ATP-DEPENDENT PROTEASE ATP-BINDING SUBUNIT CLPC1 7  II.B.3 A, D 22, 24
 Rv3597c  lsr2  PROBABLE IRON-REGULATED LSR2 PROTEIN PRECURSOR 10  V D 22, 24
 Rv3614c  Rv3614c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 22
 Rv3615c  Rv3615c  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv3623  lpqG  PROBABLE CONSERVED LIPOPROTEIN LPQG 3  II.C.1 C 22, 24
 Rv3646c  topA  DNA TOPOISOMERASE I TOPA (OMEGA-PROTEIN) (RELAxING ENZYME) 2  II.A.5 D 22, 24
 Rv3651  Rv3651  CONSERVED HYPOTHETICAL PROTEIN 10  VI D
 Rv3666c  dppA  PROBABLE PERIPLASMIC DIPEPTIDE-BINDING LIPOPROTEIN DPPA 3  III.A.1 C
 Rv3670  ephE  POSSIBLE EPOxIDE HYDROLASE EPHE (EPOxIDE HYDRATASE) (ARENE-OxIDE HYDRATASE) 0  III.F A 24
 Rv3671c  Rv3671c  POSSIBLE MEMBRANE-ASSOCIATED SERINE PROTEASE 7  II.B.3 D 16
 Rv3676  Rv3676  PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN (PROBABLY CRP/FNR-FAMILY) 9  I.J.1 D 42, 22
 Rv3682  ponA2  PROBABLE BIFUNCTIONAL MEMBRANE-ASSOCIATED PENICILLIN-BINDING PROTEIN 3  II.C.3 A 22, 16, 24
 Rv3688c  Rv3688c  CONSERVED HYPOTHETICAL PROTEIN 10  V D
 Rv3690  Rv3690  PROBABLE CONSERVED MEMBRANE PROTEIN 3  VI D
 Rv3699  Rv3699  CONSERVED HYPOTHETICAL PROTEIN 10  IV.H D 42
 Rv3708c  asd  ASPARTATE-SEMIALDEHYDE DEHYDROGENASE ASD (ASA DEHYDROGENASE) 7  I.D.2 D 22
 Rv3709c  ask  ASPARTOKINASE ASK (ASPARTATE KINASE) 7  I.D.2 D 22
 Rv3718c  Rv3718c  CONSERVED HYPOTHETICAL PROTEIN 10  VI D 42, 22
 Rv3720  Rv3720  POSSIBLE FATTY ACID SYNTHASE 1  I.H.3 D 22
 Rv3725  Rv3725  POSSIBLE OxIDOREDUCTASE 7  I.B.7 B 16
 Rv3763  lpqH  19 KDA LIPOPROTEIN ANTIGEN PRECURSOR LPQH 3  II.C.1 C, D 22, 24
 Rv3778c  Rv3778c  POSSIBLE AMINOTRANSFERASE 7  V B 22
 Rv3780  Rv3780  CONSERVED HYPOTHETICAL PROTEIN 10  VI D 42, 22
 Rv3786c  Rv3786c  HYPOTHETICAL PROTEIN 16  VI A, B, C 24
 Rv3792  Rv3792  PROBABLE CONSERVED TRANSMEMBRANE PROTEIN 3  II.C.5 C 24
 Rv3799c  accD4  PROBABLE PROPIONYL-CoA CARBOxYLASE BETA CHAIN 4 ACCD4 (PCCASE) 1  I.H.1 B 22
 Rv3800c  pks13  POLYKETIDE SYNTHASE PKS13 1 I.I A, D 22, 24
 Rv3801c  fadD32  PROBABLE FATTY-ACID-CoA LIGASE FADD32 (FATTY-ACID-CoA SYNTHETASE) 1  I.A.3 D 22, 24
 Rv3804c  fbpA  SECRETED ANTIGEN 85-A FBPA (MYCOLYL TRANSFERASE 85A)(FIBRONECTIN-BINDING PROTEIN A) 1  I.H.3 B, D 42, 22, 16, 24
 Rv3809c  glf  UDP-GALACTOPYRANOSE MUTASE GLF (UDP-GALP MUTASE) 3  II.C.3 A 24
 Rv3816c  Rv3816c  POSSIBLE ACYLTRANSFERASE 7  IV.H D 22
 Rv3823c  mmpL8  PROBABLE CONSERVED INTEGRAL MEMBRANE TRANSPORT PROTEIN MMPL8 3  II.C.4 C 24
 Rv3825c  pks2  PROBABLE POLYKETIDE SYNTHASE PKS2 1  I.I A, C, D 22, 24
 Rv3835  Rv3835  PROBABLE CONSERVED MEMBRANE PROTEIN 3  VI A 16, 24
 Rv3841  bfrB  POSSIBLE BACTERIOFERRITIN BFRB 7  I.G.14 D 42, 22, 16, 24
 Rv3849  Rv3849  CONSERVED HYPOTHETICAL PROTEIN 16  VI D 42, 22, 16, 24
 Rv3852  hns  POSSIBLE HISTONE-LIKE PROTEIN HNS 2  II.A.4 D
 Rv3865  Rv3865  CONSERVED HYPOTHETICAL PROTEIN 10  V D 42
 Rv3869  Rv3869  POSSIBLE CONSERVED MEMBRANE PROTEIN 3  V D 24
 Rv3870  Rv3870  POSSIBLE CONSERVED TRANSMEMBRANE PROTEIN 3  V D 24
 Rv3871  Rv3871  CONSERVED HYPOTHETICAL PROTEIN 10  V D 24
 Rv3874  es37B  10 KDA CULTURE FILTRATE ANTIGEN ESxB (LHP) (CFP10) 3  V A, B, D 42, 22, 16, 24
 Rv3877  Rv3877  PROBABLE CONSERVED TRANSMEMBRANE PROTEIN 3  V B
 Rv3880c  Rv3880c  CONSERVED HYPOTHETICAL PROTEIN 10  V D 22
 Rv3894c  Rv3894c  POSSIBLE CONSERVED MEMBRANE PROTEIN 3  II.C.5 A, B, C 24
 Rv3903c  Rv3903c  HYPOTHETICAL ALANINE AND PROLINE RICH PROTEIN 16  VI B
 Rv3914  tr37C  THIOREDOxIN TRxC (TRx) (MPT46) 7  I.G.10 D 42, 22, 16, 24
L. Gu et al
M. Malen et al 
  Biological Sample:   A - 2% SDS;  B - 6M GuHCl;  C - 4% TX-114;  D - 2DLC TX-114
  References:
X. Proteome Database System - Max Planck Institute (http://web.mpiib-berlin.mpg.de/cgi-bin/pdbs/2d-page/e37tern/menu_frame.cgi?gel=)
Y. Tuberculosis Protein Database - Stratens Serum Institute (http://www.ssi.dk/sw14644.asp)





Annotation Name Essential Functional Role Tuberculist Class Name SSI Class Name
Rv0014c pknB E
 TRANSMEMBRANE SERINE/THREONINE-PROTEIN KINASE B 
PKNB (PROTEIN KINASE B) (STPK B) 9  regulatory proteins  I.J.3
 Serine-Threonine protein kinases and 
phosphoprotein phosphatases
Rv0015c pknA E
 TRANSMEMBRANE SERINE/THREONINE-PROTEIN KINASE A PKNA 
(PROTEIN KINASE A) (STPK A) 9  regulatory proteins  I.J.3
 Serine-Threonine protein kinases and 
phosphoprotein phosphatases
Rv0046c ino1 NE
 MYO-INOSITOL-1-PHOSPHATE SYNTHASE INO1 (Inositol 1-
phosphate synthetase) (D-glucose 6-phosphate cycl 7
 intermediary metabolism and 
respiration  V  Conserved hypotheticals
Rv0088 Rv0088 NE  HYPOTHETICAL PROTEIN 16
 conserved hypotheticals with an 
orthologue in M. bovis  VI  Unknowns
Rv0211 pckA -
 PROBABLE IRON-REGULATED PHOSPHOENOLPYRUVATE 
CARBOXYKINASE [GTP] PCKA (PHOSPHOENOLPYRUVATE 
CARBOXYLAS 7
 intermediary metabolism and 
respiration  I.C.2  Gluconeogenesis
Rv0231 fadE4 NE ACYL-COA DEHYDROGENASE FADE4 1 lipid metabolism I.A.3 Fatty Acids
Rv0350 dnaK E
 PROBABLE CHAPERONE PROTEIN DNAK (HEAT SHOCK PROTEIN 
70) (HEAT SHOCK 70 KDA PROTEIN) (HSP70) 0  virulence, detoxification, adaptation  III.B  Chaperones/Heat shock
Rv0384c clpB E
 PROBABLE ENDOPEPTIDASE ATP BINDING PROTEIN (CHAIN B) 
CLPB (CLPB PROTEIN) (HEAT SHOCK PROTEIN F84.1) 0  virulence, detoxification, adaptation  III.B  Chaperones/Heat shock
Rv0440 groEL2 E
 60 KDA CHAPERONIN 2 GROEL2 (PROTEIN CPN60-2) (GROEL 
PROTEIN 2) (65 KDA ANTIGEN) (HEAT SHOCK PROTEIN 0  virulence, detoxification, adaptation  III.B  Chaperones/Heat shock
Rv0458 Rv0458 NE ALDEHYDE DEHYDROGENASE 7
intermediary metabolism and 
respiration I.B.7 Misc. Oxyidreductases
Rv0467 icl NE  ISOCITRATE LYASE ICL (ISOCITRASE) (ISOCITRATASE) 7
 intermediary metabolism and 
respiration  I.B.4  Glyoxylate bypass
Rv0468 fadB2 NE
 PROBABLE 3-HYDROXYBUTYRYL-CoA DEHYDROGENASE FADB2 
(BETA-HYDROXYBUTYRYL-CoA DEHYDROGENASE) (BHBD) 1  lipid metabolism  I.A.3  Fatty acids
Rv0475 hbhA NE
 IRON-REGULATED HEPARIN BINDING HEMAGGLUTININ HBHA 
(ADHESIN) 3  cell wall and cell processes  II.C.5  Other membrane proteins
Rv0636 Rv0636 E  CONSERVED HYPOTHETICAL PROTEIN 10  conserved hypotheticals  VI  Unknowns
Rv0652 rplL E  PROBABLE 50S RIBOSOMAL PROTEIN L7/L12 RPLL (SA1) 2  information pathways  II.A.1
 Ribosomal protein synthesis and 
modification
Rv0667 rpoB E
 DNA-DIRECTED RNA POLYMERASE (BETA CHAIN) RPOB 
(TRANSCRIPTASE BETA CHAIN) (RNA POLYMERASE BETA SUBUNI 2  information pathways  II.A.7
 RNA synthesis, RNA modification and DNA 
transcription
Rv0685 tuf E
 PROBABLE IRON-REGULATED ELONGATION FACTOR TU TUF (EF-
TU) 2  information pathways  II.A.6  Protein translation and modification
Rv0733 adk -
 PROBABLE ADENYLATE KINASE ADK (ATP-AMP 
TRANSPHOSPHORYLASE) 7
 intermediary metabolism and 
respiration  I.F.5
 Miscellaneous nucleoside/nucleotide 
reactions
Rv0772 purD E
 PROBABLE PHOSPHORIBOSYLAMINE--GLYCINE LIGASE PURD 
(GARS) (GLYCINAMIDE RIBONUCLEOTIDE SYNTHETASE) (PH 7
 intermediary metabolism and 
respiration  I.F.1  Purine ribonucleotide biosynthesis
Rv0780 purC E
 PHOSPHORIBOSYLAMINOIMIDAZOLE- SUCCINOCARBOXAMIDE 
SYNTHASE PURC (SAICAR SYNTHETASE) 7
 intermediary metabolism and 
respiration  I.F.1  Purine ribonucleotide biosynthesis
Rv0824c desA1 E
 PROBABLE ACYL-[ACYL-CARRIER PROTEIN] DESATURASE DESA1 
(ACYL-[ACP] DESATURASE) (STEAROYL-ACP DESATURA 1  lipid metabolism  I.H.2  Modification of fatty and mycolic acids
Rv0860 fadB NE  PROBABLE FATTY OXIDATION PROTEIN FADB 1  lipid metabolism  I.A.3  Fatty acids
Rv0902c prrB E  TWO COMPONENT SENSOR HISTIDINE KINASE PRRB 9  regulatory proteins  I.J.2  Two component systems
Rv0931c pknD NE
 TRANSMEMBRANE SERINE/THREONINE-PROTEIN KINASE D 
PKND (PROTEIN KINASE D) (STPK D) 9  regulatory proteins  I.J.3
 Serine-Threonine protein kinases and 
phosphoprotein phosphatases
Rv0951 sucC E
 PROBABLE SUCCINYL-CoA SYNTHETASE (BETA CHAIN) SUCC 
(SCS-BETA) 7
 intermediary metabolism and 
respiration  I.B.3  TCA cycle
Rv0952 sucD E
 PROBABLE SUCCINYL-CoA SYNTHETASE (ALPHA CHAIN) SUCD 
(SCS-ALPHA) 7
 intermediary metabolism and 
respiration  I.B.3  TCA cycle
Rv1080c greA NE
 PROBABLE TRANSCRIPTION ELONGATION FACTOR GREA 
(Transcript cleavage factor greA) 2  information pathways  II.A.6  Protein translation and modification
Rv1094 desA2 E
 POSSIBLE ACYL-[ACYL-CARRIER PROTEIN] DESATURASE DESA2 
(ACYL-[ACP] DESATURASE) (STEAROYL-ACP DESATURA 1  lipid metabolism  I.H.2  Modification of fatty and mycolic acids
Rv1112 Rv1112 NE  Probable GTP binding protein 10  conserved hypotheticals  V  Conserved hypotheticals
Rv1185c fadD21 NE
 PROBABLE FATTY-ACID--CoA LIGASE FADD21 (FATTY-ACID-CoA 




intermediary metabolism and 
respiration V Conserved hypotheticals
Rv1266c pknH NE
 PROBABLE TRANSMEMBRANE SERINE/THREONINE-PROTEIN 
KINASE H PKNH (PROTEIN KINASE H) (STPK H) 9  regulatory proteins  I.J.3
 Serine-Threonine protein kinases and 
phosphoprotein phosphatases
Rv1297 rho E
 PROBABLE TRANSCRIPTION TERMINATION FACTOR RHO 
HOMOLOG 2  information pathways  II.A.7
 RNA synthesis, RNA modification and DNA 
transcription
Rv1308 atpA E  PROBABLE ATP SYNTHASE ALPHA CHAIN ATPA 7
 intermediary metabolism and 
respiration  I.B.8  ATP-proton motive force
Rv1310 atpD E  PROBABLE ATP SYNTHASE BETA CHAIN ATPD 7
 intermediary metabolism and 
respiration  I.B.8  ATP-proton motive force
Rv1388 mihF E  PUTATIVE INTEGRATION HOST FACTOR MIHF 2  information pathways  II.A.4  Nucleoproteins
Rv1437 pgk E  PROBABLE PHOSPHOGLYCERATE KINASE PGK 7
 intermediary metabolism and 
respiration  I.B.1  Glycolysis
Rv1475 acn E
PROBABLE IRON-REGULATED ACONITATE HYDRATASE ACN 
(CITRATE HYDRO-LYASE) 7
 intermediary metabolism and 
respiration - -
Rv1521 fadD25 NE
 PROBABLE FATTY-ACID-CoA LIGASE FADD25 (FATTY-ACID-CoA 
SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) 1  lipid metabolism  I.A.3  Fatty acids
Table Key: Bold text indicates proteins identified with High Confidence labeled peptides (see text for ranking criteria). SSI functional categories can be accessed here: http://web.mpiib-
berlin.mpg.de/bioinformatik/FUNC_CLASS/overview.php?db_name=CLASS_Mtb




Annotation Name Essential Functional Role Tuberculist Class Name SSI Class Name
Rv1617 pykA E PROBABLE PYRUVATE KINASE PYKA 7
 intermediary metabolism and 
respiration  I.B.1  Glycolysis
Rv1629 polA E DNA POLYMERASE I POLA 2 information pathways II.A.5
 DNA replication, repair, recombination and 
restriction/modification
Rv1636 TB15.3 NE  IRON-REGULATED CONSERVED HYPOTHETICAL PROTEIN TB15.3 10  conserved hypotheticals  V  Conserved hypotheticals
Rv1738 Rv1738 E  CONSERVED HYPOTHETICAL PROTEIN 10  conserved hypotheticals  V  Conserved hypotheticals
Rv1743 pknE NE TRANSMEMBRANE SERINE/THREONINE PROTEIN KINASE E
Rv1746 pknF NE
 ANCHORED-MEMBRANE SERINE/THREONINE-PROTEIN KINASE 
PKNF (PROTEIN KINASE F) (STPK F) 9  regulatory proteins  I.J.3
 Serine-Threonine protein kinases and 
phosphoprotein phosphatases
Rv2004c Rv2004c NE  CONSERVED HYPOTHETICAL PROTEIN 10  conserved hypotheticals  VI  Unknowns
Rv2005c Rv2005c NE  CONSERVED HYPOTHETICAL PROTEIN 10  conserved hypotheticals  V  Conserved hypotheticals
Rv2028c Rv2028c NE  CONSERVED HYPOTHETICAL PROTEIN 10  conserved hypotheticals  V  Conserved hypotheticals
Rv2031c hspX NE
 HEAT SHOCK PROTEIN HSPX (ALPHA-CRSTALLIN HOMOLOG) (14 
kDa ANTIGEN) (HSP16.3) 0  virulence, detoxification, adaptation  III.B  Chaperones/Heat shock
Rv2032 acg NE HYPOTHETICAL PROTEIN ACG 3 cell wall and processes
Rv2074 Rv2074 -  CONSERVED HYPOTHETICAL PROTEIN 10  conserved hypotheticals  VI  Unknowns
Rv2159c Rv2159c NE CONSERVED HYPOTHETICAL PROTEIN 10 conserved hypotheticals VI Unknowns
Rv2215 dlaT E  Probable pyruvate dehydrogenase (E2 component) SucB 7
 intermediary metabolism and 
respiration  I.B.3  TCA cycle
Rv2220 glnA1 E  GLUTAMINE SYNTHETASE GLNA1 (GLUTAMINE SYNTHASE) (GS-I) 7
 intermediary metabolism and 
respiration  I.D.1  Glutamate family
Rv2241 aceE NE
 Probable pyruvate dehydrogenase E1 component aceE (PYRUVATE 
DECARBOXYLASE) (PYRUVATE DEHYDROGENASE) 7
 intermediary metabolism and 
respiration  I.B.2  Pyruvate dehydrogenase
Rv2244 acpM E  MEROMYCOLATE EXTENSION ACYL CARRIER PROTEIN ACPM 1  lipid metabolism  I.H.1  Synthesis of fatty and mycolic acids
Rv2296 Rv2296 NE  Probable haloalkane dehalogenase 7
 intermediary metabolism and 
respiration  IV.I
 Miscellaneous phosphatases, lyases, and 
hydrolases
Rv2299c htpG NE
 PROBABLE CHAPERONE PROTEIN HTPG (HEAT SHOCK PROTEIN) 
(HSP90 FAMILY PROTEIN) (HIGH TEMPERATURE PROTE 0  virulence, detoxification, adaptation  III.B  Chaperones/Heat shock
Rv2319c Rv2319c E UNIVERSAL STRESS PROTEIN 0 virulence, detoxification, adaptation VI Unknowns
Rv2376c cfp2 NE LOW MOLECULAR WEIGHT PROTEIN ANTIGEN 3 cell wall and processes V Conserved hypotheticals
Rv2428 ahpC E
 ALKYL HYDROPEROXIDE REDUCTASE C PROTEIN AHPC (ALKYL 
HYDROPEROXIDASE C) 0  virulence, detoxification, adaptation  III.F  Detoxification
Rv2477c Rv2477c E
 PROBABLE MACROLIDE-TRANSPORT ATP-BINDING PROTEIN ABC 
TRANSPORTER 3  cell wall and cell processes  II.C.5  Other membrane proteins
Rv2501c accA1 E
 PROBABLE ACETYL-/PROPIONYL-COENZYME A CARBOXYLASE 
ALPHA CHAIN (ALPHA SUBUNIT) ACCA1: BIOTIN CARBOXYL 1  lipid metabolism  I.A.3  Fatty acids
Rv2510c Rv2510c E  CONSERVED HYPOTHETICAL PROTEIN 10  conserved hypotheticals  V  Conserved hypotheticals
Rv2607 pdxH NE PYRIDOXAMINE 5-PHOSPHATE OXIDASE PDXH 7
intermediary metabolism and 
respiration I.G.6 Pyridoxine
Rv2623 TB31.7 E
 CONSERVED HYPOTHETICAL PROTEIN TB31.7; UNIVERSAL 
STRESS PROTEIN 0 virulence, detoxification, adaptation  V  Conserved hypotheticals
Rv2624c Rv2624c NE
CONSERVED HYPOTHETICAL PROTEIN;UNIVERSAL STRESS 
PROTEIN 0 virulence, detoxification, adaptation V Conserved hypotheticals
Rv2773c dapB E DIHYDRODIPICOLINATE REDUCTASE DAPB (DHPR) 7
 intermediary metabolism and 
respiration  I.D.2  Aspartate family
Rv2780 ald NE
 SECRETED L-ALANINE DEHYDROGENASE ALD (40 KDA ANTIGEN) 
(TB43) 7
 intermediary metabolism and 
respiration  I.A.2  Amino acids and amines
Rv2783c gpsI -
 BIFUNCTIONAL PROTEIN POLYRIBONUCLEOTIDE 
NUCLEOTIDYLTRANSFERASE GPSI: GUANOSINE 
PENTAPHOSPHATE SYNTHE 2  information pathways  II.A.7
 RNA synthesis, RNA modification and DNA 
transcription
Rv2858c aldC NE  PROBABLE ALDEHYDE DEHYDROGENASE ALDC 7
 intermediary metabolism and 
respiration  I.B.7
 Miscellaneous oxidoreductases and 
oxygenases
Rv2933 ppsC NE
 PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE 
SYNTHASE PPSC 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv2950c fadD29 NE
 PROBABLE FATTY-ACID-CoA LIGASE FADD29 (FATTY-ACID-CoA 
SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) 1  lipid metabolism  I.A.3  Fatty acids
Rv2984 ppk1 E POLYPHOSPHATE KINASE PPK (POLYPHOSPHORIC ACID KINASE) 7
intermediary metabolism and 
respiration I.A.4 Phosphorous Compounds
Rv3001c ilvC E
 PROBABLE KETOL-ACID REDUCTOISOMERASE ILVC (Acetohydroxy-
acid isomeroreductase) (Alpha-keto-beta-hydr 7
 intermediary metabolism and 
respiration  I.D.7  Branched amino acid family
Rv3009c gatB E
 PROBABLE GLUTAMYL-TRNA(GLN) AMIDOTRANSFERASE 
(SUBUNIT B) GATB (Glu-ADT SUBUNIT B) 2  information pathways  II.A.3
 Aminoacyl tRNA synthases and their 
modification
Rv3010c pfkA NE
 PROBABLE 6-PHOSPHOFRUCTOKINASE PFKA 
(PHOSPHOHEXOKINASE) (PHOSPHOFRUCTOKINASE) 7
 intermediary metabolism and 
respiration  I.B.1  Glycolysis
Rv3028c fixB NE
 PROBABLE ELECTRON TRANSFER FLAVOPROTEIN (ALPHA-
SUBUNIT) FIXB (ALPHA-ETF) (ELECTRON TRANSFER FLAVOPRO 7
 intermediary metabolism and 
respiration  I.B.6.c  Electron transport




Annotation Name Essential Functional Role Tuberculist Class Name SSI Class Name
Rv3029c fixA E
 PROBABLE ELECTRON TRANSFER FLAVOPROTEIN (BETA-
SUBUNIT) FIXA (BETA-ETF) (ELECTRON TRANSFER FLAVOPROTE 7
 intermediary metabolism and 
respiration  I.B.6.c  Electron transport
Rv3133c devR NE
 TWO COMPONENT TRANSCRIPTIONAL REGULATORY PROTEIN 
DEVR (PROBABLY LUXR/UHPA-FAMILY) 9  regulatory proteins  I.J.2  Two component systems
Rv3140 fadE23 E  PROBABLE ACYL-CoA DEHYDROGENASE FADE23 1  lipid metabolism  I.A.3  Fatty acids
Rv3248c sahH E
 PROBABLE ADENOSYLHOMOCYSTEINASE SAHH (S-ADENOSYL-L-
HOMOCYSTEINE HYDROLASE) (ADOHCYASE) 7
 intermediary metabolism and 
respiration  I.C.5  Sulphur metabolism
Rv3269 Rv3269 NE  CONSERVED HYPOTHETICAL PROTEIN 0  virulence, detoxification, adaptation  III.B  Chaperones/Heat shock
Rv3285 accA3 E
 PROBABLE BIFUNCTIONAL PROTEIN ACETYL-/PROPIONYL-
COENZYME A CARBOXYLASE (ALPHA CHAIN) ACCA3: BIOTIN C 1  lipid metabolism  I.H.1  Synthesis of fatty and mycolic acids
Rv3336c trpS E
 PROBABLE TRYPTOPHANYL-TRNA SYNTHETASE TRPS 
(TRYPTOPHAN--TRNA LIGASE) (TRPRS) (TRYPTOPHAN 
TRANSLASE) 2  information pathways  II.A.3
 Aminoacyl tRNA synthases and their 
modification
Rv3389c hdtY NE PROBABLE 3-HYDROXYACYL-THIOESTER DEHYDRATASE HTDY 7
intermediary metabolism and 
respiration I.B.7 Misc. Oxyidreductases
Rv3417c groEL1 E
 60 KDA CHAPERONIN 1 GROEL1 (PROTEIN CPN60-1) (GROEL 
PROTEIN 1) 0  virulence, detoxification, adaptation  III.B  Chaperones/Heat shock
Rv3418c groES E
 10 KDA CHAPERONIN GROES (PROTEIN CPN10) (PROTEIN 
GROES) (BCG-A HEAT SHOCK PROTEIN) (10 KDA ANTIGEN) 0  virulence, detoxification, adaptation  III.B  Chaperones/Heat shock
Rv3580c cysS1 E
CYSTEINYL-TRNA SYNTHETASE 1 CYSS1 (CYSTEINE--TRNA 
LIGASE 1) 2 information pathways II.A.3
Aminoacyl tRNA synthases and their 
modification
Rv3596c clpC1 E
 PROBABLE ATP-DEPENDENT PROTEASE ATP-BINDING SUBUNIT 
CLPC1 7
 intermediary metabolism and 
respiration  II.B.3  Proteins, peptides and glycopeptides
Rv3610c ftsH E  MEMBRANE-BOUND PROTEASE FTSH (CELL DIVISION PROTEIN) 3  cell wall and cell processes  III.C  Cell division
Rv3648c cspA E  PROBABLE COLD SHOCK PROTEIN A CSPA 0  virulence, detoxification, adaptation  III.E  Adaptations and atypical conditions
Rv3763 lpqH NE 19 KDA LIPOPROTEIN ANTIGEN PRECURSOR LPQH 3 cell wall and processes II.C.1 Lipoproteins(lppA-lpr0)
Rv3801c fadD32 E
 PROBABLE FATTY-ACID-CoA LIGASE FADD32 (FATTY-ACID-CoA 
SYNTHETASE) (FATTY-ACID-CoA SYNTHASE 1  lipid metabolism  I.A.3  Fatty acids
Rv3818 Rv3818 NE  HYPOTHETICAL PROTEIN 16
 conserved hypotheticals with an 
orthologue in M. bovis  VI  Unknowns
Rv3846 sodA E SUPEROXIDE DISMUTASE [FE] SODA 0 virulence, detoxification, adaptation III.F Detoxification
Rv3868 Rv3868 NE  CONSERVED HYPOTHETICAL PROTEIN 10  conserved hypotheticals  V  Conserved hypotheticals
Rv3874 esxB NE  10 KDA CULTURE FILTRATE ANTIGEN ESXB (LHP) (CFP10) 3  cell wall and cell processes  V  Conserved hypotheticals
Rv0005 gyrB E
 DNA GYRASE (SUBUNIT B) GYRB (DNA TOPOISOMERASE (ATP-
HYDROLYSING)) (DNA TOPOISOMERASE II) (TYPE II DN 2  information pathways  II.A.5
 DNA replication, repair, recombination and 
restriction/modification
Rv0407 fgd1 NE
 PROBABLE F420-DEPENDENT GLUCOSE-6-PHOSPHATE 
DEHYDROGENASE FGD1 7
 intermediary metabolism and 
respiration  IV.G  Coenzyme F420-dependent enzymes
Rv0702 rplD E  PROBABLE 50S RIBOSOMAL PROTEIN L4 RPLD 2  information pathways  II.A.1
 Ribosomal protein synthesis and 
modification
Rv0709 rpmC E  PROBABLE 50S RIBOSOMAL PROTEIN L29 RPMC 2  information pathways  II.A.1
 Ribosomal protein synthesis and 
modification
Rv0721 rpsE E  PROBABLE 30S RIBOSOMAL PROTEIN S5 RPSE 2  information pathways  II.A.1
 Ribosomal protein synthesis and 
modification
Rv0896 gltA2 -  PROBABLE CITRATE SYNTHASE I GLTA2 7
 intermediary metabolism and 
respiration  I.B.3  TCA cycle
Rv0973c accA2 E
 PROBABLE ACETYL-/PROPIONYL-COENZYME A CARBOXYLASE 
ALPHA CHAIN (ALPHA SUBUNIT) ACCA2: BIOTIN CARBOXYL 1  lipid metabolism  I.A.3  Fatty acids
Rv1630 rpsA E  PROBABLE RIBOSOMAL PROTEIN S1 RPSA 2  information pathways  II.A.1
 Ribosomal protein synthesis and 
modification
Rv1819c bacA NE
 PROBABLE DRUGS-TRANSPORT TRANSMEMBRANE ATP-BINDING 
PROTEIN ABC TRANSPORTER 3  cell wall and cell processes  III.A.6  Efflux proteins
Rv1837c glcB NE  PROBABLE MALATE SYNTHASE G GLCB 7
 intermediary metabolism and 
respiration  I.B.4  Glyoxylate bypass
Rv2158c murE NE
 ProbableUDP-N-acetylmuramoylalanyl-D-glutamate-2,6-
diaminopimelate ligase MurE 3  cell wall and cell processes  II.C.3  Murein sacculus and peptidoglycan
Rv2211c gcvT E
 Probable aminomethyltransferase GcvT (Glycine cleavage system T 
protein) 7
 intermediary metabolism and 
respiration  I.C.1  General
Rv2445c ndkA NE
 PROBABLE NUCLEOSIDE DIPHOSPHATE KINASE NDKA (NDK) 
(NDP KINASE) (NUCLEOSIDE-2-P KINASE) 7
 intermediary metabolism and 
respiration  I.F.5
 Miscellaneous nucleoside/nucleotide 
reactions
Rv2511 orn E  OLIGORIBONUCLEASE ORN 7
 intermediary metabolism and 
respiration  V  Conserved hypotheticals
Rv3224 Rv3224 NE
 POSSIBLE IRON-REGULATED SHORT-CHAIN 
DEHYDROGENASE/REDUCTASE 7
 intermediary metabolism and 
respiration  I.B.7
 Miscellaneous oxidoreductases and 
oxygenases
Rv3275c purE E
 PROBABLE PHOSPHORIBOSYLAMINOIMIDAZOLE CARBOXYLASE 
CATALYTIC SUBUNIT PURE (AIR CARBOXYLASE) (AIRC) 7
 intermediary metabolism and 
respiration  I.F.1  Purine ribonucleotide biosynthesis
Rv3410c guaB3 E
 PROBABLE INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE 
GUAB3 (IMP DEHYDROGENASE) (INOSINIC ACID DEHYDROGENA 7
 intermediary metabolism and 
respiration  I.F.1  Purine ribonucleotide biosynthesis
Rv3443c rplM E  PROBABLE 50S RIBOSOMAL PROTEIN L13 RPLM 2  information pathways  II.A.1
 Ribosomal protein synthesis and 
modification




Annotation Name Essential Functional Role Tuberculist Class Name SSI Class Name
Rv3456c rplQ NE  PROBABLE 50S RIBOSOMAL PROTEIN L17 RPLQ 2  information pathways  II.A.1
 Ribosomal protein synthesis and 
modification
Rv3457c rpoA E
 PROBABLE DNA-DIRECTED RNA POLYMERASE (ALPHA CHAIN) 
RPOA (TRANSCRIPTASE ALPHA CHAIN) (RNA POLYMERASE 2  information pathways  II.A.7
 RNA synthesis, RNA modification and DNA 
transcription
Rv2941 fadD28 NE
 FATTY-ACID-CoA LIGASE FADD28 (FATTY-ACID-CoA SYNTHETASE) 
(FATTY-ACID-CoA SYNTHASE) 1  lipid metabolism  I.A.3  Fatty acids
Rv2967c pca E
 PROBABLE PYRUVATE CARBOXYLASE PCA (PYRUVIC 
CARBOXYLASE) 7
 intermediary metabolism and 
respiration  I.B.3  TCA cycle
Rv3139 fadE24 E  PROBABLE ACYL-CoA DEHYDROGENASE FADE24 1  lipid metabolism  I.A.3  Fatty acids
Rv3157 nuoM NE
 PROBABLE NADH DEHYDROGENASE I (CHAIN M) NUOK (NADH-
UBIQUINONE OXIDOREDUCTASE CHAIN M) 7
 intermediary metabolism and 
respiration  I.B.6.a  aerobic
Rv3280 accD5 -
 PROBABLE PROPIONYL-CoA CARBOXYLASE BETA CHAIN 5 
ACCD5 (PCCASE) (PROPANOYL-COA:CARBON DIOXIDE LIGASE) 1  lipid metabolism  I.H.1  Synthesis of fatty and mycolic acids
Rv3411c guaB2 E
 PROBABLE INOSINE-5'-MONOPHOSPHATE DEHYDROGENASE 
GUAB2 (IMP DEHYDROGENASE) (INOSINIC ACID DEHYDROGENA 7
 intermediary metabolism and 
respiration  I.F.1  Purine ribonucleotide biosynthesis
Rv3774 echA21 NE
 POSSIBLE ENOYL-CoA HYDRATASE ECHA21 (ENOYL HYDRASE) 
(UNSATURATED ACYL-CoA HYDRATASE) (CROTONASE) 1  lipid metabolism  I.A.3  Fatty acids
Rv2524c fas E
 PROBABLE FATTY ACID SYNTHASE FAS (FATTY ACID 
SYNTHETASE) 1  lipid metabolism  I.H.1  Synthesis of fatty and mycolic acids
Rv2590 fadD9 NE
 PROBABLE FATTY-ACID-CoA LIGASE FADD9 (FATTY-ACID-CoA 
SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) 1  lipid metabolism  I.A.3  Fatty acids
Rv2029c pfkB NE  Probable phosphofructokinase PfkB (PHOSPHOHEXOKINASE) 7
 intermediary metabolism and 
respiration  I.B.1  Glycolysis
Rv1980c mpt64 NE  IMMUNOGENIC PROTEIN MPT64 (ANTIGEN MPT64/MPB64) 3  cell wall and cell processes  II.C.2
 Surface polysaccharides, 
lipopolysaccharides, proteins and antigens
Rv1925 fadD31 NE
 PROBABLE ACYL-CoA LIGASE FADD31 (ACYL-COA SYNTHETASE) 
(ACYL-CoA SYNTHASE) 1  lipid metabolism  I.A.3  Fatty acids
Rv1699 pyrG E  Probable CTP synthase PyrG 7
 intermediary metabolism and 
respiration  I.F.2  Pyrimidine ribonucleotide biosynthesis
Rv1712 cmk E
 Probable Cytidylate kinase cmk (CMP kinase) (Cytidine 
monophosphate kinase) (CK) 7
 intermediary metabolism and 
respiration  I.F.5
 Miscellaneous nucleoside/nucleotide 
reactions
Rv1193 fadD36 E
 PROBABLE FATTY-ACID-CoA LIGASE FADD36 (FATTY-ACID-CoA 
SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) 1  lipid metabolism  I.A.3  Fatty acids
Rv1133c metE E
 PROBABLE5-METHYLTETRAHYDROPTEROYLTRIGLUTAMATE--
HOMOCYSTEINE METHYLTRANSFERASE METE (methionine synth 7
 intermediary metabolism and 
respiration  I.D.2  Aspartate family
Rv0641 rplA NE  PROBABLE 50S RIBOSOMAL PROTEIN L1 RPLA 2  information pathways  II.A.1
 Ribosomal protein synthesis and 
modification
Rv0684 fusA1 E  PROBABLE ELONGATION FACTOR G FUSA1 (EF-G) 2  information pathways  II.A.6  Protein translation and modification
Rv0705 rpsS E  PROBABLE 30S RIBOSOMAL PROTEIN S19 RPSS 2  information pathways  II.A.1
 Ribosomal protein synthesis and 
modification
Rv0379 secE2 NE  POSSIBLE PROTEIN TRANSPORT PROTEIN SECE2 3  cell wall and cell processes  III.D  Protein and peptide secretion
Rv0041 leuS E
 PROBABLE LEUCYL-tRNA SYNTHETASE LEUS (LEUCINE--tRNA 
LIGASE) (LEURS) 2  information pathways  II.A.3
 Aminoacyl tRNA synthases and their 
modification
Rv0009 ppiA NE
 PROBABLE IRON-REGULATED PEPTIDYL-PROLYL CIS-TRANS 
ISOMERASE A PPIA (PPIase A) (ROTAMASE A) 2  information pathways  II.A.6  Protein translation and modification
Rv0066c icd2 NE
 PROBABLE ISOCITRATE DEHYDROGENASE [NADP] ICD2 
(OXALOSUCCINATE DECARBOXYLASE) (IDH) (NADP+-SPECIFIC I 7
 intermediary metabolism and 
respiration  I.B.3  TCA cycle
Rv0101 nrp NE  PROBABLE PEPTIDE SYNTHETASE NRP (PEPTIDE SYNTHASE) 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv0119 fadD7 -
 PROBABLE FATTY-ACID-CoA LIGASE FADD7 (FATTY-ACID-CoA 
SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) 1  lipid metabolism  I.A.3  Fatty acids
Rv0174 mce1F NE  MCE-FAMILY PROTEIN MCE1F 0  virulence, detoxification, adaptation  IV.A  Virulence
Rv0189c ilvD E  PROBABLE DIHYDROXY-ACID DEHYDRATASE ILVD (DAD) 7
 intermediary metabolism and 
respiration  I.D.7  Branched amino acid family
Rv0204c Rv0204c NE  PROBABLE CONSERVED TRANSMEMBRANE PROTEIN 3  cell wall and cell processes  II.C.5  Other membrane proteins
Rv0214 fadD4 NE
 PROBABLE FATTY-ACID-CoA LIGASE FADD4 (FATTY-ACID-CoA 
SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) 1  lipid metabolism  I.A.3  Fatty acids
Rv0405 pks6 NE  PROBABLE MEMBRANE BOUND POLYKETIDE SYNTHASE PKS6 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv0578c PE_PGRS7 NE  PE-PGRS FAMILY PROTEIN 6  PE/PPE  IV.C.1.b  PE_PGRS subfamily
Rv0761c adhB NE
 POSSIBLE ZINC-CONTAINING ALCOHOL DEHYDROGENASE NAD 
DEPENDENT ADHB 7
 intermediary metabolism and 
respiration  I.B.7
 Miscellaneous oxidoreductases and 
oxygenases
Rv0845 Rv0845 -  POSSIBLE TWO COMPONENT SENSOR KINASE 9  regulatory proteins  I.J.2  Two component systems
Rv0886 fprB NE
 PROBABLE NADPH:ADRENODOXIN OXIDOREDUCTASE FPRB 
(ADRENODOXIN REDUCTASE) (AR) (FERREDOXIN-NADP(+) REDU 7
 intermediary metabolism and 
respiration  I.B.6.c  Electron transport
Rv1091 PE_PGRS22 -  PE-PGRS FAMILY PROTEIN 6  PE/PPE  IV.C.1.b  PE_PGRS subfamily
Rv1127c ppdK NE  PROBABLE PYRUVATE, PHOSPHATE DIKINASE PPDK 7
 intermediary metabolism and 
respiration  I.C.1  General
Rv1161 narG NE
 PROBABLE RESPIRATORY NITRATE REDUCTASE (ALPHA CHAIN) 
NARG 7
 intermediary metabolism and 
respiration  I.B.6.b  anaerobic




Annotation Name Essential Functional Role Tuberculist Class Name SSI Class Name
Rv1177 fdxC E  PROBABLE FERREDOXIN FDXC 7
 intermediary metabolism and 
respiration  I.B.6.c  Electron transport
Rv1183 mmpL10 NE
 PROBABLE CONSERVED TRANSMEMBRANE TRANSPORT 
PROTEIN MMPL10 3  cell wall and cell processes  II.C.4  Conserved membrane proteins
Rv1358 Rv1358 NE  PROBABLE TRANSCRIPTIONAL REGULATORY PROTEIN 9  regulatory proteins  I.J.1  Repressors/activators
Rv1450c PE_PGRS27 -  PE-PGRS FAMILY PROTEIN 6  PE/PPE  IV.C.1.b  PE_PGRS subfamily
Rv1522c mmpL12 NE
 PROBABLE CONSERVED TRANSMEMBRANE TRANSPORT 
PROTEIN MMPL12 3  cell wall and cell processes  II.C.4  Conserved membrane proteins
Rv1527c pks5 NE  Probable polyketide synthase pks5 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv1661 pks7 E  Probable polyketide synthase pks7 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv1768 PE_PGRS31 E  PE-PGRS FAMILY PROTEIN 6  PE/PPE  IV.C.1.b  PE_PGRS subfamily
Rv1796 mycP5 -
 PROBABLE PROLINE RICH MEMBRANE-ANCHORED MYCOSIN 
MYCP5 (SERINE PROTEASE) (SUBTILISIN-LIKE PROTEASE) ( 7
 intermediary metabolism and 
respiration  V  Conserved hypotheticals
Rv1941 Rv1941 -  PROBABLE SHORT-CHAIN TYPE DEHYDROGENASE/REDUCTASE 7
 intermediary metabolism and 
respiration  I.B.7
 Miscellaneous oxidoreductases and 
oxygenases
Rv1992c ctpG NE
 PROBABLE METAL CATION TRANSPORTER P-TYPE ATPASE G 
CTPG 3  cell wall and cell processes  III.A.2  Cations
Rv2007c fdxA -  PROBABLE FERREDOXIN FDXA 7
 intermediary metabolism and 
respiration  I.B.6.c  Electron transport
Rv2048c pks12 NE  Probable polyketide synthase pks12 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv2089c pepE NE  Probable dipeptidase PepE 7
 intermediary metabolism and 
respiration  II.B.3  Proteins, peptides and glycopeptides
Rv2155c murD E  Probable UDP-N-acetylmuramoylalanine-D-glutamate ligase MurD 3  cell wall and cell processes  II.C.3  Murein sacculus and peptidoglycan
Rv2157c murF E
 ProbableUDP-N-acetylmuramoylalanyl-D-glutamyl-2,6-diaminopimelate-
D-alanyl-D-alanyl ligase MurF 3  cell wall and cell processes  II.C.3  Murein sacculus and peptidoglycan
Rv2222c glnA2 NE
 PROBABLE GLUTAMINE SYNTHETASE GLNA2 (GLUTAMINE 
SYNTHASE) (GS-II) 7
 intermediary metabolism and 
respiration  I.D.1  Glutamate family
Rv2245 kasA E
 3-OXOACYL-[ACYL-CARRIER PROTEIN] SYNTHASE 1 KASA (BETA-
KETOACYL-ACP SYNTHASE) (KAS I) 1  lipid metabolism  I.H.1  Synthesis of fatty and mycolic acids
Rv2384 mbtA NE
 BIFUNCTIONAL ENZYME MBTA: SALICYL-AMP LIGASE (SAL-AMP 
LIGASE) + SALICYL-S-ArCP SYNTHETASE 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv2744c 35kd_ag NE  CONSERVED 35 KDA ALANINE RICH PROTEIN 10  conserved hypotheticals  V  Conserved hypotheticals
Rv2931 ppsA NE
 PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE 
SYNTHASE PPSA 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv2934 ppsD NE
 PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE 
SYNTHASE PPSD 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv2935 ppsE NE
 PHENOLPTHIOCEROL SYNTHESIS TYPE-I POLYKETIDE 
SYNTHASE PPSE 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv2940c mas NE
 PROBABLE MULTIFUNCTIONAL MYCOCEROSIC ACID SYNTHASE 
MEMBRANE-ASSOCIATED MAS 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv2996c serA1 E
 PROBABLE D-3-PHOSPHOGLYCERATE DEHYDROGENASE SERA1 
(PGDH) 7
 intermediary metabolism and 
respiration  I.D.3  Serine family
Rv3006 lppZ -  PROBABLE CONSERVED LIPOPROTEIN LPPZ 3  cell wall and cell processes  II.C.1  Lipoproteins(lppA-lpr0)
Rv3116 moeB2 NE
 PROBABLE MOLYBDENUM COFACTOR BIOSYNTHESIS PROTEIN 
MOEB2 (MPT-SYNTHASE SULFURYLASE) (MOLYBDOPTERIN SY 7
 intermediary metabolism and 
respiration  I.G.4  Molybdopterin
Rv3132c devS E  TWO COMPONENT SENSOR HISTIDINE KINASE DEVS 9  regulatory proteins  I.J.2  Two component systems
Rv3147 nuoC -
 PROBABLE NADH DEHYDROGENASE I (CHAIN C) NUOC (NADH-
UBIQUINONE OXIDOREDUCTASE CHAIN C) 7
 intermediary metabolism and 
respiration  I.B.6.a  aerobic
Rv3158 nuoN NE
 PROBABLE NADH DEHYDROGENASE I (CHAIN N) NUON (NADH-
UBIQUINONE OXIDOREDUCTASE CHAIN N) 7
 intermediary metabolism and 
respiration  I.B.6.a  aerobic
Rv3343c PPE54 E  PPE FAMILY PROTEIN 6  PE/PPE  IV.C.2  PPE family
Rv3345c PE_PGRS50 -  PE-PGRS FAMILY PROTEIN 6  PE/PPE  IV.C.1.b  PE_PGRS subfamily
Rv3507 PE_PGRS53 NE  PE-PGRS FAMILY PROTEIN 6  PE/PPE  IV.C.1.b  PE_PGRS subfamily
Rv3508 PE_PGRS54 -  PE-PGRS FAMILY PROTEIN 6  PE/PPE  IV.C.1.b  PE_PGRS subfamily
Rv3536c hsaE -  PROBABLE HYDRATASE 7
 intermediary metabolism and 
respiration  II.B.6  Aromatic hydrocarbons
Rv3628 ppa -
 INORGANIC PYROPHOSPHATASE PPA (PYROPHOSPHATE 
PHOSPHO-HYDROLASE) (PPASE) (INORGANIC DIPHOSPHATASE) 
(D 7
 intermediary metabolism and 
respiration  I.A.4  Phosphorous compounds
Rv3800c pks13 E  POLYKETIDE SYNTHASE PKS13 1  lipid metabolism  I.I
 Polyketide and non-ribosomal peptide 
synthesis
Rv3826 fadD23 -
 PROBABLE FATTY-ACID-CoA LIGASE FADD23 (FATTY-ACID-CoA 
SYNTHETASE) (FATTY-ACID-CoA SYNTHASE) 1  lipid metabolism  I.A.3  Fatty acids
Table Key: Bold Italic - Medium Confidence; italic - low confidence. Plain - no ATP label. (see text for ranking criteria). SSI functional categories can be accessed here: http://web.mpiib-
berlin.mpg.de/bioinformatik/FUNC_CLASS/overview.php?db_name=CLASS_Mtb
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